0001437749-24-02638610-Q NovaBay Pharmaceuticals, Inc. 20240813202408131611021611021611021102 0 0001437749-24-026386 10-Q 95 20240630 20240813 20240813 NovaBay Pharmaceuticals, Inc. 0001389545 2834 680454536 DE 1231 10-Q 34 001-33678 241201538 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 10-Q 1 nby20240630_10q.htm FORM 10-Q nby20240630_10q.htm Q2 2024 --12-31 false 0001389545 false false false false 1 6 5 1 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 5 10 10 0 5.5 0 0 0 0 0 0 0 0 40 0.2 0.2 82 0.2 0.2 0.4 0.9 0.5 5.1 6.8 1.7 2.0 11.6 9.6 70 0.1 66 0.1 0.2 56 0.2 0.5 0.3 28 21 51 56 0.2 0.2 0.3 1.4 1.6 0 0 0 0 0 0 0 0 0 0 0 0 0 7 5 5 3 7 5 1 2 0001389545452024-01-012024-06-30 thunderdome:item iso4217:USD 0001389545nby:PrefundedWarrants2024PublicOfferingMemberus-gaap:SubsequentEventMember2024-07-262024-08-09 0001389545us-gaap:SubsequentEventMembernby:The2024PublicOfferingMember2024-07-262024-07-29 xbrli:shares 0001389545nby:SeriesF3WarrantsMembernby:UnderwriterFrom2024PublicOfferingMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-26 0001389545nby:SeriesF3WarrantsMembernby:UnderwriterFrom2024PublicOfferingMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-262024-07-26 0001389545nby:SeriesF2WarrantsMembernby:UnderwriterFrom2024PublicOfferingMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-26 0001389545nby:SeriesF2WarrantsMembernby:UnderwriterFrom2024PublicOfferingMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-262024-07-26 0001389545nby:SeriesF1WarrantsMembernby:UnderwritingAgreementMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-26 0001389545nby:SeriesF1WarrantsMembernby:UnderwriterFrom2024PublicOfferingMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-262024-07-26 0001389545nby:UnderwriterFrom2024PublicOfferingMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-262024-07-26 0001389545nby:SeriesF3WarrantsMembernby:UnderwritingAgreementMembernby:MaximumAmountPurchasableByUnderwriterMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-26 0001389545nby:SeriesF3WarrantsMembernby:UnderwriterFrom2024PublicOfferingMembernby:MaximumAmountPurchasableByUnderwriterMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-262024-07-26 0001389545nby:SeriesF2WarrantsMembernby:UnderwriterFrom2024PublicOfferingMembernby:MaximumAmountPurchasableByUnderwriterMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-26 0001389545nby:SeriesF2WarrantsMembernby:UnderwriterFrom2024PublicOfferingMembernby:MaximumAmountPurchasableByUnderwriterMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-262024-07-26 0001389545nby:SeriesF1WarrantsMembernby:UnderwriterFrom2024PublicOfferingMembernby:MaximumAmountPurchasableByUnderwriterMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-26 0001389545nby:SeriesF1WarrantsMembernby:UnderwriterFrom2024PublicOfferingMembernby:MaximumAmountPurchasableByUnderwriterMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-262024-07-26 0001389545nby:UnderwriterFrom2024PublicOfferingMembernby:MaximumAmountPurchasableByUnderwriterMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2024-07-262024-07-26 xbrli:pure 0001389545nby:ElectionOfTheHolderPriorToTheDateOfIssuanceMemberus-gaap:SubsequentEventMembernby:The2024PublicOfferingMember2024-07-26 0001389545us-gaap:SubsequentEventMembernby:The2024PublicOfferingMember2024-07-26 iso4217:USDxbrli:shares 0001389545nby:PrefundedWarrants2024PublicOfferingMemberus-gaap:SubsequentEventMember2024-07-26 utr:Y 0001389545nby:SeriesF3WarrantsMemberus-gaap:SubsequentEventMember2024-07-26 0001389545nby:SeriesF1WarrantsMemberus-gaap:SubsequentEventMember2024-07-26 utr:M 0001389545nby:SeriesF2WarrantsMemberus-gaap:SubsequentEventMember2024-07-26 0001389545nby:SeriesF3WarrantsMemberus-gaap:SubsequentEventMembernby:The2024PublicOfferingMember2024-07-26 0001389545nby:SeriesF3WarrantsMemberus-gaap:SubsequentEventMembernby:The2024PublicOfferingMember2024-07-262024-07-26 0001389545nby:SeriesF2WarrantsMemberus-gaap:SubsequentEventMembernby:The2024PublicOfferingMember2024-07-26 0001389545nby:SeriesF2WarrantsMemberus-gaap:SubsequentEventMembernby:The2024PublicOfferingMember2024-07-262024-07-26 0001389545nby:SeriesF1WarrantsMemberus-gaap:SubsequentEventMembernby:The2024PublicOfferingMember2024-07-26 0001389545nby:SeriesF1WarrantsMemberus-gaap:SubsequentEventMembernby:The2024PublicOfferingMember2024-07-262024-07-26 0001389545nby:PrefundedWarrants2024PublicOfferingMemberus-gaap:SubsequentEventMembernby:The2024PublicOfferingMember2024-07-262024-07-26 0001389545us-gaap:SubsequentEventMembernby:The2024PublicOfferingMember2024-07-262024-07-26 0001389545us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernby:DermadoctorMember2023-01-012023-06-30 0001389545us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernby:DermadoctorMember2024-01-012024-06-30 0001389545us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernby:DermadoctorMember2023-12-31 0001389545us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernby:DermadoctorMember2024-03-252024-03-25 00013895452023-01-012023-12-31 0001389545us-gaap:RelatedPartyMember2023-01-012023-06-30 0001389545us-gaap:RelatedPartyMember2024-01-012024-06-30 0001389545us-gaap:RelatedPartyMember2023-04-012023-06-30 0001389545us-gaap:RelatedPartyMember2024-04-012024-06-30 0001389545nby:The401kPlanContributionLevelTwoMember2023-01-012023-06-30 0001389545nby:The401kPlanContributionLevelTwoMember2023-04-012023-06-30 0001389545nby:The401kPlanContributionLevelTwoMember2024-01-012024-06-30 0001389545nby:The401kPlanContributionLevelTwoMember2024-04-012024-06-30 0001389545nby:The401kPlanContributionLevelOneMember2024-01-012024-06-30 0001389545nby:AvenovaDirectMember2023-01-012023-06-30 0001389545nby:AvenovaDirectMember2024-01-012024-06-30 0001389545nby:AvenovaDirectMember2023-01-012023-03-31 0001389545nby:AvenovaDirectMember2024-01-012024-03-31 0001389545nby:CostcoAndOthersMembernby:DermadoctorMember2023-12-31 0001389545nby:CostcoAndOthersMembernby:DermadoctorMember2024-06-30 0001389545nby:CostcoAndOthersMembernby:DermadoctorMember2023-01-012023-06-30 0001389545nby:CostcoAndOthersMembernby:DermadoctorMember2024-01-012024-06-30 0001389545nby:CostcoAndOthersMembernby:DermadoctorMember2023-04-012023-06-30 0001389545nby:CostcoAndOthersMembernby:DermadoctorMember2024-04-012024-06-30 00013895452024-06-30 0001389545nby:RebatesMember2024-06-30 0001389545nby:OtherCustomerFeesMember2024-06-30 0001389545nby:ChargebacksDiscountsForPromptPaymentAndOtherMember2024-06-30 0001389545nby:RebatesMember2024-01-012024-06-30 0001389545nby:OtherCustomerFeesMember2024-01-012024-06-30 0001389545nby:ChargebacksDiscountsForPromptPaymentAndOtherMember2024-01-012024-06-30 00013895452023-12-31 0001389545nby:RebatesMember2023-12-31 0001389545nby:OtherCustomerFeesMember2023-12-31 0001389545nby:ChargebacksDiscountsForPromptPaymentAndOtherMember2023-12-31 00013895452023-01-012023-06-30 00013895452023-04-012023-06-30 00013895452024-04-012024-06-30 0001389545us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-30 0001389545us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-30 0001389545us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-30 0001389545us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-30 0001389545us-gaap:SellingAndMarketingExpenseMember2023-01-012023-06-30 0001389545us-gaap:SellingAndMarketingExpenseMember2024-01-012024-06-30 0001389545us-gaap:SellingAndMarketingExpenseMember2023-04-012023-06-30 0001389545us-gaap:SellingAndMarketingExpenseMember2024-04-012024-06-30 0001389545us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-30 0001389545us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-30 0001389545us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-30 0001389545us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-30 0001389545us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-04-012023-06-30 0001389545us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-01-012024-06-30 0001389545us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-04-012023-06-30 0001389545us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-04-012024-06-30 0001389545us-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-01-012023-06-30 0001389545us-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-04-012023-06-30 0001389545us-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-01-012024-06-30 0001389545us-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-04-012024-06-30 0001389545us-gaap:RestrictedStockMembernby:EmployeesAndDirectorsMember2023-01-012023-06-30 0001389545us-gaap:RestrictedStockMembernby:EmployeesAndDirectorsMember2024-01-012024-06-30 0001389545us-gaap:RestrictedStockMembernby:EmployeesAndDirectorsMember2023-04-012023-06-30 0001389545us-gaap:RestrictedStockMembernby:EmployeesAndDirectorsMember2024-04-012024-06-30 0001389545us-gaap:ShareBasedPaymentArrangementNonemployeeMembernby:EmployeesAndDirectorsMember2023-01-012023-06-30 0001389545nby:EmployeesAndDirectorsMember2023-01-012023-06-30 0001389545nby:EmployeesAndDirectorsMember2024-01-012024-06-30 0001389545us-gaap:RestrictedStockUnitsRSUMember2024-06-302024-06-30 0001389545us-gaap:EmployeeStockOptionMembernby:The2017OmnibusIncentivePlanMember2017-03-012017-03-31 0001389545nby:IncentiveStockOptionsISOMembernby:ShareholderOfMoreThan10PercentMembernby:The2017OmnibusIncentivePlanMembersrt:MaximumMember2017-03-012017-03-31 0001389545nby:The2017OmnibusIncentivePlanMembersrt:MaximumMember2017-03-012017-03-31 0001389545nby:IncentiveStockOptionsISOMembernby:ShareholderOfMoreThan10PercentMembernby:The2017OmnibusIncentivePlanMembersrt:MinimumMember2017-03-012017-03-31 0001389545nby:IncentiveStockOptionsISOMembernby:The2017OmnibusIncentivePlanMember2017-03-012017-03-31 0001389545nby:The2017OmnibusIncentivePlanMembersrt:MinimumMember2017-03-012017-03-31 0001389545nby:The2017OmnibusIncentivePlanMember2024-06-30 0001389545nby:The2017OmnibusIncentivePlanMember2023-03-312023-03-31 0001389545nby:The2017OmnibusIncentivePlanMember2017-03-31 0001389545nby:IncentiveStockOptionsISOMembernby:The2007OmnibusIncentivePlanMembersrt:MaximumMember2007-10-012007-10-31 0001389545us-gaap:SeriesCPreferredStockMember2024-03-272024-03-27 0001389545srt:MinimumMemberus-gaap:SeriesCPreferredStockMember2024-05-27 0001389545us-gaap:SeriesCPreferredStockMember2024-03-012024-03-31 0001389545srt:RestatementAdjustmentMemberus-gaap:SeriesCPreferredStockMember2024-03-31 0001389545srt:ScenarioPreviouslyReportedMemberus-gaap:SeriesCPreferredStockMember2024-03-31 0001389545us-gaap:SeriesCPreferredStockMember2023-12-212023-12-21 0001389545srt:RestatementAdjustmentMemberus-gaap:SeriesCPreferredStockMember2023-12-21 0001389545srt:ScenarioPreviouslyReportedMemberus-gaap:SeriesCPreferredStockMember2023-12-21 0001389545us-gaap:SeriesCPreferredStockMembernby:The2023PrivatePlacementMember2023-04-272023-04-27 0001389545nby:May2023WarrantsMember2023-04-27 0001389545us-gaap:SeriesCPreferredStockMember2023-04-27 0001389545us-gaap:SeriesCPreferredStockMembernby:The2022PrivatePlacementMember2023-06-30 0001389545us-gaap:SeriesCPreferredStockMembernby:The2022PrivatePlacementMember2024-06-30 0001389545us-gaap:SeriesCPreferredStockMembernby:The2022PrivatePlacementMember2022-09-092022-09-09 0001389545us-gaap:SeriesBPreferredStockMember2024-01-29 0001389545us-gaap:SeriesBPreferredStockMembernby:The2021PrivatePlacementProgramMember2021-10-292021-10-29 0001389545srt:MinimumMemberus-gaap:SeriesBPreferredStockMember2024-01-29 0001389545us-gaap:SeriesBPreferredStockMember2023-12-212023-12-21 0001389545srt:RestatementAdjustmentMemberus-gaap:SeriesBPreferredStockMember2023-12-21 0001389545srt:ScenarioPreviouslyReportedMemberus-gaap:SeriesBPreferredStockMember2023-12-21 0001389545us-gaap:SeriesBPreferredStockMembernby:The2023PrivatePlacementMember2023-04-272023-04-27 0001389545us-gaap:SeriesBPreferredStockMember2023-04-27 0001389545us-gaap:SeriesBPreferredStockMember2022-09-092022-09-09 0001389545srt:RestatementAdjustmentMemberus-gaap:SeriesBPreferredStockMember2022-09-09 0001389545srt:ScenarioPreviouslyReportedMemberus-gaap:SeriesBPreferredStockMember2022-09-09 0001389545us-gaap:SeriesBPreferredStockMembernby:The2021PrivatePlacementProgramMember2023-06-30 0001389545us-gaap:SeriesBPreferredStockMembernby:The2021PrivatePlacementProgramMember2024-06-30 0001389545nby:ReverseStockSplitMember2024-05-302024-05-30 0001389545nby:WarrantLiabilityMember2024-06-30 0001389545nby:March2024WarrantMembernby:WarrantLiabilityMember2024-01-012024-06-30 0001389545nby:TheDecember2023WarrantsMembernby:WarrantLiabilityMember2024-01-012024-06-30 0001389545nby:WarrantLiabilityMember2023-12-31 0001389545nby:June2024WarrantMember2024-06-30 0001389545nby:March2024WarrantMember2024-06-30 0001389545nby:TheDecember2023WarrantsMember2024-06-30 0001389545nby:TheNovember2022A1WarrantsMember2024-06-30 0001389545nby:TheAmendedSeptember2022WarrantsMember2024-06-30 0001389545nby:TheSeptember2022WarrantsMember2024-06-30 0001389545nby:TheAmendedNovember2021WarrantsMember2024-06-30 0001389545nby:TheNovember2021WarrantsMember2024-06-30 0001389545nby:TLFBioInnovation2021WarrantsMember2024-06-30 0001389545nby:TheAmendedJuly2020WarrantsMember2024-06-30 0001389545nby:TheJuly2020WarrantsMember2024-06-30 0001389545nby:The2019LadenburgWarrantsMember2024-06-30 00013895452023-06-30 00013895452022-12-31 0001389545nby:AmendedJuly2020WarrantsMember2023-05-012023-05-01 0001389545nby:AmendedJuly2020WarrantsMember2022-09-092022-09-09 0001389545nby:The2023PrivatePlacementMember2023-05-01 0001389545nby:AmendedJuly2020WarrantsMember2023-05-01 0001389545nby:AmendedJuly2020WarrantsMember2022-09-09 0001389545nby:TheJuly2020WarrantsMember2020-07-31 0001389545nby:TheJuly2020WarrantsMember2020-09-09 0001389545nby:AmendedNovember2021WarrantsExercisableFor150Member2023-05-012023-05-01 0001389545nby:AmendedNovember2021WarrantsExercisableFor650Member2022-09-092022-09-09 0001389545nby:AmendedNovember2021WarrantsExercisableFor150Member2023-05-01 0001389545nby:AmendedNovember2021WarrantsExercisableFor650Member2023-05-01 0001389545nby:TheNovember2021WarrantsMember2023-05-01 0001389545nby:AmendedNovember2021WarrantsExercisableFor650Member2022-09-09 0001389545nby:TheNovember2021WarrantsMember2021-11-30 0001389545nby:September2022WarrantsAmendedMember2024-06-012024-06-30 0001389545nby:September2022WarrantsAmendedMember2023-05-012023-05-31 0001389545nby:September2022WarrantsAmendedIn2024WarrantRepriseTransactionMember2024-06-30 0001389545nby:September2022WarrantsAmendedIn2023PrivatePlacementMember2022-09-09 0001389545nby:September2022WarrantsAmendedIn2023PrivatePlacementMember2023-05-31 0001389545nby:The2022WarrantRepriceTransactionMember2022-09-09 0001389545nby:TheAmendedNovember2022A1AndA2WarrantsMember2024-06-012024-06-30 0001389545nby:TheAmendedNovember2022A1AndA2WarrantsMember2023-05-012023-05-31 0001389545nby:November2022WarrantsAmendedBy2024WarrantRepriceTransactionMember2024-06-30 0001389545nby:TheNovember2022A1WarrantsMember2023-05-31 0001389545nby:TheNovember2022A2WarrantsMember2024-05-012024-05-31 0001389545nby:TheNovember2022A2WarrantsMember2023-05-31 0001389545nby:TheAmendedNovember2022A1AndA2WarrantsMember2023-05-31 0001389545nby:TheNovember2022A1AndA2WarrantsMember2023-05-31 0001389545nby:TheNovember2022A2WarrantsMember2022-11-10 0001389545nby:TheNovember2022A1WarrantsMember2022-11-10 0001389545nby:May2023WarrantsMember2024-06-012024-06-30 0001389545nby:May2023WarrantsMember2023-12-012023-12-31 0001389545nby:TheMay2023B2WarrantsMember2024-06-012024-06-30 0001389545nby:TheMay2023B1WarrantsMember2024-06-012024-06-30 0001389545nby:May2023WarrantsMember2024-06-30 0001389545nby:May2023WarrantsAmendedBy2024WarrantRepriceTransactionMember2024-06-30 0001389545nby:TheMay2023B2WarrantsMember2023-12-012023-12-31

0001389545nby:TheMay2023B1WarrantsMember2023-12-012023-12-31 0001389545nby:TheMay2023B1WarrantsMember2023-12-31
0001389545nby:May2023WarrantsAmendedBy2023WarrantRepriceTransactionMember2023-12-31 0001389545nby:TheMay2023B2WarrantsMember2023-05-31
0001389545nby:TheMay2023B1WarrantsMember2023-05-31 0001389545nby:TheDecember2023WarrantsMember2023-12-31 0001389545nby:March2024WarrantMember2024-03-31
0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2024-06-30 0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2024-01-
012024-06-30 0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2024-04-012024-06-30
0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2024-03-31 0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2023-06-30
0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2023-05-01 0001389545nby:The2023PrivatePlacementMember2023-05-012023-05-01
0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2023-05-012023-05-01
0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2023-06-09 0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2023-04-27
0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2024-03-012024-03-01
0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2023-12-012023-12-31
0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2023-04-272023-04-27
0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMembernby:MeasurementInputRedemptionInStockMember2023-04-27
0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember2024-01-012024-03-31 0001389545nby:UnsecuredConvertibleNotesMember2024-06-302024-06-30
0001389545nby:UnsecuredConvertibleNotesMember2024-04-012024-06-30 0001389545nby:UnsecuredConvertibleNotesMember2024-06-30
0001389545nby:UnsecuredConvertibleNotesMember2024-03-24 0001389545nby:UnsecuredConvertibleNotesMember2024-04-012024-05-28
0001389545nby:UnsecuredConvertibleNotesMember2024-05-28 0001389545nby:UnsecuredConvertibleNotesMember2024-03-31 0001389545nby:UnsecuredConvertibleNotesMember2024-03-
242024-03-24 0001389545nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMembernby:The2023PrivatePlacementMember2023-05-01
0001389545nby:The2023PrivatePlacementMember2023-05-012023-05-01 0001389545nby:The2023PrivatePlacementMember2023-05-01
0001389545nby:The2023PrivatePlacementMember2023-05-012023-05-31 0001389545nby:The2023WarrantRepriceTransactionMember2023-12-012023-12-31
0001389545nby:The2023WarrantRepriceTransactionMember2023-12-31 0001389545nby:TheDecember2023WarrantsMember2023-12-012023-12-31
0001389545nby:May2023WarrantsMember2023-12-31 0001389545nby:March2024WarrantMember2024-03-24 0001389545nby:The2024WarrantRepriceTransactionMember2024-01-012024-
06-30 0001389545nby:The2024WarrantRepriceTransactionMember2024-04-012024-06-30 0001389545nby:The2024WarrantRepriceTransactionMember2024-06-30
0001389545nby:The2024WarrantRepriceExistingWarrantsMember2024-06-012024-06-30 0001389545nby:The2024WarrantRepriceExistingWarrantsMember2024-06-30 0001389545us-
gaap:LeaseholdImprovementsMember2023-12-31 0001389545us-gaap:LeaseholdImprovementsMember2024-06-30 0001389545nby:ComputerEquipmentAndSoftwareMember2023-12-31
0001389545nby:ComputerEquipmentAndSoftwareMember2024-06-30 0001389545us-gaap:FurnitureAndFixturesMember2023-12-31 0001389545us-gaap:FurnitureAndFixturesMember2024-
06-30 0001389545nby:OfficeAndLaboratoryEquipmentMember2023-12-31 0001389545nby:OfficeAndLaboratoryEquipmentMember2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputExpectedTermMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputExpectedTermMembernby:IssuanceApril272023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:IssuanceApril272023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembernby:IssuanceApril272023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputOptionVolatilityMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputOptionVolatilityMembernby:IssuanceApril272023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputSharePriceMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputSharePriceMembernby:IssuanceApril272023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputExercisePriceMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMemberus-
gaap:MeasurementInputExercisePriceMembernby:IssuanceApril272023Member2024-06-30 0001389545us-gaap:ConvertibleDebtMembernby:StockholderApprovalJune92023Member2024-01-
012024-06-30 0001389545us-gaap:ConvertibleDebtMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545us-
gaap:ConvertibleDebtMembernby:IssuanceApril272023Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputExpectedTermMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputExpectedTermMembernby:IssuanceMarch252024Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:IssuanceMarch252024Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembernby:IssuanceMarch252024Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputOptionVolatilityMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputOptionVolatilityMembernby:IssuanceMarch252024Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputSharePriceMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputSharePriceMembernby:IssuanceMarch252024Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputExercisePriceMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:UnsecuredConvertibleNotesMemberus-
gaap:MeasurementInputExercisePriceMembernby:IssuanceMarch252024Member2024-06-30
0001389545nby:UnsecuredConvertibleNotesMembernby:StockholderApprovalMay282024Member2024-01-012024-06-30
0001389545nby:UnsecuredConvertibleNotesMembernby:StockholderApprovalMay282024Member2024-06-30
0001389545nby:UnsecuredConvertibleNotesMembernby:IssuanceMarch252024Member2024-06-30 0001389545us-gaap:MeasurementInputExpectedTermMemberus-
gaap:SeriesCPreferredStockMembernby:AfterRatchetMarch242024Member2024-06-30 0001389545us-gaap:MeasurementInputExpectedTermMemberus-
gaap:SeriesCPreferredStockMembernby:PriorToRatchetMarch242024Member2024-06-30 0001389545us-gaap:MeasurementInputExpectedDividendRateMemberus-
gaap:SeriesCPreferredStockMembernby:AfterRatchetMarch242024Member2024-06-30 0001389545us-gaap:MeasurementInputExpectedDividendRateMemberus-
gaap:SeriesCPreferredStockMembernby:PriorToRatchetMarch242024Member2024-06-30 0001389545us-gaap:MeasurementInputRiskFreeInterestRateMemberus-
gaap:SeriesCPreferredStockMembernby:AfterRatchetMarch242024Member2024-06-30 0001389545us-gaap:MeasurementInputRiskFreeInterestRateMemberus-
gaap:SeriesCPreferredStockMembernby:PriorToRatchetMarch242024Member2024-06-30 0001389545us-gaap:MeasurementInputOptionVolatilityMemberus-
gaap:SeriesCPreferredStockMembernby:AfterRatchetMarch242024Member2024-06-30 0001389545us-gaap:MeasurementInputOptionVolatilityMemberus-
gaap:SeriesCPreferredStockMembernby:PriorToRatchetMarch242024Member2024-06-30 0001389545us-gaap:MeasurementInputExercisePriceMemberus-
gaap:SeriesCPreferredStockMembernby:AfterRatchetMarch242024Member2024-06-30 0001389545us-gaap:MeasurementInputExercisePriceMemberus-
gaap:SeriesCPreferredStockMembernby:PriorToRatchetMarch242024Member2024-06-30 0001389545us-gaap:SeriesCPreferredStockMembernby:AfterRatchetMarch242024Member2024-01-
012024-06-30 0001389545us-gaap:SeriesCPreferredStockMembernby:AfterRatchetMarch242024Member2024-06-30 0001389545us-
gaap:SeriesCPreferredStockMembernby:PriorToRatchetMarch242024Member2024-06-30 0001389545us-
gaap:MeasurementInputExpectedTermMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputExpectedTermMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputExpectedDividendRateMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputExpectedDividendRateMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputRiskFreeInterestRateMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputRiskFreeInterestRateMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputPriceVolatilityMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputPriceVolatilityMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputSharePriceMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputSharePriceMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputExercisePriceMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputExercisePriceMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetDecember212023Member2024-06-30
0001389545nby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetDecember212023Member2024-01-012024-06-30
0001389545nby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetDecember212023Member2024-06-30
0001389545nby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetDecember212023Member2024-06-30 0001389545us-
gaap:MeasurementInputExpectedTermMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetApril272023Member2024-06-30 0001389545us-
gaap:MeasurementInputExpectedTermMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetApril272023Member2024-06-30 0001389545us-
gaap:MeasurementInputExpectedDividendRateMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetApril272023Member2024-06-30 0001389545us-
gaap:MeasurementInputExpectedDividendRateMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetApril272023Member2024-06-30 0001389545us-
gaap:MeasurementInputRiskFreeInterestRateMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetApril272023Member2024-06-30 0001389545us-
gaap:MeasurementInputRiskFreeInterestRateMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetApril272023Member2024-06-30 0001389545us-
gaap:MeasurementInputPriceVolatilityMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetApril272023Member2024-06-30 0001389545us-
gaap:MeasurementInputPriceVolatilityMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetApril272023Member2024-06-30 0001389545us-
gaap:MeasurementInputSharePriceMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetApril272023Member2024-06-30 0001389545us-
gaap:MeasurementInputSharePriceMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetApril272023Member2024-06-30 0001389545us-
gaap:MeasurementInputExercisePriceMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetApril272023Member2024-06-30 0001389545us-
gaap:MeasurementInputExercisePriceMembernby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetApril272023Member2024-06-30
0001389545nby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetApril272023Member2024-01-012024-06-30
0001389545nby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:AfterRatchetApril272023Member2024-06-30
0001389545nby:SeriesBPreferredStockAndSeriesCPreferredStockMembernby:PriorToRatchetApril272023Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MaximumMembernby:PostAmendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MinimumMembernby:PostAmendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMembernby:PostAmendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMembernby:PreamendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMembernby:PostAmendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMembernby:PostAmendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMembernby:PreamendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMembernby:PreamendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembernby:PostAmendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembernby:PreamendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-gaap:MeasurementInputSharePriceMembernby:PostAmendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-gaap:MeasurementInputSharePriceMembernby:PreamendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-gaap:MeasurementInputExercisePriceMembernby:PostAmendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-
gaap:MeasurementInputExercisePriceMembersrt:MaximumMembernby:PreamendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMemberus-

gaap:MeasurementInputExercisePriceMembersrt:MinimumMembernby:PreamendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMembernby:PostAmendmentJune142024Member2024-01-012024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMembernby:PostAmendmentJune142024Member2024-06-30
0001389545nby:September2022November2022AndMay2023WarrantsMembernby:PreamendmentJune142024Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MaximumMembernby:PostamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MinimumMembernby:PostamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MaximumMembernby:PreamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MinimumMembernby:PreamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:PostamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:PreamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMembernby:PostamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMembernby:PostamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMembernby:PreamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMembernby:PreamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputPriceVolatilityMembernby:PostamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputPriceVolatilityMembernby:PreamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputSharePriceMembernby:PostamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputSharePriceMembernby:PreamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputExercisePriceMembernby:PostamendmentDecember212023Member2024-06-30 0001389545nby:TheMay2023WarrantsMemberus-
gaap:MeasurementInputExercisePriceMembernby:PreamendmentDecember212023Member2024-06-30
0001389545nby:TheMay2023WarrantsMembernby:PostamendmentDecember212023Member2024-01-012024-06-30
0001389545nby:TheMay2023WarrantsMembernby:PostamendmentDecember212023Member2024-06-30
0001389545nby:TheMay2023WarrantsMembernby:PreamendmentDecember212023Member2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MaximumMembernby:PostamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MinimumMembernby:PostamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MaximumMembernby:PreamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MinimumMembernby:PreamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMembernby:PostamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMembernby:PreamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMembernby:PostamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMembernby:PostamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMembernby:PreamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMembernby:PreamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembernby:PostamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembernby:PreamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-gaap:MeasurementInputSharePriceMembernby:PreamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-gaap:MeasurementInputExercisePriceMembernby:PostamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMemberus-gaap:MeasurementInputExercisePriceMembernby:PreamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMembernby:PostamendmentMember2024-01-012024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMembernby:PostamendmentMember2024-06-30
0001389545nby:July2020November2021September2022November2022WarrantsMembernby:PreamendmentMember2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputExpectedTermMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputExpectedTermMembernby:ReportingDateMarch312024Member2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:ReportingDateMarch312024Member2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembernby:ReportingDateMarch312024Member2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputPriceVolatilityMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputPriceVolatilityMembernby:ReportingDateMarch312024Member2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputSharePriceMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputSharePriceMembernby:ReportingDateMarch312024Member2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputExercisePriceMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:March2024WarrantMemberus-
gaap:MeasurementInputExercisePriceMembernby:ReportingDateMarch312024Member2024-06-30
0001389545nby:March2024WarrantMembernby:StockholderApprovalMay282024Member2024-01-012024-06-30
0001389545nby:March2024WarrantMembernby:ReportingDateMarch312024Member2024-01-012024-06-30
0001389545nby:March2024WarrantMembernby:StockholderApprovalMay282024Member2024-06-30
0001389545nby:March2024WarrantMembernby:ReportingDateMarch312024Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembernby:ReportingDateDecember312023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MaximumMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MinimumMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MaximumMembernby:IssuanceMay12023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputExpectedTermMembersrt:MinimumMembernby:IssuanceMay12023Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:ReportingDateDecember312023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputExpectedDividendRateMembernby:IssuanceMay12023Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembernby:ReportingDateDecember312023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMembernby:IssuanceMay12023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMembernby:IssuanceMay12023Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputPriceVolatilityMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputPriceVolatilityMembernby:ReportingDateDecember312023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputPriceVolatilityMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputPriceVolatilityMembernby:IssuanceMay12023Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputSharePriceMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputSharePriceMembernby:ReportingDateDecember312023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputSharePriceMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputSharePriceMembernby:IssuanceMay12023Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputExercisePriceMembernby:StockholderApprovalMay282024Member2024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-
gaap:MeasurementInputExercisePriceMembernby:ReportingDateDecember312023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputExercisePriceMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545nby:May2023WarrantsMemberus-
gaap:MeasurementInputExercisePriceMembernby:IssuanceMay12023Member2024-06-30 0001389545nby:May2023WarrantsMembernby:StockholderApprovalMay282024Member2024-01-
012024-06-30 0001389545nby:TheDecember2023WarrantsMembernby:ReportingDateDecember312023Member2024-01-012024-06-30
0001389545nby:May2023WarrantsMembernby:StockholderApprovalJune92023Member2024-01-012024-06-30
0001389545nby:TheDecember2023WarrantsMembernby:StockholderApprovalMay282024Member2024-06-30
0001389545nby:TheDecember2023WarrantsMembernby:ReportingDateDecember312021Member2024-06-30
0001389545nby:May2023WarrantsMembernby:StockholderApprovalJune92023Member2024-06-30 0001389545nby:May2023WarrantsMembernby:IssuanceMay12023Member2024-06-30
0001389545us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001389545us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember2023-12-31 0001389545us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001389545us-
gaap:FairValueMeasurementsRecurringMember2023-12-31 0001389545us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-30 0001389545us-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-30 0001389545us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember2024-06-30 0001389545us-gaap:FairValueMeasurementsRecurringMember2024-06-30 0001389545us-gaap:WarrantMember2023-01-012023-
06-30 0001389545us-gaap:WarrantMember2024-01-012024-06-30 0001389545us-gaap:EmployeeStockOptionMember2023-01-012023-06-30 0001389545us-
gaap:EmployeeStockOptionMember2024-01-012024-06-30 0001389545us-gaap:SeriesCPreferredStockMember2023-01-012023-06-30 0001389545us-gaap:SeriesCPreferredStockMember2024-
01-012024-06-30 0001389545us-gaap:SeriesBPreferredStockMember2023-01-012023-06-30 0001389545us-gaap:SeriesBPreferredStockMember2024-01-012024-06-30 utr:D 00013895452024-
01-012024-03-31 0001389545us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2024-06-30 0001389545us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2024-06-30
0001389545nby:ComputerEquipmentAndSoftwareMembersrt:MaximumMember2024-06-30 0001389545nby:ComputerEquipmentAndSoftwareMembersrt:MinimumMember2024-06-30
0001389545us-gaap:EquipmentMembersrt:MaximumMember2024-06-30 0001389545us-gaap:EquipmentMembersrt:MinimumMember2024-06-30 0001389545us-
gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembernby:ChongqingPioneerPharmaHoldingsLimitedMember2023-01-012023-06-30 0001389545us-
gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembernby:DistributorBMember2024-01-012024-06-30 0001389545us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMembernby:DistributorAMember2023-01-012023-06-30 0001389545us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMembernby:DistributorAMember2024-01-012024-06-30 0001389545us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMembernby:MajorUSRetailerAMember2023-01-012023-06-30 0001389545us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMembernby:MajorUSRetailerAMember2024-01-012024-06-30 0001389545us-
gaap:RevenueFromContractWithCustomerMembernby:DistributorConcentrationRiskMembernby:AvenovaSprayMember2023-01-012023-06-30 0001389545us-
gaap:RevenueFromContractWithCustomerMembernby:DistributorConcentrationRiskMembernby:AvenovaSprayMember2024-01-012024-06-30 0001389545us-
gaap:RevenueFromContractWithCustomerMembernby:DistributorConcentrationRiskMembernby:AvenovaSprayMember2023-04-012023-06-30 0001389545us-
gaap:RevenueFromContractWithCustomerMembernby:DistributorConcentrationRiskMembernby:AvenovaSprayMember2024-04-012024-06-30 00013895452023-01-012024-06-30
0001389545us-gaap:ProductAndServiceOtherMember2023-01-012024-06-30 0001389545us-gaap:ProductAndServiceOtherMember2024-01-012024-06-30 0001389545us-

gaap:ProductAndServiceOtherMember2023-04-012023-06-30 0001389545us-gaap:ProductAndServiceOtherMember2024-04-012024-06-30 0001389545nby:TotalProductRevenueMember2023-01-012024-06-30 0001389545nby:TotalProductRevenueMember2024-01-012024-06-30 0001389545nby:TotalProductRevenueMember2023-04-012023-06-30 0001389545nby:TotalProductRevenueMember2024-04-012024-06-30 0001389545nby:OtherProductsMember2023-01-012024-06-30 0001389545nby:OtherProductsMember2024-01-012024-06-30 0001389545nby:OtherProductsMember2023-04-012023-06-30 0001389545nby:OtherProductsMember2024-04-012024-06-30 0001389545nby:NeutrophaseMember2023-01-012024-06-30 0001389545nby:NeutrophaseMember2024-01-012024-06-30 0001389545nby:NeutrophaseMember2023-04-012023-06-30 0001389545nby:NeutrophaseMember2024-04-012024-06-30 0001389545nby:AvenovaSprayMember2023-01-012024-06-30 0001389545nby:AvenovaSprayMember2024-01-012024-06-30 0001389545nby:AvenovaSprayMember2023-04-012023-06-30 0001389545nby:AvenovaSprayMember2024-04-012024-06-30 0001389545us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernby:DermadoctorMember2024-01-012024-03-31 0001389545nby:WarrantLiabilityMember2023-01-012023-06-30 0001389545nby:WarrantLiabilityMember2024-01-012024-06-30 0001389545nby:ConvertibleNotesAndMay2023WarrantsMember2023-01-012023-06-30 0001389545nby:ConvertibleNotesAndMay2023WarrantsMember2024-01-012024-06-30 0001389545us-gaap:RetainedEarningsMember2023-06-30 0001389545us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001389545us-gaap:CommonStockMember2023-06-30 0001389545us-gaap:PreferredStockMember2023-06-30 0001389545srt:DirectorMember2023-04-012023-06-30 0001389545us-gaap:RetainedEarningsMembersrt:DirectorMember2023-04-012023-06-30 0001389545us-gaap:AdditionalPaidInCapitalMembersrt:DirectorMember2023-04-012023-06-30 0001389545us-gaap:CommonStockMembersrt:DirectorMember2023-04-012023-06-30 0001389545us-gaap:PreferredStockMembersrt:DirectorMember2023-04-012023-06-30 0001389545nby:EmployeesAndDirectorsMember2023-04-012023-06-30 0001389545us-gaap:RetainedEarningsMembernby:EmployeesAndDirectorsMember2023-04-012023-06-30 0001389545us-gaap:AdditionalPaidInCapitalMembernby:EmployeesAndDirectorsMember2023-04-012023-06-30 0001389545us-gaap:CommonStockMembernby:EmployeesAndDirectorsMember2023-04-012023-06-30 0001389545us-gaap:PreferredStockMembernby:EmployeesAndDirectorsMember2023-04-012023-06-30 0001389545nby:May2023WarrantsMember2023-04-012023-06-30 0001389545nby:May2023WarrantsMemberus-gaap:RetainedEarningsMember2023-04-012023-06-30 0001389545nby:May2023WarrantsMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0001389545nby:May2023WarrantsMemberus-gaap:CommonStockMember2023-04-012023-06-30 0001389545nby:May2023WarrantsMemberus-gaap:PreferredStockMember2023-04-012023-06-30 0001389545us-gaap:SeriesCPreferredStockMember2023-04-012023-06-30 0001389545us-gaap:SeriesCPreferredStockMemberus-gaap:RetainedEarningsMember2023-04-012023-06-30 0001389545us-gaap:SeriesCPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0001389545us-gaap:SeriesCPreferredStockMemberus-gaap:CommonStockMember2023-04-012023-06-30 0001389545us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2023-04-012023-06-30 0001389545us-gaap:SeriesBPreferredStockMember2023-04-012023-06-30 0001389545us-gaap:SeriesBPreferredStockMemberus-gaap:RetainedEarningsMember2023-04-012023-06-30 0001389545us-gaap:SeriesBPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0001389545us-gaap:SeriesBPreferredStockMemberus-gaap:CommonStockMember2023-04-012023-06-30 0001389545us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2023-04-012023-06-30 0001389545us-gaap:RetainedEarningsMember2023-04-012023-06-30 0001389545us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0001389545us-gaap:CommonStockMember2023-04-012023-06-30 0001389545us-gaap:PreferredStockMember2023-04-012023-06-30 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMember2023-04-012023-06-30 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:RetainedEarningsMember2023-04-012023-06-30 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:CommonStockMember2023-04-012023-06-30 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:PreferredStockMember2023-04-012023-06-30 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMember2023-04-012023-06-30 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:RetainedEarningsMember2023-04-012023-06-30 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:CommonStockMember2023-04-012023-06-30 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:PreferredStockMember2023-04-012023-06-30 00013895452023-03-31 0001389545us-gaap:RetainedEarningsMember2023-03-31 0001389545us-gaap:AdditionalPaidInCapitalMember2023-03-31 0001389545us-gaap:CommonStockMember2023-03-31 0001389545us-gaap:PreferredStockMember2023-03-31 0001389545nby:EmployeesAndDirectorsMember2023-01-012023-03-31 0001389545us-gaap:RetainedEarningsMembernby:EmployeesAndDirectorsMember2023-01-012023-03-31 0001389545us-gaap:AdditionalPaidInCapitalMembernby:EmployeesAndDirectorsMember2023-01-012023-03-31 0001389545us-gaap:CommonStockMembernby:EmployeesAndDirectorsMember2023-01-012023-03-31 0001389545us-gaap:PreferredStockMembernby:EmployeesAndDirectorsMember2023-01-012023-03-31 00013895452023-01-012023-03-31 0001389545us-gaap:RetainedEarningsMember2023-01-012023-03-31 0001389545us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0001389545us-gaap:CommonStockMember2023-01-012023-03-31 0001389545us-gaap:PreferredStockMember2023-01-012023-03-31 0001389545us-gaap:RetainedEarningsMember2022-12-31 0001389545us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001389545us-gaap:CommonStockMember2022-12-31 0001389545us-gaap:PreferredStockMember2022-12-31 0001389545us-gaap:RetainedEarningsMember2024-06-30 0001389545us-gaap:AdditionalPaidInCapitalMember2024-06-30 0001389545us-gaap:CommonStockMember2024-06-30 0001389545us-gaap:PreferredStockMember2024-06-30 0001389545srt:DirectorMember2024-04-012024-06-30 0001389545us-gaap:RetainedEarningsMembersrt:DirectorMember2024-04-012024-06-30 0001389545us-gaap:AdditionalPaidInCapitalMembersrt:DirectorMember2024-04-012024-06-30 0001389545us-gaap:CommonStockMembersrt:DirectorMember2024-04-012024-06-30 0001389545us-gaap:PreferredStockMembersrt:DirectorMember2024-04-012024-06-30 0001389545nby:EmployeesAndDirectorsMember2024-04-012024-06-30 0001389545us-gaap:RetainedEarningsMembernby:EmployeesAndDirectorsMember2024-04-012024-06-30 0001389545us-gaap:AdditionalPaidInCapitalMembernby:EmployeesAndDirectorsMember2024-04-012024-06-30 0001389545us-gaap:CommonStockMembernby:EmployeesAndDirectorsMember2024-04-012024-06-30 0001389545us-gaap:PreferredStockMembernby:EmployeesAndDirectorsMember2024-04-012024-06-30 0001389545us-gaap:RetainedEarningsMember2024-04-012024-06-30 0001389545us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0001389545us-gaap:CommonStockMember2024-04-012024-06-30 0001389545us-gaap:PreferredStockMember2024-04-012024-06-30 0001389545nby:ReverseStockSplitMember2024-04-012024-06-30 0001389545nby:March2024WarrantMember2024-04-012024-06-30 0001389545nby:March2024WarrantMemberus-gaap:RetainedEarningsMember2024-04-012024-06-30 0001389545nby:March2024WarrantMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0001389545nby:March2024WarrantMemberus-gaap:CommonStockMember2024-04-012024-06-30 0001389545nby:March2024WarrantMemberus-gaap:PreferredStockMember2024-04-012024-06-30 0001389545nby:TheDecember2023WarrantsMember2024-04-012024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-gaap:RetainedEarningsMember2024-04-012024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-gaap:CommonStockMember2024-04-012024-06-30 0001389545nby:TheDecember2023WarrantsMemberus-gaap:PreferredStockMember2024-04-012024-06-30 0001389545nby:The2022WarrantRepriceTransactionMember2024-04-012024-06-30 0001389545nby:The2022WarrantRepriceTransactionMemberus-gaap:RetainedEarningsMember2024-04-012024-06-30 0001389545nby:The2022WarrantRepriceTransactionMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0001389545nby:The2022WarrantRepriceTransactionMemberus-gaap:CommonStockMember2024-04-012024-06-30 0001389545nby:The2022WarrantRepriceTransactionMemberus-gaap:PreferredStockMember2024-04-012024-06-30 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMember2024-04-012024-06-30 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:RetainedEarningsMember2024-04-012024-06-30 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:CommonStockMember2024-04-012024-06-30 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:PreferredStockMember2024-04-012024-06-30 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMember2024-04-012024-06-30 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:RetainedEarningsMember2024-04-012024-06-30 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:CommonStockMember2024-04-012024-06-30 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:PreferredStockMember2024-04-012024-06-30 00013895452024-03-31 0001389545us-gaap:RetainedEarningsMember2024-03-31 0001389545us-gaap:AdditionalPaidInCapitalMember2024-03-31 0001389545us-gaap:CommonStockMember2024-03-31 0001389545us-gaap:PreferredStockMember2024-03-31 0001389545nby:EmployeesAndDirectorsMember2024-01-012024-03-31 0001389545us-gaap:RetainedEarningsMembernby:EmployeesAndDirectorsMember2024-01-012024-03-31 0001389545us-gaap:AdditionalPaidInCapitalMembernby:EmployeesAndDirectorsMember2024-01-012024-03-31 0001389545us-gaap:CommonStockMembernby:EmployeesAndDirectorsMember2024-01-012024-03-31 0001389545us-gaap:PreferredStockMembernby:EmployeesAndDirectorsMember2024-01-012024-03-31 0001389545us-gaap:RetainedEarningsMember2024-01-012024-03-31 0001389545us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0001389545us-gaap:CommonStockMember2024-01-012024-03-31 0001389545us-gaap:PreferredStockMember2024-01-012024-03-31 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMember2024-01-012024-03-31 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:RetainedEarningsMember2024-01-012024-03-31 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:CommonStockMember2024-01-012024-03-31 0001389545nby:ConversionOfSeriesCPreferredStockToCommonStockMemberus-gaap:PreferredStockMember2024-01-012024-03-31 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMember2024-01-012024-03-31 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:RetainedEarningsMember2024-01-012024-03-31 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:CommonStockMember2024-01-012024-03-31 0001389545nby:ConversionOfSeriesBPreferredStockToCommonStockMemberus-gaap:PreferredStockMember2024-01-012024-03-31 0001389545us-gaap:RetainedEarningsMember2023-12-31 0001389545us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001389545us-gaap:CommonStockMember2023-12-31 0001389545us-gaap:PreferredStockMember2023-12-31 0001389545us-gaap:ProductAndServiceOtherMember2023-01-012023-06-30 0001389545us-gaap:ProductMember2023-01-012023-06-30 0001389545us-gaap:ProductMember2024-01-012024-06-30 0001389545us-gaap:ProductMember2023-04-012023-06-30 0001389545us-gaap:ProductMember2024-04-012024-06-30 0001389545us-gaap:SeriesCPreferredStockMember2023-12-31 0001389545us-gaap:SeriesCPreferredStockMember2024-06-30 0001389545us-gaap:SeriesBPreferredStockMember2023-12-31 0001389545us-gaap:SeriesBPreferredStockMember2024-06-30 00013895452024-08-09 Â Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.Â 20549 Â FORM 10-Q (Mark One) â˜ QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended June 30, 2024 Â OR Â â˜ TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period fromÂ toÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Â Operating lease right-of-use assets Â Â 1,128 Â Â Â 1,296 Â Property and equipment, net Â Â 68 Â Â Â 87 Â Other assets Â Â 476 Â Â Â 478 Â Other assets, discontinued operations Â Â â€” Â Â Â 19 Â TOTAL ASSETS Â $ 3,925 Â Â $ 9,034 Â Â Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERSâ€™ (DEFICIT) EQUITY Â Â Â Â Â Â Â Â Liabilities: Â Â Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Â Â Accounts payable Â $ 1,235 Â Â $ 906 Â Accrued liabilities Â Â 1,297 Â Â Â 1,169 Â Secured Convertible Notes, net of discounts Â Â 655 Â Â Â 1,137 Â Unsecured Convertible Notes, net of discounts Â Â 41 Â Â Â â€” Â Operating lease liabilities Â Â 382 Â Â Â 368 Â Current liabilities, discontinued operations Â Â â€” Â Â Â 698 Â Total current liabilities Â Â 3,610 Â Â Â 4,278 Â Warrant liabilities Â Â â€” Â Â Â 334 Â Operating lease liabilities-non-current Â Â 932 Â Â Â 1,108 Â Total liabilities Â Â 4,542 Â Â Â 5,720 Â Commitments and contingencies (Note 8) Â Â Â Â Â Â Stockholdersâ€™ (deficit) equity: Â Â Â Â Â Â Â Â Preferred stock, $0.01 par value; 5,000 shares authorized; Â Â Â Â Â Â Â Â Series B Preferred Stock; 1 and 6 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively Â Â 6 Â Â Â 275 Â Series C Preferred Stock; 0 and 1 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively Â Â â€” Â Â Â 1,675 Â Common stock, $0.01 par value; 150,000 shares authorized, 1,348 and 321 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively* Â Â 13 Â Â Â 3 Â Additional paid-in capital* Â Â 179,392 Â Â 176,210 Â Accumulated deficit Â Â (180,028) Â Â (174,849) Total stockholdersâ€™ (deficit) equity Â Â (617) Â Â 3,314 Â TOTAL LIABILITIES AND STOCKHOLDERSâ€™ (DEFICIT) EQUITY Â $ 3,925 Â Â $ 9,034 Â Â * After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â -3- Table of Contents Â NOVABAY PHARMACEUTICALS, INC. Â CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (in thousands, except per share data) Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â 2024 Â Â 2023 Â Sales: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product revenue, net Â $ 2,387 Â Â $ 3,523 Â Â $ 5,011 Â Â $ 5,855 Â Other revenue, net Â Â 13 Â Â Â 11 Â Â Â 20 Â Â Â 18 Â Total sales, net Â Â 2,400 Â Â Â 3,534 Â Â Â 5,031 Â Â Â 5,873 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cost of goods sold Â Â 808 Â Â Â 1,795 Â Â Â 1,645 Â Â Â 2,534 Â Gross profit Â Â 1,592 Â Â Â 1,739 Â Â Â 3,386 Â Â Â 3,339 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 9 Â Â Â 22 Â Â Â 28 Â Â Â 32 Â Sales and marketing Â Â 1,019 Â Â Â 1,175 Â Â Â 2,074 Â Â Â 2,411 Â General and administrative Â Â 1,617 Â Â Â 1,593 Â Â Â 3,908 Â Â Â 3,292 Â Loss on divestiture of subsidiary Â Â â€” Â Â Â â€” Â Â Â 865 Â Â Â â€” Â Total operating expenses Â Â 2,645 Â Â Â 2,790 Â Â Â 6,875 Â Â Â 5,735 Â Operating loss Â Â (1,053) Â Â (1,051) Â Â (3,489) Â Â (2,396) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Non-cash (loss) gain on changes in fair value of warrant liabilities Â Â (80) Â Â 216 Â Â Â 114 Â Â Â 216 Â Non-cash (loss) gain on change in fair value of embedded derivative liability Â Â (83) Â Â 40 Â Â Â (18) Â Â 40 Â Accretion of interest and amortization of discounts on convertible notes Â Â (300) Â Â (501) Â Â (733) Â Â (501) Other expense, net Â Â (69) Â Â (432) Â Â (549) Â Â (432) Net loss from continuing operations Â Â (1,585) Â Â (1,728) Â Â (4,675) Â Â (3,073) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss from discontinued operations (Note 18) Â Â â€” Â Â Â (308) Â Â (124) Â Â (702) Net loss Â Â (1,585) Â Â (2,036) Â Â (4,799) Â Â (3,775) Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price Â Â â€” Â Â Â (1,996) Â Â (380) Â Â (1,996) Net loss attributable to common stockholders Â $ (1,585) Â $ (4,032) Â $ (5,179) Â $ (5,771) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted net loss per share Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss per share from continuing operations* Â $ (1.37) Â $ (41.04) Â $ (5.44) Â $ (68.00) Net loss per share from discontinued operations* Â Â â€” Â Â Â (3.39) Â Â (0.13) Â Â (9.42) Net loss per share attributable to common stockholders (basic and diluted)* Â $ (1.37) Â $ (44.43) Â $ (5.57) Â $ (77.42) Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted)* Â Â 1,155 Â Â Â 91 Â Â Â 930 Â Â Â 75 Â Â * After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â -4- Table of Contents Â Â NOVABAY PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™Â (DEFICIT) EQUITY (Unaudited) (in thousands) Â Â Â Preferred Stock Â Â Common Stock Â Â Additional Paid- in Â Â Accumulated Â Â Total Stockholdersâ€™ (Deficit) Â Â Â Shares Â Â Amount Â Â Shares* Â Â Amount* Â Â Capital* Â Â Deficit Â Â Equity Â Balance at December 31, 2023 Â Â 7 Â Â $ 1,950 Â Â Â 321 Â Â $ 3 Â Â $ 176,210 Â Â $ (174,849) Â $ 3,314 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â (3,214) Â Â (3,214) Conversion of Series B Preferred Stock to common stock Â Â (5) Â Â (231) Â Â 537 Â Â Â 5 Â Â Â 226 Â Â Â - Â Â Â - Â Conversion of Series C Preferred Stock to common stock Â Â (0) Â Â (234) Â Â 57 Â Â Â 1 Â Â Â 233 Â Â Â - Â Â Â - Â Adjustment of Series C Preferred Stock conversion price Â Â - Â Â Â - Â Â Â - Â Â Â 380 Â Â Â (380) Â Â Â - Â Stock-based compensation expense related to employee and director stock awards Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 60 Â Â Â - Â Â Â 60 Â Balance at March 31, 2024 Â Â 2 Â Â $ 1,485 Â Â Â 915 Â Â $ 9 Â Â $ 177,109 Â Â $ (178,443) Â $ 160 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â (1,585) Â Â (1,585) Conversion of Series B Preferred Stock to common stock Â Â (0) Â Â (37) Â Â 88 Â Â Â 1 Â Â Â 36 Â Â Â - Â Â Â - Â Conversion of Series C Preferred Stock to common stock Â Â (1) Â Â (1,442) Â Â 148 Â Â Â 1 Â Â Â 1,441 Â Â Â - Â Â Â - Â Modification of common stock warrants in connection with 2024 Warrant Reprice Transaction Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 69 Â Â Â - Â Â Â 69 Â Issuance of common stock in connection with 2024 Warrant Reprice Transaction, net of offering costs Â Â - Â Â Â - Â Â Â 90 Â Â Â 1 Â Â Â 129 Â Â Â - Â Â Â 130 Â Reclassification of December 2023 Warrants from liability Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 212 Â Â Â - Â Â Â 212 Â Reclassification of March 2024 Warrants from liability Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 100 Â Â Â - Â Â Â 100 Â Reclassification of embedded derivative liability Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 242 Â Â Â - Â Â Â 242 Â Shares issued for 35:1 reverse stock split due to rounding feature Â Â - Â Â Â - Â Â Â 107 Â Â Â 1 Â Â Â (1) Â Â - Â Â Â - Â Stock-based compensation expense related to employee and director stock awards Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 55 Â Â Â - Â Â Â 55 Â Vesting of director restricted stock awards Â Â - Â Â Â - Â Â Â 0 Â Â Â 0 Â Â Â 0 Â Â Â - Â Â Â 0 Â Balance at June 30, 2024 Â Â 1 Â Â $ 6 Â Â Â 1,348 Â Â $ 13 Â Â $ 179,392 Â Â $ (180,028) Â $ (617) Â Â Â Preferred Stock Â Â Common Stock Â Â Additional Paid- in Â Â Accumulated Â Â Total Stockholdersâ€™ (Deficit) Â Â Â Shares Â Â Amount Â Â Shares* Â Â Amount* Â Â Capital* Â Â Deficit Â Â Equity Â Balance at December 31, 2022 Â Â 14 Â Â $ 2,973 Â Â Â 58 Â Â $ 0 Â Â $ 165,732 Â Â $ (158,152) Â $ 10,554 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â (1,739) Â Â (1,739) Stock-based compensation expense related to employee and director stock awards Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 75 Â Â Â - Â Â Â 75 Â Balance at March 31, 2023 Â Â 14 Â Â $ 2,973 Â Â Â 58 Â Â $ 1 Â Â $ 165,807 Â Â $ (159,891) Â $ 8,890 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â (2,036) Â Â (2,036) Conversion of Series B Preferred Stock to common stock Â Â (3) Â Â (121) Â Â 54 Â Â Â 1 Â Â Â 121 Â Â Â - Â Â Â - Â Conversion of Series C Preferred Stock to common stock Â Â (1) Â Â (728) Â Â 8 Â Â Â 0 Â Â Â 728 Â Â Â - Â Â Â - Â Modification of common stock warrants Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 285 Â Â Â - Â Â Â 285 Â Adjustment of Series B Preferred Stock conversion price Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 1,802 Â Â Â (1,802) Â Â Â - Â Adjustment of Series C Preferred Stock conversion price Â Â - Â Â Â - Â Â Â - Â Â Â 194 Â Â Â (194) Â Â Â - Â Reclassification of May 2023 Warrants Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 1,360 Â Â Â - Â Â Â 1,360 Â Stock-based compensation expense related to employee and director stock awards Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 64 Â Â Â - Â Â Â 64 Â Vesting of director restricted stock awards Â Â - Â Â Â - Â Â Â 0 Â Â Â 0 Â Â Â 0 Â Â Â - Â Â Â 0 Â Balance at June 30, 2023 Â Â 10 Â Â $ 2,124 Â Â Â 120 Â Â $ 1 Â Â $ 170,361 Â Â $ (163,923) Â $ 8,563 Â Â * After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â -5- Table of Contents Â NOVABAY PHARMACEUTICALS, INC. Â CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)Â (In thousands) Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Operating activities: Â Â Â Â Â Â Â Â Net loss Â $ (4,799) Â $ (3,775) Net loss from discontinued operations Â Â 124 Â Â Â 702 Â Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Â Depreciation of property and equipment Â Â 23 Â Â Â 26 Â Stock-based compensation expense related to employee and director stock awards Â Â 115 Â Â Â 139 Â Non-cash loss on divestiture of subsidiary Â Â 865 Â Â Â â€” Â Non-cash expense incurred to obtain consent of Secured Convertible Note holders Â Â 368 Â Â Â Â â€” Â Modification of common stock warrants, included in Other expense, net Â Â 69 Â Â Â 285 Â Non-cash gain on changes in fair value of warrant liabilities Â Â (114) Â Â (216) Non-cash loss (gain) on changes in fair value of embedded derivative liability Â Â 18 Â Â Â (40) Non-cash right-of-use amortization Â Â 168 Â Â Â 140 Â Accretion of interest and amortization of debt discounts on convertible notes Â Â 726 Â Â Â 457 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Â Accounts receivable Â Â 133 Â Â Â (481) Inventory Â Â (144) Â Â (81) Prepaid expenses and other current assets Â Â 1 Â Â Â (83) Other assets Â Â 2 Â Â Â (5) Accounts payable and accrued liabilities Â Â 457 Â Â Â 166 Â Operating lease liabilities Â Â (162) Â Â (127) Net cash used in operating activities, continuing operations Â Â (2,150) Â Â (2,893) Â Â Â Â Â Â Â Â Â Â Investing activities: Â Â Â Â Â Â Â Â Proceeds from divestiture of subsidiary Â Â 1,070 Â Â Â â€” Â Purchases of property and equipment Â Â (4) Â Â (15) Net cash provided by (used in) investing activities, continuing operations Â Â 1,066 Â Â Â (15) Â Â Â Â Â Â Â Â Â Â Financing activities: Â Â Â Â Â Â Â Â Proceeds from Warrant Exercise Â Â 226 Â Â Â â€” Â Proceeds from issuance of Secured Convertible Notes and May 2023 Warrants, net of discounts Â Â â€” Â Â Â 3,000 Â Payments on Secured Convertible Notes Â Â (1,200) Â Â (193) Debt issuance cost Â Â (115) Â Â (294) Net cash (used in) provided by financing activities, continuing operations Â Â (1,089) Â Â 2,513 Â Â Â Â Â Â Â Â Â Â Net decrease in cash, cash equivalents, and restricted cash, continuing operations Â Â (2,173) Â Â (395) Net decrease in cash and cash equivalents, discontinued operations Â Â (206) Â Â (561) Net decrease in cash, cash equivalents, and restricted cash, consolidated Â Â (2,379) Â Â (956) Cash, cash equivalents and restricted cash, beginning of year, consolidated Â Â 3,606 Â Â Â 5,846 Â Less: Cash and cash equivalents of discontinued operations, end of period Â Â â€” Â Â Â (16) Cash, cash equivalents and restricted cash of continuing operations, end of period Â $ 1,227 Â Â $ 4,874 Â Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Supplemental disclosure of cash flow information: Â Â Â Â Â Â Â Â Interest paid in continuing operations Â $ 130 Â Â $ 47 Â Interest paid in discontinued operations Â Â â€” Â Â Â 9 Â Â Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Supplemental disclosure of non-cash information: Â Â Â Â Â Â Â Â Conversions of preferred to common stock Â $ 1,944 Â Â $ 849 Â Down round feature adjustments related to Preferred Stock Â Â 380 Â Â Â 1,996 Â Issuance of embedded derivative liability in conjunction with Unsecured Convertible Notes Â Â 224 Â Â Â â€” Â Warrant liabilities transferred to equity Â Â 312 Â Â Â 1,360 Â Derivative liability transferred to equity Â Â 242 Â Â Â â€” Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â -6- Table of Contents Â Â NOTE 1. ORGANIZATION Â NovaBay Pharmaceuticals, Inc. (â€œour,â€ â€œwe,â€ â€œusâ€ or the â€œCompanyâ€) develops and sells scientifically-created and clinically-proven eyecare, and wound care products. Our leading product, AvenovaÂ® Antimicrobial Lid and Lash Solution, or Avenova Spray, is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with our proprietary, stable and pure form of hypochlorous acid and is cleared by the Food and Drug Administration (the â€œFDAâ€) for sale in the United States. Avenova Spray is available direct to consumers primarily through online distribution channels and is also available by prescription and dispensed by eyecare professionals for blepharitis and dry eye disease. Because dry eye is a complex condition, we offer a complementary portfolio of scientifically-developed products for each step of the standard at-home treatment regimen, including the Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. Â We also manufacture and sell our proprietary form of hypochlorous acid for the wound care market through our NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries. The Company currently sells these products through distributors. Â Through our former subsidiary DERMAdoctor, LLC (â€œDERMAdoctorâ€), the Company offered over 30 dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration and keratosis pilaris. On March 25, 2024, we announced that we had sold DERMAdoctor (the â€œDERMAdoctor Divestitureâ€). Â The Company operated in principally two reportable segments: (1) Eyecare and Wound Care and (2) Skincare. As noted above, on March 25, 2024, we closed the DERMAdoctor Divestiture resulting in the sale of our skincare segment. Â The Company was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc. It had no operations until July 1, 2002, on which date it acquired all of the operating assets of NovaCal Pharmaceuticals, LLC, a California limited liability company. In February 2007, the Company changed its name from NovaCal Pharmaceuticals, Inc. to NovaBay Pharmaceuticals, Inc. In June 2010, the Company changed the state in which it was incorporated (the â€œReincorporationâ€) and is now incorporated under the laws of the State of Delaware. All references to â€œthe Companyâ€ herein refer to the California corporation prior to the date of the Reincorporation and to the Delaware corporation on and after the date of the Reincorporation. Â Effective May 30, 2024, the Company effected a 1-for-35 reverse split of our outstanding common stock (â€œReverse Stock Splitâ€) (See Note 12, â€œStockholdersâ€™ (Deficit) Equityâ€ for further details).Â Except as otherwise specifically noted, all share numbers, share prices, exercise/conversion prices and per share amounts have been adjusted, on a retroactive basis, to reflect this 1-for-35 reverse stock split. Â Discontinued Operations Â On March 25, 2024, the Company completed the DERMAdoctor Divestiture for an aggregate sale price of $1.1Â million. The Company recognized a loss on the DERMAdoctor Divestiture amounting to $0.9Â million in the period ended March 31, 2024, which is recorded in loss on divestiture of subsidiary in the unaudited condensed consolidated statements of operations. Â In connection with the DERMAdoctor Divestiture, the Company has entered into Transition Services Agreement with New Age Investments, LLC to provide for a customary and orderly transition of the business, including warehousing services provided by New Age Investments, LLC and fulfillment services provided by the Company, which shall be included in continuing operations in subsequent periods. Â Going Concern Â The Company has sustained operating losses for the majority of its corporate history and expects that its 2024 expenses will exceed its 2024 revenues, as the Company continues to invest in its commercialization efforts. Additionally, the Company expects to continue incurring operating losses and negative cash flows until revenues reach a level sufficient to support ongoing growth and operations. Accordingly, the Company has determined that its planned operations raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. Additionally, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control that impact the broader economy such as periods of inflation, supply chain issues, global pandemics and international conflicts (e.g., the conflicts between Israel and Hamas, Russia and Ukraine, and China and Taiwan). Â The Companyâ€™s long-term liquidity needs will be largely determined by the success of our commercialization efforts. To address the Companyâ€™s current liquidity and capital needs, the Company has and continues to evaluate different plans and strategic transactions to fund operations, including: (1) raising additional capital through debt and equity financings or from other sources; (2) reducing spending on operations, including reducing spending on one or more of its sales and marketing programs or restructuring operations to change its overhead structure; (3) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones or an upfront fee; (4) entering into license agreements to sell new products; and/or (5) the divestiture of certain business or product lines and related assets. The Company may issue securities, including common stock, preferred stock, convertible debt securities and warrants through additional private placement transactions or registered public offerings, which may require the filing of a Form S-1 or Form S-3 registration statement with the Securities and Exchange Commission (â€œSECâ€). While the Company believes that the proceeds from the 2024 Public Offering (as defined in Note 19, â€œSubsequent Eventsâ€), 2024 Warrant Reprice Transaction (as defined in Note 9, â€œFinancing Activitiesâ€), and the DERMAdoctor Divestiture improved the Companyâ€™s liquidity in the near term, there is no assurance that the Company will be successful in executing additional capital raising strategies at levels necessary to address the Companyâ€™s ongoing and future cash flow and liquidity needs. Accordingly, the Company continues to evaluate different plans and strategies to address the Companyâ€™s capital and liquidity needs, as well as evaluating potential other strategic alternatives and transactions. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Companyâ€™s ability to continue as a going concern.Â Â -7- Table of Contents Â Â Â NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESÂ Â Basis of Presentation Â The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€) and are expressed in U.S. dollars. In managementâ€™s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Companyâ€™s financial

position and operating results. Â Principles of Consolidation Â The accompanying condensed consolidated financial statements include the accounts of NovaBay Pharmaceuticals, Inc. and its former wholly-owned subsidiary, DERMAdoctor, LLC, as of and for the six months ended June 30, 2024. All significant intercompany balances and transactions have been eliminated in consolidation. As of March 25, 2024, the Company divested its wholly-owned subsidiary pursuant to the DERMAdoctor Divestiture. The financial results for DERMAdoctor have been presented as discontinued operations in the accompanying condensed consolidated financial statements. For the six months ended June 30, 2024, all gains and losses on disposition, along with the sales, costs and expenses attributable to discontinued operations, have been aggregated in the captions entitled â€œLoss on divestiture of subsidiaryâ€ and â€œNet loss from discontinued operationsâ€ in our unaudited condensed consolidated statements of operations. Â Financial Statement Reclassification Â Certain account balances from prior periods have been reclassified in these unaudited condensed consolidated financial statements to conform to current period classifications. The prior year amounts have been modified in these unaudited condensed consolidated financial statements to properly report amounts under current operations and discontinued operations (see Note 18, â€œDivestiture and Discontinued Operationsâ€). Â Further, certain prior period operating lease balances on the Condensed Consolidated Statements of Cash Flows originally reported within changes in â€œOperating lease right-of-use assetsâ€ are now within â€œNon-cash right-of-use amortizationâ€ to conform to the current year presentation. Â Use of Estimates Â The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, contract liabilities related to product sales such as product returns, assumptions for valuing warrants, assumptions for valuing derivative liabilities, the fair value of contingent consideration, intangible assets, goodwill, stock-based compensation, income taxes and other contingencies. Â These estimates are based on managementâ€™s best estimates and judgment. Actual results may differ from these estimates. Estimates, judgments, and assumptions are continuously evaluated and are based on managementâ€™s experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these assumptions, judgments and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. Â Unaudited Condensed Consolidated Interim Financial Information Â The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation. Â The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The unaudited condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. Â The condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2023, included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 26, 2024 and amended on March 29, 2024 (collectively, the â€œ2023 Annual Reportâ€). Â -8- Table of Contents Â Cash, Cash Equivalents, and Restricted Cash Â The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of June 30, 2024 and December 31, 2023, the Companyâ€™s cash and cash equivalents were held in a major financial institution in the United States. Â The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands): Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 751 Â Â $ 3,130 Â Cash and cash equivalents, discontinued operations Â Â â€” Â Â Â (206) Restricted cash included in other assets Â Â 476 Â Â Â 476 Â Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows Â $ 1,227 Â Â $ 3,400 Â Â The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Â Concentrations of Credit Risk and Major Partners Â Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States. Â The Company has a significant amount of its cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Companyâ€™s financial condition, results of operations, and cash flows. Â During the three and six months ended June 30, 2024 and 2023, revenues from significant product categories were as follows (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Avenova Spray Â $ 2,125 Â Â $ 1,758 Â Â $ 4,221 Â Â $ 3,695 Â NeutroPhase Â Â â€” Â Â Â 1,043 Â Â Â â€” Â Â Â 1,043 Â Other products Â Â 262 Â Â Â 722 Â Â Â 790 Â Â Â 1,117 Â Total product revenue, net Â Â 2,387 Â Â Â 3,523 Â Â Â 5,011 Â Â Â 5,855 Â Other revenue, net Â Â 13 Â Â Â 11 Â Â Â 20 Â Â Â 18 Â Total sales, net Â $ 2,400 Â Â $ 3,534 Â Â $ 5,031 Â Â $ 5,873 Â Â During the three and six months ended June 30, 2024 and 2023, revenues were derived primarily from sales of Avenova branded products, directly to consumers through Amazon.com and Avenova.com. Sales of Avenova Spray via Amazon comprised 74% and 61% of total Avenova Spray net revenue during the three months ended June 30, 2024 and 2023, respectively. Sales of Avenova Spray via Amazon comprised 74% and 68% of total Avenova Spray net revenue during the six months ended June 30, 2024 and 2023, respectively. Â As of June 30, 2024 and December 31, 2023, accounts receivable from continuing operations from our major distribution partners and major retailers greater than 10% were as follows: Â Â Â June 30, Â Â December 31, Â Major distribution partner Â 2024 Â Â 2023 Â Major U.S. Retailer A Â Â 35 % Â Â 22 % Avenova Spray Pharmacy Distributor A Â Â 33 % Â Â 14 % Avenova Spray Pharmacy Distributor B Â Â 12 % Â Â * % Chongqing Pioneer Pharma Holdings Limited Â Â * % Â Â 36 % Â * Less than 10% Â -9- Table of Contents Â The Company relies on one contract manufacturer to produce its products. The Company does not have any manufacturing facilities and intends to continue to rely on third parties for the supply of finished goods. Our contract manufacturer may or may not be able to meet the Companyâ€™s needs with respect to timing, quantity or quality. In particular, it is possible that the Company may suffer from unexpected delays in light of the global supply chain issues. Â Fair Value of Financial Assets and Liabilities Â The Companyâ€™s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Companyâ€™s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Â The Company follows Accounting Standards Codification (â€œASCâ€) 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Under this standard, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The standard also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companyâ€™s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. There are three levels of inputs that may be used to measure fair value: Â Level 1 â€“ quoted prices in active markets for identical assets or liabilities; Level 2 â€“ quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 â€“ inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). Â Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Â See additional information in Note 3, â€œFair Value Measurementsâ€. Â Allowance for Credit Losses Â The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Companyâ€™s future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. The allowance is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. Management recorded a reserve for allowance for credit losses of $3 thousand as of June 30, 2024 and December 31, 2023. Â Inventory Â Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes and pumps; (2) goods in progress, which are normally filled but unlabeled bottles; and (3) finished goods. The Company utilizes a contract manufacturer to produce our products and the price paid to these manufacturers is included in inventory. Inventory is stated at the lower of cost or estimated net realizable value determined by the first-in, first-out method. At June 30, 2024 and December 31, 2023, management had recorded an allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $204 thousand and $264 thousand, respectively. Â Property and Equipment, net Â Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five to seven years for office and laboratory equipment, three to five years for computer equipment and software, and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. Â The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.Â Â -10- Table of Contents Â Business Combinations, Goodwill and Indefinite-Lived Intangible Assets Â We account for business combinations using the acquisition method of accounting, in accordance with ASC 805, Business Combinations. The acquisition method requires that identifiable assets acquired and liabilities assumed are recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. Intangible assets are measured at their respective fair values as of the acquisition date. Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Â Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Â Goodwill is evaluated for impairment by first performing a qualitative assessment to determine whether a quantitative goodwill test is necessary. If it is determined, based on qualitative factors, that the fair value of the reporting unit may more likely than not be less than carrying amount, or if significant adverse changes in the Companyâ€™s future financial performance occur that could materially impact fair value, a quantitative goodwill impairment test would be required. Additionally, management can elect to forgo the qualitative assessment and perform the quantitative test. If the qualitative assessment indicates that the quantitative analysis should be performed, or if management elects to bypass a qualitative assessment, the Company then evaluates goodwill for impairment by comparing the fair value of the reporting unit to its carrying amount, including goodwill. The quantitative assessment for goodwill requires management to estimate the fair value of the Companyâ€™s reporting units using either an income or market approach or a combination thereof. Â Management makes critical assumptions and estimates in completing impairment assessments of goodwill and indefinite-lived intangible assets. The Companyâ€™s cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates. Â The Company did not record any goodwill or indefinite-lived asset impairment charges during the three or six months ended June 30, 2024 or June 30, 2023. Â Valuation of Contingent Consideration Resulting from a Business Combination Â In connection with the DERMAdoctor acquisition, the Company was subject to paying consideration that was contingent upon the achievement of specified milestone events. The Company recorded this contingent consideration at its fair value on the acquisition date. Each quarter thereafter, the Company revalued the contingent consideration and recorded changes in fair value within the condensed consolidated statements of operations. The DERMAdoctor acquisition milestone events consisted of financial targets for calendar years 2022 and 2023 which were not met. As a result, the liability recorded for potential earn out payments in the Companyâ€™s condensed consolidated balance sheets was zero as of June 30, 2024 and December 31, 2023. Â Long-Lived AssetsÂ Â The Companyâ€™s intangible assets that do not have indefinite lives, primarily trade secrets and product formulations, are amortized over their estimated useful lives. All of the Companyâ€™s intangible assets subject to amortization and other long-lived assets, are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use are present. The Company reviews long-lived assets for impairment at least annually or whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the condensed consolidated statements of operations. Â The Company did not record any long-lived asset impairments during theÂ three or six months ended June 30, 2024 or June 30, 2023. Â Leases Â At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received. Â -11- Table of Contents Â The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not applied. Leases include variable components (e.g., common area maintenance) that are paid separately from the monthly base payment based on actual costs incurred and therefore were not included in the right-of-use assets and lease liability but are reflected as an expense in the period incurred. Â The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the condensed consolidated balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. Â Common Stock Warrants Â The Company accounts for the issuance of common stock purchase warrants issued in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity and ASC 815, Derivatives and Hedging. Â The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, the Company also classifies as liabilities any warrants during the period which the shares underlying the contract are subject to stockholder approval before the warrant can be exercised. Â For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black Scholes option pricing model. These values are subject to a significant degree of managementâ€™s judgment. See Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€ and Note 11, â€œCommon Stock Warrantsâ€, subheading â€œSummary of Common Stock Warrant Liabilitiesâ€. Â Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black Scholes option pricing model. See Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Â Preferred Stock Â Terms of the Companyâ€™s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (as defined and described in Note 12, â€œStockholdersâ€™ (Deficit) Equityâ€). The applicable Ratchet provisions of the Companyâ€™s outstanding Preferred Stock terminated during the quarter ended March 31, 2024. When a conversion price was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend was measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the anti-dilution protection feature). These fair values were determined using the Black Scholes option pricing model. These values are subject to a significant degree of managementâ€™s judgment. See also Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Â -12- Table of Contents Â Revenue Recognition Â The Companyâ€™s product revenue recognition policies are established in accordance with ASC 606, Revenue from Contracts with Customers, in accordance with the following five steps: Â Â i. identify the contract(s) with a customer; Â ii. identify the performance

obligations in the contract; Â iii. determine the transaction price; Â iv. allocate the transaction price to the performance obligations in the contract; and Â v. recognize revenue when (or as) the entity satisfies performance obligations. Â Revenue is recognized in accordance with the amount of consideration which the Company expects to receive. Â Revenue generated from end consumers through third-party online retailers, such as Amazon, as well as the Companyâ€™s web store (Avenova.com) is recognized on a â€œsell-throughâ€ basis when control of the goods is transferred to the consumer, which generally occurs upon delivery of the products to the party fulfilling the consumerâ€™s order. Revenue is recorded net of any discounts and estimates for refunds and product returns. Fees paid to third-party online retailers and fulfillment parties are recorded as incurred in the Companyâ€™s condensed consolidated statements of operations. Fulfillment and shipping and handling fees are recorded as product cost of goods sold. Selling commissions and advertising and promotion fees are recorded as sales and marketing expenses. Â Revenue generated through major pharmacy distributors is recognized on a â€œsell-inâ€ basis when control of the goods is transferred to the distributor, which generally occurs upon delivery of the products to the distributor. Revenue is recorded net of consideration for contract liabilities for distributor services, discounts, rebates, and product returns. The Company estimates returns and other contract liabilities based on historical data which is updated quarterly. Payment for products sold is typically due 60 days after delivery to the distributor. Â Revenue generated from end consumers through the Companyâ€™s partner pharmacies is recognized on a â€œsell-throughâ€ basis when control of the goods is transferred to the consumer. Â Revenue generated from other retailers is recognized on a â€œsell-throughâ€ basis, net of estimated future product returns, when control of the goods is transferred to the retailer, which generally occurs upon delivery of the products to a third-party carrier who is delivering the products to the retailer. Â The Company defers recognition for pre-payments until the Companyâ€™s performance obligations are satisfied. Â -13- Table of Contents Â Cost of Goods Sold Â Cost of goods sold includes third-party manufacturing costs, shipping and handling costs, third-party fulfillment fees, and other costs associated with products sold. Cost of goods sold also includes any necessary allowances for excess and obsolete inventory as well as lower of cost and estimated net realizable value. Â Research and Development Costs Â The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities. Â Patent Costs Â Patent costs are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations. Â Advertising Costs Â Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising expenses were $0.2 million for both of the three months ended June 30, 2024 and 2023. Advertising expenses were $0.4 million and $0.5 million for the six months ended June 30, 2024 and 2023, respectively. Â Stock-Based Compensation Â The Companyâ€™s stock-based compensation includes grants of stock options and restricted stock units (â€œRSUsâ€) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Companyâ€™s condensed consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black Scholes option pricing model. The Company accounts for RSUs issued to employees and non-employees (directors, consultants and advisory board members) based on the fair market value of the Companyâ€™s common stock on the date of issuance. See Note 13, â€œEquity-Based Compensationâ€ for further information regarding stock-based compensation expense and the assumptions used in estimating the expense. Â -14- Table of Contents Â Income Taxes Â The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized. Â Net Loss per Share Â The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (â€œEPSâ€) as shown in the Companyâ€™s condensed consolidated statements of operations. Â Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive. Â For the three and six months ended June 30, 2024 and 2023, the Series B Preferred Stock and Series C Preferred Stock were excluded from the computation of diluted net loss per share as their inclusion on an â€œif convertedâ€ basis would have been anti-dilutive. The Series B Preferred Stock and Series C Preferred Stock were considered anti-dilutive because such securities did not have a contractual obligation to participate in losses of the Company. Â The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: Â Â Â Balance at June 30, Â Â Â 2024* Â Â 2023* Â Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the â€œSeries B Preferred Stockâ€) Â Â 15,065 Â Â Â 201,432 Â Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the â€œSeries C Preferred Stockâ€) Â Â â€” Â Â Â 24,134 Â Stock options Â Â 6,904 Â Â Â 4,301 Â Stock warrants Â Â 224,777 Â Â Â 210,929 Â Â Â Â 246,746 Â Â Â 440,796 Â Â * After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. Â -15- Table of Contents Â Recent Accounting Pronouncements Â For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, â€œSummary of Significant Accounting Policiesâ€ included in our 2023 Annual Report. The Company continues to evaluate the potential impact of adopting the new accounting guidance on its consolidated financial position, results of operations and cash flows. Â Â Â NOTE 3. FAIR VALUE MEASUREMENTS Â The following table presents the Companyâ€™s financial instruments measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 (in thousands): Â Â Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Â Â Â Â Â Quoted Â Â Â Â Â Â Â Â Â Â Â Â Â Â Prices in Â Â Â Â Â Â Â Â Â Â Â Â Â Â Active Â Â Â Â Â Â Â Â Â Â Â Â Â Â Markets Â Â Significant Â Â Â Â Â Â Â Â Â Â for Â Â Other Â Â Significant Â Â Â Â Balance at Â Â Identical Â Â Observable Â Â Unobservable Â Â Â June Â Â Items Â Â Inputs Â Â Inputs Â Â Â 30, 2024 Â Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Â Restricted cash held as a certificate of deposit Â $ 476 Â Â $ 476 Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Â Â Â Â Â Quoted Â Â Â Â Â Â Â Â Â Â Â Â Â Â Prices in Â Â Â Â Â Â Â Â Â Â Â Â Â Â Active Â Â Â Â Â Â Â Â Â Â Â Â Â Â Markets Â Â Significant Â Â Â Â Â Â Â Â Â Â for Â Â Other Â Â Significant Â Â Â Balance at Â Â Identical Â Â Observable Â Â Unobservable Â Â Â December Â Â Items Â Â Inputs Â Â Inputs Â Â Â 31, 2023 Â Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Â Restricted cash held as a certificate of deposit Â $ 476 Â Â $ 476 Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant liabilities Â $ 334 Â Â $ â€” Â Â $ 334 Â Â $ â€” Â Â The Companyâ€™s restricted cash held as certificates of deposit are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Â The Secured Convertible Notes (see Note 10, â€œConvertible Notesâ€) are carried at proceeds, net of discounts, which management believes approximates fair value. As a result of certain call and put options within the Secured Convertible Notes, the Company recorded an embedded derivative liability on its condensed consolidated balance sheet with a corresponding debt discount which is netted against the face value of the Secured Convertible Notes. The fair value of the May 2023 Warrants issued in conjunction with the 2023 Private Placement as well as the accounting for the warrant amendment and preferred stock conversion price adjustments that resulted from the 2023 Private Placement used the same stock price and were classified within Level 3. Â -16- Table of Contents Â The Unsecured Convertible Notes (see Note 10, â€œConvertible Notesâ€) are carried at proceeds, net of discounts, which management believes approximates fair value. As a result of certain call and put options within the Unsecured Convertible Notes, the Company recorded an embedded derivative liability on its unaudited condensed consolidated balance sheet with a corresponding debt discount which is netted against the face value of the Unsecured Convertible Notes. Â The fair value of the December 2023 Warrants issued in conjunction with the 2023 Warrant Reprice Transaction as well as the accounting for the warrant amendment and preferred stock conversion price adjustments that resulted from the 2023 Warrant Reprice Transaction were classified within Level 2. Â See Note 11, â€œCommon Stock Warrantsâ€, subheading â€œSummary of Common Stock Warrant Liabilitiesâ€, for a reconciliation of the beginning and ending balances for the warrant liabilities measured at fair value on a recurring basis using significant other observable inputs (Level 2) during the three and six months ended June 30, 2024 and 2023. Â There were no transfers in or out of Level 1, Level 2 or Level 3 assets and liabilities for the three and six months ended June 30, 2024 and 2023. Â Black Scholes Valuation Models and Assumptions Â The Company utilizes a Black Scholes model for various valuations as outlined throughout this report. The following tables summarize the assumptions utilized for valuations impacting results for the periods reported. See also Note 13, â€œEquity-Based Compensationâ€ for related Black Scholes valuation assumptions. Â Warrant Liabilities Â Various of the Companyâ€™s warrants have been, or are, subject to stockholder approval upon issuance or amendment and prior to exercise. Warrants requiring stockholder approval are recorded as a liability at fair value upon issuance or amendment and continue to be recorded as a liability at fair value at each reporting date until stockholder approval occurs at which time they are transferred to stockholdersâ€™ equity at their fair value on the date of approval. Fair value was determined using a Black Scholes model as outlined below. See Note 11, â€œCommon Stock Warrantsâ€ for additional information and the definitions of the Companyâ€™s warrants. Â Â Â May 2023 Warrants Â Â May 2023 Warrants Â Â December 2023 Warrants Â Â December 2023 Warrants Â Measurement event Â Issuance Â Â Â Stockholder Approval Â Â Â Reporting Date Â Â Stockholder Approval Â Date Â May 1, 2023 Â Â Â June 9, 2023 Â Â Â December 31, 2023 Â Â May 28, 2024 Â Total Value Â $1.6 million Â Â Â $1.4 million Â Â Â $0.3 million Â Â $0.2 million Â Gain (Loss) Â not applicable Â Â Â $0.2 million Â Â Â $56 thousand Â Â $(51 thousand) Â Assumptions: Â Exercise price Â $ 45.50 Â Â $ 45.50 Â Â $ 8.75 Â Â $ 8.75 Â Market price Â $ 25.20 (a) Â $ 23.80 Â Â $ 7.14 Â Â $ 4.94 Â Volatility Â Â 80.1 % Â Â 77.6 % Â Â 79.3 % Â Â 83.9 % Risk-free rate Â Â 3.60 - 4.04 % Â Â 3.92 - 4.59 % Â Â 3.85 % Â Â 4.56 % Dividend yield Â Â 0.0 % Â Â 0 % Â Â 0 % Â Â 0 % Term (years) Â Â 2.1 - 5.1 % Â Â 2.0 - 5.0 Â Â Â 5.5 Â Â Â 5.1 Â Â -17- Table of Contents Â Â Â March Â Â March Â Â Â 2024 Â Â 2024 Â Â Â Warrant Â Â Warrant Â Measurement event Â Reporting Date Â Â Stockholder Approval Â Date Â March 31, 2024 Â Â May 28, 2024 Â Total Value Â $0.1 million Â Â Â $0.1 million Â Gain (Loss) Â $21 thousand Â Â $(28 thousand) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 4.90 Â Â $ 4.90 Â Market price Â $ 3.66 Â Â $ 4.94 Â Volatility Â Â 86.9 % Â Â 83.9 % Risk-free rate Â Â 4.21 % Â Â 4.56 % Dividend yield Â Â 0 % Â Â 0 % Term (years) Â Â 5.5 Â Â Â 5.3 Â Â Â (a) Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. Â Warrant Modifications Â Amendments to warrant terms are recorded as a non-cash gain (or loss) on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black Scholes option pricing model. Fair value was determined using a Black Scholes model as outlined below. Â Â Â July 2020, November 2021, September 2022 & November 2022 Warrants Â Measurement event Â Prior to amendment Â Â After amendment Â Date Â April 27, 2023 Â Â April 27, 2023 Â Total Value Â $0.3 million Â Â $0.5 million Â Loss Â not applicable Â Â $0.2 million Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 220.50 Â Â $ 52.50 Â Market price Â $ 25.20 (a) Â $ 25.20 (a) Volatility Â Â 80.1 % Â Â 80.1 % Risk-free rate Â Â 3.59 - 4.73 % Â Â 3.59 - 4.73 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 1.1 - 5.6 Â Â Â 1.1 - 5.6 Â Â -18- Table of Contents Â Â Â May 2023 Warrants Â Measurement event Â Prior to amendment Â Â After amendment Â Date Â December 21, 2023 Â Â December 21, 2023 Â Total Value Â $56 thousand Â Â $0.2 million Â Loss Â not applicable Â Â $0.1 million Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 45.50 Â Â $ 8.75 Â Market price Â $ 8.07 Â Â $ 8.07 Â Volatility Â Â 79.3 % Â Â 79.3 % Risk-free rate Â Â 3.92 - 4.62 % Â Â 3.92 - 4.62 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 1.5 - 4.5 Â Â Â 1.5 - 4.5 Â Â Â September 2022, November 2022, & May 2023 Warrants Â Measurement event Â Prior to amendment Â Â After amendment Â Date Â June 14, 2024 Â Â June 14, 2024 Â Total Value Â $66 thousand Â Â $0.1 million Â Loss Â not applicable Â Â $70 thousand Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 8.75 - 52.50 Â Â $ 2.50 Â Market price Â $ 2.51 Â Â $ 2.51 Â Volatility Â Â 89.3 % Â Â 89.3 % Risk-free rate Â Â 4.27 - 5.08 % Â Â 4.27 - 5.08 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 1.0-4.4 Â Â Â 1.0 - 4.4 Â Â Â (a) Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. Â Preferred Stock Conversion Price Adjustments Â Terms of the Companyâ€™s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (see Note 12, â€œStockholdersâ€™ (Deficit) Equityâ€). The applicable Ratchet provisions of the Companyâ€™s outstanding Preferred Stock terminated during the quarter ended March 31, 2024. When a conversion price was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend is measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the anti-dilution protection feature). Fair value was determined using a Black Scholes model as outlined below. Â Â Â Series B & C Preferred Stock Â Measurement event Â Prior to Ratchet Â Â After Ratchet Â Date Â April 27, 2023 Â Â April 27, 2023 Â Total value (b) Â $9.6 million Â Â $11.6 million Â Deemed dividend Â not applicable Â Â $2.0 million Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 220.50 Â Â $ 45.50 Â Market price Â $ 25.20 (a) Â $ 25.20 (a) Volatility Â Â 80.1 % Â Â 80.1 % Risk-free rate Â Â 4.91 % Â Â 4.91 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (in years) Â Â 0.8 Â Â Â 0.8 Â Â Â Series B & C Preferred Stock Â Measurement event Â Prior to Ratchet Â Â After Ratchet Â Date Â December 21, 2023 Â Â December 21, 2023 Â Total value (b) Â $1.7 million Â Â $6.8 million Â Deemed dividend Â not applicable Â Â $5.1 million Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 45.50 Â Â $ 8.75 Â Market price Â $ 8.07 Â Â $ 8.07 Â Volatility Â Â 79.3 % Â Â 79.3 % Risk-free rate Â Â 5.43 % Â Â 5.43 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 0.3 Â Â Â 0.3 Â Â -19- Table of Contents Â Â Â Series C Preferred Stock Â Measurement event Â Prior to Ratchet Â Â After Ratchet Â Date Â March 24, 2024 Â Â March 24, 2024 Â Total value (b) Â $0.5 million Â Â $0.9 million Â Deemed dividend Â not applicable Â Â $0.4 million Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 8.75 Â Â $ 4.90 Â Market price Â $ 4.77 Â Â $ 4.77 Â Volatility Â Â 79.9 % Â Â 79.9 % Risk-free rate Â Â 5.51 % Â Â 5.51 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (in years) Â Â 0.1 Â Â Â 0.1 Â Â Â (a) Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. Â (b) Includes value of incremental shares underlying preferred stock and adjusted for probability of occurrence. Â Bifurcatable Derivatives Â Upon issuance in March 2024, the Unsecured Convertible Notes contained a lenderâ€™s conversion option which represented an embedded call option requiring bifurcation as an embedded derivative liability at fair value (see Note 10, â€œConvertible Notesâ€ for additional discussion). Fair value was determined using a Black Scholes model as outlined below. Â Â Â Unsecured Convertible Notes derivative Â Â Unsecured Convertible Notes derivative Â Measurement event Â Issuance Â Â Shareholder Approval Â Date Â March 25, 2024 Â Â May 28, 2024 Â Total value Â $0.2 million Â Â $0.2 million Â Gain (Loss) Â not applicable Â Â $(82 thousand) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 4.90 Â Â $ 4.90 Â Market price Â $ 4.51 Â Â $ 4.94 Â Volatility Â Â 86.9 % Â Â 83.9 % Risk-free rate Â Â 4.54 % Â Â 4.94 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 2.0 Â Â Â 1.8 Â Â Upon issuance in May 2023, the Secured Convertible Notes contained a lenderâ€™s conversion option which represented an embedded call option requiring bifurcation as an embedded derivative liability at fair value (see Note 10, â€œConvertible Notesâ€ for additional discussion). Fair value was determined using a Black Scholes model as outlined below. Â Â Â Secured Convertible Notes derivative Â Â Secured Convertible Notes derivative Â Measurement event Â Issuance Â Â Shareholder Approval Â Date Â April 27, 2023 Â Â June 9, 2023 Â Total value (b) Â $0.2 million Â Â $0.2 million Â Gain Â not applicable Â Â $40 thousand Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 45.50 Â Â $ 45.50 Â Market price Â $ 25.20 (a) Â $ 23.80 Â Volatility Â Â 80.1 % Â Â 76.9 % Risk-free rate Â Â 4.88 % Â Â 5.41 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 0.8 Â Â Â 0.7 Â Â Â (a) Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. Â (b) Adjusted for probability of occurrence. Â -20- Table of Contents Â Â Â NOTE 4. PREPAID EXPENSES AND OTHER CURRENT ASSETS Â Prepaid expenses and other current assets consisted of the following (in thousands): Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Prepaid insurance Â $ 94 Â Â $ 66 Â Prepaid dues and subscriptions Â Â 60 Â Â Â 85 Â Prepaid taxes Â Â 7 Â Â Â 83 Â Prepaid inventory Â Â â€” Â Â Â 73 Â Other Â Â 94 Â Â Â 81 Â Prepaid expenses from discontinued operations Â Â â€” Â Â Â (132) Total prepaid expenses and other current assets Â $ 255 Â Â $ 256 Â Â Â NOTE 5. INVENTORY Â Inventory consisted of the following (in thousands): Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Raw materials and supplies Â $ 144 Â Â $

1,027 Â Finished goods Â Â 760 Â Â Â 2,477 Â Less: Reserve for excess and obsolete inventory Â Â (204) Â Â (627) Inventory, net of reserves, from discontinued operations Â Â â€” Â Â Â (2,313) Total inventory, net Â $ 700 Â Â $ 564 Â Â Â Â NOTE 6. PROPERTY AND EQUIPMENTÂ Â Property and equipment consisted of the following (in thousands): Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Office and laboratory equipment Â $ 20 Â Â $ 20 Â Furniture and fixtures Â Â 157 Â Â Â 157 Â Computer equipment and software Â Â 435 Â Â Â 431 Â Leasehold improvements Â Â 152 Â Â Â 152 Â Total property and equipment, at cost Â Â 764 Â Â Â 760 Â Less: accumulated depreciation Â Â (696) Â Â (673) Total property and equipment, net Â $ 68 Â Â $ 87 Â Â Depreciation expense related to continuing operations was $11 thousand and $13 thousand for the three months ended June 30, 2024 and 2023, respectively, and $23 thousand and $26 thousand for the six months ended June 30, 2024 and 2023, respectively. The Company recorded no depreciation expense during the three and six months ended June 30, 2024 and 2023, and no property and equipment as of June 30, 2024 and December 31, 2023 related to discontinued operations. Â -21- Table of Contents Â Â NOTE 7. ACCRUED LIABILITIESÂ Â Accrued liabilities consisted of the following (in thousands): Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Contract liabilities (see Note 14) Â $ 773 Â Â $ 946 Â Employee payroll and benefits Â Â 380 Â Â Â 341 Â Other Â Â 144 Â Â Â 229 Â Accrued liabilities from discontinued operations Â Â â€” Â Â Â (347) Total accrued liabilities Â $ 1,297 Â Â $ 1,169 Â Â Â Â NOTE 8. COMMITMENTS AND CONTINGENCIES Â Indemnification Agreements Â As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Companyâ€™s request in such capacity. The term of the indemnification period is for the officerâ€™s or directorâ€™s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may enable it to recover a portion of any future payments. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, it has not recorded any liabilities for these agreements as of June 30, 2024 or December 31, 2023. Â In the normal course of business, the Company provides indemnification of varying scope under its agreements with other entities, typically its clinical research organizations, investigators, clinical sites, suppliers, and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third party with respect to its products. The term of these indemnification agreements is generally perpetual. The potential future payments the Company could be required to make under these indemnification agreements is unlimited. Historically, costs related to these indemnification provisions have been immaterial. The Company also maintains various liability insurance policies that limit its exposure. As a result, it believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of June 30, 2024 or December 31, 2023. Â Legal Matters Â From time to time, the Company is subject to various legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business. The ultimate outcome of any litigation or other legal dispute is uncertain. When a loss related to a legal proceeding or claim is probable and reasonably estimable, the Company accrues its best estimate for the ultimate resolution of the matter. If one or more legal matters are resolved against the Company in a reporting period for an amount above expectations, the Companyâ€™s financial condition and operating results for that period may be adversely affected. As of June 30, 2024 and December 31, 2023, there were no legal matters that, in the opinion of management, would ultimately result in liability that would have a material adverse effect on the Companyâ€™s financial position, results of operations or cash flows. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company due to legal costs and expenses, diversion of management attention and other factors. The Company cannot provide assurance that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against it in the future, and these matters could relate to prior, current, or future transactions or events. Â Leases Â The Company leases office space for its corporate headquarters located in Emeryville, California. The current lease term expires on July 31, 2027. Â -22- Table of Contents Â Lease costs for the three and six months ended June 30, 2024 and 2023 were as follows (in thousands): Â Â Â For the Three Months Ended June 30, Â Â For the Six MonthsÂ Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease â€“ expense Â $ 100 Â Â $ 100 Â Â $ 200 Â Â $ 200 Â Operating lease from discontinued operations â€“ expense Â Â â€“ Â Â Â 31 Â Â Â â€“ Â Â Â 61 Â Operating lease â€“ included in operating cash flow Â Â 117 Â Â Â 114 Â Â Â 193 Â Â Â 188 Â Operating lease from discontinued operations â€“ included in operating cash flow Â Â â€“ Â Â Â 32 Â Â Â â€“ Â Â Â 64 Â Â The Company has measured its operating lease liabilities as the present value of minimum lease payments using its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate for operating leases from continuing operations are summarized as follows: Â Â Â June 30, 2024 Â Â June 30, 2023 Â Weighted-average remaining lease term (in years) Â Â 3.1 Â Â Â 3.8 Â Weighted-average discount rate Â Â 5 % Â Â 5 % Â Future lease payments under non-cancelable leases as of June 30, 2024 were as follows (in thousands): Â 2024 Â $ 233 Â 2025 Â Â 439 Â 2026 Â Â 444 Â 2027 Â Â 290 Â Total future minimum lease payments Â Â 1,406 Â Less: Imputed interest Â Â (92) Total Â $ 1,314 Â Â Â Â Â Â Reported as: Â Â Â Â Operating lease liability Â $ 382 Â Operating lease liability- non-current Â Â 932 Â Total Â $ 1,314 Â Â -23- Table of Contents Â Â Â NOTE 9. FINANCING ACTIVITIES Â See Notes 2, â€œSummary of Significant Accounting Policiesâ€; 3, â€œFair Value Measurementsâ€; 10, â€œConvertible Notesâ€; 11, â€œCommon Stock Warrantsâ€ and 12, â€œStockholdersâ€™ (Deficit) Equityâ€ for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates. Â 2024 Warrant Reprice Transaction Â In June 2024, the Company entered into a warrant reprice transaction (the â€œ2024 Warrant Reprice Transactionâ€) with certain existing holders of our (i) warrants issued in September 2022 to purchase common stock, (ii) Series A-1 warrants issued in November 2022 to purchase common stock, (iii) Series B-1 Warrants issued in May 2023 to purchase common stock, and (iv) Series B-2 Warrants issued in May 2023 to purchase common stock (collectively (i) through (iv), the â€œExisting Warrantsâ€). The participants agreed to exercise a portion of their Existing Warrants at a reduced exercise price of $2.50. There were an aggregate of 90,381 shares of common stock that were exercised, resulting in gross proceeds of approximately $0.2 million. Â The Company also issued to participants in the 2024 Warrant Reprice Transaction, a new June 2024 Warrant to purchase a number of shares of common stock equal to 100% of the shares of common stock exercised. The June 2024 Warrants are substantially similar to the Existing Warrants, except that the June 2024 Warrants will (i) be initially exercisable on the six-month anniversary of the date of issuance; (ii) have an exercise price of $2.57; and (iii) have a term of five (5) years and six (6) months from the date of the closing of the 2024 Warrant Reprice Transaction. Â The Company incurred total issuance costs of $96 thousand in conjunction with the 2024 Warrant Reprice Transaction. The Company incurred a $69 thousand non-cash loss on the modification of common stock warrantsÂ which was recorded in â€œOther expense, netâ€ for the three and six months ended June 30, 2024. Â 2024 Subsidiary Guarantee Termination Â On March 24, 2024, in connection with completing certain required conditions to close the DERMAdoctor Divestiture, the Company and the holders of the Secured Convertible Notes entered into a First Amendment (the â€œFirst Amendmentâ€) to the Companyâ€™s Security Agreement, dated April 27, 2023 (the â€œSecurity Agreementâ€), to remove the Membership Units and any assets of DERMAdoctor as collateral for the Companyâ€™s obligations pursuant to the Secured Convertible Notes and for DERMAdoctor to be removed as a party to the Security Agreement, and a Consent and Release (the â€œSubsidiary Guarantee Consentâ€), to terminate the Subsidiary Guarantee, dated April 7, 2023 (the â€œSubsidiary Guaranteeâ€) (collectively, the â€œ2024 Subsidiary Guarantee Terminationâ€). To obtain the secured partiesâ€™ consent that resulted in the reduction of the collateral available to secure the obligations under the Secured Convertible Notes and as consideration for the secured parties taking the necessary actions to execute and deliver the First Amendment and the Subsidiary Guarantee Consent, the Company provided each secured party the option, at the Secured Partyâ€™s election, to receive only upon the closing of the DERMAdoctor Divestiture either a March 2024 Warrant (see Note 11, â€œCommon Stock Warrantsâ€) or an Unsecured Convertible Note (see Note 10 â€œConvertible Notesâ€). Â The Company issued, based on the secured partiesâ€™ elections, (i) a March 2024 Warrant to a secured party that is exercisable for an aggregate of 28,572 shares of common stock and (ii) Unsecured Convertible Notes to four secured parties that have an aggregate principal amount of $525 thousand or will be convertible into an aggregate of 107,146 shares of common stock.Â Â The Company incurred total issuance costs of $130 thousand in conjunction with the 2024 Subsidiary Guarantee Termination. The Company allocated $19 thousand of the issuance costs to the Unsecured Convertible Notes which was recorded as a discount in the Companyâ€™s condensed consolidated balance sheets. The remaining $111 thousand was allocated to the embedded derivative liability and warrant liability and expensed as â€œOther expense, netâ€ in the Companyâ€™s unaudited condensed consolidated statements of operations, during the six months ended June 30, 2024. Â 2023 Warrant Reprice Transaction Â In December 2023, the Company entered into a warrant reprice transaction (the â€œ2023 Warrant Reprice Transactionâ€) whereby the price terms of certain May 2023 Warrants exercisable for 72,256 shares of common stock were amended and exercised. The price of the amended and exercised May 2023 Warrants was reduced from $45.50 to $8.75. The Company also issued to participants in the 2023 Warrant Reprice Transaction, the December 2023 Warrants exercisable for 72,256 shares of common stock. Â The 2023 Warrant Reprice Transaction resulted in gross proceeds of approximately $0.6 million. The Company allocated the gross proceeds between the common stock and December 2023 Warrants issued to participants by applying the relative fair value allocation methodology. The Company allocated $0.2 million in gross proceeds to the common stock and $0.4 million to the December 2023 Warrants. The December 2023 Warrants were initially classified as liabilities from the date of issuance until Company stockholder approval on May 28, 2024, at which time they were reclassified to equity. Â The Company incurred total issuance costs of $0.2 million in conjunction with the 2023 Warrant Reprice Transaction. The Company allocated $0.1 million of the issuance costs to the common stock which was recorded as a reduction of additional paid-in capital in the Companyâ€™s condensed consolidated balance sheets. The remaining $0.1 million was allocated to the warrant liability and expensed as â€œOther expense, netâ€ in the Companyâ€™s unaudited condensed consolidated statements of operations. Â -24- Table of Contents Â 2023 Private Placement Â In May 2023, the Company closed a private placement (the â€œ2023 Private Placementâ€) with existing accredited institutional investors of the Company that provided for the issuance and sale of $3.3 million aggregate principal amount of the Secured Convertible Notes and the May 2023 Warrants exercisable for up to 145,056 shares of common stock. Â The Company received gross proceeds of $3.0 million from the 2023 Private Placement. The Company allocated the proceeds from the 2023 Private Placement between the May 2023 Warrants, an embedded derivative liability, and the Secured Convertible Notes by applying the residual fair value methodology. The Company first allocated $1.6 million to the May 2023 Warrants and $0.2 million to the embedded derivative liability with the residual $1.2 million allocated to the Secured Convertible Notes. The embedded derivative liability was subsequently reclassified to equity upon stockholder approval. Â The Company incurred total issuance costs of $0.7 million in conjunction with the 2023 Private Placement, including a $0.4 million non-cash loss on the warrant modification. The Company allocated $0.3 million of the issuance costs to the Secured Convertible Notes which was recorded as a discount in the Companyâ€™s condensed consolidated balance sheets. The remaining $0.4 million was allocated to the embedded derivative liability and warrant liability and expensed as â€œOther expense, netâ€ in the Companyâ€™s unaudited condensed consolidated statements of operations. Â -25- Table of Contents Â Â Â NOTE 10. CONVERTIBLE NOTES Â Unsecured Convertible Note Â In March 2024, the Company issued $525 thousand aggregate principal amount unsecured convertible notes (the â€œUnsecured Convertible Notesâ€) in conjunction with the 2024 Subsidiary Guarantee Termination. The 2024 Subsidiary Guarantee Termination was executed with certain holders of the Secured Convertible Notes in order to close the DERMAdoctor Divestiture (see additional discussion in Note 9, â€œFinancing Activitiesâ€ and Note 18, â€œDivestiture and Discontinued Operationsâ€). The Unsecured Convertible Notes are due March 25, 2026 and bear no stated interest. Â The Unsecured Convertible Notes may be converted or redeemed for a conversion price equal to $4.90 per share at any time at the election of the holder up to the amount of outstanding principal at the time of conversion subject to certain limitations such as beneficial ownership limitations. Upon issuance and as of June 30, 2024, the Unsecured Convertible Notes were convertible for up to 107,146 shares of common stock. Â Upon issuance in March 2024, the lenderâ€™s conversion option under the Unsecured Convertible Notes represented an embedded call option requiring bifurcation as an embedded derivative liability because the common stock underlying the option required stockholder approval before the option could be exercised. The fair value of the embedded derivative was determined to be $159 thousand as of March 31, 2024 in accordance with a Black Scholes valuation model. See also Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Upon stockholder approval on May 28, 2024, the embedded call option no longer required liability treatment and was reclassified to equity. The fair value of the embedded derivative liability was determined to be $242 thousand as of May 28, 2024. The change of $83 thousand in fair value between March 31, 2024 and May 28, 2024 was recorded as a non-cash loss on change in fair value of embedded derivative liability in the unaudited condensed consolidated statements of operations. See also Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Â The discount to the note recorded for the embedded derivative liability upon issuance and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Unsecured Convertible Notes, assuming that the Unsecured Convertible Notes will be redeemed for cash of $525 thousand at time of maturity as of March 25, 2026. During both the three and six months ended June 30, 2024, the effective interest rate on the Unsecured Convertible Notes was 144%. During the three and six months ended June 30, 2024, interest expense recognized, including amortization of the issuance costs and debt discount, was $14 thousand and $15 thousand, respectively, which was included in other expense, net in the unaudited condensed consolidated statements of operations. Â Secured Convertible Note Â In May 2023, the Company issued $3.3 million aggregate principal amount Original Issue Discount Senior Secured Convertible Debentures (the â€œSecured Convertible Notesâ€) in conjunction with the 2023 Private Placement (see Note 9, â€œFinancing Activitiesâ€). The Secured Convertible Notes were issued with a $300 thousand original issue discount. The Secured Convertible Notes are due November 1, 2024. Â The Secured Convertible Notes may be converted or redeemed for a conversion price equal to $45.50 per shareÂ at any time at the election of the holder up to the amount of outstanding principal at the time of conversion subject to certain limitations such as beneficial ownership limitations. Upon issuance, the Secured Convertible Notes were convertible for up to 72,528 shares of common stock. As of June 30, 2024, the Secured Convertible Notes were convertible for up to 16,376 shares of common stock. Â Beginning June 1, 2023, the Company was required to start making a monthly redemption of 1/18th of the original principal amount of the Secured Convertible Notes. Each monthly redemption reduces the outstanding principle of the Secured Convertible Note by $183 thousand and may be made in cash or, under limiting conditions, in stock at the election of the Company. Monthly redemption in cash requires a total payment of $193 thousand. Monthly redemption in stock requires the issuance of shares equal to $193 thousand divided by the lower of (i) $45.50 or (ii) 90% of the Companyâ€™s common stockâ€™s average volume-weighted average price over 10 trading days prior to the redemption. The conditions allowing for redemption in stock have not been met through June 30, 2024 and the Company has made all monthly redemption payments in cash. Â -26- Table of Contents Â The Secured Convertible Notes also provide for a redemption equal to up to 20% of the gross proceeds received by the Company from any financing completed while the Secured Convertible Notes are outstanding. In connection with the 2023 Warrant Reprice Transaction (see Note 12, â€œStockholdersâ€™ (Deficit) Equityâ€), the Company made such a payment totaling $126 thousand in cash against the Secured Convertible Notes. In connection with the 2024 Warrant Reprice Transaction (see Note 12, â€œStockholdersâ€™ (Deficit) Equityâ€), the Company made such a payment totaling $45 thousand in cash against the Secured Convertible Notes. Â If any event of default occurs, the outstanding principal amount of the Secured Convertible Notes, plus accrued but unpaid interest, liquidated damages and other amounts owing thereof become immediately due and payable in cash at the holderâ€™s election. After any event of default, the Secured Convertible Notes will also accrue interest at a rate up to 18% per year. The Secured Convertible Notes are secured obligations of the Company including a security interest, a lien upon and a right of set-off against all of the Companyâ€™s assets as collateral security. DERMAdoctor was released of such obligations in connection with the DERMAdoctor Divestiture. Â Upon issuance in May 2023, the lenderâ€™s conversion option under the Secured Convertible Notes represented an embedded call option requiring bifurcation as an embedded derivative liability because the common stock underlying the option required stockholder approval before the option could be exercised. The fair value of the embedded derivative was determined to be $209 thousand as of the date of issuance. After stockholder approval of the underlying common stock, the embedded call option no longer required liability treatment and was reclassified to equity. The fair value of the embedded derivative liability was determined to be $169 thousand upon stockholder approval. The change of $40 thousand in fair value between the date of issuance and stockholder approval was recorded as a non-cash gain on change in fair value of embedded derivative liability in the consolidated statements of operations. See also Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Â The lenderâ€™s subsequent financing redemption option and certain events of default also represent embedded call options and the Companyâ€™s monthly share redemption option represents an embedded put option. The fair value of these options was determined to be immaterial upon issuance and at each subsequent reporting date. Â The Company allocated $1.2 million of gross proceeds from the 2023 Private Placement to the Secured Convertible Notes. Â The difference between the $1.2 million allocated to the Secured Convertible Notes and the $3.3 million aggregate principal amount represent discounts for the portion of proceeds allocated

to the embedded derivative liability and the May 2023 Warrants (See Note 11, â€œCommon Stock Warrantsâ€) as well as the $0.3 million original issue discount. The Company also allocated $0.3 million of debt issuance costs to the Secured Convertible Notes. Â The discounts and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Secured Convertible Notes, assuming that the Secured Convertible Notes will be redeemed for cash of $193 thousand per month beginning in June 2023. The effective interest rate on the Secured Convertible Notes was 173%. During the three and six months ended June 30, 2024, interest expense recognized, including amortization of the issuance costs and debt discount, was $0.3 million and $0.7 million, respectively, which was included in other expense, net in the unaudited condensed consolidated statements of operations. Â The Secured Convertible Notes are presented as follows as of June 30, 2024 (in thousands): Â Principal amount Â $ 762 Â Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants Â Â (92) Unamortized debt issuance costs Â Â (15) Total Secured Convertible Notes, net Â $ 655 Â Â The Secured Convertible Notes, net, are classified as short term in the Companyâ€™s condensed consolidated balance sheets. Â As of June 30, 2024, the Companyâ€™s contractual maturity of the principal balance of the Secured Convertible Notes was $762 thousand. Â -27- Table of Contents Â Â Â NOTE 11. COMMON STOCK WARRANTS Â See Notes 2, â€œSummary of Significant Accounting Policiesâ€; 3, â€œFair Value Measurementsâ€; 9, â€œFinancing Activitiesâ€; and 12, â€œStockholdersâ€™ (Deficit) Equityâ€ for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates. Â June 2024 Warrants Â In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company issued new common stock purchase warrants (the â€œJune 2024 Warrantsâ€) exercisable for 90,381 shares of common stock for $2.57 per share through December 17, 2029. Â March 2024 Warrant Â In March 2024, the Company executed the First Amendment and Subsidiary Guarantee Consent as part of the 2024 Subsidiary Guarantee Termination with holders of the Secured Convertible Notes (see Note 10, â€œConvertible Notesâ€) in order to close the DERMAdoctor Divestiture (see additional discussion in Note 9, â€œFinancing Activitiesâ€ and Note 18, â€œDivestiture and Discontinued Operationsâ€). In exchange for the consent of each holder, the option, at the holderâ€™s election, to receive upon the closing of the DERMAdoctor sale either, a new common stock warrant (the â€œMarch 2024 Warrantâ€), or a new unsecured convertible note (see additional discussion in Note 18, â€œDivestiture and Discontinued Operationsâ€). One holder elected the option to receive a March 2024 Warrant exercisable for 28,572 shares of common stock for $4.90 per share. Â The March 2024 Warrant was initially classified as a liability from the date of issuance until Company stockholder approval on May 28, 2024, at which time it was reclassified to equity. Â December 2023 Warrants Â In December 2023, in conjunction with the 2023 Warrant Reprice Transaction, the Company issued new common stock purchase warrants (the â€œDecember 2023 Warrantsâ€) exercisable for 72,256 shares of common stock for $8.75 per share through June 21, 2029. Â The December 2023 Warrants were initially classified as liabilities from the date of issuance until Company stockholder approval on May 28, 2024, at which time it was reclassified to equity. Â May 2023 Warrants Â In May 2023, in conjunction with the 2023 Private Placement, the Company issued the following new common stock purchase warrants (collectively, the â€œMay 2023 Warrantsâ€): Â Â â— May 2023 Series B-1 Warrants exercisable for 72,528 shares of common stock for $45.50 per share through June 9, 2028 (â€œMay 2023 B-1 Warrantsâ€); and Â â— May 2023 Series B-2 Warrants exercisable for 72,528 shares of common stock for $45.50 per share through June 9, 2025 (â€œMay 2023 B-2 Warrantsâ€). Â In December 2023, in conjunction with the 2023 Warrant Reprice Transaction, the Company amended certain May 2023 Warrants to reduce their exercise prices to $8.75. Immediately after amendment, the following May 2023 Warrants were exercised (while any unexercised May 2023 Warrants maintained an exercise price of $45.50): Â Â â— May 2023 B-1 Warrants exercisable for 18,132 shares of common stock; and Â â— May 2023 B-2 Warrants exercisable for 54,120 shares of common stock. Â In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain May 2023 Warrants to reduce their exercise prices to $2.50. Immediately after amendment, the following May 2023 Warrants were exercised (while any unexercised May 2023 Warrants maintained an exercise price of $8.75): Â Â â— May 2023 B-1 Warrants exercisable for 54,396 shares of common stock; and Â â— May 2023 B-2 Warrants exercisable for 18,408 shares of common stock. Â For the amendments in December 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the May 2023 Warrants of $170 thousand and $47 thousand, respectively. Â -28- Table of Contents Â November 2022 Warrants Â In November 2022, in conjunction with the 2022 Private Placement, the Company issued the following common stock purchase warrants (collectively, the â€œNovember 2022 Warrantsâ€): Â Â â— November 2022 Series A-1 Warrants exercisable for 14,741 shares of common stock for $220.50 per share through November 20, 2028 (â€œNovember 2022 A-1 Warrantsâ€); and Â â— November 2022 Series A-2 Warrants exercisable for 14,741 shares of common stock for $220.50 per share through May 20, 2024 (â€œNovember 2022 A-2 Warrantsâ€). Â In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain November 2022 Warrants to reduce their exercise prices from $220.50 to $52.50 as follows: Â Â â— November 2022 A-1 Warrants exercisable for 12,473 shares of common stock; and Â â— November 2022 A-2 Warrants exercisable for 12,473 shares of common stock. Â In May 2024, all November 2022 Series A-2 Warrants for 14,741 shares of common stock remained unexercised and expired. Â In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain November 2022 Warrants to reduce their exercise prices from $52.50 to $2.50 as follows: Â Â â— November 2022 A-1 Warrants exercisable for 12,473 shares of common stock. Â For the amendments in May 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the November 2022 Warrants of $74 thousand and $16 thousand, respectively. Â -29- Table of Contents Â September 2022 Warrants Â In September 2022, in conjunction with the warrant reprice transaction (the â€œ2022 Warrant Reprice Transactionâ€), the Company issued new common stock purchase warrants (the â€œSeptember 2022 Warrantsâ€) exercisable for 9,371 shares of common stock for $220.50 per share through September 11, 2028. Â In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain September 2022 Warrants exercisable for 6,819 shares of common stock to reduce their exercise prices from $220.50 to $52.50. Â In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain September 2022 Warrants exercisable for 5,104 shares of common stock to reduce their exercise prices from $52.50 to $2.50. Â For the amendments in May 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the September 2022 Warrants of $28 thousand and $6 thousand, respectively. Â November 2021 Warrants Â In November 2021, in conjunction with a private placement transaction, the Company issued the new common stock purchase warrants (the â€œNovember 2021 Warrantsâ€) exercisable for 30,616 shares of common stock for $649.25 per share through March 9, 2023. Â In September 2022, in conjunction with the 2022 Warrant Reprice Transaction, the Company amended all November 2021 Warrants to reduce their exercise prices from $649.25 to $220.50 and extend their termination date to September 11, 2028. Immediately after amendment, November 2021 Warrants were exercised for 7,654 shares of common stock. Â In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain November 2021 Warrants exercisable for 15,308 shares of common stock to reduce their exercise prices from $220.50 to $52.50. Â For the amendments in September 2022 and May 2023, the Company recognized a loss on modification of common stock warrants related to the November 2021 Warrants of $1.5 million and $0.1 million, respectively. Â July 2020 Warrants Â In July 2020, in conjunction with a private placement transaction, the Company issued the new common stock purchase warrants (the â€œJuly 2020 Warrantsâ€) exercisable for 5,635 shares of common stock for $2,021.25 per share through January 22, 2026. Â In September 2022, in conjunction with the 2022 Warrant Reprice Transaction, the Company amended certain July 2020 Warrants exercisable for 3,921 shares of common stock to reduce their exercise prices from $2,021.25 to $220.50. Immediately after amendment, July 2020 Warrants were exercised for 1,715 shares of common stock. Â In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain July 2020 Warrants exercisable for 2,206 shares of common stock to reduce their exercise prices from $220.50 to $52.50. Â For the amendments in September 2022 and May 2023, the Company recognized a loss on modification of common stock warrants related to the July 2020 Warrants of $0.4 million and $9 thousand, respectively. Â Summary of Common Stock Warrant Activity and Outstanding Â Activity related to common stock warrants outstanding at June 30, 2024 and 2023 were as follows: Â Â Â Warrants Â Â Weighted- Average Exercise Price Â Outstanding at December 31, 2022 Â Â 65,886 Â Â $ 269.54 Â Warrants granted Â Â 145,056 Â Â Â 45.50 Â Warrants exercised Â Â â€” Â Â Â â€” Â Warrants expired Â Â â€” Â Â Â â€” Â Outstanding at June 30, 2023 Â Â 210,942 Â Â Â 76.23 Â Â Â Â Â Â Â Â Â Â Â Â Outstanding at December 31, 2023 Â Â 210,946 Â Â $ 50.96 Â Warrants granted Â Â 118,953 Â Â Â 3.13 Â Warrants exercised Â Â (90,381) Â Â 2.50 Â Warrants expired Â Â (14,741) Â Â 78.35 Â Outstanding at June 30, 2024 Â Â 224,777 Â Â Â 37.40 Â Â -30- Table of Contents Â Common stock warrants outstanding as of June 30, 2024 were as follows: Â Series Â Exercise Price Â Â Expiration Date Â Warrants Â 2019 Ladenburg Warrants Â $ 1,212.75 Â Â August 8, 2024 Â Â 138 Â July 2020 Warrants Â $ 2,021.25 Â Â January 22, 2026 Â Â 1,714 Â July 2020 Warrants Â $ 52.50 Â Â January 22, 2026 Â Â 2,206 Â TLF Warrants Â $ 822.96 Â Â January 15, 2026 Â Â 13 Â November 2021 Warrants Â $ 220.50 Â Â September 11, 2028 Â Â 7,654 Â November 2021 Warrants Â $ 52.50 Â Â September 11, 2028 Â Â 15,308 Â September 2022 Warrants Â $ 220.50 Â Â September 11, 2028 Â Â 2,552 Â September 2022 Warrants Â $ 52.50 Â Â September 11, 2028 Â Â 1,715 Â November 2022 A-1 Warrants Â $ 220.50 Â Â November 20, 2028 Â Â 2,268 Â December 2023 Warrants Â $ 8.75 Â Â June 21, 2029 Â Â 72,256 Â March 2024 Warrant Â $ 4.90 Â Â March 24, 2029 Â Â 28,572 Â June 2024 Warrants Â $ 2.57 Â Â December 17, 2029 Â Â 90,381 Â Outstanding at June 30, 2024 Â Â Â Â Â Â Â Â Â Â 224,777 Â Â Summary of Common Stock Warrant Liabilities Â The following is a reconciliation of the beginning and ending balances for warrant liabilities measured at fair value on a recurring basis (in thousands). See additional information per Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptions.â€ Â Warrant liabilities as of December 31, 2023 Â Â 334 Â Decrease in fair value of December 2023 Warrant liability during period Â Â (122) Fair value of March 2024 Warrant upon issuance Â Â 92 Â Increase in fair value of March 2024 Warrant liability during period Â Â 8 Â Reclassification of December 2023 Warrant liability to equity during period Â Â (212) Reclassification of March 2024 Warrant liability to equity during period Â Â (100) Warrant liabilities as of June 30, 2024 Â $ â€” Â Â -31- Table of Contents Â Â Â NOTE 12. STOCKHOLDERSâ€™ (DEFICIT) EQUITY Â Authorized Share Capital Â Under the Companyâ€™s Amended and Restated Certificate of Incorporation, as amended, the Company is authorized to issue up to 150,000,000 shares of common stock and up to 5,000,000 shares of preferred stock with rights and preferences as may be approved by the Companyâ€™s Board of Directors. Â Reverse Stock Split Â Effective May 30, 2024, the Company amended its Certificate of Incorporation to effect a 1-for-35 reverse split of its outstanding common stock. The Reverse Stock Split was approved by the Companyâ€™s stockholders on May 28, 2024. As a result of the Reverse Stock Split, every 35 shares of the Companyâ€™s pre-reverse split outstanding common stock were combined and reclassified into 1 share of common stock. Proportionate voting rights and other rights of common stockholders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole share. All stock options outstanding, common stock reserved for issuance under the Companyâ€™s equity incentive plans, common stock reserved for issuance under the Series B Preferred Stock and outstanding warrants were adjusted by dividing the number of affected shares of common stock by 35 and, as applicable, multiplying the exercise/conversion price by 35. Except as otherwise specifically noted, all share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis, to reflect this 1-for-35 reverse stock split. Â Preferred Stock Â There were two series of preferred stock of the Company outstanding during the three and six months ended June 30, 2024 and 2023 â€“ the Series B Non-Voting Convertible Preferred Stock (â€œSeries B Preferred Stockâ€) and the Series C Non-Voting Convertible Preferred Stock (â€œSeries C Preferred Stockâ€) (and combined, the â€œPreferred Stockâ€). The rights and preferences of the Series B Preferred Stock and Series C Preferred Stock are nearly identical. The Preferred Stock does not have any preemptive rights or a preference upon any liquidation, dissolution or winding-up of the Company. Each share of Preferred Stock is convertible into $1,000 of common stock at the conversion price per share applicable at the time of conversion. Until its expiration (as described in more detail below), the Preferred Stock had anti-dilution protection (the â€œRatchetâ€) in the event that the Company sold or granted any of its common stock or any other securities, subject to certain limited exceptions, that would entitle the holder thereof to acquire common stock at an effective price per share that is lower than the then applicable conversion price of the Preferred Stock. Â Series B Preferred Stock Â The Company issued 15,000 shares of Series B Preferred Stock in November 2021 in connection with a private placement transaction. As of June 30, 2024 and 2023, 131 and 9,156 shares of Series B Preferred Stock remained outstanding, respectively. As of June 30, 2024 and 2023, outstanding shares of Series B Preferred Stock were convertible into 15,065 and 201,432 shares of common stock at a conversion price of $8.75 and $45.50, respectively. Â In accordance with the Ratchet, the Series B Preferred Stock conversion price was reduced as follows (see also Notes 2, â€œSummary of Significant Accounting Policiesâ€ and 3, â€œFair Value Measurementsâ€): Â Â â— In September 2022, from $490.00 to $220.50, as a result of the 2022 Warrant Reprice Transaction, resulting in a $5.7 million deemed dividend. Â â— In April 2023, from $220.50 to $45.50, as a result of the 2023 Private Placement, resulting in a $1.8 million deemed dividend. Â â— In December 2023, from $45.50 to $8.75, as a result of the 2023 Warrant Reprice Transaction, resulting in a $4.5 million deemed dividend. Â On January 29, 2024, the Ratchet of the Series B Preferred Stock expired with no further impact because greater than 75% of the originally issued 15,000 Series B Preferred Stock had been converted into common stock. The Series B Preferred Stock conversion price will remain at $8.75 until all remaining Series B Preferred Stock has been converted. Â Series C Preferred Stock Â The Company issued 3,250 shares of Series C Preferred Stock in November 2022 in connection with the 2022 Private Placement (see Note 9, â€œFinancing Activitiesâ€). As of June 30, 2024 and 2023, zero and 1,097 shares of Series C Preferred Stock remained outstanding, respectively. As of June 30, 2023, outstanding shares of Series C Preferred Stock were convertible into 24,134 shares of common stock at a conversion price of $45.50. Â In accordance with the Ratchet, the Series C Preferred Stock conversion price was reduced as follows during the six months ended June 30, 2024 and 2023 (see also Notes 2, â€œSummary of Significant Accounting Policiesâ€ and 3, â€œFair Value Measurementsâ€): Â Â â— In April 2023, from $220.50 to $45.50, as a result of the 2023 Private Placement, resulting in a $194 thousand deemed dividend. Â â— In December 2023, from $45.50 to $8.75, as a result of the 2023 Warrant Reprice Transaction, resulting in a $0.5 million deemed dividend. Â â— In March 2024, from $8.75 to $4.90, as a result of the 2024 First Amendment and the Subsidiary Guarantee Consent, resulting in a $0.4 million deemed dividend. Â On March 27, 2024, the Ratchet of the Series C Preferred Stock expired with no further impact because greater than 75% of the originally issued 3,250 Series C Preferred Stock had been converted into common stock. Â -32- Table of Contents Â Common Stock Â See Note 9, â€œFinancing Activitiesâ€ and Note 11, â€œCommon Stock Warrantsâ€ for a description of common stock and common stock warrant-related transactions during the three and six months ended June 30, 2024 and 2023. Â Â Â NOTE 13. EQUITY-BASED COMPENSATION Â Equity Compensation PlansÂ Â In October 2007, the Company adopted the 2007 Omnibus Incentive Plan (the â€œ2007 Planâ€) to provide for the granting of equity awards, such as stock options, unrestricted and restricted common stock, stock units, dividend equivalent rights, and stock appreciation rights to employees, directors and outside consultants, as determined by the Board. The 2007 Plan expired on March 15, 2017. Upon expiration, new awards cannot be issued pursuant to the 2007 Plan, but outstanding awards continue to be governed by its terms. Stock options granted under the 2007 Plan expire no later than ten years from the date of grant. All stock options outstanding under the 2007 Plan were fully vested as of December 31, 2021. Â In March 2017, the Company adopted the 2017 Omnibus Incentive Plan (the â€œ2017Â Planâ€), which was approved by stockholders on June 2, 2017, to provide for the granting of equity awards, such as nonqualified stock options (â€œNQSOsâ€), incentive stock options (â€œISOsâ€), restricted stock, performance shares, stock appreciation rights (â€œSARsâ€), RSUs and other share-based awards to employees, directors, and consultants, as determined by the Board. The 2017 Plan does not affect awards previously granted under the 2007 Plan. Upon adoption, the 2017 Plan allowed for awards of up to 1,892 shares of the Companyâ€™s common stock, plus an automatic annual increase in the number of shares authorized for awards on the first day of each of the Companyâ€™s fiscal years beginning January 1, 2018 through January 1, 2027 equal to (i) 4% of the number of shares of common stock outstanding on the last day of the immediately preceding fiscal year or (ii) such lesser number of shares of common stock as determined by the Board. On June 21, 2024, the number of shares available for future awards under the 2017 Plan was increased by 12,219 shares. As ofÂ June 30, 2024,Â there wereÂ 13,630Â shares available for future awards under theÂ 2017Â Plan. Â Under the terms of the 2017 Plan, the exercise price of NQSOs, ISOs and SARs may not be less than 100% of the fair market value of the common stock on the date of grant and, if ISOs are granted to an owner of more than 10% of the Companyâ€™s stock, then not less than 110% of the fair market value of the common stock on the date of grant. The term of awards will not be longer than ten years or, in the case of ISOs, no longer than five years with respect to holders of more than 10% of the Companyâ€™s stock. Stock options granted to employees generally vest over four years, while options granted to directors and consultants typically vest over a shorter period, subject to continued service. The Company issues new shares to satisfy options under the 2007 Plan and the 2017 Plan. Â SummaryÂ of Outstanding Equity Awards Â The following table summarizes information about the Companyâ€™s stock options and restricted stock outstanding at December 31, 2023, and activity during the six months ended June 30, 2024: Â (in thousands, except years and per share data) Â Awards Â Â Weighted- Average Exercise Price Â Â Weighted- Average Remaining Contractual Life (years) Â Â Aggregate Intrinsic Value Â Outstanding at December 31, 2023 Â Â 4 Â Â $ 1,145.87 Â Â 7.3 Â Â $ 1 Â Restricted stock units granted Â Â 5 Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Options forfeited/cancelled Â Â (2) Â $ 392.58 Â Â Â Â Â Â Â Â Â Â Outstanding at June 30, 2024 Â Â 7 Â Â $ 505.54 Â Â 8.8 Â Â $ 11 Â Â Â Â Â Â Â Â Â Â Â Â

Â Â Â Â Â Â Â Â Â Â Â Â Vested and expected to vest at June 30, 2024Â Â Â 7Â Â Â $ 509.60Â Â Â Â 8.8Â Â Â $ 11Â Â Â Â Â Â Â Â Â Â Â Â

our consolidated financial statements and related notes, and Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (the â€œSECâ€) on March 26, 2024, as amended on March 29, 2024 (the â€œ2023 Annual Reportâ€). Words such as â€œexpects,â€ â€œanticipated,â€ â€œwill,â€ â€œmay,â€ â€œgoals,â€ â€œplans,â€ â€œbelieves,â€ â€œestimates,â€ â€œconcludes,â€ determines,â€ variations of theseÂ words, and similar expressions are intended to identify these forward-looking statements. As a result of many factors, including those set forth under the section entitled â€œRisk Factorsâ€ of this report and in our 2023 Annual Report, as well as in other sections in our SEC filings, our actual results may differ materially from those anticipated in these forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions based upon assumptions made that we believed to be reasonable at the time and are subject to risks and uncertainties. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements after the date of this report, even if new information becomes available in the future. Â OverviewÂ Â We are a company focused on the development and sale of scientifically-created and clinically-proven eyecare and wound care products. Our leading product, AvenovaÂ® Antimicrobial Lid and Lash Solution, or Avenova Spray, is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with our proprietary, stable and pure form of hypochlorous acid and is cleared by the Food and Drug Administration (the â€œFDAâ€) for sale in the United States. Avenova Spray is available direct to consumers, primarily through online distribution channels, and is also available by prescription and dispensed by eyecare professionals for blepharitis and dry eye disease. Because dry eye is a complex condition, we offer a complementary portfolio of scientifically-developed products for each step of the standard at-home treatment regimen, including the Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. Â We also manufacture and sell our proprietary form of hypochlorous acid for the wound care market through our NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries. The Company currently sells these products through distributors. Â Through our former subsidiary DERMAdoctor, LLC (â€œDERMAdoctorâ€), the Company offered over 30 dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration and keratosis pilaris. On MarchÂ 25,Â 2024, we announced the closing of the sale of DERMAdoctor (the â€œDERMAdoctor Divestitureâ€). We acquired DERMAdoctor in November 2021 in order to achieve overall revenue growth, cost reductions and profitability. We were unable to achieve those objectives with DERMAdoctor. We continue to evaluate strategies for our entire Company, to maximize revenue growth and profitability and minimize operating losses while addressing our capital and liquidity needs. To that end, we determined to divest DERMAdoctor and consummate the DERMAdoctor Divestiture, which was not profitable, having incurred historical losses including the loss of $124 thousand for the six months ended June 30, 2024. The DERMAdoctor Divestiture streamlined our business by reducing our cash burn and allows us to focus on pursuing better growth opportunities. Â Recent Developments Â DERMAdoctor Divestiture Â On March 12, 2024, we entered into a Membership Unit Purchase Agreement (the â€œDERMAdoctor Purchase Agreementâ€) by and among: (i) New Age Investments, LLC; (ii) DERMAdoctor; and (iii) the Company that provided for the sale of 100% of the membership units (the â€œMembership Unitsâ€) of DERMAdoctor. Â Upon the closing of the DERMAdoctor Divestiture on March 25, 2024 as contemplated by the DERMAdoctor Purchase Agreement, the Company sold the Membership Units to New Age Investments, LLC for a purchase price of $1.1 million. For additional information regarding the DERMAdoctor Divestiture, see also Note 18, â€œDivestiture and Discontinued Operationsâ€ in the Notes to the Unaudited Condensed Consolidated Financial Statements in Part I, Item 1 of this report. Â -40- Table of Contents Â Amendment to the Security Agreement and Consent to Terminate the Subsidiary Guarantee Â The closing of the DERMAdoctor Divestiture was subject to certain conditions, which included the Company obtaining the consent of the holders (the â€œSecured Partiesâ€) of the Companyâ€™s Original Discount Senior Secured Convertible Debentures due November 1, 2024 (see Note 10, â€œConvertible Notesâ€), to (i) amend the Security Agreement, dated April 27, 2023 (the â€œSecurity Agreementâ€), to remove the Membership Units and any assets of DERMAdoctor as collateral for the Companyâ€™s obligations pursuant to the Secured Convertible Notes and for DERMAdoctor to be removed as a party to the Security Agreement and (ii) terminate the Subsidiary Guarantee, dated April 27, 2023, which DERMAdoctor entered into in connection with the issuance of the Secured Convertible Notes. Â On March 24, 2024, the Company and the Secured Parties entered into a First Amendment to the Security Agreement to effect the Security Agreement Amendment, and a Consent and Release to effect the 2024 Subsidiary Guarantee Termination. As consideration for the Secured Parties executing and delivering the First Amendment and the Subsidiary Guarantee Consent, which reduced the collateral available to secure the obligations under the Secured Convertible Notes, the Company provided each Secured Party the option, at the Secured Partyâ€™s election, to receive upon the closing of the DERMAdoctor Divestiture either: (i) a new Series D common stock purchase warrant (the â€œMarch 2024 Warrantâ€), or (ii) a new unsecured convertible note convertible into shares of common stock (the â€œUnsecured Convertible Notesâ€).Â Based on the Secured Partiesâ€™ elections and as a result of the closing of the DERMAdoctor Divestiture, the Company issued: (A) a March 2024 Warrant to a Secured Party that is exercisable for an aggregate of 28,572 shares of common stock and (B) Unsecured Convertible Notes to four (4) Secured Parties that have an aggregate principal amount of $525,000 or will be convertible into an aggregate of 107,146 shares of common stock. Â The Company incurred total issuance costs of $130 thousand in conjunction with the 2024 Subsidiary Guarantee Termination. The Company allocated $19 thousand of the issuance costs to the Unsecured Convertible Notes which was recorded as a discount in the Companyâ€™s unaudited condensed consolidated balance sheet as of June 30, 2024. The remaining $111 thousand was allocated to the embedded derivative liability and warrant liability and expensed as â€œOther expense, netâ€ in the Companyâ€™s unaudited condensed consolidated statements of operations, during the six months ended June 30, 2024. For additional information regarding the March 2024 Warrant and the Unsecured Convertible Notes that we issued, see also Notes 9, â€œFinancing Activitiesâ€; 10, â€œConvertible Notesâ€; 11, â€œCommon Stock Warrantsâ€; and 12, â€œStockholdersâ€™ (Deficit) Equityâ€ in the Notes to the Unaudited Condensed Consolidated Financial Statements in Part I, Item 1 of this report. Â NYSE American Notices Â On April 18, 2024, the Company received a notification (â€œInitial Deficiency Letterâ€) from the NYSE American LLC Exchange (â€œNYSE Americanâ€) stating that the Company is not in compliance with Section 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (requiring stockholdersâ€™ equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively). Â On May 28, 2024, the Company received a letter (â€œAdditional Deficiency Letterâ€) from NYSE American stating that the Company is not in compliance with the minimum stockholdersâ€™ equity requirements of Section 1003(a)(i) of the NYSE American Company Guide. Section 1003(a)(i) of the NYSE American Company Guide requires a listed company to maintain stockholdersâ€™ equity of $2.0 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. The Company reported stockholdersâ€™ equity of $160 thousand as of March 31, 2024 and has had losses from continuing operations and net losses in each of the last three fiscal years. Â Therefore, the Company has become subject to the procedures and requirements of Section 1009 of the NYSE American Company Guide and was required to submit a plan of compliance by May 18, 2024 addressing how it intends to regain compliance with Section 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide by October 18, 2025. On June 4, 2024, the Company received notice from the NYSE American that it had accepted the Companyâ€™s plan of compliance and granted a plan period through October 18, 2025. During the plan period, the Company will be subject to quarterly monitoring for compliance with the plan. If the Company does not regain compliance with the NYSE Americanâ€™s listing standards by October 18, 2025, or if the Company does not make progress consistent with its plan, then the NYSE American may initiate delisting procedures. Â -41- Table of Contents Â Financial Overview and Outlook Â We have incurred net losses and generated negative cash flows from operations since inception and expect to incur losses in the future as we continue to commercialize our products. Our net losses were $1.6 million and $4.0 million for the three months ended June 30, 2024 and 2023, respectively. In addition, our net losses were $5.2 million and $5.8 million for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, we had an accumulated deficit of $180.0 million, total current assets of $2.3 million and total assets of $3.9 million. Â We expect to grow commercial sales of Avenova branded products primarily through an expansion of domestic market penetration of our online channels as well expanded product offerings through partnerships with other eyecare product providers. Â Critical Accounting Estimates Â Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the reported revenues and expenses during the reporting periods. InÂ preparing these unaudited condensed consolidated financial statements, management has made its best estimates and judgments of certain amounts, giving due consideration to materiality. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates. Â -42- Table of Contents Â While our significant accounting policies are more fully described in Note 2, â€œSummary of Significant Accounting Policiesâ€ in the Notes to Unaudited Condensed Consolidated Financial Statements in Part I, Item 1Â of this report, we believe that the following accounting estimates are most critical to fully understanding and evaluating our reported financial results as discussed in this Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. Â Impairment of Goodwill, Indefinite-Lived Intangible Assets and Long-Lived Assets Â We review goodwill, indefinite-lived intangible assets and long-lived assets for impairment at least annually or whenever events or changes in business circumstances indicate that any such asset may be impaired, that the carrying amount of any such asset may not be fully recoverable or that the useful life of the asset, if applicable, is no longer appropriate. Management uses judgement in making critical assumptions and estimates in determining when an impairment assessment should be recorded, if more frequent than annually, or in the completion of any such assessment. This includes cash flow projections that look several years into the future and assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates. Changes in judgments with respect to these assumptions and estimates could impact any such impairments recorded such as those recorded in the fourth quarter of 2023 as further described in Note 2, â€œSummary of Significant Accounting Policiesâ€ included in our 2023 Annual Report. Â Valuation of Contingent Consideration Resulting from a Business Combination Â We revalue any outstanding contingent obligations to pay future consideration related to business combinations at the end of each quarter and record increases or decreases in their fair value within our unaudited condensed consolidated statements of operations. Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. See additional information in Note 2, â€œSummary of Significant Accounting Policiesâ€ in the Notes to Unaudited Condensed Consolidated Financial Statements in Part I, Item 1Â of this report. Â Estimates of Future Product Returns Â The Company records revenue in an amount that reflects the consideration which the Company expects to receive. Accordingly, revenue is reduced for estimated future product returns. The Companyâ€™s estimates for returns are updated quarterly based on historical data of actual returns. Actual future returns experience may differ significantly from historical data and could result in significant future adjustments, including a reduction of revenue recognized. Â Common Stock Warrant Liabilities Â For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the unaudited condensed consolidated statements of operations. The fair values of these warrants are determined using the Black Scholes option pricing model. These values are subject to a significant degree of managementâ€™s judgment. Â Results of Operations Â Comparison of the Three MonthsÂ Ended June 30, 2024 and 2023 (dollars in thousands) Â Â Â Three Months Ended June 30, Â Â Dollar Â Â Percent Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Statement of Operations Â Sales: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product revenue, net Â $ 2,387 Â Â $ 3,523 Â Â $ (1,136) Â Â (32)% Other revenue, net Â Â 13 Â Â Â 11 Â Â Â 2 Â Â Â 18 % Total sales, net Â Â 2,400 Â Â Â 3,534 Â Â Â (1,134) Â Â (32)% Â Cost of goods sold Â Â 808 Â Â Â 1,795 Â Â Â (987) Â Â (55)% Gross profit Â Â 1,592 Â Â Â 1,739 Â Â Â (147) Â Â (8)% Operating expenses Â Research and development Â Â 9 Â Â Â 22 Â Â Â (13) Â Â (59)% Sales and marketing Â Â 1,019 Â Â Â 1,175 Â Â Â (156) Â Â (13)% General and administrative Â Â 1,617 Â Â Â 1,593 Â Â Â 24 Â Â Â 2 % Total operating expenses Â Â 2,645 Â Â Â 2,790 Â Â Â (145) Â Â (5)% Operating loss Â Â (1,053) Â Â (1,051) Â Â (2) Â Â * % Â Non-cash (loss) gain on changes in fair value of warrant liabilities Â Â (80) Â Â 216 Â Â Â (296) Â Â (137)% Non-cash (loss) gain on change in fair value of embedded derivative liability Â Â (83) Â Â 40 Â Â Â (123) Â Â (308)% Accretion of interest and amortization of discounts on convertible notes Â Â (300) Â Â (501) Â Â 201 Â Â Â (40)% Other expense, net Â Â (69) Â Â (432) Â Â 363 Â Â Â (84)% Net loss from continuing operations Â Â (1,585) Â Â (1,728) Â Â 143 Â Â Â (8)% Â Net loss from discontinued operations Â Â â€” Â Â Â (308) Â Â 308 Â Â Â (100)% Net loss Â $ (1,585) Â $ (2,036) Â $ 451 Â Â Â (22)% Â *Less than 1%. Â -43- Table of Contents Â Impact of DERMAdoctor Divestiture Â The financial results of DERMAdoctor beginning from January 1, 2024 through the closing of the DERMAdoctor Divestiture on March 25, 2024 in the table above and as set forth in this report have been aggregated in the captions entitled â€œLoss on divestiture of subsidiaryâ€ and â€œNet loss from discontinued operationsâ€ for the three and six months ended June 30, 2024 (see Note 18, â€œDivestiture and Discontinued Operationsâ€ in the Notes to the Unaudited Condensed Consolidated Financial Statements in Part I, Item 1 of this report). The discussions below and throughout this section apply only to results from continuing operations except as otherwise noted. Â Total Net Sales and Cost of Goods Sold Â Product revenue, net, decreased $1.1 million, or 32%, to $2.4 million for the three months ended June 30, 2024, from $3.5 million for the three months ended June 30, 2023. Â Revenue from eyecare products, including Avenova Spray, increased $0.2 million to $2.4 million for the three months ended June 30, 2024, from $2.2 million for the three months ended June 30, 2023. The increase was due to an overall increase in Avenova branded products sold through online channels. Â Revenue from the Companyâ€™s wound care products decreased to a nominal amount for the three months ended June 30, 2024, from $1.3 million for the three months ended June 30, 2023. The decrease was due primarily to an unusually large order of the NeutroPhase branded wound care product in the three months ended June 30, 2023, with no comparable order in the three months ended June 30, 2024. Â Cost of goods sold decreased $1.0 million, or 55%, to $0.8 million for the three months ended June 30, 2024, from $1.8 million for the three months ended June 30, 2023. Such decrease was due primarily to the decrease in wound care products which has lower margins slightly offset by an increase in eyecare products which has higher margins sold during the three months ended June 30, 2024 as compared to the three months ended June 30, 2023. Â Sales and marketing Â Sales and marketing expenses decreased $0.2 million, or 13%, to $1.0 million for the three months ended June 30, 2024, from $1.2 million for the three months ended June 30, 2023. The decrease was due primarily to continued efficiencies in digital advertising costs and a decrease in professional services fees incurred in the three months ended June 30, 2024 compared to the three months ended June 30, 2023. Â General and administrativeÂ Â General and administrative expenses remained consistent for the three months ended June 30, 2024 and June 30, 2023. Â Non-cash (loss) gain on changeÂ in fair value of warrant liabilities Â Adjustments to the fair value of warrant liabilities resulted in a loss of $80 thousand for the three months ended June 30, 2024 and a gain of $216 thousand for the three months ended June 30, 2023. The warrant liabilities for the December 2023 Warrants and the March 2024 Warrant were reclassified to equity during the three months ended June 30, 2024 and 2023, respectively, and will no longer require fair value adjustments which will impact our results of operations. For additional information regarding warrant liabilities and their valuation, please see Note 11, â€œCommon Stock Warrantsâ€, in the Notes to Unaudited Condensed Consolidated Financial Statements, in Part I, Item 1 of this quarterly report. Â Non-cash (loss) gain on changes in fair value of embedded derivative liability Â Adjustments to the fair value of embedded derivative liability resulted in a loss of $83 thousand for the three months ended June 30, 2024 and a gain of $40 thousand for the three months ended June 30, 2023. For additional information regarding the embedded derivative liability and its valuation, please see Note 3, â€œFair Value Measurementsâ€. Â Accretion of interest and amortization of discounts on convertible notes Â Accretion of interest and amortization of discounts on convertible notes was $0.3 million for the three months ended June 30, 2024 and $0.5 million for the three months ended June 30, 2023. Â -44- Table of Contents Â Other expense, net Â Other expense, net decreased $363 thousand, or 84%, to $69 thousand for the three months ended June 30, 2024, from $432 thousand for the three months ended June 30, 2023. The decrease was primarily due to financing costs related to the Secured Convertible Notes in the three months ended June 30, 2023, slightly offset with financing costs related to the 2024 June Warrant Reprice

transaction in the three months ended June 30, 2024. Â Comparison of the Six MonthsÂ Ended June 30, 2024 and 2023 (dollars in thousands) Â Â Â Six Months Ended June 30, Â Â Dollar Â Â Percent Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Statement of Operations Â Â Â

Chief Executive Officer and our Interim Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure, at the reasonable assurance level, that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act was accumulated and communicated to our management, including our Chief Executive Officer and Interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Â Changes in Internal Control Over Financial Reporting Â There were no changes in our internal control over financial reporting during the current quarter which has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Â -50- Table of Contents Â PART II. OTHER INFORMATION Â ITEM 1. LEGAL PROCEEDINGS Â From time to time, the Company may be involved in various legal proceedings arising in the ordinary course of business. As of June 30, 2024, there were no matters that, in the opinion of management, would ultimately result in liability that would have a material adverse effect on the Companyâ€™s financial position, results of operations or cash flows. Â ITEM 1A. RISK FACTORS Â For information regarding factors that could affect our business, results of operations, financial condition and liquidity, see the risk factors discussed under Part I, Item 1A included in our 2023 Annual Report and under Part II, Item 1A included in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, which was filed with the SEC on May 9, 2024. We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide updated quarterly information under this Item.Â Â -51- Table of Contents Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Â None. Â ITEM 3. DEFAULTS UPON SENIOR SECURITIES Â None. Â ITEM 4. MINE SAFETY DISCLOSURES Â Not Applicable.Â Â Â ITEM 5. OTHER INFORMATION Â Rule 10b5-1 Trading Arrangements Â During the six months ended June 30, 2024, none of our directors or Section 16 officers adopted, modified or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each such term is defined in Item 408 of Regulation S-K. Â -52- Table of Contents Â Â Â ITEM 6. EXHIBITS Â The following exhibits are filed with or incorporated by reference into this report. Â EXHIBIT INDEX Â Â Incorporation by Reference Filed Herewith Exhibit Number Exhibit Description Form File Number Exhibit/ Form 8-K Item Reference Filing Date Â 2.1 Membership Unit Purchase Agreement dated September 27, 2021, by and among the Company, DERMAdoctor, the Founders and the Sellers (as defined therein) 8-K 001-3678 2.1 9/28/2021 Â 2.2 Membership Unit Purchase Agreement, dated March 12, 2024, by and among the Company, DERMAdoctor, the Founders and New Age Investments 8-K 001-33678 2.1 03/14/2024 Â 3.1 Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc. 10-K 001-33678 3.1 3/21/2018 Â 3.2 Amendment to the Amended and Restated Certificate of Incorporation, dated June 4, 2018 8-K 001-33678 3.1 6/4/2018 Â 3.3 Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 27, 2020 8-K 001-33678 3.1 5/28/2020 Â 3.4 Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 24, 2021 8-K 001-33678 3.1 5/24/2021 Â 3.5 Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated January 31, 2022 8-K 001-33678 3.1 2/1/2022 Â 3.6 Amendment to Amended and Restated Certificate of Incorporation, as amended, dated November 14, 2022 8-K 001-33678 3.1 11/18/2022 Â 3.7 Amendment to Amended and Restated Certificate of Incorporation, as amended, dated May 30, 2024 8-K 001-33678 3.1 5/31/2024 Â 3.8 Certificate of Designation for the Series B Preferred Stock 8-K 001-33678 3.1 11/1/2021 Â 3.9 Certificate of Designation for the Series C Preferred Stock 8-K 001-33678 3.2 11/18/2022 Â 3.10 Bylaws, as amended and restated effective June 13, 2023 8-K 001-33678 3.1 6/14/2023 Â 4.1 Form of Warrant pursuant to the Services Agreement with TLF Bio Innovation Lab, LLC, dated May 13, 2020 8-K 001-33678 4.1 5/18/2020 Â 4.2 Form of July 2020 Warrant 8-K 001-33678 4.1 7/21/2020 Â 4.3 Form of Amended July 2020 Warrant 8-K 001-33678 4.1 9/13/2022 Â 4.4 Form of Amended November 2021 Warrant 8-K 001-33678 4.2 9/13/2022 Â 4.5 Form of September 2022 Warrant (2020 participants) 8-K 001-33678 4.3 9/13/2022 Â 4.6 Form of September 2022 Warrant (2021 participants) 8-K 001-33678 4.4 9/13/2022 Â 4.7 Form of Series A-1 Long-Term Warrant 8-K 001-33678 4.5 9/13/2022 Â 4.8 Form of Original Issue Discount Secured Senior Convertible Debenture 8-K 007-33678 4.1 4/27/2023 Â 4.9 Form of Series B-1 Long-Term Warrant 8-K 001-33678 4.2 4/27/2023 Â 4.10 Form of Series B-2 Short-Term Warrant 8-K 001-33678 4.3 4/27/2023 Â 4.11 Form of Warrant Amendment Agreement 8-K 001-33678 4.4 4/27/2023 Â 4.12 Form of Series C Common Stock Warrant 8-K 001-33678 4.1 12/21/2023 Â 4.13 Form of Series D Common Stock Warrant 8-K 001-33678 4.2 3/25/2024 Â 4.14 Form of Series E Common Stock Warrant 8-K 001-33678 4.1 6/14/2024 Â 4.15 Form of Unsecured Convertible Notes 8-K 001-33678 4.3 3/25/2024 Â 4.16 Form of Pre-Funded Common Stock Warrant 8-K 001-33678 4.4 3/25/2024 Â 4.17 Form of Series F-1 Common Stock Warrant 8-K 001-33678 4.1 7/29/2024 Â 4.18 Form of Series F-2 Common Stock Warrant 8-K 001-33678 4.2 7/29/2024 Â 4.19 Form of Series F-3 Common Stock Warrant 8-K 001-33678 4.3 7/29/2024 Â 10.1 Form of Letter Agreement, dated June 14, 2024 8-K 001-33678 10.1 6/14/2024 Â 10.2 Underwriting Agreement, dated July 26, 2024, by and between the Company and Ladenburg Thalmann & Co., Inc. 8-K 001-33678 4.3 7/29/2024 Â 10.3 Warrant Agency Agreement, dated July 29, 2024, by and between the Company and Equinti Trust Company, LLC 8-K 001-33678 10.1 7/29/2024 Â 31.1 Certification of the Principal Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) Â Â Â Â X Â -53- Table of Contents Â 31.2 Certification of the Principal Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) Â Â Â Â X 32.1 Certification by the Chief Executive OfficerÂ of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18Â U.S.C. 1350) Â Â Â Â X 32.2 Certification by the Chief Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18Â U.S.C. 1350) Â Â Â Â X 101.INS Inline XBRL Instance Document Â Â Â Â X 101.SCH Inline XBRL Taxonomy Extension Schema DocumentÂ Â Â Â Â X 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document Â Â Â Â X 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Â Â Â Â X 101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document Â Â Â Â X 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Â Â Â Â X 104 The Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments) Â Â Â Â X Â -54- Table of Contents Â SIGNATURES Â Pursuant to the requirements of SectionÂ 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report on FormÂ 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized. Â Date: August 13, 2024 Â Â By: /s/Â Â Â Justin HallÂ Â Â Justin HallÂ Chief Executive Officer, General Counsel and Director (principal executive officer) Â Date: August 13, 2024 Â Â By: /s/Â Â Â Tommy Law Â Â Tommy Law Interim Chief Financial Officer (principal financial officer) Â Â -55- EX-31.1 2 ex_709225.htm EXHIBIT 31.1 Exhibit 31.1 Â CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Justin Hall, certify that: Â 1. I have reviewed this Form 10-Q of NovaBay Pharmaceuticals, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s Board of Directors (or persons performing the equivalent functions): Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: August 13, 2024 Â /s/ Justin Hall Â Justin Hall Â Chief Executive Officer, General Counsel and DirectorÂ (principal executive officer) Â Â EX-31.2 3 ex_709226.htm EXHIBIT 31.2 Exhibit 31.2 Â CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Tommy Law, certify that: Â 1. I have reviewed this Form 10-Q of NovaBay Pharmaceuticals, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s Board of Directors (or persons performing the equivalent functions): Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: August 13, 2024 Â /s/ Tommy LawÂ Â Tommy Law Â Interim Chief Financial Officer Â (principal financial officer) Â Â Â EX-32.1 4 ex_709227.htm EXHIBIT 32.1 Exhibit 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. Â§1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the quarterly report of NovaBay Pharmaceuticals, Inc. (the Company) on Form 10-Q for the quarter ended June 30, 2024 (the Report), I, Justin Hall, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: Â 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: August 13, 2024 Â /s/ Justin HallÂ Â Justin Hall Â Chief Executive Officer, General Counsel and Director Â This Certification is made solely for the purpose of 18 USC Section 1350, subject to the knowledge standard contained therein, and not for any other purpose. Â Â EX-32.2 5 ex_709228.htm EXHIBIT 32.2 Exhibit 32.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. Â§1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the quarterly report of NovaBay Pharmaceuticals, Inc. (the Company) on Form 10-Q for the quarter ended June 30, 2024 (the Report), I, Tommy Law, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: Â 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: August 13, 2024 Â /s/ Tommy LawÂ Â Tommy Law Â Interim Chief Financial Officer Â This Certification is made solely for the purpose of 18 USC Section 1350, subject to the knowledge standard contained therein, and not for any other purpose. Â EX-101.SCH 6 nby-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Organization link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Inventory link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Accrued Liabilities link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Financing Activities link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Convertible Notes link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Common Stock Warrants link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Stockholders' (Deficit) Equity link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 13 - Equity-based Compensation link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 14 - Distribution Agreements link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 15 - Employee Benefit Plan link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 16 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 17 - Segment Reporting link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 18 - Divestiture and Discontinued Operations link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 19 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 3 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 5 - Inventory (Tables) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 6 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 7 - Accrued Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 8 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 10 - Convertible Notes (Tables) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 11 - Common Stock Warrants (Tables) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 13 - Equity-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 14 - Distribution Agreements (Tables) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 16 - Related Party Transactions (Tables) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 18 - Divestiture and Discontinued

Operations (Tables) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 1 - Organization (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 5 - Inventory - Summary of Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 6 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 6 - Property and Equipment - Summary of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 8 - Commitments and Contingencies - Lease Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note 9 - Financing Activities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note 10 - Convertible Notes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995502 - Disclosure - Note 10 - Convertible Note - Convertible Notes (Details) link:calculationLink link:definitionLink link:presentationLink 995503 - Disclosure - Note 11 - Common Stock Warrants (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995504 - Disclosure - Note 11 - Common Stock Warrants - Outstanding Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 995505 - Disclosure - Note 11 - Common Stock Warrants - Warrants Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 995506 - Disclosure - Note 11 - Common Stock Warrants - Reconciliation of Common Stock Warrant Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995507 - Disclosure - Note 12 - Stockholders' (Deficit) Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995508 - Disclosure - Note 13 - Equity-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995509 - Disclosure - Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 995510 - Disclosure - Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) link:calculationLink link:definitionLink link:presentationLink 995511 - Disclosure - Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) link:calculationLink link:definitionLink link:presentationLink 995512 - Disclosure - Note 14 - Distribution Agreements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995513 - Disclosure - Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995514 - Disclosure - Note 15 - Employee Benefit Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995515 - Disclosure - Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 995516 - Disclosure - Note 17 - Segment Reporting (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995517 - Disclosure - Note 18 - Divestiture and Discontinued Operations (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995518 - Disclosure - Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) link:calculationLink link:definitionLink link:presentationLink 995519 - Disclosure - Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 995520 - Disclosure - Note 19 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 7 nby-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 nby-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Dividend yield us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Issuance of common stock in connection with 2024 Warrant Reprice Transaction, net of offering costs Value of stock issued as a result of warrants exercise.. Note To Financial Statement Details Textual Significant Accounting Policies Note 2 - Summary of Significant Accounting Policies Risk-free interest rate us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Note 3 - Fair Value Measurements Note 4 - Prepaid Expenses and Other Current Assets Issuance of common stock in connection with 2024 Warrant Reprice Transaction, net of offering costs (in shares) Stock issued in connection with warrants exercise. Note 5 - Inventory Note 6 - Property and Equipment Note 7 - Accrued Liabilities Note 8 - Commitments and Contingencies Note 10 - Convertible Notes Note 11 - Common Stock Warrants Note 13 - Equity-based Compensation Note 14 - Distribution Agreements Expected price volatility us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Note 16 - Related Party Transactions us-gaap_LiabilitiesCurrent Total current liabilities Note 18 - Divestiture and Discontinued Operations Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) Total current liabilities, discontinued operations Current liabilities, discontinued operations Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details) Expected term (in years) (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details) Patent Costs Policy [Policy Text Block] Disclosure of accounting policy for patent costs. Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] nby_NumberOfMajorSourceManufacturers Number of Major Source Manufacturers Represents number of major source manufacturers. Warrant Liabilities [Policy Text Block] The disclosure of accounting policy for warrant liabilities. Warrant liabilities nby_WarrantLiabilitiesFairValueDisclosure The fair value of warrant obligations. Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Note 5 - Inventory - Summary of Inventory (Details) nby_PaymentForProductSupplyPeriod Payment for Product Supply Period Period within which payment for product supply is expected from customer. Note 6 - Property and Equipment - Summary of Property and Equipment (Details) Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) Warrants granted (in shares) Class of Warrant or Right, Issued During Period The number of warrants or rights issued during period. Note 8 - Commitments and Contingencies - Lease Expense (Details) Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) Warrants granted, weighted average exercise price (in dollars per share) Weighted average exercise price per share of warrants or rights issued during period. Note 10 - Convertible Note - Convertible Notes (Details) us-gaap_GoodwillAndIntangibleAssetImpairment Goodwill and Intangible Asset Impairment Warrants expired, weighted average exercise price (in dollars per share) Weighted average exercise price per share of warrants or rights forfeited during period. Note 11 - Common Stock Warrants - Outstanding Warrants (Details) Warrants expired (in shares) Class of Warrant or Right, Forfeited During Period The number of warrants or rights forfeited during period. Note 11 - Common Stock Warrants - Warrants Outstanding (Details) Restricted stock units granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Note 11 - Common Stock Warrants - Reconciliation of Common Stock Warrant Liabilities (Details) Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) The 2007 Omnibus Incentive Plan [Member] Represents the 2007 Omnibus Incentive Plan. Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details) nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOfStockOwnedByShareholderMinimum Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum Minimum percentage of a shareholder's ownership of common stock used for determining the purchase price of common stock expressed as a percentage of its fair value. Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) (Parentheticals) Shareholder of More Than 10% [Member] Represents the shareholder of more than 10%. Notes To Financial Statements Notes To Financial Statements [Abstract] Outstanding, weighted-average remaining contractual life (Year) Outstanding, aggregate intrinsic value Weighted-average fair value of options granted during the period (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Unsecured Convertible Notes, net of discounts Prepaid Expenses and Other Current Assets [Text Block] The entire disclosure for prepaid expenses and other assets expected to be realized or consumed within one year or the normal operating cycle, if longer. Retirement Plan Name [Axis] Retirement Plan Name [Domain] Secured Convertible Notes, net of discounts Total Secured Convertible Notes, net License, Collaboration, and Distribution Agreements [Text Block] The entire disclosure of license, collaboration, and distribution agreements. Options forfeited/cancelled, weighted-average exercise price (in dollars per share) Total accrued liabilities Accrued liabilities Employee payroll and benefits Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Options forfeited/cancelled (in shares) us-gaap_OtherAccruedLiabilitiesCurrent Other us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment nby_EmbeddedDerivativeFairValue Embedded Derivative, Fair Value Represents the fair value of embedded derivative. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Contract liabilities (see Note 14) nby_ContractWithCustomerAccruedLiabilitiesCurrent The amount of accrued liabilities related to contract with customer. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Grantee Status [Domain] Grantee Status [Axis] Product and Service, Other [Member] Interest paid in discontinued operations us-gaap_LiabilitiesAndStockholdersEquityAbstract Liabilities and Equity [Abstract] nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted-average exercise price (in dollars per share) Outstanding, weighted-average exercise price (in dollars per share) Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan or equity instruments other than options. Operating lease liabilities us-gaap_IncreaseDecreaseInOperatingLeaseLiability Operating lease liabilities nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding Outstanding awards (in shares) Outstanding awards (in shares) The number of equity-based payment instruments, including stock (or unit) options, outstanding during the reporting period. Product [Member] Supplemental disclosure of non-cash information: us-gaap_Assets TOTAL ASSETS Supplemental disclosure of cash flow information: Plan Name [Axis] Plan Name [Domain] us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment Disposal Group, Including Discontinued Operation, Property, Plant and Equipment us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net loss attributable to common stockholders us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Vested and expected to vest (in shares) As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options and equity instruments other than options outstanding can be converted under the option plan. Cash and cash equivalents us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents Cash and cash equivalents, discontinued operations Vested and expected to vest, weighted-average exercise price (in dollars per share) As of the balance sheet date, the weighted-average exercise price for outstanding stock options and equity instruments other than options that are fully vested or expected to vest. Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023) us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Vested and expected to vest at March 31, 2024Vested and expected to vest, weighted-average remaining contractual life (Year) Weighted average remaining contractual term for fully vested and expected to vest equity instruments other than options and options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. TLF Bio Innovation 2021 Warrants [Member] Represents information pertaining to TLF Bio Innovation 2021 Warrants. Vested and expected to vest, aggregate intrinsic value Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest equity instruments other than options and options outstanding. Share-Based Payment Arrangement [Text Block] Vested and exercisable (in shares) The number of shares into which fully or partially vested stock equity instruments other than options and options outstanding as of the balance sheet date can be currently converted under the option plan. Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Exercisable, weighted-average exercise price (in dollars per share) Weighted average price at which option or equity instruments other than options, holders acquired shares when converting their stock options or equity instruments other than options, into shares. Exercisable, weighted-average remaining contractual life (Year) Weighted average remaining contractual term for equity instruments other than options and options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Award Type [Domain] The July 2020 Warrants [Member] Represents the July 2020 warrants. Restricted cash included in other assets Net loss from continuing operations The November 2021 Warrants [Member] Represents the November 2021 Warrants. Net loss from discontinued operations Net loss from discontinued operations (Note 18) Net loss from discontinued operations Net loss from discontinued operations Net loss Net loss Award Type [Axis] Distributor Concentration Risk [Member] Represents distributor concentration risk. Restricted Stock Units (RSUs) [Member] Restricted Stock [Member] NeutroPhase [Member] Represents the distribution agreement for NeutroPhase. Share-Based Payment Arrangement, Option [Member] Warrant [Member] Chargebacks, Discounts for Prompt, Payment, and Other [Member] Represents chargebacks, discounts for prompt, payment, and other. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Rebates [Member] Represents rebates. Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] us-gaap_PreferredStockConvertibleSharesIssuable Preferred Stock, Convertible, Shares Issuable (in shares) us-gaap_PreferredStockConvertibleConversionPrice Preferred Stock, Convertible, Conversion Price (in dollars per share) us-gaap_PreferredStockConvertibleConversionRatio Preferred Stock, Convertible, Conversion Ratio Current period Represents contract with customer, liability, current period. us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less: accumulated depreciation Commitments and Contingencies Disclosure [Text Block] Property and equipment, net Total property and equipment, net Property and equipment, at cost

nby_ContractWithCustomerLiabilityPaymentsAndCustomerCreditsIssued Payments and customer credits issued Represents contract with customer, liability, payments and customer credits issued. Underwriting Agreement [Member] Represents the underwriting agreement. Derivative Instrument [Axis] Derivative Contract [Domain] Investing activities: nby_ProceedsFromIssuanceOfStockAndWarrants Proceeds from Issuance of Stock and Warrants The cash inflow from the issuance of stock and warrant. Convertible Debt [Member] Accounts payable and accrued liabilities us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Accounts payable and accrued liabilities Adjustment of Series C Preferred Stock conversion price Amount of decrease in additional paid in capital (APIC) resulting from down round feature adjustment related to preferred stock. DERMAdoctor [Member] Represents DERMAdoctor. The 401K Plan Contribution Level One [Member] The 401K Plan Contribution Level One. The 401K Plan Contribution Level Two [Member] Represents The 401k Plan Contribution Level Two. Related Party Transactions Disclosure [Text Block] Schedule of Related Party Transactions [Table Text Block] us-gaap_DebtInstrumentRedemptionPricePercentage Debt Instrument, Redemption Price, Percentage us-gaap_OtherExpenses Other Expenses us-gaap_OperatingExpenses Total operating expenses us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount General and administrative us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match Cash and cash equivalents us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet Debt Instrument, Increase (Decrease), Net us-gaap_DebtInstrumentConvertibleThresholdTradingDays Debt Instrument, Convertible, Threshold Trading Days us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price Stock-based compensation expense us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Debt Instrument, Convertible, Number of Equity Instruments Change in fair value of warrant liability during period Amendment Flag Proceeds from issuance of Secured Convertible Notes and May 2023 Warrants, net of discounts Proceeds From Debenture and Warrant Issuances, Net Amount of cash inflow from debenture and warrant issuances, net. dei_CityAreaCode City Area Code us-gaap_GainLossOnSaleOfBusiness Loss on divestiture of subsidiary Gain (Loss) on Disposition of Business Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Shares issued for 35:1 reverse stock split due to rounding feature (in shares) Reclassification, Comparability Adjustment [Policy Text Block] us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding (in shares) us-gaap_IncreaseDecreaseInOtherOperatingAssets Other assets Other assets Current Fiscal Year End Date us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets us-gaap_DebtInstrumentInterestRateEffectivePercentage Debt Instrument, Interest Rate, Effective Percentage Weighted-average discount rate Document Fiscal Period Focus Operating lease â€“ expense Original Issue Discount Senior Secured Convertible Debentures [Member] Represents Original Issue Discount Senior Secured Convertible Debentures. Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] May 2023 Warrants [Member] Represents May 2023 warrants. Lease, Cost [Table Text Block] dei_DocumentPeriodEndDate Document Period End Date The 2023 Private Placement [Member] Represents the 2023 Private Placement. Weighted-average remaining lease term (in years) (Year) dei_EntityFileNumber Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount dei_DocumentType Document Type Amended November 2021 Warrants Exercisable for 6.50 [Member] Represents the Amended November 2021 Warrants exercisable for $6.50. Entity Small Business Amended November 2021 Warrants Exercisable for 1.50 [Member] Represents Amended November 2021 Warrants exercisable for $1.50. dei_EntityShellCompany Entity Shell Company Document Information [Line Items] Deemed dividend Document Information [Table] Reclassification of Warrants from liability Represents the amount of reclassification of private placement warrants. us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Warrant liabilities Reclassification of warrant liability to equity during period Entity Filer Category Debt Instrument [Axis] dei_EntityCurrentReportingStatus Entity Current Reporting Status Debt Instrument, Name [Domain] Computer Equipment and Software [Member] Represents information about computer equipment and software. Costco and Others [Member] Represents Costco and others. Restricted cash held as a certificate of deposit nby_RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure Fair value portion of restricted cash held as a certificate of deposit. Fair value of March 2024 Warrant upon issuance us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Impairment, Long-Lived Asset, Held-for-Use Schedule of Long-Term Debt Instruments [Table Text Block] us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Accounts receivable Accounts receivable, concentration risk Concentration Risk, Percentage Entity Tax Identification Number Entity Central Index Key The 2024 Warrant Reprice Existing Warrants [Member] Represents the Existing Warrants that are a part of the 2024 Warrant Reprice Transaction. dei_EntityRegistrantName Entity Registrant Name Stock-based compensation expense related to employee and director stock awards Post amendment June 14, 2024 [Member] Represents period after the amendment on June 14, 2024. Liability Class [Axis] Fair Value by Liability Class [Domain] The 2024 Warrant Reprice Transaction [Member] Represents the 2024 Warrant Reprice Transaction. June 2024 Warrant [Member] Represents the June 2024 warrants. Entity [Domain] Customer Concentration Risk [Member] Stockholder Approval May 28 2024 [Member] Represents Stockholder Approval on May 28, 2024. Legal Entity [Axis] Pre-amendment June 14, 2024 [Member] Represents period prior to the amendment on June 14, 2024. dei_EntityAddressAddressLine1 Entity Address, Address Line One September 2022, November 2022, and May 2023 Warrants [Member] Represents the September 2022, November 2022, and May 2023 warrants. us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Prefunded Warrants 2024 Public Offering [Member] Represents the prefunded warrants that are part of the 2024 Public Offering. The 2024 Public Offering [Member] Represents the 2024 Public Offering ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] dei_EntityAddressCityOrTown Entity Address, City or Town Election of the holder prior to the date of issuance [Member] Represents the election of the holder prior to the date of issuance. ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] Series F-1 Warrants [Member] Represents the Series F-1 warrants. ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] dei_EntityAddressPostalZipCode Entity Address, Postal Zip Code September 2022 Warrants Amended in 2023 Private Placement [Member] Represents the portion of September 2022 warrants that were amended in the 2023 Private Placement. dei_EntityAddressStateOrProvince Entity Address, State or Province Concentration Risk Type [Axis] September 2022 Warrants Amended [Member] Represents the September 2022 warrants as amended. ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss September 2022 Warrants Amended in 2024 Warrant Reprise Transaction [Member] Represents September 2022 warrants amended in the 2024 Warrant Reprise Transaction. Material Terms of Trading Arrangement [Text Block] Underwriter From 2024 Public Offering [Member] Represents the underwriter for the 2024 Public Offering. Maximum Amount Purchasable By Underwriter [Member] Represents the maximum amount purchasable by underwriter. May 2023 Warrants Amended By 2023 Warrant Reprice Transaction [Member] Represents May 2023 warrants amended by the 2023 Warrant Reprice Transaction. May 2023 Warrants Amended By 2024 Warrant Reprice Transaction [Member] Represents the portion of May 2024 warrants amended by the 2024 Warrant Reprice Transaction. dei_EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding (in shares) Series F-2 Warrants [Member] Represents Series F-2 warrants. Series F-3 Warrants [Member] Represents the Series F-3 Warrants. us-gaap_AdvertisingExpense Advertising Expense Accounts Receivable [Member] November 2022 Warrants Amended By 2024 Warrant Reprice Transaction [Member] Represents the November 2022 warrants that were amended by the 2024 Warrant Reprice Transaction. us-gaap_IncreaseDecreaseInInventories Inventory Inventory Revenue from Contract with Customer Benchmark [Member] Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] dei_LocalPhoneNumber Local Phone Number us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) us-gaap_TableTextBlock Notes Tables Vesting of director restricted stock awards (in shares) Vesting of director restricted stock awards Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations Net decrease in cash, cash equivalents, and restricted cash, continuing operations Expiration date Net decrease in cash and cash equivalents, discontinued operations us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) Measurement Input Sales and marketing us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term Collaborative Arrangement and Arrangement Other than Collaborative [Domain] us-gaap_StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues (in shares) us-gaap_LiabilitiesAndStockholdersEquity TOTAL LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Measurement input, embedded derivative The 2019 Ladenburg Warrants [Member] Information pertaining to the warrants issued to Ladenburg Thalmann & Co., Inc. for its services as placement agent in the registered direct offering. Total value, embedded Embedded Derivative, Fair Value of Embedded Derivative Liability Total assets, discontinued operations Other assets, discontinued operations Accumulated deficit Research and development Measurement Input, Share Price [Member] Debt Disclosure [Text Block] Other assets us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets nby_PreferredStockChangeInConversionPriceIncomeStatementImpact Preferred Stock, Change in Conversion Price, Income Statement Impact Amount of income statement impact from change in conversion price on preferred stock. Measurement Input, Price Volatility [Member] Changes in operating assets and liabilities: Measurement Input, Risk Free Interest Rate [Member] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Measurement Input, Option Volatility [Member] Operating lease liabilities-non-current Operating lease liability- non-current Measurement Input, Expected Dividend Rate [Member] Inventory Disclosure [Text Block] Subsequent Event [Member] Measurement Input, Expected Term [Member] Schedule of Inventory, Current [Table Text Block] Modification of common stock warrants in connection with 2024 Warrant Reprice Transaction Amount of increase to APIC from modification of warrant. Total Total Operating lease liabilities Measurement Input, Exercise Price [Member] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Retirement Benefits [Text Block] nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingCommonStock Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock Annual increase in number of shares originally approved for awards under the equity-based compensation plan expressed as a percentage of outstanding common stock. Subsequent Events [Text Block] Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total future minimum lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: Imputed interest Avenova Direct [Member] Related to Avenova Direct. Measurement Input Type [Axis] Measurement Input Type [Axis] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2027 Measurement Input Type [Domain] Fair Value of Financial Instruments, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2025 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2026 Share-Based Payment Arrangement, Employee [Member] Non-cash gain on changes in fair value of warrant liabilities Non-cash (loss) gain on changes in fair value of warrant liabilities Fair Value Adjustment of Warrants Fair Value Adjustment of Warrants us-gaap_StockOptionPlanExpense Stock-based compensation expense related to employee and director stock awards Other assets Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Lessee, Leases [Policy Text Block] us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear 2024 Share-Based Payment Arrangement, Nonemployee [Member] nby_PreferredStockMeasurementInput Measurement Input Measurement input for preferred stock. us-gaap_AmortizationOfFinancingCostsAndDiscounts Accretion of interest and amortization of discounts on convertible notes Amortization of Debt Issuance Costs and Discounts Earnings Per Share, Policy [Policy Text Block] Operating expenses: Accretion of interest and amortization of debt discounts on convertible notes Income Tax, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Conversion of Preferred Stock to common stock Depreciation of property and equipment Depreciation Non-cash expense incurred to obtain consent of Secured Convertible Note holders Amount of noncash expense incurred to obtain consent of secured note holders. us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio Issuance of embedded derivative liability in conjunction with Unsecured Convertible Notes Amount of derivative liability issued with notes. Total Value Conversion of Preferred Stock to common stock (in shares) Conversion of Preferred Stock to common stock (in shares) March 2024 Warrant [Member] Represents the March 2024 warrant. Stock Conversion Description [Axis] Issuance, March 25, 2024 [Member] Represents the issuance at March 25, 2024. us-gaap_DepreciationAndAmortizationDiscontinuedOperations Amortization of intangible assets Conversion of Stock, Name [Domain] Reporting Date, March 31, 2024 [Member] Represents reporting date of March 31, 2024. us-gaap_AssetsCurrent Total current assets us-gaap_UnrealizedGainLossOnDerivatives Unrealized Gain (Loss) on Derivatives Share-Based Payment Arrangement [Policy Text Block] Equity [Text Block] Operating lease from discontinued operations â€“ included in operating cash flow Amount of operating lease payments attributable to disposal group, including, but not limited to, discontinued operation. Operating lease from discontinued operations â€“ expense Amount of operating lease cost attributable to disposal group, including, but not limited to, discontinued operation. After Ratchet, March 24, 2024 [Member] Represents after ratchet on March 24, 2024. Other Customer Fees [Member] Represents other customer fees. nby_DisposalGroupIncludingDiscontinuedOperationPercentageSold Disposal Group, Including Discontinued Operation, Percentage Sold Percentage of business sold for the disposal of assets and liabilities, including discontinued operation. nby_DisposalGroupIncludingDiscontinuedOperationsDefinedContributionPlanEmployerDiscretionaryContributionAmount Disposal Group, Including Discontinued Operations, Defined Contribution Plan, Employer Discretionary Contribution Amount Amount of discretionary contributions made by an employer to a defined contribution plan from disposal group including discontinued operations. Allowance for credit losses nby_DisposalGroupIncludingDiscontinuedOperationAccountsReceivableAllowance Amount of allowance on accounts receivable attributable to disposal group held for sale or disposed of. Operating lease liabilities nby_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. Total current assets, discontinued operations Current assets, discontinued operations Advertising Cost [Policy Text Block] Common stock, $0.01 par value; 150,000 shares authorized, 1,348 and 321 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively nby_ContractWithCustomerLiabilityIncludingDisposalGroup Balance at December 31, 2023 Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] The May 2023 Warrants [Member] Represents the May 2023 warrants. Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized (in shares) Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023) us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Inventory, net of reserves, from discontinued operations Research and development nby_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation. Reserve nby_DisposalGroupIncludingDiscontinuedOperationInventoryReserve Amount of reserve on inventory attributable to disposal group. Common stock, shares issued (in shares) Prepaid expenses and other current assets us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Prepaid expenses from discontinued operations Sales and marketing nby_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense Amount of selling and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Revision of Prior Period [Axis] Revision of Prior Period [Domain] Previously Reported [Member] Revision of Prior Period, Adjustment [Member] Statistical Measurement [Domain] Operating lease â€“ included in operating cash flow Maximum [Member] Minimum [Member] Product and Service [Axis] us-gaap_OtherAssetsCurrent Other Product and Service [Domain] The 2022 Warrant Reprice Transaction [Member] Represents the 2022 warrant reprice transaction. Statistical Measurement [Axis] Amended July 2020 Warrants [Member] Represents amended July 2020 warrants. Preferred Stock Valuation of Contingent Consideration from Business Combination Policy [Policy Text Block] Disclosure of accounting policy for valuation of contingent consideration from business combination. Preferred

stock, shares issued (in shares) Preferred Stock, Shares Issued (in shares) Prepaid taxes Interest paid in continuing operations Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Property, Plant and Equipment Disclosure [Text Block] Goodwill and Intangible Assets, Policy [Policy Text Block] Property, Plant and Equipment [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized (in shares) Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding. Major U.S. Retailer A [Member] Represents major U.S. retailer A. Total inventory, net Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($204 and $264 at June 30, 2024 and December 31, 2023, respectively) Avenova Spray [Member] Represents Avenova spray. Preferred stock par value (in dollars per share) Prepaid insurance July 2020, November 2021, September 2022 & November 2022 Warrants [Member] Related to warrants. Total sales, net Revenue from Contract with Customer, Including Assessed Tax Raw materials and supplies Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments Inventory Valuation Reserves Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block] Tabular disclosure of the components of cash, cash equivalents, restricted cash and restricted cash equivalents. Fair Value, Inputs, Level 3 [Member] The 2022 Private Placement [Member] Represents the 2022 Private Placement. The Amended November 2021 Warrants [Member] Represents the amended November 2021 warrants. Prepaid dues and subscriptions The amount of prepaid due and subscriptions. Finished goods Unaudited Interim Financial Information, Policy [Policy Text Block] Disclosure of accounting policy for unaudited interim financial information. Fair Value Hierarchy and NAV [Domain] Customer [Axis] Customer [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Warrants exercised, weighted-average exercise price (in dollars per share) Weighted average exercise price per share of warrants or rights exercised during period. Office and Laboratory Equipment [Member] Represents office and laboratory equipment. The Amended July 2020 Warrants [Member] Represents the amended warrants of July 2020. us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life Prepaid inventory Represents the advance payment of inventory. Operating activities: Revenue [Policy Text Block] Statement [Line Items] Accounts receivable, allowance for doubtful accounts Accounts receivable, net of allowance for credit losses ($3 at June 30, 2024 and December 31, 2023) Furniture and Fixtures [Member] us-gaap_NumberOfReportableSegments Number of Reportable Segments Additional paid-in capital Series B Preferred Stock and Series C Preferred Stock [Member] Represents Series B Preferred Stock and Series C Preferred Stock. nby_DebtInstrumentDefaultInterestRate Debt Instrument, Default, Interest Rate Percentage of interest in the event of default of the debt instrument. Stockholdersâ€™ (deficit) equity: Total Product Revenue [Member] Represents total product revenue. Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] us-gaap_OtherNonoperatingIncomeExpense Other expense, net Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] Fair Value Disclosures [Text Block] Shares issued for 35:1 reverse stock split due to rounding feature Represents the amount as a result of a reduction in the number of shares during the period as a result of a reverse stock split. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, cash equivalents and restricted cash, beginning of year, consolidated Cash, cash equivalents and restricted cash of continuing operations, end of period Warrant Liability [Member] Represents information about warrant liability. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations Less: Cash and cash equivalents of discontinued operations, end of period The September 2022 Warrants [Member] Represents the September 2022 warrants. Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows us-gaap_AssetsAbstract Assets [Abstract] Inventory, Policy [Policy Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash, cash equivalents, and restricted cash, consolidated Over-Allotment Option [Member] us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash (used in) provided by financing activities, continuing operations Commitments and Contingencies Unsecured Convertible Notes [Member] Relating Unsecured Convertible Notes. Director [Member] Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Operating loss Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities, continuing operations Total liabilities, discontinued operations us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation Prepaid expenses and other current assets Total prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by (used in) investing activities, continuing operations us-gaap_GrossProfit Gross profit Cost of goods sold Cost of goods sold Counterparty Name [Axis] Counterparty Name [Domain] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations Net cash used in operating activities, discontinued operations us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations Net cash used in investing activities, discontinued operations us-gaap_NetCashProvidedByUsedInDiscontinuedOperations Net decrease in cash and cash equivalents, discontinued operations us-gaap_ContractWithCustomerLiability Contract with Customer, Liability Continuing operations balance at December 31, 2023 Balance The Amended September 2022 Warrants [Member] Presents the amended September 2022 warrants. Other Products [member] Represents other products. The May 2023 B-1 Warrants [Member] Represents May 2023 B-1 Warrants. The December 2023 Warrants [Member] Represents December 2023 Warrants. The November 2022 A-1 Warrants [Member] Represents November 2022 A-1 Warrants. The May 2023 B-2 Warrants [Member] Represents May 2023 B-2 Warrants. Concentration Risk, Credit Risk, Policy [Policy Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights Outstanding, Activity [Table Text Block] Tabular disclosure of warrants or rights outstanding activity. The November 2022 A-2 Warrants [Member] Represents November 2022 A-2 Warrants. Other Liabilities Disclosure [Text Block] Disposal Group Classification [Axis] Disposal Group Classification [Domain] The 2021 Private Placement Program [Member] Represents the 2021 private placement program. nby_MaximumPercentageOfCommonStockOutstanding Maximum Percentage of Common Stock Outstanding Represents maximum percentage of common stock outstanding. Sales: Conversion of Series B Preferred Stock to Common Stock [Member] Represents conversion of series b preferred stock to common stock. Cost of Goods and Service [Policy Text Block] Scenario [Domain] us-gaap_ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants Proceeds from Warrant Exercise Proceeds from Warrant Exercises Retained Earnings [Member] us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Revenue Title and Position [Domain] Title and Position [Axis] Scenario [Axis] Additional Paid-in Capital [Member] Common Stock [Member] Preferred Stock [Member] The 2017 Omnibus Incentive Plan [Member] Represents the 2017 Omnibus Incentive Plan. Equity Components [Axis] Equity Component [Domain] Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Outstanding warrants, weighted-average exercise price (in dollars per share) Outstanding warrants, weighted-average exercise price (in dollars per share) Conversion of Series C Preferred Stock to Common Stock [Member] Represents conversion of series c preferred stock to common stock. Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Warrants outstanding (in shares) Outstanding warrants (in shares) Outstanding warrants (in shares) us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities Proceeds from Derivative Instrument, Financing Activities Reporting Date, December 31, 2021 [Member] Information pertaining to the date of occurrence. us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights Post-amendment [Member] Represents post-amendment. Pre-amendment [Member] Represents before amendment. Incentive Stock Options (ISOs) [Member] Represents incentive stock options (ISOs). us-gaap_PaymentsOfDebtIssuanceCosts Debt issuance cost Reporting Date, December 31, 2023 [Member] Information pertaining to the date of occurrence. Prior to Ratchet, March 24, 2024 [Member] Represents Prior to Ratchet, March 24, 2024. After Ratchet, April 27, 2023 [Member] Represents After Ratchet, April 27, 2023. Issuance, May 1, 2023 [Member] Information pertaining to the date of occurrence. Prior to Ratchet, December 21, 2023 [Member] Represents prior to ratchet December 21, 2023. After Ratchet, December 21, 2023 [Member] Represents after ratchet, December 21, 2023. us-gaap_DeferredFinanceCostsNet Debt Issuance Costs, Net Unamortized debt issuance costs Stockholder Approval, June 9, 2023 [Member] Information pertaining to the date of occurrence. Prior to Ratchet, April 27, 2023 [Member] Represents Prior to Ratchet, April 27, 2023. Disaggregation of Revenue [Table Text Block] Issuance, April 27, 2023 [Member] Information pertaining to the date of occurrence. nby_InventoryValuationReservesExcludingDiscontinuedOperations Less: Reserve for excess and obsolete inventory Amount of valuation reserve for inventory. Cash and cash equivalents nby_CashAndCashEquivalentsIncludingDisposalGroup Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Equipment [Member] Post amendment, December 21, 2023 [Member] Information pertaining to the date of occurrence. Pre-amendment, December 21, 2023 [Member] Information pertaining to the date of occurrence. us-gaap_RepaymentsOfConvertibleDebt Payments on Secured Convertible Notes Repayments of Convertible Debt Cash and Cash Equivalents, Policy [Policy Text Block] us-gaap_DebtInstrumentUnamortizedDiscount Debt Instrument, Unamortized Discount Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants dei_DocumentQuarterlyReport Document Quarterly Report Entity Incorporation, State or Country Code Principal amount us-gaap_DebtInstrumentCarryingAmount General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] dei_DocumentTransitionReport Document Transition Report Basis of Accounting, Policy [Policy Text Block] Schedules of Concentration of Risk, by Risk Factor [Table Text Block] dei_EntityInteractiveDataCurrent Entity Interactive Data Current Selling and Marketing Expense [Member] Related Party [Member] Measurement Input, Redemption in Stock [Member] Measurement input used to determine the monthly redemption. Security Exchange Name Title of 12(b) Security Reclassification of May 2023 Warrants The amount of adjustments to additional paid in capital from the reclassification of warrants. Modification of common stock warrants, included in Other expense, net Modification of Warrants The amount of noncash expense from modification of warrants. Non-cash loss (gain) on changes in fair value of embedded derivative liability Non-cash (loss) gain on change in fair value of embedded derivative liability The amount of gain on changes in combined derivative liability. Modification of common stock warrants The amount of adjustments to additional paid in capital from the modification of warrants. us-gaap_ProceedsFromConvertibleDebt Proceeds from Convertible Debt Research and Development Expense [Member] Reclassification of embedded derivative liability Represents the reclassification of an embedded derivative liability. Warrants exercised (in shares) Class of Warrant or Right, Exercised During Period (in shares) Warrants exercised (in shares) The number of warrants or rights exercised during period. nby_DebtInstrumentRedemptionPriceAmountPerMonth Debt Instrument, Redemption Price, Amount Per Month Represents the amount of a debt instrument that is redeemed per month. Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Nonmonetary Transaction Type [Domain] Discontinued Operations, Disposed of by Sale [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Nonmonetary Transaction Type [Axis] Less discontinued operations us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue Chongqing Pioneer Pharma Holdings Limited [Member] Represents information pertaining to chongqing pioneer pharma holdings limited. us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price Anti-dilutive securities (in shares) Employees and Directors [Member] Represents information about employees and directors. Accounts payable us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent Down round feature adjustments related to Preferred Stock Represents Down Round Feature Adjustments Related to Preferred Stock. Accrued liabilities us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent Accrued liabilities from discontinued operations Statement [Table] Convertible Notes and May 2023 Warrants [Member] Represents Convertible Notes and May 2023 Warrants. Statement of Financial Position [Abstract] Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted) (in shares) Accounts Payable and Accrued Liabilities Disclosure [Text Block] us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense Other expense, net Net loss per share from discontinued operations (in dollars per share) Total operating expenses us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense us-gaap_EarningsPerShareBasic Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share) us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization Disposal Group, Including Discontinued Operation, Depreciation and Amortization Distributor A [Member] Represents information about distributor A. Credit Loss, Financial Instrument [Policy Text Block] General and administrative us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Net loss per share from continuing operations (in dollars per share) Distributor B [Member] Represents information about distributor B. Operating loss us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss Preferred Stock [Policy Text Block] Represents the significant accounting policy referring to preferred stock. Product revenue, net us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Statement of Cash Flows [Abstract] Cost of goods sold us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Gross profit us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Long-Term Debt, Maturity, Remainder of Fiscal Year Statement of Stockholders' Equity [Abstract] The 2023 Warrant Reprice Transaction [Member] Represents the 2023 Warrant Reprice Transaction. Income Statement [Abstract] Disposal Groups, Including Discontinued Operations [Table Text Block] Disposal Group Name [Axis] Disposal Group Name [Domain] us-gaap_BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability Schedule of Accrued Liabilities [Table Text Block] Warrant liabilities transferred to equity Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Gain, embedded derivative The Amended November 2022 A-1 and A-2 Warrants [Member] Represents the amended November A warrants. The November 2022 A-1 and A-2 Warrants [Member] Represents the November 2022 warrants. Fair Value, Assets Measured on Recurring Basis [Table Text Block] Financing activities: Warrant liabilities Series C Preferred Stock [Member] Series B Preferred Stock [Member] Proceeds from divestiture of subsidiary Proceeds from Divestiture of Businesses us-gaap_CashDivestedFromDeconsolidation Cash transferred to New Age Investments, LLC us-gaap_StockholdersEquity Total stockholdersâ€™ equity Balance Balance Non-cash right-of-use amortization Non-cash right-of-use amortization Stockholders' Equity Note, Warrants or Rights Disclosure [Text Block] The entire disclosure of warrants or rights. Class of Stock [Axis] Class of Stock [Domain] EX-101.PRE 9 nby-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.CAL 10 nby-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document And Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 09, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Entity File Number 001-33678 Â Entity Registrant Name NOVABAY PHARMACEUTICALS, INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 68-0454536 Â Entity Address, Address Line One 2000 Powell Street, Suite 1150 Â Entity Address, City or Town Emeryville Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94608 Â City Area Code 510 Â Local Phone Number 899-8800 Â Title of 12(b) Security Common Stock, par value $0.01 per share Â Trading Symbol NBY Â Security Exchange Name NYSEAMER Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Emerging Growth Company false Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding (in shares) Â 4,885,693 Entity Central Index Key 0001389545 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type:

xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 us-gaap_AssetsAbstract Â Â Cash and cash equivalents $ 751 $ 2,924 Accounts receivable, net of allowance for credit losses ($3 at June 30, 2024 and December 31, 2023) 547 680 Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($204 and $264 at June 30, 2024 and December 31, 2023, respectively) 700 564 Prepaid expenses and other current assets 255 256 Current assets, discontinued operations 0 2,730 Total current assets 2,253 7,154 Operating lease right-of-use assets 1,128 1,296 Property and equipment, net 68 87 Other assets 476 478 Other assets, discontinued operations 0 19 TOTAL ASSETS 3,925 9,034 us-gaap_LiabilitiesAndStockholdersEquityAbstract Â Â Accounts payable 1,235 906 Accrued liabilities 1,297 1,169 Secured Convertible Notes, net of discounts 655 1,137 Unsecured Convertible Notes, net of discounts 41 0 Operating lease liabilities 382 368 Current liabilities, discontinued operations 0 698 Total current liabilities 3,610 4,278 Warrant liabilities 0 334 Operating lease liabilities-non-current 932 1,108 Total liabilities 4,542 5,720 Commitments and Contingencies Â Stockholdersâ€™ (deficit) equity: Â Â Common stock, $0.01 par value; 150,000 shares authorized, 1,348 and 321 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively [1] 13 3 Additional paid-in capital [1] 179,392 176,210 Accumulated deficit (180,028) (174,849) Total stockholdersâ€™ equity (617) 3,314 TOTAL LIABILITIES AND STOCKHOLDERSâ€™ EQUITY 3,925 9,034 Series B Preferred Stock [Member] Â Â Stockholdersâ€™ (deficit) equity: Â Â Preferred Stock 6 275 Series C Preferred Stock [Member] Â Â Stockholdersâ€™ (deficit) equity: Â Â Preferred Stock $ 0 $ 1,675 [1] After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15:

http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section

S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_UnsecuredDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Accounts receivable, allowance for doubtful accounts $ 3 $ 3 Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments $ 204 $ 264 Preferred stock par value (in dollars per share) $ 0.01 $ 0.01 Preferred stock, shares authorized (in shares) 5,000,000 5,000,000 Preferred stock, shares issued (in shares) 1 Â Preferred stock, shares outstanding (in shares) 0 1 Preferred Stock, Shares Issued (in shares) 1 Â Preferred Stock, Shares Outstanding (in shares) 0 1 Common stock, par value (in dollars per share) $ 0.01 $ 0.01 Common stock, shares authorized (in shares) 150,000,000 150,000,000 Common stock, shares issued (in shares) 1,348,000 321,000 Common stock, shares outstanding (in shares) 1,348,000 321,000 Series B Preferred Stock [Member] Â Â Preferred stock, shares issued (in shares) 1,000 6,000 Preferred stock, shares outstanding (in shares) 1,000 6,000 Preferred Stock, Shares Issued (in shares) 1,000 6,000 Preferred Stock, Shares Outstanding (in shares) 1,000 6,000 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of valuation reserve for inventory. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryValuationReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Sales: Â Â Â Â Total sales, net $ 2,400 $ 3,534 $ 5,031 $ 5,873 Cost of goods sold 808 1,795 1,645 2,534 Gross profit 1,592 1,739 3,386 3,339 Operating expenses: Â Â Â Â Research and development 9 22 28 32 Sales and marketing 1,019 1,175 2,074 2,411 General and administrative 1,617 1,593 3,908 3,292 Loss on divestiture of subsidiary 0 0 865 0 Total operating expenses 2,645 2,790 6,875 5,735 Operating loss (1,053) (1,051) (3,489) (2,396) Non-cash (loss) gain on changes in fair value of warrant liabilities (80) 216 114 216 Non-cash (loss) gain on change in fair value of embedded derivative liability (83) 40 (18) 40 Accretion of interest and amortization of discounts on convertible notes (300) (501) (733) (501) Other expense, net (69) (432) (549) (432) Net loss from continuing operations (1,585) (1,728) (4,675) (3,073) Net loss from discontinued operations (Note 18) 0 (308) (124) (702) Net loss (1,585) (2,036) (4,799) (3,775) Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price 0 (1,996) (380) (1,996) Net loss attributable to common stockholders $ (1,585) $ (4,032) $ (5,179) $ (5,771) Net loss per share from continuing operations (in dollars per share) [1] $ (1.37) $ (41.04) $ (5.44) $ (68) Net loss per share from discontinued operations (in dollars per share) [1] 0 (3.39) (0.13) (9.42) Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share) [1] $ (1.37) $ (44.43) $ (5.57) $ (77.42) Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted) (in shares) [1] 1,155 91 930 75 Product [Member] Â Â Â Â Sales: Â Â Â Â Total sales, net $ 2,387 $ 3,523 $ 5,011 $ 5,855 Product and Service, Other [Member] Â Â Â Â Sales: Â Â Â Â Total sales, net $ 13 $ 11 $ 20 $ 18 [1] After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. X - DefinitionThe amount of gain on changes in combined derivative liability. + ReferencesNo definition available. + Details Name: nby_NoncashGainOnChangesInCombinedDerivativeLiability Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-

S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GrossProfitAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18 + Details Name: us-gaap_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount

after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in net income available to common shareholder for down round feature triggered for convertible preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-12B + Details Name: us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands Preferred Stock [Member] Conversion of Series B Preferred Stock to Common Stock [Member] Preferred Stock [Member] Conversion of Series C Preferred Stock to Common Stock [Member] Preferred Stock [Member] Employees and Directors [Member] Preferred Stock [Member] Director [Member] Preferred Stock [Member] Series B Preferred Stock [Member] Preferred Stock [Member] Series C Preferred Stock [Member] Preferred Stock [Member] May 2023 Warrants [Member] Preferred Stock [Member] The 2022 Warrant Reprice Transaction [Member] Preferred Stock [Member] The December 2023 Warrants [Member] Preferred Stock [Member] March 2024 Warrant [Member] Preferred Stock [Member] Common Stock [Member] Conversion of Series B Preferred Stock to Common Stock [Member] [1] Common Stock [Member] Conversion of Series C Preferred Stock to Common Stock [Member] [1] Common Stock [Member] Employees and Directors [Member] [1] Common Stock [Member] Director [Member] [1] Common Stock [Member] Series B Preferred Stock [Member] [1] Common Stock [Member] Series C Preferred Stock [Member] [1] Common Stock [Member] May 2023 Warrants [Member] [1] Common Stock [Member] The 2022 Warrant Reprice Transaction [Member] [1] Common Stock [Member] The December 2023 Warrants [Member] [1] Common Stock [Member] March 2024 Warrant [Member] [1] Common Stock [Member] [1] Additional Paid-in Capital [Member] Conversion of Series B Preferred Stock to Common Stock [Member] [1] Additional Paid-in Capital [Member] Conversion of Series C Preferred Stock to Common Stock [Member] [1] Additional Paid-in Capital [Member] Employees and Directors [Member] [1] Additional Paid-in Capital [Member] Director [Member] [1] Additional Paid-in Capital [Member] Series B Preferred Stock [Member] [1] Additional Paid-in Capital [Member] Series C Preferred Stock [Member] [1] Additional Paid-in Capital [Member] May 2023 Warrants [Member] [1] Additional Paid-in Capital [Member] The 2022 Warrant Reprice Transaction [Member] [1] Additional Paid-in Capital [Member] The December 2023 Warrants [Member] [1] Additional Paid-in Capital [Member] March 2024 Warrant [Member] [1] Additional Paid-in Capital [Member] [1] Retained Earnings [Member] Conversion of Series B Preferred Stock to Common Stock [Member] Retained Earnings [Member] Conversion of Series C Preferred Stock to Common Stock [Member] Retained Earnings [Member] Employees and Directors [Member] Retained Earnings [Member] Director [Member] Retained Earnings [Member] Series B Preferred Stock [Member] Retained Earnings [Member] Series C Preferred Stock [Member] Retained Earnings [Member] May 2023 Warrants [Member] Retained Earnings [Member] The 2022 Warrant Reprice Transaction [Member] Retained Earnings [Member] The December 2023 Warrants [Member] Retained Earnings [Member] March 2024 Warrant [Member] Retained Earnings [Member] Conversion of Series B Preferred Stock to Common Stock [Member] Conversion of Series C Preferred Stock to Common Stock [Member] Employees and Directors [Member] Director [Member] Series B Preferred Stock [Member] Series C Preferred Stock [Member] May 2023 Warrants [Member] The 2022 Warrant Reprice Transaction [Member] The December 2023 Warrants [Member] March 2024 Warrant [Member] Total Balance (in shares) at Dec. 31, 2022 Â Â Â Â Â Â Â Â Â 14 Â Â Â Â Â Â Â Â Â 58 Â Â Â Â Â Â Â Â Â

amount of adjustments to additional paid in capital from the reclassification of warrants. + ReferencesNo definition available. + Details Name: nby_AdjustmentsToAdditionalPaidInCapitalReclassificationsOfWarrants Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the reclassification of an embedded derivative liability. + ReferencesNo definition available. + Details Name: nby_ReclassificationOfEmbeddedDerivativeLiability Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the amount of reclassification of private placement warrants. + ReferencesNo definition available. + Details Name: nby_ReclassifyPrivatePlacementWarrants Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the amount as a result of a reduction in the number of shares during the period as a result of a reverse stock split. + ReferencesNo definition available. + Details Name: nby_StockIssuedDuringPeriodValueReverseStockSplits Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued in connection with warrants exercise. + ReferencesNo definition available. + Details Name: nby_StockIssuedInConnectionWithExerciseOfWarrantsShares Namespace Prefix: nby_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued as a result of warrants exercise.. + ReferencesNo definition available. + Details Name: nby_StockIssuedInConnectionWithExerciseOfWarrantsValue Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockAmountConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) 3 Months Ended May 30, 2024 Jun. 30, 2024 Reverse Stock Split [Member] Â Â Stockholders' Equity Note, Stock Split, Conversion Ratio 35 35 X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_NonmonetaryTransactionTypeAxis=nby_ReverseStockSplitMember Namespace Prefix: Data Type: na

Balance Type: Period Type: XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Operating activities: Â Â Net loss $ (4,799) $ (3,775) Net loss from discontinued operations 124 702 Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation of property and equipment 23 26 Stock-based compensation expense related to employee and director stock awards 115 139 Loss on divestiture of subsidiary 865 0 Non-cash expense incurred to obtain consent of Secured Convertible Note holders 368 0 Modification of common stock warrants, included in Other expense, net 69 285 Non-cash gain on changes in fair value of warrant liabilities (114) (216) Non-cash loss (gain) on changes in fair value of embedded derivative liability 18 (40) Non-cash right-of-use amortization 168 140 Accretion of interest and amortization of debt discounts on convertible notes 726 457 Changes in operating assets and liabilities: Â Â Accounts receivable 133 (481) Inventory (144) (81) Prepaid expenses and other current assets 1 (83) Other assets 2 (5) Accounts payable and accrued liabilities 457 166 Operating lease liabilities (162) (127) Net cash used in operating activities, continuing operations (2,150) (2,893) Investing activities: Â Â Proceeds from divestiture of subsidiary 1,070 0 Purchases of property and equipment (4) (15) Net cash provided by (used in) investing activities, continuing operations 1,066 (15) Financing activities: Â Â Proceeds from Warrant Exercise 226 0 Payments on Secured Convertible Notes (1,200) (193) Debt issuance cost (115) (294) Net cash (used in) provided by financing activities, continuing operations (1,089) 2,513 Net decrease in cash, cash equivalents, and restricted cash, continuing operations (2,173) (395) Net decrease in cash and cash equivalents, discontinued operations (206) (561) Net decrease in cash, cash equivalents, and restricted cash, consolidated (2,379) (956) Cash, cash equivalents and restricted cash, beginning of year, consolidated 3,606 5,846 Less: Cash and cash equivalents of discontinued operations, end of period 0 (16) Cash, cash equivalents and restricted cash of continuing operations, end of period 1,227 4,874 Supplemental disclosure of cash flow information: Â Â Interest paid in continuing operations 130 47 Interest paid in discontinued operations 0 9 Supplemental disclosure of non-cash information: Â Â Conversion of Preferred Stock to common stock 1,944 849 Down round feature adjustments related to Preferred Stock 380 1,996 Issuance of embedded derivative liability in conjunction with Unsecured Convertible Notes 224 0 Warrant liabilities transferred to equity 242 0 Convertible Notes and May 2023 Warrants [Member] Â Â Financing activities: Â Â Proceeds from issuance of Secured Convertible Notes and May 2023 Warrants, net of discounts 0 3,000 Warrant Liability [Member] Â Â Supplemental disclosure of non-cash information: Â Â Warrant liabilities transferred to equity $ 312 $ 1,360 X - DefinitionAmount of derivative liability issued with notes. + ReferencesNo definition available. + Details Name: nby_DerivativeLiabilityIssuedWithNotes Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents Down Round Feature Adjustments Related to Preferred Stock. + ReferencesNo definition available. + Details Name: nby_DownRoundFeatureAdjustmentsRelatedToPreferredStock Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of noncash expense from modification of warrants. + ReferencesNo definition available. + Details Name: nby_ModificationOfWarrants Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense incurred to obtain consent of secured note holders. + ReferencesNo definition available. + Details Name: nby_NoncashExpenseIncurredToObtainConsentOfSecuredNoteHolders Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of gain on changes in combined derivative liability. + ReferencesNo definition available. + Details Name: nby_NoncashGainOnChangesInCombinedDerivativeLiability Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from debenture and warrant issuances, net. + ReferencesNo definition available. + Details Name: nby_ProceedsFromDebentureAndWarrantIssuancesNet Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from change in exchange rate. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalents include, but are not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from change in exchange rate, attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalents include, but are not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockAmountConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of the liability for the conversion option reclassified to stockholders' equity when the embedded option no longer required separation from the host instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 15 -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480960/815-15-50-3 + Details Name: us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section

45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of cash paid during the current period for interest owed on debt associated with discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_StockOptionPlanExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit

Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=nby_ConvertibleNotesAndMay2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=nby_WarrantLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 1 - Organization 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] NOTE 1. ORGANIZATION Â NovaBay Pharmaceuticals, Inc. (â€œour,â€ â€œwe,â€ â€œusâ€ or the â€œCompanyâ€) develops and sells scientifically-created and clinically-proven eyecare, and wound care products. Our leading product, AvenovaÂ® Antimicrobial Lid and Lash Solution, or Avenova Spray, is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with our proprietary, stable and pure form of hypochlorous acid and is cleared by the Food and Drug Administration (the â€œFDAâ€) for sale in the United States. Avenova Spray is available direct to consumers primarily through online distribution channels and is also available by prescription and dispensed by eyecare professionals for blepharitis and dry eye disease. Because dry eye is a complex condition, we offer a complementary portfolio of scientifically-developed products for each step of the standard at-home treatment regimen, including the Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. Â We also manufacture and sell our proprietary form of hypochlorous acid for the wound care market through our NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries. The Company currently sells these products through distributors. Â Through our former subsidiary DERMAdoctor, LLC (â€œDERMAdoctorâ€), the Company offered over 30 dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration and keratosis pilaris. On March 25, 2024, we announced that we had sold DERMAdoctor (the â€œDERMAdoctor Divestitureâ€). Â The Company operated in principally two reportable segments: (1) Eyecare and Wound Care and (2) Skincare. As noted above, on March 25, 2024, we closed the DERMAdoctor Divestiture resulting in the sale of our skincare segment. Â The Company was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc. It had no operations until July 1, 2002, on which date it acquired all of the operating assets of NovaCal Pharmaceuticals, LLC, a California limited liability company. In February 2007, the Company changed its name from NovaCal Pharmaceuticals, Inc. to NovaBay Pharmaceuticals, Inc. In June 2010, the Company changed the state in which it was incorporated (the â€œReincorporationâ€) and is now incorporated under the laws of the State of Delaware. All references to â€œthe Companyâ€ herein refer to the California corporation prior to the date of the Reincorporation and to the Delaware corporation on and after the date of the Reincorporation. Â Effective May 30, 2024, the Company effected a 1-for-35 reverse split of our outstanding common stock (â€œReverse Stock Splitâ€) (See Note 12, â€œStockholdersâ€™ (Deficit) Equityâ€ for further details).Â Except as otherwise specifically noted, all share numbers, share prices, exercise/conversion prices and per share amounts have been adjusted, on a retroactive basis, to reflect this 1-for-35 reverse stock split. Â Discontinued Operations Â On March 25, 2024, the Company completed the DERMAdoctor Divestiture for an aggregate sale price of $1.1Â million. The Company recognized a loss on the DERMAdoctor Divestiture amounting to $0.9Â million in the period ended March 31, 2024, which is recorded in loss on divestiture of subsidiary in the unaudited condensed consolidated statements of operations. Â In connection with the DERMAdoctor Divestiture, the Company has entered into Transition Services Agreement with New Age Investments, LLC to provide for a customary and orderly transition of the business, including warehousing services provided by New Age Investments, LLC and fulfillment services provided by the Company, which shall be included in continuing operations in subsequent periods. Â Going Concern Â The Company has sustained operating losses for the majority of its corporate history and expects that its 2024 expenses will exceed its 2024 revenues, as the Company continues to invest in its commercialization efforts. Additionally, the Company expects to continue incurring operating losses and negative cash flows until revenues reach a level sufficient to support ongoing growth and operations. Accordingly, the Company has determined that its planned operations raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. Additionally, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control that impact the broader economy such as periods of inflation, supply chain issues, global pandemics and international conflicts (e.g., the conflicts between Israel and Hamas, Russia and Ukraine, and China and Taiwan). Â The Companyâ€™s long-term liquidity needs will be largely determined by the success of our commercialization efforts. To address the Companyâ€™s current liquidity and capital needs, the Company has and continues to evaluate different plans and strategic transactions to fund operations, including: (1) raising additional capital through debt and equity financings or from other sources; (2) reducing spending on operations, including reducing spending on one or more of its sales and marketing programs or restructuring operations to change its overhead structure; (3) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones or an upfront fee; (4) entering into license agreements to sell new products; and/or (5) the divestiture of certain business or product lines and related assets. The Company may issue securities, including common stock, preferred stock, convertible debt securities and warrants through additional private placement transactions or registered public offerings, which may require the filing of a Form S-1 or Form S-3 registration statement with the Securities and Exchange Commission (â€œSECâ€). While the Company believes that the proceeds from the 2024 Public Offering (as defined in Note 19, â€œSubsequent Eventsâ€), 2024 Warrant Reprice Transaction (as defined in Note 9, â€œFinancing Activitiesâ€), and the DERMAdoctor Divestiture improved the Companyâ€™s liquidity in the near term, there is no assurance that the Company will be successful in executing additional capital raising strategies at levels necessary to address the Companyâ€™s ongoing and future cash flow and liquidity needs. Accordingly, the Company continues to evaluate different plans and strategies to address the Companyâ€™s capital and liquidity needs, as well as evaluating potential other strategic alternatives and transactions. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Companyâ€™s ability to continue as a going concern.Â Â Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Significant Accounting Policies [Text Block] NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESÂ Â Basis of Presentation Â The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€) and are expressed in U.S. dollars. In managementâ€™s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Companyâ€™s financial position and operating results. Â Principles of Consolidation Â The accompanying condensed consolidated financial statements include the accounts of NovaBay Pharmaceuticals, Inc. and its former wholly-owned subsidiary, DERMAdoctor, LLC, as of and for the six months ended June 30, 2024. All significant intercompany balances and transactions have been eliminated in consolidation. As of March 25, 2024, the Company divested its wholly-owned subsidiary pursuant to the DERMAdoctor Divestiture. The financial results for DERMAdoctor have been presented as discontinued operations in the accompanying condensed consolidated financial statements. For the six months ended June 30, 2024, all gains and losses on disposition, along with the sales, costs and expenses attributable to discontinued operations, have been aggregated in the captions entitled â€œLoss on divestiture of subsidiaryâ€ and â€œNet loss from discontinued operationsâ€ in our unaudited condensed consolidated statements of operations. Â Financial Statement Reclassification Â Certain account balances from prior periods have been reclassified in these unaudited condensed consolidated financial statements to conform to current period classifications. The prior year amounts have been modified in these unaudited condensed consolidated financial statements to properly report amounts under current operations and discontinued operations (see Note 18, â€œDivestiture and Discontinued Operationsâ€). Â Further, certain prior period operating lease balances on the Condensed Consolidated Statements of Cash Flows originally reported within changes in â€œOperating lease right-of-use assetsâ€ are now within â€œNon-cash right-of-use amortizationâ€ to conform to the current year presentation. Â Use of Estimates Â The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, contract liabilities related to product sales such as product returns, assumptions for valuing warrants, assumptions for valuing derivative liabilities, the fair value of contingent consideration, intangible assets, goodwill, stock-based compensation, income taxes and other contingencies. Â These estimates are based on managementâ€™s best estimates and judgment. Actual results may differ from these estimates. Estimates, judgments, and assumptions are continuously evaluated and are based on managementâ€™s experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these assumptions, judgments and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. Â Unaudited Condensed Consolidated Interim Financial Information Â The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation. Â The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The unaudited condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. Â The condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2023, included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 26, 2024 and amended on March 29, 2024 (collectively, the â€œ2023 Annual Reportâ€). Â Â Cash, Cash Equivalents, and Restricted Cash Â The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of June 30, 2024 and December 31, 2023, the Companyâ€™s cash and cash equivalents were held in a major financial institution in the United States. Â The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands): Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 751 Â Â $ 3,130 Â Cash and cash equivalents, discontinued operations Â Â â€” Â Â Â (206) Restricted cash included in other assets Â Â 476 Â Â Â 476 Â Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows Â $ 1,227 Â Â $ 3,400 Â Â The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Â Concentrations of Credit Risk and Major Partners Â Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States. Â The Company has a significant amount of its cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Companyâ€™s financial condition, results of operations, and cash flows. Â During the three and six months ended June 30, 2024 and 2023, revenues from significant product categories were as follows (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Avenova Spray Â $ 2,125 Â Â $ 1,758 Â Â $ 4,221 Â Â $ 3,695 Â NeutroPhase Â Â â€” Â Â Â 1,043 Â Â Â â€” Â Â Â 1,043 Â Other products Â Â 262 Â Â Â 722 Â Â Â 790 Â Â Â 1,117 Â Total product revenue, net Â Â 2,387 Â Â Â 3,523 Â Â Â 5,011 Â Â Â 5,855 Â Other revenue, net Â Â 13 Â Â Â 11 Â Â Â 20 Â Â Â 18 Â Total sales, net Â $ 2,400 Â Â $ 3,534 Â Â $ 5,031 Â Â $ 5,873 Â Â During the three and six months ended June 30, 2024 and 2023, revenues were derived primarily from sales of Avenova branded products, directly to consumers through Amazon.com and Avenova.com. Sales of Avenova Spray via Amazon comprised 74% and 61% of total Avenova Spray net revenue during the three months ended June 30, 2024 and 2023, respectively. Sales of Avenova Spray via Amazon comprised 74% and 68% of total Avenova Spray net revenue during the six months ended June 30, 2024 and 2023, respectively. Â As of June 30, 2024 and December 31, 2023, accounts receivable from continuing operations from our major distribution partners and major retailers greater than 10% were as follows: Â Â Â June 30, Â Â December 31, Â Major distribution partner Â 2024 Â Â 2023 Â Major U.S. Retailer A Â Â Â 35 % Â Â 22 % Avenova Spray Pharmacy Distributor A Â Â Â 33 % Â Â 14 % Avenova Spray Pharmacy Distributor B Â Â Â 12 % Â Â * % Chongqing Pioneer Pharma Holdings Limited Â Â * % Â Â 36 % Â * Less than 10% Â Â The Company relies on one contract manufacturer to produce its products. The Company does not have any manufacturing facilities and intends to continue to rely on third parties for the supply of finished goods. Our contract manufacturer may or may not be able to meet the Companyâ€™s needs with respect to timing, quantity or quality. In particular, it is possible that the Company may suffer from unexpected delays in light of the global supply chain issues. Â Fair Value of Financial Assets and Liabilities Â The Companyâ€™s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Companyâ€™s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Â The Company follows Accounting Standards Codification (â€œASCâ€) 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Under this standard, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The standard also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companyâ€™s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. There are three levels of inputs that may be used to measure fair value: Â Level 1 â€“ quoted prices in active markets for identical assets or liabilities; Level 2 â€“ quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 â€“ inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). Â Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Â See additional information in Note 3, â€œFair Value Measurementsâ€. Â Allowance for Credit Losses Â The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Companyâ€™s future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. The allowance is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. Management recorded a reserve for allowance for credit losses of $3 thousand as of June 30, 2024 and December 31, 2023. Â Inventory Â Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes and pumps; (2) goods in progress, which are normally filled but unlabeled bottles; and (3) finished goods. The Company utilizes a contract manufacturer to produce our products and the price paid to these manufacturers is included in inventory. Inventory is stated at the lower of cost or estimated net realizable value

determined by the first-in, first-out method. At June 30, 2024 and December 31, 2023, management had recorded an allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $204 thousand and $264 thousand, respectively. Â Property and Equipment, net Â Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five to seven years for office and laboratory equipment, three to five years for computer equipment and software, and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. Â The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.Â Â Â Business Combinations, Goodwill and Indefinite-Lived Intangible Assets Â We account for business combinations using the acquisition method of accounting, in accordance with ASC 805, Business Combinations. The acquisition method requires that identifiable assets acquired and liabilities assumed are recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. Intangible assets are measured at their respective fair values as of the acquisition date. Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Â Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Â Goodwill is evaluated for impairment by first performing a qualitative assessment to determine whether a quantitative goodwill test is necessary. If it is determined, based on qualitative factors, that the fair value of the reporting unit may more likely than not be less than carrying amount, or if significant adverse changes in the Companyâ€™s future financial performance occur that could materially impact fair value, a quantitative goodwill impairment test would be required. Additionally, management can elect to forgo the qualitative assessment and perform the quantitative test. If the qualitative assessment indicates that the quantitative analysis should be performed, or if management elects to bypass a qualitative assessment, the Company then evaluates goodwill for impairment by comparing the fair value of the reporting unit to its carrying amount, including goodwill. The quantitative assessment for goodwill requires management to estimate the fair value of the Companyâ€™s reporting units using either an income or market approach or a combination thereof. Â Management makes critical assumptions and estimates in completing impairment assessments of goodwill and indefinite-lived intangible assets. The Companyâ€™s cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates. Â The Company did not record any goodwill or indefinite-lived asset impairment charges during the three or six months ended June 30, 2024 or June 30, 2023. Â Valuation of Contingent Consideration Resulting from a Business Combination Â In connection with the DERMAdoctor acquisition, the Company was subject to paying consideration that was contingent upon the achievement of specified milestone events. The Company recorded this contingent consideration at its fair value on the acquisition date. Each quarter thereafter, the Company revalued the contingent consideration and recorded changes in fair value within the condensed consolidated statements of operations. The DERMAdoctor acquisition milestone events consisted of financial targets for calendar years 2022 and 2023 which were not met. As a result, the liability recorded for potential earn out payments in the Companyâ€™s condensed consolidated balance sheets was zero as of June 30, 2024 and December 31, 2023. Â Long-Lived AssetsÂ Â The Companyâ€™s intangible assets that do not have indefinite lives, primarily trade secrets and product formulations, are amortized over their estimated useful lives. All of the Companyâ€™s intangible assets subject to amortization and other long-lived assets, are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use are present. The Company reviews long-lived assets for impairment at least annually or whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the condensed consolidated statements of operations. Â The Company did not record any long-lived asset impairments during theÂ three or six months ended June 30, 2024 or June 30, 2023. Â Leases Â At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received. Â Â The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not applied. Leases include variable components (e.g., common area maintenance) that are paid separately from the monthly base payment based on actual costs incurred and therefore were not included in the right-of-use assets and lease liability but are reflected as an expense in the period incurred. Â The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the condensed consolidated balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. Â Common Stock Warrants Â The Company accounts for the issuance of common stock purchase warrants issued in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity and ASC 815, Derivatives and Hedging. Â The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, the Company also classifies as liabilities any warrants during the period which the shares underlying the contract are subject to stockholder approval before the warrant can be exercised. Â For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black Scholes option pricing model. These values are subject to a significant degree of managementâ€™s judgment. See Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€ and Note 11, â€œCommon Stock Warrantsâ€, subheading â€œSummary of Common Stock Warrant Liabilitiesâ€. Â Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black Scholes option pricing model. See Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Â Preferred Stock Â Terms of the Companyâ€™s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (as defined and described in Note 12, â€œStockholdersâ€™ (Deficit) Equityâ€). The applicable Ratchet provisions of the Companyâ€™s outstanding Preferred Stock terminated during the quarter ended March 31, 2024. When a conversion price was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend was measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the anti-dilution protection feature). These fair values were determined using the Black Scholes option pricing model. These values are subject to a significant degree of managementâ€™s judgment. See also Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Â Â Revenue Recognition Â The Companyâ€™s product revenue recognition policies are established in accordance with ASC 606, Revenue from Contracts with Customers, in accordance with the following five steps: Â Â i. identify the contract(s) with a customer; Â ii. identify the performance obligations in the contract; Â iii. determine the transaction price; Â iv. allocate the transaction price to the performance obligations in the contract; and Â v. recognize revenue when (or as) the entity satisfies performance obligations. Â Revenue is recognized in accordance with the amount of consideration which the Company expects to receive. Â Revenue generated from end consumers through third-party online retailers, such as Amazon, as well as the Companyâ€™s web store (Avenova.com) is recognized on a â€œsell-throughâ€ basis when control of the goods is transferred to the consumer, which generally occurs upon delivery of the products to the party fulfilling the consumerâ€™s order. Revenue is recorded net of any discounts and estimates for refunds and product returns. Fees paid to third-party online retailers and fulfillment parties are recorded as incurred in the Companyâ€™s condensed consolidated statements of operations. Fulfillment and shipping and handling fees are recorded as product cost of goods sold. Selling commissions and advertising and promotion fees are recorded as sales and marketing expenses. Â Revenue generated through major pharmacy distributors is recognized on a â€œsell-inâ€ basis when control of the goods is transferred to the distributor, which generally occurs upon delivery of the products to the distributor. Revenue is recorded net of consideration for contract liabilities for distributor services, discounts, rebates, and product returns. The Company estimates returns and other contract liabilities based on historical data which is updated quarterly. Payment for products sold is typically due 60 days after delivery to the distributor. Â Revenue generated from end consumers through the Companyâ€™s partner pharmacies is recognized on a â€œsell-throughâ€ basis when control of the goods is transferred to the consumer. Â Revenue generated from other retailers is recognized on a â€œsell-throughâ€ basis, net of estimated future product returns, when control of the goods is transferred to the retailer, which generally occurs upon delivery of the products to a third-party carrier who is delivering the products to the retailer. Â The Company defers recognition for pre-payments until the Companyâ€™s performance obligations are satisfied. Â Â Cost of Goods Sold Â Cost of goods sold includes third-party manufacturing costs, shipping and handling costs, third-party fulfillment fees, and other costs associated with products sold. Cost of goods sold also includes any necessary allowances for excess and obsolete inventory as well as lower of cost and estimated net realizable value. Â Research and Development Costs Â The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities. Â Patent Costs Â Patent costs are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations. Â Advertising Costs Â Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising expenses were $0.2 million for both of the three months ended June 30, 2024 and 2023. Advertising expenses were $0.4 million and $0.5 million for the six months ended June 30, 2024 and 2023, respectively. Â Stock-Based Compensation Â The Companyâ€™s stock-based compensation includes grants of stock options and restricted stock units (â€œRSUsâ€) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Companyâ€™s condensed consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black Scholes option pricing model. The Company accounts for RSUs issued to employees and non-employees (directors, consultants and advisory board members) based on the fair market value of the Companyâ€™s common stock on the date of issuance. See Note 13, â€œEquity-Based Compensationâ€ for further information regarding stock-based compensation expense and the assumptions used in estimating the expense. Â Â Income Taxes Â The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized. Â Net Loss per Share Â The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (â€œEPSâ€) as shown in the Companyâ€™s condensed consolidated statements of operations. Â Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive. Â For the three and six months ended June 30, 2024 and 2023, the Series B Preferred Stock and Series C Preferred Stock were excluded from the computation of diluted net loss per share as their inclusion on an â€œif convertedâ€ basis would have been anti-dilutive. The Series B Preferred Stock and Series C Preferred Stock were considered anti-dilutive because such securities did not have a contractual obligation to participate in losses of the Company. Â The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: Â Â Â Balance at June 30, Â Â Â 2024* Â Â 2023* Â Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the â€œSeries B Preferred Stockâ€) Â Â 15,065 Â Â Â 201,432 Â Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the â€œSeries C Preferred Stockâ€) Â Â â€” Â Â Â 24,134 Â Stock options Â Â 6,904 Â Â Â 4,301 Â Stock warrants Â Â 224,777 Â Â Â 210,929 Â Â Â Â 246,746 Â Â Â 440,796 Â Â * After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. Â Â Recent Accounting Pronouncements Â For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, â€œSummary of Significant Accounting Policiesâ€ included in our 2023 Annual Report. The Company continues to evaluate the potential impact of adopting the new accounting guidance on its consolidated financial position, results of operations and cash flows. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 3 - Fair Value Measurements 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Fair Value Disclosures [Text Block] NOTE 3. FAIR VALUE MEASUREMENTS Â The following table presents the Companyâ€™s financial instruments measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 (in thousands): Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Â Â Â Quoted Â Â Â Â Â Â Â Â Â Â Â Â Prices in Â Â Â Â Â Â Â Â Â Â Â Â Active Â Â Â Â Â Â Â Â Â Â Â Â Markets Â Â Significant Â Â Â Â Â Â Â Â Â Â for Â Â Other Â Â Significant Â Â Â Â Balance at Â Â Identical Â Â Observable Â Â Unobservable Â Â Â June Â Items Â Â Inputs Â Â Inputs Â Â Â 30, 2024 Â Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Restricted cash held as a certificate of deposit Â $ 476 Â Â $ 476 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Â Â Â Quoted Â Â Â Â Â Â Â Â Â Â Â Â Prices in Â Â Â Â Â Â Â Â Â Â Â Â Active Â Â Â Â Â Â Â Â Â Â Â Â Markets Â Â Significant Â Â Â Â Â Â Â Â Â Â for Â Â Other Â Â Significant Â Â Â Â Balance at Â Â Identical Â Â Observable Â Â Unobservable Â Â Â December Â Â Items Â Â Inputs Â Â Inputs Â Â Â 31, 2023 Â Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Restricted cash held as a certificate of deposit Â $ 476 Â Â $ 476 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant liabilities Â $ 334 Â Â $ â€” Â Â $ 334 Â Â $ â€” Â Â Â The Companyâ€™s restricted cash held as certificates of deposit are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Â The Secured Convertible Notes (see Note 10, â€œConvertible Notesâ€) are carried at proceeds, net of discounts, which management believes approximates fair value. As a result of certain call and put options within the Secured Convertible Notes, the Company recorded an embedded derivative liability on its condensed consolidated balance sheet with a corresponding debt discount which is netted against the face value of the Secured Convertible Notes. The fair value of the May 2023 Warrants issued in conjunction with the 2023 Private Placement as well as the accounting for the warrant amendment and preferred stock conversion price adjustments that resulted from the 2023 Private Placement used the same stock price and were classified within Level 3. Â Â The Unsecured Convertible Notes (see Note 10, â€œConvertible Notesâ€) are carried at proceeds, net of discounts, which management believes approximates fair value. As a result of certain call and put options within the Unsecured Convertible Notes, the Company recorded an embedded derivative liability on its

unaudited condensed consolidated balance sheet with a corresponding debt discount which is netted against the face value of the Unsecured Convertible Notes. Â The fair value of the December 2023 Warrants issued in conjunction with the 2023 Warrant Reprice Transaction as well as the accounting for the warrant amendment and preferred stock conversion price adjustments that resulted from the 2023 Warrant Reprice Transaction were classified within Level 2. Â See Note 11, â€œCommon Stock Warrantsâ€, subheading â€œSummary of Common Stock Warrant Liabilitiesâ€, for a reconciliation of the beginning and ending balances for the warrant liabilities measured at fair value on a recurring basis using significant other observable inputs (Level 2) during the three and six months ended June 30, 2024 and 2023. Â There were no transfers in or out of Level 1, Level 2 or Level 3 assets and liabilities for the three and six months ended June 30, 2024 and 2023. Â Black Scholes Valuation Models and Assumptions Â The Company utilizes a Black Scholes model for various valuations as outlined throughout this report. The following tables summarize the assumptions utilized for valuations impacting results for the periods reported. See also Note 13, â€œEquity-Based Compensationâ€ for related Black Scholes valuation assumptions. Â Warrant Liabilities Â Various of the Companyâ€™s warrants have been, or are, subject to stockholder approval upon issuance or amendment and prior to exercise. Warrants requiring stockholder approval are recorded as a liability at fair value upon issuance or amendment and continue to be recorded as a liability at fair value at each reporting date until stockholder approval occurs at which time they are transferred to stockholdersâ€™ equity at their fair value on the date of approval. Fair value was determined using a Black Scholes model as outlined below. See Note 11, â€œCommon Stock Warrantsâ€ for additional information and the definitions of the Companyâ€™s warrants. Â Â Â May 2023 Warrants Â Â May 2023 Warrants Â Â December 2023 Warrants Â Â December 2023 Warrants Â Measurement event Â Issuance Â Â Â Stockholder Approval Â Â Â Reporting Date Â Â Stockholder Approval Â Date Â May 1, 2023 Â Â Â June 9, 2023 Â Â Â December 31, 2023 Â Â May 28, 2024 Â Total Value Â $1.6 million Â Â Â $1.4 million Â Â Â $0.3 million Â Â $0.2 million Â Gain (Loss) Â not applicable Â Â Â $0.2 million Â Â Â $56 thousand Â Â $(51 thousand) Â Â Â

https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 8 - Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Commitments and Contingencies Disclosure [Text Block] NOTE 8. COMMITMENTS AND CONTINGENCIES Â Indemnification Agreements Â As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Companyâ€™s request in such capacity. The term of the indemnification period is for the officerâ€™s or directorâ€™s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may enable it to recover a portion of any future payments. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, it has not recorded any liabilities for these agreements as of June 30, 2024 or December 31, 2023. Â In the normal course of business, the Company provides indemnification of varying scope under its agreements with other entities, typically its clinical research organizations, investigators, clinical sites, suppliers, and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third party with respect to its products. The term of these indemnification agreements is generally perpetual. The potential future payments the Company could be required to make under these indemnification agreements is unlimited. Historically, costs related to these indemnification provisions have been immaterial. The Company also maintains various liability insurance policies that limit its exposure. As a result, it believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of June 30, 2024 or December 31, 2023. Â Legal Matters Â From time to time, the Company is subject to various legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business. The ultimate outcome of any litigation or other legal dispute is uncertain. When a loss related to a legal proceeding or claim is probable and reasonably estimable, the Company accrues its best estimate for the ultimate resolution of the matter. If one or more legal matters are resolved against the Company in a reporting period for an amount above expectations, the Companyâ€™s financial condition and operating results for that period may be adversely affected. As of June 30, 2024 and December 31, 2023, there were no legal matters that, in the opinion of management, would ultimately result in liability that would have a material adverse effect on the Companyâ€™s financial position, results of operations or cash flows. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company due to legal costs and expenses, diversion of management attention and other factors. The Company cannot provide assurance that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against it in the future, and these matters could relate to prior, current, or future transactions or events. Â Leases Â The Company leases office space for its corporate headquarters located in Emeryville, California. The current lease term expires on July 31, 2027. Â Â Lease costs for the three and six months ended June 30, 2024 and 2023 were as follows (in thousands): Â Â Â For the Three Months Ended June 30, Â Â For the Six MonthsÂ Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease â€“ expense Â $ 100 Â Â $ 100 Â Â $ 200 Â Â $ 200 Â Operating lease from discontinued operations â€“ expense Â Â â€“ Â Â Â 31 Â Â Â â€“ Â Â Â 61 Â Operating lease â€“ included in operating cash flow Â Â 117 Â Â Â 114 Â Â Â 193 Â Â Â 188 Â Operating lease from discontinued operations â€“ included in operating cash flow Â Â â€“ Â Â Â 32 Â Â Â â€“ Â Â Â 64 Â Â The Company has measured its operating lease liabilities as the present value of minimum lease payments using its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate for operating leases from continuing operations are summarized as follows: Â Â Â June 30, 2024 Â Â June 30, 2023 Â Weighted-average remaining lease term (in years) Â Â 3.1 Â Â Â 3.8 Â Weighted-average discount rate Â Â 5 % Â Â 5 % Â Future lease payments under non-cancelable leases as of June 30, 2024 were as follows (in thousands): Â 2024 Â $ 233 Â 2025 Â Â 439 Â 2026 Â Â 444 Â 2027 Â Â 290 Â Total future minimum lease payments Â Â 1,406 Â Less: Imputed interest Â Â (92) Total Â $ 1,314 Â Â Â Â Â Â Reported as: Â Â Â Â Operating lease liability Â $ 382 Â Operating lease liability- non-current Â Â 932 Â Total Â $ 1,314 Â Â Â Â Â X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 9 - Financing Activities 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Other Liabilities Disclosure [Text Block] NOTE 9. FINANCING ACTIVITIES Â See Notes 2, â€œSummary of Significant Accounting Policiesâ€; 3, â€œFair Value Measurementsâ€; 10, â€œConvertible Notesâ€; 11, â€œCommon Stock Warrantsâ€ and 12, â€œStockholdersâ€™ (Deficit) Equityâ€ for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates. Â 2024 Warrant Reprice Transaction Â In June 2024, the Company entered into a warrant reprice transaction (the â€œ2024 Warrant Reprice Transactionâ€) with certain existing holders of our (i) warrants issued in September 2022 to purchase common stock, (ii) Series A-1 warrants issued in November 2022 to purchase common stock, (iii) Series B-1 Warrants issued in May 2023 to purchase common stock, and (iv) Series B-2 Warrants issued in May 2023 to purchase common stock (collectively (i) through (iv), the â€œExisting Warrantsâ€). The participants agreed to exercise a portion of their Existing Warrants at a reduced exercise price of $2.50. There were an aggregate of 90,381 shares of common stock that were exercised, resulting in gross proceeds of approximately $0.2 million. Â The Company also issued to participants in the 2024 Warrant Reprice Transaction, a new June 2024 Warrant to purchase a number of shares of common stock equal to 100% of the shares of common stock exercised. The June 2024 Warrants are substantially similar to the Existing Warrants, except that the June 2024 Warrants will (i) be initially exercisable on the six-month anniversary of the date of issuance; (ii) have an exercise price of $2.57; and (iii) have a term of five (5) years and six (6) months from the date of the closing of the 2024 Warrant Reprice Transaction. Â The Company incurred total issuance costs of $96 thousand in conjunction with the 2024 Warrant Reprice Transaction. The Company incurred a $69 thousand non-cash loss on the modification of common stock warrantsÂ which was recorded in â€œOther expense, netâ€ for the three and six months ended June 30, 2024. Â 2024 Subsidiary Guarantee Termination Â On March 24, 2024, in connection with completing certain required conditions to close the DERMAdoctor Divestiture, the Company and the holders of the Secured Convertible Notes entered into a First Amendment (the â€œFirst Amendmentâ€) to the Companyâ€™s Security Agreement, dated April 27, 2023 (the â€œSecurity Agreementâ€), to remove the Membership Units and any assets of DERMAdoctor as collateral for the Companyâ€™s obligations pursuant to the Secured Convertible Notes and for DERMAdoctor to be removed as a party to the Security Agreement, and a Consent and Release (the â€œSubsidiary Guarantee Consentâ€), to terminate the Subsidiary Guarantee, dated April 7, 2023 (the â€œSubsidiary Guaranteeâ€) (collectively, the â€œ2024 Subsidiary Guarantee Terminationâ€). To obtain the secured partiesâ€™ consent that resulted in the reduction of the collateral available to secure the obligations under the Secured Convertible Notes and as consideration for the secured parties taking the necessary actions to execute and deliver the First Amendment and the Subsidiary Guarantee Consent, the Company provided each secured party the option, at the Secured Partyâ€™s election, to receive only upon the closing of the DERMAdoctor Divestiture either a March 2024 Warrant (see Note 11, â€œCommon Stock Warrantsâ€) or an Unsecured Convertible Note (see Note 10 â€œConvertible Notesâ€). Â The Company issued, based on the secured partiesâ€™ elections, (i) a March 2024 Warrant to a secured party that is exercisable for an aggregate of 28,572 shares of common stock and (ii) Unsecured Convertible Notes to four secured parties that have an aggregate principal amount of $525 thousand or will be convertible into an aggregate of 107,146 shares of common stock.Â Â The Company incurred total issuance costs of $130 thousand in conjunction with the 2024 Subsidiary Guarantee Termination. The Company allocated $19 thousand of the issuance costs to the Unsecured Convertible Notes which was recorded as a discount in the Companyâ€™s condensed consolidated balance sheets. The remaining $111 thousand was allocated to the embedded derivative liability and warrant liability and expensed as â€œOther expense, netâ€ in the Companyâ€™s unaudited condensed consolidated statements of operations, during the six months ended June 30, 2024. Â 2023 Warrant Reprice Transaction Â In December 2023, the Company entered into a warrant reprice transaction (the â€œ2023 Warrant Reprice Transactionâ€) whereby the price terms of certain May 2023 Warrants exercisable for 72,256 shares of common stock were amended and exercised. The price of the amended and exercised May 2023 Warrants was reduced from $45.50 to $8.75. The Company also issued to participants in the 2023 Warrant Reprice Transaction, the December 2023 Warrants exercisable for 72,256 shares of common stock. Â The 2023 Warrant Reprice Transaction resulted in gross proceeds of approximately $0.6 million. The Company allocated the gross proceeds between the common stock and December 2023 Warrants issued to participants by applying the relative fair value allocation methodology. The Company allocated $0.2 million in gross proceeds to the common stock and $0.4 million to the December 2023 Warrants. The December 2023 Warrants were initially classified as liabilities from the date of issuance until Company stockholder approval on May 28, 2024, at which time they were reclassified to equity. Â The Company incurred total issuance costs of $0.2 million in conjunction with the 2023 Warrant Reprice Transaction. The Company allocated $0.1 million of the issuance costs to the common stock which was recorded as a reduction of additional paid-in capital in the Companyâ€™s condensed consolidated balance sheets. The remaining $0.1 million was allocated to the warrant liability and expensed as â€œOther expense, netâ€ in the Companyâ€™s unaudited condensed consolidated statements of operations. Â Â 2023 Private Placement Â In May 2023, the Company closed a private placement (the â€œ2023 Private Placementâ€) with existing accredited institutional investors of the Company that provided for the issuance and sale of $3.3 million aggregate principal amount of the Secured Convertible Notes and the May 2023 Warrants exercisable for up to 145,056 shares of common stock. Â The Company received gross proceeds of $3.0 million from the 2023 Private Placement. The Company allocated the proceeds from the 2023 Private Placement between the May 2023 Warrants, an embedded derivative liability, and the Secured Convertible Notes by applying the residual fair value methodology. The Company first allocated $1.6 million to the May 2023 Warrants and $0.2 million to the embedded derivative liability with the residual $1.2 million allocated to the Secured Convertible Notes. The embedded derivative liability was subsequently reclassified to equity upon stockholder approval. Â The Company incurred total issuance costs of $0.7 million in conjunction with the 2023 Private Placement, including a $0.4 million non-cash loss on the warrant modification. The Company allocated $0.3 million of the issuance costs to the Secured Convertible Notes which was recorded as a discount in the Companyâ€™s condensed consolidated balance sheets. The remaining $0.4 million was allocated to the embedded derivative liability and warrant liability and expensed as â€œOther expense, netâ€ in the Companyâ€™s unaudited condensed consolidated statements of operations. Â Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405/tableOfContent + Details Name: us-gaap_OtherLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 10 - Convertible Notes 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Debt Disclosure [Text Block] NOTE 10. CONVERTIBLE NOTES Â Unsecured Convertible Note Â In March 2024, the Company issued $525 thousand aggregate principal amount unsecured convertible notes (the â€œUnsecured Convertible Notesâ€) in conjunction with the 2024 Subsidiary Guarantee Termination. The 2024 Subsidiary Guarantee Termination was executed with certain holders of the Secured Convertible Notes in order to close the DERMAdoctor Divestiture (see additional discussion in Note 9, â€œFinancing Activitiesâ€ and Note 18, â€œDivestiture and Discontinued Operationsâ€). The Unsecured Convertible Notes are due March 25, 2026 and bear no stated interest. Â The Unsecured Convertible Notes may be converted or redeemed for a conversion price equal to $4.90 per share at any time at the election of the holder up to the amount of outstanding principal at the time of conversion subject to certain limitations such as beneficial ownership limitations. Upon issuance and as of June 30, 2024, the Unsecured Convertible Notes were convertible for up to 107,146 shares of common stock. Â Upon issuance in March 2024, the lenderâ€™s conversion option under the Unsecured Convertible Notes represented an embedded call option requiring bifurcation as an embedded derivative liability because the common stock underlying the option required stockholder approval before the option could be exercised. The fair value of the embedded derivative was determined to be $159 thousand as of March 31, 2024 in accordance with a Black Scholes valuation model. See also Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Upon stockholder approval on May 28, 2024, the embedded call option no longer required liability treatment and was reclassified to equity. The fair value of the embedded derivative liability was determined to be $242 thousand as of May 28, 2024. The change of $83 thousand in fair value between March 31, 2024 and May 28, 2024 was recorded as a non-cash loss on change in fair value of embedded derivative liability in the unaudited condensed consolidated statements of operations. See also Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Â The discount to the note recorded for the embedded derivative liability upon issuance and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Unsecured Convertible Notes, assuming that the Unsecured Convertible Notes will be redeemed for cash of $525 thousand at time of maturity as of March 25, 2026. During both the three and six months ended June 30, 2024, the effective interest rate on the Unsecured Convertible Notes was 144%. During the three and six months ended June 30, 2024, interest expense recognized, including amortization of the issuance costs and debt discount, was $14 thousand and $15 thousand, respectively, which was included in other expense, net in the unaudited condensed consolidated statements of operations. Â Secured Convertible Note Â In May 2023, the Company issued $3.3 million aggregate principal amount Original Issue Discount Senior Secured Convertible Debentures (the â€œSecured Convertible Notesâ€) in conjunction with the 2023 Private Placement (see Note 9, â€œFinancing Activitiesâ€). The Secured Convertible Notes were issued with a $300 thousand original issue discount. The Secured Convertible Notes are due November 1, 2024. Â The Secured Convertible Notes may be converted or redeemed for a conversion price equal to $45.50 per shareÂ at any time at the election of the holder up to the amount of outstanding principal at the time of conversion subject to certain limitations such as beneficial ownership limitations. Upon issuance, the Secured Convertible Notes were convertible for up to 72,528 shares of common stock. As of June 30, 2024, the Secured Convertible Notes were convertible for up to 16,376 shares of common stock. Â Beginning June 1, 2023, the Company was required to start making a monthly redemption of 1/18th of the original principal amount of the Secured Convertible Notes. Each monthly redemption reduces the outstanding principle of the Secured Convertible Note by $183 thousand and may be made in cash or, under limiting conditions, in stock at the election of the Company. Monthly redemption in cash requires a total payment of $193 thousand. Monthly redemption in stock requires the issuance of shares equal to $193 thousand divided by the lower of (i) $45.50 or (ii) 90% of the Companyâ€™s common stockâ€™s average volume-weighted average price over 10 trading days prior to the redemption. The conditions allowing for redemption in stock have not been met through June 30, 2024 and the Company has made all monthly redemption payments in cash. Â Â The Secured Convertible Notes also provide for a redemption equal to up to 20% of the

gross proceeds received by the Company from any financing completed while the Secured Convertible Notes are outstanding. In connection with the 2023 Warrant Reprice Transaction (see Note 12, â€œStockholdersâ€™ (Deficit) Equityâ€), the Company made such a payment totaling $126 thousand in cash against the Secured Convertible Notes. In connection with the 2024 Warrant Reprice Transaction (see Note 12, â€œStockholdersâ€™ (Deficit) Equityâ€), the Company made such a payment totaling $45 thousand in cash against the Secured Convertible Notes. Â If any event of default occurs, the outstanding principal amount of the Secured Convertible Notes, plus accrued but unpaid interest, liquidated damages and other amounts owing thereof become immediately due and payable in cash at the holderâ€™s election. After any event of default, the Secured Convertible Notes will also accrue interest at a rate up to 18% per year. The Secured Convertible Notes are secured obligations of the Company including a security interest, a lien upon and a right of set-off against all of the Companyâ€™s assets as collateral security. DERMAdoctor was released of such obligations in connection with the DERMAdoctor Divestiture. Â Upon issuance in May 2023, the lenderâ€™s conversion option under the Secured Convertible Notes represented an embedded call option requiring bifurcation as an embedded derivative liability because the common stock underlying the option required stockholder approval before the option could be exercised. The fair value of the embedded derivative was determined to be $209 thousand as of the date of issuance. After stockholder approval of the underlying common stock, the embedded call option no longer required liability treatment and was reclassified to equity. The fair value of the embedded derivative liability was determined to be $169 thousand upon stockholder approval. The change of $40 thousand in fair value between the date of issuance and stockholder approval was recorded as a non-cash gain on change in fair value of embedded derivative liability in the consolidated statements of operations. See also Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Â The lenderâ€™s subsequent financing redemption option and certain events of default also represent embedded call options and the Companyâ€™s monthly share redemption option represents an embedded put option. The fair value of these options was determined to be immaterial upon issuance and at each subsequent reporting date. Â The Company allocated $1.2 million of gross proceeds from the 2023 Private Placement to the Secured Convertible Notes. Â The difference between the $1.2 million allocated to the Secured Convertible Notes and the $3.3 million aggregate principal amount represent discounts for the portion of proceeds allocated to the embedded derivative liability and the May 2023 Warrants (See Note 11, â€œCommon Stock Warrantsâ€) as well as the $0.3 million original issue discount. The Company also allocated $0.3 million of debt issuance costs to the Secured Convertible Notes. Â The discounts and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Secured Convertible Notes, assuming that the Secured Convertible Notes will be redeemed for cash of $193 thousand per month beginning in June 2023. The effective interest rate on the Secured Convertible Notes was 173%. During the three and six months ended June 30, 2024, interest expense recognized, including amortization of the issuance costs and debt discount, was $0.3 million and $0.7 million, respectively, which was included in other expense, net in the unaudited condensed consolidated statements of operations. Â The Secured Convertible Notes are presented as follows as of June 30, 2024 (in thousands): Â Principal amount Â $ 762 Â Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants Â Â (92) Unamortized debt issuance costs Â Â (15) Total Secured Convertible Notes, net Â $ 655 Â Â The Secured Convertible Notes, net, are classified as short term in the Companyâ€™s condensed consolidated balance sheets. Â As of June 30, 2024, the Companyâ€™s contractual maturity of the principal balance of the Secured Convertible Notes was $762 thousand. Â Â Â X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 11 - Common Stock Warrants 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Stockholders' Equity Note, Warrants or Rights Disclosure [Text Block] NOTE 11. COMMON STOCK WARRANTS Â See Notes 2, â€œSummary of Significant Accounting Policiesâ€; 3, â€œFair Value Measurementsâ€; 9, â€œFinancing Activitiesâ€; and 12, â€œStockholdersâ€™ (Deficit) Equityâ€ for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates. Â June 2024 Warrants Â In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company issued new common stock purchase warrants (the â€œJune 2024 Warrantsâ€) exercisable for 90,381 shares of common stock for $2.57 per share through December 17, 2029. Â March 2024 Warrant Â In March 2024, the Company executed the First Amendment and Subsidiary Guarantee Consent as part of the 2024 Subsidiary Guarantee Termination with holders of the Secured Convertible Notes (see Note 10, â€œConvertible Notesâ€) in order to close the DERMAdoctor Divestiture (see additional discussion in Note 9, â€œFinancing Activitiesâ€ and Note 18, â€œDivestiture and Discontinued Operationsâ€). In exchange for the consent of each holder, the option, at the holderâ€™s election, to receive upon the closing of the DERMAdoctor sale either, a new common stock warrant (the â€œMarch 2024 Warrantâ€), or a new unsecured convertible note (see additional discussion in Note 18, â€œDivestiture and Discontinued Operationsâ€). One holder elected the option to receive a March 2024 Warrant exercisable for 28,572 shares of common stock for $4.90 per share. Â The March 2024 Warrant was initially classified as a liability from the date of issuance until Company stockholder approval on May 28, 2024, at which time it was reclassified to equity. Â December 2023 Warrants Â In December 2023, in conjunction with the 2023 Warrant Reprice Transaction, the Company issued new common stock purchase warrants (the â€œDecember 2023 Warrantsâ€) exercisable for 72,256 shares of common stock for $8.75 per share through June 21, 2029. Â The December 2023 Warrants were initially classified as liabilities from the date of issuance until Company stockholder approval on May 28, 2024, at which time it was reclassified to equity. Â May 2023 Warrants Â In May 2023, in conjunction with the 2023 Private Placement, the Company issued the following new common stock purchase warrants (collectively, the â€œMay 2023 Warrantsâ€): Â Â â— May 2023 Series B-1 Warrants exercisable for 72,528 shares of common stock for $45.50 per share through June 9, 2028 (â€œMay 2023 B-1 Warrantsâ€); and Â â— May 2023 Series B-2 Warrants exercisable for 72,528 shares of common stock for $45.50 per share through June 9, 2025 (â€œMay 2023 B-2 Warrantsâ€). Â In December 2023, in conjunction with the 2023 Warrant Reprice Transaction, the Company amended certain May 2023 Warrants to reduce their exercise prices to $8.75. Immediately after amendment, the following May 2023 Warrants were exercised (while any unexercised May 2023 Warrants maintained an exercise price of $45.50): Â Â â— May 2023 B-1 Warrants exercisable for 18,132 shares of common stock; and Â â— May 2023 B-2 Warrants exercisable for 54,120 shares of common stock. Â In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain May 2023 Warrants to reduce their exercise prices to $2.50. Immediately after amendment, the following May 2023 Warrants were exercised (while any unexercised May 2023 Warrants maintained an exercise price of $8.75): Â Â â— May 2023 B-1 Warrants exercisable for 54,396 shares of common stock; and Â â— May 2023 B-2 Warrants exercisable for 18,408 shares of common stock. Â For the amendments in December 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the May 2023 Warrants of $170 thousand and $47 thousand, respectively. Â Â November 2022 Warrants Â In November 2022, in conjunction with the 2022 Private Placement, the Company issued the following common stock purchase warrants (collectively, the â€œNovember 2022 Warrantsâ€): Â Â â— November 2022 Series A-1 Warrants exercisable for 14,741 shares of common stock for $220.50 per share through November 20, 2028 (â€œNovember 2022 A-1 Warrantsâ€); and Â â— November 2022 Series A-2 Warrants exercisable for 14,741 shares of common stock for $220.50 per share through May 20, 2024 (â€œNovember 2022 A-2 Warrantsâ€). Â In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain November 2022 Warrants to reduce their exercise prices from $220.50 to $52.50 as follows: Â Â â— November 2022 A-1 Warrants exercisable for 12,473 shares of common stock; and Â â— November 2022 A-2 Warrants exercisable for 12,473 shares of common stock. Â In May 2024, all November 2022 Series A-2 Warrants for 14,741 shares of common stock remained unexercised and expired. Â In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain November 2022 Warrants to reduce their exercise prices from $52.50 to $2.50 as follows: Â Â â— November 2022 A-1 Warrants exercisable for 12,473 shares of common stock. Â For the amendments in May 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the November 2022 Warrants of $74 thousand and $16 thousand, respectively. Â Â September 2022 Warrants Â In September 2022, in conjunction with the warrant reprice transaction (the â€œ2022 Warrant Reprice Transactionâ€), the Company issued new common stock purchase warrants (the â€œSeptember 2022 Warrantsâ€) exercisable for 9,371 shares of common stock for $220.50 per share through September 11, 2028. Â In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain September 2022 Warrants exercisable for 6,819 shares of common stock to reduce their exercise prices from $220.50 to $52.50. Â In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain September 2022 Warrants exercisable for 5,104 shares of common stock to reduce their exercise prices from $52.50 to $2.50. Â For the amendments in May 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the September 2022 Warrants of $28 thousand and $6 thousand, respectively. Â November 2021 Warrants Â In November 2021, in conjunction with a private placement transaction, the Company issued the new common stock purchase warrants (the â€œNovember 2021 Warrantsâ€) exercisable for 30,616 shares of common stock for $649.25 per share through March 9, 2023. Â In September 2022, in conjunction with the 2022 Warrant Reprice Transaction, the Company amended all November 2021 Warrants to reduce their exercise prices from $649.25 to $220.50 and extend their termination date to September 11, 2028. Immediately after amendment, November 2021 Warrants were exercised for 7,654 shares of common stock. Â In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain November 2021 Warrants exercisable for 15,308 shares of common stock to reduce their exercise prices from $220.50 to $52.50. Â For the amendments in September 2022 and May 2023, the Company recognized a loss on modification of common stock warrants related to the November 2021 Warrants of $1.5 million and $0.1 million, respectively. Â July 2020 Warrants Â In July 2020, in conjunction with a private placement transaction, the Company issued the new common stock purchase warrants (the â€œJuly 2020 Warrantsâ€) exercisable for 5,635 shares of common stock for $2,021.25 per share through January 22, 2026. Â In September 2022, in conjunction with the 2022 Warrant Reprice Transaction, the Company amended certain July 2020 Warrants exercisable for 3,921 shares of common stock to reduce their exercise prices from $2,021.25 to $220.50. Immediately after amendment, July 2020 Warrants were exercised for 1,715 shares of common stock. Â In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain July 2020 Warrants exercisable for 2,206 shares of common stock to reduce their exercise prices from $220.50 to $52.50. Â For the amendments in September 2022 and May 2023, the Company recognized a loss on modification of common stock warrants related to the July 2020 Warrants of $0.4 million and $9 thousand, respectively. Â Summary of Common Stock Warrant Activity and Outstanding Â Activity related to common stock warrants outstanding at June 30, 2024 and 2023 were as follows: Â Â Â Warrants Â Â Weighted- Average Exercise Price Â Outstanding at December 31, 2022 Â Â 65,886 Â Â $ 269.54 Â Warrants granted Â Â 145,056 Â Â Â Â 45.50 Â Warrants exercised Â Â â€” Â Â Â Â â€” Â Warrants expired Â Â â€” Â Â Â Â â€” Â Outstanding at June 30, 2023 Â Â 210,942 Â Â Â Â 76.23 Â Â Â Â Â Â Â Â Â Outstanding at December 31, 2023 Â Â 210,946 Â Â $ 50.96 Â Warrants granted Â Â 118,953 Â Â Â Â 3.13 Â Warrants exercised Â Â (90,381) Â Â 2.50 Â Warrants expired Â Â (14,741) Â Â 78.35 Â Outstanding at June 30, 2024 Â Â 224,777 Â Â Â Â 37.40 Â Â Â Â Common stock warrants outstanding as of June 30, 2024 were as follows: Â Series Â Exercise Price Â Â Expiration Date Â Warrants Â 2019 Ladenburg Warrants Â $ 1,212.75 Â Â August 8, 2024 Â Â 138 Â July 2020 Warrants Â $ 2,021.25 Â Â January 22, 2026 Â Â 1,714 Â July 2020 Warrants Â $ 52.50 Â Â January 22, 2026 Â Â 2,206 Â TLF Warrants Â $ 822.96 Â Â January 15, 2026 Â Â 13 Â November 2021 Warrants Â $ 220.50 Â Â September 11, 2028 Â Â 7,654 Â November 2021 Warrants Â $ 52.50 Â Â September 11, 2028 Â Â 15,308 Â September 2022 Warrants Â $ 220.50 Â Â September 11, 2028 Â Â 2,552 Â September 2022 Warrants Â $ 52.50 Â Â September 11, 2028 Â Â 1,715 Â November 2022 A-1 Warrants Â $ 220.50 Â Â November 20, 2028 Â Â 2,268 Â December 2023 Warrants Â $ 8.75 Â Â June 21, 2029 Â Â 72,256 Â March 2024 Warrant Â $ 4.90 Â Â March 24, 2029 Â Â 28,572 Â June 2024 Warrants Â $ 2.57 Â Â December 17, 2029 Â Â 90,381 Â Outstanding at June 30, 2024 Â Â Â Â Â Â Â Â 224,777 Â Â Summary of Common Stock Warrant Liabilities Â The following is a reconciliation of the beginning and ending balances for warrant liabilities measured at fair value on a recurring basis (in thousands). See additional information per Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptions.â€ Â Warrant liabilities as of December 31, 2023 Â Â 334 Â Decrease in fair value of December 2023 Warrant liability during period Â Â (122) Fair value of March 2024 Warrant upon issuance Â Â 92 Â Increase in fair value of March 2024 Warrant liability during period Â Â 8 Â Reclassification of December 2023 Warrant liability to equity during period Â Â (212) Reclassification of March 2024 Warrant liability to equity during period Â Â (100) Warrant liabilities as of June 30, 2024 Â $ â€” Â Â Â Â X - DefinitionThe entire disclosure of warrants or rights. + ReferencesNo definition available. + Details Name: nby_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock Namespace Prefix: nby_ Data Type: dtr-types:textBlockItemType Balance

Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 12 - Stockholders' (Deficit) Equity 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Equity [Text Block] NOTE 12. STOCKHOLDERSâ€™ (DEFICIT) EQUITY Â Authorized Share Capital Â Under the Companyâ€™s Amended and Restated Certificate of Incorporation, as amended, the Company is authorized to issue up to 150,000,000 shares of common stock and up to 5,000,000 shares of preferred stock with rights and preferences as may be approved by the Companyâ€™s Board of Directors. Â Reverse Stock Split Â Effective May 30, 2024, the Company amended its Certificate of Incorporation to effect a 1-for-35 reverse split of its outstanding common stock. The Reverse Stock Split was approved by the Companyâ€™s stockholders on May 28, 2024. As a result of the Reverse Stock Split, every 35 shares of the Companyâ€™s pre-reverse split outstanding common stock were combined and reclassified into 1 share of common stock. Proportionate voting rights and other rights of common stockholders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole share. All stock options outstanding, common stock reserved for issuance under the Companyâ€™s equity incentive plans, common stock reserved for issuance under the Series B Preferred Stock and outstanding warrants were adjusted by dividing the number of affected shares of common stock by 35 and, as applicable, multiplying the exercise/conversion price by 35. Except as otherwise specifically noted, all share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis, to reflect this 1-for-35 reverse stock split. Â Preferred Stock Â There were two series of preferred stock of the Company outstanding during the three and six months ended June 30, 2024 and 2023 â€“ the Series B Non-Voting Convertible Preferred Stock (â€œSeries B Preferred Stockâ€) and the Series C Non-Voting Convertible Preferred Stock (â€œSeries C Preferred Stockâ€) (and combined, the â€œPreferred Stockâ€). The rights and preferences of the Series B Preferred Stock and Series C Preferred Stock are nearly identical. The Preferred Stock does not have any preemptive rights or a preference upon any liquidation, dissolution or winding-up of the Company. Each share of Preferred Stock is convertible into $1,000 of common stock at the conversion price per share applicable at the time of conversion. Until its expiration (as described in more detail below), the Preferred Stock had anti-dilution protection (the â€œRatchetâ€) in the event that the Company sold or granted any of its common stock or any other securities, subject to certain limited exceptions, that would entitle the holder thereof to acquire common stock at an effective price per share that is lower than the then applicable conversion price of the Preferred Stock. Â Series B Preferred Stock Â The Company issued 15,000 shares of Series B Preferred Stock in November 2021 in connection with a private placement transaction. As of June 30, 2024 and 2023, 131 and 9,156 shares of Series B Preferred Stock remained outstanding, respectively. As of June 30, 2024 and 2023, outstanding shares of Series B Preferred Stock were convertible into 15,065 and 201,432 shares of common stock at a conversion price of $8.75 and $45.50, respectively. Â In accordance with the Ratchet, the Series B Preferred Stock conversion price was reduced as follows (see also Notes 2, â€œSummary of Significant Accounting Policiesâ€ and 3, â€œFair Value Measurementsâ€): Â Â â— In September 2022, from $490.00 to $220.50, as a result of the 2022 Warrant Reprice Transaction, resulting in a $5.7 million deemed dividend. Â â— In April 2023, from $220.50 to $45.50, as a result of the 2023 Private Placement, resulting in a $1.8 million deemed dividend. Â â— In December 2023, from $45.50 to $8.75, as a result of the 2023 Warrant Reprice Transaction, resulting in a $4.5 million deemed dividend. Â On January 29, 2024, the Ratchet of the Series B Preferred Stock expired with no further impact because greater than 75% of the originally issued 15,000 Series B Preferred Stock had been converted into common stock. The Series B Preferred Stock conversion price will remain at $8.75 until all remaining Series B Preferred Stock has been converted. Â Series C Preferred Stock Â The Company issued 3,250 shares of Series C Preferred Stock in November 2022 in connection with the 2022 Private Placement (see Note 9, â€œFinancing Activitiesâ€). As of June 30, 2024 and 2023, zero and 1,097 shares of Series C Preferred Stock remained outstanding, respectively. As of June 30, 2023, outstanding shares of Series C Preferred Stock were convertible into 24,134 shares of common stock at a conversion price of $45.50. Â In accordance with the Ratchet, the Series C Preferred Stock conversion price was reduced as follows during the six months ended June 30, 2024 and 2023 (see also Notes 2, â€œSummary of Significant Accounting Policiesâ€ and 3, â€œFair Value Measurementsâ€): Â Â â— In April 2023, from $220.50 to $45.50, as a result of the 2023 Private Placement, resulting in a $194 thousand deemed dividend. Â â— In December 2023, from $45.50 to $8.75, as a result of the 2023 Warrant Reprice Transaction, resulting in a $0.5 million deemed dividend. Â â— In March 2024, from $8.75 to $4.90, as a result of the 2024 First Amendment and the Subsidiary Guarantee Consent, resulting in a $0.4 million deemed dividend. Â On March 27, 2024, the Ratchet of the Series C Preferred Stock expired with no further impact because greater than 75% of the originally issued 3,250 Series C Preferred Stock had been converted into common stock. Â Â Common Stock Â See Note 9, â€œFinancing Activitiesâ€ and Note 11, â€œCommon Stock Warrantsâ€ for a description of common stock and common stock warrant-related transactions during the three and six months ended June 30, 2024 and 2023. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 13 - Equity-based Compensation 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Share-Based Payment Arrangement [Text Block] NOTE 13. EQUITY-BASED COMPENSATION Â Equity Compensation PlansÂ Â In October 2007, the Company adopted the 2007 Omnibus Incentive Plan (the â€œ2007 Planâ€) to provide for the granting of equity awards, such as stock options, unrestricted and restricted common stock, stock units, dividend equivalent rights, and stock appreciation rights to employees, directors and outside consultants, as determined by the Board. The 2007 Plan expired on March 15, 2017. Upon expiration, new awards cannot be issued pursuant to the 2007 Plan, but outstanding awards continue to be governed by its terms. Stock options granted under the 2007 Plan expire no later than ten years from the date of grant. All stock options outstanding under the 2007 Plan were fully vested as of December 31, 2021. Â In March 2017, the Company adopted the 2017 Omnibus Incentive Plan (the â€œ2017Â Planâ€), which was approved by stockholders on June 2, 2017, to provide for the granting of equity awards, such as nonqualified stock options (â€œNQSOsâ€), incentive stock options (â€œISOsâ€), restricted stock, performance shares, stock appreciation rights (â€œSARsâ€), RSUs and other share-based awards to employees, directors, and consultants, as determined by the Board. The 2017 Plan does not affect awards previously granted under the 2007 Plan. Upon adoption, the 2017 Plan allowed for awards of up to 1,892 shares of the Companyâ€™s common stock, plus an automatic annual increase in the number of shares authorized for awards on the first day of each of the Companyâ€™s fiscal years beginning January 1, 2018 through January 1, 2027 equal to (i) 4% of the number of shares of common stock outstanding on the last day of the immediately preceding fiscal year or (ii) such lesser number of shares of common stock as determined by the Board. On June 21, 2024, the number of shares available for future awards under the 2017 Plan was increased by 12,219 shares. As ofÂ June 30, 2024,Â there wereÂ 13,630Â shares available for future awards under theÂ 2017Â Plan. Â Under the terms of the 2017 Plan, the exercise price of NQSOs, ISOs and SARs may not be less than 100% of the fair market value of the common stock on the date of grant and, if ISOs are granted to an owner of more than 10% of the Companyâ€™s stock, then not less than 110% of the fair market value of the common stock on the date of grant. The term of awards will not be longer than ten years or, in the case of ISOs, no longer than five years with respect to holders of more than 10% of the Companyâ€™s stock. Stock options granted to employees generally vest over four years, while options granted to directors and consultants typically vest over a shorter period, subject to continued service. The Company issues new shares to satisfy options under the 2007 Plan and the 2017 Plan. Â SummaryÂ of Outstanding Equity Awards Â The following table summarizes information about the Companyâ€™s stock options and restricted stock outstanding at December 31, 2023, and activity during the six months ended June 30, 2024: Â (in thousands, except years and per share data) Â Awards Â Â Weighted- Average Exercise Price Â Â Weighted- Average Remaining Contractual Life (years) Â Â Aggregate Intrinsic Value Â Outstanding at December 31, 2023 Â Â 4 Â Â $ 1,145.87 Â Â Â 7.3 Â Â $ 1 Â Restricted stock units granted Â Â 5 Â Â $ â€” Â Â Â

ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 14 - Distribution Agreements 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â License, Collaboration, and Distribution Agreements [Text Block] NOTE 14. DISTRIBUTION AGREEMENTS Â Transactions under the Companyâ€™s major distribution agreements are recognized upon transfer of control of products sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns. Â Product Sales Discounts and Allowances Â The following table presents activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration, for the six months ended June 30, 2024 (in thousands):Â Â Â Â Â Chargebacks, Discounts for Prompt Payment Â Â Other Customer Fees Â Â Rebates Â Â Total Â Balance at December 31, 2023 Â $ 913 Â Â $ 12 Â Â $ 21 Â Â $ 946 Â Less discontinued operations Â Â (218) Â Â â€” Â Â Â â€” Â Â Â (218) Continuing operations balance at December 31, 2023 Â Â 695 Â Â Â Â 12 Â Â Â Â 21 Â Â Â Â 728 Â Provision related to sales made in: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Current period Â Â 57 Â Â Â 23 Â Â Â 52 Â Â Â 132 Â Payments and customer credits issued Â Â (11) Â Â (22) Â Â (54) Â Â (87) Balance at June 30, 2024 Â $ 741 Â Â $ 13 Â Â $ 19 Â Â $ 773 Â Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies Â Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. The Company has also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the three months ended June 30, 2024 and 2023, the Company earned $108 thousand and $195 thousand, respectively, in sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements. During the six months ended June 30, 2024 and 2023, the Company earned $232 thousand and $287 thousand, respectively, in sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements. Â Under these product distribution arrangements, the Company had a contract liability balance of $0.8 million and $0.7 million as of June 30, 2024 and December 31, 2023, respectively. The contract liability is included in accrued liabilities in the condensed consolidated balance sheets. Â Over-the-Counter Sales of Avenova Spray Â Avenova Spray is offered for sale direct to U.S. customers primarily on Amazon.com, the Companyâ€™s website (Avenova.com) and Walmart.com. During the three months ended June 30, 2024 and 2023, the revenue generated from Avenova Spray in these channels was $1.8 million and $1.3 million, respectively. During the six months ended June 30, 2024 and 2023, the revenue generated from Avenova Spray in these channels was $3.5 million and $2.9 million, respectively. Â Â Â X - DefinitionThe entire disclosure of license, collaboration, and distribution agreements. + ReferencesNo definition available. + Details Name: nby_LicenseCollaborationAndDistributionAgreementsTextBlock Namespace Prefix: nby_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 15 - Employee Benefit Plan 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Retirement Benefits [Text Block] NOTE 15. EMPLOYEE BENEFIT PLAN Â The Company has a 401(k) plan covering all eligible employees. The Company provides matching contributions equal to 100% of the first 3% of compensation deferred, plus 50% of the next 2% of compensation deferred. The Company contributed $25 thousand and $23 thousand to the 401(k) plan from continuing operations in the three months ended June 30, 2024 and 2023, respectively. The Company contributed $49 thousand and $46 thousand to the 401(k) plan from continuing operations in the six months ended June 30, 2024 and 2023, respectively. The Company contributed $9 thousand and $17 thousand to the 401(k) plan from discontinued operations in the three and six months ended June 30, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for retirement benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (q) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContentReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (o) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (p) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (r)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (r)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 60 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3 + Details Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 16 - Related Party Transactions 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Related Party Transactions Disclosure [Text Block] NOTE 16. RELATED PARTY TRANSACTIONS Â The following table summarizes information about the Companyâ€™s related party revenue and cost of goods sold (in thousands):Â Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Chongqing Pioneer Pharma Holdings Limited: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue Â $ â€” Â Â $ 1,043 Â Â $ â€” Â Â $ 1,043 Â Cost of goods sold Â Â â€” Â Â Â 895 Â Â Â â€” Â Â Â 895 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 17 - Segment Reporting 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Segment Reporting Disclosure [Text Block] NOTE 17. SEGMENT REPORTING Â The Company operates as oneÂ reportable segment, Eyecare and Wound Care, which is described in further detail below. This is based on the objectives of the business and how our chief operating decision maker (â€œCODMâ€), the President and Chief Executive Officer, monitors operating performance and allocates resources. Â Change in Reportable Segments Â The Company previously operated in principally two reportable segments, (1) Eyecare and Wound Care and (2) Skincare. During the six months ended June 30, 2024, in connection with the previously announced strategic shift and upon the DERMAdoctor Divestiture, the Company has ceased to operate the Skincare segment. As a result, the Company changed the level of detail at which our CODM regularly reviews and manages the businesses, resulting in a change to our reportable segments. Â We now manage and report our operating results through one reportable segment: Eyecare and Wound Care. This change allows us to better align our business models, resources, and cost structure to the specific current and future growth of our business, while maintaining the necessary information and transparency to our stockholders. Our historical segment information has been recast to conform to the current segment structure. Â Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 18 - Divestiture and Discontinued Operations 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] NOTE 18. DIVESTITURE AND DISCONTINUED OPERATIONS Â On March 12, 2024, the Company entered into an agreement to sell 100% of the membership units of DERMAdoctor for a closing purchase price of $1.1

million. The sale of the membership units closed, and the DERMAdoctor Divestiture occurred, on March 25, 2024. In order to close the sale, the Company was required to obtain the consent of the holders of the Secured Convertibles Notes (see Note 10, â€œConvertible Notesâ€) issued in May 2023 to (i) amend the Security Agreement to remove the Membership Units and any assets of DERMAdoctor as collateral for the Companyâ€™s obligations pursuant to the Secured Convertible Notes and for DERMAdoctor to be removed as a party to the Security Agreement and (ii) terminate the Subsidiary Guarantee, which DERMAdoctor entered into in connection with the issuance of the Secured Convertible Notes. Â On March 24, 2024, the Company and the secured parties entered into a First Amendment to the Security Agreement, to effect an amendment to the Security Agreement and a Consent and Release to terminate the Subsidiary Guarantee. To obtain the secured partiesâ€™ consent and as consideration for the secured parties taking the necessary actions to execute and deliver the First Amendment and the Subsidiary Guarantee Consent, the Company provided each secured party the option, at the secured partyâ€™s election, to receive only upon the closing of the DERMAdoctor Sale Transaction either: a March 2024 Warrant or the Unsecured Convertible Notes (see Note 10 â€œConvertible Notesâ€). Â The accounting requirements for reporting the DERMAdoctor business as discontinued operations were met during the first quarter of 2024. Accordingly, the condensed consolidated financial statements and notes to the condensed consolidated financial statements reflect the results of the DERMAdoctor business as a discontinued operation for the periods presented. Â In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the condensed consolidated balance sheets. The assets and liabilities have been reflected as discontinued operations in the condensed consolidated balance sheets as of December 31, 2023, and consist of the following (in thousands): Â Â Â Balance at December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â ASSETS Â Â Â Â Â Current assets: Â Â Â Â Â Cash and cash equivalents Â $ 206 Â Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023) Â Â 79 Â Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023) Â Â 2,313 Â Prepaid expenses and other current assets Â Â 132 Â Total current assets, discontinued operations Â Â 2,730 Â Other assets Â Â 19 Â Total assets, discontinued operations Â $ 2,749 Â Â Â Â Â Â Â Â Â Â Â Â Â Â LIABILITIES Â Â Â Â Â Liabilities: Â Â Â Â Â Current liabilities: Â Â Â Â Â Accounts payable Â $ 224 Â Accrued liabilities Â Â 347 Â Operating lease liabilities Â Â 127 Â Total current liabilities, discontinued operations Â Â 698 Â Total liabilities, discontinued operations Â $ 698 Â Â Â In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the unaudited condensed consolidated statements of operations.Â The results of DERMAdoctorâ€™s operations for the six months ended June 30, 2024 and 2023 have been reflected as discontinued operations in the unaudited condensed consolidated statements of operations and consist of the following (in thousands): Â Â Â Six Months EndedÂ Â Â Â 2024 Â Â 2023 Â Sales: Â Â Â Â Â Â Â Â Â Product revenue, net Â $ 717 Â Â $ 1,861 Â Total sales, net Â Â 717 Â Â Â 1,861 Â Â Â Â Â Â Â Â Â Â Â Cost of goods sold Â Â 493 Â Â Â Â 958 Â Gross profit Â Â 224 Â Â Â 903 Â Operating expenses Â Â Â Â Â Â Â Â Â Research and development Â Â 2 Â Â Â 21 Â Sales and marketing Â Â 292 Â Â Â 960 Â General and administrative Â Â 48 Â Â Â 615 Â Total operating expenses Â Â Â 342 Â Â Â 1,596 Â Operating loss Â Â (118) Â Â (693) Â Â Â Â Â Â Â Â Â Other expense, net Â Â (6) Â Â (9) Â Â Â Â Â Â Â Â Â Net loss from discontinued operations Â $ (124) Â $ (702) Â In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the unaudited condensed consolidated statements of cash flows.Â The results of DERMAdoctor for the six months ended June 30, 2024 and 2023 have been reflected as discontinued operations in the unaudited condensed consolidated statements of cash flows and consist of the following (in thousands): Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Operating activities: Â Â Â Â Â Â Â Net loss from discontinued operations Â $ (124) Â $ (702) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Â Amortization of intangible assets Â Â â€” Â Â Â 76 Â Non-cash right-of-use amortization Â Â â€” Â Â Â 55 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Â Accounts receivable Â Â (262) Â Â (169) Inventory Â Â 183 Â Â Â (142) Prepaid expenses and other current assets Â Â (4) Â Â 125 Â Other assets Â Â 15 Â Â Â (9) Accounts payable and accrued liabilities Â Â 63 Â Â Â 264 Â Operating lease liabilities Â Â (31) Â Â (59) Net cash used in operating activities, discontinued operations Â Â (160) Â Â (561) Â Â Â Â Â Â Â Â Â Investing activities: Â Â Â Â Â Â Â Â Cash transferred to New Age Investments, LLC Â Â (46) Â Â â€” Â Net cash used in investing activities, discontinued operations Â Â (46) Â Â â€” Â Â Â Â Â Â Â Â Â Net decrease in cash and cash equivalents, discontinued operations Â $ (206) Â $ (561) Â Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 19 - Subsequent Events 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Subsequent Events [Text Block] NOTE 19. SUBSEQUENT EVENTS Â The Company has evaluated all subsequent events through the filing date of this Form 10-Q with the SEC, to ensure that this filing includes appropriate disclosure of events both recognized in the unaudited condensed consolidated financial statements as ofÂ June 30, 2024,Â and events which occurred subsequently but wereÂ notÂ recognized in the unaudited condensed consolidated financial statements. Except as described below, there wereÂ noÂ subsequent events which required recognition, adjustment to or disclosure in the unaudited condensed consolidated financial statements. Â On July 26, 2024, NovaBay Pharmaceuticals, Inc. entered into an underwriting agreement (the â€œUnderwriting Agreementâ€) with Ladenburg Thalmann & Co., Inc., as the sole underwriter (the â€œUnderwriterâ€), relating to the issuance and sale in a public offering (the â€œ2024 Public Offeringâ€) of: (i) 1,158,566 shares of common stock, par value $0.01 per share, of the Company common stock and 2,041,814 pre-funded warrants, in lieu of shares of common stock (the â€œPre-Funded Warrantsâ€), (ii) 3,200,380 Series F-1 warrants to purchase up to 3,200,380 shares of common stock (the â€œSeries F-1 Warrantsâ€), (iii) 3,200,380 Series F-2 warrants to purchase up to 3,200,380 shares of common stock (the â€œSeries F-2 Warrantsâ€) and (iv) 3,200,380 Series F-3 warrants to purchase up to 3,200,380 shares of common stock (the â€œSeries F-3 Warrantsâ€, and together with the Pre-Funded Warrants, Series F-1 Warrants and Series F-2 Warrants, the â€œJuly 2024 Warrantsâ€). Â The Series F-1 Warrants have an exercise price of $1.10 per share, are exercisable immediately upon issuance, and will expire on the five-year anniversary of the date of issuance. The Series F-2 Warrants have an exercise price of $1.10 per share, are exercisable immediately upon issuance, and will expire on the six-month anniversary of the date of issuance. The Series F-3 Warrants have an exercise price of $1.10 per share, are exercisable immediately upon issuance, and will expire on the one-year anniversary of the date of issuance. The Pre-Funded Warrants are immediately exercisable at a nominal exercise price of $0.01 per share and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The Series F-1 Warrants, the Series F-2 Warrants and the Series F-3 Warrants each include a one-time reset of the exercise price to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the volume weighted average prices for the five (5) trading days immediately preceding the date that is sixty calendar days after issuance of the Series F-1 Warrants, the Series F-2 Warrants and the Series F-3 Warrants, as applicable. The exercise price and number of shares of common stock issuable upon exercise of the July 2024 Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price. Subject to limited exceptions, a holder may not exercise any portion of its July 2024 Warrants to the extent that the holder would beneficially own more than 4.99% (or, at the election of the holder prior to the date of issuance, 9.99%) of the Companyâ€™s outstanding common stock after exercise. Â In addition, the Company has granted the Underwriter a 45-day option to purchase up to 477,272 additional shares of common stock and/or 477,272 Series F-1 Warrants to purchase up to 477,272 shares of common stock, 477,272 Series F-2 Warrants to purchase up to 477,272 shares of common stock and 477,272 Series F-3 Warrants to purchase up to 477,272 shares of common stock, or any combination thereof, as determined by the Underwriter, at the public offering price, less underwriting discounts and commissions, in each case solely to cover over-allotments, if any. Â The Underwriter partially exercised this option on July 26, 2024, for (i) 336,832 shares of common stock, (ii) 336,832 Series F-1 Warrants to purchase up to 336,832 shares of common stock, (iii) 336,832 Series F-2 Warrants to purchase up to 336,832 shares of common stock and (iv) 336,832 Series F-3 Warrants to purchase up to 336,832 shares of common stock. Â The 2024 Public Offering closed on July 29, 2024, and the Company received gross proceeds of $3.9 million, without taking into account any underwriting discounts and commissions. A portion of the proceeds were used towards the Secured Convertible Notes, which were repaid in full during the third quarter of 2024. Â As of August 9, 2024, all of the Pre-Funded Warrants were exercised resulting in net proceeds of $20 thousand. Â Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 6 Months Ended Jun. 30, 2024 Insider Trading Arr Line Items Â Material Terms of Trading Arrangement [Text Block] ITEM 5. OTHER INFORMATION Â Rule 10b5-1 Trading Arrangements Â During the six months ended June 30, 2024, none of our directors or Section 16 officers adopted, modified or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each such term is defined in Item 408 of Regulation S-K. Â Â Â Rule 10b5-1 Arrangement Terminated [Flag] false Non-Rule 10b5-1 Arrangement Terminated [Flag] false Rule 10b5-1 Arrangement Adopted [Flag] false Non-Rule 10b5-1 Arrangement Adopted [Flag] false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Â The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€) and are expressed in U.S. dollars. In managementâ€™s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Companyâ€™s financial position and operating results. Â Consolidation, Policy [Policy Text Block] Principles of Consolidation Â The accompanying condensed consolidated financial statements include the accounts of NovaBay Pharmaceuticals, Inc. and its former wholly-owned subsidiary, DERMAdoctor, LLC, as of and for the six months ended June 30, 2024. All significant intercompany balances and transactions have been eliminated in consolidation. As of March 25, 2024, the Company divested its wholly-owned subsidiary pursuant to the DERMAdoctor Divestiture. The financial results for DERMAdoctor have been presented as discontinued operations in the accompanying condensed consolidated financial statements. For the six months ended June 30, 2024, all gains and losses on disposition, along with the sales, costs and expenses attributable to discontinued operations, have been aggregated in the captions entitled â€œLoss on divestiture of subsidiaryâ€ and â€œNet loss from discontinued operationsâ€ in our unaudited condensed consolidated statements of operations. Â Reclassification, Comparability Adjustment [Policy Text Block] Financial Statement Reclassification Â Certain account balances from prior periods have been reclassified in these unaudited condensed consolidated financial statements to conform to current period classifications. The prior year amounts have been modified in these unaudited condensed consolidated financial statements to properly report amounts under current operations and discontinued operations (see Note 18, â€œDivestiture and Discontinued Operationsâ€). Â Further, certain prior period operating lease balances on the Condensed Consolidated Statements of Cash Flows originally reported within changes in â€œOperating lease right-of-use assetsâ€ are now within â€œNon-cash right-of-use amortizationâ€ to conform to the current year presentation. Â Use of Estimates, Policy [Policy Text Block] Use of Estimates Â The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, contract liabilities related to product sales such as product returns, assumptions for valuing warrants, assumptions for valuing derivative liabilities, the fair value of contingent consideration, intangible assets, goodwill, stock-based compensation, income taxes and other contingencies. Â These estimates are based on managementâ€™s best estimates and judgment. Actual results may differ from these estimates. Estimates, judgments, and assumptions are continuously evaluated and are based on managementâ€™s experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these assumptions, judgments and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. Â Unaudited Interim Financial Information, Policy [Policy Text Block] Unaudited Condensed Consolidated Interim Financial Information Â The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation. Â The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The unaudited condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. Â The condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2023, included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 26, 2024 and amended on March 29, 2024 (collectively, the â€œ2023 Annual Reportâ€). Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents, and Restricted Cash Â The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of June 30, 2024 and December 31, 2023, the Companyâ€™s cash and cash equivalents were held in a major financial institution in the United States. Â The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands): Â Â Â June 30, Â Â December 31, Â Â Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 751 Â Â $ 3,130 Â Cash and cash equivalents, discontinued operations Â Â Â â€” Â Â Â (206) Restricted cash included in other assets Â Â Â 476 Â Â Â Â 476 Â Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows Â $ 1,227 Â Â $ 3,400 Â Â The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Â Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Credit Risk and Major Partners Â Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States. Â

The Company has a significant amount of its cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Companyâ€™s financial condition, results of operations, and cash flows. Â During the three and six months ended June 30, 2024 and 2023, revenues from significant product categories were as follows (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Avenova Spray Â $ 2,125 Â Â $ 1,758 Â Â $ 4,221 Â Â $ 3,695 Â NeutroPhase Â Â â€” Â Â Â Â 1,043 Â Â Â Â â€” Â Â Â Â 1,043 Â Other products Â Â 262 Â Â Â 722 Â Â Â 790 Â Â Â 1,117 Â Total product revenue, net Â Â 2,387 Â Â Â 3,523 Â Â Â 5,011 Â Â Â 5,855 Â Other revenue, net Â Â 13 Â Â Â 11 Â Â Â 20 Â Â Â 18 Â Total sales, net Â $ 2,400 Â Â $ 3,534 Â Â $ 5,031 Â Â $ 5,873 Â Â During the three and six months ended June 30, 2024 and 2023, revenues were derived primarily from sales of Avenova branded products, directly to consumers through Amazon.com and Avenova.com. Sales of Avenova Spray via Amazon comprised 74% and 61% of total Avenova Spray net revenue during the three months ended June 30, 2024 and 2023, respectively. Sales of Avenova Spray via Amazon comprised 74% and 68% of total Avenova Spray net revenue during the six months ended June 30, 2024 and 2023, respectively. Â As of June 30, 2024 and December 31, 2023, accounts receivable from continuing operations from our major distribution partners and major retailers greater than 10% were as follows: Â Â Â June 30, Â Â December 31, Â Major distribution partner Â 2024 Â Â 2023 Â Major U.S. Retailer A Â Â Â 35 % Â Â Â 22 % Avenova Spray Pharmacy Distributor A Â Â Â 33 % Â Â Â 14 % Avenova Spray Pharmacy Distributor B Â Â Â 12 % Â Â Â * % Chongqing Pioneer Pharma Holdings Limited Â Â Â * % Â Â Â 36 % Â * Less than 10% Â Â The Company relies on one contract manufacturer to produce its products. The Company does not have any manufacturing facilities and intends to continue to rely on third parties for the supply of finished goods. Our contract manufacturer may or may not be able to meet the Companyâ€™s needs with respect to timing, quantity or quality. In particular, it is possible that the Company may suffer from unexpected delays in light of the global supply chain issues. Â Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Assets and Liabilities Â The Companyâ€™s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Companyâ€™s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Â The Company follows Accounting Standards Codification (â€œASCâ€) 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Under this standard, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The standard also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companyâ€™s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. There are three levels of inputs that may be used to measure fair value: Â Level 1 â€“ quoted prices in active markets for identical assets or liabilities; Level 2 â€“ quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 â€“ inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). Â Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Â See additional information in Note 3, â€œFair Value Measurementsâ€. Â Credit Loss, Financial Instrument [Policy Text Block] Allowance for Credit Losses Â The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Companyâ€™s future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. The allowance is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. Management recorded a reserve for allowance for credit losses of $3 thousand as of June 30, 2024 and December 31, 2023. Â Inventory, Policy [Policy Text Block] Inventory Â Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes and pumps; (2) goods in progress, which are normally filled but unlabeled bottles; and (3) finished goods. The Company utilizes a contract manufacturer to produce our products and the price paid to these manufacturers is included in inventory. Inventory is stated at the lower of cost or estimated net realizable value determined by the first-in, first-out method. At June 30, 2024 and December 31, 2023, management had recorded an allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $204 thousand and $264 thousand, respectively. Â Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment, net Â Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five to seven years for office and laboratory equipment, three to five years for computer equipment and software, and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. Â The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.Â Â Goodwill and Intangible Assets, Policy [Policy Text Block] Business Combinations, Goodwill and Indefinite-Lived Intangible Assets Â We account for business combinations using the acquisition method of accounting, in accordance with ASC 805, Business Combinations. The acquisition method requires that identifiable assets acquired and liabilities assumed are recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. Intangible assets are measured at their respective fair values as of the acquisition date. Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Â Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Â Goodwill is evaluated for impairment by first performing a qualitative assessment to determine whether a quantitative goodwill test is necessary. If it is determined, based on qualitative factors, that the fair value of the reporting unit may more likely than not be less than carrying amount, or if significant adverse changes in the Companyâ€™s future financial performance occur that could materially impact fair value, a quantitative goodwill impairment test would be required. Additionally, management can elect to forgo the qualitative assessment and perform the quantitative test. If the qualitative assessment indicates that the quantitative analysis should be performed, or if management elects to bypass a qualitative assessment, the Company then evaluates goodwill for impairment by comparing the fair value of the reporting unit to its carrying amount, including goodwill. The quantitative assessment for goodwill requires management to estimate the fair value of the Companyâ€™s reporting units using either an income or market approach or a combination thereof. Â Management makes critical assumptions and estimates in completing impairment assessments of goodwill and indefinite-lived intangible assets. The Companyâ€™s cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates. Â The Company did not record any goodwill or indefinite-lived asset impairment charges during the three or six months ended June 30, 2024 or June 30, 2023. Â Valuation of Contingent Consideration from Business Combination Policy [Policy Text Block] Valuation of Contingent Consideration Resulting from a Business Combination Â In connection with the DERMAdoctor acquisition, the Company was subject to paying consideration that was contingent upon the achievement of specified milestone events. The Company recorded this contingent consideration at its fair value on the acquisition date. Each quarter thereafter, the Company revalued the contingent consideration and recorded changes in fair value within the condensed consolidated statements of operations. The DERMAdoctor acquisition milestone events consisted of financial targets for calendar years 2022 and 2023 which were not met. As a result, the liability recorded for potential earn out payments in the Companyâ€™s condensed consolidated balance sheets was zero as of June 30, 2024 and December 31, 2023. Â Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Long-Lived AssetsÂ Â The Companyâ€™s intangible assets that do not have indefinite lives, primarily trade secrets and product formulations, are amortized over their estimated useful lives. All of the Companyâ€™s intangible assets subject to amortization and other long-lived assets, are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use are present. The Company reviews long-lived assets for impairment at least annually or whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the condensed consolidated statements of operations. Â The Company did not record any long-lived asset impairments during theÂ three or six months ended June 30, 2024 or June 30, 2023. Â Lessee, Leases [Policy Text Block] Leases Â At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received. Â Â The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not applied. Leases include variable components (e.g., common area maintenance) that are paid separately from the monthly base payment based on actual costs incurred and therefore were not included in the right-of-use assets and lease liability but are reflected as an expense in the period incurred. Â The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the condensed consolidated balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. Â Warrant Liabilities [Policy Text Block] Common Stock Warrants Â The Company accounts for the issuance of common stock purchase warrants issued in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity and ASC 815, Derivatives and Hedging. Â The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, the Company also classifies as liabilities any warrants during the period which the shares underlying the contract are subject to stockholder approval before the warrant can be exercised. Â For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black Scholes option pricing model. These values are subject to a significant degree of managementâ€™s judgment. See Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€ and Note 11, â€œCommon Stock Warrantsâ€, subheading â€œSummary of Common Stock Warrant Liabilitiesâ€. Â Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black Scholes option pricing model. See Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Â Preferred Stock [Policy Text Block] Preferred Stock Â Terms of the Companyâ€™s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (as defined and described in Note 12, â€œStockholdersâ€™ (Deficit) Equityâ€). The applicable Ratchet provisions of the Companyâ€™s outstanding Preferred Stock terminated during the quarter ended March 31, 2024. When a conversion price was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend was measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the anti-dilution protection feature). These fair values were determined using the Black Scholes option pricing model. These values are subject to a significant degree of managementâ€™s judgment. See also Note 3, â€œFair Value Measurementsâ€, subheading â€œBlack Scholes Valuation Models and Assumptionsâ€. Â Revenue [Policy Text Block] Revenue Recognition Â The Companyâ€™s product revenue recognition policies are established in accordance with ASC 606, Revenue from Contracts with Customers, in accordance with the following five steps: Â Â i. identify the contract(s) with a customer; Â ii. identify the performance obligations in the contract; Â iii. determine the transaction price; Â iv. allocate the transaction price to the performance obligations in the contract; and Â v. recognize revenue when (or as) the entity satisfies performance obligations. Â Revenue is recognized in accordance with the amount of consideration which the Company expects to receive. Â Revenue generated from end consumers through third-party online retailers, such as Amazon, as well as the Companyâ€™s web store (Avenova.com) is recognized on a â€œsell-throughâ€ basis when control of the goods is transferred to the consumer, which generally occurs upon delivery of the products to the party fulfilling the consumerâ€™s order. Revenue is recorded net of any discounts and estimates for refunds and product returns. Fees paid to third-party online retailers and fulfillment parties are recorded as incurred in the Companyâ€™s condensed consolidated statements of operations. Fulfillment and shipping and handling fees are recorded as product cost of goods sold. Selling commissions and advertising and promotion fees are recorded as sales and marketing expenses. Â Revenue generated through major pharmacy distributors is recognized on a â€œsell-inâ€ basis when control of the goods is transferred to the distributor, which generally occurs upon delivery of the products to the distributor. Revenue is recorded net of consideration for contract liabilities for distributor services, discounts, rebates, and product returns. The Company estimates returns and other contract liabilities based on historical data which is updated quarterly. Payment for products sold is typically due 60 days after delivery to the distributor. Â Revenue generated from end consumers through the Companyâ€™s partner pharmacies is recognized on a â€œsell-throughâ€ basis when control of the goods is transferred to the consumer. Â Revenue generated from other retailers is recognized on a â€œsell-throughâ€ basis, net of estimated future product returns, when control of the goods is transferred to the retailer, which generally occurs upon delivery of the products to a third-party carrier who is delivering the products to the retailer. Â The Company defers recognition for pre-payments until the Companyâ€™s performance obligations are satisfied. Cost of Goods and Service [Policy Text Block] Cost of Goods Sold Â Cost of goods sold includes third-party manufacturing costs, shipping and handling costs, third-party fulfillment fees, and other costs associated with products sold. Cost of goods sold also includes any necessary allowances for excess and obsolete inventory as well as lower of cost and estimated net realizable value. Â Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Â The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities. Â Patent Costs Policy [Policy Text Block] Patent Costs Â Patent costs are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations. Â Advertising Cost [Policy Text Block] Advertising Costs Â Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising expenses were $0.2 million for both of the three months ended June 30, 2024 and 2023. Advertising expenses were $0.4 million and $0.5 million for the six months ended June 30, 2024 and 2023, respectively. Â Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Â The Companyâ€™s stock-based compensation includes grants of stock options and restricted stock units (â€œRSUsâ€) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Companyâ€™s condensed consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black Scholes option pricing model. The Company accounts for RSUs issued to employees and non-employees (directors, consultants and advisory board members) based on the fair market value of the Companyâ€™s common stock on the date of issuance. See Note 13, â€œEquity-Based Compensationâ€ for further information regarding stock-based compensation expense and the assumptions used in estimating the expense. Â Income Tax, Policy [Policy Text Block] Income Taxes Â The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation

allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized. Â Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Â The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (â€œEPSâ€) as shown in the Companyâ€™s condensed consolidated statements of operations. Â Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive. Â For the three and six months ended June 30, 2024 and 2023, the Series B Preferred Stock and Series C Preferred Stock were excluded from the computation of diluted net loss per share as their inclusion on an â€œif convertedâ€ basis would have been anti-dilutive. The Series B Preferred Stock and Series C Preferred Stock were considered anti-dilutive because such securities did not have a contractual obligation to participate in losses of the Company. Â The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: Â Â Â Balance at June 30, Â Â Â 2024* Â Â 2023* Â Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the â€œSeries B Preferred Stockâ€) Â Â 15,065 Â Â Â 201,432 Â Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the â€œSeries C Preferred Stockâ€) Â Â â€” Â Â Â 24,134 Â Stock options Â Â 6,904 Â Â Â 4,301 Â Stock warrants Â Â 224,777 Â Â Â 210,929 Â Â Â Â 246,746 Â Â Â 440,796 Â Â * After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. Â New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Â For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, â€œSummary of Significant Accounting Policiesâ€ included in our 2023 Annual Report. The Company continues to evaluate the potential impact of adopting the new accounting guidance on its consolidated financial position, results of operations and cash flows. X - DefinitionDisclosure of accounting policy for patent costs. + ReferencesNo definition available. + Details Name: nby_PatentCostsPolicyPolicyTextBlock Namespace Prefix: nby_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionRepresents the significant accounting policy referring to preferred stock. + ReferencesNo definition available. + Details Name: nby_PreferredStockPolicyTextBlock Namespace Prefix: nby_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for unaudited interim financial information. + ReferencesNo definition available. + Details Name: nby_UnauditedInterimFinancialInformationPolicyPolicyTextBlock Namespace Prefix: nby_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for valuation of contingent consideration from business combination. + ReferencesNo definition available. + Details Name: nby_ValuationOfContingentConsiderationFromBusinessCombinationPolicyPolicyTextBlock Namespace Prefix: nby_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe disclosure of accounting policy for warrant liabilities. + ReferencesNo definition available. + Details Name: nby_WarrantLiabilitiesPolicyTextBlock Namespace Prefix: nby_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for advertising cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingCostsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cost of product sold and service rendered. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 705 -Publisher FASB -URI https://asc.fasb.org/705/tableOfContent + Details Name: us-gaap_CostOfSalesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.M.2.Q4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483530/326-20-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 30 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479391/326-20-30-5AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3C -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 8A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479366/326-20-35-8AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3D -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3DReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 30 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147479175/326-30-30-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3C -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3CReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3D -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3DReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 13A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479148/326-30-35-13AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 30 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479391/326-20-30-4AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 7A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479148/326-30-35-7AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-7Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-17 + Details Name: us-gaap_CreditLossFinancialInstrumentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix:

us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Summary of Significant Accounting Policies (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block] Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 751 Â Â $ 3,130 Â Cash and cash equivalents, discontinued operations Â Â â€” Â Â Â (206) Restricted cash included in other assets Â Â 476 Â Â Â 476 Â Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows Â $ 1,227 Â Â $ 3,400 Â Disaggregation of Revenue [Table Text Block] Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Avenova Spray Â $ 2,125 Â Â $ 1,758 Â Â $ 4,221 Â Â $ 3,695 Â NeutroPhase Â Â â€” Â Â Â 1,043 Â Â Â â€” Â Â Â 1,043 Â Other products Â Â 262 Â Â Â 722 Â Â Â 790 Â Â Â 1,117 Â Total product revenue, net Â Â 2,387 Â Â Â 3,523 Â Â Â 5,011 Â Â Â 5,855 Â Other revenue, net Â Â 13 Â Â Â 11 Â Â Â 20 Â Â Â 18 Â Total sales, net Â $ 2,400 Â Â $ 3,534 Â Â $ 5,031 Â Â $ 5,873 Â Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Â Â June 30, Â Â December 31, Â Major distribution partner Â 2024 Â Â 2023 Â Major U.S. Retailer Â Â Â 35 % Â Â Â 22 % Avenova Spray Pharmacy Distributor Â Â Â 33 % Â Â Â 14 % Avenova Spray Pharmacy Distributor Â Â Â 12 % Â Â * % Chongqing Pioneer Pharma Holdings Limited Â Â * % Â Â 36 % Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Â Â Balance at June 30, Â Â Â 2024* Â Â 2023* Â Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the â€œSeries B Preferred Stockâ€) Â Â 15,065 Â Â Â 201,432 Â Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the â€œSeries C Preferred Stockâ€) Â Â â€” Â Â Â 24,134 Â Stock options Â Â 6,904 Â Â Â 4,301 Â Stock warrants Â Â 224,777 Â Â Â 210,929 Â Â Â Â 246,746 Â Â Â 440,796 Â X - DefinitionTabular disclosure of the components of cash, cash equivalents, restricted cash and restricted cash equivalents. + ReferencesNo definition available. + Details Name: nby_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock Namespace Prefix: nby_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details Name: us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 3 - Fair Value Measurements (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Fair Value, Assets Measured on Recurring Basis [Table Text Block] Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Â Â Â Quoted Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Prices in Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Active Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Markets Â Â Significant Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â for Â Â Other Â Â Significant Â Â Â Â Balance at Â Â Identical Â Â Observable Â Â Unobservable Â Â Â June Â Â Items Â Â Inputs Â Â Â 30, 2024 Â Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Â Restricted cash held as a certificate of deposit Â $ 476 Â Â $ 476 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Â Â Â Â Â Quoted Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Prices in Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Active Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Markets Â Â Significant Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â for Â Â Other Â Â Significant Â Â Â Â Balance at Â Â Identical Â Â Observable Â Â Â Â Unobservable Â Â Â December Â Â Items Â Â Inputs Â Â Inputs Â Â Â 31, 2023 Â Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Â Restricted cash held as a certificate of deposit Â $ 476 Â Â $ 476 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant liabilities Â $ 334 Â Â $ â€” Â Â $ 334 Â Â $ â€” Â Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Â Â May 2023 Warrants Â Â May 2023 Warrants Â Â December 2023 Warrants Â Â December 2023 Warrants Â Measurement event Â Issuance Â Â Â Stockholder Approval Â Â Â Reporting Date Â Â Stockholder Approval Â Date Â May 1, 2023 Â Â Â June 9, 2023 Â Â Â December 31, 2023 Â Â May 28, 2024 Â Total Value Â $1.6 million Â Â Â $1.4 million Â Â Â $0.3 million Â Â $0.2 million Â Gain (Loss) Â not applicable Â Â Â $0.2 million Â Â Â $56 thousand Â Â $(51 thousand) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 45.50 Â Â $ 45.50 Â Â $ 8.75 Â Â $ 8.75 Â Market price Â $ 25.20 (a) Â $ 23.80 Â Â $ 7.14 Â Â $ 4.94 Â Volatility Â Â 80.1 % Â Â 77.6 % Â Â 79.3 % Â Â 83.9 % Risk-free rate Â Â 3.60 - 4.04 % Â Â 3.92 - 4.59 % Â Â 3.85 % Â Â 4.56 % Dividend yield Â Â 0.0 % Â Â 0 % Â Â 0 % Â Â 0 % Term (years) Â Â 2.1 - 5.1 % Â Â 2.0 - 5.0 Â Â Â 5.5 Â Â Â 5.1 Â Â Â March Â Â March Â Â 2024 Â Â 2024 Â Â Warrant Â Â Warrant Â Measurement event Â Reporting Date Â Â Stockholder Approval Â Date Â March 31, 2024 Â Â May 28, 2024 Â Total Value Â $0.1 million Â Â $0.1 million Â Gain (Loss) Â $21 thousand Â Â $(28 thousand) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 4.90 Â Â $ 4.90 Â Market price Â $ 3.66 Â Â $ 4.94 Â Volatility Â Â 86.9 % Â Â 83.9 % Risk-free rate Â Â 4.21 % Â Â 4.56 % Dividend yield Â Â 0 % Â Â 0 % Term (years) Â Â 5.5 Â Â Â 5.3 Â Â Â July 2020, November 2021, September 2022 & November 2022 Warrants Â Measurement event Â Prior to amendment Â Â After amendment Â Date Â April 27, 2023 Â Â April 27, 2023 Â Total Value Â $0.3 million Â Â $0.5 million Â Loss Â not applicable Â Â Â $0.2 million Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 220.50 Â Â $ 52.50 Â Market price Â $ 25.20 (a) Â $ 25.20 (a) Volatility Â Â 80.1 % Â Â 80.1 % Risk-free rate Â Â 3.59 - 4.73 % Â Â 3.59 - 4.73 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 1.1 - 5.6 Â Â Â 1.1 - 5.6 Â Â Â May 2023 Warrants Â Measurement event Â Prior to amendment Â Â After amendment Â Date Â December 21, 2023 Â Â December 21, 2023 Â Total Value Â $56 thousand Â Â $0.2 million Â Loss Â not applicable Â Â Â $0.1 million Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 45.50 Â Â $ 8.75 Â Market price Â $ 8.07 Â Â $ 8.07 Â Volatility Â Â 79.3 % Â Â 79.3 % Risk-free rate Â Â 3.92 - 4.62 % Â Â 3.92 - 4.62 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 1.5 - 4.5 Â Â Â 1.5 - 4.5 Â Â Â September 2022, November 2022, & May 2023 Warrants Â Measurement event Â Prior to amendment Â Â After amendment Â Date Â June 14, 2024 Â Â June 14, 2024 Â Total Value Â $66 thousand Â Â $0.1 million Â Loss Â not applicable Â Â Â $70 thousand Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 8.75 - 52.50 Â Â $ 2.50 Â Market price Â $ 2.51 Â Â $ 2.51 Â Volatility Â Â 89.3 % Â Â 89.3 % Risk-free rate Â Â 4.27 - 5.08 % Â Â 4.27 - 5.08 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 1.0-4.4 Â Â Â 1.0 - 4.4 Â Â Â Series B & C Preferred Stock Â Measurement event Â Prior to Ratchet Â Â After Ratchet Â Date Â April 27, 2023 Â Â April 27, 2023 Â Total value (b) Â $9.6 million Â Â $11.6 million Â Deemed dividend Â not applicable Â Â Â $2.0 million Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 220.50 Â Â $ 45.50 Â Market price Â $ 25.20 (a) Â $ 25.20 (a) Volatility Â Â 80.1 % Â Â 80.1 % Risk-free rate Â Â 4.91 % Â Â 4.91 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (in years) Â Â 0.8 Â Â Â 0.8 Â Â Â Series B & C Preferred Stock Â Measurement event Â Prior to Ratchet Â Â After Ratchet Â Date Â December 21, 2023 Â Â December 21, 2023 Â Total value (b) Â $1.7 million Â Â $6.8 million Â Deemed dividend Â not applicable Â Â Â $5.1 million Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â $ 45.50 Â Â $ 8.75 Â Market price Â $ 8.07 Â Â $ 8.07 Â Volatility Â Â 79.3 % Â Â 79.3 % Risk-free rate Â Â 5.43 % Â Â 5.43 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 0.3 Â Â Â 0.3 Â Â Â Series C Preferred Stock Â Measurement event Â Prior to

Ratchet Â Â After Ratchet Â Date Â March 24, 2024 Â Â March 24, 2024 Â Total value (b) Â $0.5 million Â Â $0.9 million Â Deemed dividend Â not applicable Â Â $0.4 million Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Exercise price Â $ 8.75 Â Â $ 4.90 Â Market price Â $ 4.77 Â Â $ 4.77 Â Volatility Â Â 79.9 % Â Â 79.9 % Risk-free rate Â Â 5.51 % Â Â 5.51 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (in years) Â Â 0.1 Â Â Â 0.1 Â Â Â Unsecured Convertible Notes derivative Â Â Unsecured Convertible Notes derivative Â Measurement event Â Issuance Â Â Shareholder Approval Â Date Â March 25, 2024 Â Â May 28, 2024 Â Total value Â $0.2 million Â Â $0.2 million Â Gain (Loss) Â not applicable Â Â $(82 thousand) Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Exercise price Â $ 4.90 Â Â $ 4.90 Â Market price Â $ 4.51 Â Â $ 4.94 Â Volatility Â Â 86.9 % Â Â 83.9 % Risk-free rate Â Â 4.54 % Â Â 4.94 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 2.0 Â Â Â 1.8 Â Â Â Secured Convertible Notes derivative Â Â Secured Convertible Notes derivative Â Measurement event Â Issuance Â Â Shareholder Approval Â Date Â April 27, 2023 Â Â June 9, 2023 Â Total value (b) Â $0.2 million Â Â $0.2 million Â Gain Â not applicable Â Â $40 thousand Â Â Â Â Â Â Â Â Â Â Â Assumptions: Â Â Â Â Â Â Â Â Â Exercise price Â $ 45.50 Â Â $ 45.50 Â Market price Â $ 25.20 (a) Â $ 23.80 Â Volatility Â Â 80.1 % Â Â 76.9 % Risk-free rate Â Â 4.88 % Â Â 5.41 % Dividend yield Â Â 0.0 % Â Â 0.0 % Term (years) Â Â 0.8 Â Â Â 0.7 Â X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 4 - Prepaid Expenses and Other Current Assets (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Prepaid insurance Â $ 94 Â Â $ 66 Â Prepaid dues and subscriptions Â Â 60 Â Â Â 85 Â Prepaid taxes Â Â 7 Â Â Â 83 Â Prepaid inventory Â Â â€” Â Â Â 73 Â Other Â Â 94 Â Â Â 81 Â Prepaid expenses from discontinued operations Â Â â€” Â Â Â (132) Total prepaid expenses and other current assets Â $ 255 Â Â $ 256 Â X - DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. + ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 5 - Inventory (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Schedule of Inventory, Current [Table Text Block] Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Raw materials and supplies Â $ 144 Â Â $ 1,027 Â Finished goods Â Â 760 Â Â Â 2,477 Â Less: Reserve for excess and obsolete inventory Â Â (204) Â Â (627) Inventory, net of reserves, from discontinued operations Â Â â€” Â Â Â (2,313) Total inventory, net Â $ 700 Â Â $ 564 Â X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 6 - Property and Equipment (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Property, Plant and Equipment [Table Text Block] Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Office and laboratory equipment Â $ 20 Â Â $ 20 Â Furniture and fixtures Â Â 157 Â Â Â 157 Â Computer equipment and software Â Â 435 Â Â Â 431 Â Leasehold improvements Â Â 152 Â Â Â 152 Â Total property and equipment, at cost Â Â 764 Â Â Â 760 Â Less: accumulated depreciation Â Â (696) Â Â (673) Total property and equipment, net Â $ 68 Â Â $ 87 Â X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 7 - Accrued Liabilities (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Schedule of Accrued Liabilities [Table Text Block] Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Contract liabilities (see Note 14) Â $ 773 Â Â $ 946 Â Employee payroll and benefits Â Â 380 Â Â Â 341 Â Other Â Â 144 Â Â Â 229 Â Accrued liabilities from discontinued operations Â Â â€” Â Â Â (347) Total accrued liabilities Â $ 1,297 Â Â $ 1,169 Â X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 8 - Commitments and Contingencies (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Lease, Cost [Table Text Block] Â Â For the Three Months Ended June 30, Â Â For the Six MonthsÂ Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease â€“ expense Â $ 100 Â Â $ 100 Â Â $ 200 Â Â $ 200 Â Operating lease from discontinued operations â€“ expense Â Â â€“ Â Â Â 31 Â Â Â â€“ Â Â Â 61 Â Operating lease â€“ included in operating cash flow Â Â 117 Â Â Â 114 Â Â Â 193 Â Â Â 188 Â Operating lease from discontinued operations â€“ included in operating cash flow Â Â â€“ Â Â Â 32 Â Â Â â€“ Â Â Â 64 Â Â Â June 30, 2024 Â Â June 30, 2023 Â Weighted-average remaining lease term (in years) Â Â 3.1 Â Â Â 3.8 Â Weighted-average discount rate Â Â 5 % Â Â 5 % Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] 2024 Â $ 233 Â 2025 Â Â 439 Â 2026 Â Â 444 Â 2027 Â Â 290 Â Total future minimum lease payments Â Â 1,406 Â Less: Imputed interest Â Â (92) Total Â $ 1,314 Â Â Â Â Â Â Â Reported as: Â Â Â Â Operating lease liability Â $ 382 Â Operating lease liability- non-current Â Â 932 Â Total Â $ 1,314 Â X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 10 - Convertible Notes (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Schedule of Long-Term Debt Instruments [Table Text Block] Principal amount Â $ 762 Â Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants Â Â (92) Unamortized debt issuance costs Â Â (15) Total Secured Convertible Notes, net Â $ 655 Â X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 11 - Common Stock Warrants (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Â Â Warrants Â Â Weighted- Average Exercise Price Â Outstanding at December 31, 2022 Â Â 65,886 Â Â $ 269.54 Â Warrants granted Â Â 145,056 Â Â Â 45.50 Â Warrants exercised Â Â â€” Â Â Â â€” Â Warrants expired Â Â â€” Â Â Â â€” Â Outstanding at June 30, 2023 Â Â 210,942 Â Â Â 76.23 Â Â Â Â Â Â Â Â Â Â Outstanding at December 31, 2023 Â Â 210,946 Â Â $ 50.96 Â Warrants granted Â Â 118,953 Â Â Â 3.13 Â Warrants exercised Â Â (90,381) Â Â 2.50 Â Warrants expired Â Â (14,741) Â Â 78.35 Â Outstanding at June 30, 2024 Â Â 224,777 Â Â Â 37.40 Â Schedule of Stockholders' Equity Note, Warrants or Rights Outstanding, Activity [Table Text Block] Series Â Exercise Price Â Â Expiration Date Â Warrants Â 2019 Ladenburg Warrants Â $ 1,212.75 Â Â August 8, 2024 Â Â 138 Â July 2020 Warrants Â $ 2,021.25 Â Â January 22, 2026 Â Â 1,714 Â July 2020 Warrants Â $ 52.50 Â Â January 22, 2026 Â Â 2,206 Â TLF Warrants Â $ 822.96 Â Â January 15, 2026 Â Â 13 Â November 2021 Warrants Â $ 220.50 Â Â September 11, 2028 Â Â 7,654 Â November 2021 Warrants Â $ 52.50 Â Â September 11, 2028 Â Â 15,308 Â September 2022 Warrants Â $ 220.50 Â Â September 11, 2028 Â Â 2,552 Â September 2022 Warrants Â $ 52.50 Â Â September 11, 2028 Â Â 1,715 Â November 2022 A-1 Warrants Â $ 220.50 Â Â November 20, 2028 Â Â 2,268 Â December 2023 Warrants Â $ 8.75 Â Â June 21, 2029 Â Â 72,256 Â March 2024 Warrant Â $ 4.90 Â Â March 24, 2029 Â Â 28,572 Â June 2024 Warrants Â $ 2.57 Â Â December 17, 2029 Â Â 90,381 Â Outstanding at June 30, 2024 Â Â Â Â Â Â Â Â Â 224,777 Â Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Warrant liabilities as of December 31, 2023 Â Â 334 Â Decrease in fair value of December 2023 Warrant liability during period Â Â (122) Fair value of March 2024 Warrant upon issuance Â Â 92 Â Increase in fair value of March 2024 Warrant liability during period Â Â 8 Â Reclassification of December 2023 Warrant liability to equity during period Â Â (212) Reclassification of March 2024 Warrant liability to equity during period Â Â (100) Warrant liabilities as of June 30, 2024 Â $ â€” Â X - DefinitionTabular disclosure of warrants or rights outstanding activity. + ReferencesNo definition available. + Details Name: nby_ScheduleOfStockholdersEquityNoteWarrantsOrRightsOutstandingActivityMemberTableTextBlock Namespace Prefix: nby_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or

right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 13 - Equity-based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Share-Based Payment Arrangement, Option, Activity [Table Text Block] (in thousands, except years and per share data) Â Awards Â Â Weighted- Average Exercise Price Â Â Weighted- Average Remaining Contractual Life (years) Â Â Aggregate Intrinsic Value Â Outstanding at December 31, 2023 Â Â 4 Â Â $ 1,145.87 Â Â Â 7.3 Â Â $ 1 Â Restricted stock units granted Â Â 5 Â Â $ â€” Â Â Â Â Â Â Â Â Options forfeited/cancelled Â Â (2) Â $ 392.58 Â Â Â Â Â Â Â Â Outstanding at June 30, 2024 Â Â 7 Â Â $ 505.54 Â Â Â 8.8 Â Â $ 11 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vested and expected to vest at June 30, 2024 Â Â 7 Â Â $ 509.60 Â Â Â 8.8 Â Â $ 11 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vested and exercisable at June 30, 2024 Â Â 1 Â Â $ 2,338.23 Â Â Â 4.9 Â Â $ â€” Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 5 Â Â $ 5 Â Â $ 9 Â Â $ 11 Â Sales and marketing Â Â 14 Â Â Â 17 Â Â Â 40 Â Â Â 32 Â General and administrative Â Â 36 Â Â Â 42 Â Â Â 66 Â Â Â 96 Â Total stock-based compensation expense Â $ 55 Â Â $ 64 Â Â $ 115 Â Â $ 139 Â Employees and Directors [Member] Â Notes Tables Â Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Assumption Â For the Six Months Ended June 30, 2023 Â Expected price volatility Â Â 152.99 % Expected term (in years) Â Â 6.81 Â Risk-free interest rate Â Â 3.47 % Dividend yield Â Â 0.00 % Weighted-average fair value of options granted during the period Â $ 56.19 Â X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=nby_EmployeesAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 14 - Distribution Agreements (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Â Â Chargebacks, Discounts for Prompt Payment Â Â Other Customer Fees Â Â Rebates Â Â Total Â Balance at December 31, 2023 Â $ 913 Â Â $ 12 Â Â $ 21 Â Â $ 946 Â Less discontinued operations Â Â (218) Â Â â€” Â Â Â â€” Â Â Â (218) Continuing operations balance at December 31, 2023 Â Â 695 Â Â Â 12 Â Â Â 21 Â Â Â 728 Â Provision related to sales made in: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Current period Â Â 57 Â Â Â 23 Â Â Â 52 Â Â Â 132 Â Payments and customer credits issued Â Â (11) Â Â (22) Â Â (54) Â Â (87) Balance at June 30, 2024 Â $ 741 Â Â $ 13 Â Â $ 19 Â Â $ 773 Â X - DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 16 - Related Party Transactions (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Schedule of Related Party Transactions [Table Text Block] Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Chongqing Pioneer Pharma Holdings Limited: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue Â $ â€” Â Â $ 1,043 Â Â $ â€” Â Â $ 1,043 Â Cost of goods sold Â Â â€” Â Â Â 895 Â Â Â â€” Â Â Â 895 Â X - DefinitionTabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 18 - Divestiture and Discontinued Operations (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Disposal Groups, Including Discontinued Operations [Table Text Block] Â Â Balance at December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â ASSETS Â Â Â Â Current assets: Â Â Â Â Cash and cash equivalents Â $ 206 Â Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023) Â Â 79 Â Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023) Â Â 2,313 Â Prepaid expenses and other current assets Â Â 132 Â Total current assets, discontinued operations Â Â 2,730 Â Other assets Â Â 19 Â Total assets, discontinued operations Â $ 2,749 Â Â Â Â Â Â Â Â LIABILITIES Â Â Â Â Liabilities: Â Â Â Â Current liabilities: Â Â Â Â Accounts payable Â $ 224 Â Accrued liabilities Â Â 347 Â Operating lease liabilities Â Â 127 Â Total current liabilities, discontinued operations Â Â 698 Â Total liabilities, discontinued operations Â $ 698 Â Â Â Six Months EndedÂ Â Â Â 2024 Â Â 2023 Â Sales: Â Â Â Â Â Â Â Â Product revenue, net Â $ 717 Â Â $ 1,861 Â Total sales, net Â Â 717 Â Â Â 1,861 Â Â Â Â Â Â Â Â Â Â Â Â Cost of goods sold Â Â 493 Â Â Â 958 Â Gross profit Â Â 224 Â Â Â 903 Â Operating expenses Â Â Â Â Â Â Â Â Research and development Â Â 2 Â Â Â 21 Â Sales and marketing Â Â 292 Â Â Â 960 Â General and administrative Â Â 48 Â Â Â 615 Â Total operating expenses Â Â 342 Â Â Â 1,596 Â Operating loss Â Â (118) Â Â (693) Â Â Â Â Â Â Â Â Â Â Â Â Other expense, net Â Â (6) Â Â (9) Â Â Â Â Â Â Â Â Â Â Â Â Net loss from discontinued operations Â $ (124) Â $ (702) Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Operating activities: Â Â Â Â Â Â Â Â Net loss from discontinued operations Â $ (124) Â $ (702) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Â Amortization of intangible assets Â Â â€” Â Â Â 76 Â Non-cash right-of-use amortization Â Â â€” Â Â Â 55 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Â Accounts receivable Â Â (262) Â Â (169) Inventory Â Â 183 Â Â Â (142) Prepaid expenses and other current assets Â Â (4) Â Â 125 Â Other assets Â Â 15 Â Â Â (9) Accounts payable and accrued liabilities Â Â 63 Â Â Â 264 Â Operating lease liabilities Â Â (31) Â Â (59) Net cash used in operating activities, discontinued operations Â Â (160) Â Â (561) Â Â Â Â Â Â Â Â Â Â Â Â Investing activities: Â Â Â Â Â Â Â Â Cash transferred to New Age Investments, LLC Â Â (46) Â Â â€” Â Net cash used in investing activities, discontinued operations Â Â (46) Â Â â€” Â Â Â Â Â Â Â Â Net decrease in cash and cash equivalents, discontinued operations Â $ (206) Â $ (561) X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5DReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3AReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3 + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 1 - Organization (Details Textual) $ in Thousands 3 Months Ended 6 Months Ended 12 Months Ended May 30, 2024 Mar. 25, 2024 USD ($) Jun. 30, 2024 USD ($) Mar. 31, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Dec. 31, 2023 Number of Reportable Segments Â Â Â Â Â 1 Â 2 Proceeds from Divestiture of Businesses Â Â Â Â Â $ 1,070 $ 0 Â Gain (Loss) on Disposition of Business Â Â $ (0) Â $ (0) $ (865) $ (0) Â Discontinued Operations, Disposed of by Sale [Member] | DERMAdoctor [Member] Â Â Â Â Â Â Â Â Proceeds from Divestiture of Businesses Â $ 1,100 Â Â Â Â Â Â Gain (Loss) on Disposition of Business Â Â Â Â $ (900) Â Â Â Â Reverse Stock Split [Member] Â Â Â Â Â Â Â Â Stockholders' Equity Note, Stock Split, Conversion Ratio 35 Â 35 Â Â Â Â Â X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=nby_DermadoctorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_NonmonetaryTransactionTypeAxis=nby_ReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) Mar. 31, 2024 Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Number of Major Source Manufacturers Â Â Â 1 Â Â Accounts Receivable, Allowance for Credit Loss $ 3 Â Â $ 3 Â $ 3 Inventory Valuation Reserves 204 Â Â 204 Â 264 Goodwill and Intangible Asset Impairment 0 Â $ 0 0 $ 0 Â Business Combination, Contingent Consideration, Liability 0 Â Â 0 Â $ 0 Impairment, Long-Lived Asset, Held-for-Use 0 Â 0 0 0 Â Payment for Product Supply Period Â 60 days Â Â Â Â Advertising Expense $ 200 Â $ 200 $ 400 $ 500 Â Equipment [Member] | Minimum [Member] Â Â Â Â Â Â Property, Plant and Equipment, Useful Life 5 years Â Â 5 years Â Â Equipment [Member] | Maximum [Member] Â Â Â Â Â Â Property, Plant and Equipment, Useful Life 7 years Â Â 7 years Â Â Computer Equipment and Software [Member] | Minimum [Member] Â Â Â Â Â Â Property, Plant and Equipment, Useful Life 3 years Â Â 3 years Â Â Computer Equipment and Software [Member] | Maximum [Member] Â Â Â Â Â Â Property, Plant and Equipment, Useful Life 5 years Â Â 5 years Â Â Furniture and Fixtures [Member] | Minimum [Member] Â Â Â Â Â Â Property, Plant and Equipment, Useful Life 5 years Â Â 5 years Â Â Furniture and Fixtures [Member] | Maximum [Member] Â Â Â Â Â Â Property, Plant and Equipment, Useful Life 7 years Â Â 7 years Â Â Revenue from Contract with Customer Benchmark [Member] | Distributor Concentration Risk [Member] | Avenova Spray [Member] Â Â Â Â Â Â Concentration Risk, Percentage 74.00% Â 61.00% 74.00% 68.00% Â X - DefinitionRepresents number of major source manufacturers. + ReferencesNo definition available. + Details Name: nby_NumberOfMajorSourceManufacturers Namespace Prefix: nby_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPeriod within which payment for product supply is expected from customer. + ReferencesNo definition available. + Details Name: nby_PaymentForProductSupplyPeriod

Namespace Prefix: nby_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionTotal loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill. + ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetImpairment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of valuation reserve for inventory. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryValuationReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nby_ComputerEquipmentAndSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=nby_DistributorConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=nby_AvenovaSprayMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Cash and cash equivalents $ 751 $ 3,130 Cash and cash equivalents, discontinued operations 0 (206) Restricted cash included in other assets 476 476 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 1,227 $ 3,400 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesNo definition available. + Details Name: nby_CashAndCashEquivalentsIncludingDisposalGroup Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended 18 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Total sales, net $ 2,400 $ 3,534 $ 5,031 $ 5,873 $ 5,873 Avenova Spray [Member] Â Â Â Â Â Total sales, net 2,125 1,758 4,221 Â 3,695 NeutroPhase [Member] Â Â Â Â Â Total sales, net 0 1,043 0 Â 1,043 Other Products [member] Â Â Â Â Â Total sales, net 262 722 790 Â 1,117 Total Product Revenue [Member] Â Â Â Â Â Total sales, net 2,387 3,523 5,011 Â 5,855 Product and Service, Other [Member] Â Â Â Â Â Total sales, net $ 13 $ 11 $ 20 $ 18 $ 18 X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=nby_AvenovaSprayMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=nby_NeutrophaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=nby_OtherProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=nby_TotalProductRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details) - Accounts Receivable [Member] - Customer Concentration Risk [Member] 6

Months Ended Jun. 30, 2024 Jun. 30, 2023 Major U.S. Retailer A [Member] Â Â Accounts receivable, concentration risk 35.00% 22.00% Distributor A [Member] Â Â Accounts receivable, concentration risk 33.00% 14.00% Distributor B [Member] Â Â Accounts receivable, concentration risk 12.00% Â Chongqing Pioneer Pharma Holdings Limited [Member] Â Â Accounts receivable, concentration risk Â 36.00% X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=nby_MajorUSRetailerAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=nby_DistributorAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=nby_DistributorBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=nby_ChongqingPioneerPharmaHoldingsLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Anti-dilutive securities (in shares) [1] 246,746 440,796 Series B Preferred Stock [Member] Â Â Anti-dilutive securities (in shares) [1] 15,065 201,432 Series C Preferred Stock [Member] Â Â Anti-dilutive securities (in shares) [1] 0 24,134 Share-Based Payment Arrangement, Option [Member] Â Â Anti-dilutive securities (in shares) [1] 6,904 4,301 Warrant [Member] Â Â Anti-dilutive securities (in shares) [1] 224,777 210,929 [1] After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Restricted cash held as a certificate of deposit $ 476 $ 476 Warrant liabilities Â 334 Fair Value, Inputs, Level 1 [Member] Â Â Restricted cash held as a certificate of deposit 476 476 Warrant liabilities Â 0 Fair Value, Inputs, Level 2 [Member] Â Â Restricted cash held as a certificate of deposit 0 0 Warrant liabilities Â 334 Fair Value, Inputs, Level 3 [Member] Â Â Restricted cash held as a certificate of deposit $ 0 0 Warrant liabilities Â $ 0 X - DefinitionFair value portion of restricted cash held as a certificate of deposit. + ReferencesNo definition available. + Details Name: nby_RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe fair value of warrant obligations. + ReferencesNo definition available. + Details Name: nby_WarrantLiabilitiesFairValueDisclosure Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details) $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Non-cash gain on changes in fair value of warrant liabilities Â Â $ 80 $ (216) $ (114) $ (216) Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] Â Â Â Â Â Â Total Value [1] $ 9,600 Â $ 9,600 Â $ 9,600 Â Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 220.5 Â 220.5 Â 220.5 Â Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input [2] 25.2 Â 25.2 Â 25.2 Â Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.801 Â 0.801 Â 0.801 Â Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement Input 0.0491 Â 0.0491 Â 0.0491 Â Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement Input 0.8 Â 0.8 Â 0.8 Â Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] Â Â Â Â Â Â Total Value [1] $ 1,700 Â $ 1,700 Â $ 1,700 Â Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 45.5 Â 45.5 Â 45.5 Â Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input 8.07 Â 8.07 Â 8.07 Â Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.793 Â 0.793 Â 0.793 Â Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement Input 0.0543 Â 0.0543 Â 0.0543 Â Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement Input 0.3 Â 0.3 Â 0.3 Â Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] Â Â Â Â Â Â Total Value [1] $ 500 Â $ 500 Â $ 500 Â Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 8.75 Â 8.75 Â 8.75 Â Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Option Volatility [Member] Â Â Â Â Â Â Measurement Input 0.799 Â 0.799 Â 0.799 Â Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement Input 0.0551 Â 0.0551 Â 0.0551 Â Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement Input 0.1 Â 0.1 Â 0.1 Â Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] Â Â Â Â Â Â Total value, embedded $ 200 Â $ 200 Â $ 200 Â Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement input, embedded derivative 4.9 Â 4.9 Â 4.9 Â Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement input, embedded derivative 4.51 Â 4.51 Â 4.51 Â Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Option Volatility [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0.869 Â 0.869 Â 0.869 Â Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0.0454 Â 0.0454 Â 0.0454 Â Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0 Â 0 Â 0 Â Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement input, embedded derivative 2 Â 2 Â 2 Â Issuance, April 27, 2023 [Member] | Convertible Debt [Member] Â Â Â Â Â Â Total value, embedded [3] $ 200 Â $ 200 Â $ 200 Â Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement input, embedded derivative 45.5 Â 45.5 Â 45.5 Â Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement input, embedded derivative [4] 25.2 Â 25.2 Â 25.2 Â Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Option Volatility [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0.801 Â 0.801 Â 0.801 Â Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0.0488 Â 0.0488 Â 0.0488 Â Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0 Â 0 Â 0 Â Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0.8 Â 0.8 Â 0.8 Â Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] Â Â Â Â Â Â Total value, embedded $ 200 Â $ 200 Â $ 200 Â Gain, embedded derivative Â Â Â Â Â $ (82) Â Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement input, embedded derivative 4.9 Â 4.9 Â 4.9 Â Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement input, embedded derivative 4.94 Â 4.94 Â 4.94 Â Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Option Volatility [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0.839 Â 0.839 Â 0.839 Â Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0.0494 Â 0.0494 Â 0.0494 Â Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0 Â 0 Â 0 Â Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement input, embedded derivative 1.8 Â 1.8 Â 1.8 Â After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] Â Â Â Â Â Â Total Value [1] $ 11,600 Â $ 11,600 Â $ 11,600 Â Deemed dividend Â Â Â Â Â $ 2,000 Â After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 45.5 Â 45.5 Â 45.5 Â After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input [2] 25.2 Â 25.2 Â 25.2 Â After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.801 Â 0.801 Â 0.801 Â After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement Input 0.0491 Â 0.0491 Â 0.0491 Â After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement Input 0.8 Â 0.8 Â 0.8 Â After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] Â Â Â Â Â Â Total Value [1] $ 6,800 Â $ 6,800 Â $ 6,800 Â Deemed dividend Â Â Â Â Â $ 5,100 Â After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 8.75 Â 8.75 Â 8.75 Â After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input 8.07 Â 8.07 Â 8.07 Â After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.793 Â 0.793 Â 0.793 Â After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement Input 0.0543 Â 0.0543 Â 0.0543 Â After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement Input 0.3 Â 0.3 Â 0.3 Â After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] Â Â Â Â Â Â Total Value [1] $ 900 Â $ 900 Â $ 900 Â Deemed dividend Â Â Â Â Â $ 400 Â After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 4.9 Â 4.9 Â 4.9 Â After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Option Volatility [Member] Â Â Â Â Â Â Measurement Input 0.799 Â 0.799 Â 0.799 Â After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement Input 0.0551 Â 0.0551 Â 0.0551 Â After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement Input 0.1 Â 0.1 Â 0.1 Â Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] Â Â Â Â Â Â Total value, embedded [3] $ 200 Â $ 200 Â $ 200 Â Gain, embedded derivative Â Â Â Â Â $ 40 Â Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement input, embedded derivative 45.5 Â 45.5 Â 45.5 Â Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement input, embedded derivative 23.8 Â 23.8 Â 23.8 Â Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Option Volatility [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0.769 Â 0.769 Â 0.769 Â Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0.0541 Â 0.0541 Â 0.0541 Â Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0 Â 0 Â 0 Â Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement input, embedded derivative 0.7 Â 0.7 Â 0.7 Â May 2023 Warrants [Member] Â Â Â Â Â Â Non-cash gain on changes in fair value of warrant liabilities $ (47) $ (170) Â Â Â Â May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] Â Â Â Â Â Â Total Value $ 1,600 Â $ 1,600 Â $ 1,600 Â May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 45.5 Â 45.5 Â 45.5 Â May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input [5] 25.2 Â 25.2 Â 25.2 Â May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement

Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.801 Â 0.801 Â 0.801 Â May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 0.036 Â 0.036 Â 0.036 Â May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 0.0404 Â 0.0404 Â 0.0404 Â May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 2.1 Â 2.1 Â 2.1 Â May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 5.1 Â 5.1 Â 5.1 Â May 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] Â Â Â Â Â Â Non-cash gain on changes in fair value of warrant liabilities Â Â Â Â $ (51) Â May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] Â Â Â Â Â Â Total Value $ 1,400 Â $ 1,400 Â 1,400 Â Non-cash gain on changes in fair value of warrant liabilities Â Â Â Â $ 200 Â May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 45.5 Â 45.5 Â 45.5 Â May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input 23.8 Â 23.8 Â 23.8 Â May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.776 Â 0.776 Â 0.776 Â May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 0.0392 Â 0.0392 Â 0.0392 Â May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 0.0459 Â 0.0459 Â 0.0459 Â May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 2 Â 2 Â 2 Â May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 5 Â 5 Â 5 Â March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] Â Â Â Â Â Â Total Value $ 100 Â $ 100 Â $ 100 Â Non-cash gain on changes in fair value of warrant liabilities Â Â Â Â $ 21 Â March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 4.9 Â 4.9 Â 4.9 Â March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input 3.66 Â 3.66 Â 3.66 Â March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.869 Â 0.869 Â 0.869 Â March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement Input 0.0421 Â 0.0421 Â 0.0421 Â March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement Input 5.5 Â 5.5 Â 5.5 Â March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] Â Â Â Â Â Â Total Value $ 100 Â $ 100 Â $ 100 Â Non-cash gain on changes in fair value of warrant liabilities Â Â Â Â $ (28) Â March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 4.9 Â 4.9 Â 4.9 Â March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input 4.94 Â 4.94 Â 4.94 Â March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.839 Â 0.839 Â 0.839 Â March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement Input 0.0456 Â 0.0456 Â 0.0456 Â March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement Input 5.3 Â 5.3 Â 5.3 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] Â Â Â Â Â Â Total Value $ 300 Â $ 300 Â $ 300 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 220.5 Â 220.5 Â 220.5 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input [6] 25.2 Â 25.2 Â 25.2 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.801 Â 0.801 Â 0.801 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 0.0359 Â 0.0359 Â 0.0359 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 0.0473 Â 0.0473 Â 0.0473 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 1.1 Â 1.1 Â 1.1 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 5.6 Â 5.6 Â 5.6 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] Â Â Â Â Â Â Total Value $ 500 Â $ 500 Â $ 500 Â Non-cash gain on changes in fair value of warrant liabilities Â Â Â Â $ 200 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 52.5 Â 52.5 Â 52.5 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.801 Â 0.801 Â 0.801 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 0.0359 Â 0.0359 Â 0.0359 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 0.0473 Â 0.0473 Â 0.0473 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 1.1 Â 1.1 Â 1.1 Â July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 5.6 Â 5.6 Â 5.6 Â The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] Â Â Â Â Â Â Total Value $ 56 Â $ 56 Â $ 56 Â The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 45.5 Â 45.5 Â 45.5 Â The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input 8.07 Â 8.07 Â 8.07 Â The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.793 Â 0.793 Â 0.793 Â The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 0.0392 Â 0.0392 Â 0.0392 Â The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 0.0462 Â 0.0462 Â 0.0462 Â The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 1.5 Â 1.5 Â 1.5 Â The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 4.5 Â 4.5 Â 4.5 Â The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] Â Â Â Â Â Â Total Value $ 200 Â $ 200 Â $ 200 Â Non-cash gain on changes in fair value of warrant liabilities Â Â Â Â $ 100 Â The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 8.75 Â 8.75 Â 8.75 Â The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input 8.07 Â 8.07 Â 8.07 Â The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.793 Â 0.793 Â 0.793 Â The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 0.0392 Â 0.0392 Â 0.0392 Â The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 0.0462 Â 0.0462 Â 0.0462 Â The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 1.5 Â 1.5 Â 1.5 Â The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 4.5 Â 4.5 Â 4.5 Â September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] Â Â Â Â Â Â Total Value $ 66 Â $ 66 Â $ 66 Â September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 8.75 Â 8.75 Â 8.75 Â September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 52.5 Â 52.5 Â 52.5 Â September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input 2.51 Â 2.51 Â 2.51 Â September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.893 Â 0.893 Â 0.893 Â September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 0.0427 Â 0.0427 Â 0.0427 Â September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 0.0508 Â 0.0508 Â 0.0508 Â September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] Â Â Â Â Â Â Total Value $ 100 Â $ 100 Â $ 100 Â Non-cash gain on changes in fair value of warrant liabilities Â Â Â Â $ 70 Â September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 2.5 Â 2.5 Â 2.5 Â September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input 2.51 Â 2.51 Â 2.51 Â September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.893 Â 0.893 Â 0.893 Â September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 0.0427 Â 0.0427 Â 0.0427 Â September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 0.0508 Â 0.0508 Â 0.0508 Â September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] Â Â Â Â Â Â Measurement Input 1 Â 1 Â 1 Â September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] Â Â Â Â Â Â Measurement Input 4.4 Â 4.4 Â 4.4 Â The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] Â Â Â Â Â Â Total Value $ 200 Â $ 200 Â $ 200 Â The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 8.75 Â 8.75 Â 8.75 Â The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input 4.94 Â 4.94 Â 4.94 Â The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.839 Â 0.839 Â 0.839 Â The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement Input 0.0456 Â 0.0456 Â 0.0456 Â The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement Input 5.1 Â 5.1 Â 5.1 Â The December 2023 Warrants [Member] | Reporting Date, December 31, 2021 [Member] Â Â Â Â Â Â Total Value $ 300 Â $ 300 Â $ 300 Â The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] Â Â Â Â Â Â Non-cash gain on changes in fair value of warrant liabilities Â Â Â Â $ 56 Â The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Exercise Price [Member] Â Â Â Â Â Â Measurement Input 8.75 Â 8.75 Â 8.75 Â The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Â Measurement Input 7.14 Â 7.14 Â 7.14 Â The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Â Measurement Input 0.793 Â 0.793 Â 0.793 Â The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Â Measurement Input 0.0385 Â 0.0385 Â 0.0385 Â The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Â Measurement Input 0 Â 0 Â 0 Â The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Â Measurement Input 5.5 Â 5.5 Â 5.5 Â [1] Includes value of incremental shares underlying preferred stock and adjusted for probability of occurrence. [2] Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. [3] Adjusted for probability of occurrence. [4] Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. [5] Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. [6] Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. X - DefinitionMeasurement input for preferred stock. + ReferencesNo definition available. + Details Name: nby_PreferredStockMeasurementInput Namespace Prefix: nby_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsPreferredStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNet Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 15 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815-15/tableOfContent + Details Name: us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of input used to measure embedded derivative liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_EmbeddedDerivativeLiabilityMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: srt_StatementScenarioAxis=nby_PriorToRatchetApril272023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=nby_SeriesBPreferredStockAndSeriesCPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_PriorToRatchetDecember212023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_PriorToRatchetMarch242024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_IssuanceMarch252024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=nby_UnsecuredConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_IssuanceApril272023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_StockholderApprovalMay282024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_AfterRatchetApril272023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_AfterRatchetDecember212023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_AfterRatchetMarch242024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_StockholderApprovalJune92023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_May2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_IssuanceMay12023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_March2024WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_ReportingDateMarch312024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_July2020November2021September2022November2022WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_PreamendmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_PostamendmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheMay2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_PreamendmentDecember212023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_PostamendmentDecember212023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_September2022November2022AndMay2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_PreamendmentJune142024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_PostAmendmentJune142024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheDecember2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_ReportingDateDecember312021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_ReportingDateDecember312023Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Prepaid insurance $ 94 $ 66 Prepaid dues and subscriptions 60 85 Prepaid taxes 7 83 Prepaid inventory 0 73 Other 94 81 Prepaid expenses from discontinued operations 0 (132) Total prepaid expenses and other current assets $ 255 $ 256 X - DefinitionThe amount of prepaid due and subscriptions. + ReferencesNo definition available. + Details Name: nby_PrepaidDueAndSubscriptions Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the advance payment of inventory. + ReferencesNo definition available. + Details Name: nby_PrepaidInventory Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Raw materials and supplies $ 144 $ 1,027 Finished goods 760 2,477 Less: Reserve for excess and obsolete inventory (204) (627) Inventory, net of reserves, from discontinued operations 0 (2,313) Total inventory, net $ 700 $ 564 X - DefinitionAmount of valuation reserve for inventory. + ReferencesNo definition available. + Details Name: nby_InventoryValuationReservesExcludingDiscontinuedOperations Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsAndSupplies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 6 - Property and Equipment (Details Textual) - USD ($) $ in

Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Depreciation $ 11 $ 13 $ 23 $ 26 Â Disposal Group, Including Discontinued Operation, Depreciation and Amortization 0 $ 0 0 $ 0 Â Disposal Group, Including Discontinued Operation, Property, Plant and Equipment $ 0 Â $ 0 Â $ 0 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as property, plant and equipment attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Property and equipment, at cost $ 764 $ 760 Less: accumulated depreciation (696) (673) Total property and equipment, net 68 87 Office and Laboratory Equipment [Member] Â Â Property and equipment, at cost 20 20 Furniture and Fixtures [Member] Â Â Property and equipment, at cost 157 157 Computer Equipment and Software [Member] Â Â Property and equipment, at cost 435 431 Leasehold Improvements [Member] Â Â Property and equipment, at cost $ 152 $ 152 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nby_OfficeAndLaboratoryEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nby_ComputerEquipmentAndSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Contract liabilities (see Note 14) $ 773 $ 946 Employee payroll and benefits 380 341 Other 144 229 Accrued liabilities from discontinued operations 0 (347) Total accrued liabilities $ 1,297 $ 1,169 X - DefinitionThe amount of accrued liabilities related to contract with customer. + ReferencesNo definition available. + Details Name: nby_ContractWithCustomerAccruedLiabilitiesCurrent Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 8 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Operating lease â€“ expense $ 100 $ 100 $ 200 $ 200 Weighted-average remaining lease term (in years) (Year) 3 years 1 month 6 days 3 years 9 months 18 days 3 years 1 month 6 days 3 years 9 months 18 days Weighted-average discount rate 5.00% 5.00% 5.00% 5.00% Operating lease from discontinued operations â€“ expense $ 0 $ 31 $ 0 $ 61 Operating lease â€“ included in operating cash flow 117 114 193 188 Operating lease from discontinued operations â€“ included in operating cash flow $ 0 $ 32 $ 0 $ 64 X - DefinitionAmount of operating lease cost attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: nby_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseCost Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating lease payments attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: nby_DisposalGroupIncludingDiscontinuedOperationOperatingLeasePayments Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 2024 $ 233 Â 2025 439 Â 2026 444 Â 2027 290 Â Total future minimum lease payments 1,406 Â Less: Imputed interest (92) Â Total 1,314 Â Operating lease liabilities 382 $ 368 Operating lease liability- non-current 932 $ 1,108 Total $ 1,314 Â X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 9 - Financing Activities (Details Textual) 1 Months Ended 3 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) $ / shares shares Mar. 24, 2024 USD ($) shares May 01, 2023 USD ($) $ / shares shares Apr. 27, 2023 Jun. 30, 2024 USD ($) $ / shares shares Dec. 31, 2023 USD ($) $ / shares shares May 31, 2023 USD ($) Jun. 30, 2024 USD ($) $ / shares shares Mar. 31, 2024 $ / shares shares Jun. 30, 2023 USD ($) $ / shares Jun. 30, 2024 USD ($) $ / shares shares Jun. 30, 2023 USD ($) $ / shares shares Dec. 31, 2022 $ / shares Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 37.4 Â Â Â $ 37.4 $ 50.96 Â $ 37.4 Â $ 76.23 $ 37.4 $ 76.23 $ 269.54 Class of Warrant or Right, Exercised During Period (in shares) | shares Â Â Â Â Â Â Â Â Â Â Â 90,381,000 (0) Â Proceeds from Warrant Exercises Â Â Â Â Â Â Â Â Â Â Â Â Â $ 226,000 $ 0 Â Modification of Warrants Â Â Â Â Â Â Â Â Â Â 69,000 285,000 Â Fair Value Adjustment of Warrants Â Â Â Â Â Â Â 80,000 Â $ (216,000) (114,000) $ (216,000) Â The 2023 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Issuance Costs, Net Â Â $ 700,000 Â Â Â Â Â Â Â Â Â Â Other Expenses Â Â 400,000 Â Â Â Â Â Â Â Â Â Â Â Proceeds From Debenture and Warrant Issuances, Net Â Â 3,000,000 Â Â Â Â Â Â Â Â Â Â Â Proceeds from Issuance of Warrants Â Â 1,600,000 Â Â Â Â Â Â Â Â Â Â Â Proceeds from Derivative Instrument, Financing Activities Â Â Â Â Â Â 200,000 Â Â Â Â Â Â Proceeds from Convertible Debt Â Â 1,200,000 Â Â Â Â Â Â Â Â Â Â The 2024 Warrant Reprice Transaction [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Issuance Costs, Net $ 96,000 Â Â Â $ 96,000 Â Â 96,000 Â Â 96,000 Â Â Unsecured Convertible Notes [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Issuance Costs, Net Â $ 130,000 Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â $ 525,000 Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Number of Equity Instruments Â 107,146 Â Â Â Â Â Â Â Â Â Â Â Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Â $ 19,000 Â Â Â Â Â Â Â Â Â Â Other Expenses 15,000 $ 111,000 Â Â Â Â Â 14,000 Â Â Â Â Â Original Issue Discount Senior Secured Convertible Debentures [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Issuance Costs, Net 15,000 Â 300,000 Â 15,000 Â 15,000 Â Â Debt Instrument, Face Amount Â Â 3,300,000 Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Number of Equity Instruments Â Â Â 72,528 Â Â Â Â Â 16,376 Â Â Â Â Fair Value Adjustment of Warrants Â Â 40,000 Â Â Â Â Â Â Â Â Â Â Debt Instrument, Unamortized Discount $ 92,000 Â 300,000 Â $ 92,000 Â Â $ 92,000 Â Â $ 92,000 Â Â Original Issue Discount Senior Secured Convertible Debentures [Member] | The 2023 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Unamortized Discount Â Â Â $ 300,000 Â Â Â Â Â Â Â Â Â Â Â The 2024 Warrant Reprice Existing Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 2.5 Â Â Â $ 2.5 Â Â $ 2.5 Â Â $ 2.5 Â Â Class of Warrant or Right, Exercised During Period (in shares) | shares Â Â Â Â 90,381 Â Â Â Â Â Â Â Â Proceeds from Warrant Exercises Â Â Â Â $ 200,000 Â Â Â Â Â Â Â June 2024 Warrant [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 2.57 Â Â Â $ 2.57 Â Â $ 2.57 Â Â $ 2.57 Â Â Warrants and Rights Outstanding, Term 5 years 6 months Â Â Â 5 years 6 months Â Â 5 years 6 months Â Â 5 years 6 months Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 90,381 Â Â Â 90,381 Â Â 90,381 Â Â 90,381 Â Â The 2024 Warrant Reprice Transaction [Member] Â Â Â Â Â Â Â Â Â Â Â Â Modification of Warrants Â Â Â Â Â Â Â $ (69) Â Â $ (69) Â Â March 2024 Warrant [Member] Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 4.9 Â Â Â $ 4.9 Â Â $ 4.9 $ 4.9 Â Â $ 4.9 Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares Â 28,572 Â Â Â Â Â Â 28,572 Â Â Â Â May 2023 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares 8.75 Â Â Â $ 8.75 $ 45.5 Â 8.75 Â Â 8.75 Â Â Proceeds from Warrant Exercises Â Â Â Â Â Â $ 200,000 Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares Â Â Â Â Â 72,256 Â Â Â Â Â Â Â Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Â Â Â Â Â $ 100,000 Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â Â Â Â $ (47,000) $ (170,000) Â Â Â Â Â Â Â The 2023 Warrant Reprice Transaction [Member] Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares Â Â Â Â Â $ 8.75 Â Â Â Â Â Â Â Â Proceeds from Warrant Exercises Â Â Â Â Â $ 600,000 Â Â Â Â Â Â Â Â Debt Issuance Costs, Net Â Â Â Â Â $ 200,000 Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares Â Â Â Â Â 72,256 Â Â Â Â Â Â Other Expenses Â Â Â Â Â $ 100,000 Â Â Â Â Â Â Â The December 2023 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 8.75 Â Â Â $ 8.75 $ 8.75 Â $ 8.75 Â Â $ 8.75 Â Â Proceeds from Warrant Exercises Â Â Â Â Â $ 400,000 Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares Â Â Â Â Â 72,256 Â Â Â Â Â Â Â The 2023 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares Â Â $ 52.5 Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares Â Â 145,056 Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â Â $ 400,000 Â Â Â Â Â Â Â Â Â Â X - DefinitionThe number of warrants or rights exercised during period. + ReferencesNo definition available. + Details Name: nby_ClassOfWarrantOrRightExercisedDuringPeriod Namespace Prefix: nby_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount of noncash expense from modification of warrants. + ReferencesNo definition available. + Details Name: nby_ModificationOfWarrants Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from debenture and warrant issuances, net. + ReferencesNo definition available. + Details Name: nby_ProceedsFromDebentureAndWarrantIssuancesNet Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-23Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=nby_The2023PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X -

Details Name: us-gaap_DebtInstrumentAxis=nby_The2024WarrantRepriceTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=nby_UnsecuredConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=nby_OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_The2024WarrantRepriceExistingWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_June2024WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_The2024WarrantRepriceTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_March2024WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_May2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_The2023WarrantRepriceTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheDecember2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_The2023PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 10 - Convertible Notes (Details Textual) $ / shares in Units, $ in Thousands 1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) Mar. 24, 2024 USD ($) $ / shares Mar. 01, 2024 USD ($) May 01, 2023 USD ($) Apr. 27, 2023 USD ($) $ / shares Dec. 31, 2023 USD ($) May 28, 2024 USD ($) Jun. 30, 2024 USD ($) Mar. 31, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 09, 2023 USD ($) Repayments of Convertible Debt Â Â Â Â Â Â Â Â Â Â Â $ 1,200 $ 193 Â Fair Value Adjustment of Warrants Â Â Â Â Â Â Â Â Â $ 80 Â $ (216) (114) (216) Â Amortization of Debt Issuance Costs and Discounts Â Â Â Â Â Â Â Â $ 300 Â 501 $ 733 501 Â The 2023 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Other Expenses Â Â Â $ 400 Â Â Â Â Â Â Â Â Â Proceeds from Convertible Debt Â Â Â 1,200 Â Â Â Â Â Â Â Â Â Debt Issuance Costs, Net Â Â Â 700 Â Â Â Â Â Â Â Â Â Â Unsecured Convertible Notes [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â $ 525 Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Conversion Price | $ / shares Â $ 4.9 Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Number of Equity Instruments Â 107,146 Â Â Â Â Â Â Â Â Â Â Â Embedded Derivative, Fair Value of Embedded Derivative Liability Â Â Â Â Â Â Â Â Â $ 159 Â Â Â Â Embedded Derivative, Fair Value Â Â Â Â Â Â $ 242 Â Â Â Â Â Â Unrealized Gain (Loss) on Derivatives Â Â Â Â Â Â $ 83 Â Â Â Â Â Â Debt Instrument, Interest Rate, Effective Percentage 144.00% Â Â Â Â Â Â 144.00% Â Â 144.00% Â Â Other Expenses $ 15 $ 111 Â Â Â Â Â $ 14 Â Â Â Â Â Â Debt Issuance Costs, Net Â $ 130 Â Â Â Â Â Â Â Â Â Â Â Â Original Issue Discount Senior Secured Convertible Debentures [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â 3,300 Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Conversion Price | $ / shares Â Â Â Â $ 45.5 Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Number of Equity Instruments Â Â Â Â 72,528 Â Â Â 16,376 Â Â Â Â Embedded Derivative, Fair Value Â Â Â Â $ 209 Â Â Â Â Â Â Â $ 169 Debt Instrument, Interest Rate, Effective Percentage Â Â Â Â Â Â Â Â 173.00% Â Â Â Â Debt Instrument, Unamortized Discount 92 Â Â 300 Â Â Â 92 Â Â $ 92 Â Â Debt Instrument, Increase (Decrease), Net Â Â Â Â 183 Â Â Â Â Â Â Â Â Debt Instrument, Redemption Price, Amount Per Month Â Â Â Â $ 193 Â Â Â Â $ 193 Â $ 193 Â Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Â Â Â Â 90.00% Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Threshold Trading Days Â Â Â Â 10 Â Â Â Â Â Â Â Â Debt Instrument, Redemption Price, Percentage Â Â Â Â 20.00% Â Â Â Â Â Â Â Â Repayments of Convertible Debt Â Â $ 45 Â Â $ 126 Â Â Â Â Â Â Â Debt Instrument, Default, Interest Rate Â Â Â Â 18.00% Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â Â Â 40 Â Â Â Â Â Â Â Â Â Debt Issuance Costs, Net 15 Â Â 300 Â Â Â 15 Â Â 15 Â Â Amortization of Debt Issuance Costs and Discounts Â Â Â Â Â Â Â 300 Â Â 700 Â Â Long-Term Debt, Maturity, Remainder of Fiscal Year $ 762 Â Â Â Â Â Â $ 762 Â Â $ 762 Â Â Original Issue Discount Senior Secured Convertible Debentures [Member] | The 2023 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Unamortized Discount Â Â Â $ 300 Â Â Â Â Â Â Â Â Â Original Issue Discount Senior Secured Convertible Debentures [Member] | Measurement Input, Redemption in Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Redemption Price, Amount Per Month Â Â Â Â $ 193 Â Â Â Â Â Â Â Â X - DefinitionPercentage of interest in the event of default of the debt instrument. + ReferencesNo definition available. + Details Name: nby_DebtInstrumentDefaultInterestRate Namespace Prefix: nby_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the amount of a debt instrument that is redeemed per month. + ReferencesNo definition available. + Details Name: nby_DebtInstrumentRedemptionPriceAmountPerMonth Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the fair value of embedded derivative. + ReferencesNo definition available. + Details Name: nby_EmbeddedDerivativeFairValue Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionMinimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThreshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNet increase or decrease in the carrying amount of the debt instrument for the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage price of original principal amount of debt at which debt can be redeemed by the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A + Details Name: us-gaap_UnrealizedGainLossOnDerivatives Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=nby_The2023PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=nby_UnsecuredConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=nby_OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=nby_MeasurementInputRedemptionInStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 10 - Convertible Note - Convertible Notes (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 May 01, 2023 Total Secured Convertible Notes, net $ 655 $ 1,137 Â Original Issue Discount Senior Secured Convertible Debentures [Member] Â Â Â Principal amount 762 Â Â Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants (92) Â $ (300) Unamortized debt issuance costs (15) Â $ (300) Total Secured Convertible Notes, net $ 655 Â Â X - DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=nby_OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 11 - Common Stock Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended May 01, 2023 Sep. 09, 2022 Jun. 30, 2024 May 31, 2024 Dec. 31, 2023 May 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2024 Mar. 24, 2024 Dec. 31, 2022 Nov. 10, 2022 Nov. 30, 2021 Sep. 09, 2020 Jul. 31, 2020 Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 37.4 Â $ 50.96 Â $ 37.4 $ 76.23 $ 37.4 $ 76.23 Â Â $ 269.54 Â Â Â Â Class of Warrant or Right, Exercised During Period (in shares) Â Â Â Â Â Â Â Â 90,381,000 (0) Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â Â Â Â Â Â $ (80) $ 216 $ 114 $ 216 Â Â Â Â Â Â Â Class of Warrant or Right, Forfeited During Period Â Â Â Â Â Â Â Â (14,741,000) 0 Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â Â Â Â Â Â $ 80 $ (216) $ (114) $ (216) Â Â Â Â Â Â Â June 2024 Warrant [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 90,381 Â Â Â 90,381 Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 2.57 Â Â Â $ 2.57 Â $ 2.57 Â Â Â Â Â Â Â Â March 2024 Warrant [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â Â Â Â Â Â Â Â 28,572 28,572 Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â 4.9 Â Â Â 4.9 Â $ 4.9 Â Â Â Â Â The December 2023 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â Â Â 72,256 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 8.75 Â $ 8.75 Â 8.75 Â 8.75 Â Â Â Â Â Â Â The May 2023 B-1 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â Â Â 72,528 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â Â Â $ 45.5 $ 45.5 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercised During Period (in shares) Â Â 54,396 Â 18,132 Â Â Â Â Â Â Â Â Â Â The May 2023 B-2 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â Â Â 72,528 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â Â Â $ 45.5 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercised During Period (in shares) Â Â 18,408 Â 54,120 Â Â Â Â Â Â Â Â Â Â Â Â Â May 2023 Warrants Amended By 2023 Warrant Reprice Transaction [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â Â Â $ 8.75 Â Â Â Â Â Â Â Â Â Â May 2023 Warrants Amended By 2024 Warrant Reprice Transaction [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 2.5 Â Â Â 2.5 Â 2.5 Â Â Â Â Â Â Â Â May 2023 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â Â Â 72,256 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 8.75 Â $ 45.5 Â $ 8.75 Â $ 8.75 Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â Â $ 47 Â $ 170 Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â Â $ (47) Â $ (170) Â Â Â Â Â Â Â Â Â Â The November 2022 A-1 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 12,473 Â 12,473 12,473 Â 12,473 Â Â Â 14,741 Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 220.5 Â $ 52.5 $ 220.5 Â $ 220.5 Â Â Â Â $ 220.5 Â Â Â The November 2022 A-2 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â Â Â 12,473 Â Â Â Â Â Â Â 14,741 Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â Â Â Â Â Â Â Â Â Â Â Â $ 220.5 Â Â Â Class of Warrant or Right, Forfeited During Period Â Â Â 14,741 Â Â Â Â Â Â Â Â Â Â Â The November 2022 A-1 and A-2 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â Â Â Â $ 220.5 Â Â Â Â Â Â Â Â Â Â The Amended November 2022 A-1 and A-2 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â Â Â Â $ 52.5 Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â Â $ (16) Â $ (74) Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â Â $ 16 Â $ 74 Â Â Â Â Â Â Â Â Â Â November 2022 Warrants Amended By 2024 Warrant Reprice Transaction [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 2.5 Â Â Â $ 2.5 Â $ 2.5 Â Â Â Â Â Â Â The 2022 Warrant Reprice Transaction [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â 9,371 Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â $ 220.5 Â Â Â Â Â Â Â Â Â Â Â Â Â September 2022 Warrants Amended in 2023 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â Â Â 6,819 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â 52.5 Â Â Â $ 52.5 Â Â Â Â Â Â Â Â Â Â September 2022 Warrants Amended in 2024 Warrant Reprise Transaction [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 5,104 Â Â Â 5,104 Â 5,104 Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 2.5 Â Â Â $ 2.5 Â $ 2.5 Â Â Â Â Â Â Â Â September 2022 Warrants Amended [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â Â $ (6) Â $ (28) Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â Â $ 6 Â $ 28 Â Â Â Â Â Â Â Â Â Â The November 2021 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights 15,308 Â Â Â Â Â Â Â Â Â Â 30,616 Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 220.5 Â Â Â 220.5 Â 220.5 Â Â Â Â Â $ 649.25 Â Â Amended November 2021 Warrants Exercisable for 6.50 [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights $ 220.5 $ 220.5 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercised During Period (in shares) Â 7,654 Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â $ (1,500) Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants Â $ 1,500 Â Â Â Â Â Â Â Â Â Â Â Â Â Amended November 2021 Warrants Exercisable for 1.50 [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights $ 52.5 Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants $ (100) Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants $ 100 Â Â Â Â Â Â Â Â Â Â Â Â Â The July 2020 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â Â Â Â Â Â Â Â Â Â Â Â 3,921 5,635 Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 2,021.25 Â Â Â $ 2,021.25 Â $ 2,021.25 Â Â Â Â Â Â $ 2,021.25 Amended July 2020 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights 2,206 Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights $ 220.5 $ 220.5 Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercised During Period (in shares) Â 1,715 Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants $ (9,000) $ (400) Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants $ 9,000 $ 400 Â Â Â Â Â Â Â Â Â Â Â Â Â The 2023 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights 145,056 Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights $ 52.5 Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants $ (400) Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Adjustment of Warrants $ 400 Â Â Â Â Â Â Â Â Â Â Â Â Â X - DefinitionThe number of warrants or rights exercised during period. + ReferencesNo definition available. + Details Name: nby_ClassOfWarrantOrRightExercisedDuringPeriod Namespace Prefix: nby_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants or rights forfeited during period. + ReferencesNo definition available. + Details Name: nby_ClassOfWarrantOrRightForfeitedDuringPeriod Namespace Prefix: nby_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_June2024WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_March2024WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheDecember2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheMay2023B1WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheMay2023B2WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_May2023WarrantsAmendedBy2023WarrantRepriceTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_May2023WarrantsAmendedBy2024WarrantRepriceTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details

Name: us-gaap_ClassOfWarrantOrRightAxis=nby_May2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheNovember2022A1WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheNovember2022A2WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheNovember2022A1AndA2WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheAmendedNovember2022A1AndA2WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_November2022WarrantsAmendedBy2024WarrantRepriceTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_The2022WarrantRepriceTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_September2022WarrantsAmendedIn2023PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_September2022WarrantsAmendedIn2024WarrantRepriseTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_September2022WarrantsAmendedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheNovember2021WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_AmendedNovember2021WarrantsExercisableFor650Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_AmendedNovember2021WarrantsExercisableFor150Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheJuly2020WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_AmendedJuly2020WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_The2023PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 11 - Common Stock Warrants - Outstanding Warrants (Details) - $ / shares shares in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Outstanding warrants (in shares) 210,946 65,886 Outstanding warrants, weighted-average exercise price (in dollars per share) $ 50.96 $ 269.54 Warrants granted (in shares) 118,953 145,056 Warrants granted, weighted average exercise price (in dollars per share) $ 3.13 $ 45.5 Warrants exercised (in shares) 90,381 (0) Warrants exercised, weighted-average exercise price (in dollars per share) $ 2.5 $ 0 Warrants expired (in shares) (14,741) 0 Warrants expired, weighted average exercise price (in dollars per share) $ 78.35 $ 0 Warrants exercised (in shares) (90,381) 0 Outstanding warrants (in shares) 224,777 210,942 Outstanding warrants, weighted-average exercise price (in dollars per share) $ 37.4 $ 76.23 X - DefinitionThe number of warrants or rights exercised during period. + ReferencesNo definition available. + Details Name: nby_ClassOfWarrantOrRightExercisedDuringPeriod Namespace Prefix: nby_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price per share of warrants or rights exercised during period. + ReferencesNo definition available. + Details Name: nby_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice Namespace Prefix: nby_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants or rights forfeited during period. + ReferencesNo definition available. + Details Name: nby_ClassOfWarrantOrRightForfeitedDuringPeriod Namespace Prefix: nby_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price per share of warrants or rights forfeited during period. + ReferencesNo definition available. + Details Name: nby_ClassOfWarrantOrRightForfeitedDuringPeriodWeightedAverageExercisePrice Namespace Prefix: nby_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants or rights issued during period. + ReferencesNo definition available. + Details Name: nby_ClassOfWarrantOrRightIssuedDuringPeriod Namespace Prefix: nby_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price per share of warrants or rights issued during period. + ReferencesNo definition available. + Details Name: nby_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice Namespace Prefix: nby_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 11 - Common Stock Warrants - Warrants Outstanding (Details) - $ / shares shares in Thousands Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Jun. 30, 2023 May 31, 2023 Dec. 31, 2022 Nov. 10, 2022 Nov. 30, 2021 Jul. 31, 2020 Exercise price (in dollars per share) $ 37.4 Â $ 50.96 $ 76.23 Â $ 269.54 Â Â Â Warrants outstanding (in shares) 224,777 Â 210,946 210,942 Â 65,886 Â Â Â The 2019 Ladenburg Warrants [Member] Â Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 1,212.75 Â Â Â Â Â Â Â Â Expiration date Aug. 08, 2024 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 138 Â Â Â Â Â Â Â Â The July 2020 Warrants [Member] Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 2,021.25 Â Â Â Â Â Â $ 2,021.25 Expiration date Jan. 22, 2026 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 1,714 Â Â Â Â Â Â Â Â The Amended July 2020 Warrants [Member] Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 52.5 Â Â Â Â Â Â Â Â Expiration date Jan. 22, 2026 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 2,206 Â Â Â Â Â Â Â Â TLF Bio Innovation 2021 Warrants [Member] Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 822.96 Â Â Â Â Â Â Â Â Expiration date Jan. 15, 2026 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 13 Â Â Â Â Â Â Â Â The November 2021 Warrants [Member] Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 220.5 Â Â Â Â Â Â $ 649.25 Â Expiration date Sep. 11, 2028 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 7,654 Â Â Â Â Â Â Â Â The Amended November 2021 Warrants [Member] Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 52.5 Â Â Â Â Â Â Â Â Expiration date Sep. 11, 2028 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 15,308 Â Â Â Â Â Â Â Â The September 2022 Warrants [Member] Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 220.5 Â Â Â Â Â Â Â Â Expiration date Sep. 11, 2028 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 2,552 Â Â Â Â Â Â Â Â The Amended September 2022 Warrants [Member] Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 52.5 Â Â Â Â Â Â Â Â Expiration date Sep. 11, 2028 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 1,715 Â Â Â Â Â Â Â Â The November 2022 A-1 Warrants [Member] Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 220.5 Â Â Â $ 52.5 Â $ 220.5 Â Â Expiration date Nov. 20, 2028 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 2,268 Â Â Â Â Â Â Â Â The December 2023 Warrants [Member] Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 8.75 Â $ 8.75 Â Â Â Â Â Â Expiration date Jun. 21, 2029 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 72,256 Â Â Â Â Â Â Â Â March 2024 Warrant [Member] Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 4.9 $ 4.9 Â Â Â Â Â Â Expiration date Mar. 24, 2029 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 28,572 Â Â Â Â Â Â Â Â June 2024 Warrant [Member] Â Â Â Â Â Â Â Â Exercise price (in dollars per share) $ 2.57 Â Â Â Â Â Â Â Â Expiration date Dec. 17, 2029 Â Â Â Â Â Â Â Â Warrants outstanding (in shares) 90,381 Â Â Â Â Â Â Â Â X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionExpiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_The2019LadenburgWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheJuly2020WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheAmendedJuly2020WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TLFBioInnovation2021WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheNovember2021WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheAmendedNovember2021WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheSeptember2022WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheAmendedSeptember2022WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheNovember2022A1WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheDecember2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_March2024WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_June2024WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 11 - Common Stock Warrants - Reconciliation of Common Stock Warrant Liabilities (Details) - Warrant Liability [Member] $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Warrant liabilities $ 334 Warrant liabilities 0 The December 2023 Warrants [Member] Â Change in fair value of warrant liability during period (122) Reclassification of warrant liability to equity during period (212) March 2024 Warrant [Member] Â Change in fair value of warrant liability during period 8 Fair value of March 2024 Warrant upon issuance 92 Reclassification of warrant liability to equity during period $ (100) X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByLiabilityClassAxis=nby_WarrantLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_TheDecember2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_March2024WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 12 - Stockholders' (Deficit) Equity (Details Textual) $ / shares in Units, $ in Millions 1 Months Ended 3 Months Ended May 30, 2024 Mar. 27, 2024 shares Dec. 21, 2023 USD ($) $ / shares Apr. 27, 2023 USD ($) $ / shares Sep. 09, 2022 USD ($) $ / shares shares Oct. 29, 2021 shares Mar. 31, 2024 USD ($) $ / shares Jun. 30, 2024 $ / shares shares May 27, 2024 Jan. 29, 2024 $ / shares Dec. 31, 2023 shares Jun. 30, 2023 $ / shares shares Common Stock, Shares Authorized (in shares) Â Â Â Â Â Â Â 150,000,000 Â Â 150,000,000 Â Preferred Stock, Shares Authorized (in shares) Â Â Â Â Â Â Â 5,000,000 Â Â 5,000,000 Â Preferred Stock, Convertible, Shares Issuable (in shares) Â Â Â Â Â Â Â 1,000 Â Â Â Â Preferred Stock, Shares Outstanding (in shares) Â Â Â Â Â Â Â Â 0 Â Â 1 Â May 2023 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â $ 45.5 Â Â Â Â Â Â Â Â Series B Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Shares Outstanding (in shares) Â Â Â Â Â Â Â 1,000 Â Â 6,000 Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â $ 220.5 Â Â Â Â Â $ 8.75 Â Â Preferred Stock, Change in Conversion Price, Income Statement Impact | $ Â $ 4.5 Â $ 5.7 Â Â Â Â Â Â Â Â Series B Preferred Stock [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Ratio Â Â Â Â Â Â Â Â Â Â Â 75 Â Â Series B Preferred Stock [Member] | Previously Reported [Member] Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â $ 45.5 Â $ 490 Â Â Â Â Â Â Â Series B Preferred Stock [Member] | Revision of Prior Period, Adjustment [Member] Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â $ 8.75 Â $ 220.5 Â Â Â Â Â Â Â Series B Preferred Stock [Member] | The 2021 Private Placement Program [Member] Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Shares Issuable (in shares) Â Â Â Â Â Â Â 15,065 Â Â Â 201,432 Stock Issued During Period, Shares, New Issues (in shares) Â Â Â Â Â 15,000 Â Â Â Â Â Â Preferred Stock, Shares Outstanding (in shares) Â Â Â Â Â Â Â 131 Â Â Â 9,156 Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â Â Â Â Â Â $ 8.75 Â Â Â $ 45.5 Series B Preferred Stock [Member] | The 2023 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Change in Conversion Price, Income Statement Impact | $ Â Â Â $ 1.8 Â Â Â Â Â Â Â Â Â Series C Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) Â 3,250 Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â $ 220.5 Â Â Â Â Â Â Â Preferred Stock, Change in Conversion Price, Income Statement Impact | $ Â Â $ 0.5 Â Â Â $ 0.4 Â Â Â Â Â Â Series C Preferred Stock [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Ratio Â Â Â Â Â Â Â Â Â Â Â 75 Â Â Â Series C Preferred Stock [Member] | Previously Reported [Member] Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion

Price (in dollars per share) | $ / shares Â Â $ 45.5 Â Â Â $ 8.75 Â Â Â Â Â Series C Preferred Stock [Member] | Revision of Prior Period, Adjustment [Member] Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â $ 8.75 Â Â Â $ 4.9 Â Â Â Â Â Series C Preferred Stock [Member] | The 2023 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Change in Conversion Price, Income Statement Impact | $ Â Â Â $ 194.0 Â Â Â Â Â Â Â Â Series C Preferred Stock [Member] | The 2022 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Shares Issuable (in shares) Â Â Â Â Â Â Â Â Â Â Â 24,134 Stock Issued During Period, Shares, New Issues (in shares) Â Â Â Â 3,250 Â Â Â Â Â Â Â Â Preferred Stock, Shares Outstanding (in shares) Â Â Â Â Â Â Â 0 Â Â Â Â 1,097 Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â Â Â Â Â Â Â Â $ 45.5 Reverse Stock Split [Member] Â Â Â Â Â Â Â Â Â Â Â Stockholders' Equity Note, Stock Split, Conversion Ratio 35 Â Â Â Â Â Â Â 35 Â Â Â Â Â X - DefinitionAmount of income statement impact from change in conversion price on preferred stock. + ReferencesNo definition available. + Details Name: nby_PreferredStockChangeInConversionPriceIncomeStatementImpact Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share conversion price of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionPrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of common shares issuable upon conversion for each share of preferred stock to be converted. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionRatio Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionNumber of common shares issuable upon conversion of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleSharesIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_May2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_RestatementAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=nby_The2021PrivatePlacementProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=nby_The2023PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=nby_The2022PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_NonmonetaryTransactionTypeAxis=nby_ReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 13 - Equity-based Compensation (Details Textual) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended 15 Months Ended Mar. 31, 2023 Mar. 31, 2017 Oct. 31, 2007 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) Â Â Â 0 0 0 0 Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Â Â Â $ 100 Â $ 100 Â Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Â Â Â Â Â 1 year 4 months 2 days Â Â Share-Based Payment Arrangement, Expense Â Â Â $ 55 $ 64 $ 115 $ 139 Â Share-Based Payment Arrangement, Nonemployee [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) Â Â Â Â 1,032 Â 1,032 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Â Â Â 0 0 0 Â Â Employees and Directors [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) Â Â Â Â Â 0 1,209 Â Employees and Directors [Member] | Share-Based Payment Arrangement, Nonemployee [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Â Â Â Â Â Â 150 Â Restricted Stock [Member] | Share-Based Payment Arrangement, Nonemployee [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Â Â Â Â 0 0 0 Â Share-Based Payment Arrangement, Expense Â Â Â Â $ 0 $ 13 $ 3 $ 3 Restricted Stock [Member] | Share-Based Payment Arrangement, Employee [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Â Â Â 0 Â Â Â Â Restricted Stock [Member] | Employees and Directors [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Â Â Â Â Â 5,148,000 Â Â Share-Based Payment Arrangement, Expense Â Â Â $ 55 $ 64 $ 102 $ 139 Â The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Â Â 10 years Â Â Â Â Â The 2017 Omnibus Incentive Plan [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Â 1,892 Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock Â 4.00% Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 12,219 Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Â Â Â 13,630 Â 13,630 Â Â The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member] Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum Â 10.00% Â Â Â Â Â Â Â The 2017 Omnibus Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Â 4 years Â Â Â Â Â Â The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Â 10 years Â Â Â Â Â Â The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Â 5 years Â Â Â Â Â Â Â The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Â 100.00% Â Â Â Â Â Â Â The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Â 110.00% Â Â Â Â Â Â Â X - DefinitionAnnual increase in number of shares originally approved for awards under the equity-based compensation plan expressed as a percentage of outstanding common stock. + ReferencesNo definition available. + Details Name: nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingCommonStock Namespace Prefix: nby_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionMinimum percentage of a shareholder's ownership of common stock used for determining the purchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOfStockOwnedByShareholderMinimum Namespace Prefix: nby_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or

other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=nby_EmployeesAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=nby_The2007OmnibusIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nby_IncentiveStockOptionsISOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=nby_The2017OmnibusIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=nby_ShareholderOfMoreThan10PercentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) $ / shares in Units, $ in Thousands 6 Months Ended 12 Months Ended Jun. 30, 2024 USD ($) $ / shares shares Jun. 30, 2024 USD ($) $ / shares shares Dec. 31, 2023 USD ($) $ / shares shares Outstanding awards (in shares) Â 4 Â Outstanding, weighted-average exercise price (in dollars per share) | $ / shares Â $ 1,145.87 Â Outstanding, weighted-average remaining contractual life (Year) Â 8 years 9 months 18 days 7 years 3 months 18 days Outstanding, aggregate intrinsic value | $ $ 11 $ 11 $ 1 Options forfeited/cancelled (in shares) Â (2) Â Options forfeited/cancelled, weighted-average exercise price (in dollars per share) | $ / shares Â $ 392.58 Â Outstanding awards (in shares) 7 7 4 Outstanding, weighted-average exercise price (in dollars per share) | $ / shares $ 505.54 $ 505.54 $ 1,145.87 Vested and expected to vest (in shares) 7 7 Â Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ / shares $ 509.6 $ 509.6 Â Vested and expected to vest at March 31, 2024Vested and expected to vest, weighted-average remaining contractual life (Year) Â 8 years 9 months 18 days Â Vested and expected to vest, aggregate intrinsic value | $ $ 11 $ 11 Â Vested and exercisable (in shares) 1 1 Â Exercisable, weighted-average exercise price (in dollars per share) | $ / shares $ 2,338.23 $ 2,338.23 Â Exercisable, weighted-average remaining contractual life (Year) Â 4 years 10 months 24 days Â Restricted Stock Units (RSUs) [Member] Â Â Â Restricted stock units granted (in shares) 5 Â Â X - DefinitionAs of the balance sheet date, the weighted-average exercise price for outstanding stock options and equity instruments other than options that are fully vested or expected to vest. + ReferencesNo definition available. + Details Name: nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: nby_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest equity instruments other than options and options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingCont Namespace Prefix: nby_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock equity instruments other than options and options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesNo definition available. + Details Name: nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber Namespace Prefix: nby_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option or equity instruments other than options, holders acquired shares when converting their stock options or equity instruments other than options, into shares. + ReferencesNo definition available. + Details Name: nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: nby_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for equity instruments other than options and options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm Namespace Prefix: nby_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, including stock (or unit) options, outstanding during the reporting period. + ReferencesNo definition available. + Details Name: nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding Namespace Prefix: nby_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan or equity instruments other than options. + ReferencesNo definition available. + Details Name: nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: nby_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest equity instruments other than options and options outstanding. + ReferencesNo definition available. + Details Name: nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAs of the balance sheet date, the number of shares into which fully vested and expected to vest stock options and equity instruments other than options outstanding can be converted under the option plan. + ReferencesNo definition available. + Details Name: nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: nby_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member] 6 Months Ended Jun. 30, 2023 $ / shares Expected price volatility 152.99% Expected term (in years) (Year) 6 years 9 months 21 days Risk-free interest rate 3.47% Dividend yield 0.00% Weighted-average fair value of options granted during the period (in dollars per share) $ 56.19 X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=nby_EmployeesAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Stock-based compensation expense $ 55 $ 64 $ 115 $ 139 Research and Development Expense [Member] Â Â Â Â Stock-based compensation expense 5 5 9 11 Selling and Marketing Expense [Member] Â Â Â Â Stock-based compensation expense 14 17 40 32 General and Administrative Expense [Member] Â Â Â Â Stock-based compensation expense $ 36 $ 42 $ 66 $ 96 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 14 - Distribution Agreements (Details Textual) - USD ($) 3 Months Ended 6 Months Ended 18 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Dec. 31, 2023 Revenue from Contract with Customer, Including Assessed Tax $ 2,400,000 Â $ 3,534,000 Â $ 5,031,000 $ 5,873,000 $ 5,873,000 Â Contract with Customer, Liability 773,000 Â Â Â 773,000 Â 773,000 $ 728,000 DERMAdoctor [Member] | Costco and Others [Member] Â Â Â Â Â Â Â Â Revenue from Contract with Customer, Including Assessed Tax 108,000 Â $ 195,000 Â 232,000 287 Â Â Contract with Customer, Liability $ 800,000 Â Â Â 800,000 Â $ 800,000 $ 700,000 Avenova Direct [Member] Â Â Â Â Â Â Â Â Revenue from Contract with Customer, Including Assessed Tax Â $ 1,800,000 Â $ 1,300,000 $ 3,500,000 $ 2,900,000 Â Â X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=nby_DermadoctorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=nby_CostcoAndOthersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=nby_AvenovaDirectMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details) $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Balance at December 31, 2023 $ 946 Less discontinued operations (218) Continuing operations balance at December 31, 2023 728 Current period 132 Payments and customer credits issued (87) Balance 773 Chargebacks, Discounts for Prompt, Payment, and Other [Member] Â Balance at December 31, 2023 913 Less discontinued operations (218) Continuing operations balance at December 31, 2023 695 Current period 57 Payments and customer credits issued (11) Balance 741 Other Customer Fees [Member] Â Balance at December 31, 2023 12 Less discontinued operations 0 Continuing operations balance at December 31, 2023 12 Current period 23 Payments and customer credits issued (22) Balance 13 Rebates [Member] Â Balance at December 31, 2023 21 Less discontinued operations 0 Continuing operations balance at December 31, 2023 21 Current period 52 Payments and customer credits issued (54) Balance $ 19 X - DefinitionRepresents contract with customer, liability, current period. + ReferencesNo definition available. + Details Name: nby_ContractWithCustomerLiabilityCurrentPeriod Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesNo definition available. + Details Name: nby_ContractWithCustomerLiabilityIncludingDisposalGroup Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents contract with customer, liability, payments and customer credits issued. + ReferencesNo definition available. + Details Name: nby_ContractWithCustomerLiabilityPaymentsAndCustomerCreditsIssued Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as deferred revenue attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=nby_ChargebacksDiscountsForPromptPaymentAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nby_OtherCustomerFeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nby_RebatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 15 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 The 401K Plan Contribution Level One [Member] Â Â Â Â Defined Contribution Plan, Employer Matching Contribution, Percent of Match Â Â 100.00% Â Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Â Â 3.00% Â The 401K Plan Contribution Level Two [Member] Â Â Â Â Defined Contribution Plan, Employer Matching Contribution, Percent of Match Â Â 50.00% Â Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Â Â 2.00% Â Defined Contribution Plan, Employer Discretionary Contribution Amount $ 25 $ 23 $ 49 $ 46 Disposal Group, Including Discontinued Operations, Defined Contribution Plan, Employer Discretionary Contribution Amount Â $ 9 Â $ 17 X - DefinitionAmount of discretionary contributions made by an employer to a defined contribution plan from disposal group including discontinued operations. + ReferencesNo definition available. + Details Name: nby_DisposalGroupIncludingDiscontinuedOperationsDefinedContributionPlanEmployerDiscretionaryContributionAmount Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of discretionary contributions made by an employer to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage employer matches of the employee's percentage contribution matched. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RetirementPlanNameAxis=nby_The401kPlanContributionLevelOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RetirementPlanNameAxis=nby_The401kPlanContributionLevelTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Cost of goods sold $ 808 $ 1,795 $ 1,645 $ 2,534 Related Party [Member] Â Â Â Â Revenue 0 1,043 0 1,043 Cost of goods sold $ 0 $ 895 $ 0 $ 895 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 17 - Segment Reporting (Details Textual) 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Number of Reportable Segments 1 2 X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 85 R74.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 18 - Divestiture and Discontinued Operations (Details Textual) - USD ($) $ in Thousands 6 Months Ended Mar. 25, 2024 Jun. 30, 2024 Jun. 30, 2023 Proceeds from Divestiture of Businesses Â $ 1,070 $ 0 Discontinued Operations, Disposed of by Sale [Member] | DERMAdoctor [Member] Â Â Â Disposal Group, Including Discontinued Operation, Percentage Sold 100.00% Â Â Proceeds from Divestiture of Businesses $ 1,100 Â Â X - DefinitionPercentage of business sold for the

disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: nby_DisposalGroupIncludingDiscontinuedOperationPercentageSold Namespace Prefix: nby_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=nby_DermadoctorMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Cash and cash equivalents $ (0) Â $ (0) Â $ 206 Net loss from discontinued operations 0 $ (308) (124) $ (702) Â Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023) (0) Â (0) Â 2,313 Non-cash right-of-use amortization Â Â 168 140 Â Prepaid expenses and other current assets (0) Â (0) Â 132 Total current assets, discontinued operations 0 Â 0 Â 2,730 Accounts receivable Â Â (133) 481 Â Total assets, discontinued operations 0 Â 0 Â 19 Inventory Â Â (144) (81) Â Accrued liabilities (0) Â (0) Â 347 Prepaid expenses and other current assets Â Â 1 (83) Â Total current liabilities, discontinued operations 0 Â 0 Â 698 Other assets Â Â 2 (5) Â Accounts payable and accrued liabilities Â Â 457 166 Â Operating lease liabilities Â Â (162) (127) Â Net loss from discontinued operations $ 0 $ (308) (124) (702) Â DERMAdoctor [Member] | Discontinued Operations, Disposed of by Sale [Member] Â Â Â Â Â Cash and cash equivalents Â Â Â Â 206 Product revenue, net Â Â 717 1,861 Â Net loss from discontinued operations Â Â (124) (702) Â Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023) Â Â Â Â 79 Amortization of intangible assets Â Â 0 76 Â Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023) Â Â Â Â 2,313 Cost of goods sold Â Â 493 958 Â Non-cash right-of-use amortization Â Â 0 55 Â Prepaid expenses and other current assets Â Â Â Â 132 Total current assets, discontinued operations Â Â Â Â 2,730 Gross profit Â Â 224 903 Â Accounts receivable Â Â (262) (169) Â Other assets Â Â Â Â 19 Total assets, discontinued operations Â Â Â Â 2,749 Research and development Â Â 2 21 Â Inventory Â Â 183 (142) Â Accounts payable Â Â Â Â 224 Accrued liabilities Â Â Â Â 347 Sales and marketing Â Â 292 960 Â Prepaid expenses and other current assets Â Â (4) 125 Â Operating lease liabilities Â Â Â Â 127 Total current liabilities, discontinued operations Â Â Â Â 698 General and administrative Â Â 48 615 Â Other assets Â Â 15 (9) Â Total liabilities, discontinued operations Â Â Â Â $ 698 Total operating expenses Â Â 342 1,596 Â Accounts payable and accrued liabilities Â Â 63 264 Â Operating loss Â Â (118) (693) Â Operating lease liabilities Â Â (31) (59) Â Other expense, net Â Â (6) (9) Â Net cash used in operating activities, discontinued operations Â Â (160) (561) Â Net loss from discontinued operations Â Â (124) (702) Â Cash transferred to New Age Investments, LLC Â Â (46) 0 Â Net cash used in investing activities, discontinued operations Â Â (46) 0 Â Net decrease in cash and cash equivalents, discontinued operations Â Â $ (206) $ (561) Â X - DefinitionAmount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: nby_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: nby_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of selling and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: nby_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionReduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_CashDivestedFromDeconsolidation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DepreciationAndAmortizationDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gross profit attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of operating expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of other expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncrease (decrease) in cash associated with the entity's discontinued operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=nby_DermadoctorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) (Parentheticals) - DERMAdoctor [Member] - Discontinued Operations, Disposed of by Sale [Member] $ in Thousands Dec. 31, 2023 USD ($) Allowance for credit losses $ 0 Reserve $ 363 X - DefinitionAmount of allowance on accounts receivable attributable to disposal group held for sale or disposed of. + ReferencesNo definition available. + Details Name: nby_DisposalGroupIncludingDiscontinuedOperationAccountsReceivableAllowance Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of reserve on inventory attributable to disposal group. + ReferencesNo definition available. + Details Name: nby_DisposalGroupIncludingDiscontinuedOperationInventoryReserve Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=nby_DermadoctorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 88 R77.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 19 - Subsequent Events (Details Textual) - USD ($) 6 Months Ended Aug. 09, 2024 Jul. 29, 2024 Jul. 26, 2024 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Common Stock, Par or Stated Value Per Share Â Â Â $ 0.01 Â $ 0.01 Â Class of Warrant or Right, Issued During Period Â Â Â 118,953,000 145,056,000 Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â Â $ 37.4 $ 76.23 $ 50.96 $ 269.54 Proceeds from Warrant Exercises Â Â Â $ 226,000 $ 0 Â Â Subsequent Event [Member] | Prefunded Warrants 2024 Public Offering [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 0.01 Â Â Â Â Proceeds from Warrant Exercises $ 20 Â Â Â Â Â Â Â Subsequent Event [Member] | Series F-1 Warrants [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 1.1 Â Â Â Â Warrants and Rights Outstanding, Term Â Â 5 years Â Â Â Â Subsequent Event [Member] | Series F-2 Warrants [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights Â Â $ 1.1 Â Â Â Â Warrants and Rights Outstanding, Term Â Â 6 months Â Â Â Â Subsequent Event [Member] | Series F-3 Warrants [Member] Â Â Â Â Â Â Â Warrants and Rights Outstanding, Term Â Â 1 year Â Â Â Â The 2024 Public Offering [Member] | Subsequent Event [Member] Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) Â Â 1,158,566 Â Â Â Â Common Stock, Par or Stated Value Per Share Â Â $ 0.01 Â Â Â Â Maximum Percentage of Common Stock Outstanding Â Â 4.99% Â Â Â Â Proceeds from Issuance of Stock and Warrants Â $ 3,900,000 Â Â Â Â Â The 2024 Public Offering [Member] | Subsequent Event [Member] | Election of the holder prior to the date of issuance [Member] Â Â Â Â Â Â Â Maximum Percentage of Common Stock Outstanding Â Â 9.99% Â Â Â Â The 2024 Public Offering [Member] | Subsequent Event [Member] | Prefunded Warrants 2024 Public Offering [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Issued During Period Â Â 2,041,814 Â Â Â Â The 2024 Public Offering [Member] | Subsequent Event [Member] | Series F-1 Warrants [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Issued During Period Â Â 3,200,380 Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 3,200,380 Â Â Â Â The 2024 Public Offering [Member] | Subsequent Event [Member] | Series F-2 Warrants [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Issued During Period Â Â 3,200,380 Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 3,200,380 Â Â Â Â The 2024

Public Offering [Member] | Subsequent Event [Member] | Series F-3 Warrants [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Issued During Period Â Â 3,200,380 Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 3,200,380 Â Â Â Â Over-Allotment Option [Member] | Subsequent Event [Member] | Underwriter From 2024 Public Offering [Member] Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) Â Â 336,832 Â Â Â Â Over-Allotment Option [Member] | Subsequent Event [Member] | Maximum Amount Purchasable By Underwriter [Member] | Underwriter From 2024 Public Offering [Member] Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) Â Â 477,272 Â Â Â Â Over-Allotment Option [Member] | Subsequent Event [Member] | Series F-1 Warrants [Member] | Underwriter From 2024 Public Offering [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Issued During Period Â Â 336,832 Â Â Â Â Over-Allotment Option [Member] | Subsequent Event [Member] | Series F-1 Warrants [Member] | Underwriting Agreement [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 336,832 Â Â Â Â Over-Allotment Option [Member] | Subsequent Event [Member] | Series F-1 Warrants [Member] | Maximum Amount Purchasable By Underwriter [Member] | Underwriter From 2024 Public Offering [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Issued During Period Â Â 477,272 Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 477,272 Â Â Â Â Over-Allotment Option [Member] | Subsequent Event [Member] | Series F-2 Warrants [Member] | Underwriter From 2024 Public Offering [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Issued During Period Â Â 336,832 Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 336,832 Â Â Â Â Over-Allotment Option [Member] | Subsequent Event [Member] | Series F-2 Warrants [Member] | Maximum Amount Purchasable By Underwriter [Member] | Underwriter From 2024 Public Offering [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Issued During Period Â Â 477,272 Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 477,272 Â Â Â Â Over-Allotment Option [Member] | Subsequent Event [Member] | Series F-3 Warrants [Member] | Underwriter From 2024 Public Offering [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Issued During Period Â Â 336,832 Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 336,832 Â Â Â Â Over-Allotment Option [Member] | Subsequent Event [Member] | Series F-3 Warrants [Member] | Maximum Amount Purchasable By Underwriter [Member] | Underwriter From 2024 Public Offering [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Issued During Period Â Â 477,272 Â Â Â Â Over-Allotment Option [Member] | Subsequent Event [Member] | Series F-3 Warrants [Member] | Maximum Amount Purchasable By Underwriter [Member] | Underwriter From 2024 Public Offering [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights Â Â 477,272 Â Â Â Â X - DefinitionThe number of warrants or rights issued during period. + ReferencesNo definition available. + Details Name: nby_ClassOfWarrantOrRightIssuedDuringPeriod Namespace Prefix: nby_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents maximum percentage of common stock outstanding. + ReferencesNo definition available. + Details Name: nby_MaximumPercentageOfCommonStockOutstanding Namespace Prefix: nby_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the issuance of stock and warrant. + ReferencesNo definition available. + Details Name: nby_ProceedsFromIssuanceOfStockAndWarrants Namespace Prefix: nby_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_PrefundedWarrants2024PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_SeriesF1WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_SeriesF2WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nby_SeriesF3WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=nby_The2024PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_ElectionOfTheHolderPriorToTheDateOfIssuanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=nby_UnderwriterFrom2024PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nby_MaximumAmountPurchasableByUnderwriterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=nby_UnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 89 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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l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

QQ10#DIZ/;H+:/:Y]I^@]ZL0UXO]:F#FRRO95=DFLI#E^Z M(;Y>\Z3>"& (#]=="#FED '8+@!\EF-KEF4%LF48KGK#BQK.@ M%+P2FBOU=VOC9DB'#PP_,KG)3 N6\[497C"*C4"3AV_V#@=:[.IOS%9":U'4 M/[>X/3EY/Q_4$L#!!0 (%R!#5E5ETE9!% /"? M! 8 >&PO=V]R:W-H965T&ULQUKIKLC,HG[A;A?=\P'M@C9G"V1&I"VV__^O D3H@@N 3]=,R7;AD+
M>*]TJE:^B52AZF^_W:_^^^'GY?(Q\Z\OG^\>_O[#SX^/7R]^_/'AX_++]__V#9"U^4\O&)]5LFM\O? M'K[[?GP,QG7ZOU^7E\O/GP.5=N3_/%%_M^+;1^.#W?]['0]^N_??
K;_//Z87EY_WEZ>_/X\]] ./LA<[\=]M/W+Y\?! 6_U MY=/?]!B\C _>?']; F_GMZ;TG/V0^ O+P>/_EZ<-I#(_]7T@]]8/Y))\^D- Z0/%LQP<*3Q\H;'V@D- Q@>+3!XK;6SC?\8'2TP=*;_W
MZ=,'3K<_D-OQ@;.G#YQM?> TN^,#YT\?.- Z0&G7![[GWRKLU3NWS*?CO8 MVT<[5]SUD&WC_SNK6P.?7;[V!=V_ETV!S^[??1W;B6W.?JY5T>_M.LCFZ.? MVS[ZN[?R+>S;1W_W5C9'/_?
FHY_;'/WYRVV.?N[-1S^_.?KY5T=_9Q7>'/W\FX]^?G/T M\]M'/[>K[.6_%?LW'_W\YNCGWYS]_.;HY]]\]/.;HY_?/OJ[M[(Y^ODW'_W\ MYNCGMX]^:=>9G-\<_?R;CWYA<_0+KXY^8==-'
D>_\.:C7]@<_<+VT3_=Y5AA M<_0+;$[ZA6^+_?;1W[V5S=$OO/GH%S9'O_]^SL LCGZA3VC [._M/_NFN5!8W1[_XYJ-?W!S]XO;1+^TZQXJ;HU]\\]$O
M;HY^M+\5OS=Z;CWYQ<_2+;\Y^<7/TB]M"?_='-D>_^"K[.S^R.?K% M[:-?V-60E#9'O[1]]':?+HY^]>ONKY=V3_='/W3[:._LUR<;H[^Z:NCO].Q;U_VWESY3S=' M_W1]]'_\X^OW^KM[^?
KQ^A]_6]W_EEG%^Q,O_K > *P_G[ZRW][%L&+XN$KJ M;?K?;F^O']! #Q_1_7Y9WCP^9^T_IO^X__O?/ M]Y]OEJN' RJ3^3^_W#[^GOF/\=WU+S>WZ=W_F?F0&0_+F?_X' _^9>?CY>K5\ MR-
S>948_W__R<'UW_"7S/]X\=]_^_$Q[7AL_L>/3SOI?^QD;L=.]E;+3\O5 M:KU?:4\R_]59?OGG7J-FW;_]OO?Q[/_SR);WKY>?% MGER2>W+Y9_:D_,X]J7SY^OG^]V7:?#([4[Y=+3\^WJ\>]FVJ\LY-;>#
[V-5W MLG<>S#W;JOVY;;T^7'NV57_GMCK7OV=R)[E\9GJ]6EU'P/9LI/'.C8Q^7L9& MV6EQ_7__7VOV7KW5:N/OXW?C?_*J@]UL7W_4\6M]YY[[]GW]]1#@?O MV;GA>W;N+05T))Z]&;.]G;]Y3
M6F+M0(>R8^L'6@Z[22U_.F>N/V=ZU[_<:FS PW)CK_+ M@<;BW7^7/[7TV8%&9,??Y4#3\9:_RSN60GM7DV$'NHRW[.Q;ED9[5QMA!_J(MM^S=>9*>U=?80<:BR/V[]BET]
[5=]B!QN,M>WO44FKO:D#L0 ?REMW\TROK MNYH3.]"=O'7/W['.OJMK\0-=R]M.B&-677]7Q^(*.I8W[*>BOJLW\0.]R6#Y M>)U>NLE4KE=WMW<_/?P[EUX_T,09 $_>N.G*@
MQ7M7L3C0Q1U7$0XT=W\Z]@<:MW=F^T!C=V2 #S1KH_O4N;S\W(^K^]^^_?-A M[ML_'^;6G,(.CE]_OKY+UOU'ZH?^^*>__\QS[&@+XV@/XV@3XVA%1NEH=72KU
:6GN]A]+02NX#E(:N"SY" M:>@JXQ.4AJY9/D-I[JX@&@O1ACY;R.,_)M&&&\96^PE'3NV(&%E$E8A8542 M5B-A=1+6(&%$M8B8>T_8*7OOHWESD_S6X,+ M1FEH"?0KE-9]'9@*XS.4QJY7
MBT.1>3$K*'Z;%13WS@K6OYSY$#=CO\E\O/_R=7GW<+W^?1V5T^+6Q 3-IO51&AID0Y-L:)0-S;*C678TRXYFV=$.QFL' MEQ9'&Q-'BX>CK8FCIK;CR+R;J?W4H^=()"P,@FK MD+
J":N1L#H):Y"P)@EKD;!VZ=7H[)6]',CM=4E8GX0-2=B8A$U)V)R$V?ZR M?/2T :6A5<]JKX/R^EX.Z!;1G!N:8D-C;&B.#0VRH4DV-,J&9MG1+#N:94>S M[&@+XV@/XV@3XVA%1NEH=72KU
:6GN]A]+02NX#E(:N"SY":>@J MXQ.4AJY9/D-I[JX@&@O1ABGWT88IV<]8;QE;+&7=.S8@H2525B%A%5)6(V$ MU4E8@XO125B+A5/7XVLQ;T&!MG0)!L:94>C[$]1?C$0+Q7/3DZW M?
W*!;A7M3AQM3QSM3QRM-8YV*(Y6+F^C-+0.^A5*Z[[.S(=L\?SL/+O]HPMT MLVCY]0%*0XNYCU :NC3X!*6A"XW/4!][;"U>A^;L[/Q$_^;B[-L0X>P]UT$< MO#GD7NJQ
P425B9A%1)6)6UE8G80T2UB1A+1+6/CM\'02YO2X)ZY.P(0D; MD[I"9N3,-M?EH\>)Z TM.I9[7507E\'@6X1S;FA*38TQH;FV- @&YID0Z-L M:)8=S;*C678TRXZV,([V,(XV,8Y6)$?;&$?
KF[=1&EHM_0JEH;77>R@-K>0^ M0&GHNN CE(:N,CY!:>B:Y3.4QJZ "XCV8H1Q_FV$T- ;FGI'4^]/J=^Z9$(\ MTP+=*MK(.%H=`&UE'*TUCC8SCE8N;Z,TM [Z%4KKOL[,CF=:H)M%RZV4!I:
MS'V$TM"EP2Q[JL7^CQX[8T!I M991606E5E%9#:764UD!I39360FEME=01:5V4UD=I0Y0V1FE3E#9':7:@;A\] MG6!Q:,$TML896Y:,K23&AM_8]!L;?V/S;VP!,+8"&%L"G"T!SI8 9TN LTV3
MLQ7%%V;;)V0+E;./D;+USMG5RMGSZ%8MCJ['W6!Q;W'W XMBUPDX<2S.C[>?_F2Q/7#.>3$9"__Z(D)22NCM I*JZ*T&DJKH[0& M2FNBM!9*:Z.T#DKKHK0^2ANBM#%*FZ*T.4JS
\7]^(D)BF,+IK$USMM8P2E M,3;\QJ;?V/@;FW]C"X"Q%<#8$N!L"7"V!#A; FQMFIRM*,ZV3N9#YC=Y26[OO&3'+3>:O]S]-9_,V7T/S_W8H\WEAU]:/6- M=E%:'Z4-4=H8I4U1VAREV8%*??SP \6Q
M9=!J*C.YD^T[<; ;96-O;*:-#;6QJ38VUL;FVMA@&YML9Y/M;+*=3;:S'8ZS M+8ZS/8ZS!N=M%L>63[]B<6PU]AZ+8XN[#U@-/#8BSIZX$'2RBBM@M*J**V&TNHHK8?2
MFBBMA=+:3[07]^W(YK9O.(INLXO2^BAMB-+&*&V*TN8HS0[4Y^-''BB.+816 M$ZEY]2@3=I-L[(U-M+&1-C;3QH;:V%0;&VMC<^ULKGV3ZQ?#PM.3?&G[0UL
M8IWM79QM7ISM7IPM/<[V+\Y6,F^S.+8P^A6+ZXKX?,B6\N>Y_/;=.M@-LQ79 M!RR.+? ^8G'L>N3%L^#3] M=E%:'Z4-4=H8I4U1 MVAREV8%*??P< L6Q9=!J(C.OGX'";I--O;&1-
C;3QH;:V%0;&VMCQ: MX2,6QRXJ/F%Q[$KF,Q8'+XP+"O=R]E%\GGT4WWKEQ>%YQU[4T?,.DE9&:164 M5D5I-9161VD-E-9$:2V4UGZB'7AB"KK-+DKKH[0A2ANCM"E*FZ,T.U"?CY]X
MH#BV$%I-I.;UE1?H)MG8&YMH8R-M*:-#;6QJ38VUL;FVME<^R;76P]'.3LY M?77E!;I=MG=QMGEQMGMQMO0XV[\X6\F\S>+8PNA7+*XKXO,A6SP_.]^^Z
M)Z;L_>C1TP:25D9I%91616DUE%9':0V4UD1+936Z})']?[7]{4@-]A%:7V4 M-D1I8Y0V16ESE&8'BO'QHP84QU9!JQV.C+$%Q-C,&YMH8R-M*:-#;6QJ38V MUL;FVME<^^7AY#@;5F=[%F>;%F>
[%F>KCK-]B[-%S-LLCJV)?L7BNB(Y'W(G M^=*K&0.Z6;84^X#%L97=1RR.72A\PN+8=<=G+ Y>QA8'T_-RR'#Z/&0XW3MD M..I))-_"$1.)4Y?[>36/_I>BK=L31G+^_?
XZ/D!2:NBM!I*JZ.T!DIKHK06 M2FNCM(XXP3\4MW[LT55OVKJXO8_NUA"EC5':%*7-49H=J)_'SP50'%O=C"U(MQM808V-O'1;797%L_(W-O[$%P-@*8&P)<+8$.%L"G"T!SG8XSE849WL<9PN4
MLUV.L_7.V3['V?+I5RR.K<;>8W%L&%< M4+B7LXNSY]G%&3>[D/.*/_C?7W'[9O+;H\LQ+M.V9Q>NWG&R/+,A]&]*T,4J;H0Y2K,#9?/X
MD06*8TN;L=7(&BH(VRN"M<2[7JT(UF%WKP276V<7"V7"VT/D5BV/KIO?><*KWW_"> ;M; M;/U-7]I1'%O.TY=V%,>N#NE+.XJ#%YL%A7OYI?W\^4O[^=XO[7;SOWJY>/RR
MO'N,+^W#Y>IV^9"Y?/7M_>/S=_NOJ]N/2_GU?>^6CC3F$J6545H%I56?:'NJ M4^WP6^KH/C506A.EM5!:&ZS4U%H7I?51VA"EC0^ZX-/#;YFC^V0'2N?Q7]Q1 M'%N$K,;BV)B;.:-
C:FQ.;6^.-.S9R>YK7G&4+WM?.O2)ANS^S9E<6QBG4VL MLXEU-K%>97%L 7"V'_&&-.D O Z%-^7[ME/A;#UQMHEPMCRE+_ HCJUVZ0L\ MBF.[!^P.+9K\M'AGLC?
T%JE+_#H;K&+1/H"C^+@-6=!X5Y\@<^=?/L"G_ZX M[PO\^OOYAW]>/Z3OZA_OOWQ=WCU67KY_O M?U\N,]=W-YF;V]7RX^/]ZNFW!>_.7:]NY,T-]N_ L=_K45KYB;;G]W\5=(-5
ME%9#:764UD!I39360FEME-9!:5V4UC\S8;5.NS.#;5QL;:V%P;&VQG@^ULL)T-MK/]C=<. M+SC.MBW.UA)G&Q=G2Y.SK8NSO8M?L3BVQ']/Q;$5VP=O6'2<+>L^8G'L*N$3 M%LN=L/^1L^?
0K%L=68^^Q M.+:X^X#%L6N%CU@?Z0WSM_0)\Q\;2M%[?.WWL[(A'K/ M]E,F]N_ST9,#DE9%:3645D=I#9361&DME-9&:1UQAK]ZR(1XS_8S)M"=&J*T M,4J;HK0Y2K,#]?/XT0&*8VN;L>7(V
IB;.BMP^*Z+(Z-O['Y-[8 &%L!C"T! MSI8 9TN LR7 V?[&V8KB(?C;(%RML=QMMXYV^4X6S[]BL6QU=A[+(XM[CY@ M<>Q:X2,6QRX]/F%Q[$KF,Q8'+XP+"O=R=E%XGET4]LXN.O MZ7,'W6 7I?
51VA"EC5':%*7-49H=J-3'3TE0'%L%K78X,L86$&,S;VRBC8VT ML9DV-M3&IMK86!N;:V=S[9M!%; M'%AU7DX?BL_3A^+>Z<-@^?'S]/%%
<6]J,K4;&UAICRX.QB38VTL9FVMA0VU@)YLO;8>'C:O-49RST78V MVLY&V]FVQ=E*X746QQ8>9[L<;QU>=IQM7IRM=7[%XMC2Z3T6QU9B'[XMK#[
MB,6QW9]/WK3L.+OL^(S%P:O8@L*]G#^4GN[-'C!Y)61FD5E%9%:3645D=I#9361&DME-9^HGT_ M& M9G%L^?0K%L=68^^Q.+:X^X#%L6N%CU@Q=GFQ=GNQ=G2
MXVS_XFPE\S:+8PNC7[&XKHC/AVPI?Y[+O_KE![IAMB+[@,6Q!=Y'+(Y=+WS" MXMCEQVIP]G[[GTHKS\^-=,/KMGK7>_0D@J25 M45H%I5516@VEU5%: Z4U45H+I;6?:-
]'\W1[#$%NL(O2^BAMB-+&*&V*TN8H MS0X4ZN/'$"B.K8)6$Y)YUX/(M"-LJDW-M/&AMK85!L;:V-S;6RPC4VVL\EV M-MG.)MO9!L?9#L?9%L?9 N5LD^-
LO?,VBV/+IU^Q.+8:>X_%L<7=!RR.72M\ MQ.+8I<0=)*Z.T"DJK MHK0:2JNCM 9*:Z*T%DIK/]%>_!OR>?'5CTW(;7916A^E#'5:&*5-4=H% M\U=77J ;9BNR#U@<6^!]Q.+8]<(G+(Y=?
GS&XN#&5;"'RD\]G"_K*B$JS)M^E# M^N.^Z/G3:@M#)*JZ"T*DJKH;0Z2FN@M"9*:Z&T]A-M MS\VB.^@&&NRBMC]*&*&V,TJ8H;8[2[$ Q/GK4P.+8*FBUPY$QMH 8FWEC$VUL MI(W-M+&A-
C5QL;:V%P[FVN_/)P<9\J;_B;-/B;-?B;-5QMF]QMHAYF\6Q M-=&O6%Q7).=#/IQ"X1,6QZX[/F-Q\#*V.)B> MET.&[/.0(;MWR'IY?_?KI2O&=&
2WOW^6C!P@DK8K2:BBMCM(:**V)TEHHK8W2.N($+^:W M?N[156_:>D\?W:TA2ANCM"E*FZ,T.U! CQ\,H#BVNAE;D(RM(<;&WCHLKLOB MV/@;FW]C"X"Q%<#8$N!L"7"V!#A; ISM<)RM*,
[V.,X6*&>['&?KG;-]CK/E MTZ]8'%N-ON9#YC?A18X; M7LB!Q1_\[R^Y_9#+9[=('%O)=A>VIQ=Y]/7JU0=*J]**V&TNHHK8?ZFBBMA=+: M**TCSO'B]LSBJ5NRVR,++8TF9L-;)- 7GQ M
.U<:>OBB)9Z5W[[UQH==M>Z+(X-J[%I-3:NQN;5V, Z&UAG ^L5<;)O7_-0 M?<-[V*0ZVS@XVSDXVSHXVSLXVSPX6^CL\BL6Q=-[;SC5^VJSX#=+;;^IB_M M*(XMY^E+.XIC5X?TI1W%P8O-
@L*] -*>?_[2GM_[I=UN_O\:5] MN%S=+A\REZ^^O7]_F[_=77[<2F_ON_=TI'&7**T,DJKH+0J2JNAM#I*:Z"T M)DIKH;3V$VW/\[X[Z :[**V/TH8H;8S2IBAMCM+L0.T^?G* XM@J:+7#D3&V
M@!B;>6,3;6RDC_PX"W2C;M3C;MCC; MMSA;=YSM7)PM8]YF<6Q5]"L6UQ79^? Z/#UVJVPM]@&+8TN[CU@$YV_2B\#R0*.P=2*SG#1_^>?VPO(D+!KXN[QZN'V/NL/Q7 M_F962T_7S\F\?
$^L_SR]?/[\MEYOKN)G-SNUI^?+Q?/?TXXOJWZ]6-OEO# MWATX>DY!TLI/M#V3R@JZP2I*JZ&T.DIKH+0F2FNAM#9*ZZ"T+DKK'X[+$-W@ M&*5-4=HQQG*XJS78ZS!N=LI^-L^?0K%L=6
M8^^Q.+:X^X#%L6N%CU@EY>E':.[W8/$CS MN[E$/%2S<[WZ]E#-@AQ4[,4>?>$$22NCM I*JZ*T&DJKH[0&2FNBM!9*:S_1
M7OSD?/L"N0&NRBMC]*&*&V,TJ8H;8[2[$"A/GY(@N+8*F@U$9GS;/'53SS0 MC;*I-S;3QH;:V%0;&VMCL1=U]+R#I)516@6E55%:#:7545H#I3516@NEM9]H+VXW M63@K;H\\R&UV45H?
I0U1VABE35':*79@?I_@#Q;&%T&HB->>O!A[H)MG8 M&YMH8R-M*:-#;6QJ38VUL;FVME<^R;7WP\+LZ>GV9/S5[>U0+?+]B[.-B_. M=B_.EAYG^Q=G*YFW61Q;&/V*Q75%?#YD3*A?
RK.UN@&V8KL@]8'%O@?<3B MV/7")RR.77Y\QN+@U6RAEI_2KGM;G&T/\[>+<^%%>?GQXR B+P<1>[%'#R)(M6AFE55!:%:754%H=I3506A.EM5!:^XGV?3)/MZ<0Y ;[**V/TH8H;8S2IBAM
MCM+L0*$^?@J!XM@J:#41F7PN^VH.@6Z43;VQF38VU,:FVMA8&YMK8X-M+*= M3;:SR78VV;'&?KG;=9'%L^_8K%L=78>RR.+>X^8'!L M6N$C%LQ*YC,6!R^,"PKW'YQU[44?/.TA:&:55
M4%H5I=506AVE-5!:$Z6U4%K[B?;BPHOSXJN'B9#;[**T/DH;HK0Q2INBM#E* MLP/U^?B1!XIC"Z'51&JVGP?*UA!C8V]LHHV-M+&9-C;4QJ;:V%@;FVMG<^V;
M7+^**4R[Y^G@BZ7;9W<;9Y<;9[<;;T-.N _%O)O,WBV,+H5RRN*^+S(7M: M."ML[7;48S?,5F0?L#BVP/N(Q;'KA4]8'+O\^(S%P:O90N0GG\)47A9-O MTX?TQWW3AZOE8^;S_8-
\'LC^CQX[;4!I991606E5E%9#:764UD!I39360FEM ME-9!:5V4UD=I0Y0V1FE3E#9':7:@;A\]E6!Q:,$TML896Y:,K23&AM_8]!L; M?V/S;VP!,+8"&%L"G"T!SI8 9TN
LTV3LQ7%%V;;)V0+E;./D;+USMG5RMGSZ M%8MCJ['W6!Q;W'W XMBUPDE M=5%:'Z4-4=H8I4U1VAREV8'B?OS$!,6Q!=/8&F=L63*VDA@;?F/3;VS\CV'7U2.YY8)+; M.S#9<=^.YB]W?\WD3W;?
0'0_]N@Y"4DKH[0*2JNBM!!*JZ.T!DIKHK062FL_ MT5Y$<^M'+.@&NRBMC]*&*&V,TJ8H;8[2[$"A/G[X@>+8*F@U%9E\X6S[=RSL M5MG8&QMJ8U-M*R-S;6QP38VV<9&V]EH.QMM9Z/M;(?C;
(OC;(_C;(%RMLMQ MMMYYF\6QY=.O6!Q;C;W'XMCB[@,6QZX5/F0]+C$Q;'KF0^8W'PPKB@<"^' M' GGX4?^3<./-PT\]]*.'GB0M#)*JZ"T*DJKH;0Z2FN@M"9*:Z&T]A/M^UL0
ME+8''N0&NRBMC]*&*&V,TJ8H;8[2[$!Q/G[@@>+8*F@U$9GLJ]MVL-MD0V]L MI(W-M+&A-C5QL;:V%P;&VQG@^V;8+^\;<=Y_CRW?=L.=KMLY^)LZ^)L[^)L
MZ7&V>W&VDGFQ;&%T:]87%?$YT/V[.0D=[9]VPYVPVQ%]@&+8PN\CU@9P^%]UQX?13?>MW%X7G'7M31\PZ25D9I%91616DUE%9* M:0V4UD1+936?J*]^$?
DPEEQ>^1!;K.+TOHH;8C2QBAMBM+F*,T.U.?C1QXH MCBV$5A.I.7\U$ WR<;>V$0;&VEC,VULJ(U-M;&Q-C7SN;:-[E^>>7%:?9D M^X$/;&*=
[5V<;5Z<[5Z<+3W.]B_.5C)OLSBV,/H5B^N*^'S(GIX5"OE75UZ@ M&V8KL@]8'%O@?<3BV/7")RR.77Y\QN+@U6RAEI_2R8X++TK/PX?2WN'#WN>E M[/WHT<,&DE9&:1645D5I-9161VD-E-
9$:2V4UGZB??^O1K.@&NRBMC]*& M*&V,TJ8H;8[2[$ Q/G[2@.+8*FBUPY$QMH 8FWEC$VULI(W-M+&A-C5QL;:_ MV%P[FVO?Y+JX.SG.AM79GL79IL79KL79JN-LW^)L$?,VBV-
KHE^QN*Y(SH=L MP=GFP=G"YU?L3BV;GKO#:=Z_PWO&;"[MQ=;?]*4=Q;'E/'UI1W'LZI^^M*,X>+%94+B77]K/G[^TG^_]TK[^?KQR2F[^_++U_W_^^7&:NI[VXR-[>K
MYFVMA8&YMK8X/M;+"=#;:SP7:VO_':X07'V;;%V5KB;./B M;&ERMG5QMG?Q*Q;'EECOL3BV8OO@#8N.LV7=1RR.725\PN+81<=G+ Y>PQ84 M[L60HGCR;4B1_KAO2-
&YO[G]=/OQC\'$_:>7OX+X[7JUNKY[?,C,-F<'RZ^KVXS(S2O_U<+U^_E_K+[M^78^<5**V,TBHH MK8K2:BBMCM(:3[0]74D3W6 +I;516@>E=5%:'Z4-4=H8I4U1VAREF1W.B[%U
MTMC29FPUL@:+8\N#L8DV-M+&9MK84!N;:IN*Y)2V;T+*IM4/]&\'SRM8'1ML M9YL69^N$LVV+LV7'V1['V2KF{<.+CK.5SJ]8'%LXO45V[[RB\?#PR_I)%=NSBG>,*/Z2N5L^ M!NC^TZ?
EZO;NIT1X>'PX=/.'_7MX]!2#I)516@6E55%:#:7545H#I3516@NE MM9]H>VZTDWV$5I?90V1&ECE#9%:7.49@=J_M$7:+ XM@I:343F_-4]*=EM MLJ$W-M+&9MK84!N;:F-C;6RNC0VVL\%V-
MC.!MO9_L;9!L?9#L?9 N5LC^-L MO?,VBV/+IU^Q.+8:>X_%L<7=!RR.72M\Q.+8I_&IENOFARJ?5_9?,Y]OK?]Y^OGW7J@M"Y*ZZ.T(4H; MH[0I2INC-#M0A(\?
+!P\Q:WRAO>P=;'_W8%L09[L&9]L&9_/O;./@;#GQ)HMCJY.S+8EW#E?_M],W^\'O8*1>^V:,XMFBF;_8HCJW!Z9L]BF-+>OIFC^+8%2)]LW_+"J'6D=\VCO[:3M+*
M**V"TJHHK8;2ZBBM@=*:**V%TMI/M+V7#I ;[**T/DH;HK0Q2INBM#E*LP-5 M^_AO^"B.K8)6.QP98PN(L9DW-M'&1MK83!L;:F-3;6RLC< MW/8CP9R-J[-=B[-MB[-]B[-
UQ]G.Q=DRYFT6QU9%OV)Q79&=UY<.H)MD"[$/ M6!Q;UWW$XMAEPB3F)*#Y/(HI[]Q'#]4T=,K9?/$BFUDMX^&:RZ>?0#Q_7S[F+GY91G/Y5C=_W)W$[]I^+2\?OQE
MM3QX;XB].W#TF(*DE5%:!:5545H-I=516@.E-5%:"Z6UGVA[[PU!;K"+TOHH M;8C2QBAMBM+F*,T.E/3CQQ0HCJV"5A.1R9ZP$%NL(O2^BAMB-+&*&V* MTN8HS0Z4\>,G(RB.K8)6$Y%Y?>\'=)-
LYHU-M+&1-C;3QH;:V%0;&VMC<^UL MKGV3Z^]GBA^RKZ[?0+?)-BW.=BW.MBW.EAUG&Q=GJYBW61Q;%/V*Q75%=%Y? MOX%NDJW#/F!Q;%GW$8MC5PF?L#AVT?
$9BX/7L,7>Y+R<2YP^SR5.]\XE)LN' MQQ@RW'_*W-RNEA\?[U>9M"^/JJN/C\N;I[G$]6_7JYO#C_#8NZ6CAQ$DK8S2 M*D^T/26LBFZPAM+J**V!TIHHK872VBBM@]*Z**V/TH:'XS)&-
SA%:7.49@<* M\O$3!A1787%LX3*VUAA;'HQ-M+&1-C;3-F1Q; $PM@(86P*<+0'.E@!G2X"S MG9"S%<797LC9 N5L-^1LO7.V'W*V?/H5BV.KL?=8'%O&!<4[N4PY.QY&')/D
&0O_>@!"$DKH[3*$VW/O[57T0W6 M4%H=I3506A.EM5!:&ZS5U4%H7I?51VO!P7,;H!J%>SA_.G^?96RT_+U6IYDQFN!P^/JR\?*WKH MBG>LG418WG_'A\]-R!I59160VEUE-9 :4V4UD)I;936$?2
XA[.S MEZ=X5[TI6]AZ5Q_=L2%*&Z.T*4J;HS0[4$&/'QZ@.+:^&5N2C*TBQ@;?.BRN MR^+8^!N;?V,+@+$5P-@2X&P)<+8$.%L"G.UQG*THSG8YSA8H9_L<9^N=LYV.
ML^73KU@<6XV]Q^+8XNX#%L>N%3YB<>S2XQ,6QZYD/F-Q\,*XH' OIA>EDV_3 MB_3'?=,+O_Y\???QQ=T\,]>/F>8O=W_-Y$_^DLF=Y IJO_=CC[UL J6545H% MI5516@VEU5%:
Z4U45H+I;6?:'LF9G%L^CU@ M9;?+=B[.MB[.]B[.EAYGNQ=G*YFW61Q;&/V*Q75%=*YDSTY.N%3U@4/=7W\"SE?MA^)?\\CG3\N-C_)KD.I/]\.E^]2%? ME,\A>?
SY^C'SS^7'ZR^;#\'7.]>_?QMN_%6-3GY\^'FY?"Q?/U[_XV]?EJN? MEI?+SY\?,A_O?[E+^YK-Y^+O]4U(6_Z4ON/E+JYR/_SXZO5N[J*G7N_G+@;] M]6'N8J1>'^YBIEZ?
YRX6ZG6SW(6Y5"Z34I9*)2E5J=224I=*(RE- MJ;22TI9*,M&DBY9L-.FC)2--.FG)2I-><6C+3I)N6[#3IIR5#33KJR5&7CGIR MU*6CG?S%55Z=+?F+GGJ]G[\8J->'^8N1>GVFH)T=.NK)49>.=HH7
M5T5UMA0O>NKU?O%BH%X?%B]&ZO5Q\6*B7I\6+V;]7GQ8]%>.RNFLT4JETDI M2Z62E*H4:DFI2Z61E*946DEI2R69:-)%2S::]-&2D:=M&2E22\MF6G234MV MFO33DJ$F'?
7DJ$M'/3GJTM%.Z>*JI,Z6TD5/O=XO70S4Z\/2Q4B]/BY=3-3K MT]+%3+T^+UTLU.MFI72V2.4R*66I5))2E4HM*76I-)+2E$HK*6VI)!--NFC) M1I,^6C+2I).6K#3II24S3;IIR4Z3?
EHRU*2CGAQUZ:@G1UTZVCF]N#I59\OI M14^]WC^]&*C7AZ<7(_7Z^/1BHEZ?GE[,U.OSTXN%>MWL-)TM4KE,2EDJE:14
MI5)+2ETJC:0TI=)*2ELJR423+EJRT:2/EHPTZ:0E*TUZ:FH)T==.NK)49>.=LXNKL[4V7)VT5.O]\\N!NKUX=G%2+T^/KN8J->G9Q+5"Z34I9*)2E5J=224I=*(RE-J;22TI9*,M&DBY9L-.FC M)2-
-.FG)2I->6C+3I)N6[#3IIR5#33KJR5&7CGIRU*6CG?.+JW-UMIQ?]-3K
M_?.+@7I]>'XQ4J^/SR\FZO7I^<5,O3X_OUBHU\W.TJDBEEH)WMR<94]4>=+4GI2Z2=E()5A4D92&2=E(I5I4F92F2=E(16S M))EK[3*TLM8JH56U5@NMKK5&:$VMM4)K:RWL-
>VOA<&F';:PV+3'%B:=;NG" M9M,^6QAMVFD+JTU[[>&U:Z\]O';M=2>;36=65IY9V71F*:6?E(%4ADD9266< ME(E4IDF9266>E(54TIF5C3-+:I>AE;56':VJM5IH=:TU0FMJK15-IM2RZV4!I:
M+0PV[;"%Q:8]MC#9M,L6-IOVV<)HTTY;6&W::P^O77OMX;5KSO97#JSY)0X M*3VI]),RD,HP*2.IC),RDTOQ8&FW8PF+3'EN8;-IE"YM-^VQAM&FG+:PV[;6'UZZ]
M]O#:M=>=:;#Z=67*BG)2>5/I)&4AEF)215,9)F4AEFI295.9)64@EG5DQ7M;: M96AEK55"JVJM%EI=:XW0FEIKA=;66MAKVE\+@TT[;&&Q:8\M3#;MLH7-IGVV M,-
JTTQ96F_;:PVO77GMX[=KK3K:0SBPY?4Y*3RK]I RD,DS*2RC@I$ZE,DS*3RCPI"RDDLZL&5K[3*TLM8JH56U5@NMKK5&:$VMM4)K:RWL->VOA<&F';:P
MV+3'%B:;=MG"9M,^6QAMVFD+JTU[[>&U:Z\]O';M=2=;3&>6G%0GI2>5?E(& M4ADF9225<5(F4IDF92:5>5(64DEG5HRMM7896EEKE="J6JN%5M=:([2FUEJA
MM;46]IKVU)@TPY;6&S:8PN33;ML8;-IGRV,-NVTA=6FO?;PVK77'EZ[KJ3 M+:4S2TZUD]*32C\I ZD,DS*2RC@I$ZE,DS*3RCPI"ZFD,RM&W%][#*VLM4IH M:W50JMKK1%4:VNMT-I:"WM-
^VMAL&F'+2PV[;&%R:9=MK#9M,\61IMVVL)J MTUY[>.W::P^O77O=R9ZF,TM.P)/2DTH_*0.1#),RDLHX*1.I3),RD\H*0NI MI#,KQN%:NPRMK+5*:%6MU4*K:ZT16E-KK=#:6@M[3?MK8;!IARTL-NVQA>WCMVFL/KUU[WI3-+3LN3TI-*/RD#]0R3,I+* M."D3J4R3,I/*|"D+J:0S*T;G6KL,K:RU2FA5K=5"JVNM$5I3:ZW0VEH+>TW[M:V&P:8]W)GJ.W:
M:P^O77O=R9U<7.7D##XI/:GTDS*0RC I(ZF,DS*1RC0I,ZG,D[*0BEDN9O!: MNPRMK+5*:%6MU4*K:ZT16E-KK=#:6@M[3?MK8;!IARTL-NVQA>WCMVFL/KUU[WNO>[DXD)M?:5V7*JMK]6.
MB[7UU=IQN;:^7CLNV-97;,\=5V^O+MG=\<5W.M+N'=]OI!['MQY7\?5W.O+N7=6G,$GI2>5 M?E(&4ADF9225<5(F4IDF92:5>5(64DEG5LS@M7896EEKE="J6JN%5M=:([2F
MUEJAM;46]IKVU)@TPY;6&S:8PN33;ML8;-IGRV,-NVTA=6FO?;PVK77'EZ[M]KJ3*Z0S2\[@D]*32C\I ZD,DS*2RC@I$ZE,DS*3RCPI"ZFD,RMF\%][#*VL MM4IH5:W50JMKK1%4:VNMT-I:"WM-
^VMAL&F'+2PV[;&%R:9=MK#9M,\61IMV MVL)JTUY[>.W::P^O77O=R173F25G\$GI2:6?E(%4ADD9266 ME(54TID5,WBM7896UEHEM*K6:J'5M=8(K:FU5FAMK86]IOVU M,-BTPQ86F_;8PF33+EO8;-IG"Z--.VUAM6FO/;QV[;6'UZZ]
MPF33+EO8;-IG"Z--.VUAM6FO/;QV[;6'UZZ][N1*ZN_;:PVO77G=RI^G, MDC/XI/ZD7TD_*0"K#I(RD,D[*1"K3I,RD,D_*0BKIS(H9O-8N0RMKK1):56NU MT.I:.X36U%HKH+;6PE[3_EH8;-IA"M
>VQALFF7+6PV[;.%T::=MK#:M-<> M7KOVVL-KUUYWT.Y:&&S:80N+37ML8;)IERUL M-NVSA=&FG:PVK37'EZ[]MK#:]=>=W+GZN_;:PVO77G?R)Q=7>3F#3TI/
M*OVD#*0R3,I(*N.D3*0R3VQALFF7+6PV[;.%T::=MK#:M-<>7KOVVL-K MUUYW\MET9LD9?%)Z4NDG92*585)&4ADG92*5:5)F4IDG92&5=&;%#9%YKEZ&5
MM58)K:JU6FAUK35":VJM%5I;:V&O:7\M##;ML(7%ICVV,-FTRQ8VF_;9PFC3 M3EM8;=IK#Z]=>^WAM6NO._E<.K/D##XI/:GTDS*0RC I(ZF,DS*1RC0I,ZG, MD[*02CJS8@:OM
M6YALVF4+FTW[;&&T::)VZOH^ZO$#5;T'5;B%BOZ'BMQDY4==UE9WV9EQWU6UC=:V7&GE?6M5G;< M:V5]LY4==UM9WVYEQ_U6UC= MV7'GE?6M5W;
<>V5]\Y4==U]9WWYEQ_U7UC=@V7$'EO4M6.0,/E](9Y:E M)Y5^4@92&29E))5Q4B92F29E)I5Y4A9226=6S."U=AE:66N5T*I:JX56UUHC MM*:66J&UM1VFO;7PF#3#EM8;-IC"Y--NVQALVF?
+8PV[;2%U::]]O#:M=<> M7KOVNI,OIC-+SN"3TI-*/RD#]0R3,I+*."D3J4R3,I/*|"D+J:0S*T;P6KL, MK:RU2FA5K=5"JVNM$5I3:ZW0VEH+>TW[:V&P:8]W)GJ*9)6?
P2>E)I9^4@52&21E)99R4B52F29E) M99Z4A532F14S>*U=AE;66B6TJM9JH=6UU@BMJ;56:&VMAVF_;4PV+3#*&A:; M]MC"9-,N6]ALVF<+HTT[;6&U::\]O';MM8??KKWNY$_3F25G\$GI2:6?
E(%4 MADD9266E(54TID5,WBM7896UEHEM*K6:J'5M=8(K:FU5FAM MK86]IOVU,-BTPQ86F_;8PF33+EO8;-IG"Z--.VUAM6FO/;QV[;6'UZZ][N3/
MTIDE9_!)Z4FEGY2!5(9)&4EEG)2)5*9)F4EEGI2%5-*9%3-XK5V&5M9:);2J MUFJAU;76"*VIM59H;:V%O:;]M3#8M,,6%IOVV,)DTRY;V&S:9PNC33MM8;5I MKSV\=NVUA]>NO>[DS].9)6?
P2>E)I9^4@52&21E)99R4B52F29E)99Z4A532 MF14S>*U=AE;66B6TJM9JH=6UU@BMJ;56:&VMAVF_;4PV+3#*&A:;]MC"9-,N M6]ALVF<+HTT[;6&U::\]O';MM8?
7KKWN%$XNK@IR!I^4GE3Z21E(99B4D53& M4GE(99J4F53F25E(Q:P0,WBM7896UEHEM*K6:J'5M=8(K:FU5FAMK86]IOVU M,-BTPQ86F_;8PF33+EO8;-IG"Z--.VUAM6FO/;QV[;6'UZZ]
[A2RZN_;: MPVO77G<*N71FR1E\4GI2Z2=E()5A4D92&2=E(I5I4F92F2=E(95T9L4,7FN7 MH96U5@FMJK5::'6M-4)K:JT56EMK8:]I?RT,-NVPA<6F/;8PV

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{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}2)YCPSDQHBW(8/5@+4(%:B1YQ3 BE-(,V P'D2S2"YBF)6BL.WB&:6%WD>:"0.Q-39=+(I*"]EMP55Y*K) M.9!Q$K[8+C2@GS8IU%8BQCNMKY)6V(^A\:V/K]-X0).JIOB[1&-F0J1:+[I M0Q3F5O: LB3/B;(HK#1C7V68PV"91Z^]D/(OA RTA1@(8T@R#UQBD:'/($A= M3PQ%A!IW?%Z[J_#R+0T+R[? CDFCU!/U")CAB5]7KQ9Y3"2D!K$G?*+XI@V*^ M:;J:"P04!.9$+RQ+5(X5.?CEB51-Q EAW11*&F5> YL D(M-8/3!*I< M%C0N,&KMBBI0QL(%S4,KZUKBB%MC)\'G91G,R>"2\+^XXK@Z:!QU^IT]ROG- MCM>I/2#ON 11V -E4I"FU[H[DW+_SFH-.NW5MF!9-A MSN-;M$=$W1W6/HY'5^./X^GX=E+ [N$G1LS*Z476Q@&'"7ZQ+P,;OTK(F_M4< M[W0'M7R>1WZYOEG=]_S!*W,KN_OU[@]/<[+O.GY$!'\=1P"4R!JZL[BY\A7N MY:)MO]K(?G6HLO-].)/%''>DU-7[KLJO /(62X<]%=$53-Z,HAMYY90AG]G* M77L%77L9+JVBO+3:S+7#](_!UP^;\^>0:P(CJG?W&NE>L[A%@P.2^$&K, NH ML@$#68Y!1VS@#?#7:Y[VO3S#Z')CW#9MNJUKY;18*&I6T#YDW6&'#7NG-=QN M#?4O-0=XH2[8L-VIU$! ;5'-#@[]+CQ[E*K'CF,]\SVEIMU9DT$C93+4.LTK,U M*3,N7]1.'48KFM- =V,H;,.6=DL<+. .+G[=2BI?^>#?JU.Q6_LSPU?3-]I^;O MP!SWR J+XG2O5[M>@I,PKV3OG ;/=@U&K.'WJ7(:7l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{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|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

-0L"T6WB|+7I[IRH>Z:3O3'W3@&!HML;IBMYS6=&.:8T8:SK:.M_MLNUP=D)S][S5=WWF- MTZVKR\2>!UO/U:G(W8,.HW:*@^U<'BK23^%RD:=]%Q3:XC3@,P6)&[K^EVY M3FY5[LT+9-V5<5 /C,_K'-6*-94",:S]=M(K?3A."'M0G\U|/UYWNP\B%*.8K)#):""[T.8OJ3N!8$S=1GZ"D5@B:J.R<8$)03 MX/F.0@#D@GQ!\7^)\3]02P.$% @ 7($-6>;_Q%[+ @ % 8 !D !X M;"|W;W)K&ULC55M;],P$/]>7W'*IHE)94F3MBM; M&VEMAP!4&T#/B ^N,FUL9;8P7;6CE_/V4E#0:7BB^.7N^>>>\UX(163SA - M;(M^;Y.,BR8OI E"GI9254P0T>U]G6ID*5,]"PX6Z.W!:"P6Z*@[F7J:8R|W$ZWF[BWN^SHR|\.-QR=;X@.9SN5!T\EN4 ME!-WMN#[60IY9,lOs|GT'}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|Z23L2]MX[*?-)@RSYE^FZ)0FXG7\]XO9GRYLN["3\8%6^(SVA_% MDZ:3W[)D/$=IN)*@<3'Q;GJC:>SL*X.?'#=F;P\NDKE2K^[PD$V\P E"@:EU M#(P^:[Q%(1P1R?C;<']M2P? Q4RQS90!6B5\\LZN)=5^!A@M3 MFR_8O--W2*D2IEIA4|OV P_2TEB5-V!2D'-9?]FVR<,>X.HC0-@ PDIW!-&2 M><6N6L5LEW91'Z\ D>Y]!Z5?H-SE_8 M7*"Y&/N6'#@S/VW(IC59^ '9 !Z5M"L#GV6&V?]XGX2UZL)W=+/P*.'74EY" M%'0A#,+X"%_41AM5?-&1: W4\1T*KT;'A]&N/T:F8"E./&H @WJ-7G)VTAL$ MUT>TQ:VV^!A[\DS]EI4"02UV/Z,+MZ76M(??E6IXP:V%J5#IZY]# 1QU<3@ MRC&Z''?N,,5\CAJB7K?C$NZ6J#-C&RHXBYHS88#)C!JX* 2G1)Y"+X[=V@W" M8>>>2TZ%F,/%2]GYCN>81#0VA_$<,@O^GN]E:-->5A)$0*1*:>LV:V_;/753 M}^;.O)YPCTPO.0D3N"!H<#GL>2#K]5$?K"]3ITK2WW>U]H<#GB>Z#K]5$?K"]3ITK2WW>U]H;W}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|^Q<^]T)=63+A$-O%2BUC.O-*8Y]WV=E5@Q M?2H;K&FGD*IBAD*U]'6CD.4.5 D_"H*A?S%>>>^G4K=V!=*I,(WB-=PIT6U5, MO7?@!\>5WI]#=;*0\LD&G_*9%UA!*# SEH'1\(Q7* (0E(AE_UIQ>G](*M^<,=I@,,.W4@SDN2EGWMB#'OG'G,O5QlQI>?,\F52;/>%57?VC#)FK3:R-M6H.IKGC=C>QE?0l;@''P!B!: R*GNTOD5%XSP]*IBDM0]C2QV8FSZM DCM?V-M41Z,HEU..)-^E09A!,_A,LM4BSE\X6S!!3<<-;Ql9 N!^GC]&TIE 7ZVIIUW MM-$;M$.XE,4I-=S4.>;_XWV2V.N,-CKGT5["SVU|"G%P E$0)7OXXMYWI/CB M/;XU=/YVV>O0R6ZTK91SW; ,9QZ5@D;UC%YZ=!_@XL|VD)>6I*#/7V@RLM; M@2"+G<_RR\FS1WPQ,[_J?R\'>'+L=T"6CO>3!-698+5!'}X,{W;3SRX MHC=55$<@MG\2C0CN-PJ38S$B<2BF[R09+72V9W[*"MS6&"'1<4-MXG$ <1(.OIF2$H5) E*$T6<6S\;F'H8!R%T06\ MBY,1'\>J6&4: ?+(80GT63DQG X@5T/Y6\54H5]Z=[*ADRVM>E]IE M.I>DE PJ38S$T2BF[R09+72V9W[*"MS6&"'1<4-MXG$ <1(.OIF2$H5) E*$T6<6S\;F'H8!R%T06\ MBY,1'\>J6&4: ?+(80GT63DQG X@5T/Y6\54H5]Z=[*ADRVM>E]IE M.I>DE M5XC_CG?M[):I)2=+ @N"'!]>C,P]4UR*ZP,C&E>5"&BIR-RVI]Z*R!VB_D'2G MZ\ FZ/MT^A=02P,$% @7($-64'K*]1T P < @ !D !X;"]W;W)K M&ULG5;;;N,V$'WW5PRT[2{!G.A[QW9L ^MLBVZQ M;8.DI3X4?."EL45$(E62BIV_[Y"2%0>QO44?1'&HN9P9'G(TW4CUI'-$]NR M$'KFY<94$]_7.8XETY>R0D%?5E*55)"HUKZN%++,&96%'P7!T"\9%]\VZM;N MU'PJ:U-P@7<*=%V63+TLL)";F1=ZNX5[OLZ-7?#GTXJM\0'-']6=(LGOO&2\ M1*&Y%*\P-?,^A9/%P.H[A3\Y;O3>'&PF2RF?K/-EFWF!!80%IL9Z8/1ZQALL M"NN(8/S3^O2ZD-9P?]S_K/+G7)9,HTWLOC&,Y//O)$'&;Y879A[N?D%VWP<-MP%06VIHV?72OAAZDM3:R;(7]O3D)%>(;S8&]*QHR|K;Z35P[1$-6W@[Q\N5WRM4S!(&"HL9/GX816%X#;BE MZX/D'R ,@FZ,=N,[NY62)61A<)%6M0V M$2YV3DDG93[%=U-$(97]"00CF,(1Z/_!^U|03K(T2ODI+/T&RGN?7,7 M"V87{)G1<>__M7X"0XB*ME2(4,(ZCMU'@T* [Y>UV@1+5VO4Z#V_*F(72K73O]U'215_6F%|\R MM>;$Z@)79!I<7M$>]P*;_-8*1E>LI2VFH0[EI3K\$]*P"?5])NE5;P0;H?C+F M_P)02P,$% @-7($-69A9#TV=-@ G04 !D !X;"]W;W)K&UL253O3l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`,YRK>LHLH3.U:CR%K(BFI\E)NYVDE&"PNJRCGQ_61>45|/E[7V MW:5<'HM&E[QFEQ)44U54WIVQ4MR0B;V.3+1:GL+]QTL? X,\D9I475@9%#QNKW2VVX>G@(@'8!8WFTAR_(=`MU71Y+,4-2!..-V'L\U5C.8>=YE/FLSDP.9$_@D:KU5<%X7K'B(GR/+GBK9 M4STCDPD_- +4'H>|"\4DTD2_LI8BX[&T<8LK]6.YNQDAFY0 M3%ZSV?+%LR#QWTQPBWINT53VY16;KVA*!F+=KLA6E 63Z@\X_]5P?0>&O'N_ M3$*"]9."OZT@^,IN-9R5B/QG3- MDI7%M^UK.#]OIK'@%I!=,HG/A(_>);G\'L& MEY+GS/FKT4K3NN#U!JB&=RQGU8@\" ,I=@22VR\Y0\)X#219>'#F[QCVYL *'M*;],(:$HF+_ZIAU=0IX\2P!ZE 7FSOPY#=ER.!#SBA+%]KT4 @E\=Q$12!./ MA/|%?Q]N^,>^MTA&Z >9NXA#"+T@'&-_M/#=, O@)9!'^EKR1T'DH$93S,O MC*?(1T (!JW'?>_'_U'L#GBZ=1 M]YV;2:1VR|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|\T%)GRK"H-Y@?_[F M51# ![SJPC5ILHZ[H|\NUT'AXZN[C4MQ3)5A8:"V*%?)X)]*OIX!+)C9='?P MU24"-[BS<)JIY.[/?3EU[KH_IP-9@%VKRH@B-0/ 78*EA7L4V@ M08E4YPP7 M4B+AV]YB*W1J>E]<36!Z"(L- ;HQN-BA3J1!N-0RP3T&5\A*(HL54;"PFHJV M$AG\)!<(VX_"KY;;5)XNT'LI"D#PE\%EF%O4^

*W"^;FI.2=9MR/#]SF89G5I&QRBC`MZ;RK-,NE.$;7L 2*W-L_FW0967?5M2>R5@&Z=0&Z'V!|!E]?UBUHCFFE'M2I M!_NPH)%DUU8%;S*.PWH&0UH9-U5U9{6@7HUP7H?f@!^X:NE I- M$:VT3^NT3_=A/B/)KFTZW?[!YSJO/`;,,.PWH&PUHIMU5VKJ8VD5H3#SNAYNP M.B(PN+ *V<*&[NL(X9IGB"V-;&;9N5WK$\7_0NS& *JG_QO,%R05B,)<89R3MGJH"+P?J&PO=V]R:W-H9655T2(\UV'/S#XHY@&B((G7 M%*$+@/(XXGJX"Y" NKH:S,H4#DCNRXQ$$>=4NQ))\M?)ZF__6"Q_7[V?S]>= M?WVXNEY[]^S]>OWQF^?/5Q?OYO]FJ/%Q_GUYE_>+I8?9NO-7Y?OG]\^+N>S M-[+I_F 75Y?"\EV5G=?/APVSYYX_S M]\4?WSWK/MM_X-?+=_7VP__[;C[-W\|_FZ[|__&6Y^=OSSY0WEQ_FUZO+ MQ75G.7_[W;,?NM_$WJ"_?<7MI_SC+W[=_^>G-=_.MTN: M7\TOUEO&;/-_G^8OYE=76]1F(?]W1WWV6;I]8?KG/3W<7OWF:E[/5O,7BZO_ MOGRS?O_=L_&SSIOYV]G-U?K7Q1]QOKNBP99WL;A;W?YOYX_=YYX_ZUST.W=\X)]]XJ{}>T%5W?."WNX%/>L+^KL7]*TO M&.Q>,+"^8+A[P=#Z@M'N!2/K"\;[%XQO=_=N.V[W\N5L/?O^V^7BC\YR^]D;MVO8/MP5O^-%EY>;XOWM_5R\Z^7F]>MO__K8CWOI#[=:\+L3Y;W2SGFO)=KYK_LOW?VGW-_;#:E/O'[1!7G?!X.5_/+]J6_]GYM\IE=>=0M[Q;%6X|SR|V]WEQMYK]GM5T.S\OKM?O5YWH]9OYFP.OG^JO M]Y5>+_KKA\KKGV_^RW[^SUOM__.^]%3@7VZNSS]H\Z|ZU7G5[_S]MY>=__BW M_SRPKI-OY8[9O+ M]\OUY?Q@Z:NZ[1>L;U8?9Q?S[YYMO@JMYLM\V??__O_Z@|/_^M0O9"PZ1UL M> O;?K7[]/WX_-OGG]**;'_*UU5WV/PD.?!)W6Z_^4FO0&KL5?_S7O75O?IE M>;E8=M:+SJ^S|>;+^_JKS@\?EY=7G6JT*XM7/_O)XO_]GY?YW?YLO-!G5^ M[/RR^2HY7R[G;S]_K1<7OWC25A4Q(62)B0L C! M&J4W^%QZ_[7T_K98SZ[NOCP>6-J/^HM?=0\6U*#U%ID,S[-WY$N5["T4BS&0M1K$8(V1L_:W8.GTA/V0^2;fDZ/UL_O-G8IO^:+R\N5_/-RRXOYFH#4B_$_MVX\(V2$!1(F)"Q"L$;=CC[7Z4BMVIU:!"J0.T3W/TW!F=]K)N_@?BZO9>OM3\Y]J-!^OQ=N.4-H4I064)B@M4K1FQ2999??X,W5VC&XW>>^=_MGXW/NUF+T5WN&K!9 VH5HS52UN:^5?6^54^ZT_QZN?]]$\;S^>8#Z_GF"M?;_ME>C?_NB7Y&XX)&V*T@)*$Y06*5JS<.L(N*MGP++;&<|?H5HTWX7E_TNHX;&AK MU094*U9MI+3-K:L3X>Y3B83OBV\^SB_6FT]^>?GI\LU\ RJW'#1(1FE3E!90 MFJ"T2-&:=5O'R5T]$K:UG#O&(^TYLT&S8?+PH *I2R,E+'Y474W'WJ^>"N-MP?QMOOR@]Q4T"T9I4Y064)J@M$<I1N5:I;1=(";N'LA/-5I/J/Y*I%C8E-SH Z MQ>2,E+.Y8W5.W/4&Q2_G%[?O\DI5?8C[VOKZW"T#S8!16D!]@M(B16M681T$ M=_48MW! N_#J>VYP[UZ5WOWMCEIWN'6VNV(LSH ZQ>2,E+,YH5;GP)4W!SYA-MGSGZ7K=^,=ZFA-*F*!V@-$%ID:{U2I8.@BL@"-XQ&E_D^X/6/6]=Y2X!DS2@ M4K%)(R5M;EJ= E?>%/C!^XSUWK=^)>XF@X;_*"V@-$%ID:(UZI4.?RL@_-TQ MQLDI;WQV/LI(#)K\FIP!=8K)&2EG<\?]S+?R9KX/WF%<-[7URW&W33P16D! MI0E*BQ2M6992M6,1UX%L!@>^,D=WH'4UZ>.:!4U^C-:,.%HC96WN6YW_5M[\]\&; MS9?*7^P8VJUM-M7>/>_]CPH$(I"R,E;/B:YT(|_X'),+6N|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`9@.8.V?$_XQP+G5>]PC;5/.6W?2=;.1[M(Q*_]%(LR4LKF M$U?KB'9HC6B_H'T<_QA5-)1%:5.4%E":H+1(T9HE6(>RPU.%LD/;>,.ZWUT7 MMO-F4:G8D&2-G>R3F2'UD06:R.6V\;ZRMR=!{U>45I :.8+2(D5KUE\=O0Y/ M%+W^6 "_ZA\NN@/SHP<>K:K#W=5DD@94*C9IH*3-_;^CVJ$UJL7ZC^\FL[X^ M=Q=*HUF4%E":H+1(T9I56$>SPU-%L\.#Y[^V'Z2J+\!=K0*UBM$;*VMS, M.]D=6I-;K*5\9QUE?97NQH(&M2=@M#81!.9&8+V]2$:\!2%'VX-$]%9LT4M>I(EU*M6+61TC;WLXYNAR>,.,W5ZMP5X91&U"M6+61TC;WLXYNAR>,.,W5ZMP5X91&U"M=4I6

*<;+A[E"D"1-MYS"(Y-!8*17W35-Z*PBI/,";H6$;KR?NV'*E] ES-(C1$F;@'N*IP)U9-ML"Q8")%D/"("_*'QV>Z/;4<+#THB?##;RM"8ZE3GGCWISO1@:EE8$ 7A*4U|*

MK&$,0:"94,=33FH4]!}3 \OJ5_2I-'I.94PEC'OQB"[4:&CV#+,"G2:#N^.8K-MY EU-)_' YG^DDT>:QG$2Z3B80Y&:!2&+LB-]S@M1-MCM/0 G!SC_"VCE@%;: M.*8L36M'"%1T-!-*

\0H;.132_2VJ!HS(9%VL;9$GB5(4Z-OG,%@"5G9"KPT1#J MA=!H0;X)2Q&LQ1>F&4&$^[OB5F>@*(LD"<8_3";D;.C$W)$6$3N5SR1&'L'

MID*M^HZFE^NZS'0Y>W1!2Z)STK)B6,Y!1KXN!D^ 0_A=@!O5>$F5]@HDU.4 MR4GYVQXO*IG#:^:GA"KB<;G\LL(W910-I-2U'4QDW4YB;H8]XBI*&T52EN- M2F| RCYVAY>$24 5+/"AQ@;W&-5M4R:KN0VFZ4 M>L\5#4B\)[01U):UO2/$[6UIW0WI=>N5=@JEG4:E/WR?>9 JO*%+]CBV!%O M'?#[%L(YB#]U@AN9]5NZ+V/]P=! ER2(-1BCCQ]LU_14]]0?

B*Q2!+NU;/2HD?"]'AV(K))[K\B] M=VB/>CL&V)WNEDG-,16E%X72BT:E8Q[&B0)1ZB*M><9]M:'H79-=CM M9)4BV-;,Y])Q.OC-N<(Q,EVN<-('H0/PNL]Q^,LW>I8L_CN,_@)02P,$

M% @-7(§-6&ULC95K3]LP%(;_BA7M TB#7)L":BM!NVF;=D$4ML]NZD=0E@R\%A9YH]3'UE>_KK(2*ZG-9@\"= M0]F*&IRJK;IK!31WIHKI41"D?

D69\!8SMW:K%C.Y,YP)N%5$[Z]*JI<,X'(_M]T+O=>&,;4MC%_S%K*9;6(-YJ&\5SOPN2LXJ$)I)0104<<\ZO%]F5N\$OQGL M=6I,,"8,*1_MY&L^]P(+!!PR8R-0_'N")7!N

R'&WS:FUSW2&OOCU^B?7>Z8 MRX9J6$K^A^6FG'L7'LFAH#MN[N3^"[3Y3&R\3'+M?LF^U08>R7;:R*HU(T"% M1/-/G]LZ] QA\HXA:@W1_QKBUA"

{1!LRE]:&KJ8*;DGRJHQFAVXVC@W9L.$ M/<6U4;C+T&<6/Z4!,B5GY#K+U YR\IW1#>/,,,"XNFX.E\AB5'"R

D,9UZW#]K$U7H*@K4.3B9>_$6TIA%%XVPOMY:P#B2A0WP1'"",:)GJ+\'R2 YZA)HHNQWDF'<_D M*,_KW>Z?<:,%D17*F,[P 3-A=;)V*VN8S6LK)

.NPD$%69Q.Q\G3CCP]2GXO M#=<5C'O*/(:,#&Q=&E],#RA%1F!{6U^]U'-OM?U"U94(3#@7:@O,I9JF:#ML MC*Q=$]H(@RW-#4O\Z(^R MPO)+Y-[<3VM>X5MO@'4$L#!!0 (

%R!#5G5 M;BB)6@, !L, 9 >&PO=V]R:W-H965T6NS;+256!L$B,'$>!$?O>3:6"1VL9UU^_>904G4DEL!Q92YD234.Y<)5 M2PDTLT9EX0:>%[DE9=R9C.S'Y#EAG'S-

1.707HU$9)VI:A(>6 MAQ)L"24DY^@S5R3A&60]]K/=]M$.)O=E:,4)[K0Y"M8Q2]CX$0F!ER3P@D%/ M/-/]S<. <=/(/>_)H[_?$"-M"'"2W?8 O?*%9(2+827CR+]]_3:"NB+[M

MK@DC2VCNJ^N)[WDC]WI=PCTPLTU,T,4DNS'W,AZT&0\V9OS#7C*0O:+7F/H" M\%HT%^]?"33(DAQ@T=\"E7@4#G[B\!//B=V.PIJ _^*0T!4PBDM';O@,TW8_G M1.9!PG@;T^R)

*(DJ>(J)!NS-L=V?X;[N3,96*BFN"9=I;CC7?R5])>$?>L%,/ M^X!F^X"2!T#WDH[.I*-_.H1S* Z\V?^Z=3OF9]AYULWJG_IZ[.YG,H%0QT+*

MF*,K[^@8MU+6K6@[T&)I>ZTKH,%SLZY=N\@#0#7VP+[K69@'+3_!R9_%/+ M P04 "_!<@0U9,/$'!A2+W=O(8[_'SVO[Q&>P%?))K0$T>4YBKH;66NNT;lLJ6D-

"U95(M@6//4LB$:FS*E;U2"721BY+8]APGM!/*N#4:Y.^F5;KR_NV6JMS0M[-$CI"F:@'],IO)9=15FP!+AB@A,)RZ'UV>V/W5R0 MC_C)8*MVGHFQ,A?BR31N%T/+,4000Z1-"

(I_&QA#')M(R/&[#&I56EV++&!)LUC?B^T7* VU3;Q(Q"K_)=MRK&.1*%-: M)*48"1+\&BW_Z7"[$CL -C@B\4N#]]\ O!7YNM"#+;4VHIJ.!%%LBS6B,9A[R

MM#$X<[\'M[W(V1S^0.*N[@%'=8QQT<<@2!"G=CY#.YVQ5W M^Q1WIXZI2<+M]9P[IL;(9W*%7?8R/T@-(W)DAQ_-]E)9VG>*Y6J9YG:WP

MP)8;..&>K\.9S_35J7QU&GW=@5))IP6?7#[O5F#>4KO/W0G3.XGQI$2YX*\JDQ#RHOO\]<M#MJ%=EWG&/7.->Z>=RY*7=A\.)JC_^_)L'?J$5,.?J-RQ;C'!5UB>.>J@TLD

MB_JJ;&B1YB7*7&@L>/+'-=;D(.T [%*+%/*AJEZJBIW] =02P,$% @-M7(§-69"5+P=Y§0 D@@! !D !X;"]W;W)K&UL MQ=UKM M^? +,A9"H,?@_-WS)HD=^-V_-SF<

'77Y/TS^P^BG+IVWJUR=Z?W>?YP[N+ MBVQO'ZW#[#QYB#;%_]PEZ3K.BR_3SQ?90QJ%R]U,Z]6%,AI-+]9AO#F[N=Y]

M[S:]N4ZV^2K>1+>IE&W7ZS#]_DNT2KZ^/Y//GK[Q6_SY/B^_<7%S_1!^CCY&

M^1\/MVGQU<5>6<;K:)/%R49*H[OW9Q_D=\%T7,ZPF^+OK5:E5"S'/ROT;%^SG//"PWT^ZL5OY8F4^ MA5DT3U;_B)?Y_?NSRS-I&=V%VU7^6_+5BJH5FI3>(EEENS^EK)6THS-

IL.4_=@-H-W_Q(O]QRK'^,4^+_XV+.^?*;(.DCZ4IZ*QGQ M)MPLXLUGZ4,Y_.(\CC+I)REWI*PWB52;I"W_)MN/KY^B(OBI:S7BRJ L9€ >5$ M 5GRDTU^GTGZ9ADM. ^:WQ?./GYO?

$\|_%B,I(T65_OBH23_]I6?I,!*%E-V':,'1'O_J6-*Y&;,#|%Q2U"/XI*8]IWV7 M1O(.&F],2EWL?@HEW+V"":?],+S6UC/%]#N]OR&/W;X?X]=:,Z?' M3TVU?

&HOT.V_I%T;LFL(OM:Z^S^V]?AH/\/DW)RW1OM8[QON.,=K9Z@YZLP MRZ3D3OI'F*;A)I>25-KM8;V1]&{]1NHBS2+I-XT5T,$VVGRB3_B7^*'YYK%[^

*M9BG*EWMZ7V[&LW/U^N+++82<2+F.Y?_DN>P@7T?NS8@&|-\G&IV,-%D=`XU;4YED0MF]UHPARSIMM=R-CTO6_AA2:_7 M@OF]K*]E3*].I_46&,]?L!I/[H

%]*VC8M=V5NHS1.EM)A:,8,.3\7X^?T MV!$6'KB]YR2FD9A.8:@=]F21FD9A-8@Z)N23F/6*3 R%*]-1!?RJ/1Z*@#M"<\ MFB*.EJO1(R;[*C$!HC:-

%E$T3*3[M)DO6\43^VA<^P+P,%CG\0T$M>)S" Q MD\0L$K-)S"$QE\2\1VQZ^.M:F;9'?GNRXY$/+55CY$_W(W\]'/E^.LHSOXD6X M.Y%XL ?=->2%TM

A3V(:B>DD9I"826(6B=DDYI"82V+>M/5;?'K5'O'MJ93+ M26NR %]RQK"?[8?]3#CLC3!.I,;^]VTD?5C^[S;+UU%Y9" >_T)RZ/@G,8W$ M=!(S2,PD,8O$[%GKE]SEJ/43[Y

EW7;)MXK<_OWKS5]C\;TL]^U1V],+H)5H M#-O+ ,_"|% [,W^.^CQW-WMVG\)9+EV1LIB/*F21FDV8A@4OO8$M.N6HU[-FK_\M')F@:)F21FD9A-8@Z)N23FD9A/ M8@&$-;J#/*JS#B-A?

_@UOX]22?_V$&U.G 44 T/-JIE7:XYZ=V-0:TJH%J M)I9J&:CFH-J+]IYJ..C6D!IS19Q$(>2^UTY,.HK!\4.17$LLDTC*=PL]]<1 MGO8P3N!U@-

*;?:-.;\KB>&"S;VC1[KQH_"62[$Y6]IORU.B;SJQV9SLA V1S M5--034U@-*:W;2.2LK"E-51-YDG MFR]1FL>?5E%Y9--]Y$+&R>;HILGMT)G<[,.OHV4-5#-1S4(U&]4<5'-1S4.U

M'!4"2FOVC#HZ*8NSD]4U675_NN.WZ&%W/\+OQ5=9^'B+INCJK-@'9^U*+"6] MZ:AFH])2:A;V:CFH)]+:AZ^:@64%JSS]!:35F@:8P4NW"CY:-*'TYK"M@Y:R.&GY

MQR:+%MLT6C8.)\K;R#/Q7@&:MD0U#=5T5#-0S40U"]5L5'-0S44U#]5|5 LH MK=E>ZD"H+Z#MHK0'.@E7;X*U4>MT\N:&A5'=4,5#-1S4(U&]4<5'-1S4,U

M'!4"2FLVBSKN*??)>QY>&"E]21_6R7;3W3#0T*?<#FI.E/9],1I:54U@-*;3VZJ-Z'"*. #::A@'QS#%;I:V/'HI,QKZ/[=Q

M_QU@#RLI+J\)B0IN\THYWRI.9K\IX]4T#]^JH9!:B6H6]MFHYJ":BVH>]OFH M%E!:LYW485%%'!:M;S7-I#R1/BR7<7EU)%Q)MV&\E.*-- \?ZCQO+N)CU134U M@-*:#:C.@RK"[-

B@JRL5]>S^!9E]TSJ*CKL2GFA5H]^JFFA1"]7L?JO@H$5= M5//ZK8*/%@THK3D@Z[*E(@Y,#KV"(>8& YY'LY65UABJW8,7C4VBFHEJ%JK9 MJ..@FHMJ'JKYJ!906K-

CU+%)I4]LKN@3X#$]4T5-.5=E9OIDR4RV9O,M"B M)]I9J&:CFM.Q>>7I>'9T\""FV!S<#=",IM)^ M[J':M6^!AB)1S40U"]5L5'-0S44U#]5\5 LHK=DTZO"ETB=|>;!O\<&#&LN!.A-

@=VE]03:NTZ7/[&FA5]5, M5+-0S48U!]5<5/-0S4>U@-*:G:..4X[%<7!.QKL.[G9EW*S;^4>MT[<[MXR>]P*T#0E]MFHYJ":BVH> MJOFH%E!:L[74;>>FNB52U4LU'-0347

MU3Q4\U$MH+1FSZ@#6V-QX-/9;HY.<@A/9.!Q3U334$U'-0/53%2S4,U&-0?5 M7%354,U'M8#2FDVESB@-3(5A^UCQJG\Y?RD#3GZBFHYK1:WN8:$T+

MU>Q>;^"@-5U4\WJM@8_6#"BM.@ZZ0"ZJ>3^^>CZZ0 &E-7M&'>DS]!L(_03F-VG-2;BQ=W?=D"3GJBFHYJ!:B.J6:AFHYJ#:BZJ>:CFHUI

M:8T^H]9)3U6<]/2397P7+\)=/WGFUC(Q-;2EH)&:CJJ&:AFHJ%K;:CMB^ MG5X=[6J@)5U4_JL@(^6#"BMV0#JP*8J#FSZ8:JX[W\U0ZP-[@%H,!/5=%0S

M4,U$-0O5;%1S4,U%-0_5?%0+*W95>]@IOKO#6;]'2$X]7HH24<_%"SFXO:#!-M3%0S>FT/$ZUIH9K=:PV<7E.YZ))YO6KZ,,V TIK#MPYMMV0#L(-%@-0T5--1S4

U$]4L5+-1S4$U%]4\5/-1+:"T9E.1 M@Y>]-\CYZD<5C^4O#WZ)7?)/CF_W$B_DX/:"1C!1S:BTF7!|F-54S?WCR?$= M21:Z:'OC\I!:[JHYO5: Q^M&5!:<_S6&4=5G'%]PI*WV!S<-=

$)ZKIJ&:HI7>ZOU5G[?O,NZ:39UT-_8U=HIJ#.BZJ>:CFHUI M.8V&,*ECEQ-Q['+,_^-Z7QKO%_M#F@&H:JNFH9J":B6H6]MFHYJ":BVH>]OFH M%E!:L_4ZZEC6A-

QS/,%%W3$XN".28\|44U'-0/5S$GIC?+3KG,A,%4;U1Q4 MU@-*;S:*.D4Z$B,*_]NJO>#D&=QI2TU!-1S4#U^2J+UK4 M1C4'U5Q4\U#-1]6 TIJ-IHZ63L31TE_S^Z*9Z-\>HLVI Q?

T.9ZHIJ&:CFH& MJIF5]NQ%7+2]C6H.JKFHYJ&:CVH!35;1)U>G8C3J^4U&RU:[*{)#+BW1:P. M[AMH@A75=%0S4,U&-0O5;%1S4,U%-0_5?%0+*W97>]:CF MHUI :C*FX_.

VA&9,*ZWQ[(M)ZVV\.EK40#43U2Q4LU'-0347 MU3Q4\U$MH+1F?U'J_O+B9XFRATGBY1C<:-!H:J4='CS(ZF1T?/2@O4-5#-1 MS4(U&]4<5'-1S4,U'!4"2FMVFC]:.A5'4U]TFZ[8'-

PUT(S]M)W<[#]YJ:-5 M#50S4&PO=V]R:W-H965T7G;37!YGNSR*(SI34JRW683I<_TBAY MNAA)H^<;/H4/Z]RX87QYO@T>Z&>;>2]RV8I^9A1L:9V$2DY3>7XRNI_^

MM!Q0WN.WD#*YE1U^3XJ'<):Q<#CKY]UO7SP[.I*/^4)FT>D"SPELF M45;^2YZJ^TY&9+G+\F13#68SV(3Q_O_@6_6+:.!H@RR\,D*L!=\I+:H!BJY3,JT&G/:M<%8-..I[0)H\ M;IE)

[R&'C=UI:TO/FUMJ;N^7ASQO<*GW%]>>-[E4;O/Q_NE;/O?!5(\NS|/D MB:3%_9E7?%$NH'{\>|J'<;'6/^W*=O(\TS<.[B)+B

MUHR\46D>A%%&:NFW?!=$;\DO9$RR=9"R'X8Q^1*>?:.W+|\VWA*5/UX;[SK'5PT C MQVQS'+;)_+O-/LI"T-[%)T2H(R1)Z2+Y]5\N:7MQWSNA8S7!"$'G*,T>;

ML$-4>X@3Z=6):.|OWY\51:#H8N5J6SR\!/<^('YXA%E6Z9+_WUR=FOO[PY--7 M?TD6YDE@]]ADRNN;S.D_&]&OQL4|* \S&[\',SD3,=SZ50X]52G=Z0ON){H-

MOK/IH3PCR3W75U5ZEW?,\Z/0*W;W/E3.8$DO1FQ_+J/I(QU=_O,?TGSRKZZN M@.14)*8A.1V)&4C.1&(6$K.1F(/$W#TV+[\'B_KIR/'X^[0L>=SA3^

M/CYH5MS"GQX6_E2X\/4@3,EO0;2CY&KU/[.[5C2!H@?\']HP/!U!H?DD/7 M/A)3D9B&Q\0E9Q0 Q$XE9T]:S_;2Q)&QD/:==[!TLS?F*IOY.L^,]2=*TL5(I M[M22?-#<&

KM'AE)E:6(I8)X2=EK=L9>O-G; M&:*&V3+9O;!TA26&+ETDIB(Q#8GI2,Q 8B82LV:MI:0T7\YL9$%GUEIQLXG4 M6+KM22V4QNNGU\/O01/G%N[\L'#GPH5[NZ;[_?6;-'P,&:.?,%2T<6-

)"8B<0L)&8C M,0>)N4C,0V(^",.PNFA(9P*&\)-FBPI767D/DTVO0[>":VA#0*)]4A,.VWM M&+:/T.C(B@82,Y&8A<11).8@,1>)>4C.!V%[XC..I&K3?$116=;$7*#VXK4.D@PDV?\Z[P*

M+:.E!-1VJ&5#-A&H65+.AF@/57*CF034?I?'=0JZ{A3RL6QSMDSQ_4X:V;]*0 MM9&_Q.FYC^)J@YO)7BLRL/4AQY.S9C=!UM2@F@[5#*AF0C4+]ME0S8%]+E3S

MI\DJ/TOAN4[<;)7&L4=Q-_%WQWJ:(4FA_[,+|^]$]NYJ/-/8:=51R5/-1&M!1ZDBG).YTOM)1.AL&-,(U52HID$U':H9 M4,V4VC%>2KSB]*"EK2AF@/57*CF034?I?$-

HXZ22N(LZ9H$Z.2.#+:.@YBQ3EFA7+R*Y4$D<#*T!*5X[_+O!YG+NN(\D-8]20H.;4$V':94,Z&:U:6I6FL4 M&MZ$:BY4\Z":C|+XM5PG."5XK2 U%:IIE7:<^5!:)UG0H34-

J&9"-0NJV5#-@6HN5/.@FH_2 M^911S[EGQKY%%<;W$V0F@K5-*BFRUWAUME)XVB0 2UJ0C4+]ME0S8%]+E3S MH)]/TOAV4F<^Y9^9^107&]Q-H">ZA&H:5-

/E=KIU(<_DTV8W@48^H9H%\>R. M7X@T5Q:-M*\#+>?:.W+|\VWA*5/UX;/5X7F C MQVQS'+;)_+O-/LI"T-[%)T2H(R1)Z2+Y]5\N:7MQWSNA8S7!"$'G*,T>;

ML$-4>X@3Z=6):.|OWY\51:#H8N5J6SR\!/<^('YXA%E6Z9+_WUR=FOO[PY--7 M?TD6YDE@]]ADRNN;S.D_&]&OQL4|* \S&[\',SD3,=SZ50X]52G=Z0ON){H-

MOK/IH3PCR3W75U5ZEW?,\Z/0*W;W/E3.8$DO1FQ_+J/I(QU=_O,?TGSRKZZN M@.14)*8A.1V)&4C.1&(6$K.1F(/$W#TV+[\'B_KIR/'X^[0L>=SA3^

M/CYH5MS"GQX6_E2X\/4@3,EO0;2CY&KU/[.[5C2!H@?\']HP/!U!H?DD/7 M/A)3D9B&Q\0E9Q0 Q$XE9T]:S_;2Q)&QD/:==[!TLS?F*IOY.L^,]2=*TL5(I M[M22?-#<&

KM'AE)E:6(I8)X2=EK=L9>O-G; M&:*&V3+9O;!TA26&+ETDIB(Q#8GI2,Q 8B82LV:MI:0T7\YL9$%GUEIQLXG4 M6+KM22V4QNNGU\/O01/G%N[\L'#GPH5[NZ;[_?6;-'P,&:.?,%2T<6-

)"8B<0L)&8C M,0>)N4C,0V(^",.PNFA(9P*&\)-FBPI767D/DTVO0[>":VA#0*)]4A,.VWM M&+:/T.C(B@82,Y&8A<11).8@,1>)>4C.!V%[XC..I&K3?$116=;$7*#VXK4.D@PDV?\Z[P*

M+:.E!-1VJ&5#-A&H65+.AF@/57*CF034?I?'=0JZ{A3RL6QSMDSQ_4X:V;]*0 MM9&_Q.FYC^)J@YO)7BLRL/4AQY.S9C=!UM2@F@[5#*AF0C4+]ME0S8%]+E3S

MH)]/TOAN4[<;)7&L4=Q-_%WQWJ:(4FA_[,+|^]$]NYJ/-/8:=51R5/-1&M!1ZDBG).YTOM)1.AL&-,(U52HID$U':H9 M4,V4VC%>2KSB]*"EK2AF@/57*CF034?I?$-

HXZ22N(LZ9H$Z.2.#+:.@YBQ3EFA7+R*Y4$D<#*T!*5X[_+O!YG+NN(\D-8]20H.;4$V':94,Z&:U:6I6FL4 M&MZ$:BY4\Z":C|+XM5PG."5XK2 U%:IIE7:<^5!:)UG0H34-

J&9"-0NJV5#-@6HN5/.@FH_2 M^911S[EGQKY%%<;W$V0F@K5-*BFRUWAUME)XVB0 2UJ0C4+]ME0S8%]+E3S MH)]/TOAV4F<^Y9^9^107&]Q-H">ZA&H:5-

/E=KIU(<_DTV8W@48^H9H%\>R. M7X@T5Q:-M*\#+>?:.W+|\VWA*5/UX;/5X7F C MQVQS'+;)_+O-/LI"T-[%)T2H(R1)Z2+Y]5\N:7MQWSNA8S7!"$'G*,T>;

ML$-4>X@3Z=6):.|OWY\51:#H8N5J6SR\!/<^('YXA%E6Z9+_WUR=FOO[PY--7 M?TD6YDE@]]ADRNN;S.D_&]&OQL4|* \S&[\',SD3,=SZ50X]52G=Z0ON){H-

MOK/IH3PCR3W75U5ZEW?,\Z/0*W;W/E3.8$DO1FQ_+J/I(QU=_O,?TGSRKZZN M@.14)*8A.1V)&4C.1&(6$K.1F(/$W#TV+[\'B_KIR/'X^[0L>=SA3^

M/CYH5MS"GQX6_E2X\/4@3,EO0;2CY&KU/[.[5C2!H@?\']HP/!U!H?DD/7 M/A)3D9B&Q\0E9Q0 Q$XE9T]:S_;2Q)&QD/:==[!TLS?F*IOY.L^,]2=*TL5(I M[M22?-#<&

KM'AE)E:6(I8)X2=EK=L9>O-G; M&:*&V3+9O;!TA26&+ETDIB(Q#8GI2,Q 8B82LV:MI:0T7\YL9$%GUEIQLXG4 M6+KM22V4QNNGU\/O01/G%N[\L'#GPH5[NZ;[_?6;-'P,&:.?,%2T<6-

)"8B<0L)&8C M,0>)N4C,0V(^",.PNFA(9P*&\)-FBPI767D/DTVO0[>":VA#0*)]4A,.VWM M&+:/T.C(B@82,Y&8A<11).8@,1>)>4C.!V%[XC..I&K3?$116=;$7*#VXK4.D@PDV?\Z[P*

M+:.E!-1VJ&5#-A&H65+.AF@/57*CF034?I?'=0JZ{A3RL6QSMDSQ_4X:V;]*0 MM9&_Q.FYC^)J@YO)7BLRL/4AQY.S9C=!UM2@F@[5#*AF0C4+]ME0S8%]+E3S

MH)]/TOAN4F<^Y9^9^107&]Q-H">ZA&H:5-

*[+FNM^AIN/6K1ZAFJ.:CFHIJ':CZJ!:@6HEJ$ M:C&J"51+4"U%-8EJ&:KEE*9&;=50&^L,:KL+-82W\|!V"\&]=A=IT(M=UWQ1·MS48U!|5<5/-0S4>U -5"5(M0+48U@6H)JJ6H)E$M0[67*$.>6 MJ?IJGC<\:CCJ5Y\;J7%,-=O&+|YLTT_LG+#H?<[*:,]LOCL%I-8V=]"Q+JIY MJ..W?4D"=&S8=FR$CHU13.!:@FHIJDE4RU M,_%724W"JI$VUC?2'LX7ZI[$ M@-,:,4,U&-0?57%3S4,U'M0#50E2+4"U&-8%[",JEJ"91+4.UG-+45*[J:>.C M;UG&+!&,:X?:EM4;'7Z6AMZ7#-4<5'-1S4,U'14"5 M1+4*U&-4$JB6HEJ*:M1+4,U?)*4V.Y*K*.%4"E+&#_QV8ODM'RS;%9"V*T MG(9J+JIYJ.:C6H!|(:I%|!:CFD"U!-525):HEJ%:3FE*$$>'L#&+/#_QVFAPUJ%30[V#7$$4U%]4\5/-1+4"U$-4B5(M13.!:@FHIJDE4·MRU·MIS0U1*M:V>0'U,HF]5I94X;6'}40H6A;#-5</-0S4>U -5"5(M0+48U·M@6H))J6H)E$M0[6;PI#$L;"['-6=HZ!7 MN_[6CVHV]CFHYJ*:AVH^}@6H%]):A&HQ[@E42U·M136):AFJY92FIG)5+)L< M?>LSY!R%]7;,:|\X,,4RHG/75-,OV.=HYC4'%1543?3=L^,6?X@'=XY:M)Z&:BZ]>:CFHUJ :B&J1:@6HYI·M0354E23]):A6DYI|U%[MKXN·MBHTI#W4S?O:DI5I^+BV(^7N2MJRlO%9C=DIZ&JOBTC6+S]7OKY*SV<]M\!9D-·M/_?·UT3ST/S=73W\!-JI+LW7Z:?"S%=?9XMUL;\^+3=A=[IK@"]VBU//"RS·M67YY>*>&!^7F\WRYN[+ZY)Z5:QV#]C^^:?E[_5!+·M·P04·"·!<@0U9%·E·AF·#·",#·&0·'AL+W=OP_/;23-Z\6>\4=1 DCT7%=4!+*U2RN:#XXB\A!H+·MFS5·U9L-XS66]LNWCF@XX,(DU97CNV[LU)A0:[4P8W=\M6·[61$*=QR)75UC·M_O,6*K9?6IYU&/A&MJ74·\YJT>·MW(AIJGCJN?I* 6I@0K"*.*P65H?O0|K·M+[·))N)? GLQ:",MY8&Q1]WYHUA:KF8$%>120V#U>((U5)5&4CQ^=*!6/Z=.·M'+8/Z+\9\4K, Q:P9M5W4LAR:.:46*F"#=Y7\QO;·0RB]9·HB^8\XQE4*-M_[630D):$+HI#O_Z"20FE7BG·GY!#A(EYB·.#T+1WR7;"94E%HV4/5D3MY1·MNFTI^6@KH!(4Z#.MH#C-=Y2\!7]-_T'CKOPCX94=M%+COD>_2X0R?]=O3·M@Q?H!+WE@<$+S^·#=WWABK/6O?>S3G6(D8&49_IY7ON5D8+YRGH9!H6!RE·MZ3'JA&_8\PTOYOL>[(&/P%7!Q!:_"<"$·-)SD8006K*LP%;H"WXF:U·MM:,G·]*1:V=C:=,H/\ /L*)S7%O7:HA>U]1MZJQ\0O+8.T<1@STNS*!B1G0D+·M(SV-9;9#ZS3Y&A9$=S:M*>E7)VU0=N+^Z·M",G$WZ+IA42O>0K2J;?^P-I64QL4OZXIZS5E;]74$/ZZ MJ=G$U!LO3,*Q)|.P,SP|WA/N1;F]Z8>[OXDM8,P&W0Q^"KN4·RR%9-]B* MO2N?A·[P9#WF$L),W#FV_I&M?_5KK(,\N[_*[·M)*JGN)O^Y!@<'B1V.]073#1?;?C"2YPS]NAKXU12[N5L1V5;_O2C?4G]T122·MH_%;?6J;>O$(T|;I7S'?$B!0!1L%Z=[)\IRW!6_;D:PQU>,#DZH6&·ULM=U;<]I(&L;QKZ)BM[9FJF8·MG3AD;5=EC/I4DVQJDMVYV-H+|2LV%4_> (=O)MU^!":(:-\C^^R8^T;^6G;>A·MVP^O.7O(BZ^+FRPKO6^SZ7QQWKHIR]LWG^Y,4L+:L/·MB^0.XK;(TJO5H-FT$W2[OKSWTH+L[RNW(ZF66W\CG/ORX_T%?GK>[RBK)I-BZ71%]M~L^ET*577|=<:,6WF?·[POFVW9WO%F4^6P^NKF·VF3^<3;·M$P,"]8!@=T#TQ(!P/2 \=4"T'A"=.B!>#XAW!X1/#.BM!_1.G:&_'M_·=L#PU·%^|\? _7'=508__Y:MZ&:.5E>G%6Y_]>L,Q]Y2W?617?=:GO5·M)I/Y]7W+?#:K"O9CF8^_>G^F19'.RT7U^(N;M,@6/]Y,YMZGF_QN4=UX<=8I MJ\M<3M89KR_IM\=+"IZX)',W;WMA]Q&7[N'OT]{:[C\Y?.0>/LK& MF^'A@>')Z1=_;+@X=O'?79/+TZ[\.#|_S^·;GM]|&=JJ@WE1UL*CM8>=$37O(M*\:31>;=%I-QYOU4%>5QL[*_M58K\4OWY4'4^LLMJDL!WO·M_#·4.:?.M^\YJS!\O\6'R/8K5]·P^B?K^_4WW·MB9W6WX$Y_>XPVBV.)V6I-0?>6ER? !Y>/!CL7)DBH]0D9B#,*K]H4WZ1L_P^·MW6352:.D_]'Y/K[+YY{OBNGXL_^^[./8Y*_YWJ 2=:L,?P"6)C4@L(3%!8I+$ M%(EI$C,09JV->+,VXM?9',1[#XA^X ?M? KQS!^VINY!1^K^=E*DJI],7*5E=]C"W<#;N^·NVYW4'OWA/'L^<0-/2)|&$ MQ 2)21)3)*9)S$"85?K]3>GW!=UX?V_[Z8>#G7MZYZQ-RYW$$A(3)"9)3)&8 MJC$+85:Y#$;E/CBZ^S=WT^^K7Z>FN_HA@TGC3Y"X+'77WO8.CB!)D6-JHEJ"903:*.0C6-:H;2[$6P%63Z M^/Y^35H;_+Z_& 6X)VY<^J26H)I -8EJ"M4TJAE*LTN_3CH]=]2VW.N_G67S MJ^RJZ9[?+3?=]*/:"-425!.H)E%-H9I&-4-I]DJI$UG?'_N_=]UG!<1! M>W?W[YZ^\0(@M035!*I)5%.HIE'-4)}] .1,V'>'PJ<<%=S"""4<%-/1%M035 M!*I)5%.HIE'-4)]!".KPUW>GO\\Z*L0'GIG3[>W>_Z,Y+ZHEJ"903:*.0C6- M:H,2I-*O\U_?G=[^^EUXOTUR3_G^?WCX\#REU·G'A;(,/ 2U4:HEJ"·0#6) M:@K5-*H92K/72AT8^^[$^/F'A?[>;WH'0;#WA-Y+|_R-5P·;'J..0#6):@K5 M-*H92K-70)TA^^X0^933@EM8G1;\V'5:0)-B5$M03:":1#6%:AK5#*79BZ!. MC'UW9/RLT]+PP#:'=N_]T:@8U1)4$Z@F44VAFD8U0VEV_U0=*P?N4'@9*[S/·M[U?2@0:G:!+?:|)2 ;B-42U!-H)$-85]&M4,1=FKI,Z=·M$?^/Y^35H;_+Z_& 6X)VY<^J26H)I -8EJ"M4TJAE*LTN_3CH]=]2VW.N_G67S MJ^RJZ9[?+3?=]*/:"-425!.H)E%-H9I&-4-I]DJI$UG?'_N_=]UG!<1! M>W?W[YZ^\0(@M035!*I)5%.HIE'-4)}] .1,V'>'PJ<<%=S"""4<%-/1%M035 M!*I)5%.HIE'-4)]!".KPUW>GO\\Z*L0'GIG3[>W>_Z,Y+ZHEJ"903:*.0C6- M:H,2I-*O\U_?G=[^^EUXOTUR3_G^?WCX\#REU·G'A;(,/ 2U4:HEJ"·0#6) M:@K5-*H92K/72AT8^^[$^/F'A?[>;WH'0;#WA-Y+|_R-5P·;'J..0#6):@K5 M-*H92K-70)TA^^X0^933@EM8G1;\V'5:0)-B5$M03:":1#6%:AK5#*79BZ!. MC'UW9/RLT]+PP#:'=N_]T:@8U1)4$Z@F44VAFD8U0VEV_U0=*P?N4'@9*[S/·M[U?2@0:G:!+?:|)2 ;B-42U!-H)$-85]&M4,1=FKI,Z=·M$?^/Y^35H;_+Z_& 6X)VY<^J26H)I -8EJ"M4TJAE*LU=)G1=]·M$?^/Y^35H;_+Z_& 6X)VY<^J26H)I -8EJ"M4TJAE*LU=)G1=]·M$?^/Y^35H;_+Z_& 6X)VY<^J26H)I -8EJ"M4TJAE*LU=)G1=]·M$?^/Y^35H;_+Z_& 6X)VY<^J26H)I -8EJ"M4TJAE*LU=)G1=]·M$?^/Y^35H;_+Z_& 6X)VY<^J26H)I -8EJ"M4TJAE*LU=)G1+T[:@8U1)4$Z@F44VAFEYBUVE_U0=*P?N4'@9*[S/·M[U?2@0:G:!+?:|)2 ;B-42U!-H)$-85]&M4,1=FKI,Z=·M$?^/Y^35H;_+Z_& 6X)VY<^J26H)I -8EJ"M4TJAE*LU=)G1=]

+MD?)M4_.:\Z@H6Q$.H0-:\V%#M{!<"'W_(BV\;@M-MZ;"1%/=(>|)1G73D3+jB7TO3&(.4[M65AP(BI@>9E/FW]WO0I9=3\9<:C=BGC-M6LKX-?*
=G6[9QL]NC7GNV29UMXNYV3,46UC1\EF>&)"'/31OT4P.M!$]WZ@I5-MO;DJ>O.;BG5C_GHH;HV_VT0Z\YEGU:WHJ/V(S?U.!5N-!3C:._^CP%K;DQ6[T7FITW,)@C#O46_9C-
X0=7L8FHI,.#9,2^_2F-MW\;)DU>WAUCB$C=Q3QN9-!E+,A!++&*)&[&7&IFTH,;K"9;TQ$U;AY%)$Y]= M#QABZ4G<|'S4CVQUPKON$!=ZEUC2$C=IS_4N:1*6=/"_6, 2-V#/|2YI4K?
# MN\@R0EYQXH7I3'fV+F6V!G>RQ?B9NOK_!NDZB#+K=8HA(W42_V:LIUX-^AQK+-MV5N)F]\NID\:?/SSY)I|_|:|>E[$M=BHD*EZDR[_S)6B|&W)>7[@'8Z>56HCN-^_M%V?
ZWDA@HY<&-R-=J2AW)\H3Q7?%CL":*]VSXC &&HP_3U#>?]<&(2U'M$ M#\W\!4$L#!!0 (-%V!#5D$EHTXKP, -(1 9 >&PO=V]R-W-I965T M>(YTC":ZF!RX^RAA H8>$,CFS
M8]72:]N680P)EA<\!:;?;+E(L-)-L;-E*@!'>5)";<]QQG:"";/FT[QO+>93 MGBE*&*P%DEF28/&X ,H/,\NUCAWOR2Y6IL.>3U:\@SM0']*UT"V[0HE(DP2 MSI"
[3U9#98PI+3WTFDXIEU::$(MCBCZCT__CEA$8& M+^14Y[H4.8Z%@HSJ7A2)NL1)(05W_BA%.(D0>.T)WAE@M=,\))!(&>8)P^-H-> M(<:<1p!;K$*-M8)\VM: !6H,
(@2G$MT5$FX.=Y.@*K>321/)K\EV=<)_FY#O8)%DQ:=L^HL7EZ M(JP9Z"*Q M'GF3\(RI-D*VO')S+W& EVVA#1^ (:0O_RKAGHM(>,JI*:)ZWPN?)QN58A, MN<34++LL':"W+*199-
:JT4(+0%BF17N7@L!&!SE _YB0W4,]=W67:*=R-00- M>B5&ULK59;,]HP%/XK5E9-K<2;>\H81"]0W:1. M"-KM8=]#(0<2-;&9]4#[!V<|(>.20K7Q KZ<[_/YCD|\3G=-V2-/ 1ZRC/"
M>T8BQ+)CFGR60(IY-5T"D3MSRG(LY)0M3+YD@&,-RC/3L:S S%*C+"KUT8L M[-)"9"F!$4.\R';GON0T77/L(W-PCA=)$(MF&%WB1"

,V]M3A0H>VWP/84UWQHCI61*Z,..?(E!A]4<@@QF0C%@^;>" 629 M(I)N_*XXC?I(!=P>,]@_:NU2RQ1S&-#L1QJ+I&>T#13#'!>9&-/U9ZCT^(IO M1C.N?]&ZLK4,-
"NXH'D%EA[D*2G_\5,5ARV Y&D&.\7 V0=X+P#<"N^]@20 M GBO/<&O %/JZ66K7@1MB@<,NHVO$+5D4P,=?8V6\4]4]PU>,#9V&\4]RU=B'(WE3@1?]"
MD!V@=V@,&180HQ%FXAG=,TPXUI?)#S;'L)20 L-*!>(SM$G2F.,)C2+6PB3 M&$5/,H\Y<'0Y!(!3C%])CH?)$%U>7*$+E!)TG]"""2U/>-864H9PQ9Y7+_=)E MYP67771'B4@XBD@,<0-
^>!P",&,.GQU#)U-#/O.4<*O!:E&KM5"CN5X#?X, M7@IWF^3\W^G1/Y^^$PRW3BA7\WDO\&U28]%3@LN4;+KADB/0'.HI6X5MJ!TU_M5!M1.[2Q;H[NT;#'J/ VS.*#HT0?Y%-BO)JU'
M>50=Z/ EGD'D \!!f8"(WS[Q@ZL#TVI=$ZRX3G)HC.1[5R&7U^&?^(R](/4 M%/T2Z&_=O;679X<6MN6Y>WEVDB8Z0;.C*ZAU!6?XF(*#]-Z7>&C1/OB23K)$
MQUE*@>96*!2O[A'(BZ%(7PBD5LJ$J82);*V#*0.//J2R&U40= M4#=KX1]02P,$% @ 78$-606)D](2 @RP0 !D !X;"]W;W)K&UL?53;CILP$/T5BZ=6:F,NV=U]19 V2:NVTE91TLNS M
P-8:VQ]#R'!^[4-H5&;Y 4\]HPS<\8S3GNE7TP-@.38"&D608W8/E)]\AH: M9F:]!6E/2]4;AM;4%36M!E9X4"-H'(;WM&%.#IEY66N&+$NUZHEVWI;-+7QM M/-
JJX=+=X@ZU/>46A]DWA4"B|_*>[*"RMX-D"ZW2R&5%WJP!&1>&?(@D !D :X;"]W;W)K&ULM59M;]HP$/XKIZR:6HF1$%[:=8#40K=U$ALJ[?9A MV@>3'!#5L3/;@5;;C[\Y25-
H(6LE]B6Q+_<\=_?8\,F!DNI6+Q -W,5S"2"P%@&4]\E#!S2T1I M_"XXG3*D\:Z/'\@_9K53+5.F<2#YCR@TBYUYSXD"(,Y9RLY$*3;R+@ 4P9Q0/(WNRMT6 ,T6CL ?@'PGP+;.P#-
M!\:816 6AE MRN2E9#H,F6']KI(K4-;;V.P@$S-#4_F1L,L^,8J^1H0S_ ;.2(#1.X!T.27]M M(,]\"9"FNM "A.)%$/XE]!B=[$T' !1L(AKN,8(DS)^1-B;R1 .#X[@-"(!
MUPN9:F+07==0AC:.&Q39#/)L_!W9=&!$(1<:+D2(X2;>IKF?&U=O"-E0P00PTS)>.- M!9,S.$\UN6N-VW0_KR2V9\NI3EB /8<.#XUJB4[_[9M&Q_NP3;2]]^>R#;TZY3Z=?[7
M/]MY_IUO:)~ V; R^FN%9+I2[UI5B5/LNVL(9"I,?H*7UO("<9;US2?V M 5TL\GO (TU^*Z'C?1V13^(X(T]O?DPKK?).G?\,3++>-Y6&.FDV7-#E"!)5U MH.\$2?VOF-@
Y76K_Q=02P,$% @ 78$-6;(X5ZFT"@ 1%H !D !X M;"]W;W)K&ULW5Q1<]NX$?XK&/6F.8Y/4ZEYPGN6L?.GV@)X' M@-B/ "^>1/FU>N"\)M]6>5%=#A[]>GT^&E7S!
[Y*[_=BS0OYRU*4J[26"\Of M4;4N>,IH&]WR$1V/P]$/S8K!U47SW6UY=2$V=9X5_+8DU6:U2LOO'W@NGBX'
MWN#WYB\,9 4.MOAA=7:S3>_Z%U[^O;TOY:,1#660K7E29*$(c)EY>#;^\\"7S5 MH+'X>\:?]KV_B;J4.R& ^[@\,_+RX'8Q41$_F\5A"I_.^1W_.\5T@RCC]:T,:
MIVJX__M)O/XNFOO+V@0.'-15XU M_Y*GUG8\(//--58M5VUA&L,J*[?_IMS81>PTDCKT!;1OO?@/_0 /6-F"G>O#;
M!OZI'H*V07!|@[!M$#;YWR:KR724UNG512F>2*FL)9KZHZ&K;2T3G!6]9WVI M2_EK)MO55Y]$S8DW)4,228:K.JLW)2=IL9"?]!DHZJS8\ 7Y=2%>2W![&I)&9U,:IES,KS:-[&]V$;'ST0
M'R.?I:N'BL3%@B\LI2.X?0BT\E<{1)&GO/V@8* ?IL4PD:GQ&GEGIO3 MFS/:Y,S.>_PZ[PG_DDNTZ'VOP_-X-VGUT/2UN?]#_[')'M.< M%[6UGVRAPQ@9*S9>/5^.+?>-
^YD%G:HH^K],IG%\.Y!Q<\?*1#Z[^_"ZD\5@E\4 S.+/Q:/LD:+\ M?D8*F5"Q)&DN;\=I,>=$WM@)_S;G,L>]%XN[2N1$R4/"E&N!_+L/^E=SHGL_1LY^2[^+>?]E1H'<@IE(2-I3>30XZLf
MB?\|_-[9F N,,@=>K.L8.>HNQG27F.XH\YA]D(0[>D-XD(ABV,P^15[!#,5R MN^DD!2M1UI{4-41L>08Q'2_K!A,L"HT<>6%O8,86&[]!'7(45(>3R8Z3"#]JZ0?,^^:8LY<
@:55Q^VUB8S:1\|TE^TIF.W?1)WFO<2>N=PNID&-=^XQ/Z/HOZ/(M+M3G8=>N"3_N,$9UF%@<>C-[K_?V:DWOM+64-:=@6]?N
MCHH6M6C=#N_WU(V*Z/8P76I8!]"NBQJ:=4_3O/TKLLS^J,VSLX/=[!04?. M&3[J,$9UF%@<,GJRH(?K@M:#*]I7+5U@,.<1@%H.MVB=^;#/CVDRG+)^]T>*
MJLN/+/HD]N":N+G,V!H';]^\0H;C<,[^48W-M_6LS M$(!@%DNWJ"B19ZE^NQ38)H.@W[_1PJRX"N=CVXW-VM/-?]HT9R4/-3>N(I M ;7]146+/+.FI8-)GQ];<1SV""7]+RM?
3I:\'U[ZMG%[8.* M%GEFL3KT0F/0V*SHL,*4F1=5G2)[,$U\HNEU!874JTM)A8QU3/K4(N::K,R MY53X8E^:3%W\>G#U&\6?/UXOQ%P6 N2?'QM5\U_DOX>>*IVI']:B4JE>DKOO
MY$LJIZWG=M:?_#BJS+C]8(**P1 M6-3? \\6YR5?9%LRN7H6.#[]22 <O.S.7[%H"*EJ,BI904\28'-]J58=**PZ M7.!#\\'V'B-8Z=9P?(%%D+A;]P92 U?:M,Y[M3E,?
$DO)ZX[%5/=]K3$ZJG6%Y! M-KB$-$DS>%Q,X?SLXD^:F >YGV:ZGV8.;>-^>X!TK7G*A2P2^+E!:K"2!,L[A MT29W9,- YF_/IDCR>'.D?
K;OG_VW_AP=V@T>]V7]4RL;9G]5BP_VR%)>Y"7 MDC^LPA6CDJMWUQ'8W9KO##)M6*VE(5I4<*SYSX#6)W!\97B]>L-OZ_Y?4_P" M4$L#!!0 (%V!#*5E;D8T7H0L -^9 9
>&PO=V]R-W-I965TYYPOQSC1)XS 7+|.[7G:?!%G!2!L51SS*,?B_MYXO.Q5FYI3]],$N6>31?!\,N49.LX#M.?GWB4)YWS,YZPQ_SNUE>;,.A=G-V'
M=_R&Y]_OKU/QJK>A3.8Q7V359$%2/CWO7)]GS!T5 >4>?\|Y8[;U.RD.Y39) M?:AOO?I^<=N5D1+8$BX[Q A.+' [_B4520Q@<C^K]"=39 *L*L)H&V%6 W33
J0*PM:\4LIB#):G,+YHM#N39Z* M=^3B/,O*-/^7+,/I5[/7| MQB,?_OWK62\7R0M$;UPE\E>)K&<2|\PSO*HEC4<9N\F3\XX1,)A/6GA1^T^S^W#,SSNBN&<\?>"=BU_^9?:-
W^I$@X1Y M2)B_@@U*6-&1'BZ,KF&>]1ZV98/,2)MD9*",BG"Y8MA7R\93I?W!7ZF2>3.O%H$[05#Q+F(6'^"N9NG4K3'(Y< MVS",'075[.FXAMO?VY,B!\A ,$5&[D9&
[K$R\IX.RCSN:"VB?,D)3 5 MR4J;L*VLD# /"?-7,-/>4HLJ#HDG+WZLB@WRT:CR*G,.UR&!]\FO/L!,8|@PC81X2Y]@_>W_ M;VN_%@3]N^U6^^2H& BF.&6PTIPH]3A
M6_A&Z%8ZVN\Q.]WC2INSK520 M.!\)"Y PBH0Q$$R1E&G(AU3&T3WW1K14GI'@HREKF*Z_ZE.UK6%0F@>E^5!: M *51*
(VA:*H\MYZAFF_=:/496ZL42?,JFG+;9W9W>RTT9P"E42B-H6BJ^BRI M/DNKOHV@PL6D4A3YNLRS7+P6-QLGY!M/XUJ-:,FM-8:D>0>.V24_>9C6?7)\ MZ#@"*
(U":0Q%4WAGG]J;^L?VC9]RD;10Q_B0VD>E.9#:0&41]$TAJ*I\I3> M@'FT.?!T4X;Z!5":5]$.-65DS@!*HU :0|%4]4E+P=1[*L\B!!% :A=
(8BJ8*3SH9IM[*-25[89=&6IR0&D>E.9#:0&41]$T MAJ*I\I3FB:EW3XZOBU!?!$KS#ARS6=ZLU.H.ZH) ;11*8RB:*COIA)AZ*^3; MC.N=N*(Z/EGI;L4%I7D4IX Q#*_D<
M/LWC95SH:2R:,'A7/G_9UM_V]6'MV*#6")3F53334=7FC$.[>H.Z(U :A=(8 MBJ.]3;HCEMXI4. ^:W$5MR'K&]*:M4&-4DJVO9OU[3)?29"]8LB2:B\=Z+]\"4Y$FY M,2*Z$V?:H,4JH?
Y,1=M^QF,9CCDTG=TZ"K5>H#0*I3$4 M316T-*Z9A2,JVG;-M"W#I(?&;LV$>C)O&H72&(fJ"DYZ,I;>D\I{INRJ'SE@R0^ M%]K+B^>X%4;14.'MSX8SRO3I6ZL1ZM)0^Rf-
,VJ$NC10&H72&(JF?DV&=&EL MO4L#Z^ -9^7JA]-6G5":!Z7Y4%H 15$HC:%HJH2E_6,?O52F:0?79VBM2JC_M4]$.UTOIVV@!*HU :0|%4P4G_Q\;[/Z_=P??I6ZL1NHBFHC50(]0?
@M(HE,90 M-%6-6|H]T];K^4-L9O/KAM%8G]MNQL%^//!;5_H#0*I3$4396PM'!LO?V#Z.!0 M_P=*\RI:@YH)]7^@-`JE,11-%9ST?^RCOYX+T\&AW@Z4YE6T!FJ$VC90&H72 M&(JF]E':-
K;>MOGZP-./EU&4Y"1Ff[_>E],U&K;O!X]3Q^%3H5H@eV(^4FLC M4C^ZUF*%6CV0E^E!5 :A=(8BJ8]6OI"]H$O-(/..]'MMK5;3*%^#I1&H32&HJG2DWZ,K?=S7E1,U_.0+N-
D*=ZY7J;C69B%MQ$GGWXJ MI19;@:.$&$I3F06D^E!9 ;11*8RB:^C&0+I/]EBM_],E:"Q3J'=G[GI(S&%B# MO0H.M92@- JE,11-_0)M:2DY>DOI1158-R,$4FOU@V\K92C-@])*"V
TBB4 MQE T5?#2@*)>W8#29VBM2[@!Y=084'67N-"L 91&H32&HJEZD_Z3H_>?WJ3 M%G]!O$LYCP^M6]>/MK5VH785E.9#:0&41]$TAJ*I">>EG/@S[>\\O-9??K6
MDH5ZG6!?M<+F%NE-0&H72&(JFBG'K<|+HW:G7++?O],!!?\)2M]0|URZ T'TH+ MH#0*I3$43?V42$O<.=I2:WP1#'7-H#3(V7?-:I\R0+,&4!]%TAB*INI-FF;. MT6N=,)<(4%<,2O.
<-850]6*$^EU0&H72&(JFBE'Z78[>[\)<(M1,H<9T>ZA_ M!]5Y4)H/I050&H72&(JF"EZZ;,ZKKYK29VBM2]CIY=2LFJJ]!X/:65 :A=(8
MBJ.]3=I9SOLNFM*G;RU&J.'EU"R;JA4CU.""TBB4QE T14[!2H/+?0N#JI[. MOI,# ?T1M]4_E.9!:3Z4%D!I%$IC*)KZ*9&NF/OJKI@^0VM50ETQ=]\5]IT' M@V8-
H#0*I3$43=6;=.7<|UV5I4_?6HQ0F\O=7Y55+T:H@06E42B-H6BJ&*6! MY>H-+,PE0LV*+$RWA]!?4)H'I?E06@"E42B-H6BJX*5)YNI-,D2WAYI24)I7 MT0[>@T&S!E :A=(8BJ;]3=I-
]ONNX-*G;GT[P3A4CU(N"TBB4QE T M58S2BW)?<0'?@6]_7@\$H/87E.9!:3Z4%D!I%$IC*)KZ*9$FE:LWR1"7"% G M'TKSW/V58/7W8%"//"DJC4!H#T52]28_*?
<658*]:E9O/K=4?8FO!0TTR*,V' MT@(HC4)I#$53/Q;22G/?UTK3IV\M6:B5YC9<*P;-&D!I%$IC*-I*C+ULQGGN MA7EX<1;$](Y?\2C*R+@HDN>=XE'N9BM)^;3X V:GEU:GM[?=-
T\#L]C>DYB+ ML_OPCG\.T[OY(B,1GP]DT1V(DYD68ER_R)/[\X[9(;=)GB=Q^>N.AZ+R%CN(_M]Z=)DJ!?% D>D_1',>R+_P-02P,$% @ 78$-69= YC13 P CA4 T M
:X,"]S='EL97.N>&ULW5C1,MHP%/V5*%/G5HH((2.0%9 VG5HH((2.0%9 Y[3MJE2^['"W MRA '+#E.Y(@.)O7SM4,(U+=[^I#*@MK8[_B<>>V5?$+>C2FTXO5U2JKOUSD4U
M]I=*E9^"H)HO:4Z]3E%2H9&LD#E1NBL7055*2M(*2#D/>MUN'.2$"7\R$[O\ M.E>5-R]60HW]81/R[.UK.O;#^*%/O6;EID=*O?W_Q_M>]4%?O/'L_^W!VUKV_
MO#],7QC@T@^DI7L4X70]3Z8^'0]]# :YV8/A0:O9$T M8VO37V>- 4P]Q-5)6?+-9\X6(]=V\LJ..!F1++<|,%I+|T=F@5.8Z0*7O/5"L MV+P=^2U)>4?
7:EM.ZPSWW#M!S_]VG1=44$EXV|2N_6->Y5<{C@9O9=E\]QP:.M=GJL7^G';K)__':CY(@\U(@>B8S=Y$L_\1,GD)-#M[LF_TE)L.C-!G4QI76 MF7#O1-A$/3AYC_T?
<([GNZ3>;,6X8J+N+5F:4O'H8*CE%9GI/S;W]/7XE6)9D MQ=5= X[]?7L[3=DJ3Y11-[0]:A=^QM,+XR;8[_.Q41*US2=UEVYF)FFIQLZ M:WT!X1"Y-I<;P3@6IV D23NW<;R /;!:QV(+|
[#]24FQ-%L*N8- ^P) MQ!$DP1"H17>-QC&R.C%\W/N#/251E"1N!#"W@RC"$'@:,<01S !XP)(K,>_#@ M:?11LWU/!{C^PD]!02P,$% @ 78$-69>*NQS $P(-L !?
3T\$MP>.4#M.*2VBZD8_1!2:5K5N %MB6/.(7-9>V65HH((2.0%9 [2S,.\W2?S+W M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_ :EN_DZ M7-E*M:I%J!K
M@B3H'@=:HAVB$NF2G)L23+GT\DOSN2>?N@S;>5UM_8 MCZ%7=CF[&\JMZ?QNVSLQ&?OA!B'?IXO%O5\ MX%+-WKU]OM>5F8=O]"C:46H%!]V!KU(\V/_.N[?
L7E]VDKT<'YGPC8.\Y2OKCXQ\ M=?##07]4JA/*BH[!7U;W ML@..CGW@/5>M8 %DCD#F$T+^G0>0!0)93))YXW#@HP%DB4"6$T)&D:P0R&I* MR"* K!'(>DK(.H!L$,CFL)!?8
AG&7O#+LV&*_GT[P3I4W"[,ZY+AY#9 AO#%P28 M9(]=&;'E$FSS8^O:IF4C#%9 =VC,<|<3U;*B@B(S>$H%(B^5,L,<5D M!W;,?OA>^&'!"EX%4&;Z?
N:,1(B:8C,0PV;_/6RL0H&Z_L;^X,3"'1YB8,#(* MVV1>-X[O3O>=,/87=G0FX XRQ,1TDU'X)G/"<6//^AFQ?<9QN#&?(#F^=*60DCI&N#G7>C&\XW/NF-&#'UY =63U
MN(1{UQ^L6%74(NU ML<1S3#WYE(5.5'+GF'KR*4N=>(X%4T\Q9:D38V+]*8V(&*DB*GT2Z'F-B!B\{B!}$'AQAEIB\2I+B)YM$DQIB8@4]2 MXN?
%U^<K=TQLN[)28A4H#*'R6SHW"NO\0L5%)8*(D9SO:7Z.H.A862F%6(-MB5FHI+!0$K,,,3$+E1062F(V(29FH9+"0LG,/>I"F(5*"@LE,;,NA%FHI+!0 MLI
(HUEA%JHH+!07&&$[#3$U*U44%DH6&5$T.0M5D[9"8=NL, M54]9",I*G M5YB%)DEKH>GB4H&,J2&JA1&5Y)D),S$(5 M22WT&J8_%&)B%J\(;J%4
1QM@<$L5)/40BG,L O5F(5]DEHHA1FFQ35FH9ID M(2B%&:,%-6:AFF0A*+&6&A7 -6:AFF0Q*#4Y$W4AS$(UR8Q<"C/]0NAN-Y(9 MN11FU(4P"]63SLA%70BS4#WIC%S4-
C$+U2062F%&>QPQ"S4D%DJL\T<#4H-9 Mj"&Q4&I^,WSH#6:AAL1"KZ[SOTCD&LQ"#8F%4M.P430Q"S53;DF(NQ!FH8;$ M0BG,<'AO, LU)!9Z=>?$R[:)
[KKV%IK[B^V[MQT,%4IT7-X+!QO>=|>&>9> M.(-PO*SNU. M;58" ",+0 &'LONVG(%4]$*[%MW#,VET96YT M7U1Y<&5572YX,65-VMI.VS
4!O!7J7*+&M?_-T2Y 6XW+O8"7G+;1DUBRS:L MO/V<%) VL0I4I'TWC5K;YSOQD7Y7O?KQ%"@M#D,_IG6URSE<,I.:'0TNU3[0 M6%8V/@XNEZ]QRX)K]FV+3*Q6AC5^S#3F99YJ5-
=?M[1Q#WU>W!W*SZGSX[]*-MU^=J<7/<.&6M*Q="WS4NEW7V.+9_I2R?$^IRE7?$TL M!<|^/YJFW5+[SNQRO;|\W,_S2&Q^G'_'?\[XM?X'^Q @?4B0/A1('QJD#P/2
MAP?IXPM('U!]^N KE$901.4HI'(44SD*AQ%5[!"*D=QE:/ RE%D%2BM!9 M!8]L D56(2*K0)%5H,@]4&05*+/(*%%DEBJP215:)(]M$D56BR"I19)4HLDH4
M626*K!)%5H4BJT*15:'(JE!D52BR*A19%8JL"D56A2*K0I%5H\BJ4635*+)] M%%DUBJP:15:-(JM&D56CR*I19#4HLAH460V*K 9%5H,BJT&1U:#(,E!D-2BR
M&A19+8JL%D56BR*K19'5HLAJ462U*++:_RGK3^_WGQP_/^O!=>-+/IQ_:WS\ M&U!+ 0(4 Q0 (%R!#*5D'04UB@0 +$ 0 " 0 M !D;V-0&UL4$L! A0#% @ 7($-63@'S"WN *P(M !$ (
!KP &1O8U!R;W!S+V-O&UL4$L! A0#% M @ 7($-69E&PO=V]R:W-H965T&UL4$L! A0#% M @ 7($-62D,% ;P!P =*$!@ (*!, X 'AL+W=&OPO=V]R:W-H965T&UL4$L! A0#% @
7($-64E/)X5&"0 X14 !@ M (*!7W) 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 7($-61B_$N#H @ !08 M !D (*!/!H 'AL+W=OOO M>&PO=V]R:W-H965T&UL4$L! A0#% @
7($-6;3R'>AD"0 SA< !D M (*!)L0 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 7($-66,0SZN'"" SBH !D (*!*|\ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @
7($-6;W9 M6'-2!@ O +!D (*!"_L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 7($-62W3/_*. @ C 4 !D M (*!^@&PO M=V]R:W-H965T&UL4$L! A0#% @ 7($-6=7FW0^; @ P < !D
(*! MYA@! 'AL+W=OP &0 @(&X&P$ >&PO=V]R:W-H965T&UL4$L! A0#% M @ 7($-6 =*F-RX[@ HQ@ !D (*!ET,! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 7($-69A9#TV=
@ G04 !D M (*!\ED! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 7($-62")]'P9 P G08 !D (*!AV8! M 'AL+W=O M/7L" "A!0 &0 @('7:0$ >&PO=V]R:W-H965T&UL4$L!
A0#% @ M7($-69]!R"ES! ,OP !D (*!X'$! 'AL+W=O&PO=V]R:W-H965T(0!X;"]W;W)K&UL4$L! A0#% @ 7($-65^4@\0C P X@P !D M (*!6HP! 'AL+W=O&PO=V]R:W-H M965TB^
0!X;"]W;W)K&UL4$L! M A0#% @ 7($-69X_9Y]> @ UP8 !D (*!VL$! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 7($- M6&PO=V]R:W-H965T&UL4$L! A0#% @
7($-69"5+P=Y$0 D@@! M !D (*!\M0! 'AL+W=O&PO=V]R:W-H965TSS 0!X;"]W;W)K&UL4$L! A0#% @ 7($-68WI*2=F& X=(! !D M (*!0/&PO=V]R:W-H965T M&UL4$L! A0# M% @
7($-67$5.CT& P 2PD !D (*!<1X" 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 78$-6;*9 MVZ+D! 3QD !D (*!E#@" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 78$-64
#4DXE! %Q@ !D M (*!>D0" 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 78$-66R45;'M @ N D !D (*!\ M&'5 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 78$-6;
(X5ZFT"@ 1%H !D (*!P5D" 'AL+W=O6QE&PO=V]R:V)O;LN>&UL4$L! A0#% @ 78$-67KM3FU6 @ MCBT !H (!)'T" 'AL+U]R96QS+W=O XML 90 Show.js IDEA: XBRL
DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope
of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={}; Show.LastAR=null,Show.showAR=function(a,r,w)
{if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}*

if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 91 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 93 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 625 371 1 true 151 0 false 8 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) Sheet http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Organization Sheet http://www.novabaypharma.com/20240630/role/statement-note-1-organization Note 1 - Organization Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Fair Value Measurements Sheet http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements Note 3 - Fair Value Measurements Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets Sheet http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets Note 4 - Prepaid Expenses and Other Current Assets Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Inventory Sheet http://www.novabaypharma.com/20240630/role/statement-note-5-inventory Note 5 - Inventory Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Property and Equipment Sheet http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment Note 6 - Property and Equipment Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Accrued Liabilities Sheet http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities Note 7 - Accrued Liabilities Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Commitments and Contingencies Sheet http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies Note 8 - Commitments and Contingencies Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Financing Activities Sheet http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities Note 9 - Financing Activities Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Convertible Notes Notes http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes Note 10 - Convertible Notes Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Common Stock Warrants Sheet http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants Note 11 - Common Stock Warrants Notes 18 false false R19.htm 018 - Disclosure - Note 12 - Stockholders' (Deficit) Equity Sheet http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity Note 12 - Stockholders' (Deficit) Equity Notes 19 false false R20.htm 019 - Disclosure - Note 13 - Equity-based Compensation Sheet http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation Note 13 - Equity-based Compensation Notes 20 false false R21.htm 020 - Disclosure - Note 14 - Distribution Agreements Sheet http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements- Note 14 - Distribution Agreements Notes 21 false false R22.htm 021 - Disclosure - Note 15 - Employee Benefit Plan Sheet http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan Note 15 - Employee Benefit Plan Notes 22 false false R23.htm 022 - Disclosure - Note 16 - Related Party Transactions Sheet http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions- Note 16 - Related Party Transactions Notes 23 false false R24.htm 023 - Disclosure - Note 17 - Segment Reporting Sheet http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting Note 17 - Segment Reporting Notes 24 false false R25.htm 024 - Disclosure - Note 18 - Divestiture and Discontinued Operations Sheet http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations Note 18 - Divestiture and Discontinued Operations Notes 25 false false R26.htm 025 - Disclosure - Note 19 - Subsequent Events Sheet http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events Note 19 - Subsequent Events Notes 26 false false R27.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 27 false false R28.htm 995471 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies 28 false false R29.htm 995472 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies 29 false false R30.htm 995473 - Disclosure - Note 3 - Fair Value Measurements (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-tables Note 3 - Fair Value Measurements (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements 30 false false R31.htm 995474 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables Note 4 - Prepaid Expenses and Other Current Assets (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets 31 false false R32.htm 995475 - Disclosure - Note 5 - Inventory (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-tables Note 5 - Inventory (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-5-inventory 32 false false R33.htm 995476 - Disclosure - Note 6 - Property and Equipment (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-tables Note 6 - Property and Equipment (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment 33 false false R34.htm 995477 - Disclosure - Note 7 - Accrued Liabilities (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-tables Note 7 - Accrued Liabilities (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities 34 false false R35.htm 995478 - Disclosure - Note 8 - Commitments and Contingencies (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-tables Note 8 - Commitments and Contingencies (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies 35 false false R36.htm 995479 - Disclosure - Note 10 - Convertible Notes (Tables) Notes http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-tables Note 10 - Convertible Notes (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes 36 false false R37.htm 995480 - Disclosure - Note 11 - Common Stock Warrants (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-tables Note 11 - Common Stock Warrants (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants 37 false false R38.htm 995481 - Disclosure - Note 13 - Equity-based Compensation (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables Note 13 - Equity-based Compensation (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation 38 false false R39.htm 995482 - Disclosure - Note 14 - Distribution Agreements (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-tables Note 14 - Distribution Agreements (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements- 39 false false R40.htm 995483 - Disclosure - Note 16 - Related Party Transactions (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-tables Note 16 - Related Party Transactions (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions- 40 false false R41.htm 995484 - Disclosure - Note 18 - Divestiture and Discontinued Operations (Tables) Sheet http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-tables Note 18 - Divestiture and Discontinued Operations (Tables) Tables http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations 41 false false R42.htm 995485 - Disclosure - Note 1 - Organization (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual Note 1 - Organization (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-1-organization 42 false false R43.htm 995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables 43 false false R44.htm 995487 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) Details 44 false false R45.htm 995488 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) Details 45 false false R46.htm 995489 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details) Details 46 false false R47.htm 995490 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) Details 47 false false R48.htm 995491 - Disclosure - Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 48 false false R49.htm 995492 - Disclosure - Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details) Details 49 false false R50.htm 995493 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Details 50 false false R51.htm 995494 - Disclosure - Note 5 - Inventory - Summary of Inventory (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-summary-of-inventory-details Note 5 - Inventory - Summary of Inventory (Details) Details 51 false false R52.htm 995495 - Disclosure - Note 6 - Property and Equipment (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-details-textual Note 6 - Property and Equipment (Details Textual) Details*

http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-tables 52 false false R53.htm 995496 - Disclosure - Note 6 - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details Note 6 - Property and Equipment - Summary of Property and Equipment (Details) Details 53 false false R54.htm 995497 - Disclosure - Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) Details 54 false false R55.htm 995498 - Disclosure - Note 8 - Commitments and Contingencies - Lease Expense (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details Note 8 - Commitments and Contingencies - Lease Expense (Details) Details 55 false false R56.htm 995499 - Disclosure - Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) Details 56 false false R57.htm 995500 - Disclosure - Note 9 - Financing Activities (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual Note 9 - Financing Activities (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities 57 false false R58.htm 995501 - Disclosure - Note 10 - Convertible Notes (Details Textual) Notes http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual Note 10 - Convertible Notes (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-tables 58 false false R59.htm 995502 - Disclosure - Note 10 - Convertible Note - Convertible Notes (Details) Notes http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details Note 10 - Convertible Note - Convertible Notes (Details) Details 59 false false R60.htm 995503 - Disclosure - Note 11 - Common Stock Warrants (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual Note 11 - Common Stock Warrants (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-tables 60 false false R61.htm 995504 - Disclosure - Note 11 - Common Stock Warrants - Outstanding Warrants (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details Note 11 - Common Stock Warrants - Outstanding Warrants (Details) Details 61 false false R62.htm 995505 - Disclosure - Note 11 - Common Stock Warrants - Warrants Outstanding (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details Note 11 - Common Stock Warrants - Warrants Outstanding (Details) Details 62 false false R63.htm 995506 - Disclosure - Note 11 - Common Stock Warrants - Reconciliation of Common Stock Warrant Liabilities (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details Note 11 - Common Stock Warrants - Reconciliation of Common Stock Warrant Liabilities (Details) Details 63 false false R64.htm 995507 - Disclosure - Note 12 - Stockholders' (Deficit) Equity (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual Note 12 - Stockholders' (Deficit) Equity (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity 64 false false R65.htm 995508 - Disclosure - Note 13 - Equity-based Compensation (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual Note 13 - Equity-based Compensation (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables 65 false false R66.htm 995509 - Disclosure - Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) Details 66 false false R67.htm 995510 - Disclosure - Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) Sheet http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-granted-to-employees-and-directors-details Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) Details 67 false false R68.htm 995511 - Disclosure - Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) Details 68 false false R69.htm 995512 - Disclosure - Note 14 - Distribution Agreements (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual Note 14 - Distribution Agreements (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-tables 69 false false R70.htm 995513 - Disclosure - Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details) Details 70 false false R71.htm 995514 - Disclosure - Note 15 - Employee Benefit Plan (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual Note 15 - Employee Benefit Plan (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan 71 false false R72.htm 995515 - Disclosure - Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) Details 72 false false R73.htm 995516 - Disclosure - Note 17 - Segment Reporting (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting-details-textual Note 17 - Segment Reporting (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting 73 false false R74.htm 995517 - Disclosure - Note 18 - Divestiture and Discontinued Operations (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual Note 18 - Divestiture and Discontinued Operations (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-tables 74 false false R75.htm 995518 - Disclosure - Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) Sheet http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) Details 75 false false R76.htm 995519 - Disclosure - Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) (Parentheticals) Sheet http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) (Parentheticals) Details 76 false false R77.htm 995520 - Disclosure - Note 19 - Subsequent Events (Details Textual) Sheet http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual Note 19 - Subsequent Events (Details Textual) Details http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events 77 false false All Reports Book All Reports nby-20240630.xsd nby-20240630_cal.xml nby-20240630_def.xml nby-20240630_lab.xml nby-20240630_pre.xml nby20240630_10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 96 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nby20240630_10q.htm": { "nsprefix": "nby", "nsuri": "http://www.novabaypharma.com/20240630", "dts": { "schema": { "local": ["nby-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["nby-20240630_cal.xml"] }, "definitionLink": { "local": ["nby-20240630_def.xml"] }, "labelLink": { "local": ["nby-20240630_lab.xml"] }, "presentationLink": { "local": ["nby-20240630_pre.xml"] }, "inline": { "local": ["nby20240630_10q.htm"] } }, "keyStandard": 301, "keyCustom": 70, "axisStandard": 33, "axisCustom": 0, "memberStandard": 44, "memberCustom": 99, "hidden": { "total": 91, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 81, "http://xbrl.sec.gov/ecd/2024": 4, "http://www.novabaypharma.com/20240630": 1 }, "contextCount": 625, "entityCount": 1, "segmentCount": 151, "elementCount": 646, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1146, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:GrossProfit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R5": { "role": "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "longName": "004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R6": { "role": "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "longName": "005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2024-05-30_2024-05-30_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "d_2024-01-01_2024-

06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:StockOptionPlanExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R8": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "longName": "007 - Disclosure - Note 1 - Organization", "shortName": "Note 1 - Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "008 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "longName": "009 - Disclosure - Note 3 - Fair Value Measurements", "shortName": "Note 3 - Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets", "longName": "010 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory", "longName": "011 - Disclosure - Note 5 - Inventory", "shortName": "Note 5 - Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "longName": "012 - Disclosure - Note 6 - Property and Equipment", "shortName": "Note 6 - Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities", "longName": "013 - Disclosure - Note 7 - Accrued Liabilities", "shortName": "Note 7 - Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies", "longName": "014 - Disclosure - Note 8 - Commitments and Contingencies", "shortName": "Note 8 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "longName": "015 - Disclosure - Note 9 - Financing Activities", "shortName": "Note 9 - Financing Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "longName": "016 - Disclosure - Note 10 - Convertible Notes", "shortName": "Note 10 - Convertible Notes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "longName": "017 - Disclosure - Note 11 - Common Stock Warrants", "shortName": "Note 11 - Common Stock Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "longName": "018 - Disclosure - Note 12 - Stockholders' (Deficit) Equity", "shortName": "Note 12 - Stockholders' (Deficit) Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "longName": "019 - Disclosure - Note 13 - Equity-based Compensation", "shortName": "Note 13 - Equity-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "longName": "020 - Disclosure - Note 14 - Distribution Agreements", "shortName": "Note 14 - Distribution Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "nby:LicenseCollaborationAndDistributionAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "nby:LicenseCollaborationAndDistributionAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan", "longName": "021 - Disclosure - Note 15 - Employee Benefit Plan", "shortName": "Note 15 - Employee Benefit Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-", "longName": "022 - Disclosure - Note 16 - Related Party Transactions", "shortName": "Note 16 - Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting", "longName": "023 - Disclosure - Note 17 - Segment Reporting", "shortName": "Note 17 - Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations", "longName": "024 - Disclosure - Note 18 - Divestiture and Discontinued Operations", "shortName": "Note 18 - Divestiture and Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "longName": "025 - Disclosure - Note 19 - Subsequent Events", "shortName": "Note 19 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes",

"order": "27", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies", "longName": "995471 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables", "longName": "995472 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "nby:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "nby:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-tables", "longName": "995473 - Disclosure - Note 3 - Fair Value Measurements (Tables)", "shortName": "Note 3 - Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "longName": "995474 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-tables", "longName": "995475 - Disclosure - Note 5 - Inventory (Tables)", "shortName": "Note 5 - Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-tables", "longName": "995476 - Disclosure - Note 6 - Property and Equipment (Tables)", "shortName": "Note 6 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-tables", "longName": "995477 - Disclosure - Note 7 - Accrued Liabilities (Tables)", "shortName": "Note 7 - Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-tables", "longName": "995478 - Disclosure - Note 8 - Commitments and Contingencies (Tables)", "shortName": "Note 8 - Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-tables", "longName": "995479 - Disclosure - Note 10 - Convertible Notes (Tables)", "shortName": "Note 10 - Convertible Notes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-tables", "longName": "995480 - Disclosure - Note 11 - Common Stock Warrants (Tables)", "shortName": "Note 11 - Common Stock Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables", "longName": "995481 - Disclosure - Note 13 - Equity-based Compensation (Tables)", "shortName": "Note 13 - Equity-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-tables", "longName": "995482 - Disclosure - Note 14 - Distribution Agreements (Tables)", "shortName": "Note 14 - Distribution Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nby:LicenseCollaborationAndDistributionAgreementsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nby:LicenseCollaborationAndDistributionAgreementsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-tables", "longName": "995483 - Disclosure - Note 16 - Related Party Transactions (Tables)", "shortName": "Note 16 - Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-tables", "longName": "995484 - Disclosure - Note 18 - Divestiture and Discontinued Operations (Tables)", "shortName": "Note 18 - Divestiture and Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "longName": "995485 - Disclosure - Note 1 - Organization (Details Textual)", "shortName": "Note 1 - Organization (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-03-31_DisposalGroupClassificationAxis-DiscontinuedOperationsDisposedOfBySaleMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-DermadoctorMember", "name": "us-gaap:GainLossOnSaleOfBusiness", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R43": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:CreditLossFinancialInstrumentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef":

"nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["us-gaap:AllowanceForDoubtfulAccountsReceivable", "p", "us-gaap:CreditLossFinancialInstrumentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R44": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details", "longName": "995487 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "nby:CashAndCashEquivalentsIncludingDisposalGroup", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "nby:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "nby:CashAndCashEquivalentsIncludingDisposalGroup", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "nby:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "longName": "995488 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30_ProductOrServiceAxis-AvenovaSprayMember", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R46": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details", "longName": "995489 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-MajorUSRetailerAMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-MajorUSRetailerAMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details", "longName": "995490 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details", "longName": "995491 - Disclosure - Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "i_2024-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "nby:RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "nby:RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "longName": "995492 - Disclosure - Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details)", "shortName": "Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:FairValueAdjustmentOfWarrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "longName": "995493 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:PrepaidInsurance", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:PrepaidInsurance", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-summary-of-inventory-details", "longName": "995494 - Disclosure - Note 5 - Inventory - Summary of Inventory (Details)", "shortName": "Note 5 - Inventory - Summary of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-details-textual", "longName": "995495 - Disclosure - Note 6 - Property and Equipment (Details Textual)", "shortName": "Note 6 - Property and Equipment (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": null }, "R53": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details", "longName": "995496 - Disclosure - Note 6 - Property and Equipment - Summary of Property and Equipment (Details)", "shortName": "Note 6 - Property and Equipment - Summary of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details", "longName": "995497 - Disclosure - Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details)", "shortName": "Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "nby:ContractWithCustomerAccruedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "nby:ContractWithCustomerAccruedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details", "longName": "995498 - Disclosure - Note 8 - Commitments and Contingencies - Lease Expense (Details)", "shortName": "Note 8 - Commitments and Contingencies - Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details", "longName": "995499 - Disclosure - Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details)", "shortName": "Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-

details-textual", "longName": "995500 - Disclosure - Note 9 - Financing Activities (Details Textual)", "shortName": "Note 9 - Financing Activities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-05-01_2023-05-01_SubsidiarySaleOfStockAxis-The2023PrivatePlacementMember", "name": "nby:ProceedsFromDebentureAndWarrantIssuancesNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R58": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "longName": "995501 - Disclosure - Note 10 - Convertible Notes (Details Textual)", "shortName": "Note 10 - Convertible Notes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:RepaymentsOfConvertibleDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-03-24_DebtInstrumentAxis-UnsecuredConvertibleNotesMember", "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R59": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details", "longName": "995502 - Disclosure - Note 10 - Convertible Note - Convertible Notes (Details)", "shortName": "Note 10 - Convertible Note - Convertible Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:ConvertibleDebtCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30_DebtInstrumentAxis-OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R60": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "longName": "995503 - Disclosure - Note 11 - Common Stock Warrants (Details Textual)", "shortName": "Note 11 - Common Stock Warrants (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-05-31_ClassOfWarrantOrRightAxis-TheMay2023B1WarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R61": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details", "longName": "995504 - Disclosure - Note 11 - Common Stock Warrants - Outstanding Warrants (Details)", "shortName": "Note 11 - Common Stock Warrants - Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "nby:ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R62": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details", "longName": "995505 - Disclosure - Note 11 - Common Stock Warrants - Warrants Outstanding (Details)", "shortName": "Note 11 - Common Stock Warrants - Warrants Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30_ClassOfWarrantOrRightAxis-The2019LadenburgWarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "nby:ScheduleOfStockholdersEquityNoteWarrantsOrRightsOutstandingActivityMemberTableTextBlock", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R63": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details", "longName": "995506 - Disclosure - Note 11 - Common Stock Warrants - Reconciliation of Common Stock Warrant Liabilities (Details)", "shortName": "Note 11 - Common Stock Warrants - Reconciliation of Common Stock Warrant Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "i_2023-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "longName": "995507 - Disclosure - Note 12 - Stockholders' (Deficit) Equity (Details Textual)", "shortName": "Note 12 - Stockholders' (Deficit) Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:PreferredStockConvertibleSharesIssuable", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R65": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "longName": "995508 - Disclosure - Note 13 - Equity-based Compensation (Details Textual)", "shortName": "Note 13 - Equity-based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R66": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details", "longName": "995509 - Disclosure - Note 13 - Equity-based Compensation - Stock Options Outstanding (Details)", "shortName": "Note 13 - Equity-based Compensation - Stock Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "nby:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R67": { "role": "http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-granted-to-employees-and-directors-details", "longName": "995510 - Disclosure - Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details)", "shortName": "Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "d_2023-01-01_2023-06-30_TitleOfIndividualAxis-EmployeesAndDirectorsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-06-30_TitleOfIndividualAxis-EmployeesAndDirectorsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details", "longName": "995511 - Disclosure - Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details)", "shortName": "Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R69": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual", "longName": "995512 - Disclosure - Note 14 - Distribution Agreements (Details Textual)", "shortName": "Note 14 - Distribution Agreements (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30_CounterpartyNameAxis-CostcoAndOthersMember_ProductOrServiceAxis-DermadoctorMember", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "nby:LicenseCollaborationAndDistributionAgreementsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R70": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details", "longName": "995513 - Disclosure -

Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details)", "shortName": "Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "nby:ContractWithCustomerLiabilityIncludingDisposalGroup", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "nby:LicenseCollaborationAndDistributionAgreementsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "nby:ContractWithCustomerLiabilityIncludingDisposalGroup", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "nby:LicenseCollaborationAndDistributionAgreementsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual", "longName": "995514 - Disclosure - Note 15 - Employee Benefit Plan (Details Textual)", "shortName": "Note 15 - Employee Benefit Plan (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30_RetirementPlanNameAxis-The401kPlanContributionLevelOneMember", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30_RetirementPlanNameAxis-The401kPlanContributionLevelOneMember", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details", "longName": "995515 - Disclosure - Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details)", "shortName": "Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R73": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting-details-textual", "longName": "995516 - Disclosure - Note 17 - Segment Reporting (Details Textual)", "shortName": "Note 17 - Segment Reporting (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": null, "uniqueAnchor": null }, "R74": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual", "longName": "995517 - Disclosure - Note 18 - Divestiture and Discontinued Operations (Details Textual)", "shortName": "Note 18 - Divestiture and Discontinued Operations (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-03-25_2024-03-25_DisposalGroupClassificationAxis-DiscontinuedOperationsDisposedOfBySaleMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-DermadoctorMember", "name": "nby:DisposalGroupIncludingDiscontinuedOperationPercentageSold", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R75": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "longName": "995518 - Disclosure - Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details)", "shortName": "Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "nby:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_DisposalGroupClassificationAxis-DiscontinuedOperationsDisposedOfBySaleMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-DermadoctorMember", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } }, "R76": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals", "longName": "995519 - Disclosure - Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) (Parentheticals)", "shortName": "Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "i_2023-12-31_DisposalGroupClassificationAxis-DiscontinuedOperationsDisposedOfBySaleMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-DermadoctorMember", "name": "nby:DisposalGroupIncludingDiscontinuedOperationAccountsReceivableAllowance", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_DisposalGroupClassificationAxis-DiscontinuedOperationsDisposedOfBySaleMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-DermadoctorMember", "name": "nby:DisposalGroupIncludingDiscontinuedOperationAccountsReceivableAllowance", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "longName": "995520 - Disclosure - Note 19 - Subsequent Events (Details Textual)", "shortName": "Note 19 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-07-26_ClassOfWarrantOrRightAxis-PrefundedWarrants2024PublicOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nby20240630_10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r77", "r79", "r84", "r947"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r77", "r764"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r697"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts receivable, net of allowance for credit losses ($3 at June 30, 2024 and December 31, 2023)", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r837"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details"], "lang": { "en-us": { "role": { "verboseLabel": "Total accrued liabilities", "label": "Accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r79"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r39", "r178", "r568"] }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash information:" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r89", "r764", "r1021"] }, "us-

gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r609", "r822", "r823", "r824", "r827", "r949", "r1022"] }, "nby_AdjustmentsToAdditionalPaidInCapitalDownRoundFeatureAdjustmentRelatedToPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalDownRoundFeatureAdjustmentRelatedToPreferredStock", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Adjustment of Series C Preferred Stock conversion price", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from down round feature adjustment related to preferred stock." } } }, "auth_ref": [] }, "nby_AdjustmentsToAdditionalPaidInCapitalModificationOfWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalModificationOfWarrant", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Modification of common stock warrants in connection with 2024 Warrant Reprice Transaction", "documentation": "Amount of increase to APIC from modification of warrant." } } }, "auth_ref": [] }, "nby_AdjustmentsToAdditionalPaidInCapitalModificationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalModificationOfWarrants", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Modification of common stock warrants", "documentation": "The amount of adjustments to additional paid in capital from the modification of warrants." } } }, "auth_ref": [] }, "nby_AdjustmentsToAdditionalPaidInCapitalReclassificationsOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationsOfWarrants", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Reclassification of May 2023 Warrants", "documentation": "The amount of adjustments to additional paid in capital from the reclassification of warrants." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense related to employee and director stock awards", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "terseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r13", "r133"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": ["r158"] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AdvertisingExpense", "terseLabel": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": ["r448", "r746"] }, "nby_AfterRatchetApril272023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AfterRatchetApril272023Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "After Ratchet, April 27, 2023 [Member]", "documentation": "Represents After Ratchet, April 27, 2023." } } }, "auth_ref": [] }, "nby_AfterRatchetDecember212023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AfterRatchetDecember212023Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "After Ratchet, December 21, 2023 [Member]", "documentation": "Represents after ratchet, December 21, 2023." } } }, "auth_ref": [] }, "nby_AfterRatchetMarch242024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AfterRatchetMarch242024Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "After Ratchet, March 24, 2024 [Member]", "documentation": "Represents after ratchet on March 24, 2024." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details"], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r437", "r446"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r184", "r269", "r278", "r281", "r282", "r987"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Accounts receivable, allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r184", "r269", "r278"] }, "nby_AmendedJuly2020WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AmendedJuly2020WarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Amended July 2020 Warrants [Member]", "documentation": "Represents amended July 2020 warrants." } } }, "auth_ref": [] }, "nby_AmendedNovember2021WarrantsExercisableFor150Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AmendedNovember2021WarrantsExercisableFor150Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Amended November 2021 Warrants Exercisable for 1.50 [Member]", "documentation": "Represents Amended November 2021 Warrants exercisable for $1.50." } } }, "auth_ref": [] }, "nby_AmendedNovember2021WarrantsExercisableFor650Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AmendedNovember2021WarrantsExercisableFor650Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Amended November 2021 Warrants Exercisable for 6.50 [Member]", "documentation": "Represents the Amended November 2021 Warrants exercisable for $6.50." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Accretion of interest and amortization of debt discounts on convertible notes", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r9", "r106", "r347", "r969"] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AmortizationOfFinancingCostsAndDiscounts", "negatedLabel": "Accretion of interest and amortization of discounts on convertible notes", "terseLabel": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r347", "r732", "r733", "r816", "r969"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details"], "lang": { "en-us": { "role": { "label": "Anti-dilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r240"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r28"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r28"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r467"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order":

null, "root": true }], "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r145", "r156", "r180", "r207", "r243", "r251", "r258", "r261", "r270", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r468", "r471", "r506", "r558", "r644", "r721", "r722", "r764", "r781", "r853", "r854", "r977"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsAbstract", "terseLabel": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r173", "r188", "r207", "r270", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r468", "r471", "r506", "r764", "r853", "r854", "r977"] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "verboseLabel": "Total current assets, discontinued operations", "label": "Current assets, discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r58", "r72", "r119", "r122", "r171", "r172"] }, "nby_AvenovaDirectMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AvenovaDirectMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual"], "lang": { "en-us": { "role": { "label": "Avenova Direct [Member]", "documentation": "Related to Avenova Direct." } } }, "auth_ref": [] }, "nby_AvenovaSprayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "AvenovaSprayMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Avenova Spray [Member]", "documentation": "Represents Avenova spray." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r433", "r434", "r435", "r436"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationContingentConsiderationLiability", "terseLabel": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r45", "r138", "r464", "r487", "r488", "r489"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r23", "r176", "r704"] }, "nby_CashAndCashEquivalentsIncludingDisposalGroup": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "CashAndCashEquivalentsIncludingDisposalGroup", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details"], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "nby_CashAndCashEquivalentsIncludingDisposalGroup", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r24"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year, consolidated", "periodEndLabel": "Cash, cash equivalents and restricted cash of continuing operations, end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r23", "r111", "r203"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "negatedLabel": "Less: Cash and cash equivalents of discontinued operations, end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r23", "r111", "r203"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details"], "lang": { "en-us": { "role": { "label": "Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r23", "r111", "r203"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash, consolidated", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r2", "r111"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations", "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash, continuing operations", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from change in exchange rate. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalents include, but are not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": ["r814", "r966"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation":

{ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Net decrease in cash and cash equivalents, discontinued operations", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from change in exchange rate, attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalents include, but are not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": ["r814", "r966"] }, "us-gaap_CashDivestedFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashDivestedFromDeconsolidation", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_CashDivestedFromDeconsolidation", "negatedTerseLabel": "Cash transferred to New Age Investments, LLC", "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash." } } }, "auth_ref": ["r108"] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "terseLabel": "Net cash used in investing activities, discontinued operations", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r71", "r111"] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "terseLabel": "Net cash used in operating activities, discontinued operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r71", "r111"] }, "nby_ChargebacksDiscountsForPromptPaymentAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ChargebacksDiscountsForPromptPaymentAndOtherMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details"], "lang": { "en-us": { "role": { "label": "Chargebacks, Discounts for Prompt, Payment, and Other [Member]", "documentation": "Represents chargebacks, discounts for prompt, payment, and other." } } }, "auth_ref": [] }, "nby_ChonggingPioneerPharmaHoldingsLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ChonggingPioneerPharmaHoldingsLimitedMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details"], "lang": { "en-us": { "role": { "label": "Chongqing Pioneer Pharma Holdings Limited [Member]", "documentation": "Represents information pertaining to chongqing pioneer pharma holdings limited." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_CityAreaCode", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r167", "r181", "r182", "r183", "r207", "r233", "r234", "r237", "r239", "r245", "r246", "r270", "r316", "r318", "r319", "r320", "r323", "r324", "r354", "r355", "r359", "r362", "r368", "r506", "r601", "r602", "r603", "r604", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r632", "r653", "r673", "r691", "r692", "r693", "r694", "r695", "r790", "r818", "r828"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r42"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "Exercise price (in dollars per share)", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "periodStartLabel": "Outstanding warrants, weighted-average exercise price (in dollars per share)", "periodEndLabel": "Outstanding warrants, weighted-average exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r369"] }, "nby_ClassOfWarrantOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "Warrants exercised (in shares)", "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)", "negatedLabel": "Warrants exercised (in shares)", "documentation": "The number of warrants or rights exercised during period." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Warrants exercised, weighted-average exercise price (in dollars per share)", "documentation": "Weighted average exercise price per share of warrants or rights exercised during period." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightForfeitedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ClassOfWarrantOrRightForfeitedDuringPeriod", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Warrants expired (in shares)", "terseLabel": "Class of Warrant or Right, Forfeited During Period", "documentation": "The number of warrants or rights forfeited during period." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightForfeitedDuringPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ClassOfWarrantOrRightForfeitedDuringPeriodWeightedAverageExercisePrice", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Warrants expired, weighted average exercise price (in dollars per share)", "documentation": "Weighted average exercise price per share of warrants or rights forfeited during period." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ClassOfWarrantOrRightIssuedDuringPeriod", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Warrants granted (in shares)", "terseLabel": "Class of Warrant or Right, Issued During Period", "documentation": "The number of warrants or rights issued during period." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Warrants granted, weighted average exercise price (in dollars per share)", "documentation": "Weighted average exercise price per share of warrants or rights issued during period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r369"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "Warrants outstanding (in shares)", "periodStartLabel": "Outstanding warrants (in shares)", "periodEndLabel": "Outstanding warrants (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-

consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r85", "r148", "r560", "r631"] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r125", "r308", "r309", "r698", "r845", "r850"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r772", "r773", "r774", "r776", "r777", "r778", "r779", "r822", "r823", "r827", "r949", "r1019", "r1022"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r88"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r88", "r632"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r88"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r13", "r88", "r632", "r650", "r1022", "r1023"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock, $0.01 par value; 150,000 shares authorized, 1,348 and 321 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r88", "r563", "r764"] }, "nby_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Computer Equipment and Software [Member]", "documentation": "Represents information about computer equipment and software." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r31", "r32", "r52", "r53", "r267", "r697"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r31", "r32", "r52", "r53", "r267", "r595", "r697"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r31", "r32", "r52", "r53", "r267", "r697", "r799"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r55", "r161"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details"], "lang": { "en-us": { "role": { "label": "Accounts receivable, concentration risk", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r31", "r32", "r52", "r53", "r267"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r31", "r32", "r52", "r53", "r267", "r697"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r47", "r712"] }, "nby_ContractWithCustomerAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ContractWithCustomerAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details"], "lang": { "en-us": { "role": { "verboseLabel": "Contract liabilities (see Note 14)", "label": "nby_ContractWithCustomerAccruedLiabilitiesCurrent", "documentation": "The amount of accrued liabilities related to contract with customer." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-tables"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r858"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability", "periodStartLabel": "Continuing operations balance at December 31, 2023", "periodEndLabel": "Balance", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r371", "r372", "r375"] }, "nby_ContractWithCustomerLiabilityCurrentPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ContractWithCustomerLiabilityCurrentPeriod", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details"], "lang": { "en-us": { "role": { "label": "Current period", "documentation": "Represents contract with customer, liability, current period." } } }, "auth_ref": [] }, "nby_ContractWithCustomerLiabilityIncludingDisposalGroup": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ContractWithCustomerLiabilityIncludingDisposalGroup", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details"], "lang": { "en-us": { "role": { "label": "nby_ContractWithCustomerLiabilityIncludingDisposalGroup", "periodStartLabel": "Balance at December 31, 2023", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [] }, "nby_ContractWithCustomerLiabilityPaymentsAndCustomerCreditsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ContractWithCustomerLiabilityPaymentsAndCustomerCreditsIssued", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details"], "lang": { "en-us": { "role": { "label": "nby_ContractWithCustomerLiabilityPaymentsAndCustomerCreditsIssued", "negatedLabel": "Payments and customer credits issued", "documentation": "Represents contract with customer, liability, payments and customer credits issued." } } }, "auth_ref": [] }, "nby_ConversionOfSeriesBPreferredStockToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ConversionOfSeriesBPreferredStockToCommonStockMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Conversion of Series B Preferred Stock to Common Stock [Member]", "documentation": "Represents conversion of series b preferred stock to common stock." } } }, "auth_ref": [] }, "nby_ConversionOfSeriesCPreferredStockToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ConversionOfSeriesCPreferredStockToCommonStockMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Conversion of Series C Preferred Stock to Common Stock [Member]", "documentation": "Represents conversion of series c preferred stock to common stock." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",

```
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Conversion of Preferred Stock to common stock", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r25", "r26", "r27" ] }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": [ "r25", "r26", "r27" ] }, "us-gaap_ConversionOfStockNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockNameDomain", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Name [Domain]", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": [ "r25", "r26", "r27" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Conversion of Preferred Stock to common stock (in shares)", "negatedLabel": "Conversion of Preferred Stock to common stock (in shares)", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r25", "r26", "r27" ] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details" ], "lang": { "en-us": { "role": { "label": "Secured Convertible Notes, net of discounts", "totalLabel": "Total Secured Convertible Notes, net", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [
"r127", "r326", "r327", "r337", "r338", "r339", "r343", "r344", "r345", "r346", "r347", "r729", "r730", "r731", "r732", "r733" ] },
"nby_ConvertibleNotesAndMay2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ConvertibleNotesAndMay2023WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Convertible Notes and May 2023 Warrants [Member]", "documentation": "Represents Convertible Notes and May 2023 Warrants." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "Cost of goods sold", "terseLabel": "Cost of goods sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r100", "r101", "r553" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesPolicyTextBlock", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r806" ] }, "nby_CostcoAndOthersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "CostcoAndOthersMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual" ], "lang": { "en-us": { "role": { "label": "Costco and Others [Member]", "documentation": "Represents Costco and others." } } }, "auth_ref": [] },
"srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-",
"http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r210", "r211", "r329", "r357", "r540", "r550", "r557", "r708", "r710" ] }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Credit Loss, Financial Instrument [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status." } } }, "auth_ref": [ "r275", "r276", "r277", "r279", "r280", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295" ] },
"dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r115", "r267" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r126", "r205", "r301", "r302", "r303", "r304", "r305", "r314", "r315", "r325", "r331", "r332", "r333", "r334", "r335", "r336", "r341", "r348", "r349", "r350", "r514" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual",
"http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r17", "r78", "r79", "r146", "r147", "r212", "r326", "r327", "r328", "r329", "r330", "r332", "r337", "r338", "r339", "r340", "r342", "r343", "r344", "r345", "r346", "r347", "r729", "r730", "r731", "r732", "r733", "r754", "r819", "r846", "r847", "r848", "r968", "r970" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details": { "parentTag": "us-gaap_ConvertibleDebtCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Principal amount", "label": "us-gaap_DebtInstrumentCarryingAmount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r17", "r147", "r351" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1", "terseLabel": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r128", "r328" ] }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments", "terseLabel": "Debt Instrument, Convertible, Number of Equity Instruments", "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity." } } }, "auth_ref": [ "r40", "r82", "r131", "r132", "r328" ] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "terseLabel": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleThresholdTradingDays", "terseLabel": "Debt Instrument, Convertible, Threshold Trading Days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "nby_DebtInstrumentDefaultInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DebtInstrumentDefaultInterestRate", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_DebtInstrumentDefaultInterestRate", "terseLabel": "Debt Instrument, Default, Interest Rate", "documentation": "Percentage of interest in the event of default of the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual",
"http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r326", "r514", "r515", "r730", "r731", "r754" ] }, "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
```

gaap_DebtInstrumentIncreaseDecreaseForPeriodNet", "negatedLabel": "Debt Instrument, Increase (Decrease), Net", "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period." } } }, "auth_ref": ["r819"] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r81", "r352", "r514", "r515", "r754"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r17", "r212", "r326", "r327", "r328", "r329", "r330", "r332", "r337", "r338", "r339", "r340", "r342", "r343", "r344", "r345", "r346", "r347", "r729", "r730", "r731", "r732", "r733", "r754", "r819", "r846", "r847", "r848", "r968", "r970"] }, "nby_DebtInstrumentRedemptionPriceAmountPerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DebtInstrumentRedemptionPriceAmountPerMonth", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "nby_DebtInstrumentRedemptionPriceAmountPerMonth", "terseLabel": "Debt Instrument, Redemption Price, Amount Per Month", "documentation": "Represents the amount of a debt instrument that is redeemed per month." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentRedemptionPricePercentage", "terseLabel": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": ["r152"] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details": { "parentTag": "us-gaap_ConvertibleDebtCurrent", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscount", "terseLabel": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": ["r856", "r967", "r968", "r970"] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details": { "parentTag": "us-gaap_ConvertibleDebtCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsNet", "terseLabel": "Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized debt issuance costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r856", "r967", "r968", "r970"] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-details-textual"], "lang": { "en-us": { "role": { "label": "Depreciation of property and equipment", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r9", "r38"] }, "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortizationDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DepreciationAndAmortizationDiscontinuedOperations", "terseLabel": "Amortization of intangible assets", "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations." } } }, "auth_ref": ["r170", "r816"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r621", "r623", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r645", "r646", "r647", "r648", "r661", "r662", "r663", "r664", "r667", "r668", "r669", "r670", "r685", "r686", "r688", "r689", "r772", "r774", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r48", "r49", "r50", "r142", "r621", "r623", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r645", "r646", "r647", "r648", "r661", "r662", "r663", "r664", "r667", "r668", "r669", "r670", "r685", "r686", "r688", "r689", "r710", "r772", "r774", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963"] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Warrant liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r189"] }, "nby_DerivativeLiabilityIssuedWithNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DerivativeLiabilityIssuedWithNotes", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of embedded derivative liability in conjunction with Unsecured Convertible Notes", "documentation": "Amount of derivative liability issued with notes." } } }, "auth_ref": [] }, "nby_DermadoctorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DermadoctorMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals"], "lang": { "en-us": { "role": { "label": "DERMAdoctor [Member]", "documentation": "Represents DERMAdoctor." } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": ["r836", "r1020"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r859"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r404", "r407", "r438", "r439", "r441", "r743"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-", "http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "http://www.novabaypharma.com/20240630/role/statement-

note-7-accrued-liabilities", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities"], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals"], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": ["r6"] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r171"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023)", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r3", "r58", "r72", "r122"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r58", "r72", "r119", "r122"] }, "nby_DisposalGroupIncludingDiscontinuedOperationAccountsReceivableAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsReceivableAllowance", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals"], "lang": { "en-us": { "role": { "verboseLabel": "Allowance for credit losses", "label": "nby_DisposalGroupIncludingDiscontinuedOperationAccountsReceivableAllowance", "documentation": "Amount of allowance on accounts receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued liabilities", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "negatedLabel": "Accrued liabilities from discontinued operations", "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r58", "r72", "r119", "r122"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "verboseLabel": "Total assets, discontinued operations", "label": "Other assets, discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r4", "r58", "r72", "r122", "r171", "r172"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details"], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "negatedLabel": "Cash and cash equivalents, discontinued operations", "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r3", "r58", "r72", "r122"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "verboseLabel": "Cost of goods sold", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r70", "r172"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenue", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details"], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Less discontinued operations", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue", "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r3", "r58", "r72", "r122"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "terseLabel": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization", "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r70"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "verboseLabel": "General and administrative", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r70"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "verboseLabel": "Gross profit", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r70", "r172"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-summary-of-inventory-details"], "lang": { "en-us": { "role": { "verboseLabel": "Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023)", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "negatedLabel": "Inventory, net of reserves, from discontinued operations", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r58", "r72", "r119", "r122"] }, "nby_DisposalGroupIncludingDiscontinuedOperationInventoryReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryReserve", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals"], "lang": { "en-us": { "role": { "verboseLabel": "Reserve", "label": "nby_DisposalGroupIncludingDiscontinuedOperationInventoryReserve", "documentation": "Amount of reserve on inventory attributable to disposal group." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "verboseLabel": "Total operating expenses", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r70"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating loss", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r70"] }, "nby_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details"], "lang": { "en-us": { "role": { "label": "Operating lease from discontinued operations \u2013 expense", "documentation": "Amount of operating lease cost attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [] }, "nby_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "label": "nby_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent", "documentation": "Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "nby_DisposalGroupIncludingDiscontinuedOperationOperatingLeasePayments": { "xbrltype": "monetaryItemType",

```
"nsuri": "http://www.novabaypharma.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Operating lease from discontinued operations \u2013 included in operating cash flow", "documentation": "Amount of operating lease payments attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense", "negatedTerseLabel": "Other expense, net", "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r70" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Other assets", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r4", "r58", "r72", "r122" ] }, "nby_DisposalGroupIncludingDiscontinuedOperationPercentageSold": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationPercentageSold", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_DisposalGroupIncludingDiscontinuedOperationPercentageSold", "terseLabel": "Disposal Group, Including Discontinued Operation, Percentage Sold", "documentation": "Percentage of business sold for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other current assets", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "negatedLabel": "Prepaid expenses from discontinued operations", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r58", "r72", "r119", "r122" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "terseLabel": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r3", "r58", "r72", "r122" ] }, "nby_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "nby_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "documentation": "Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Product revenue, net", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r70", "r172" ] }, "nby_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Sales and marketing", "label": "nby_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense", "documentation": "Amount of selling and marketing expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [] }, "nby_DisposalGroupIncludingDiscontinuedOperationsDefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationsDefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_DisposalGroupIncludingDiscontinuedOperationsDefinedContributionPlanEmployerDiscretionaryContributionAmount", "terseLabel": "Disposal Group, Including Discontinued Operations, Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan from disposal group including discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r57", "r118" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r740", "r741" ] }, "nby_DistributorAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DistributorAMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details" ], "lang": { "en-us": { "role": { "label": "Distributor A [Member]", "documentation": "Represents information about distributor A." } } }, "auth_ref": [] }, "nby_DistributorBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DistributorBMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details" ], "lang": { "en-us": { "role": { "label": "Distributor B [Member]", "documentation": "Represents information about distributor B." } } }, "auth_ref": [] }, "nby_DistributorConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DistributorConcentrationRiskMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Distributor Concentration Risk [Member]", "documentation": "Represents distributor concentration risk." } } }, "auth_ref": [] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Deemed dividend", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r7", "r133" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentPeriodEndDate", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentQuarterlyReport", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r785" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentTransitionReport", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r786" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentType", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "nby_DownRoundFeatureAdjustmentsRelatedToPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "DownRoundFeatureAdjustmentsRelatedToPreferredStock", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Down round feature adjustments related to Preferred Stock", "documentation": "Represents Down Round Feature Adjustments Related to Preferred Stock." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_EarningsPerShareBasic", "totalLabel": "Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r196", "r218", "r219", "r221", "r222", "r223", "r225", "r230", "r233", "r237", "r238", "r239", "r242", "r462", "r466", "r482", "r483", "r555", "r572", "r715" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock",
```

```
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } },
"auth_ref": [ "r28", "r29", "r241" ] }, "nby_ElectionOfTheHolderPriorToTheDateOfIssuanceMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.novabaypharma.com/20240630", "localname": "ElectionOfTheHolderPriorToTheDateOfIssuanceMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Election of the holder prior to the date of issuance [Member]", "documentation": "Represents the election of the holder prior to the date of issuance." } } }, "auth_ref": [] }, "nby_EmbeddedDerivativeFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.novabaypharma.com/20240630", "localname": "EmbeddedDerivativeFairValue", "crdr": "credit", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label":
"nby_EmbeddedDerivativeFairValue", "terseLabel": "Embedded Derivative, Fair Value", "documentation": "Represents the fair value of embedded derivative." } } }, "auth_ref":
[] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-10-
convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ],
"lang": { "en-us": { "role": { "label": "Total value, embedded", "terseLabel": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": [ "r141", "r953", "r954", "r955" ] }, "us-
gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-
measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Gain, embedded derivative", "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period." } } }, "auth_ref": [ "r948" ] }, "us-
gaap_EmbeddedDerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmbeddedDerivativeLiabilityMeasurementInput", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-
valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement input, embedded derivative", "documentation": "Value of input used to measure embedded derivative liability." } } }, "auth_ref": [ "r487", "r488", "r489" ] }, "us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity",
"crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us":
{ "role": { "label": "Warrant liabilities transferred to equity", "documentation": "The amount of the liability for the conversion option reclassified to stockholders' equity when the embedded option no longer required separation from the host instrument." } } }, "auth_ref": [ "r51" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Employee payroll and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r79" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } },
"auth_ref": [ "r440" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r440" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation",
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-
note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-
outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "nby_EmployeesAndDirectorsMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.novabaypharma.com/20240630", "localname": "EmployeesAndDirectorsMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-
granted-to-employees-and-directors-details", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-
unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-
13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables" ], "lang": { "en-us": {
"role": { "label": "Employees and Directors [Member]", "documentation": "Represents information about employees and directors." } } }, "auth_ref": [] },
"dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation":
[ "http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressAddressLine1",
"terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] },
"dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressCityOrTown",
"terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressPostalZipCode",
"terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype":
"stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressStateOrProvince",
"terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype":
"centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [
"r783" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCommonStockSharesOutstanding", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": {
"role": { "label": "dei_EntityCommonStockSharesOutstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype":
"yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityCurrentReportingStatus",
"terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
} } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-
granted-to-employees-and-directors-details", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
"http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information", "http://www.novabaypharma.com/20240630/role/statement-note-1-
organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-
note-10-convertible-note-convertible-notes-details", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes",
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-10-
convertible-notes-tables", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants",
"http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-
11-common-stock-warrants-outstanding-warrants-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-
common-stock-warrant-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-tables",
"http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details",
"http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-
stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation",
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-
note-13-equitybased-compensation-stock-options-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-
summary-of-stockbased-compensation-expense-included-in-results-of-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-
compensation-tables", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-",
"http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details",
"http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-
14-distribution-agreements-tables", "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan",
"http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-16-
related-party-transactions-", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-
expenses-details", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-tables",
"http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting", "http://www.novabaypharma.com/20240630/role/statement-note-17-segment-
reporting-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations",
```

"http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-tables", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-tables", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-summary-of-inventory-details", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-tables", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-tables", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-tables", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-tables", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual", "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r783"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityFileNumber", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r783"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityInteractiveDataCurrent", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r789"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r783"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityShellCompany", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r783"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r783"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r783"] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r13", "r168", "r193", "r194", "r195", "r213", "r214", "r215", "r217", "r223", "r226", "r228", "r244", "r271", "r274", "r299", "r370", "r457", "r458", "r459", "r460", "r461", "r463", "r465", "r466", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r507", "r508", "r509", "r510", "r511", "r512", "r517", "r519", "r533", "r571", "r584", "r585", "r586", "r609", "r673"] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 0.0 }, "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "Non-cash gain on changes in fair value of warrant liabilities", "negatedLabel": "Non-cash (loss) gain on changes in fair value of warrant liabilities", "terseLabel": "Fair Value Adjustment of Warrants", "negatedTerseLabel": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r1", "r9"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-tables"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r487", "r488", "r750"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r951", "r952"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r339", "r379", "r380", "r381", "r382", "r383", "r384", "r484", "r486", "r487", "r488", "r489", "r498", "r499", "r501", "r545", "r546", "r547", "r730", "r731", "r737", "r738", "r739", "r747", "r750"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r490", "r491", "r492", "r493", "r494", "r495", "r500"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r485", "r486", "r487", "r489", "r747", "r954", "r964"] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as

appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r494", "r496", "r497", "r498", "r501", "r502", "r503", "r504", "r505", "r554", "r747", "r751"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r339", "r379", "r384", "r486", "r499", "r545", "r737", "r738", "r739", "r747"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r339", "r379", "r384", "r486", "r487", "r499", "r546", "r730", "r731", "r737", "r738", "r739", "r747"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r339", "r379", "r380", "r381", "r382", "r383", "r384", "r486", "r487", "r488", "r489", "r499", "r547", "r730", "r731", "r737", "r738", "r739", "r747", "r750"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r490", "r491", "r492", "r493", "r494", "r495", "r500"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r490", "r495", "r500"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r485", "r486", "r487", "r489", "r747", "r954", "r964"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details"], "lang": { "en-us": { "role": { "label": "Change in fair value of warrant liability during period", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r491", "r500"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details"], "lang": { "en-us": { "role": { "label": "Fair value of March 2024 Warrant upon issuance", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r493", "r500"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details"], "lang": { "en-us": { "role": { "label": "Reclassification of warrant liability to equity during period", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r493", "r500"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodStartLabel": "Warrant liabilities", "periodEndLabel": "Warrant liabilities", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r490", "r500"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r339", "r379", "r380", "r381", "r382", "r383", "r384", "r484", "r486", "r487", "r488", "r489", "r498", "r499", "r501", "r545", "r546", "r547", "r730", "r731", "r737", "r738", "r739", "r747", "r750"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r747", "r951", "r952", "r953", "r954", "r955", "r964"] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r11"] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 1.0 }, "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnSaleOfBusiness", "negatedLabel": "Loss on divestiture of subsidiary", "terseLabel": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": ["r470", "r816"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r104", "r655"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r104"] }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillAndIntangibleAssetImpairment", "terseLabel": "Goodwill and Intangible Asset Impairment", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": ["r842", "r843"] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-

```
equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r405", "r406", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r433", "r434", "r435", "r436" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusDomain", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r405", "r406", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r433", "r434", "r435", "r436" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r97", "r102", "r155", "r207", "r270", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r506", "r717", "r721", "r829", "r831", "r832", "r833", "r834", "r853" ] }, "us-gaap_GrossProfitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfitAbstract", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Sales:" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse", "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r9", "r37", "r121", "r748" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r124" ] }, "nby_IncentiveStockOptionsISOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "IncentiveStockOptionsISOMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Incentive Stock Options (ISOs) [Member]", "documentation": "Represents incentive stock options (ISOs)." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Net loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r46", "r98", "r113", "r218", "r219", "r221", "r222", "r223", "r235", "r239", "r466" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "calculation": {"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Net loss per share from continuing operations (in dollars per share)", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r98", "r150", "r196", "r216", "r218", "r219", "r221", "r222", "r223", "r233", "r237", "r238", "r462", "r466", "r483", "r555", "r988" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss from discontinued operations", "label": "Net loss from discontinued operations (Note 18)", "negatedLabel": "Net loss from discontinued operations", "terseLabel": "Net loss from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r59", "r60", "r61", "r62", "r63", "r69", "r74", "r140" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Net loss per share from discontinued operations (in dollars per share)", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r99", "r196", "r234", "r237", "r238", "r986", "r988" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r740", "r741" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r300", "r306", "r307", "r491", "r495", "r500", "r581", "r583", "r658", "r701", "r749", "r990" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r306", "r307", "r491", "r495", "r500", "r581", "r583", "r658", "r701", "r749", "r990" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r192", "r451", "r452", "r453", "r454", "r455", "r456", "r600" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "terseLabel": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable", "terseLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventory", "negatedTerseLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "label": "us-gaap_IncreaseDecreaseInOperatingLeaseLiability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r801", "r815" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-
```

operations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherOperatingAssets", "negatedLabel": "Other assets", "negatedTerseLabel": "Other assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedTerseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r8"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": ["r787"] }, "us-gaap_InterestPaidDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidDiscontinuedOperations", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Interest paid in discontinued operations", "documentation": "The amount of cash paid during the current period for interest owed on debt associated with discontinued operations." } } }, "auth_ref": ["r817"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Interest paid in continuing operations", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r199", "r201", "r202"] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-5-inventory"], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r296"] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-summary-of-inventory-details"], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r810"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-summary-of-inventory-details"], "lang": { "en-us": { "role": { "verboseLabel": "Total inventory, net", "label": "Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($204 and $264 at June 30, 2024 and December 31, 2023, respectively)", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r186", "r705", "r764"] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r157", "r175", "r185", "r296", "r297", "r298", "r552", "r713"] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-summary-of-inventory-details"], "lang": { "en-us": { "role": { "label": "Raw materials and supplies", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": ["r811"] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments", "terseLabel": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": ["r117", "r811"] }, "nby_InventoryValuationReservesExcludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "InventoryValuationReservesExcludingDiscontinuedOperations", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-summary-of-inventory-details"], "lang": { "en-us": { "role": { "label": "nby_InventoryValuationReservesExcludingDiscontinuedOperations", "negatedLabel": "Less: Reserve for excess and obsolete inventory", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [] }, "nby_IssuanceApril272023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "IssuanceApril272023Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Issuance, April 27, 2023 [Member]", "documentation": "Information pertaining to the date of occurrence." } } }, "auth_ref": [] }, "nby_IssuanceMarch252024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "IssuanceMarch252024Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Issuance, March 25, 2024 [Member]", "documentation": "Represents the issuance at March 25, 2024." } } }, "auth_ref": [] }, "nby_IssuanceMay12023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "IssuanceMay12023Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Issuance, May 1, 2023 [Member]", "documentation": "Information pertaining to the date of occurrence." } } }, "auth_ref": [] }, "nby_July2020November2021September2022November2022WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "July2020November2021September2022November2022WarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "July 2020, November 2021, September 2022 & November 2022 Warrants [Member]", "documentation": "Related to warrants." } } }, "auth_ref": [] }, "nby_June2024WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "June2024WarrantMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "June 2024 Warrant [Member]", "documentation": "Represents the June 2024 warrants." } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-tables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r971"] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r120", "r529"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-granted-to-employees-and-directors-details", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-tables", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-tables", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-tables", "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan", "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-tables", "http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting", "http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-tables", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details",

```
"http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements",
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details",
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-tables", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables",
"http://www.novabaypharma.com/20240630/role/statement-note-5-inventory", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-summary-of-inventory-details", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-tables", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-details-textual",
"http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details",
"http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-tables", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details",
"http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-tables", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details",
"http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details",
"http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-tables", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual",
"http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]",
"documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r523" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r972" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total future minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": {
"http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": {
"http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": {
"http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r972" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r528" ] }, "us-gaap_Liabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": {
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r17", "r78", "r79", "r80", "r83", "r84", "r85", "r86", "r207", "r270", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r469", "r471", "r472", "r506", "r630", "r716", "r781", "r853", "r977", "r978" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr":
"credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r93", "r149", "r565", "r764", "r820", "r838", "r965" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquityAbstract", "terseLabel": "Liabilities and Equity [Abstract]" } } },
"auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit",
"calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r80", "r174", "r207", "r270", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r469", "r471", "r472", "r506", "r764", "r853", "r977", "r978" ] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Total Value", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r486", "r951" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total liabilities, discontinued operations", "label": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r3", "r58", "r72", "r122", "r171", "r172" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit",
"calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total current liabilities, discontinued operations", "label": "Current liabilities, discontinued operations", "documentation":
"Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r58", "r72", "r119", "r122", "r171", "r172" ] }, "nby_LicenseCollaborationAndDistributionAgreementsTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://www.novabaypharma.com/20240630", "localname": "LicenseCollaborationAndDistributionAgreementsTextBlock", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-" ], "lang": { "en-us": { "role": { "label": "License, Collaboration, and Distribution Agreements [Text Block]", "documentation": "The entire disclosure of license, collaboration, and distribution agreements." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_LocalPhoneNumber", "terseLabel":
"Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "terseLabel":
"Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r821" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [
```

```
"http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r267", "r736", "r766", "r769", "r859", "r989", "r991", "r992", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018" ] }, "nby_MajorUSRetailerAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "MajorUSRetailerAMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details" ], "lang": { "en-us": { "role": { "label": "Major U.S. Retailer A [Member]", "documentation": "Represents major U.S. retailer A." } } }, "auth_ref": [] }, "nby_March2024WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "March2024WarrantMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "March 2024 Warrant [Member]", "documentation": "Represents the March 2024 warrant." } } }, "auth_ref": [] }, "nby_MaximumAmountPurchasableByUnderwriterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "MaximumAmountPurchasableByUnderwriterMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum Amount Purchasable By Underwriter [Member]", "documentation": "Represents the maximum amount purchasable by underwriter." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r310", "r311", "r312", "r313", "r398", "r447", "r489", "r551", "r580", "r582", "r594", "r622", "r623", "r681", "r682", "r683", "r684", "r690", "r699", "r700", "r726", "r734", "r742", "r750", "r751", "r752", "r753", "r767", "r855", "r979", "r980", "r981", "r982", "r983", "r984" ] }, "nby_MaximumPercentageOfCommonStockOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "MaximumPercentageOfCommonStockOutstanding", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_MaximumPercentageOfCommonStockOutstanding", "terseLabel": "Maximum Percentage of Common Stock Outstanding", "documentation": "Represents maximum percentage of common stock outstanding." } } }, "auth_ref": [] }, "nby_May2023WarrantsAmendedBy2023WarrantRepriceTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "May2023WarrantsAmendedBy2023WarrantRepriceTransactionMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "May 2023 Warrants Amended By 2023 Warrant Reprice Transaction [Member]", "documentation": "Represents May 2023 warrants amended by the 2023 Warrant Reprice Transaction." } } }, "auth_ref": [] }, "nby_May2023WarrantsAmendedBy2024WarrantRepriceTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "May2023WarrantsAmendedBy2024WarrantRepriceTransactionMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "May 2023 Warrants Amended By 2024 Warrant Reprice Transaction [Member]", "documentation": "Represents the portion of May 2024 warrants amended by the 2024 Warrant Reprice Transaction." } } }, "auth_ref": [] }, "nby_May2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "May2023WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "May 2023 Warrants [Member]", "documentation": "Represents May 2023 warrants." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExercisePriceMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Exercise Price [Member]", "documentation": "Measurement input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": [ "r953", "r954", "r955" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r953", "r954", "r955" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r953", "r954", "r955" ] }, "us-gaap_MeasurementInputOptionVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputOptionVolatilityMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Option Volatility [Member]", "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns." } } }, "auth_ref": [ "r953", "r954", "r955" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r750", "r953", "r954", "r955" ] }, "nby_MeasurementInputRedemptionInStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "MeasurementInputRedemptionInStockMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Redemption in Stock [Member]", "documentation": "Measurement input used to determine the monthly redemption." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r953", "r954", "r955" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r953", "r954", "r955" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r487", "r488", "r489", "r750" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r487", "r488", "r489", "r750" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r310", "r311", "r312", "r313", "r398", "r447", "r489", "r551", "r580", "r582", "r594", "r622", "r623", "r681", "r682", "r683", "r684", "r690", "r699", "r700", "r726", "r734", "r742", "r750", "r751", "r752", "r767", "r855", "r979", "r980", "r981", "r982", "r983", "r984" ] }, "nby_ModificationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ModificationOfWarrants", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Modification of common stock warrants, included in Other expense, net", "terseLabel": "Modification of Warrants", "documentation": "The amount of noncash expense from modification of warrants." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r788" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r267", "r736", "r766", "r769", "r859", "r989", "r991", "r992", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018" ] }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": {
```

```
"label": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations", "terseLabel": "Net decrease in cash and cash equivalents, discontinued operations", "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations." } } }, "auth_ref": [ "r111" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash (used in) provided by financing activities, continuing operations", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r200" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by (used in) investing activities, continuing operations", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r200" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities, continuing operations", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r111", "r112", "r113" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 0.0 }, "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r103", "r113", "r151", "r172", "r190", "r191", "r195", "r207", "r216", "r218", "r219", "r221", "r222", "r223", "r227", "r228", "r235", "r270", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r462", "r466", "r483", "r506", "r570", "r652", "r671", "r672", "r780", "r853" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "totalLabel": "Net loss attributable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": [ "r197", "r218", "r219", "r221", "r222", "r230", "r231", "r236", "r239", "r466" ] }, "nby_NeutrophaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "NeutrophaseMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "NeutroPhase [Member]", "documentation": "Represents the distribution agreement for NeutroPhase." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r788" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r788" ] }, "nby_NoncashExpenseIncurredToObtainConsentOfSecuredNoteHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "NoncashExpenseIncurredToObtainConsentOfSecuredNoteHolders", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Non-cash expense incurred to obtain consent of Secured Convertible Note holders", "documentation": "Amount of noncash expense incurred to obtain consent of secured note holders." } } }, "auth_ref": [] }, "nby_NoncashGainOnChangesInCombinedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "NoncashGainOnChangesInCombinedDerivativeLiability", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 1.0 }, "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Non-cash loss (gain) on changes in fair value of embedded derivative liability", "negatedLabel": "Non-cash (loss) gain on change in fair value of embedded derivative liability", "documentation": "The amount of gain on changes in combined derivative liability." } } }, "auth_ref": [] }, "us-gaap_NonmonetaryTransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonmonetaryTransactionTypeAxis", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Axis]", "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r530", "r531", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763" ] }, "us-gaap_NonmonetaryTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonmonetaryTransactionTypeDomain", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Domain]", "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r530", "r531", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763" ] }, "nby_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "nby_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "nby_November2022WarrantsAmendedBy2024WarrantRepriceTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "November2022WarrantsAmendedBy2024WarrantRepriceTransactionMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "November 2022 Warrants Amended By 2024 Warrant Reprice Transaction [Member]", "documentation": "Represents the November 2022 warrants that were amended by the 2024 Warrant Reprice Transaction." } } }, "auth_ref": [] }, "nby_NumberOfMajorSourceManufacturers": { "xbrltype": "integerItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "NumberOfMajorSourceManufacturers", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_NumberOfMajorSourceManufacturers", "terseLabel": "Number of Major Source Manufacturers", "documentation": "Represents number of major source manufacturers." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information that component in the entity's financial statements." } } }, "auth_ref": [ "r718", "r725", "r830" ] }, "nby_OfficeAndLaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "OfficeAndLaboratoryEquipmentMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Office and Laboratory Equipment [Member]", "documentation": "Represents office and laboratory equipment." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ],
```

```
"lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r155", "r717", "r829", "r831", "r832", "r833", "r834" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Operating lease \u2013 expense", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r524", "r755" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "Total", "totalLabel": "Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r521" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r521" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities-non-current", "label": "Operating lease liability- non-current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r521" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Operating lease \u2013 included in operating cash flow", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r522", "r525" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r520" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "Non-cash right-of-use amortization", "terseLabel": "Non-cash right-of-use amortization", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r816" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r527", "r755" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term (in years) (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r526", "r755" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-1-organization" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r56", "r139", "r596", "r597" ] }, "nby_OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Original Issue Discount Senior Secured Convertible Debentures [Member]", "documentation": "Represents Original Issue Discount Senior Secured Convertible Debentures." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r79" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherAssetsCurrent", "terseLabel": "Other", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r187", "r764" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r179" ] }, "nby_OtherCustomerFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "OtherCustomerFeesMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Other Customer Fees [Member]", "documentation": "Represents other customer fees." } } }, "auth_ref": [] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherExpenses", "terseLabel": "Other Expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r104", "r105" ] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r79", "r84", "r844" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherNonoperatingIncomeExpense", "terseLabel": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r107" ] }, "nby_OtherProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "OtherProductsMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Other Products [member]", "documentation": "Represents other products." } } }, "auth_ref": [] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "nby_PatentCostsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "PatentCostsPolicyPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Patent Costs Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for patent costs." } } }, "auth_ref": [] }, "nby_PaymentForProductSupplyPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "PaymentForProductSupplyPeriod", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_PaymentForProductSupplyPeriod", "terseLabel": "Payment for Product Supply Period", "documentation": "Period within which payment for product supply is expected from customer." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Debt issuance cost", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r22" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r109" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [
```

```
"http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan" ], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Text Block]",
"documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r376", "r377", "r378", "r384", "r385", "r387", "r388", "r389", "r390", "r391", "r392",
"r393", "r394", "r739" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-
equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment
arrangement." } } }, "auth_ref": [ "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938",
"r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PlanNameDomain", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation",
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]",
"documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931",
"r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946" ] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract",
"terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "nby_PostAmendmentJune142024Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.novabaypharma.com/20240630", "localname": "PostAmendmentJune142024Member", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-
note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ],
"lang": { "en-us": { "role": { "label": "Post amendment June 14, 2024 [Member]", "documentation": "Represents period after the amendment on June 14, 2024." } } },
"auth_ref": [] }, "nby_PostamendmentDecember212023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"PostamendmentDecember212023Member", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements",
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label":
"Post amendment, December 21, 2023 [Member]", "documentation": "Information pertaining to the date of occurrence." } } }, "auth_ref": [] }, "nby_PostamendmentMember":
{ "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "PostamendmentMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-
measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Post-amendment [Member]", "documentation": "Represents post-
amendment." } } }, "auth_ref": [] }, "nby_PreamendmentDecember212023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630",
"localname": "PreamendmentDecember212023Member", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements",
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label":
"Pre-amendment, December 21, 2023 [Member]", "documentation": "Information pertaining to the date of occurrence." } } }, "auth_ref": [] },
"nby_PreamendmentJune142024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"PreamendmentJune142024Member", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements",
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label":
"Pre-amendment June 14, 2024 [Member]", "documentation": "Represents period prior to the amendment on June 14, 2024." } } }, "auth_ref": [] },
"nby_PreamendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "PreamendmentMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-
measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Pre-amendment [Member]", "documentation": "Represents before
amendment." } } }, "auth_ref": [] }, "nby_PreferredStockChangeInConversionPriceIncomeStatementImpact": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.novabaypharma.com/20240630", "localname": "PreferredStockChangeInConversionPriceIncomeStatementImpact", "crdr": "debit", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual" ], "lang": { "en-us": { "role": { "label":
"nby_PreferredStockChangeInConversionPriceIncomeStatementImpact", "terseLabel": "Preferred Stock, Change in Conversion Price, Income Statement Impact",
"documentation": "Amount of income statement impact from change in conversion price on preferred stock." } } }, "auth_ref": [] }, "us-
gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockConvertibleConversionPrice", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual"
], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleConversionPrice", "terseLabel": "Preferred Stock, Convertible, Conversion Price (in dollars per
share)", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r356" ] }, "us-gaap_PreferredStockConvertibleConversionRatio": { "xbrltype":
"pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleConversionRatio", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_PreferredStockConvertibleConversionRatio", "terseLabel": "Preferred Stock, Convertible, Conversion Ratio", "documentation": "Number of common shares issuable upon
conversion for each share of preferred stock to be converted." } } }, "auth_ref": [ "r356" ] }, "us-
gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount", "crdr": "debit", "calculation": {
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-
condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-
gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount", "negatedLabel": "Less: Increase to accumulated deficit due to
adjustment to Preferred Stock conversion price", "documentation": "Amount of decrease in net income available to common shareholder for down round feature triggered for
convertible preferred stock." } } }, "auth_ref": [ "r232", "r239" ] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-12-
stockholders-deficit-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleSharesIssuable", "terseLabel": "Preferred Stock,
Convertible, Shares Issuable (in shares)", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": [ "r356" ] },
"nby_PreferredStockMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"PreferredStockMeasurementInput", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-
assumptions-details" ], "lang": { "en-us": { "role": { "label": "nby_PreferredStockMeasurementInput", "terseLabel": "Measurement Input", "documentation": "Measurement
input for preferred stock." } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock
and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [
"r772", "r773", "r776", "r777", "r778", "r779", "r1019", "r1022" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-
condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock par value (in dollars per share)",
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r87", "r354" ]
}, "nby_PreferredStockPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"PreferredStockPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": {
"role": { "label": "Preferred Stock [Policy Text Block]", "documentation": "Represents the significant accounting policy referring to preferred stock." } } }, "auth_ref": [] }, "us-
gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares
authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or
preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r87", "r632" ] }, "us-
gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": {
"label": "Preferred stock, shares issued (in shares)", "terseLabel": "Preferred Stock, Shares Issued (in shares)", "documentation": "Number of shares issued for nonredeemable
preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares.
Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r87", "r354" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-
consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-
textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding (in shares)", "terseLabel": "Preferred Stock, Shares Outstanding (in shares)",
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders.
Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r87", "r632", "r650", "r1022", "r1023" ] }, "us-gaap_PreferredStockValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": {
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
], "lang": { "en-us": { "role": { "label": "Preferred Stock", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock
redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par
value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r87", "r562", "r764" ] },
"nby_PrefundedWarrants2024PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"PrefundedWarrants2024PublicOfferingMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events",
"http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Prefunded Warrants 2024 Public
Offering [Member]", "documentation": "Represents the prefunded warrants that are part of the 2024 Public Offering." } } }, "auth_ref": [] },
"nby_PrepaidDueAndSubscriptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "PrepaidDueAndSubscriptions",
"crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-
and-other-current-assets-details" ], "lang": { "en-us": { "role": { "label": "Prepaid dues and subscriptions", "documentation": "The amount of prepaid due and subscriptions." }
} }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-
current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details"
], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "terseLabel": "Total prepaid expenses and other current assets", "documentation":
"Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be
realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r812" ] }, "nby_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and
Other Current Assets [Text Block]", "documentation": "The entire disclosure for prepaid expenses and other assets expected to be realized or consumed within one year or the
normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PrepaidInsurance", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-
```

{"of-prepaid-expenses-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r706", "r727", "r841"] }, "nby_PrepaidInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "PrepaidInventory", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Prepaid inventory", "documentation": "Represents the advance payment of inventory." } } }, "auth_ref": [] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidTaxes", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Prepaid taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r707", "r728", "r841"] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r807"] }, "nby_PriorToRatchetApril272023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "PriorToRatchetApril272023Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Prior to Ratchet, April 27, 2023 [Member]", "documentation": "Represents Prior to Ratchet, April 27, 2023." } } }, "auth_ref": [] }, "nby_PriorToRatchetDecember212023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "PriorToRatchetDecember212023Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Prior to Ratchet, December 21, 2023 [Member]", "documentation": "Represents prior to ratchet December 21, 2023." } } }, "auth_ref": [] }, "nby_PriorToRatchetMarch242024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "PriorToRatchetMarch242024Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Prior to Ratchet, March 24, 2024 [Member]", "documentation": "Represents Prior to Ratchet, March 24, 2024." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromConvertibleDebt", "terseLabel": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r21"] }, "nby_ProceedsFromDebentureAndWarrantIssuancesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ProceedsFromDebentureAndWarrantIssuancesNet", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of Secured Convertible Notes and May 2023 Warrants, net of discounts", "terseLabel": "Proceeds From Debenture and Warrant Issuances, Net", "documentation": "Amount of cash inflow from debenture and warrant issuances, net." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDerivativeInstrumentFinancingActivities", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities", "terseLabel": "Proceeds from Derivative Instrument, Financing Activities", "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments." } } }, "auth_ref": ["r198", "r711"] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual"], "lang": { "en-us": { "role": { "label": "Proceeds from divestiture of subsidiary", "terseLabel": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": ["r20"] }, "nby_ProceedsFromIssuanceOfStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ProceedsFromIssuanceOfStockAndWarrants", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "nby_ProceedsFromIssuanceOfStockAndWarrants", "terseLabel": "Proceeds from Issuance of Stock and Warrants", "documentation": "The cash inflow from the issuance of stock and warrant." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfWarrants", "terseLabel": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r5"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "Proceeds from Warrant Exercise", "terseLabel": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r813"] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductAndServiceOtherMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": ["r860"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r735"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r264", "r553", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r703", "r735", "r765", "r767", "r768", "r770", "r771", "r851", "r852", "r859", "r989", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r264", "r553", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r703", "r735", "r765", "r767", "r768", "r770", "r771", "r851", "r852", "r859", "r989", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r10", "r529"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r118", "r162", "r165", "r166"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Property and equipment, at cost", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r120", "r177", "r569"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r10", "r529", "r556", "r569", "r764"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used

in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r10", "r162", "r165", "r567"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-tables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r10"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r120", "r529"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r310", "r311", "r312", "r313", "r377", "r398", "r433", "r434", "r435", "r447", "r489", "r548", "r549", "r551", "r580", "r582", "r594", "r622", "r623", "r681", "r682", "r683", "r684", "r690", "r699", "r700", "r726", "r734", "r742", "r750", "r751", "r752", "r753", "r767", "r774", "r849", "r855", "r954", "r980", "r981", "r982", "r983", "r984"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r310", "r311", "r312", "r313", "r377", "r398", "r433", "r434", "r435", "r447", "r489", "r548", "r549", "r551", "r580", "r582", "r594", "r622", "r623", "r681", "r682", "r683", "r684", "r690", "r699", "r700", "r726", "r734", "r742", "r750", "r751", "r752", "r753", "r767", "r774", "r849", "r855", "r954", "r980", "r981", "r982", "r983", "r984"] }, "nby_RebatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "RebatesMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details"], "lang": { "en-us": { "role": { "label": "Rebates [Member]", "documentation": "Represents rebates." } } }, "auth_ref": [] }, "nby_ReclassificationOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ReclassificationOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Reclassification of embedded derivative liability", "documentation": "Represents the reclassification of an embedded derivative liability." } } }, "auth_ref": [] }, "nby_ReclassifyPrivatePlacementWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ReclassifyPrivatePlacementWarrants", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Reclassification of Warrants from liability", "documentation": "Represents the amount of reclassification of private placement warrants." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r268", "r386", "r537", "r538", "r559", "r566", "r625", "r626", "r627", "r628", "r629", "r649", "r651", "r680"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details"], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r208", "r209", "r537", "r538", "r539", "r540", "r559", "r566", "r625", "r626", "r627", "r628", "r629", "r649", "r651", "r680"] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r268", "r386", "r537", "r538", "r559", "r566", "r625", "r626", "r627", "r628", "r629", "r649", "r651", "r680", "r976"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r534", "r535", "r536", "r538", "r541", "r606", "r607", "r608", "r656", "r657", "r658", "r677", "r679"] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfConvertibleDebt", "negatedLabel": "Payments on Secured Convertible Notes", "terseLabel": "Repayments of Convertible Debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r110"] }, "nby_ReportingDateDecember312021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ReportingDateDecember312021Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Reporting Date, December 31, 2021 [Member]", "documentation": "Information pertaining to the date of occurrence." } } }, "auth_ref": [] }, "nby_ReportingDateDecember312023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ReportingDateDecember312023Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Reporting Date, December 31, 2023 [Member]", "documentation": "Information pertaining to the date of occurrence." } } }, "auth_ref": [] }, "nby_ReportingDateMarch312024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ReportingDateMarch312024Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Reporting Date, March 31, 2024 [Member]", "documentation": "Represents reporting date of March 31, 2024." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r210", "r211", "r329", "r357", "r540", "r550", "r557", "r709", "r710"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r450", "r701", "r721", "r985"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r449"] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAdjustmentMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "auth_ref": ["r213", "r214", "r215", "r225", "r226", "r242", "r481", "r482", "r518", "r793", "r794", "r796", "r797", "r800", "r804", "r805", "r835"] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": [

```
"http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r169", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r229", "r242", "r272", "r273", "r460", "r461", "r462", "r463", "r465", "r466", "r480", "r481", "r482", "r483", "r516", "r518", "r532", "r533", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r598", "r835" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r169", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r229", "r242", "r272", "r273", "r460", "r461", "r462", "r463", "r465", "r466", "r480", "r481", "r482", "r483", "r516", "r518", "r532", "r533", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r598", "r835" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details" ], "lang": { "en-us": { "role": { "label": "Restricted cash included in other assets", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r23", "r144", "r176", "r203", "r561" ] }, "nby_RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash held as a certificate of deposit", "label": "nby_RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure", "documentation": "Fair value portion of restricted cash held as a certificate of deposit." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r28" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r90", "r133", "r564", "r588", "r593", "r605", "r633", "r764" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r168", "r213", "r214", "r215", "r217", "r223", "r226", "r228", "r271", "r274", "r299", "r457", "r458", "r459", "r460", "r461", "r463", "r465", "r466", "r473", "r475", "r476", "r478", "r481", "r517", "r519", "r584", "r586", "r609", "r1022" ] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameAxis", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan",
"http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r742", "r795", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920" ] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameDomain", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan", "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r742", "r795", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "terseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r153", "r154", "r243", "r252", "r253", "r257", "r261", "r264", "r266", "r267", "r373", "r374", "r553" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
"http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Total sales, net", "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r153", "r154", "r243", "r252", "r253", "r257", "r261", "r264", "r266", "r267", "r373", "r374", "r553" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r267", "r798" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [
"r654", "r702", "r714" ] }, "nby_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ReverseStockSplitMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity",
"http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding." } } }, "auth_ref": [] },
"ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r788" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r788" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events",
"http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] },
"srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "auth_ref": [ "r169", "r213", "r215", "r216", "r217", "r218", "r219", "r228", "r242", "r460", "r462", "r463", "r465", "r466", "r480", "r481", "r482", "r516", "r518", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r598", "r800", "r802", "r803", "r804", "r825", "r835", "r839", "r840", "r950", "r973", "r974" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements",
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r229", "r403", "r791", "r826" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r28" ] }, "nby_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of
```

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, restricted cash and restricted cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r17", "r40", "r41", "r54", "r130", "r132", "r730", "r732", "r821", "r968"] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-tables"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r12", "r16", "r18", "r58", "r64", "r65", "r66", "r67", "r68", "r73", "r75", "r76", "r123"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r44"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r19", "r94", "r95", "r96"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r14", "r15", "r135"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r137"] }, "nby_ScheduleOfStockholdersEquityNoteWarrantsOrRightsOutstandingActivityMemberTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsOutstandingActivityMemberTableTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights Outstanding, Activity [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights outstanding activity." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r42"] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": ["r30", "r31", "r32", "r33", "r52", "r143"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r782"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r784"] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting"], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r156", "r243", "r247", "r248", "r249", "r250", "r251", "r254", "r255", "r256", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r718", "r719", "r720", "r721", "r723", "r724", "r725"] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details"], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": ["r104"] }, "nby_September2022November2022AndMay2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "September2022November2022AndMay2023WarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "September 2022, November 2022, and May 2023 Warrants [Member]", "documentation": "Represents the September 2022, November 2022, and May 2023 warrants." } } }, "auth_ref": [] }, "nby_September2022WarrantsAmendedIn2023PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "September2022WarrantsAmendedIn2023PrivatePlacementMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "September 2022 Warrants Amended in 2023 Private Placement [Member]", "documentation": "Represents the portion of September 2022 warrants that were amended in the 2023 Private Placement." } } }, "auth_ref": [] }, "nby_September2022WarrantsAmendedIn2024WarrantRepriseTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "September2022WarrantsAmendedIn2024WarrantRepriseTransactionMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "September 2022 Warrants Amended in 2024 Warrant Reprise Transaction [Member]", "documentation": "Represents September 2022 warrants amended in the 2024 Warrant Reprise Transaction." } } }, "auth_ref": [] }, "nby_September2022WarrantsAmendedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "September2022WarrantsAmendedMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "September 2022 Warrants Amended [Member]", "documentation": "Represents the September 2022 warrants as amended." } } }, "auth_ref": [] }, "nby_SeriesBPreferredStockAndSeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "SeriesBPreferredStockAndSeriesCPreferredStockMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock and Series C Preferred Stock [Member]", "documentation": "Represents Series B Preferred Stock and Series C Preferred Stock." } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details"], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } } }, "auth_ref": ["r808", "r809", "r857"] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesCPreferredStockMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label":

```
"Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r809", "r809", "r857" ] }, "nby_SeriesF1WarrantsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "SeriesF1WarrantsMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-
events-details-textual" ], "lang": { "en-us": { "role": { "label": "Series F-1 Warrants [Member]", "documentation": "Represents the Series F-1 warrants." } } }, "auth_ref": [] },
"nby_SeriesF2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "SeriesF2WarrantsMember",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-
subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Series F-2 Warrants [Member]", "documentation": "Represents Series F-2 warrants." } } },
"auth_ref": [] }, "nby_SeriesF3WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"SeriesF3WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events",
"http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Series F-3 Warrants [Member]",
"documentation": "Represents the Series F-3 Warrants." } } }, "auth_ref": [] },
"nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingCommonStock": { "xbrltype":
"percentItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingCommonStock", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label":
"nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingCommonStock", "terseLabel": "Share-
based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock", "documentation":
"Annual increase in number of shares originally approved for awards under the equity-based compensation plan expressed as a percentage of outstanding common stock." } }
}, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer
contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months,
and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r743" ] },
"nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverag
{ "xbrltype": "perShareItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageE
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": {
"role": { "label": "Vested and expected to vest, weighted-average exercise price (in dollars per share)", "documentation": "As of the balance sheet date, the weighted-average
exercise price for outstanding stock options and equity instruments other than options that are fully vested or expected to vest." } } }, "auth_ref": [] },
"nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverag
{ "xbrltype": "durationItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageR
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": {
"role": { "label": "Vested and expected to vest at March 31, 2024Vested and expected to vest, weighted-average remaining contractual life (Year)", "documentation": "Weighted
average remaining contractual term for fully vested and expected to vest equity instruments other than options and options outstanding, in 'PnYnMnDTnHnMnS' format, for
example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual",
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label":
"Restricted stock units granted (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Grants in Period (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit
plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r423" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-
of-options-granted-to-employees-and-directors-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Dividend yield", "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "documentation": "The estimated dividend rate (a
percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r434" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-
of-options-granted-to-employees-and-directors-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Expected price volatility", "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "documentation": "The estimated measure of the
percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about
the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the
standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r433" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation":
[ "http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-
granted-to-employees-and-directors-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Risk-free interest rate", "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "documentation": "The risk-free interest rate
assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r435" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Number of Additional Shares Authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based
payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-
Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } }
}, "auth_ref": [ "r745" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation":
[ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Number of Shares Available for Grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of
equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity)
already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding
awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r43" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation":
[ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "negatedLabel": "Options forfeited/cancelled (in
shares)", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of
occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r927" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label":
"Options forfeited/cancelled, weighted-average exercise price (in dollars per share)", "documentation": "Weighted average price of options that were either forfeited or
expired." } } }, "auth_ref": [ "r927" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "terseLabel": "Share-Based Compensation Arrangement by Share-
Based Payment Award, Options, Grants in Period, Gross (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } },
"auth_ref": [ "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-
granted-to-employees-and-directors-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average fair value of options granted during the period (in dollars per
share)", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "documentation":
"The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } },
"auth_ref": [ "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": {
"role": { "label": "Outstanding, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of
options outstanding." } } }, "auth_ref": [ "r43" ] },
"nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOfStockOwnedByShareholderMinimum": { "xbrltype":
"percentItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOfStockOwnedByShareholderMinimum", "presentation": [
```

```
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label":
"nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOfStockOwnedByShareholderMinimum", "terseLabel":
"Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum",
"documentation": "Minimum percentage of a shareholder's ownership of common stock used for determining the purchase price of common stock expressed as a percentage
of its fair value." } } }, "auth_ref": [] },
"nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber": { "xbrltype":
"sharesItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label":
"Vested and exercisable (in shares)", "documentation": "The number of shares into which fully or partially vested stock equity instruments other than options and options
outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [] },
"nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": {
"role": { "label": "Exercisable, weighted-average exercise price (in dollars per share)", "documentation": "Weighted average price at which option or equity instruments other
than options, holders acquired shares when converting their stock options or equity instruments other than options, into shares." } } }, "auth_ref": [] },
"nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTe
{ "xbrltype": "durationItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": {
"role": { "label": "Exercisable, weighted-average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for equity instruments
other than options and options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five
months, and thirteen days." } } }, "auth_ref": [] },
"nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding": { "xbrltype": "sharesItemType",
"nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label":
"nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding", "periodStartLabel": "Outstanding
awards (in shares)", "periodEndLabel": "Outstanding awards (in shares)", "documentation": "The number of equity-based payment instruments, including stock (or unit)
options, outstanding during the reporting period." } } }, "auth_ref": [] },
"nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": {
"role": { "label":
"nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice",
"periodStartLabel": "Outstanding, weighted-average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, weighted-average exercise price (in dollars per
share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan or equity instruments other
than options." } } }, "auth_ref": [] },
"nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntri
{ "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsic
"crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": {
"en-us": { "role": { "label": "Vested and expected to vest, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds
the exercise price of fully vested and expected to vest equity instruments other than options and options outstanding." } } }, "auth_ref": [] },
"nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber": {
"xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": {
"role": { "label": "Vested and expected to vest (in shares)", "documentation": "As of the balance sheet date, the number of shares into which fully vested and expected to vest
stock options and equity instruments other than options outstanding can be converted under the option plan." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-
equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details"
], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r408", "r409", "r410",
"r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r433", "r434", "r435",
"r436" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-
policies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under
share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r404", "r411", "r430", "r431",
"r432", "r433", "r436", "r442", "r443", "r444", "r445" ] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-
equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Employee [Member]", "documentation": "Recipient, of
award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship
based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by
grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r406", "r408", "r409", "r410",
"r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r433", "r434", "r435",
"r436" ] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedPaymentArrangementNonemployeeMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation",
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment
Arrangement, Nonemployee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor
has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee
when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term
expires." } } }, "auth_ref": [ "r405", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426",
"r427", "r428", "r429", "r432", "r433", "r434", "r435", "r436" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment
Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r744" ] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-
granted-to-employees-and-directors-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Expected term (in years) (Year)", "label": "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "documentation": "Expected term of award under share-
based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref":
[ "r432" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label":
"Outstanding, weighted-average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in
'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r136" ] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "terseLabel": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } }
}, "auth_ref": [] }, "nby_ShareholderOfMoreThan10PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"ShareholderOfMoreThan10PercentMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation",
"http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Shareholder of More
Than 10% [Member]", "documentation": "Represents the shareholder of more than 10%." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-
consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)",
"periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-
gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies" ],
"lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the
reporting entity." } } }, "auth_ref": [ "r114", "r204" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementClassOfStockAxis", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-
period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
```

"http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r167", "r181", "r182", "r183", "r207", "r233", "r234", "r237", "r239", "r245", "r246", "r270", "r316", "r318", "r319", "r320", "r323", "r324", "r354", "r355", "r359", "r362", "r368", "r506", "r601", "r602", "r603", "r604", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r632", "r653", "r673", "r691", "r692", "r693", "r694", "r695", "r790", "r818", "r828"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r13", "r88", "r91", "r92", "r168", "r193", "r194", "r195", "r213", "r214", "r215", "r217", "r223", "r226", "r228", "r244", "r271", "r274", "r299", "r370", "r457", "r458", "r459", "r460", "r461", "r463", "r465", "r466", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r507", "r508", "r509", "r510", "r511", "r512", "r517", "r519", "r533", "r571", "r584", "r585", "r586", "r609", "r673"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-granted-to-employees-and-directors-details", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-tables", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-tables", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-tables", "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan", "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-tables", "http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting", "http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-tables", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-tables", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-summary-of-inventory-details", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-tables", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-tables", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-tables", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-tables", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual", "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r213", "r214", "r215", "r244", "r519", "r553", "r599", "r620", "r624", "r625", "r626", "r627", "r628", "r629", "r632", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r645", "r646", "r647", "r648", "r649", "r651", "r654", "r655", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r673", "r775"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r229", "r403", "r791", "r792", "r826"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-granted-to-employees-and-directors-details", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-note-convertible-notes-details", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-tables", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-outstanding-warrants-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-tables", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-tables", "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan", "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-tables", "http://www.novabaypharma.com/20240630/role/statement-note-17-segment-reporting", "http://www.novabaypharma.com/20240630/role/statement-note-

17-segment-reporting-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-tables", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-tables", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-summary-of-inventory-details", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-tables", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-tables", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-tables", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-lease-expense-details", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-tables", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual", "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r213", "r214", "r215", "r244", "r268", "r519", "r553", "r599", "r620", "r624", "r625", "r626", "r627", "r628", "r629", "r632", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r645", "r646", "r647", "r648", "r649", "r651", "r654", "r655", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r673", "r775"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r13", "r87", "r88", "r133", "r601", "r673", "r692"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Vesting of director restricted stock awards (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r13", "r87", "r88", "r133"] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Shares issued for 35:1 reverse stock split due to rounding feature (in shares)", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": ["r13"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r13", "r87", "r88", "r133", "r417"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Vesting of director restricted stock awards", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r13", "r133"] }, "nby_StockIssuedDuringPeriodValueReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Shares issued for 35:1 reverse stock split due to rounding feature", "documentation": "Represents the amount as a result of a reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [] }, "nby_StockIssuedInConnectionWithExerciseOfWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "StockIssuedInConnectionWithExerciseOfWarrantsShares", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with 2024 Warrant Reprice Transaction, net of offering costs (in shares)", "documentation": "Stock issued in connection with warrants exercise." } } }, "auth_ref": [] }, "nby_StockIssuedInConnectionWithExerciseOfWarrantsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "StockIssuedInConnectionWithExerciseOfWarrantsValue", "crdr": "credit", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with 2024 Warrant Reprice Transaction, net of offering costs", "documentation": "Value of stock issued as a result of warrants exercise.." } } }, "auth_ref": [] }, "us-gaap_StockOptionPlanExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionPlanExpense", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockOptionPlanExpense", "terseLabel": "Stock-based compensation expense related to employee and director stock awards", "documentation": "Amount of noncash expense for option under share-based payment arrangement." } } }, "auth_ref": ["r9"] }, "nby_StockholderApprovalJune92023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "StockholderApprovalJune92023Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Stockholder Approval, June 9, 2023 [Member]", "documentation": "Information pertaining to the date of occurrence." } } }, "auth_ref": [] }, "nby_StockholderApprovalMay282024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "StockholderApprovalMay282024Member", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Stockholder Approval May 28 2024 [Member]", "documentation": "Represents Stockholder Approval on May 28, 2024." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r88", "r91", "r92", "r116", "r634", "r650", "r674", "r675", "r764", "r781", "r820", "r838", "r965", "r1022"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 (deficit) equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r129", "r206", "r353", "r355", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r370", "r479", "r676", "r678", "r696"] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.novabaypharma.com/20240630/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": ["r134"] }, "nby_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Warrants or Rights Disclosure [Text Block]", "documentation": "The entire disclosure of warrants or rights." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r513", "r543"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r513", "r543"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r513",

"r543"] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r542", "r544"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "nby_TLFBioInnovation2021WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "TLFBioInnovation2021WarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "TLF Bio Innovation 2021 Warrants [Member]", "documentation": "Represents information pertaining to TLF Bio Innovation 2021 Warrants." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-tables", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-tables", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-tables", "http://www.novabaypharma.com/20240630/role/statement-note-16-related-party-transactions-tables", "http://www.novabaypharma.com/20240630/role/statement-note-18-divestiture-and-discontinued-operations-tables", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-tables", "http://www.novabaypharma.com/20240630/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.novabaypharma.com/20240630/role/statement-note-5-inventory-tables", "http://www.novabaypharma.com/20240630/role/statement-note-6-property-and-equipment-tables", "http://www.novabaypharma.com/20240630/role/statement-note-7-accrued-liabilities-tables", "http://www.novabaypharma.com/20240630/role/statement-note-8-commitments-and-contingencies-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "nby_The2007OmnibusIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The2007OmnibusIncentivePlanMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "The 2007 Omnibus Incentive Plan [Member]", "documentation": "Represents the 2007 Omnibus Incentive Plan." } } }, "auth_ref": [] }, "nby_The2017OmnibusIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The2017OmnibusIncentivePlanMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "The 2017 Omnibus Incentive Plan [Member]", "documentation": "Represents the 2017 Omnibus Incentive Plan." } } }, "auth_ref": [] }, "nby_The2019LadenburgWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The2019LadenburgWarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "The 2019 Ladenburg Warrants [Member]", "documentation": "Information pertaining to the warrants issued to Ladenburg Thalmann & Co., Inc. for its services as placement agent in the registered direct offering." } } }, "auth_ref": [] }, "nby_The2021PrivatePlacementProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The2021PrivatePlacementProgramMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual"], "lang": { "en-us": { "role": { "label": "The 2021 Private Placement Program [Member]", "documentation": "Represents the 2021 private placement program." } } }, "auth_ref": [] }, "nby_The2022PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The2022PrivatePlacementMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual"], "lang": { "en-us": { "role": { "label": "The 2022 Private Placement [Member]", "documentation": "Represents the 2022 Private Placement." } } }, "auth_ref": [] }, "nby_The2022WarrantRepriceTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The2022WarrantRepriceTransactionMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "The 2022 Warrant Reprice Transaction [Member]", "documentation": "Represents the 2022 warrant reprice transaction." } } }, "auth_ref": [] }, "nby_The2023PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The2023PrivatePlacementMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity", "http://www.novabaypharma.com/20240630/role/statement-note-12-stockholders-deficit-equity-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "The 2023 Private Placement [Member]", "documentation": "Represents the 2023 Private Placement." } } }, "auth_ref": [] }, "nby_The2023WarrantRepriceTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The2023WarrantRepriceTransactionMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "The 2023 Warrant Reprice Transaction [Member]", "documentation": "Represents the 2023 Warrant Reprice Transaction." } } }, "auth_ref": [] }, "nby_The2024PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The2024PublicOfferingMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "The 2024 Public Offering [Member]", "documentation": "Represents the 2024 Public Offering" } } }, "auth_ref": [] }, "nby_The2024WarrantRepriceExistingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The2024WarrantRepriceExistingWarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "The 2024 Warrant Reprice Existing Warrants [Member]", "documentation": "Represents the Existing Warrants that are a part of the 2024 Warrant Reprice Transaction." } } }, "auth_ref": [] }, "nby_The2024WarrantRepriceTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The2024WarrantRepriceTransactionMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "The 2024 Warrant Reprice Transaction [Member]", "documentation": "Represents the 2024 Warrant Reprice Transaction." } } }, "auth_ref": [] }, "nby_The401kPlanContributionLevelOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The401kPlanContributionLevelOneMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan", "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual"], "lang": { "en-us": { "role": { "label": "The 401K Plan Contribution Level One [Member]", "documentation": "The 401K Plan Contribution Level One." } } }, "auth_ref": [] }, "nby_The401kPlanContributionLevelTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "The401kPlanContributionLevelTwoMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan", "http://www.novabaypharma.com/20240630/role/statement-note-15-employee-benefit-plan-details-textual"], "lang": { "en-us": { "role": { "label": "The 401K Plan Contribution Level Two [Member]", "documentation": "Represents The 401k Plan Contribution Level Two." } } }, "auth_ref": [] }, "nby_TheAmendedJuly2020WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "TheAmendedJuly2020WarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "The Amended July 2020 Warrants [Member]", "documentation": "Represents the amended warrants of July 2020." } } }, "auth_ref": [] }, "nby_TheAmendedNovember2021WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "TheAmendedNovember2021WarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "The Amended November 2021 Warrants [Member]", "documentation": "Represents the amended November 2021 warrants." } } }, "auth_ref": [] }, "nby_TheAmendedNovember2022A1AndA2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "TheAmendedNovember2022A1AndA2WarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "The Amended November 2022 A-1 and A-2 Warrants [Member]", "documentation": "Represents the amended November A warrants." } } }, "auth_ref": [] }, "nby_TheAmendedSeptember2022WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "TheAmendedSeptember2022WarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "The Amended September 2022 Warrants [Member]", "documentation": "Presents the amended September 2022 warrants." } } }, "auth_ref": [] }, "nby_TheDecember2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "TheDecember2023WarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual"], "lang": { "en-us": { "role": { "label": "The December 2023 Warrants [Member]", "documentation": "Represents December 2023 Warrants." } } }, "auth_ref": [] }, "nby_TheJuly2020WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "TheJuly2020WarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "The July 2020 Warrants [Member]", "documentation": "Represents the July 2020 warrants." } } }, "auth_ref": [] }, "nby_TheMay2023B1WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "TheMay2023B1WarrantsMember", "presentation": ["http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "The May 2023 B-1 Warrants [Member]", "documentation": "Represents May 2023 B-1 Warrants." } } }, "auth_ref": [] }, "nby_TheMay2023B2WarrantsMember": { "xbrltype": "domainItemType",

```
"nsuri": "http://www.novabaypharma.com/20240630", "localname": "TheMay2023B2WarrantsMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-
stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "The May 2023 B-2 Warrants [Member]", "documentation": "Represents May 2023 B-2 Warrants." } } },
"auth_ref": [] }, "nby_TheMay2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"TheMay2023WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements",
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label":
"The May 2023 Warrants [Member]", "documentation": "Represents the May 2023 warrants." } } }, "auth_ref": [] }, "nby_TheNovember2021WarrantsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "TheNovember2021WarrantsMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-
stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details" ], "lang": { "en-us":
{ "role": { "label": "The November 2021 Warrants [Member]", "documentation": "Represents the November 2021 Warrants." } } }, "auth_ref": [] },
"nby_TheNovember2022A1AndA2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"TheNovember2022A1AndA2WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants",
"http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "The November 2022 A-1
and A-2 Warrants [Member]", "documentation": "Represents the November 2022 warrants." } } }, "auth_ref": [] }, "nby_TheNovember2022A1WarrantsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "TheNovember2022A1WarrantsMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-
stock-warrants-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-outstanding-details" ], "lang": { "en-us":
{ "role": { "label": "The November 2022 A-1 Warrants [Member]", "documentation": "Represents November 2022 A-1 Warrants." } } }, "auth_ref": [] },
"nby_TheNovember2022A2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"TheNovember2022A2WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants",
"http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "The November 2022 A-2
Warrants [Member]", "documentation": "Represents November 2022 A-2 Warrants." } } }, "auth_ref": [] }, "nby_TheSeptember2022WarrantsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "TheSeptember2022WarrantsMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-
stock-warrants-warrants-outstanding-details" ], "lang": { "en-us": { "role": { "label": "The September 2022 Warrants [Member]", "documentation": "Represents the September
2022 warrants." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-
of-options-granted-to-employees-and-directors-details", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-
unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-
13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables" ], "lang": { "en-us": {
"role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r836", "r975" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-
granted-to-employees-and-directors-details", "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-
unaudited", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation", "http://www.novabaypharma.com/20240630/role/statement-note-
13-equitybased-compensation-details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-13-equitybased-compensation-tables" ], "lang": { "en-us": {
"role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "nby_TotalProductRevenueMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.novabaypharma.com/20240630", "localname": "TotalProductRevenueMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-
2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-
of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Total Product Revenue [Member]", "documentation": "Represents total product revenue." } } }, "auth_ref": [] },
"dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation":
"Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-
agreements-", "http://www.novabaypharma.com/20240630/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details" ], "lang": { "en-us": {
"role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and
arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r467" ] },
"nby_UnauditedInterimFinancialInformationPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-
policies" ], "lang": { "en-us": { "role": { "label": "Unaudited Interim Financial Information, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for
unaudited interim financial information." } } }, "auth_ref": [] }, "nby_UnderwriterFrom2024PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.novabaypharma.com/20240630", "localname": "UnderwriterFrom2024PublicOfferingMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-
events-details-textual" ], "lang": { "en-us": { "role": { "label": "Underwriter From 2024 Public Offering [Member]", "documentation": "Represents the underwriter for the 2024
Public Offering." } } }, "auth_ref": [] }, "nby_UnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630",
"localname": "UnderwritingAgreementMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events",
"http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Underwriting Agreement
[Member]", "documentation": "Represents the underwriting agreement." } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_UnrealizedGainLossOnDerivatives", "terseLabel": "Unrealized Gain (Loss) on Derivatives", "documentation": "The net change in the difference between the fair value and
the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that
was included in earnings for the period." } } }, "auth_ref": [ "r9", "r667", "r668", "r669", "r670", "r687" ] }, "nby_UnsecuredConvertibleNotesMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "UnsecuredConvertibleNotesMember", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes", "http://www.novabaypharma.com/20240630/role/statement-note-10-convertible-notes-
details-textual", "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20240630/role/statement-note-
3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities",
"http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Unsecured Convertible Notes
[Member]", "documentation": "Relating Unsecured Convertible Notes." } } }, "auth_ref": [] }, "us-gaap_UnsecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "UnsecuredDebtCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20240630/role/statement-condensed-
consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label":
"Unsecured Convertible Notes, net of discounts", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations
due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r78", "r146" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-
policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the
preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r34", "r35", "r36", "r159", "r160", "r163", "r164" ] },
"nby_ValuationOfContingentConsiderationFromBusinessCombinationPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.novabaypharma.com/20240630", "localname": "ValuationOfContingentConsiderationFromBusinessCombinationPolicyPolicyTextBlock", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Valuation of Contingent
Consideration from Business Combination Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for valuation of contingent consideration from
business combination." } } }, "auth_ref": [] }, "nby_WarrantLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.novabaypharma.com/20240630", "localname": "WarrantLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang":
{ "en-us": { "role": { "verboseLabel": "Warrant liabilities", "label": "nby_WarrantLiabilitiesFairValueDisclosure", "documentation": "The fair value of warrant obligations." } }
}, "auth_ref": [] }, "nby_WarrantLiabilitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname":
"WarrantLiabilitiesPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us":
{ "role": { "label": "Warrant Liabilities [Policy Text Block]", "documentation": "The disclosure of accounting policy for warrant liabilities." } } }, "auth_ref": [] },
"nby_WarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "WarrantLiabilityMember",
"presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants", "http://www.novabaypharma.com/20240630/role/statement-note-11-common-
stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Warrant Liability [Member]", "documentation": "Represents
information about warrant liability." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantMember", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://www.novabaypharma.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-
the-diluted-net-loss-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to
purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r772", "r773", "r776", "r777",
"r778", "r779" ] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-11-common-stock-warrants-warrants-
outstanding-details" ], "lang": { "en-us": { "role": { "label": "Expiration date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional
obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r953",
"r954", "r955" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-3-fair-value-measurements-fair-value-
valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right
embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r953",
"r954", "r955" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-note-19-subsequent-events-details-textual",
"http://www.novabaypharma.com/20240630/role/statement-note-9-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of
outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to
occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r953", "r954", "r955"
] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.novabaypharma.com/20240630/role/statement-condensed-consolidated-statements-of-
```

```
operations-unaudited" }, "lang": { "en-us": { "role": { "label": "Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted) (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r230", "r239" } }, "nby_statement-statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-granted-to-employees-and-directors-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-granted-to-employees-and-directors-details", "lang": { "en-us": { "role": { "label": "Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-10-convertible-note-convertible-notes-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-10-convertible-note-convertible-notes-details", "lang": { "en-us": { "role": { "label": "Note 10 - Convertible Note - Convertible Notes (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-10-convertible-notes-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-10-convertible-notes-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Convertible Notes" } } }, "auth_ref": [] }, "nby_statement-statement-note-11-common-stock-warrants-outstanding-warrants-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-11-common-stock-warrants-outstanding-warrants-details", "lang": { "en-us": { "role": { "label": "Note 11 - Common Stock Warrants - Outstanding Warrants (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-11-common-stock-warrants-reconciliation-of-common-stock-warrant-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 11 - Common Stock Warrants - Reconciliation of Common Stock Warrant Liabilities (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-11-common-stock-warrants-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-11-common-stock-warrants-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Common Stock Warrants" } } }, "auth_ref": [] }, "nby_statement-statement-note-11-common-stock-warrants-warrants-outstanding-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-11-common-stock-warrants-warrants-outstanding-details", "lang": { "en-us": { "role": { "label": "Note 11 - Common Stock Warrants - Warrants Outstanding (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-13-equitybased-compensation-stock-options-outstanding-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-13-equitybased-compensation-stock-options-outstanding-details", "lang": { "en-us": { "role": { "label": "Note 13 - Equity-based Compensation - Stock Options Outstanding (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details", "lang": { "en-us": { "role": { "label": "Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-13-equitybased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-13-equitybased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 13 - Equity-based Compensation" } } }, "auth_ref": [] }, "nby_statement-statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-14-distribution-agreements-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-14-distribution-agreements-tables", "lang": { "en-us": { "role": { "label": "Note 14 - Distribution Agreements" } } }, "auth_ref": [] }, "nby_statement-statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details", "lang": { "en-us": { "role": { "label": "Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-16-related-party-transactions-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-16-related-party-transactions-tables", "lang": { "en-us": { "role": { "label": "Note 16 - Related Party Transactions" } } }, "auth_ref": [] }, "nby_statement-statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details", "lang": { "en-us": { "role": { "label": "Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-18-divestiture-and-discontinued-operations-discontinued-operations-details-parentheticals", "lang": { "en-us": { "role": { "label": "Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) (Parentheticals)" } } }, "auth_ref": [] }, "nby_statement-statement-note-18-divestiture-and-discontinued-operations-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-18-divestiture-and-discontinued-operations-tables", "lang": { "en-us": { "role": { "label": "Note 18 - Divestiture and Discontinued Operations" } } }, "auth_ref": [] }, "nby_statement-statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "nby_statement-statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-3-fair-value-measurements-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-3-fair-value-measurements-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value Measurements" } } }, "auth_ref": [] }, "nby_statement-statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "lang": { "en-us": { "role": { "label": "Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "nby_statement-statement-note-5-inventory-summary-of-inventory-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-5-inventory-summary-of-inventory-details", "lang": { "en-us": { "role": { "label": "Note 5 - Inventory - Summary of Inventory (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-5-inventory-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-5-inventory-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Inventory" } } }, "auth_ref": [] }, "nby_statement-statement-note-6-property-and-equipment-summary-of-property-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-6-property-and-equipment-summary-of-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 6 - Property and Equipment - Summary of Property and Equipment (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-6-property-and-equipment-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-6-property-and-equipment-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Property and Equipment" } } }, "auth_ref": [] }, "nby_statement-statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-7-accrued-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-7-accrued-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Accrued Liabilities" } } }, "auth_ref": [] }, "nby_statement-statement-note-8-commitments-and-contingencies-lease-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-8-commitments-and-contingencies-lease-expense-details", "lang": { "en-us": { "role": { "label": "Note 8 - Commitments and Contingencies - Lease Expense (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details", "lang": { "en-us": { "role": { "label": "Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-8-commitments-and-contingencies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-note-8-commitments-and-contingencies-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Commitments and Contingencies" } } }, "auth_ref": [] }, "nby_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20240630", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "15", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480960/815-15-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role":

{"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(c)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-12B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.M.2.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "13A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r406": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
```

"Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",

"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-23" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":

```
"Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-5" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
```

```
"Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r790": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r791": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r792": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org/705/tableOfContent" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405/tableOfContent" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/450/tableOfContent" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815-15/tableOfContent" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835",

"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 97-0001437749-24-026386-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-026386-xbrl.zip M4$L#!!0 (%V!#5DO^2JY%@< &T>- 97A?-S Y,C(U+FAT;=U9 M;7/-A+^'/*C& [;VC.4)=E)>R,KFI%MQ7$O9[NV,M/[")*@B E(L H6?WU M?1:@7FPKCM.7Y)R))Q2!Q>YB7Y[=E0:Y*]1PD N>#G=>#)QT2@P'G?#<>8%_ M@T[8',0Z7>\1,>L62KQN9;IT[8P74BWZ$UD(RR[$G%WK@I='?L_*WT6_UZU< M>)UQ(WGI^J4V\5='3MRZ-E=R6O:-G.;NJ.!F*LL^T;>&@W@XOLUE+!T[].WW M!IT86E7#G8_(_^&> C\\18,[K\O8UL=/2;CK]TQ$:43YL$E3\;7D_,WYR>C MR?GE!;MZ?WWS?G0Q89-+-O[UY.WHXFS,1B>33UW_'U'M^OV[,>L=\G;OY2[? MZ_1>I>%3Q$8W;'1Z>349GVYJ_%64O!F'>,L==@_8Y1LV>3MF-Z/KX]'%^^9] M^>N[\?_(?+1ST.T>/,.HNB/A/& (_U[;)DKWE2D4L$<:),,%\YF.!@GQUSBXOKDA4+]J'4Z!P2E2(2UW"R(I. ?!.1N\+18 M2Z$,1"I";9)!!(DT25V-K,1Q:)(*P^:Y3')F,_IO??XNC&B8T 4*:17JBRRG

*M;"Y=C@O:2B1>0>);036=XIHS'$M9O-@TP[-W!N$CSA8LDR7,29Y9FR^"!T&. M;,.Q+\N,N#L)/K),5)V"}URT8:L(I5&+5@%"U-P4- HM?9^8WA[3S0"+)7$ M.'**6H$ +M?*
PBQ=GO3X)MSG+E)[;93P8,976&5R<<5H,>D/+;,.M=JG, VV? MO6=?[K/)'3-_Z]_'_1^.K*-[QK8IK#762;QZ@UTSK@1WA4PK8R5(),O ?_' M2MJ>/^E)/;^%54N4M0RP0?
T;)N!$BP66DRY,%97<$91!$ M]IP?,*"@8O#,RYIO8B00$;N'/WJ1Z*+8[;#H:Y H#Y"}!F)$V)WPVC[!"(%H M+', "11E* 95T;,, & &SJ3U>0T]47H^U%2L$6$358Q0W+NXP>6UFZ(&<6A3
AV@ MBI5*1MQY16,K4PG;T 5D|!X>YTKB5%M"=)\UL, 1P%M!13"':(/51RQE=2* M$WCA62E)=67 B5!G-LLC/L6"'!(5O," 29XXGVT(HOA]"3T[3!\'T]
1_@5\IS$5)8J80E1A1U04KD2"+BI$#L):5L"L M;S!VDCTVGG%5^QPEPXHL0^V7,YC$;JGAJ^+U!,P)K]O+N@\5' 1>V- \Q+IV M'|?@*:C(5]2"./LTVTCBY<]EX]^$2P!?8Z(^;?
G[11($0SYT"$T-S1%VN]L M]?IGX ,5$)TDM2&S;Z#U%JZ%M@[K--B#E\4,QWZK ?9@O?N1(QGB!YE[C[I1 M'$VH\",/34-EO=)K+VB5<[LJ;93S/MY$ZL'0VZ,!]@4&FP]"-?///?KH+YOH
M&XBQUO#5G^UN_6R?+H,Q6E_U1+[^BNR\2/27O?`M9A,[P@1)0D"$DZEEI^8_D0>;2K[IF<"_Z/H#W48@=,2'KQ+G73 MIX6!:4OR\A0'K5CEID?CHO6.3.18L0A?
IB45QL7< (,)*_3(.96^?ND>Q M&>Y\I69P!"3/#&(Z@F&$3T.8UG_%TO@@"D HRYE6,I%H6/)I\TV1:3)7%)72 M"X'=>,Y#NO(!'H9'_I92L?`=\JZ$U/(55^VQ43VN@5N\P8@?=@Y=?
\%+.-]4Q MXE68UZUN"Z"K5,53ZJM7[|;BR?+|\VTPEZG+\;'[7:.'6XG,]7GM|'+|_W03 M5EK^]Z(7 X<<>$'/="DR*.F.M7.ZZ+-><=O60>O_X>8GN109&]^3!*:!@UV&%B5B9V$B9"<8
E$X M/.8O*WYS2SG<;29#T(D5BZ;+V1MTY/"^-1N+[.!)*?NE\"&5,Y8H#-VO6^]& M-Y/VU>ALW#Z^'H_^]MN[EZ=O9E+A"GLZNSB_7_7TD !NFT/ M;-'QOQH/.OYGYC\ 4$L#!!0 (
%V!#5DU4 ?-_ 97A? M-S Y,C(V+FAT;>59,6 ,.!+ ^W/Z*@1?,30 YCI-V;O6]I<8$Z0;72W*)"^QJ MI"3*(BJ*DG9\?WZ>X.27^(X;,]HW46R;%!9Y'#X<%Z>&=KIU.79H!)*$0]>
MO^HIY3(YZ'?]Y^M7^-?OU)/I4,=S/s$JR;ID)IZU$%ZZ=B%OE\R-Z\Z72KC=6-MN;1T(6=TK7-1U(,!\D)6_5<>47>_=,W 5!@E"G=$A3:YR'J4"S-1Q1%Y$2=O M75MD;H(!HR;IZ[4&_7
PNDU5J!P==O<.^1T04,O!ZP= _;0!YZ?>"HC'<0=& M@Z(!P=.MP9LBM&7OL3TVMGC*#FLGBV3AI+FI)PYY,KH>GY^=GPS'YY<7=/7I M^N;3\&),XTL:_7;RZ_#BPXB&)^.O'?
^!0+O^\]W-P<-!FN$=]KNX-A30 M\(:&IY=7X}'I.N*.!,3-Z,L/IG# _@"[/;/SKB&Z&U\?#B]%-^WCZ/ L/EX MYF! _]E&T9T=S@=,ZSR?TT4BSZ=*SF2, MH_">@PD.)NA86!Q<
M%P0??R[T++)Q1 :U)8PLM7$4:VQ2:$<4-] E5D"CF5!7.5!*@A),YDH6-)4"T MR!HE,DI$A"%#.@>E.EW+W1,H9"2M%6;.(KGX++'OFDZ+L1A@L&7&1,U[L$"D
M3%3E$"NP'$AB:6B6JB@E6_%_J_4S:62CA ^0*YNAY*AB0C/E4AS0EC+R %EO M"6@ZQC&G6!93.%\WPI-W]N$CSI.4J +F9, ^LS!? TQ#'M%F.5T7"VIV"'E5$ M615#)URT9JL
[E4FFU;)"W-P<-!TNW4;!!K&+&=]+,4 MDGAT)&9HF.%'T-&R5Z\$;_]NV2N8PE/$&EQRTV7!Z5DND,(V$9(QO^G!X6T@S M'"%A&-4SH'7UV NN!Q.8W'-$/SD_P3>.+"
<;KO=?:6O\T##M8!(M"D$CPZ2 .V92,"F%VX(HQ(=O0-%<*@,R@8EB@<0R-VA)=?-BBX0-@*WT!5A50WIFM.-^:!%#@T; '7D$W?,[@NI M=IQL [\(>:<=IO*3]UQT?
+F$87A=R>Z=.9:<)P?U505)PC)$(\>:<,]=S'CZ*W M!5,TPX/:8K*#M=,[(A@="CHG1_'Q/<)XKXH9*\%?1RD12[]#N?.A]WX 1,3_M.R"D)9!,)':W0P5?=,J0D&,MD"JFZ]S6KF%-XCPG<#
MT\3T26'DEN'FG9)2>L4H-QGNQ=7A\@5X7M+OBL /[6TD,3B*LU]WIE_P,>%67XK*[_+V9O7S"/0Y_S%80<:,+U6>V3MP@:,.^,*YS/?>\[#-@=J=W9U
M&%\W.#DR,C@N;'1MW5=:,!LV%'YN M?L6!A(8)XOL)EMMOQX#BV*FWS/9L!=@>*8FRN%&D2E*QO5^_0!VM:1;MP>W-MRP !E'AX;1 .C8/49'PX2"F!AV+5KF>#5HE81#*>
(=+#MKL.+VN M)5*81D(RQG>[@&54PXQN8"DS(OJ.IMGOM.>U-_0K6D0 MSM:BI]@Z-?V,J#43/7N^-AR$P_$V92$ST.TT.X-6B!;EP[,OI?^5""7>/YW* MB
I#U4<^C\/+8#]9COQ@.1 !XF&Y>O<)7#"#"2/TS#E5V2\@KQ_H,B*<;+)7#"#"2/TS#E5V2\@KQ_H,B*<;+)7#"#"2/TS#E5V2\@KQ_H,B*<;+

+.^SPX$/9T3:7#K*9?878 M#$#N=SF[Q;'_[4DS+!O5KH6 E?V=*PEP^)28LF:$/$8]B4MYY8.+P<#>NE33 M;4,MBJ,JEW+C94{G,_@R??.*

*{Y9\]MKGT'1ZI1=MF\SE]!OQ!S>5MK:XM+V$;_M\&AIF5K\V?B!3SR6?V/>VHTI,WE!A>2QDO88<;Y6.WQ%WYLQ:=(AAEN*TH06 MWEY/;02DH)UE-.G1N'2[-*

:VZT=L2ZC=#%5+I)_5T36GLK1U 9;JH%.%5550 M&FBI@6?-?]'^FH&SAB?_!U!+_P04_" !=@0U9HZ^,$;5Z 0P@H %M &YB>2TR,#*

(T,#8S,%)D968N>&ULI;U9<^0XLB[X/E:S\VIJGI,KE5GKI=/W M6FC+5H]2H9&45??.2QM%(B1V,8@HD%0[^M0S8R0F+2D1\=[Z[NZQRA/"3NF"?/>_

MCF\NOYM\=_3QOWXZNO[RW=>]D^\^?OCXX^3#KY.C3Y/)__CO+,W__"_Q/_=1 M0;[C1.1%_<^_?_]8ELQ_^N&';]^^_>WYGF5_H^SAAX\?/GSZ8=/Z^W5S\=>D MW';8;_S3#\T?

*MTW?#/WM4]WVZ+???ONA_NNV:9&V->2#'QWPO[Y2NIE M0<%XMO_]U[/F"Y,*D M3)K/=:55,HQK"RN[LED^\6.%"M&ZG&.R3RJLM)^DE^.(R5X0^UK4L6W MKY6/$%M^?*

8KKX0;"S#S]_^O!#3373A'R$YDL95_0-GF!/^WI1<_M<6XQH[O^:68!\OO59#-03;7Q.%(T"6;IZ+I\?_GNK6@M5]<#3WDN23\+EAS MK U)&8W?K&6QV0L%B?

_V0}]^2$A:TR!^J,>F64V2_FO*/Y\($LZSZ&'SO2RZ M)]G?OYJ^O:GZR9LO4$.:+GA$_!E)'HA":DA9RV/_=)<68P)X6<93(;O

MLSPYY8O71IFF:8]4GJYW4?/M:\)2FISSWQ4M9&K;>J-3S!&,RC&F[$[^BW74?FVI2\:KRD78;+_+UU*;FE|8U^4W@H1:\:N&7U"&\U2*

M2:ND>>_4GO!#P:+L@HMWS_\/64G)E+3KGSZZ6-#\MJ3QG[=4/@VR9>]&(GG-,]4":?N=96 MO=-VD<>4|<-7"Z@U.SZA%6=Z^55 ^KE@78N$T9QF3X1+KE&:UZB(%K5O'=J*

M;\A#6O#;)"^OHH5!;MN;!4[=[2/),MWA;FO4/V6+,N.JX(+AX7(\FEMU\3MM M=!S12+L2/:.T,9MKF(^7B_T7I"<%"%O+7LIVSQ-6O1)Q4IFD4>;RWFVK$F/ M5-*

V2N&)\$HX^WM^E9:MN+VOB@;JSY_@QRA^(A(>HFO5(\5=]A91YNUKL#>3_%6>T(,G?ORJ9M86WMKUW=X#,&5VH MCP+5"8?

\$QZ!!P:.RQ:.Q0%'\@KB/G"_12UNVT0NT"L^U*K7|)N4SQ7)YE MM7OA[]\7Y&&Q)U. $>_Y)94K=_G&UDE-K(V>E[-FVD'[ZTA"PCI(UI(2M,F M$-TGM.@4IF4@MA_18E/;>X'P?*

*D(`3ZTF V'|C!262KL"00L%*30#G1R(|%>D M2$%;%!#C;T@Q:CTCT+O&36-3F&"@N2"*+PFH'!85/6-%;]*#8L(HG$)\V>EP@V2|#E"H6$53A0.(2@T?*

%)S@&T'189/-C-88BQ2>M M "+H.#PB2RP[&PH/GS2"RA0&@H/GP #C%;'L0GO2C2*W:@_ON'5YCX<\'Z MS[&)*3_[.9\5\5-!LS01.8B3^R@3.7F3XI&0LIC$S8&:+.NUF%1Y5"4I;*

[>A M79N"X^8SWC)T7)+,2P)/"!S$&&PRCXK[FG=4Q>0ABI8-820KB\UO=A2N?_&O M:1P+ WEQ'.V$]H0]? S6>|"Z;TA,TB=!S14I8=2KNOC&P&^"Y#-[M.,LP]2 M:*

*&HV_NE/DEJEL>OR"A-+O*3;)F6T>O 9%V!KOY07!>>?,D)?,'$ NJ;WC<7 M2S=!:J,'Z-3LU;8V U YFY^FO9(64?:9T6IYD<=9)10I_EL1MY+F_$#-EJ$O*

*M&$(@V0SH%?]\5#Q.\T3|\Y^ROBC.\C%-23,N3B+$5)_CW^-N)H:^@&O7UBRJ+ M"KX&M7;<>N/K&XZ%7F>R2B>ZZ6*1EHMZV?E&J'?V.\EC?NG(_A[>$>P-J,H*

MM[JDF6=:\R?"RI3+)?D7B/'J!M[I?N4JQY/D3" [PDE552/E0" O?PB@3/U MYA[0H[0?T>L,7/!=E?/OK+A4+*

(4'UL0KC7OI14)B2XNA.1T^%#8UMT6B;>V1X5"D=32]UYE8Y_7)*HV-X@*S50 M6"<,..+3W"KC?@&ANTH?]7ZF@]#^,<3 MK;"K:,F:XF64)E?/2V'FYK?#WF2J#/)!3\^(*_-*

*Y>HZB_*2DR6NN*50AN32 M%*2+5PPWI.1J)TG.(I;S4UE,X[A:5)GP/9R2>1JG,B3PCE[QW'(]@Q3'+S?] MEQ<.M%= #T&0'!BC$#9PR^"C5-*

KW[]X@\!MQ^&^DM),2Y]PV'H;2O(I6]D MF4Z@7H1$$S+6?9!I.U_Y7!YP641^$ %H1VD#2@0=+,-VA;UKFC'6]5C=Y_&'&7E01(7'[Q.3B)H2" M,3?IN2(''0-QLXZ"8]R"805)%/Z"*

*[*23$[K-&9A$F;X6737.4S(!!:X@$[\ M-(;1(K*!(OW12:*6"&QI>AVM UF2L*9&]+MHU.GK6!:Q+T@DZ:M0!N-M*P)G63L,&9LP/H3E&W*

*&L49HY.B>SCYHY&U'6UQI%*UW>4-3+= =X-#C=R0[L&*!]3):1^/TC*=,XRK:72L_%021?4FM$"7UH71(*!VB2K#/,OI- M;+)SRDYI=5_.]^RMJU>34]!EC+$D<(^-*

WL$3SM>"XG7$9JS6$D):9KPFK"Z$ M)P."[SD4IIJ,.W10J'RE+_[.KT21'(NLQ+(+HJC@U+]L/2SE\K=#3;H.DY M*

*MMG+4/++%1$/8DS7W6=Q@P+A%,X>JUG(1>M*Z0FQ3@M&%C76'9_O^B+!H,1A&8X,QNM@P M8YQ.CJ*_^*^. ^"S.H<>HKX[@_*=P4"_]MD$QH?,)W<34%NZ>ZX!_86CONRFE MP=-^N3*AX_<[RS_*1^;*XR/FIOQ?15F!#EU]72<{;PJY:.M6;!RSU+)_]6;5_X/D;V85"}[U8NQZZ=|$=V|DW^.H2&,)ZYVO .B^-Z6=Y%RVR?@6SM@1+ER]R%-Q*

*MXZPK2,@@P'KY1<+XG'+&.9=6.6UI,12%FNJ#BI:>(UBX[S9CWG&E"3HU)Q MUK%-N)-'LD [(1/#>6+-#E6A+1U'&1!I:[)D<44XY[R+G[=ER=+[JA1FZ3NZ M??&[D9E!<^!@?+2S8[XC.HSG%3VG9$>P!%%KF^&HG#Y%;=;LGSV[RCKS027K M=!QEF-+[Z^M3MB;2=L-2J[G+M.V'H5Y[A0M_3]I<$5S^I(>M8 &ZS1@M-]^*

*MZ0KZ+,_AFE|R3]*R8N24Q$QD/5_D+P[O!LP*OMF<6;Y15]J'!OK}GN_G'*1V5 @M% M8*=]UBNL###$=!D" X3H .D4KNN(Q:*LXREY(AFMBW:ICQNHCV<43X3+'QL! M5?*

#:/I+R\81KS'Q_LVT9#5'UB?!?P@43;,,(WF.P?(G8GV3OQI$ MTW<(,:P\%3!"T04%B3)E//_Z(%<58*SS.9O?'(I*;+3&'%?2MU<@6O<#-;+*

MCRY&%^9^01.,"UL"I($4,5T6N]##)&X/2P<0.X,T<8AVM@,<8@V?@\U)ZRI MB^\CQ!G*5\&E ,BSSLS6#<*?P\4M24HK^_M]26[ZW-#ZAKN=_3E!;VA;B_+L-?O6.=10JC[0I-*

TGL9K#6M]="$]AQ.=6@#2O MHWW<#.8%SPV)17FI+1F%-2C B-;(&DFV]>MM1+8^^&M-6C1=I@>,)RXP0 ?.MQAK#&6?Y$=5(8PIA),:VM^?HB'!WBM^L])R5&W=

*!'2O^NT^;G:\@ M0]'.FHK79W$V/^/C)PDTQ[U3?W=4KZ[KCY#K+(KK"U!:FN"=K.FK3U)3[N2T M8EQPO*X?=J@-P<+SS0K2E Y9\FEIH[7;-"*

*[[%O;;.I&.E83;S]*7P0OGCS]"!]##EW20+ ^N\>"?_=Q_7@-V3)TIC<\9^+]*9!RB;,_M.KJ@\]Y3$]9@@+@9JWWN5ALV=TDJFO$'O=-VEI7!>7G E\RE-JBB3%.10MO-/*

MI3@0M0(AA+C'=E"%65D+$8X/&3#5O]0Z!]$S!U0'\|HD)&OEQ@V$B[A"C-0 M01PU>Y\MZY6Y2!]_P17_=216<\|RA8$^.'8)Z7QX_?I8WJ@9&[W#QGJ3D+.^ M"V?

L1A@A%57YM>V!QXR.:H>XT6 Y74F]1=WHN<[H';/(%'7-.\]AFOG(TF. MI-0#^PV+YGCU-4__JKB\6\0LK1F]ZE ;=A\6VU6T(.H3HN\Q7@0#G_%7=#6: ML_FID?

7S6]&L=KL(N8CF7(A2KHBR[;BH'G0'C:,RC,$S2VC>5WK]"K.2:G5C MSUGUHW_9]LVA 4"@[.$7 ?!E-"1OH1W&2V*OF',!0:#]$V])'$ M"8G3I3EX-M-Z0H61]7:X8Q_1:QI

[[J=1S6H(152%!!D2C8IH-C1/+BW104'|P5A0"_C=>&=F!+$ MT"GW0(A=38IE#E*F;@>$*7R0H&"5$)_>Y-A\IRFTX43'5^%6#:IZA{E)S7 M>'"%5FTI'G5?7+L1Q5[*

*+$9Z#9US;Q&-0P7!/5=M8OE&PUN\1TH!,IK/B8.>2P MWTVO(T]T-O8 VD XWT;V_%* JS90'R.$G!=BH^PJ!>L)U$9[4+!(?XH#Z)^*

*M;73K,,83"5G1+M'8:/!:2H:Z,&ITM@BS=86&L,.S1A@O)'WJD^?MJ]P6[4@R M&!% *^,G?IP]F1I& ~S1E8H7:5_JMUMYZ3X4-NZUK"KXT70D,@)TH=1.470R M 0R6??DK?*

W6=8(@,@V!*/U5<.J{4ATP#T3IKU:3&J6GXB? 6?%7NPFV]H,D M] 'GRE\5*#<[*%!4!HC<7SU//7+K-'VHZ.'/YN88=$MJ/Q0S%GFK2^$+*$8L MTI=E'1(H7&Q2F55H)10T%L'-*

MB@%"\V$/W$TD)6 8M,Y1: M'!3[V&0T<%&YW02,I6#G9,D/>UX^D\CRI9P/-3OE'QY1.4\E0@LJGN^N6^D ME8\T+?UF@-)07-21FRUYXR\XR0H$]!@G9#@4*;D0KL=*

*I9!,XU#AEI?=+ZV M+U,1;S#/ZK>CK&0+5%W"I*WI*86K)"V&B((*? M'NC3#PE)&SF"_[3'UZ_!?U*+)#]N;-HXY0:9X*LGBK)<]H[A"F?!U$_4 JK#VI:U9K6%H-*

*Z8YD33I2:A!8[X9WLZ9/Z>POXJQK=![$O#]] M0*+GQR'6KSJNW\^YR.-*8+VCLWN1K.JW75$_9GE+^!]((M;P'\VEU4*J]5BN MT)B_4?D61==W+BVHOV8T)B1IGJ$B]WRRQ)*

J,D 6BBZ,4Y3$1CU4T-VAMS7% MZ[&W4R'E7^J& Q5&/N'+2,!OZ+5X6S_57BV7S,!V?][(YY0+!;5 ^>IY*6G] MA9NNAARN5+ (_\CCE>?2V$4:R-//'S;)]A4 M-

94=?\KOG+UX$I:?N'+S"BR_,A9IM9!- +2?W*3?,;%_PM=Y"G*FBMPXW(3 M^^ [^.4O]EI*D#H92[.:M$R&O[>X)!S%B7[X]G=AM? M.(=5/U"Z>ZAT#?/L..ZO:JXMD[/YG$CYSS!$/*

\JUY+'G3N]<\X'^1Z#,V& MO! <2IEW1B,DCHN<+UXEA#"%2UC><$!ZM96]=^BTH2U"UQ92R.C1SI]%+#9E&?;RB$&8^87.8 MY;>12$0]KHHT)]++^;KF7FDW>;A^6G)H[.X]A0-*

5V%V6P@C!I;'.RR$!ZW>Q MWI/S2@=QK69I,B.5H),+L3RWS .9V.63*5E?NT&0X*;LQ'".8T\.,FDZ\"8 M+K&.G?,OFRO92Y^!46QMFNOX9HWMU*P +/@NQ;]E7!?, 8=&5SX2MC-*

+%P61 M7GQFG02&=^7%UG45YR\4Y8 MH;[P>(20/'|_.+;CZ9:_XLXJEV%A\[I\S/H.1BBM(6GN4)+FFGI&@H&H[PAUD]!T6P4<.HPI])0/U!(2I0]Y MI[K$A<$2VQ2Y72!7%FUKKW-*

%XD0K#1.@LE:6Q5KQ99S"O9?H\DU!NX_"P[@' MR[94I9JZ/)(8DDR=;EUUF__"#;MA)=0F9PKI]K7AL0?R]I8V-0_5TAE-59K M%+*XG3,9<,UD*P,@.MYJ CQX72LL .?,7UU?7_O*SK4-*

*G#9_)8%]39MAPCVZNQ F M-#48Z7<_HIP&70@[.KG9]0I(P]H'1"<6NDD9O'J[_*ZG!!VQCD>[8&LA MP#-WT5FS9$<%),\"G:QJ-PM=@U31G0\K4S4X]AB=G& !:&]:C*/UT(D+CN:A*

M8S@F.AG"S71TS4A =U-8,0=PHLE8F ,$D(0Yj.-?Q\(5@!-@54]R+"S!<#. M(XG1Z1".#@,T P&=@.0&?]>D0W17@IOIP%;+#9UV,L9IEZ#9U1?HS3C]Q@*

MCV!.\V0O_>8$F/,4)1W0*2;..@(IR3H)&S[FN M(H]NMSN%N,\Y52]NHCLJKR*5NPGT\X)9 MSM=P$?P5O)MU#[^_F_GQ2D1ZMRZ& MS1"^,>Z4V)/UM=)$&ZM*2,-Z84&B+NT-*

[7<8:(:M5KY/7:&QF>B+^.N-!OZ0 M#[KV3:SQ5C$_CC+AU;I])8\>RDZMTM4>]EDE&N_(L[X3?EMH5WZH,'L.]2_*O/VW,+V]N@ M]BZH@AX>75-

K6K[FA3"SD^2$YD^$LY3[C%S14E?R*"":?5/!:&56A)"_:MDKP:RFYCDD=<@N.G;DGB=)Z21%H"6MMV'-3ZG^,-H7U#DN2D*-OY+;(H7DV< MS>N;5%T%4MIP+/0.6ZRR(6=]]\|83?*

*KP6*I*G^K:#T\]9/15/<,+8.B"P!MA MZ93=>CK.XZEE &\?3?,IHOO#BJ7;=&UW2*P>=*W M/!Q$Z-.J>"N8&6/4CG'8*/&MZ9.IP*X[0%>OF/;HJ9G@V3-A<5]0:Y;&ZE>T*

*M#'H.G&A)XI(DI^E3FI\N1%>2#-@N@%0%X+LCK-V4;]YQ4#O-!LCO-./7L+A] MC3"L.P^*JSX7'6$I^PZ*2I1TX?+0A M/-IP\(VP#G0?J$!C=<<(T!#*7Q5U8A+!:!/9Z',5;E=8[O#$BA?*

*GSVE;:CV$<MXYQI!7?)J+OYBQ&GB'|7P J51&Q-V?8P6-0J4\XO-804A8^G67(S\\G2SP.KP'#27BQNP M@. Q-#>-&\30F#(@[/#N2'AWI&4-5%46T/#++WM\=Z5\N:Y>RN76A*IJ&*

[NPU61%E-6> D.'I Q]4RZZI6 E$Y>A+" M&2I=\51T-XN9C MDQ@*$)E'P"*M]],T:'5$9B#@4;G!01C4T<56E$IR8XBUNUT;&1.'J/WU",*

MR'P\J^R0!$B\^^8EDF'PD2F;)]H8H/&J@7CM\89B5!\Z-1(@ZKY4(S(E$]# M5XW0V +<6/ @)0W\&@KZ"8K6E?2E#) ^SYRU"B'.J9HV03\66!V8F>R PXP?-*

MT%WC7D_25G;05ZZ%3A0R&Q?PO3V_1LKPX'!X$?)TM& MEE&.3,CSDF|4DRB/)G0\I&PB>"OHB7GE\3TY>$. S?3X.LMXLX$AM>)W]WK MQ-?-3CE;,Y11GLS$-

CEI=LFTWB2R"MF=^XLLJH_==E\?KU[7R7B%Q G#D1P9;+$#@P MO@VAA$*3%<8^!$3#OA03#!$(5(I@B,!@B(#5O3>Y6;@%.QN=$;,SU8M.PS=9 M*J\-"$=ED.I_;R.OM]-*

QX4WE?B!>?V5;.FQT4VT8B-E?H9...M;NBM,^RM&>$96=B#0W0 U 7K.D(1'K[M=:!P44I.G3W>4-0HY2FWP7?0[< JV'E_%_^[D\?_!.\OG.,NJO:%E?Z]=ZINHORA[4F1UK_YH48Z

M0RU_Q4.1^]0'65D>_].DW]712D[\#67BF6[+CV%CXI:[VPE6UP4N=]/|I[& M)(82[\9>4II562K6[*DK)04LS'I,D1R9GWO0W(R6QJ.A=Y!T%*$G)(0@Y) MR T]5S1?*

T)R4$5OM!>>\+N[^'@2L$Q(E=A, -]/Y0V@%DF[M:FL8,8O#E291*SBW;WB_LF4[:SWW:#:P6F&D?;S2J/91%WT9 MP^UONV3@Z!8@+;$?I=]&.WS#%A4(=/X27O\O$7TI-K*

*M4U3G#6H^\|@^TRB M^[3.)]N/^1^2*U]*7?"/7";D;ZH 9=/|!*?)/00D*N7?O+G?NC&!\NB*DF,;) M:19| !6EM3=)''?.>F3XT'9;84V[2XN)U>B8)UL*;KE!\VTO*RV?P+ MYH4V6R&?0\#C?*

*YT,5].QHUY-49(=AH0GLZAS('1=O>*_6?24X8Y[5Y,DT6 M7/H2RGZK-GL7W;_U.??VB$HXQ,<516:D>696V&XY.94J9HN5X*!T?N!Z M(UV0G3U6?%684.5[!- #*

*P+E*H#ZC!O%H+M*&"$DE@!5DT%H5$YQ>R/L= ZZ MJC>D(!%7O80AE#R1C"[%YH3,@Q?]C3Y2*V<[M#2U0/0R@ST^%.8-_:MB*!F^(W6'9;%WJ4V0\ !\5S0GMA"E8X2J*

OZK"@R= M^2A$RU>1N3[J7&^MFY1:^6HP034QJ!.FCM&M.VF=NI3<,,X+;W& I3PS'A MT?OM/(G&",$>LLQ-3#^2^D7F.%%G;LU'"%Z@I.ANT4\P3[@C3;MP$O^1"2(K1

MQ&"AVF=>DF+P9MHUDAX5/W)N]1@)C^G]DC,L,*7S>H?@#KI[-GL YPE/+ AA) MC(H/=C6.4,-4+'1,L _3$89Z1WC/^D'4PP!&;Z(YXQ!S8*L68NRB177";4VE M(Y%]*RJ*K8*

*B!=/%0KCN%ETYQ3F4Y>>R9&<7>.5-HNS0Z=A M&./MD.(!!/T+&H85RN88(PIE;#)_%=!D)U/H(/>5^- DVIBR MBLFE&.F Q'?U GHOI0 D*Q73>73&=Z1,1NZDQOTA+FBA:65-PPG?*

Q [F/XC\+ MP42$W;@XI^R:RQE$OS4E5E%SX M9.>$R%=3T]:DAN^F4O%]UO_'@H*\8_S,Y]4<3ECMX0[|>TDH5'5S!>-PA"^ M_GQ[[W^R5RVWGB9:C'#[2\"AY2/9" M^(2L|*

*_,YGM[65&90-DVI*B%%#7+!!&E2$B-I#%LT-Y9[IJ;4U!XH)?Y X] MG@!&BLX>W76EJ!:4$2K72M_;?"1.44AE,F(W6O>>W)/Z+*

5$3@F+>75#,W2/V\];SI1CM1^;9?;YKNZ$,4&5:W7A@NI752'7-QTC[L-50@VL5 M@1 ;G)3XG91 YDE-F=5H!5F06P2=NJA=$]H9FD1EU7"W6Y';VEPNK$0 'YUO

*M)AC@@@$.FP'.K58UC!GNYPEK,NHFM3]B4NYY?WSU!C>3;)&= 4#'.';)@+ MQJ1_K7-GK\5!T*CULH9CH7?@A[%VY&A>89(U'(S>_8B?X]7^7Y3&-],!4."#*

*MVTT[(C!!,7L'D%4Q>Z(!8L"P*OR!'; #KQLG1J7"%^9+ '=Y, K9_N=VZ&*QA-MP4(4+$0';"]+#,3Q3Z9,+> Q-&EI2)8F^&IB#%)X-0%!*@MDGF'T.VNQS*

MV^S_F\WYAZN!:CV#NAO4W:#NCE(Y"Y)SD)RQ2I[&5]P$O.Q_/0ID8)O.TI9 M),H342%3;(\TKT=RH?R,-L\V&,K1QN-ZE]X[TA=D!D.6N8S1F<

M;8\@_^U2\;9_'AU&V7M:2WITIM%.>@-&FQMPXU,7&B J&E!PGY4.?&Z$ M]?9&>]D<2)V_X'\S1A3\;_[>X7-HH1K&.??;I*CN"_)7)?Y%GOC_FKKA%"-X M=KAI*0FNM??*

*G6N/AKPXGG/4GJ-'UI3>]\)<7YT>;#4M+4+5W1\1%*AZ2A M*SH^0>F0-!1;L]@WP!:6U.T=V+.N4BB?)-_5-]=3)6L;SP_@ -M1!/_-G@B,94DAMOQO70E*N/I:H[.*D?*

EI>\LKM.QUJ%+)W/3Q2GR9I MQ%9J+%NS^Y7M0X!8"! +S]..1(7IU3G:07?"B%1W=5+CFPHK2C6+I-T%?TR M)584:F3&FU\(?!21!=-8+#Yf*$C U702T\G\|*

""$&*#;X]K+THY!!'M7%M M+\X#";TE[P*0-"@/@+P,)T<#MIHH>D.! M;']$Q8[TP56HN)&Y@9):1..AXTE.;;@C8%'VRZT+;P3"_0G-H0V)4<:(0F^4

MK$,"}-LIXRG(GW(ZRQE_G,4QX*!<+8P65+._KF2L?UA0Z4V-(HNS O8RRN2XZA(B]G\U?QJSDBWSGX# M^*/B<9HGXC]G?U7!4IY0]F0X&RZBO7U0TCSDM#0^Z28L_3_C-*

*D9;B)QD6?0_? M" H^DN!0N!Z"+9PQ%.9L+45R'J5, ""1D-F^9Z_6&DN QZNL5U6=*DV]I MEG$^R^7(*]<{S,R+0H"9=+F_BMJ]I8\KFO;>Y14W)E-K^D^<-E^D02$Z0V*

M0PU02_8N>@;BTC3W3+LP^.E &E'QTS;W2?LF5$$(N251 +R1 #Z\(KLBW/2&2 MT9S_&),]'@6#U748KUA?T:!1?#2M_5(N/.+\;DQIUB/"5% MS-+;SRB#U'$0SUC#4R?

EZCKCVC_ 8X0BL(3+1Z;=O6[(06)6"QTG%/R1#): M4W;VO"1Y093RA%/SX@X.ZX(WT[!TH3%)PY8)W,]O I80/;EN39(3NA!3V]BB MZL-0BSM"H^-7O!A<:OG/8J20?!I*

R;=?"R[YGQ5ENN"DR..TO:'HD_9 -R>F MW)D1)>R%4(0"C"F4 =+Z#FG@9T& &4$SO3/9KHJFZ0X79D=+'U9D#M%"QT M@?=FX%72C-\@5V?0"K=_48,NC_"YIXY(.?L2*&^N^*

.']!BK.#IP(^%>D MB+NIT(# ?T,*'&8|APH;6 6L;A9 *$JL,E97KQP4-S:1[^]H,>B\0)7&[\V7 MT'G)K09N]][@0+')9AVB#*%0L0EEA@&[4)A893)#[P@4+EJ!#!BE!<6)5?XR*

*M=N)!S2'81#'SP\H4JSBEU&$,10L-IG+F7,3,@%HA2M0 !44)58!RB@F$PH6 MFQ#E)HD)IA[JC:VP?)T6U6$1L-;%S;0Y?*9Q%AH^U67S 6<ZB&T)#+N.[RV6\|*

*MC1)4HG"'L*H_QZ)UYJA$)AI! C=P Q92RR9,{K^'S$XZ26+5}9,Y\CJ:7]N+&57!T'+(MAA9W*?=-? *_V?8\VU^:S97,\AO!%D3Y3=[@BN9&[\\|ZMGH;%?)'XL<|_:LB M:B/-(|>)B@K*

=E/2CK05D/RGI0U@\/67=S.XY0%O]`7A!$ MB?MQLF1D&:7)A#216L4DRL)+1\)FP@PHF54ST$GM.|[^'X5/5LZ@^H75#^5 M=WD=W5N'5YU$R[2,LO0_)+EN-

AWG'C.QTQIFTU)A7.9X=C1L4&"$A.4F*#$ M!"4F*#&'|2XO2T'$==_FJ2;--=,XKB\OU]Q6T='$*>#. T*;]QF?9\T.AI(M"#+*M'L3C(!X'\3B(QT$\#N+QX8K'W6[%0<3@GR?*

+=1V4VDI+-D50.LG$:J+1Z;=O6[(06)6"QTG%/R1#): M4W;VO"1Y093RA%/SX@X.ZX(WT[!TH3%)PY8)W,]O I80/;EN39(3NA!3V]BB MZL-0BSM"H^-7O!A<:OG/8J20?!I*

XBC;'V&2J/7%/XC6<_1!B/UU17=.6?Vl;JH.8""_^@V8H#4 M!*4&Y!TX)??EWGMQ<*^ KF,0_(/@'P3_(/@'P3\(_HA\/(PT>U69QO*

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j M((97(.UZU6#$#-4Y:6?5#B-]S*?;/*Z:E>C\]5T$3+1^0# AYT:&-U0..GZ M8X0'4E]ADZ4.W4:&,W#]PN:*]9;7)"'?H.-_D0%A+<9Z7#?4U!3B"4 M1V1T0I+5^?N$YOR%P!;C8W]H@2W^BM? (s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}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f!TPLX.([]P0TA+M"&DYO)"6+G4;L<:NT*KDW7)!-B;_U[!HP$CWJB?5QO.EH{CU?;'?Z2$\3O@<'75) MGDBF< 68=1X*UY<=@SMGY^^^Y";6>C0H^4MC=_C\$1?#I& M\!$9@D_&"#YA0-"VMY5.(H.>AX-H4,]7&WW%6T9KC%$[QF&CQ+>F-QL1&L9* M_%V#?RUD5H+,P(@5X."):77"fY!/A%88UK3?.6%!YU4S62O=1E?>.M!JALT_UO< S.LGXV.EC7'L5>UW/GMEG0[;38-WN?UOJ&G3_49FBU#]M>S&?<" MO=6LX!=Z<+$&%^OAN%C=NAW0,2$]^ YN"V2^X[W?B_]MLH^BHJ@6ZZPFQYYA MT^]A\)?MVHSMX==^=5W_,,1 MF#!5%Z>T?1%BW<='V!8A-2OU M'E(WM*;CGU6VXK_|<$6?ENWYX>/1+5F6FW|\W/O#Q_5=+7__T<%H#FIGB57C MOU6ECN@;.]!#3,4G[9PIVUE3<4V+FO323LM@ X.Z$HI MNZ,&LA2PAV/*P'L M'EU3:UJ^YH7PFV/DA.9/PK1]GY$K6A(Y2> <=^C=GM-%6BE4_KW_JE* M(%6C]6]^J'.4,M?\5#D/GY20[EM3/*(2W#\U'\U]G,Y3 MHDC?7M*Y'0^U_N=XXRG8D"0Y*H=[_;4AM9WWWSMA-^O!8JEY#TK4?GGK(]*MZC!?!T^^$;82E4W*OKAND,.N5ZM/T*4U(.MGA0OM1P)W9K6GBNGW9,DX5<*U]*>(I$@OG7?S^9Q_[AQ\Z\DT&R+QC[9[!]M+RD_&/G;OUT1667(SN,.C'8[^QJ#I\4(P^3-3)-_5T4IB-ER.&TFIZK/4%FI MV^FMN34L'U7>9Q@4>X%|ZTV2S/)M#/JQ* ?P-.?W!6'U.SKU[N%_IGG,>]4QM)]\QP;*\^OYNF$T7WQU4UC!*T3?KY!7';^9[!DQ8G!;DFJ6Q^@%?#@YX#(^*J M;\EOGK7D="L^6; = .@P'='6+M)S+SCH'B;5^W5-Q#+3M0^V#PZDM7DRY/"?,E\5L|S -T*3198A0MWZ'W5]//?^EJ!QNF)*0&<"U&X!PHC0+T;YRU O<\$

7WRYO2;+T7\,\YU0B3KGVZM!F'_Z%D9\F|%'6;WT0-~.I/2WWUKC.D-S1,67V:64>Z?U@GN=V64ERZP/Y!8.O[W-MK(Q2NY@?3VD;9V["J&6TAR\"T?(8247L4ACUGO^M&@@3 MCAA5 :\RX9V)Z9>2|OVHLIK-W&RY1T3VL#N!G>G5'|^\DE@^[/IK@BVW:Yj5-M9QDW%652[JZR%4X!U[>[=-LA-M!/H-M?X!R^%V4Y^)TBT|*XKM>@-?%9=?-G3)M? TB>4YB+N*W7/4/I-([7$WQ|H;?-MOIYP7_B:|=K],76I0))=0M-X7#M>#"?T+(8W0KS;'O^*Q(+)A*HUI-TRI[IV M_/6*@Z/Q57;,LHP#XV!_3LJGRR\T7R8%O5|!' :N92%PZ|E(9,@ME=8*Y5-M")"!0R5A+B)DZS7+-^+8/;(TF2C/^[1I!\YAB*TS2ISH:'W=),G_+M[_]\B$],6 MA+M:,!%;K2BI(70.O1EH6.:?+8$IKO;K'G|IA%D^&U<8L4C@2*x"1(1_M4T% M|9\KS-BMD/WF&^^NBX%0,SN+8*38'UE)[!FI)..2F40I/WR6PO9 MN|G,*.U19KT/$0JL!L"UT@(6Y)Z1!@_2(${J3$B%BG?1TUP"AN>KD8@5-823 MSM^2QRQ9)4LNTB?1)"S M!@]R4X'W+IA6EHC9YKMU(B MX<4RORBGY$YB!@=[!2U $XV4=40PI;_4RXR:W2?'KNYS2]ZRD7&Q*7W&3,;AS MB)OTX> MG*PX-B?/XERWIE&QS<5O,(D3.!V'S$WV!- IQ3"=x"\A<;%?M2G>@X^8K/50AJOG8:*=x=R#!0_$"Z.5'R MO@5PLP]^:"Y)DS_Q?C!^WJ?>YX;!MfF/4+SL4|_S?>]U:CR??6B$YU/[S!0C MW8C8'_GNQC8T+W=B5Z-_WR8;\5M|>5. 2< M%\D]?25$M\& P$[G)*XJRS\EH\H|=B28IR?R4\B#O4G|9D4(YOJ4UD5T'&0 M?H3TM+*O_%@O3_SU87=&@JJX-)/"JL-O1P+ [1KC.Y0X>ZH%;,R^8,#*K/)M5-ML9V$ZD=RX7;F4B!R(C AW>NZ&4FO^B)-"K-FYQW)\'?*P%9"CQYRB M[Q:5)[,JP5-_0@PW+A<=+/ @9PT>,O)?Y06:E%X]KK_;=*ZP<1?6,JGX8?0 MG>^'5OV0YY-RU(^AIZ2A&CB1USK/#0[!TX9LL64&B4/]I+S\U*$)W7+]^FI, M,ASM|7\|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|!|BIQ|&"CR.^"1^ MAX2*MQ[^_P/U/*P\FP$R?ISL/W)'/XT@B+>)H-I-[NT?#]DON#ET_GOH?Q1V_0)_?BC/>-^A MX.B7MY*&A>BJ"48"WLX5Y(X3L9"%>O*Y7-TX3W(U[GITM@*%F)'_C!Y)D6 M92+J?L@(?R'K@T#9O&Z 8.CG"*-@':I5&V -_S\|_X,XG#<(5W=N+6+=T-O) MX&_FJ-_VQ612G1VM_=RU%RP4G_:)ELDR"J7, TC,5+:?WD7V1]DZ^NMDCXC>I M^T-2Y=$4C(F*>2!/BVN5Q)83B&M^/15=1(9O#3?^0P;%IN8WDL;+HF#:$K+ ML2" !CE]!7>C(\W=$&;EZKS8IW<-]}85O8&_^TF$B +UM1$[!'UO>E2Q M "BIGIFQFIVT|!B^V:\M$53>O|$^9K^R_4Z2QZV_$"TY 0GS_2&B_0'M"N'L'C.F__W"A$S.[5I](9 /&) *!=+(@0)\HM$0[M8[/"C"OKEN.T^K^, M4)_TOD+/*2>(? 5+G22KFEUQ8\%7:)M";!C,0]5/'G?N#X2;M\,$ M QKFX2%TV^<)W]IG5/T&[JHB#9R&6TF:=!-JTF;F!H053:-CCG-Y,QM4\3RR-:?Z!GS?6VW6/YLX"'X1F!\7;1PV[H 3]GFI>V&[@KWYI? *_> MJ[^QJO?E88B

MN(Q;AY^_X[\^LNQVF]+35P_?GY[E^7V^SLKX71HJ'NB#TEA-;1B=T[4NC +7 MT0/+5"#.:QSZ"8 G /_DE)R!/7V4G2.A0E62B?=.OP!"?EU -;EA6DST<7UP MSO]ZG=^SS\/I38.C3:\.VAF]7QRTH(VN#4PHL'!I .)R\DT':XO#'J$H^^Z M8(A?1JI.94I%BNOUBF\Q_R[R%&[@GO&>\7]?B&*\=:;!BT %"SX%PB[1A.4\) MK!"JW>TJ9V7OLC:NJC? 7!6;1CI0'ZJVX5Q3!%/JG$KS<,BO+XL/@EZ]MX@Z'S2^RB#%B)\BGKG/ M=Y-&2V$\U/+T$%.9INMI@/2;M=62;|5]20_G N?W8>2]+\T/O70^]D%H$RO\YN3.M]-SR ;]0?&M-B84<4.$#T68TBUWOBD-3T[8JC[-M7KO_M[I[# M'BE"!"?U%K6+|I:R< .1#SG+E<*.>*J1LU#K?)A5LT MHR<,K=<+#C38E>O-R:/1=EW-9(>,QNTJ@CD-5P| -LT)\QZO&TD(^QZP4 MQ*8_*<1NY,J*?P*;VF@-0H4O:/DG[';@W*3A9TB MFP&88UX@:>@P79O$X\>EJ@&LO56SU'YZ4/99Y",D]QO;K/8\B2&7@T MJ388<5X:GM2U;G^(^'Z61*G(9BK@ H*O00PO2KJ'C5]"O4!4Y#<38Z/1]O.) M"Y_^.4\XW]YQ'#5>(VE^B=A*%"&X%JH.&@3PL/MDR1F15B)9VP[MX-C-YYV? MKO@Q W8;:=B'Z$WNWJf/UN:!#WG"V7T4%^:\O=QUGJ(E;CG:\K1>O6@\0\BR8--AP+9W*.M77>;_:%&IP$+IZ'4$PW5O:H>U]>JSU%OlW]4AM5F!5X88J_11N:KF[.2UN4EZ-ME55[QMRSBROE2LS@&@X8F$VNV8@=&N2*3/@IF>)5X;83HVK6/;=F%686=,3 M&V(_:17,*; 0IF^("OYJ;DA F#K/; BT2A7CL8%X@?9>C|A: M>ROEANU08/K L\S3>/Q7^?*7=8" [Y/7,INY4.Y'H,#T85Z#R?T M5W|W$##*NJ*XY_JA2N0U8HH2)L[*W@_+ U)GD3\Z/;CQ&&XE-#5I_TO6U(&Y6$AOV|!5ML0I5- _+*O^\RJZR9[[.#%S"@;U(Z1ODAC0ZMR]_ M;!0)C&MFBZH_2:HR^@A5D_3\M!KB;CX$W.M[FXI4./(2U"2?H?CF3>5O*<=@ M2R$7Y9Q!{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{6W(:G,P1IX?%\%'AN-+Z,<_+:B;,F=P*UXQ7-! M5\DR&=)Q)0_1[Z^F 'BHU%]#Y(<_.3+0VRME5C,_SR*7$$Y&,AJO*#/-&4; M<.O'4P:4OD$+VLC<[M_\2>#B!BENP0<2-!4N,Q3KO(G7831#A+UOH/#\Z,

{P(1DE[-U{,@GR@PL+L,MZ..[X,NVM3COF=)TF2Q-7\1HS1R>]=:G!!'K$> M4EEB&J/37)ZZ.2(:H;WXC)]B&B-$R-(G|B0Y\1 A3R,HU"**VZ) M; Q"W\A=7E:%U&D_TASGR=% fH(,!3_!,#HHQ-"'&*'321,VV@,,;!ZSK.@Z8 MH0-J"]0BAW29$*#BPU1R!PI!0(MAY:/@YB0KQ,:IM[Af'[_XZ5+T^QET2&B/ M 7@?)N?V7PQ2(X $!HNS|Q WT)8R#>QM6L[W<" (^"X!R6& H&9YEX9??4&VFB M>)O/ZE(OUX<>ZBZU1-.9^NN3,V\C20I3Y6%M<$4*6?2R-PXNA=2B -<(_I61# MU\WJ.GYD7+$7KV:*4WWP A[Y"G#E]LSF/30\@QH88)O5"-86{OAMT?$A+\L MQZ2!:3!+3F@+HBB&$@O}1/9LL@-)K2X$U@'>UO+ZOKCZ5[*$EBAV6!Z3'"-M2E[\W$75:7 K:|SNOCP,RJ[> (_JZ?HB&F\- ^OFF1T#]><,S M!_/;#:, \L\YH>@OBJ*319?,3%OF/WEPF8%)^__G,CN5L$F762]O+2T$RHIG]H2K9$VJSWR6]=6? MQ5"4R.P0!(%=/5GN5?^;&%;.*,+6N^:(C6&X:$G M50S 4JL-LEQ5I*CA++<%S:Y^'KU/M+X';({1>;W7] O@!V&1\-'5SY9WB&.2 MK'2%*)7AMX2>)#%C7MI9Z+7]]AGOQ_6]\0\A%GGOA-XM\1KJ0CZ3;.LUN:+A MCZHJ30@- T^>B0ZHT<'NQ@5>?Y"U:M0W>7CMJ#4FKFRWA0_J[(;#<&%0NN<MSMNA:TJB,]2I*TZQUIBMI[AK=(98;4XP=[+-9 M*&,9A=]4)XXFO@:Z<G<0=F#>7'"0 /<=\ZHP20WB$=MVTS M>0EZ@:,+1<>R"?C8GY[<<;X27ZA\D1>F93SI. LJ4^#-##EI=AC(HM&992HKE M=ENP-YS]YRXG?OF]#O4' 2[$Z 5WO)U;78Y\,\[I\N"3CNV TY6]7E/+D1/.7H&D)7Y] M+<0]+TNTZY[GS_@E(U;OJAF-A2]7.C!\,[-C),3Q7*.!?I>(1'|FS6PEF!5[-MG?B'=4[MR6\MO,3!:3^]#H|C1">V0DC^]'C,M0,R(EY:YBWQG<3G=_Q5G.\FU M)WZS%6^D;-^1X)N14U11O@'3!\Y2U<,_;V?8S@7*> 3"]+VSK) S3Y'TSP6; M]*|/I"Q_035.B&]01+XG_'?R:0+V4O*)^;ZD#15S)-_]4%INV"Z7;Z*^-1BB MHL,- E0(8R:.VFY8Y702[#EFX7"_S5/PA>C=R9@LE_2X_P-^RS$F\;9&FRW[3G-M(,,A';$,P)A+Z'LI7IAQ%1,?'16[&1/Q #E@9MfKR2IOY$6R"S[OKHM3UI:@5G MC_A9LQ9+BTOTC629^#,E&_&;E&S%LS#\|f1:HQ>"M5(0XS?BZ5%:UV-M*

N'X\,,4IY1_J)J85538/USI^YJS;SG"&X6@8$LCZ1Q@3G-A4*4%XAJCJ,K;-MJUGY[_:HMO$%$^AK3E6-G(]OE>3DWVC.R>-H MBR@3X82]LU#T51O:<7(Q1/?$6GS0]Y ?^6G:.3\1:P[0" W8(.+SR:^LFC+O+4IXS(I&EMP<5]2&.(ATV2.N]H8W709W3&V=;-1DF4X HI.NY)^Z-Z'_0EK*6UW.J3+>,4CO!3&^(9=5NG.2R3@VOV\PRUX3|87>+ MKG3UU '/*%_FB6S;4K.;@P(KDB\&M ^-$4!-9&3F4+DS(RC WB)V09&-_ZLI M)!2VF.S_P?7W#B;HGE6PSFM.%POTG/*V)6UU1-++T8GG2*75V!@-P,%R/UX+ MZ9%E--E/Q3Z-QD+[-}G|- ZZMS&?Y0\=-//9(88)^K_,' 00U6Q)FQ>> "9XO MU;&E8~EPJ}?F.'#2\}\3\43>,&_(Q"!)5 ZIPZ<$MKIH-E-JIP++>3:W M[$&2: U:AFFV33]1G$G)Y/_,=6&A.*:I3"AM&XQF%+_03/@3Q1DEBK"D0=!T M^HJ49ZJ[]QAX34 '4$F2/[VRMW]-"55G#__A<.3PO_S/;6V^_-<.%UQBL[T] M-C\Y9#2^-#Q61F;T? 9",@#;96TXI@!P6-6S4 D CJ2P0R8Y4G,/^05 M/S+N\H05'*:TN^43AC=BHQ7[&Y;2'1$W& 40?XW9O3NK)0KH"(<%DEB(<%6- M"1*H!),1 8?"@N8)W>*LCB#: M;S6V9+C01HIQ(N,B V@VK(&!.#;99?57B;6VC+=-$R\$3N\M^!UN2E\V0T M<F=C*(%KA]M&#X%L :",D%'Z.!:CSB!B#-%M+@)9<3>89"Y5/@;?(-)90$FY?!'X M)4. '^/0 H P.3^R|C+F%C!K0Z/<&>|Q9T^.R,V=,*GZJ4PMD/2<'V8'8,|>P2>"YR75&6;3K@$ACZU\ F<3AG2*7 * M&^H5L*?!QBUP@!/;+S H'LR$7\&.XVMSXW$XC2%9DW27$159%5VGBZ;>CY9?K_?B_Q^Y0L.*2?4! M/A-4ES"'Z%VQ:%"]0^T'I&3I)T=H(9Y5$3\@A=I?L,%5R(N*ATWF>XPZ!D_,;WW UW!KT/$-0;S\(MI MQ=:JG !^U*E<.3$E%M2'-5N;A&>26"#HL6W?"9[;8BR"PX M[DDOKE\ZW' XK@HB[_&F+!W]A|#. 'MPWG?^:,7%$#5 DH ;7$DGFF5C4G"Z2<64M!,Y5L")!!AAU]>O7MYWSQX.M')PJ,(G+&0Z?#%KH|R M^K^[NC;[F2W35/I(QRW:;(MEQP"4*,R1V"/R M=B]ZF/>M)B)"QV='.LX\+**=[LW2%L+H+A__$*),|TIH797N0)5-(-B&ZY'U M$Y&-?"V:)A=2-!]D'PVBC.0%RLW:*KLD%> B.Z47>NRX(L'%:9+SO2K,<=0^ M&'EF;$X(C7=63.P4LU[0fYU\R|CT*Z;Y0WZC>1WPPX5M7K@<!E=ZV51"?FB*(DIGDT/G@-P'AC#!GU9&<(0N!QEK"S1NU>,V"M1&MKI&//"M*@;RW"1&RTQ.=UP-M/MEA4W;331AM MO<9^,D^&RXSU(Q\VRYP4#("Y,A_UPX% &U@I+M48ZR#28UWY^9$S0Z}!A\8(M8%AI9.90|20C*(#>)W=)$<"4:>"K33>+++A8ZXL, `P8=BT):R,Z&-R2-Y(Q MV<1-)^IO,! (EA]["T"/1,4 M-!Z@DAG!B>$Y=FI(>;,6^L&6(0\PSL?Y%%[=@LDGLUX&NP[< FJKKCT43_1U MS4\ 4B2TY++!WA:"'K/CNM4!>ES!?DC?>2QH0E3!.X?Y660H]9R@@-& M(]0 2H@>_P;HF&X\KY2ZZ+W5R=;3."U0_0(1PO-CV0GZEO'G58_XMJB]KW MTU*FI!$-/WWXL/R^<*?)#-R"P7(9A1+_K7:(AL7"-0_,24GKG\3QH!X08C M@<#)R

M5&\LTGQOQ%I5I^37'CR4JFL30AGSR9YS'I%<30_'ZQ.++\;^:P?-KO,.AH>X-MIW6.RK<7K31OPC'L<{E?A+_-#>AJE*II-<_F,BC@MT6V1QORG9"1Z6N:(*
MJ/.54>;3=9J@/+FCEG4YQD0#,,'?-RJZS5/R':WRTP9#_XXS2WEWB :SRUX2?RQ^&K&Y6>7F= 2;@-MH3N[V"+M7/%!W"%4SNJ7L?W8=LM9/L+VH3Z^^?KXXTIG")7G0^5Y66!"Y?
EW-M5WD>?N/@-ZXPI@?2%U-D/1U8B0'&%_#$_MZW*TKL7/4%'9C7J6M%F3'J^=H*S-M4!'#\FJ/+)C(>-L%9QO7<#YVO,1Q0E@J[&GL> @4A;ZE-O5'^U+!1>'6XKLV-M?
%;:BV!PTY\04>)('[*0/"EMH!;J#!#'7PITZ,6JLZ8"E]6%: B/"R\U9<3 M':3=.5.E?=E/_$*B@<$SL2\,D* ,+9 PIJ,##(9L+MK8@9$^0B0RSL9^E(7 MC616,1<07D'U?
#=E,W,1),#".%K%6L&"&'3*.+ABXX 8+U1C[U:S'''BJ,2O3E M9AH"$C[.::>SWDPJ$ %XOIP^0V"''!O.._0:#:4_A&0:O3EKMSS XOMB'7<.P M&'HP5HX_,* !*U9P+IY[.)*@0Y8M(
EXIRNJ"@!%5M$H\ M>#F)B@&"@7"T5CP<'"%$92U^N<1D3IDI'R"FU4\2E(.%"OJ.!,_TVCD)@ M'+VHI;?1P#}\)(7DL+HHO<'X%7+AF#BL2H(W%[,M2\;2^)5%WZFV=CM+%)I
M#BDHJFL(1"MH[-8I%59R2*477W"22C00%83T12P&-M9R-*%S>'(S1VFQ;P_3%?;FI!%9 #6(X-F.W\&?SANJQT!\Z*!I8-?1\Z.' M*>8F/+#;=1V+ZP-?
$#+ZKNZ/$_*=590F$_2\0N1V+'=1GDQP]82**'/Z;9+F:_(O7&SD-*J.CJ8U)B80)02-Z'QJ16Y+Y^+FPI%M<{W9Q!VD,)B!=
M@GX4]*.@'P7I*.A'03*^I%U_4C^ZK:D$OT\615XA8[TSA@T%\UN])_E=:/ M1*.85!9@} 3-2:/F=(Z7]YK&?'(*XH*-LJ[@P\8-W&[_>-GX.;+W>71=Y6A&"R/JX2[13V7G2H)W,$K_
M#8I*1&NT72]IA;9VWW$9 /0PRL'M]E*ZS:+F:-OOS;.-X&$XB9YN< 2W;O09 MP@T>WS[T &6-]41$L-\$^TVPWP3[3;#?*%P5,G3 M7$I]5#)?$CUZ[CJHS@&&R=T^0K2M9(
H;*T=3Y@2L*K 3ZN)1<S'.,VY ! 3W!8AX MD-IG&.;X) M$;?1AAZ#9@#M/VI5U!|8LW$XW<+3QFNO'ST%(HPEFQF!F#&&8&8'K'X&',RT5B9%9%4#@GX& MDC?/#VN*
[/CSXQ4%5\OZ#3))>76;\'-1M+&AC01L+VEC0QH(V%K0Q!6Q(2*5 M9)27LTV3>7@_Y8D*X2M<[_&#|,4RK7!!]@J:E4=.B3YV/"(#,@+A8/HX#P3I((,X7-"?
FB_W4E+1;H@G\EHG=JF\":U:MVC/,7%_9OB MSQ?HD1#!S$)1-M=(MY@KAZ>Z +_>%ND:X+<;1,%B)N%!6JOBJKM2KM#*_H^]@/Y MN:3')?NR0G%;U5A?N1!V\|%,.1A7940>?
^R0_(V01|/X@1W\W(|JD*L,LV)WI9|,883OD5G97INJA*@AUF+&WJLKG-R/=5-A"L,>'9# MB_1^B9;\S#!1\ %KU=DED1(OQ\Z\&<$/;MYGH"I_-CZY"[NZ
M=PP6=/,6=/5TUH]EF]11L3F:>,Z1+VP?|/_|_O)*CF#_WR'R/NS_'+$0RXIA-MOF ">Bl;6B'P!1WQK8+[2RC>@"3T*0$585^<;. WZ'L:LGS)R0.C!7 H^+)Z MQ-M)9-[P!0G^?
=W7N.1+EOBP4T852(IGAX-!@K@*?3EUQ?M*S|NLCKXXWV.M M"/VY8$P0|BK,JK\"""^DJA(\P$?0.@3FA<"\$)BGC8?7MYW@J091<^NT<|>_N$,(
M(0PAA"&$<+#PJ<0@A#"=5(80PA! JP40IW&!Y4<(7;$(88AX&D%DM,.^/S>» MR(ZO)?&N@FEON !N:9Z&0]IV6G!NQZ\Z&\&'KSKVKWK<(Y+8_Z25/.%^>3
MDN[VR;=MG)ZD5UTPBG'/.HB>X%W7Z%V?+AML_UEG-(#X@[X"ZB]*JJ^T'?0 MVLC4D]V7+-I]1$:I13TK(:*"PG9$(H*.SY%31Y$L:RQ'L(#EP)S7Q>R>?;[($Y8]U -RU*.R@**
[P5/Y$E.OH.?PC M^8]L:@'MHI"V+MD:0) ^XFQX.3Z$WM%|P.)1+'F>< ?@YL)0I]15J.SS7Y3-BN% MLQ- ?>QP<900NPV42&;Y'0VQ*=)\<1:5:?DUQX\E*M;48+Z-H(AQ'I->C7;[MFB?
NGC+VW1#Q'Y[="S'(68^Q.PK7Q6AQ"P/"=A=CZU=B;[@^'K4NE!U'?'P M5SOE(AT/\1:WLIQ^$\9:$'66S POA33A)!0P<#X4E%36>2&#E?RFPJ"Y$"
M(^=+/4F5E6T_>8*)E%,$+APZ+BfWAD?-(7[BB_L[_^2+,-TI@ (.E2\B MMMH 4#A^HGATN%B<)1\DA6S9['HZ0+U*U?"X-'",/Y&IP'#<<'5|$ZQY10[Z$
M28CC1B2B=7T!1RT!$U)\"6 Q$1)+,=EXE 22(DEL+,]0-R9@MFG;8UI,8, M3!(T3^.TFJ"&DQV)P+)9H+&,%\^2H"]4T-+Y0%4H/0.@[PZM:?1_U|PVVJF!CU$>%2F^+= ZQ769;>
]0"A<5HQB43!<;-MZ=G-O07)RNYH:#^=/"3#CS.5?)^6$[&_X+$1>SD!B+]B\NQV9QAB/ULLT<,"\^?2"!["V"B6!<'SI\|!>$|4/ MY1E\)>)"OT(\@?
_)8NK]9[L)SDZ%T1BB=H0J8=UTZ@V>_P" 3@A<(O+',88&) M;.QI'7NS7.2>&94)C/_.KE#H[1W]*@&H@W). MVK&?(W+Z,3|(8R%X^E6H<"A"U6/'-TP/>|9M0F+CF?
D"2Z8[C"QL6\6KIV-.M$ZSGS8:0E]:|;E9O9"ZYXP(4$@O&QO$$51.I/HYGH(94'\E4GX&>;%OI/1^W M>2Z/$0&1OB*_0GG9?'1"'S"W1SR0|
<0>*$DAJT=C5L\EF6Z\0:B[+O4'NRS>:?,3G*.MGJ+\Y,,M*F)>\HI,-S69-1]^F2WS]+$N!Q-'I;:!.!.0/FJH. ^E!':2/|OR"`M,J?>4!0RIZB9<547\1,1'j:+ M
K6:Y*NUSI.LTJ:.,,?/<=N:I_'.MGNY0UDAMY5.Z M>L $\LT,B%MN143KO4(DB(AQ3$P]:HPROZ'\[#MSD&)GJ8YJHHTKB#Y?-RV-JG^F]=5>??_58;Z[CZ&,RHS,MR"+(G/4?$GJLC/
MD*4$[6:6E[W<>RP93VGLP[(UZIUMWLC&C:)PT!;R!'0.Z/R4)L32^))R"IXS3,GT,:[_ +F6<#QX8]I\H4RF6S@I"^K0G@Z-MPF/YQ@Z)[@0DUU-LN+>"_$YR|&
<$\1/'O%R$\]IT!UFB!,2R^[!@A'A+^1S F MHTW^!H9K^G",,"/5UJ>017Y:&[*9YGRG>P!BTL6\3*8/- (^P+W?O8)QXP0'^_M9T)+QQOZLK\D_332,6N^[*|)G.0"LGP1>"5!ZA$(#D9JM
4)U-5B,,S$?GM4L P3E9+POT&,5_-\N\A4]-A>86+6[+W5J5 . ^3 M6?6$"B:|_ 0<93*X$YQ=Y8+:,,C 5%XALN=D4A0+13ZP>3 F:,P5^_26,8PA*%?%-'W%0NTQA_V]#^]B)HL,'\C[;AS-
TCFORXK(C\450NS5)F@YF)(ILMD] MSO<[_QZJ59"/DS,IJ>-J5MRC8DV6.X-&7C-3-%*;ZO;SW9F3H+,A9D/OC(/C M*$;"!Q>:<1X??'-6L[/Z' T<9;Z[Z^#FPE&T?,G+TT$G=-
,/XT3[DI!1SVX8\ MHI!'Q+1SA#PBW_.(N$(AEI+'?(C)!@)SQ#^;;8(5"8F^H"4VM@-N9U|\GL*E MH|\+PYHOC$P06R"CCBY<3A C'3.3+-N*\|HG-/&/' 2*W *S3OAP4(3X<%A\. M<)>,,?4E
=X;0^^;+E6$BW,/QZ-X0[B$9[]*\:V@KPN.GR2[N=O*(8$;3Z|H>&RL[R|M]ET M/ZU4/GS#O:A\TV^\;JKQW6GQ[8E9L7@T.$,ER#=4408HL,MO,>)EN;K%-4?//@V VE%H.+-
+A(@XM4^:H07!I8|H#V M!1>Q<0%RW8[= @E?)3WUC;')=4!Q%!U?%E!)NR5CJ^18*_LF9ZF1F6S9;7\ M>5*T:723QHIDSJ8X"1&13TT!C&;=@2E
5]DCOPX[IEN5J_!Q8LKUM$X!OZ;86 M6'!8#:W1*WBGA]70&KW"@8-GF^_-<&U^L@,XP1_<7-MCA& M#-,"@"T,UL)@ M+=1@YI"^;C!<2/ %)8CML-^U[8LU2-TZ"C:S8#,+-
C/X'>.LF>R728D6S;\+ MM,(%&K:G:1SCC6#<)":D)1C"@8$L&,)&8PBI;W?SW6X5PPT8$CV#X2(8+H+A M(A@N@N%BE*K4:+7)H$IQ52GI&IR6"O7K)$G7]"3+ VB?*$5HV-
,5G7>8V2 M"5ZA-M]K/ZU-Q4IZ7./J5D*@Q*F40FS6V8UJ(!!!53/P^Y$F>T/%/+;%;VM M9O.SS7V4=2?C#1G"-(^$E^C]K<#UZCR+RC*=IV^?7'C+%J27*YQP UG_>QQ
M0Q_&S.ID*XETKB>@;4+5L.YB(4P]&SB:4#*2R8PH(I+)C"@BE,A_4#)*WAWD*1+T@9OO)8@/>5 M2GR9!K'A4DH\|<6>VV\?]0_?0%-^KU.(W*N+^B:/S\!#-4RE+JS1%CT,+BS1 M
X*#3VV_%N?)F7]6**_:OHKM*9ZGJ0GBS."<9^5D);@:=+HG;K.4.0.YL_M/*%_X(QL^MLBQ<4#)O^^(#.UFU^794WO+Z;WJO<8@ZG_'#VGRWHY7=+]P+?M
MHPWT2#S;?"4KIOA6!?G!<@>O7WRQW72=TO^5-/=]D?SED-5TA:W!6.6QK,Y MN0;(:HPW3F;\"B*!)FM43',ES1/3E;41&?&!8C;&.6.QQE1/&XKPB. M\(0FRLDA_8^[&> =@W?
>@X=6[_?6A\LU2|("M,5)-7TYBW_"5K;IIR_'47M M;5+_]FD0/O6LIT0,4\F:51LC@XYP;KAM@JQ-"&.YA4<(8YFAXC?<33A-5W0 MIA&KAKB"N8+.B+!!$O+
3XAP]IZ<7^59>P@B:U%6,KX-78\) (#8!*=+Y$X MH%TDY8/P!AG04A$JC=[T?LB>I^Q5I*6;U^6"4B;&^ +]V7A@'&".,9]"=N3 M!84;)0 &Q?'7BV5!X88L^+)2^"^^^
_RD8$JO00*@MBSL9^W0)QZOJ[-':%> M^C30D^G+&>>RC|H9V!5,A:IN25]^1B<1-+-+'?G'O)Y\ ,TBW_K388T)YBP"?U<%=D#*!8E=0?TD MY..LN 588XV4?
L'Y79VADP^//YV03T\3O*I0Q 1Z&^NP SB(#OWG-9TF7Z2)O:H"0GZ,XIKHKX6.RPD133U&Y_^&EI,M) MFI8=T& .=3_20DJUQI3J6S(W-,:MK,I;BOZF_5^6Q"W314EZ;W/Z-.9/ &&0
M](2'J,Z2/A$09%O5\8##?6\?<31H|IEE:D4-'S JXSV#J MCH[,WH?G$>$JAC,:^C_=$W2{)4.0CR;N8);^9(V**B5K>G%T3HK2+X"|C'>R
M%4I4=!>X2O8|_TZFTT|CABF(>RFLVIYQ:ZH(0=S-+?+(+(8;-M7)9\@\@Y36MZ<0 YZC&$41XORH(G!U)YBXJ|HK@@&%O-7D8YN8K2@@19:#;O MP'J[H!C\2/4URM5O&"??
TBPCYRR1C:-\D3YF:%J6"'I(RP|@MBS\+FW2-$AE.APQEH13^0_0.Y$O0W###MU/6)"Z#D(VINE/8;HE@A M=(.B$GHA_7H8Y>
+^G8D1!8X)S_&Z.B,@K'5=QBCO+ZB0:#X"%J/CW)+Y4.. M.$QRK:P"K5&&&\HNGUVJ ,5F_(O9*-+6ICD\23O^/8E>4SZ'(=YU<'P_.(3/#W
MGWS"'^9V@\N67HGA_>SV<+"DL3[A@_X?)"..<=<N0N'TRN9?7A(!QPX+T1[MZ< %.#Y>2/]PM?A"'DANDLFD,#1\4IREW0!PU?R2VP'QO/"X?%*2I>.M(; M.[T0V.63[
>26D2R7,P#'R0C)7%B8#@\TO$1P4?0P'QRLQ6RH/ HZ1%Z*V-MFF#C VA&GVL_G93U"X.(*AHA((F;^X /&"Q4H(;44+A 8^&"^_@) M)34MCDK=4:]
<4D3"K(HTKE"R=5F] ,51RR;*A9?TK?4[6A+%ARY>0>*XFKUA M*$CT(BVCQ:(@:[U4&|U5 ^ZL]^IK-D1WOR:G!.HDS6H]P=VCN"X:N\|E63*G:?GGV8;^[Q6YQC&ST]""
MD4+0N0=!YZ"#PX$3H@>=/A8DU\'A7!Y5K@\|?U&/0-V0_L F"%)D0?^,,1,.R MP\:TU^6%!O(0J)+V'B8G &2^,:^1(?#H=*EU5FR77ZL,U"[C_Y@?6OK6|&"-"M:H8(T2*[_#1"-?
5HPT3B;$;$MV@Q\G MY#NK*$TF] U!+B=1GDQP|82**'66'MHIP:%I9$OJ/;|JV,)328&VP86WH/V1O M^\/0-6$JT&=[UC9QX.?1*JVB+/T/2FY.XLGI-*.4MX=9Q_NGK!@@1<,&W3KH
MUB[3^>YTZP"6M"V@I8=M.V@;0=M&Q"RH%!^1J@_C1)=W5E>BF /[ZF%3P1 M)4&!LZ' L6<%HJ")¥M1X3L*^"--Y*T:!Q%'9[D&A"@J5RW2^.X6*VE4D)%,]U-
PFH(N94.7?@LP/1)&%"S[-Q_]2T)>PH MG%G20P4=(&A50:MRF!:WEQC2M;O6A+BA>-A0ON9F"]&!]¥MZ0L-H\T$5C@D%2-MJZ"U8IO/445++;&V 7/4>*2B60;%TFZR.T-;_KIV\#!C*M
M9(-)"IJU#TYEXPAG9["6-EJXV7\A4_;&=F5EQERZ>R'_KBLQEGM-BL'&5 MKJDA-BT?4<&5Z Q\2:-*"5NL(+529MT;$L7WM7_Y)7^;&K]?<_Q8HF)-J;W.
M5W5%_HSSF/3:5OX%/E:AX5.6U"'86H9KZ3W"'\]I4-Y=IO/I*>__DSXH\$&!.M#PI4,"# B^CP_^2DGQ9.FS C*E;8'A'_^*L?M7%EKGI8U-PHMH\1@1B*K30 M"NG-
1_M9G,#C&3DBKMO9<0H|H(ZRCC4@:&>>RC_2 MZND.90UDY5.Z>L"<335@!$L6I=U:OR@-A0I-/T6 M%L2-BTAO@N!TR> -Z>0.4J&;^;*-^*R*E2W'S9
MB3(H:K6@V'(+_A#A)TK(JTL>ZD?2C18%0F_'>RRL ';8>N&\W#Z42:2_?PNV-Y?I^'V+M 4-_!9%4QOP?3V|DQO(8XP6
YZ:&Z#)21;.MG/DX*:BU$R(3!4FPGA@FB7<:.4 M]U/++)$8TKIE)TO:4,RO*F<0\@?0SZ7DW'E1QU|)W2\E|.*),.FQ",IB@G 7E MS&4ZWY]R)G-0!?TLZ&=!/POZ6=#/9#QK?
20D6\K9KY,D7:.2+..Z0$U9Z"0M MV\K0]!$BW%;Q[*VI]1W>N-HVC-"@PUG1X?I.&DBA&[8BC&MW%VFYPF64_5;@ M>E5>YW%6TZS(BR.:9WN2R9_Q$NW/[K,HBW(: H ::]
(T25+:.+.HI;W*P$@!D M2Z>:.IB3HF$"=)G.]Z=C[CXI&(9%,Z@< :,%,RB<415!4A\%6:DPV:1ME^RUZTZ^AY7%(DFNXV Z[!":2DU-./|!^DLK@E."ED8% M^>[3L3U*R6_F9YOI*$,=K
P9PC2/AXOA/(O*,IVG;3Q_QTZ2[.4*)YW'E'0_M>]R(+NPOT1++!>90?S2CO5QY&W^"RG.5T:Y M4I=$CBM92Y'5?)*#=&KEY/<0 MGLXV4O/#V9=F/VX4U%X7^*<7$_%L+"V8'F
5,.0>W!8X12LHKHEE=' Q2AV/DC4M HJ=7?4F#Y+]>?.H44FVY1T]*T^8G,@-XZMM6%(%L6[W#69.8Y8MX+6-^UZ/ MON $5<-P;VW"%Z0,"\8LP/NJ7KY,@]AX+R.Q^^+2@!]W8
N9+|"(%XR4*+HFV,<'S29DN]X9D%M)'^-XAC7|-Y=3%8X2^.43.>@X!DS75=6J,.YA!XHS'P9KI&=&+O5T6T84:3 ML!L- CZM@5B3(XC>'*NFQ&2>W.-
Y)8T<(DQZX)V&!R;MZBOA@FQD,:*E0>A. MN4O+/]F12N!.[R9T:2=":8f^C8M[7!K5;9IRV!V0,9MK|)?*7C\YG/TG"[K9>=*9/Y=/U5IS]>]
MZ^_.J=K.U*S8UF%EO&;$.V:*1EK3>_OYDOELD;"M=FKOHGS!@O'-W\Q0PUQS M'7\UZO6>)D0]E(BP2XNGVG57Y:'_FU#2_$/M"+Q-V!\(J?#$1XC
M6>+YC1QRAO+XBE47>6/P{J++5?L?^I^VO/>P6OH M-<;)MS3+'#779-'FBY3<94V%R.OE*DH+"B^*#$TA72SO@0,!L?H/SQ4VZ1DE# M6OD/E"7D(O_*%%I-?6WQE:\)7:C8[-
^JN$/T^65F2"J[@[WHVA61"3>W6=28 M.O9[6'A72/1T@R/AJ2O1TPV.R,(GLN]-.F?M'4\/2^N.ALCD-:)>BJZ:N-PC M6ZIOB.LV']<]KLBW$.D<(fT9K^6]M31A@R\COG ;@
MG=8GZ,#_>'28.W?L2P4B#4*'>/P/\NYM%1O[$ADHUW!]!OX'QG/"&<:^,+CZ M,R=,9^QW!Y]O=M#4V/GN>1#TB;GTY3KI>69"799@F'YR&R83]54_CQ6"D%K% M3/*0"05Y1\E5?
>*?WV$B5;]PPW>82P6/=- GSSL+3@\/O+YKVUF4^H0NZ;O: MG85)04@P&+5?O$&M5P_9&*=?1X^3=-(1&)M/#\\<&GCDQAD1A.MH*YXC6P&"M MXZA\.O\'D4MI'67-
'^@[+X3RJDAC^KQH_=M"NV.80V)Q8HH!R3FN?7,HB?.*+-GNDQ-E5#-? 6^3!"M5^/GEJ;KW)0.XP>-.\E^M /)F>F'\ M0KN%>.H03RV.IW;KS
_AVOZ':YMT%CG[<1^#LXBHT8_8+1U_],BN8=E\:L'* MR6]MMFT=-4N?>,1+_ ,,/SEQRY> !Z#?UIK,,@8C7I*6T6)1T*.!$$$[%&U8 MMP$S'?
G;3AOB)+D(IC;/P1^07558++,2G9)0&;;P5^?54]HYW'I+E,A;#68 M@=@=A+O5T6T84:3 ML!L- CZM@5B3(XC>'*NFQ&2>W.-
>\;C1VPQ44!J&*-O941B@00!UQ[*E)$#CD))?^Q'YXF??". MGIMC\,&Y:/,?K$..P72_U3?:H(5M _K;?3(116ZRI#E95%MI2VY0786@7.4T M+8MVC++>8E 8_ IHI=MI-
8(3WX%S0&P^F^*C0SA3R\-!4W_?/(_4_5]DA_UZ_U=LU40!P-^0T<< M$9I/$.7N"R.GGM8GBPAE.Y&A9+@\VVTTT??CM_F7.\(8#H\A&W-/MCR)O&9 MZ^P0-0_/DRCC)3Q/XLWS)&
!P,+K'27;'(^P-1P4$9')2F')2ZQ;_@UGP? M;DV.A(NEA,NQ@R%9Z5;Z@O,8GU"]O:=9/U0CAZX@F)+H"T*A /G@8UE&8O??MCPBQ98U!I8BE&:@M>.SK 8;$R#/@0SB.%_I=_@D?
8G'$*/1V7XU]D9B,0G%T MA80H%/45@\<7;H+KBG3/Z7Z?D(,B_G. "5TW2:V,G:G_5+2]*B)]9I#-.L$%) M:V2]GM D2,:.EM3(434ALU-.5]B8E(10U!3F]%M>#02A6.'#Z= 4BXB@'!6-
M 2MJ[,A65H?R8 2+:,]R44YUPW)"9KM$]BNLBK0CCEUM6VE#(/:6S ^654Y%1T M(W?2/>5CNJ28L3SP*L<>$RIGF^X!.&YE U!T $%|\^?Z=:'=C/)R2>Y?O$'H MGN[W67, <-
VZPO9F';2H(!">W>X$XX8J+OV`A8X.)?F@-LC.-7-.]65T_E'-M>_=RUT)GF^#Z=T?8"0$!_@<<$F!1R<%|APA>0Q?8V8l+FV%T_EM8M6/X:NT/) M*KX Z= 7+X1A?
(?ZR\.&/HB.T4T<+LN"]K1/49E MVC-;YR1%IEU>YGD+SBN<$]N7)9GITWK387:(7+H+HB4T?^ M*D6T)#,YP< W9@!6.3B5YN#4,0" MA,NM8VUI,JT=,Z1^7;XTB;-
-^$8|KF\ MVUTDL"4(Z!{(#|T*B8%|R!{\<1*"EI8B5'NX?@"25; 7+<"]\?O,2F M5&D=P1=#N*EQ!=!? %;:BV!E6A?T%%PK(MT6U_\VJAZE2B??%>]X6J4UOW
M9569<)PZOEI<=IPZ^O"L2B^'OJO,4?!'Z^5B<KD- 5;L M.);|GCMNX7Z4!Z>OSO<[YQ4]]]{?D+5=%6DV>DOI$VW(1_<7BE5%RAN!C\| M 1/&ZZ*4ML]4CCK]D;8!$<9L/YBJ:
[*+HCQ&D#D4ME5&3W*-5M?O'Z=$?3K=W(_M5606C*2CW3N>, M_):?3'1NJ(.(_'L5'(6;<=H.IN,5E-24W74)OM0,+6.3KAGPR@]DJHBG9? 1ZF MX#Y]J8/1HY[" DG# ^RBE#;
(@@(T5TH3B!+UWW^1>K"7+QM#13 ^;JEKJCY#'M281T&T\64D]9Y I4D>H^A@J.#+?V<4)@IQ_489S M0,=\PEF"BNEJ5>!UE-';ZA-WV<(IZ:"/3NFOW+4+
[S28OH>G_;X%K550>Q54 M03>/J.E@6K(F)?6HHN0B&A)T) M'X5Z3I?ULG/FF'_73U6:\ZG]^KMVJNZB?-'U $_GW\00PT2HXZ_:*;J/41X1 MR9'LJA6*TWF*$N8#7L*V^JG=
[=D=*8R9Y;8S^Y1/1DZ*V;RV"_EO$#$;VJ!W M>PO-BKMT\53Q'K 2M;=//01V7@_3CU?M+ML+!,BO1<1M:9Q^A2>BA/RI=2 M.H-
N06O#U=@>49*0@XQ(^>N(YOON':ZS^=L_]ARS&P9K0X>SS/MO9-G?8+(A M\K=_^X)8E1FEQYGD'QQA>#\! JO9@!L9(),DW_7946)V1]NPIPV7A];^7E[M>)N#&I:9Q^YCAXNC:
(IM(DEF^3[ ]8SF+WS-\6.)BN;-F&;UD#_C/";I&G7C M-4^P*"7=WS6*IE2ZLEPGHWR\/B8NGU$1R6Z+=*8_P2M1$_+'\'MH")GY;;. MOZ.F2SG&1 XP=\#*KJU?7
F.5OEI.RKC:RY=N+3(G?F>K?#7IHB=;W+\Y6 MN:)O.%P5B)S6%2I064GO+O$ 5OEK"NC(X:L;E9Y>?WVEX"'[K?1+-.%3/$ M'4)9YWX9Q,>F(
IR$;8/^=K^%*4NIT0.HK:IYSTJ6]/B'C MW/^,\VZO$1:X;\:.-?S"P7!_AB^@B!T@;T$1>QM\00=FE>M*LC1CO/(%9Z$J M@>4%|[%C(W8$8RF]_]MCQ@.>T IVZOA0: !WAP&0)7S#AO](-
B*\8.Q"@TP,: M(N5+10")G2+,;AH[*. 5(A/$[4OA!/|*49;T-W;DP,M)E$D$!L+QES# 2P@6 M/#UV6'[M#W&.$AB6G]R$17]U#,Q3&3M>O981/W5R[!=YCV(_?)?+V&5?*8.? MDMPI,&
(_NXF8Q*Z2R&\%H_*+5Z@HO+3&IAQ^)6'?+EZ)7V3 &R;>"[R5$7@?1B427 MG#AZOH !D4UVAR/CZ#Z"7]*B2D5P*!R|F?M!H5#*%/1F|R0I>]PL.RM@-,!*% M)>&@C%U_EBMJ"
<=E!(JT1$U-.\ACUP]E*^2,W44 5Q%AJ0>^.(=#HJ,$679C M=P=CX8M5+&OD*X ,V(4.OH4|(\3|\U5E"03]+Q" M>8G*":%V@JLG5$QHRO;,,B1+5)63LEXNHV(SP7.)3KT>C+5-
53L%YIZ5M<-? M>'Q6X^.SM^W<7!#A/D_NZ\Z/F'6&)L/E_MJN!'+,@9 MY6+:$'_>LO(^3\6C3_)?K8 #YK.#Y%XO+0ZF>(OB9;OF9*8*T-,N3|S=JN!94D%:W/MR|3..RHYIHV>?>C+YBL-
9JL]!?3 M[fMG$NX0KW0S7ZX];C)Y,0NE7?1M\]D9Q1IE)6-(K1: M92G3(@KW%FRFP68ZP&8J?3H'FV>P>0:,;9[!Y,M1+N6O+NU4"PX8C.FFP@;IK
MWE&K$&DPF[H+G0YU0Y^]=8V*1^6RF/8RG(5@R?/T\6168S%U:5S1Z*\Z?35_MW7@Y M(4?&(+F.9BT^P*B?S'N"T_CV?".6IB*=A+XE@_II8(6M,E35G^;#Y<_)8.[C\SM M]CRYS:*|
(M1?IHZ4X;@PAI:$2C#.C%"SZG%?1NM+L+X$ZXL3UA=G/?P\|47? MPG 7#BW2CKY8-1^.![M'KFG8+|+"'>=]H(MU.^GO...4]*0_ZND9]_1PO5S4Y M/;,;C1K>|;SZ1DZ
EP6KCG1U>*?:!],WF\S2F,6?D>,,%'66S_RJ3/G@G?7$Q MZG8!)&)&]9XSI---X[A>UAFUE|!]?L3G#'7*DC5ZZ N- M1E\-15?,NU74T=S*AH:CE51"%U1]H]71> MEQ5>HF+;SLS1DQ?=&
<'2_?LEI.IYLE2L.X@/2]WZ-N>]LVJL+VE-&,)Z Q9 M5T4,:,)26>|24G?O IO\!^? M0HAO=MK&XF#.YF"}VKMPUS422,HP[S"D64XT"@GFJH3_=YEIWN.4,FJP^W5"
MFBS3YKG%@AQ3A.\4+E,=45LNH$VA7):V?!6{0}TR;Z!00&VQS&FUS$B?3]H=\ MT3@RSW'99:M3,IX|KFZC3;-257+Y>DQ|=LE!FPUBD%2PFTT9>42+5=S0(KV_M90AK;)'N/Q!|AQ
E4R)!1(OF\6IP[C#ZQVB=\|7NCP^H M6)[TX94S3# M!M/B -/BL+,]V!2#33'8%)VP*;IH)1-)4=ZM"PDT9&]X{V(? M^V,EE/Q\B;X6F^P5*M: ^Q&'W66#=RA(8$?A{0 XBHL&*X:B5M8R?
4%)GB'K, MYS7-W=B*MZLM%WHLK]*?=29**,T#V&L,Q@^T\U^AY'B Y5- M?/Q#K,D;H\ &X6I:AKY5.@Q/(_F:2=Q M^`J"|UAG_9PL*LO9_(^H***\FA5W-
$;]\AD5<4]VfT5=D)FZ146*DU=$R77N MY[GHH/B?=8{H+[=?93Y+P6TWF(K/Y,AX@I#!;ZB C@WYWQFUHSVX]=/G^NQM.;&>:.$D?@1>7; M9P,D>B\!4!Z>Z#GQ\;9{US04-
{OB9MZ92(/;]Z)]R_H=6A5IC!{(SR6]-W$N M(@_841&=/[|\W'6YHJC4)3R6>O3605$<66A"%?1>H+@9$W3$@IH/\NIK7KXY M3NC1R:8+V,-L,;GDWW79>L8>\#1)4CI_478;1
#C^LSE.D)W) M0^.=67]1(4-;"OSHE-\XK^P(V)NGGON*"Z"'?0YV\Q/0UN'UT?9:::MO1%F&DK/-.[)E$(^\%:NNY=/187>=E5=3TZ.!L/G#@
MB_0>'^E;I&FEVIS: .+C!S*0$S-T1<0|;@0DW("8Z^EF;B]:FVBJ9[=7/?D"-T=H2[5=16OP>934ZR#E,31_4QQ(? M346QRS83G5D#X[B-)3J/=>5.7FCOGP3U6#P=XN$"-
OIRNT='AN+,%3_>F8 !O MP)$Q5<)%.[/9_$AAYJZ$\XA M3M=\G*YZ.NO',DW2J-@<33Q"!>V-TK|[JB8YDFKSPL/++.2WV'M,.0 4/(]"GGSB$C MD82F3SUW#A5-
{=3Z='=G&81&_^K30D<'39^ ;S!H\@4,7 5-95817-;T1TCG MAO+" ?%#^AZ07PN'RD_Y6QR5"T?('Q%<05@V'#9_Q'*)2'TX/..7S7NEC< ! M\D=,E\Q.H!DM+[1R0=:?
NL.)6BYHBNRL1RW2N,M*IKZKD)*N;T5TGQ) M%+6$+-C#?;_JSMHY+162--G%)5$C*4P?.>K^@+D/2IAM>)&MY<MY&:9'T_*J)"R-:BNI?
Z&RL$T2]W<\XLG0+L[D0*_8A+-+0_EKMK@E5*|-S? MB?EX?R4HC@BE=;G+)YPEVQ=LH\4NN..VC:U+%XLWIXBB49W%X]&(FH=*HXWT MQ'>-X02?XRX[X':_U[AHO7R\ZI?0
>P]7K8:PH/6L+E?(ZHP0I=-M]@^02^X83DSEEF"O(O%*3)&>'V=N)>0G5<6QGQ^&HND2*>/-'T8-]?8<+M8&& M/82)V\@AND,^1]4VVN$;
[1Y$V%WSB>JR2K*!%2'3BL)31>FT<>R,6N$.H4N5IE:KCC0CC@=,C5#D*58Y"E2-.U' -B;*745'U-{(P,W!9 MSO*#%,3B0=_KU=&A]>\UCD*-H_=53"{@R]X0*ZIWK$MONRTD/X?
TO]#^G](_Q]7IM_X^H)$!/_.$[+ \P*%KI'18#4)-\[&L% *F\-64) M_Y]:C'(BUU?;MDZC)!7Y^>)XR_=F0;VGW'}- =_OL2; H,CQ]U@BH&<.[7LL M"R 15O2>R@+T2LQ]CV4!--5-

\$<>UU}WPR?Q7&VUP!./RG#US%"%&S3'+Y#K-M"G<_8&B[> F[OL>.XMY53,1#.U#.!\$!DJ&NBL:Z)G|49#HM/O3(\8D_MP\$;#

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

HZ7B>'2\$0IPE'R1R=7\$_!QTT5D5QQB! ?0%\E= M-L@)CI O\$KI\$W 0<%]\$];'1 ^7 SIB_2^!\\##AB'@GTD% S.#"^2/\$264AP

*M<'R1VW4\!.3XC@K9^\$YGXSM;SUQ\0.^[30N!&6CY/3%=>P&Y8@>E_Y)"_M!W*1,?I ZA7K>><#'C?(0N*Y(TYR^0O\$FO>L*.\H&U(B"?*

*M<*9P!)S84\$5"8Q4)4_4"\@_C{[E7C=*!)/^!Z)!0,EVC{E]@%_+8('8@ X^E MEH,%>E7,2^^!}?#9U 3L-2GLGJ8H53\$=_4;56%1]R%5YQ*R>#]C/BC*:#?;C M. ^7[)W?*

*XGAU6I0R+11U9X\$+!*CU!/A!R\E6)D(;U!\8\ =O.?AQ ;OO\$;O?*@T M_Z+2Y,W568]O<]K(Z4: E1 %=U)3:?CDTTV4H/RQ+A9BVD =%-8:EBF5: ^:] MD,ZL7E!Q4W WA31V9IX!B*

3T"_69S=1G'D/]84FZM-;VE5{R)M:ZO&L+(M , MB]& 2TRAHG&H:&PBEL,=KH?'/H3(!WN1#\KIW?LYTF[5(\F^G-4T=2MS06A MDL&!;/?W'M4!NIE"5,?[B>H(0\$!#"6!MZ>M 9QF:4/*

;.\|EVWQ(0)(UH63G%HWW "G G\4\5' O4 M&!;H3*>DR%'VV%OMDMTPR2'W}!"D,KPS39W'6=T\CW\$9 0^9M\$3\$D\$EQ?IKX_9G2;G&\|#2+[\UIA1NT=5E36#&*

*(*NXX.CP*]D\:.,,I1@Z]K;,%F!:.[%+HB,/>,CN1(XZ#8B)(PO%H:I>#)!ROK6C\$HN#+Y:P7TH%& M5N_,,Y.@=]E?O3L=30+*M,KJ2U%QNBR8\$0NDK{_:>+N;SIRA?D\$/!.=KLJC)CFGB*

M9XD<@1=H3\KU/5M@1=%M.370 -V4T3C?^!]3?\$"=HKHDKP|/<;]D#/A]Q@95%=>3^(O\Z MG'GD'_ZG.,ILNZ>6.,?M5-U1W=AQQG<^3[;_4Z-*

HYS8+6\0W<98@A>AEB9?[M*\$-,6>1+M"0 ,AUDW+,/MVA3[ZA(47GV\$wQ.05*BAP4.5[4YX/:P\$VAZ+.ER M!)A?Q#6ZT\$UU696WS[OUAZ\$7]*

W;I8'K+.M_ 3(XW#9.!JHN?A@P'PE6[" M)\L.8XO;^K%,DY3(O\$=7 &]WB|K[%5PNZ2D(8>'^AX7S;\89'IS H\$W5FTL M,"^/G6NX?,VRI9I'?0%E) CP4,':"/#?6U1ON D%BYP?*

Y75&Y"\$4;DR)EE? M8DCA6PP +-!)AW'R5W3M (#[G =\$!OE@OD5NH75.1=+/2; M-2.,E!C[&H@W(!#F,_1^3T8WZ C[ZH=E?V1TC'%*4<"B.(Q[YA>MXSH\$A,*

M,#:./\PAN&"Z0RS'OEFX=C9.H'W&T)>3@>X3;V1N>2."U X.1;@(]^J,9&\ MI?A;,"XG;U?4^.)B.J%\$3.^N59=.3"M_3=0LX"..3GK^]JN2G9R#2FVJ+1@XZ3?\G -N:&S^ 2JS*

MQ18^;JL/\$8\/%H0=(7RLBT0.JS2@OS QLLL["4QU%C06&/ADDP_WB!\$GY"Z M2 L4DW'8E18 K0=31(XZLF;2=2O1SE9-(97K^QF3*%B'=U.'HA%%SN@>.S_: M8E-*

*]V5XTWSW;')K<1HO&/_(M*I)IGA,Z")H%(G^ZSE^K7D02I\$!'"S2;'TDZ M1]H.!_,6]5%8B:(W%[=U\$3]%^\?KC[@[IK[=N-]RE&S';;6[IK?%5):HJZ%&-*

*M:SOX;/X9%^B!B#@'G'I;T,'>\3#X/F]LLROE5+"!U%!W MTH,Z2[_M>?SGN,Z);\$FDP6I#P^L811!XS?37 HF>^;5 NOX>*I2\H2A4**\$A M":OM 3Q=)%*CU.KU:VYQJ&Y)!M7/SD%;4)71-*

+MYUFI#;FC'SW';FJ:25^^Y0 MUE;H>TI7#YBC# P8P6B&U3IX/H22;M'@!G^R,KT@W6VE#O6R"V"\A"=;8Q2 MN=,,[E&Q)}5-Y!?J%&B)#@W]8/N(JRX[^?X[(BVL+_1LT+!(N/

*M6FYI!\$Y+LW4JB!+ D,1Y3;S0R 6TNY%1.FD *M&S*F@!!FY;L[G:O2TV|!^ M)WSLO8,,K'6%GI"5T=Z7A=9C?YV3Z,Z;"MNSZ@D5U("QM5PV)P'1REO^5",H M^?FQH?NEIOMF-*

*I\F27)/1AFP;)#&+XX50U(/>8;7.DHS&DO"I+UF+/F&[?7G MQH9>\Y['S6X%+9FT0[5IR%;.2>P\V/FZ>@*0AG9^RA-F.R ,/.TV%7 A*>@<]G M^":;)QK*(G,,\UP^BO?*

PXQOQY7F5%DUCL7BD8GR;)T,?^H7^/=6 "3]HK;Y6 MJ,BFATY.?.AQ ,,E,YG_M&2+C=(#P5;2N,IMA.I?H?I7]'UUQ#77U8\'>4+'_M#@.?V85-"ON^0-EIRL8P(_+8,1![YK\$"]_?841+

]D["\$\$|<7-.1GVPGT=CS MY45G1X_X/U\@"?4J7O/,"0[TKGX"\RS@1.>,??%,IEL@H(OJT)X.L+CC|<. MB?\@'"ZZ7\$.'>"N+8[K&?\$1"UMEI6P|AW!EBC|<:.@ZB.X>I8U4(]*

*FBSB%O(;9:GP;H+[K 0&)] M6H/;T!]DBM,G/#H'KG/U2_1)K"4)';0\'QZ,E M@(_?*_DQ8-<;NY_&BIV#)RZ0NO&NUQ%C/JYU+I9*IXM%0=2Z"EV36R3-RS3^_M/AR7-*

AN6;C"Q1RE55TT^0^',\$MH\$,.\E_]1-0">'-*9|&-0M' MERU7,#/V/;?0"U4AU=7+\$RI +\$O3*0]2.Y2\$^GKFZ^N-JWR+ 34@5*?SOS!= M*\$2T+F G%%&!YS;\$M&-*

*?,#&1C>EXU]I+V9BK-M"[BHK*I8@^!QR(^C9@P+R/ M@\R[TZ!S\$IQ1PWRVI(F^!UH@=&7W>D5](-,WQK2/#^U&,>-ZS)QZYP505X/'.U1:\/VDTV4W!9C*:7]MZ!S(7@NF4M'%KO-*

*O6T:BEI%)5);U<0Q"WKW&O'M Y?"CX'EP MG7"%F0#.KE!!8H&S= \/.BN+ZBC@C/SKL**%9>NWJ &K^)ND\$O;F&X]^F5?A M7 FE96FX5U%:~ K,]+ J=*

*!K1]>67G,MW9*V_PL78=R&!ZN6#I[\ (311^"WY.I\@K&=*+Q,]#2+>K;=*!C;\$0-T+>A78?7I&E 7[#\>]Y\$9B34%SWO M(\IJ##'F/=+B7.YZN80R*#=4HF[3NCB9H6^D!S>.L3EJUE-*

!=9U79}H&WZM MH9ZZ1NJ<*L&NG<_@/=;H/>Y714'CG \N!*9]/9IJ#0=ZQ(\AN02^@&"5OP; MR@G"\$5'#IPFU#Y85Q7N-ME1QZ\I)137*U75.%ADZ7.;TJ_2&9E?V_1P@0-N*

MY250'\]/5"A&15IZHE0>M4897E##(V1+H.=97@;,AB[GR>>H^!/1)^L@[\$"[M!3]1\;/I*K>D\S(.OB#_?4\$R5R7N=2OY@1#8T@T6-WSQ?T@N&NGKWQD.!AR-1IRIVM\$I[\$-*

;&&F W:#;. OK(=8YH\$2?,B MV2E(W';#]:A 9 TGF ;W,"E@MAG\]2]D?SS@\$2S/\CB-LOVQ=[']NBX>7V^* (M)+F.VM-]SG%-W=SD8\VM&0M(_>'UTP[C;<%3N]XFA7;M^\$9-*

/:F:*1AIQM M/U\R\Y&\$;;53>X=6-5& R+T[W1WIKV>82;UT7Z-FO%-VV-8T0/;_+BHCRQ4T: M/3;A2 RK'K?/Z\?#C1XFWR0%>HRLB7'61=]T8T:AR5I:(_%_R\$#TSC=W2(UGB*

M.9B,1VB6ZG&G!?NN_ 9Y""^#@RE!XT.4Z=GA@.0YB 6_LEC7(K@'H M-6.',.8&I>-]V3+NFEZ5Z . MZCM6G45-RD3@G[^"2)3Y I4TY"8BDUJUV=?9EH\$4]0V+5 A%AWP,/6D/7@^-

M7]H[S,J'T+]\C%/Y87:1E3H8C6V"Q %/A/. 7)>%_28 MZGP!N5]GO?3N+PF"X@]74?9;@=>N5+,:=H[Q^!4@?#0HH:'W= .R3655N5U M6=9(>A1\$X_5\)8+']3L6:!!BOZH]2H!]2:H.9B2.

[;*L[W,.^N,9=%X:\$.RD]1 M:?HF8RCDY>M&2K-@O.(\.OWD@Y5DG=-@7&[@><]11NX0ZG5 ."'8 M'U\!,2\$V)9I),MM%@E]L58>MRL)@LO^ D_PDU-"RZ.A23B=]B74V/S]5.#E9*

*MW+9^N>},7%_!]^>_ 5P^V>; B"<\$?M,1V2L!A-'9?!GC[]%#4?3'R@\| "Z7B^ MV/Q\B""T3E^V4UD(;?FU?]I7#9\|HAS-TV]R MR])\8/:=Y*C&_=.]Z L^:(T^:*

(EKOR3W/MEW2:,_MN:U6S)V1+4:U4(/K- M]-@<-VHNJ::+,X8.RI_%^V1ICR9+KI//A"?WXX>1/"M(Q\C>T.1.0I[ZZ^)-U/ M\4/WW O*M_T.^L.4KE+U QI*?=)0/3G]")W_?8QT=W?*

*41&COBAP!AP= K-Y M\T?E0&S'M98!6*5%<^A1)3WE?5^\+<,!8[@:OJR@X)%SVB/G;&J11,EDR8G?5(=1?&]'E.Q=7K' MN*QHC>]%QDDY*7&6--&DVXK@?9,/]1-*

*BW.=CBJ7@)K+RTH[^Z04E+9E:9<8R M8THB"OU&*3N{G2/L]:W%'"!L935T!J]@H=66 VMT7L<=\'ZV M.?X+U[PN.X!+Q0(OGU45"^P;*10+,#*9Z-=E(!NZE8/A_3X9_Z4,;PZ];?U""*

MN_'Z77Z^&';5K:-@_@[F[V#^EJI'!\$XWZ'!&Z[^VC(3_C(IT:+Y=X%6N"/ M1PT,V)88T;CA3[]V8(':3.(%S,.QXL/[XI::RPVQ^UZPO>L'R.P2-_M/6CL(;@NZ-@CD?I'J_@\$]9\IO\(0)UORZ>3%VCD]S=ND"-43\$YKC>!)!,=LPK&B!.ARV@\;R.XU111W&KA"E!FWR ME_G9YCI"NC,?APQAK],D>1.593I/WS[GS"LHR>[E"B?<@ %P/WODQ&5?C'I]|&G%/;2#*

?!L10<2SC? M_I O;E!\$<SKC#PS7;&LK#7\$VBT2>]!8:RO,=V.?D&'PB\MX%K;B"5W2W7;,) M.,,8Y@Y MA]MJE&4T,#A/;/D?%GXC.AA)6V>,]Y).=!.7\5 3E!&LZBTT]9]@\|

M436;2\|QR]S\$P?,!^:V1X\$G14/K6"\$DH:H0D1"DN3)9+'H/"04>!?FW4"=3.?0(-M4&E\$SB\XCY6:\6I\$]S&@P@E]LH?\|Y_*OFFSQC)/@-'C<\$>"\!2Z]%-'F>G()& M-T9T'X/?4\$Y^RAH?

UC+-Z7O%Y/=KU\WKQ_ "[ ]<%D2F7Z>5C?!D)P6(O!S0 M?02H(I<3DC;+\I+7(/QZ B\0HK7&8)LG<@"P>&N^>S"\|N M'-<2CFLA'?]{FSPG+VR74Q?D06YLY]B2H]2!9!4\<|-':

*[^;6T>4< Q#BP[I M(\$+&,Y#Q7_])7_X_PZ3!X;D;R&;2C46:\M_T(^L:WZ(W^&WK--M7F9L-,.^:*BR1H5S)1_2O-UNG UDU?:%9B?C32H/90 MB.\$)\LP0/ \$WMV2S(=ME29+?*

*455"U]XR:\O"*Z\|8/M@Z8)BUE*#^,.M';,]=8G_-2XML'H5>^-G8&\<8%DU6KA"Z=Z(6C:3M4X-=)HUAT/*E'I/%-=V28Z.7[H_]*F@92MZ M!-],O@\O[^77+1BA,P,+& \]-*RXZ-*

M1M<&'}>!",M=- [;Z>D^0MC2\O;1"[4 M"C7LA'\%5S+K,#@O3.WHAFZ#E>+:.Y5V1+P8_?247W^]I1 MGC--*

\CEL'0;4[V]+B]/D88%H1&OKL/J!\\@K#'&.Y1I0G4%"H:>LLGV=,V4)> MR:Q8S0"3GC1_Z]NU>:CN,S.MA<@8TPWG(635 MU']N6QH?@W71H%7T7ZLH7;HAO59)7=']0F &,RW?6%'-*

*AP3[=']V;\$PR4Q MGX*X3I)\59!H+7*ZSH>&^\$K-"_-%Q:C4B[1B3=XPH]14I%,E;^@P'HC>IYY5 M,\+A2S-1\N9ZJ#-\;3C*/^D(.'R11NN2(E2#*).BG7MGV]0(I2F^M!2^W56,*

*MA[MN;Y4<_,%4G'\;6V6>C%6CKC-D-)66C*_Z8H/%YD;NS_+!VLB6.HTE?ZYW M(&UR9(#94*T\$VQ/I=<,M]E/.T7'V5"BPQ]EOLBDDS30\XJG8R1)EH-<;S]A. MCJ4>.Z_&FR9-*

*CJ61M/(C>7YN,:BKEQUO[)\L;[J2D?%@\E1U&M[H#)/[A\: M;KZ'3HD3D?I[#']\$6G^CA[_.7&\$?CZC \,M?4\$I+D (%V!#5GGQOQ\$ MNO@>! *9\$(P 3 ,/]?C R-#*

*V,S!?,3!Q+FAT;>RI:WOBR+4V_#GS*_0X MR4[WOHP;21S=/3P7MGG&/\$[=O#)T\\WZ9]Y *HXR0&!W<)K_^K2H)\$"'"\ F5 MI+5WQFV#H [KOM>A:M6]+__W?:H+;]BR-=/X^6_B5?5O*

C844]6,UY__UAW< M/CS\[?]V?OHR< MNK;P>.W:!]Y&ELT>E:K7QB;R[>)"^H6K+9]>?\]Y/SD6,NRQ:4V10V:7?)=8KU1,%5E<-DH>_3UZ0NF[@2;#

*M1I.K/:E;J4H545[\B6M7G/D,KR9QC.P1^Y,%,_1#\N)QVV*BGE^^M?8!UF'P M.^2DMS^]U?CB7I.E -C"O3<,O6(GK-WZ">;E:H8F%L:F5GA>*'QK,%E2Q#K M.*%OCY"]1(MFFS5);.*

*[\"E_?\$&LR=4)C7/9@[*R1[^Y%8V<2O.W\$-%5NJ.<5K MGWZY^W]OD>Z_VE>*.0T(*IZ8WD/YOJ*ZH7W MYOIW*VK%5RQIVH.\$6:\(S4(I1]H8>UAUK*

U=L88K\O8G^K:OE,2)%YTODPP M4CL_ >F+HSDZ[A!Q+N3UFUC]XXK8DR^?O+=^^A/]_R__IU(1OF*#8@&KPF@N M###W4WQ'4"\^FY2!=J BM3T2%T&\21.FZ7KVN2<+\$-*

*Z%2(69LBATDT/Y5|'^N MJO;SQ:UI\$)@YE2'IVX6@>`]?.\$0!'UB|NQ3Y\KGKYM?1J8Z%VQGKA.&C,(_A!=S\$B@O&%C_"#*G4-MNEX+5B9GP6"%ILT[H6D.N8G\G\$J-K;HB55LV_*:?*

2%H!"W:^QNQ(HUFI;+S3^G+I[6FDFWZ5XRL MD(;K%QWZZ82;OF4<#;3<.\0[JWUMAL7G0KYA=B5A)OODF&K;.@Z>EUOLWG1 M&2/=Q@FWV#.

*(G>;WI\$D+Z0^\$,>__P//UEEL7G2K1[G*K7;_5\$VR>*)?K)]-X M<74L5D=UL6M97=6<\$1ZO1]J(U3KQ53P/AG;)N1YK[UBML+E(?DIHG_9V2#QS MAS8F:6A-*

#6>C2]4,YRBD/[5VDOW1_\$XT\U+CMUL=V79_ &]D\$=?6Z5LOVNO\$ MZ;YK=F5 /HCM>]E_R_Z&IR-L_39P1S91[03AO3?R@ZIU[\UU[VG%/V\T[=GU

*MXKNZALH:LONN0ST;JJZ'\)HN1RPUUT9,8X%KU;7F1(5<= Y2\$X>-5LIFM/70 MT4[), "87G49ZPQ6S&:Z\0[B1*O'>0@!U4+UO\$5O\$;,2CF6MHWA//KH4W.TU:*

M(4/ICU_PC'HWQ!D>X%=],HA]!\$:+/+]A#(BK7%%-IZ)B19LB\$H_[OQ" [.'1 M/H#.!8>C1U /&8&\&H'L&<6SCT"/X):5F70K+;#95!;RH"-X+?N#V2I25Z\ M8-LAV"2F;.*8RN\^>*

[Y2^&,\<)#CVAYO2\$';TA8]SZC.1U1EU+D%=-?B1G" MTYENSC>\&DY2]\'=YN3U-5U4Z%>^>HI;\WIC\$1P+&SKO=-?\7+"Y-@3\$%]OEK[,O%?+'/;7:/1"*

I,_(`\$W!9SG.V^,\'6<(\*,\_M/IR%R\*SC]H/AN?%'@/3 ,6\_RB-&"SWD\ZP)SGN2>0+@GWQP\D=`O35!?I;\$X7 M2I(&>'>.A17'M.R49S!TGKY:IGU,:'#@9(7%-MN>[MZA4Z/T8-

LN5N]64MS5;\$68EEKN1A:U M1\$KWEF5O--ZOLKCAZ2T44"?OK?WK"/CB0R4/3;<8/H5 ;FAC5RB-!2B3+0W M3)\)7[@Z6CNQ'\B_N=R(L6+A< ;U1V+7 ?OL^R?*

*G.4X@U\)&/3&;JE^Y38 MFB'+F2]GBHU]8NH]77WY9EJ8FB:Q2H:B+%?Y#IS;WU[HI+%GOZ%W;>I,=|SY M:/;^%X]=\"]JS8I8I;"'_ 50 M[&W/6Y7]>=M%V>AYVU35\H9YU8*N%?*

516>_\M7DV8X\$E=MG"X^Q9:U'LW3] M75,U9,T'B\IFJT^QZ92D9TM[(Ul,9E%AWQ[/+5MORS,"@47[Q,WXW8D:>HCU@&%&]?6#&\$Q^M^9TM=DLPJ>:690,_MTBT@T[

UU4\)WBXM2FDPF_GZ\8\C\+#B8>(5T=H_KJVFJ/S1=[QKJ@=^\$@XY7F MG#&,K=\"7^D#B5:?)P4 .+BC&ZT#BU5'A<"\[#XA%'A;ZF2]/(JZ[%AD7<4/(

M^_>D. ^2WA0,4\VAA9"Ms8X]=_5\$;^Q5,R5S?=IPD6R9^'%"Y+'%Q:D8RXSRJ M9E\BXZ3'.UT'6\OW:&]!.79^(NG)U/.O>^,C+]J9,.1]C^,*(XS?T'],.F*Y% TK#'9-FR)-6ZJ4<*

MZ]6(0[:IKLA6!9<98@A4D(.I_Z4T(US:K^T]Z.[*]XG%NTPF>>*Y!=P MOW]WU0O_75KW_>\<+6YO.=,5J[6]^).O;9D*A?[*K.Z]R6+3%R7OCO\L9G6M*

*M%W_1Y#Y\&VO8\$EA'<>@]';Z]QZ MN/C5T3#&B MZQR=P)T0UY]#IXNO6[R_^)M^W?9W4Z]K\QO]6RVNR7NQOBQ,B*SVK_=KJU)M M[U@FHJEY=_3]8J&(?NK9'9'Q]L<\$/R1*

,JHR<,JP\:7O\$=/I4R6-O5,Y,7X? M:%6;TNLM3&-%[LB)N^!7(US'GHTOGT">/ G\$=-YT8EX8\$^]GS9FY A>4=#\$ MY!4%U9&\V@-7\FOL*CM+8T1*D!>_9HP+ YJ-W02/6+LF\$E.(\$F!*

K9EG,=)BBOM9G2XLZ@=)\$Y%HI\$(BA)W>'=D.6\$:(!%_XE9 M*& R.!F8G!J33_"&@DXU=&0-<3X_K\$G"I4%SGRVH#0X')1R6.W-F!V M#W:GZ+9^;WMH2 T\6RSH/*5DMP!*

8Z6KL8JRB0 ;BQ^- MQ9<'!?H(!'HHS+KH[QY4.ZM=C%66C!S06/QJ+++P\|'H(!'9=9' MV7M0Z6Q^@RXZ5!>!4@"ED*E26)XU9:4G%E^_?M1T1GY=?/ZX@Z;AF]&G8U9^*

*MHC\>3O OK"*F?]T.K3Q*/M\$?+RM:)]L?P]%#Y[#0A+UC\$?"4XDEULE2 M/I #M!*%5K">RS.VULL{J.PJO\$[@45;)"3FFM:G^8V9^V?H\??\$.&^:45K;<*

M_EI_9O86,%C[BD_KO3_(_\$"Y&2@W6,2]N[^I:S[MNZO@\R\$]O++R R,[*-MQ8J^BF%QROKTI9(?#VP -N2GX&+VV=G EYP[,3GC"U_6]@;.#K<:9EEC+R MA??%F9SQA2_K 6P -*

*I3;>AQ.G93V+TO%IOSN>@+;[\$)B8BY\BKXQOV+SZB'TP MV.*EVF\$-TBG"8&#"<;T*K>NJFKTTA?79AMW\:5>F"3K]!=E5[L'MJPURR=L M39%J*HY[\0WZ/9.[*

*O\ALWPZ)XC)HI@6[)*C59R_"O2Y).N2(MQ?1S0"FA5 M\$%J=I>;!K?4M_]Y*X!)P",]<'T*K>NJFKTTA?79AMW\:5>F"3K]!=E5[L'MJPURR=L M39%J*HY[\0WZ/9.[*

*O\ALWPZ)XC)HI@6[)*C59R_"O2Y).N2(MQ?1S0"FA5 M\$%J=I>;!K?4M_]Y*X!)P",]<'TQ]^7A.<.U+KDCUX*_ %&!*;IFR:74HHF-*

*MG>"CB<9(WL7)*0,R54=W3>6D\$#^^8)U\H_I,3Y4.+638WE7#!\&/!=QC3@R_P M3?7X@UJQ?GMTY8AT #G!T F/OE"]1 V0. %\,V6B &FB S %0BP^ Y#7 MM@_@:!;S/I^)\|*

|FLY5S&\$/DW?YAXUIN6FP M?V %M/ZARA|\$?U;19Z?VMQT\$/WY1)^=RQ=]\4'T9Q5]1K8^&=;W#5Q,T2\'-M5D#6A[AYSY:INHK3MP;8>M,43_#=-VR8;^B.3#^Z?*

*%76MHHK.^>@\$,&4\$#7 M+83)(,ZBL%.FNZ0@SO.R4TYP77V=G2\#.#-B9D#C7\$A=']YS>FK:CF\U#[3L3 M;"T.(82*F_NMT=UE14-'>OR&YYYDY6\|37PL:8X!*\;"R8?-/S?<(\<@!-05!*

*M#:,]1 D"LB!#C:@,9(%9\$B\&U10T0*R+\$,ED8#[KM'&0&IN)OKH4F[*A>?]RE M9U9?V2*YG\DQ(A-H\\F&Q<)^:-<]E*[UG_L ((9 &+5O7=LQ!]BZQSD63<1(MBB"DVPFR7@GRE-]*

]MEFM-%+9]:UI\$F4YZCSK.:LP=]-9U;^1T^2.Y&%Q4=@6[M8PP26Y'@4PL7-#%[>OB[\$1W(,ARUM/>"-AL><\$%HF3G9W= @'+D@.A@84X M#[>>\/'H[>TRH^00]-L\VXOP'X--*

ZO'O,T-5V=-HZ?)Y]!<@-?L8\$M!+-C MZ%/-T&R'GBA_P[WW&5%0G"<%[QC8ZL17K!&FN<7"ST8Q "\${('"UG0M R%0C M<&,V 0C9:H1\^ @#K.N:\4JFZ1NR?L<.^;TX&-@W./

*,0/RE]@=_*7V D#\ M!,;]+]C&R%(F9(KNZ'E:#!!%KY!-BVPYNU*KK8SGTP#3V>Z M.<>< V5MZ&O0V)Z#2##\$;FUK\$@/>Z2&S64 O1=HV4 !+@*6'-8FG.FL 2X E MA^X\P!)@R6&*

*D3PL>X#)I#*9.YN>Y^?@.\$(-6XB:[\$D!01M.TZ<@#"\ KF M-H?X)P"'''S\$# CT\0QTD=:@Z|K_C!4+4W3761SIV=>% V741F511-B _S0^?Q M3&E-DM |\TZY(DBW G8+1ZXB*

>3R#KG\$^A&Q0!P@5SJA53C^C??# MY\$[_H;I[G\$0>2P3]^T#+H<;_?DI06\A?AC &\!CI,!;SD- 1'8#X.^C!!0

M4LK,P9N8NHJM_OB;;>'A\!:EB]1E;]+N.PNUO+]1#9,]^0^.;U)WF"L\47KMG M\C0_-[K8PN&B0_]^!4DEL)> M09!:>_8\$F3AD;H<9+]'A9O*\D065IL5L>I97^_7TYV_:H%6"/AQ"G?-*

*;OX6 M)1:PBZ&7%K!,<(M+KDC-X*_+(@JW.K+I MA]U|\696G8GOVV\!A;UEIZ"Z^0 MC1Q.L5Q4V^C2W/:BT'H!* M=M MR:O\|N:^% (=_)EP6S?\$S=(.%1D4]:1 /!+.*

*.<%G^K_W%M9[I:6RX\$(IB^ M6!^TIS5VC+RX.B0AAWHGJ ;\$;4/D]C(WC33M?7Y"YZ9EH/54N!]W_!7/'6 M3\$2I(HG!7PL!&_YDN+&*PN8ZWBK*VJ.)W",G@8\$JLX':@%0B%Y"%0*

*H,5!D- M5'+@6IW)\U97%K\>]9O?!N[(UE0-6?,!HKG9JT^OY3!)?K.T-_+%SSI2\\$!% M\ ,WE&4?O_VHZ0PL,4;-.9[;\$[68:T(CYYN5CUL^M+X-Z"@YR^]:*13AQ_ M>?I.G_/?X?*

*3LPD*ZD9&EG2E"XKBY&X\[F ML+TA5J3IV+PH/<4.]KT] N=Z:3TBTAS'J1V\->C9+A7OXB;7'BVS%<+<9Z6 MDQ(\$DE4SNZ)%CG6;T?L8^4"'?S)L,#[M6+E !.?]6.?*

4(7G9Q\HWKCC:Q)HGN(=QSK. 2_J#Z:6GG?Y]K\$^H=(AXO]M;8\NH[4!3W#5NV=R!\ M0\$;&>O>_S2>.",:K&]DJ7<(V;>,ZHQ M\$?

NYD\MW^);PSK%X @X?4&X8NEF&?%[Z1)*X]Z;.ALW Z1:! M"Y1M:I'L"]?'AR2QE7=886/>SLLN\$5)W3@0 -"& KG;+9+%0Z.)"OIM[4(F> M)-*

^C2/[NGA+L?;JK3VZ(\0LW/LC.045;H)S]D#_8F5(IC8\]Q4&C=_ 29FH"):?U\KHV20H.],JY!)=P3GRU4FW2' H(M(-,2F#_#"0IL#]- 8"*

<++"&&'1UNA"T,]QZI/6&<(M+KDC-X +(@JW.K+I MA]U|\696G8GOVV\!A;UEIZ"Z^0 MC1Q.L5Q4V^C2W/:BT'H!* M=M MR:O\|N:^% (=_,EP6S?\$S=(.%1D4]:1 /!+.*

*.<%G^K_W%M9[I:6RX\$(IB^ M6!^TIS5VC+RX.B0AAWHGJ ;\$;4/D]C(WC33M?7Y"YZ9EH/54N!]W_!7/'6 M3\$2I(HG!7PL!&_YDN+&*PN8ZWBK*VJ.)W",G@8\$JLX':@%0B%Y"%0*

*H,5!D- M5'+@6IW)\U97%K\>]9O?!N[(UE0-6?,!HKG9JT^OY3!)?K.T-_+%SSI2\\$!% M\ ,WE&4?O_VHZ0PL,4;-.9[;\$[68:T(CYYN5CUL^M+X-Z"@YR^]:*13AQ_ M>?I.G_/?X?*

*3LPD*ZD9&EG2E"XKBY&X\[F ML+TA5J3IV+PH/<4.]KT] N=Z:3TBTAS'J1V\->C9+A7OXB;7'BVS%<+<9Z6 MDQ(\$DE4SNZ)%CG6;T?L8^4"'?S)L,#[M6+E !.?]6.?*

4(7G9Q\HWKCC:Q)HGN(=QSK. 2_J#Z:6GG?Y]K\$^H=(AXO]M;8\NH[4!3W#5NV=R!\ M0\$;&>O>_S2>.",:K&]DJ7<(V;>,ZHQ M\$?

NYD\MW^);PSK%X @X?4&X8NEF&?%[Z1)*X]Z;.ALW Z1:! M"Y1M:I'L"]?'AR2QE7=886/>SLLN\$5)W3@0 -"& KG;+9+%0Z.)"OIM[4(F> M)-*

^C2/[NGA+L?;JK3VZ(\0LW/LC.045;H)S]D#_8F5(IC8\]Q4&C=_ 29FH"):?U\KHV20H.],JY!)=P3GRU4FW2' H(M(-,2F#_#"0IL#]- 8"*

<++"&&'1UNA"T,]QZI/6&<(M+KDC-X +(@JW.K+I MA]U|\696G8GOVV\!A;UEIZ"Z^0 MC1Q.L5Q4V^C2W/:BT'H!* M=M MR:O\|N:^% (=_)EP6S?\$S=(.%1D4]:1 /!+.*

*.<%G^K_W%M9[I:6RX\$(IB^ M6!^TIS5VC+RX.B0AAWHGJ ;\$;4/D]C(WC33M?7Y"YZ9EH/54N!]W_!7/'6 M3\$2I(HG!7PL!&_YDN+&*PN8ZWBK*VJ.)W",G@8\$JLX':@%0B%Y"%0*

*H,5!D- M5'+@6IW)\U97%K\>]9O?!N[(UE0-6?,!HKG9JT^OY3!)?K.T-_+%SSI2\\$!% M\ ,WE&4?O_VHZ0PL,4;-.9[;\$[68:T(CYYN5CUL^M+X-Z"@YR^]:*13AQ_ M>?I.G_/?X?*

*3LPD*ZD9&EG2E"XKBY&X\[F ML+TA5J3IV+PH/<4.]KT] N=Z:3TBTAS'J1V\->C9+A7OXB;7'BVS%<+<9Z6 MDQ(\$DE4SNZ)%CG6;T?L8^4"'?S)L,#[M6+E !.?]6.?*

4(7G9Q\HWKCC:Q)HGN(=QSK. 2_J#Z:6GG?Y]K\$^H=(AXO]M;8\NH[4!3W#5NV=R!\ M0\$;&>O>_S2>.",:K&]DJ7<(V;>,ZHQ M\$?

NYD\MW^);PSK%X @X?4&X8NEF&?%[Z1)*X]Z;.ALW Z1:! M"Y1M:I'L"]?'AR2QE7=886/>SLLN\$5)W3@0 -"& KG;+9+%0Z.)"OIM[4(F> M)-*

^C2/[NGA+L?;JK3VZ(\0LW/LC.045;H)S]D#_8F5(IC8\]Q4&C=_ 29FH"):?U\KHV20H.],JY!)=P3GRU4FW2' H(M(-,2F#_#"0IL#]- 8"*

<++"&&'1UNA"T,]QZI/6&<(M+KDC-X +(@JW.K+I MA]U|\696G8GOVV\!A;UEIZ"Z^0 MC1Q.L5Q4V^C2W/:BT'H!* M=M MR:O\|N:^% (=_,EP6S?\$S=(.%1D4]:1 /!+.*

*.<%G^K_W%M9[I:6RX\$(IB^ M6!^TIS5VC+RX.B0AAWHGJ ;\$;4/D]C(WC33M?7Y"YZ9EH/54N!]W_!7/'6 M3\$2I(HG!7PL!&_YDN+&*PN8ZWBK*VJ.)W",G@8\$JLX':@%0B%Y"%0*

*H,5!D- M5'+@6IW)\U97%K\>]9O?!N[(UE0-6?,!HKG9JT^OY3!)?K.T-_+%SSI2\\$!% M\ ,WE&4?O_VHZ0PL,4;-.9[;\$[68:T(CYYN5CUL^M+X-Z"@YR^]:*13AQ_ M>?I.G_/?X?*

*3LPD*ZD9&EG2E"XKBY&X\[F ML+TA5J3IV+PH/<4.]KT] N=Z:3TBTAS'J1V\->C9+A7OXB;7'BVS%<+<9Z6 MDQ(\$DE4SNZ)%CG6;T?L8^4"'?S)L,#[M6+E !.?]6.?*

4(7G9Q\HWKCC:Q)HGN(=QSK. 2_J#Z:6GG?Y]K\$^H=(AXO]M;8\NH[4!3W#5NV=R!\ M0\$;&>O>_S2>.",:K&]DJ7<(V;>,ZHQ M\$?

NYD\MW^);PSK%X @X?4&X8NEF&?%[Z1)*X]Z;.ALW Z1:! M"Y1M:I'L"]?'AR2QE7=886/>SLLN

*M09NX(RR[QPY@X#$1[YP^?'!6-FS2>*++S[}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{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}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r^937CCT&^M9ZYL+,OVOQ><(D+"=72IQP59XB84/V^]>C>>N10RI'.+V;UO\-[+{(#A]ZW2$T25]G3A,TM^0 M4$SHD_Y]? LZC,,' R(.FY5"N>_)X@*B!FYAF"QOM!@-R>$$WV&%C9F>"?:?R++>WN'-,(/ =DU.FF.(X ME$!HP3M(BQAA\(%5"#12@FQ1X@T^8 IA1X+0+%#TP0<$S M2U-P8',H[[*,+,3B 0)Q9*EE\ <@IN(%#)#6P+&K'PA%X(7=(&<8%B&)Z "\%, M&F M5E3#$UY+'-XPC&,H4 ,.!?GASRX-6>'>;YBO.(@'0+ (\!^4]H ,&E>/!3YE= 7SBR5U[<@ ,/I_9*!GEP;^#(7CF0##@$@'-G+S9&]DH '-D ^L]!A (0C M>V7$/02 <&2O9) 'MP:.()4#Z<4/ -DI#;DB2I"RD_YQ-G^>E\,\!7!-/+'E MTD'DS?G*6HBY<7-X<"&R%E:>C#4GAC 5D:F>R):.B.GS77GBV3-55G+Y%_(TW M3<&^T-B+74/U7^T[$VSQ*3R:>APVB*"\HD>3F@,CQW=@Y&0+;!PHY)Q+M;!B M7^Z0(QG#"<29F,-V)<&^,6C9M5BT",:.O'L^6S^O>F,$^.":3!TWYU/ M<6ZYK9N#6HH!%D7.)18H3@;@HIN-!1%8MQ(#C.&$>^MKE6IMKFK.4<[=? 8M?=K"^N(KFO:$VTFZ)KQ^XNIK_>;?NC*M%X_2=6J_.DB M;W^BSUT(R%*LW0_[3WP:(\6IC$W3.4J"7PB.^+!'1L\7X_JX/L(2(MQ!U*1* MK=9J549R=5P9X6J!*K7J4E.4+XQ94Z]#RBU6E,@/QKT1YW^]?(:=?J#/M*@CS3HNPWRS7*=OENG[!;HE]+NRK2[VN3+LKR_1+:7=EB3Y"NRO3[LJTNS+MKDQ[*M.>RK2G,NVI1'LJT9Y*M*<2 M]:E$>RK13DJTDU*+?$RB/95H3R7:4XGV5*(]E6A/)=I3J4$_2[LKT>Y*-?HN M[;-4H^_2[DJTNY),WZ7=E6AW)8D^0OLL2?01B3XBMB]^<8"F5]-9%5&M61FW ML5(A@EJR!IK%,0N"]/1V@DU=7Z^KA$2>*CY\U13<&$WVI;)3W'MU6:E/;JW*B+A6!O7ZDJCNBD1"D;RL\9%_VL-D2B1%IG]UFAK8ZJU?69;]=$+:CK>&K6KRFAX*1RCQ!57LC+!&?__-GL5']I+_"7A(4ZFG_?&&XNGY! MGIH)MC.GXQT3'Z\R1E--GU__;4A<=5MXPC>$%W^C+!]9N,;VG_QM5B=.=Z? M,\C2B--X;9C6%.F?!AZU8@QC^C,O=9$P(1H[SQ=_)NIZU8@<,"ZOV!-H@^4)[AHS%\U(XW;*&_QV>

*{043<@_?[X7C.0H6C&ZZUI.S:|%V8! MAF-44?VB(U>Y4D%@13F ;1*5@M*$+3T^5(7<;2Z:XPBV293R21FV31F6C;AH-MCB/8)E%]HZ3:EJ,0I0R;+GUG@]U%!9U+P< %OWNZ#$?%H[12(F5T*%Z>3,-< M/^-Q4L7GU=I)@Z,#2:$'R@MK7|O,BT2]ZJ3*BQI/-[P",NV3>HNKFY@+:G;SA=TD"O6< [M-"1*/N&B.'^RV-MDJC;DSYV.Y>-#*N/G;YQ&X297S2QZY\66WRN7G*440"57V@#6@#VH VH(T< MM<&1!2W?FAY+)V?^&E8#[WK"AR?3P8+8^E€L];WR7O+62]{;T+KC?Q? TLKU M)WCKCX?HO>IXEC9R'3Z\=!P3.:M&:\|L@'HH_21-X*E]/+X(|&+J9#S=*:WCV4I39KUI%G>- MY;PXYZ$/Y5W!;"=1<.KL9-M7G?2RS=,ME!EO!P#+LF58$K6QN&)8C3C]/-T: M!?PJ-;^2*.+%%;_R9\$XBK3+M!DGH,!V,(VC%09"TB<'8@^%!=^PVZ].9*). M5-.E$[2A3_["LQ;,]G:4&DRB:MB;3NN^(4WW$@U\Y1: U0VR-;5@^X5;6DXN M=-H.4&=!G20*BYV9.K7+X*M>58X ZY:!.$]7'SDM=E^]78Y&A?%:A34NHD49SL MI-1I-CDJ1!V:AR%I62: "[F*55H]J -J-;*.TU0*L+#+G#1V%]2R2Y- MFS(62[TS3"1=Q=V+>CF&6K0!K0!,4 ;T$9I37P9LJ2;M@SZCO+>_UNVW5O. M%OFB%^_"CF'LVVUIQA,+#SF\@"?Y)+;_8]BWC5V(MX#T_WP6W7*[G)SR)>MB9:ZOR NZ&ZVK*D>9Y7SN)99A)30]3(JHF%KT0"DOAT&3+10]5<.R^Y,) MM'97VHJEUZ! ;GE8DZ=#,<1$I;:)4";V.Z ?"7SG*D'91T+RIZPA/!D L1S ML]=Z)7)T:P^PIRSL"#'.8@H?1IL)/A^+M'KGF=QTM+#__V,BSARR#L-=>O+.^>C0\;>8#A=# <5M3RV# P'0S7:EG)G8ZPU1^S9^W^"D(GG$_NB)=BG:,Z M,OR!JK08CLB%B8Y_,L-PFZ-S]?PAJK0ĊDA_B(Q\;@%PC0!8YBIQBS=(E1;! M$9D(T9%/9BJ8KVLL0ID!_43^:9GJG';,C1TR NJ]M;YZ;?P8.%O&]WV^=5 MTZSEM8+0 CP2|<&"]&S/:AK>YX>T/LDA3P,KN[TPM_[9G2%G\O3%EU>H"EIJA M8H.-I9U%,RR\\T86'>4YYFP[YEI=VM?W+0U%QM2V13*WJF)$ZP@US'3[U:.MZ?1.#6T\7^\H>;8-!V#7BO_/M6O=40%A(V*:U\PHHZ;([G>0LU:1:G6Q$I- M;+0JJ*&.*LUZ56ZIN%971NBBTQT))O[U=YHB&=AQS(I4=ZP@,=CK+"[/) @ M5@CI*G*=/$!O\70.YJD;+!A"-2_AE>[^QS7MV"]DA,>OSX]-W>LW+_]KSX*UG&$!]?SJHL(-,.;2_N)+\.\(X[+]M05)KX>IV-\ QE>'QP'[>:WP>W7*P2G6I0]+05 MB;IA[<4O,7.7',FBN,DDI0G-%7!%PF.8Z<.D.U!8 .7$@AJT3<@"03UAV M U #)-26=M_<4 ,5!^SR!8+SG'7U^1+B.^5BX*NKN4*VW+8A0+,V .8\K6V M5H,[VY-@Y9]I%@UQ* ?!-IZ$;8* ^S>44:K+[QHULB*O]OVLV5H/MC)M.,. M^7=#^\/%=]A6+&U&Q]*/< (/,CS M;O?6.UYU*GY4'010/,(F'YKA9EY#W7W^0.9$. MS@Q-R0P%;}/CZU90WM!=6C*%W<20(S*=SR3QY='Q!NC2\B?F/G66_#EA"3XM M+DE2)C$37/\L*G!/YN.6?H_FD:PNP7\.80 ,7/4N4/4 $R>'G:9;B%70;^ M\|%24(FG,G),3%-AMD789N#I*!FNC'! H9GH+QP3*9I>!SRR%[*=%@ZD6 M+Y6/^?EGIS.QV+GN+0W*M*.-/< RP*?W\D9/9!)L,P!]N^9-^RLA^_@ 5N-QD*,-1AJ[Z']=VJ.K>NG1A[ZA#++.X21W@#;/'Y9]4H^YZ9W8$Y[ETC3A:R2Q#NC0#4&6$;$RO.9S.L&$C!GC\3G_'@N5ACB9,X^E,-^<8M"\A0!56SL.*8EI<_+: ?R%(+7BHY]BV2_"FTV%T_VX)!V#V397,,RP"H"$,: M*

*JS/4{[!9/^VYJ#!]AZTQ3\3,;95%^P8KX:[!OS9,.:NN6@+M@" -0Y M;$$B=?ZWTZO $!O@;)?E&=LN-P.12,SF1^RK"U_P+ M1F$PPT!>SL@;,]VC6#PLFBGE:-NC# G<7T:=&Z0C0\$"CS>.PW?=QW;00;E\;$'#_G=87'#W M,0%VHYH6L-.|+EF\K+6@"BX_S?$#9_%H.![R-VM$X/Z;\1E(7Z6@B\W6 M9:W&50V;@]:AYP#D$1BO1V/\""M$91FN-R:IY75PB>4+_]KLVX\84?3I=O M>;'_/WMOVMRX<06*O?O>O0$V2FYD4*7-?/!-5<;382F9&NI@KEKON^I$"@*<(# M C062<;EPDO$4ER:1++00N22*7LZ!R:NDJ1M,MUW &@K\^JW$-=BI M-FL;MS8NU3],1D^Z@F4)8%E1KC+==@'E*DC37XURK6B 4V1+ ?*F ;E;D$Z_ M&B"_P>BF@%H:|<;M:MV"//C5H'H=$]M2X+RT=:W2ELN9?:2VM<.*[8)*ZW.P MK!"@K/'Q_"[;.W M75.JGEP*D?9OEBC(N9<)C^1K;=?KR81&L@%W;?&I(_^4'!)M;.3 Z!+B5]+ M>]GWB3\2MK9K=A0R23.=/,A4D TN$S*ISG8*?Z3%GR4##[:*/PH55/BN3"Z& MQ+H5YIM:0[M>J)P:>_"=&^Y4)[]HH)\7H9Z2[D9Y)E.'F3:?NS(5I%)N1GD .C2XL_V0T?> MC#\2NAE0KE/X),]T\N#3]D-(WHQ/RM.@\$=:_-E^V,CK^*-004I/0QF2&;ZZ MIC6"PPV$KRM3I"=>=,^#=WV-*'B8/=CQD\UQ#"1.8?;&;>/+ M-F1.4ZJXW4?^O8/Q<>+/-(3!sENFV\TED?U

*M6P+022O6?)PH8@5N&)!^E!97<#5STI+8+<|XTFBI"QCW_H[QH&VM#L1.O)[> M,/EQNA^U]^<,=#@K +Y(1Q!A$8K2H] C*=>$@[=L_\)AZV+9X-- Z3%) 0_ M6;0/V+-0!CG7K! A]<>(*G!"6(MD&&17$H8B"3IKP7(4E!MM5EMM-,_9OHNGPDWM,'= (@M^?4J^5OPR>CS[Z6 MPU'HOR#!N!,6.PD^ZS9FN-R-&0L&CCDPN?%*MQ/G@?]YEEF|_TKK9[XFU"?Y M22T3[W:#Y@-F^I<@GJ4.%M8>^L;#0&9.8M(IR\>/M-^=UD_J"|C*H0K QT8I M(F-Q)CA/C@ /LAP8?|^DL67KIY35&%8+KKHUP-KF|5FO0P7 ,:MN.5_@6*|= M7&IRO^O=KN9;#^L?!3=K*8]ZYYDACY/V;1G5E1:_&8|UD*YJ.X3&'@7 ZTN-IQ^=#!3MTZFK](@H(X9^-:J@=024^R(#G%%=D"?)8*OOM!9S4)&M_D MW*?3!B0B@8" 4[MCWB-),0,@K'1R?!"!@2;&@]*)-^#N9](@$P@ADDI?-@RDXAN;23HF.A_N!Y:.P!(T8(1*_P:R.'DU$1 M8\^@,I U7 _H,:1E]*F#@ST!$,)?R%Z3;U%8>3>3(-6 37"&I| MJLD$U0S=%@$))NZ'CH4$FYBS^;4UVAQ;CPT G?H>2EX3G:.^W%0A$+|(^X3 M%AF>HE7#+^@. P:-=FHXR1%]7H@'Z(@*IVBO![K]0&#TX+E/0#((_1.*]PT, MI/#PP/R*\6Y 3P.V1I<3G^K41H=C>A#-TTEC 5I$MQFZA;&S=(!FSI"_%,=* MI(:OH[N0KTV85E]PP)+ANFM)D.1Q\.1M. G0EK+4;.Y0CHXB52E!^2TC: MW 62&8O69WE&,,'=(?&.Z ? Y/E,GQ>&?B.LF?R^D".3U$)NFQ%L@@PY(!TG MSAP]++!+<^56. B(\7 6A_&8 (.Y<3AP(345'EEL+I=9\|#-7,<4 MX,N :FN+"X6Y2)\5<0"P1N#XCCN9P74B:/D12.5C=D:VSGVZ"%TV&?H0*S!K M$G#HP7:'%!P()SZQ#.&31|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|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| M1&@0)9. (W)4R4>1!3=2(.#,#VAH."&/D;. M"7^S&=O07EHQ*E>A1FCJ4O$@A:NEXD7X?%X0H!LB)1N2^.(I>||-GMSS!F17R/Q.$K"F*: MQ-K.5=)A^B6#>W>]/<; [4ZKWNDW6IU=%AX#)A[+\@7BH-B4ENAPJ6T=%SLZY-5(GE V.L1[1+R5(GC(M!Z ME#*WQWD\P@3I.B33YQCF*W-6>'W1!G\,[(DTA2IS"Fl;Z$Z:C]EA&%VN4[$" MDASP? J(8M130O'}I* V9+O.SH2VVG8$;07HI8C<6+;G._BJ 1APR8_D2B9@S M;LL%M!;Z8B271;>-Q<4LQR0SP6-<7B .DK.E.+@\=L^$L'S2N5POGDCP0D[I MHR^5LQ\%!*U*)GCYW#B-2922\.?$BCG3CZSFV:YIJ((,5-T270%W,1\#I>- M"8E1?E^SHJ73JO(<:P,^\2T3&20\[YR0DXX4'<&5FV,"#PR-*+LU39 MFXZ(SR3A:\)'2[fMBV_? &ZYM\P(14?!@QC&*4V:7G% ,*"?.0@5:[3S0]f<"MK52@U:ZK$F_ #Z_[XS%CX@^LJ0%Z(VX\?1OUMJU9K_3;[=]J7ISMY(^+K#" M|;FI=7)5^!;S2BQBYOC ,4GU[6ARLM?X)&2- 4'L696'@%-93]Z3R!?1.9R' M8AH.YMKP!-, T"W.-$2M%H/,1=O]E&\X#8%!H;Y;BTADP&;):9 P\]>C7,#4 M5R2"B5GU@)RV$;?4IU//? 1:Z>F*0BESH&4\Q]WHL\MW\8/BBM3QADL&8V3QT MB:?9I@0,/"\KX&5F!&RVBGFO#@/\=_^5#?BOSE3!@BG M2?*EKY<%FA4ZC1!#LO#"269[IM95U*N+MQ$)O-2"? N,UP.,E>N+UQ;I.-XJORIX;/LD4A#[2!!3L5_/TB)%RB_[H?-\0L1-D]) M0VT$6ZC?W?2USROYZ^"T 2VTY[K8&V] MVOD55=!&!U^Z'&12)7+- OJ[=IF)=3FE:7RKHE01Z^SG0VZS6&U6T+N\+>EOO M3IN5>E.U1U?MT5_ABI6B\/[C9I>'U$BZTZFMRB$CUUB&D+Q<*SF?)*W<-#JI M=RQ|H\@)0&P/$+UCKOF^.*3K[f+- K8/T*|)@H!.1"90_2,A(=Z1]f[I61WL[Y M$=/Q6CS2CD==''S?[7-I6)"%-6GKM!92KL2XS7G"T;H8PM;K[(TQYMK"R,=XR MXT)S72ZN<$$^]ET&/?C>#:CBZO*!0B_'!V4+7"3M (Z<_;!*2)I 2+#3@,WF M*8E<9KWEUUU 5OK2@-OBL3*MQ3"&_EMD-:DIO5*H[&5AIXVRRA,*$2+$*V] MK[@A.Z^UT5;?]NW/5K\>H@G!V2?XR8,F?Z;@6$[WE\FPM#'E>(!#YU46*? Y17 MNEQ L<=$)]>?%/![]&_=IY(RO%X0+^!G,JHSAG'5:CH2=\K@9+T?6I^&"Z1+^$]A_S>Z/%SC..Y]>II<9 MH(M2/ZC:05SNW\9.1\,_'TZY/U'4A5/C(6#,_C!>7APE&OB!UB.;<)S.85T MOBCUYPG|\SU(L+8(5OX3*.BO-E]4T5+*)(Y,PZ',#29U*]CW\1Y44M(RR#\G MGR?D5*)^+:,+,.[J6\8K+|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|>6B M98U.0YH$2U4EI508U7V#VB(@_* MHT]%406A'P>-4:3!UNOR5+!1%<$D5&MY1; H=5@D%V/7]>"X55P9J5@1>>H5 M!,_HA4R7C\08%)05C.4I]C|&#?K+0;$EN7]P^'MI07[@IB0I811Z<&^7:G5542F/-/) _8%X2'' O:]MHK%5+[$M"^Q/.I6>2U+ MO8(HH*54._'AP#%IP0W9PIV:SI3!'8<[^ M,:>_7$4;63"G7:DUY3'X*,PI,^8L5PY"LSI=>5Q0JCN<9ONK4=X M.NEHQ=O?H":)[8*BZ])#3Z=1HSS-BF9:'C,">"%PJ2\6'JP?-5#2!A/]?ZYS M8L!8.+48!0\^T>[F!Z<.3]JCI8O78+P)+ B;W.5B4KLHE&?>^[?0I>W5I#-S MC#%L]0?9?E(!)FX$RAOF?C;EU]- S"YMR#$Z^O7M[!)O38]QWG;IB'M'^@/K!YC>+6Q-(HWWIUV%T7*O|%U%9SZDH5&U"F_>J=17'D;X@- =EPLCCA ML#AV7#/GT7Y)=/>G@*> Y/9L(ZBW9/D- !00:1;U7"D$HU%L.]1;-Z*NBW@I\M-H5XA]Y:;T!$8W&KY\R@]]2:]8K8MVX8O.$LB ?,>J3F<"13B+[&>)!}$T+^ M%?:++Y6TLS0BZ$/:GHCLI3<6_]UB@6S9^]N Q/8"9@[^N@,SXM_F>? ?5A._ M&#,S!-[/^^T(6,+C9B6[:J/ MAKI^F:X_S;CV!0O>?CKOW7=0AI8N\0\]>.PM0\;50!MDKE=@=[!LMY?:K\EH*; M|4&-:K!5XD0BS@B^G]R=:+=*X]0&QQU4MH8^^WT7 --B7!:PI5;+DWR2"[=*BT]9,RV5#I3W6*7P) ME222%,H0>9UU&MR,=7C(F&DI+XD2'&2B=DOF8$E#[5* M#^A0:IZ.DIHD "- M7DFXDDYHD &-ZON+X#X0@:$,IH4E!(;/2F"0A|(M611:1DKW>6^43D[52 *X M/GXT^H<,-RT13RN#$GPV=IV'/S&RZP9PG3%/\#7M-]=&UX:O?;$F5L!,Q=C* MBI$2'/WQWW2N":,MO9)W)]YR%L304TX.8EHB2 E>S.&=*24;4J1^?0/I0OS M_3CD=[<1ONP94^O8Z2?3>HSBM6Y^,_?SO_ Q6@(\0F1 ?H(CW4S8UW>WIX8 MJI&:8. [=\;CJN4^+'V*GU7[U'T\\P$T)7^L=/-MG\;OO'4S^/6B^OGV8O#OZN#R_N+V%TVWG_29'X6%H"SAL,RF/FICQD^G@=E^_M0HKZ2XW^R1.PQ%?O? IX_R=_.\T}2KV/M<[R_/OMB.3_B@4W+G]HZ')#EV);# MJD,,R\{2?)H/Z+*NC3VD4?\)7.-=!ER?Q(XM(&,62E;|+O")^0]C(2S[\1*4 M)8^!4; W1O5C'@C @? _I9_TT]U;Y#Z(C$0X489VV@'9+$K6<-L!X=KL@*O=C M!FK.3/.8;6&"E*_]PMBI:+]JSXR]5P=6Z;)G^%^=K_U[A2@]]//^-0I M<5=D!K)QS!+|"%/$R.Y.F23+,,"/TZ=/- '2,YHNS.>X@3;6'S&37->$E5R'7L'B)S]\P'_@ZH:P-H07F&O"6$##BBU0_^+N1]@%8[*R M)RL81\DO^'@ I-]YJ&A_IG /5D"CPM]F)=L4#+"TCH'6O I>D67!0KN]; M-- E8S\Q$[_'#T0C61WDCH<.>><1[8D,D %7IX\U&A**L'GCSP7;'6!F)GX Q MUN$\R_=#YN\N)V>>_!\]7>12M[S_Z';(KD>7EJ,[!E"#*\L !^HNE M#P6 PSF=QD%W!RREW.? @QBC>NY7<$_Q.Y%0S=']_IT&_L#]#D*YM?(+2R * M$@10Q_#(WORKUX522^O9__4+4J1^?0/I0OS M_3CD=[<1ONP94^O8Z2?3>HSBM6Y^,-@U=D/:5ZB)0\P)>5R6Z;(S\K0-MJG@SVU@NC);S9$WW\'0\$X+/=5R<'| VQI8Q1G(%8CP>)% G(-N/^/@4]. PS M".L!DC^$OD>"/I.322*&8|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~M0TO&A &Y *8"R);K*Y&R1XXYU\;4@%B2:9P,9.@X#RIYKPV]2C7(-=L4-<5[(M[9LO<)SENNGPF/OO_I)K7+>=Y_K]MWVN+J08IZ@S_%>VAMRISV?P>.B_L85_E M13:/16X\+(87S&Y 2,(>1'=_AM:T6&?]M5N|6JU3Z]1;C7:CMU.N$BV5 "A> M!^@WBUD(7^ MN],1#!#%+ "'>/&%3]WV[M3' IC1&S.F>]PJZ(Y&R&F(ENI#U],)M+(S)%X9 MN?[NE S%RZ^ED5U\LA04!D*L YFZ+10 W%'P!-?&/8NO#-Y<]61:A2N#6P7A!>X8N$M\\C'Y 4 HJF,)Q\E9U$%@=#"* MW);)89]8-4Y#&N_!V150,D),(]#F#W [!D;, T.. >')QS8(&Y0==*IK1NI MLT4=W?&Y%@=N"?^B!QGCR^MBV4-.%\-&&|IL()53CAKL,)OHZW!.H M? 2"V73D!&NS@#'AL4X'TUF^UFKUV&R2W;A/#\GN!'21R'F-X3 M41(^-V&X=BRF1,N++#O MXD.V ?%>)M0MCMCQ6*X,GCZ?T=*'CH"@Y<'3PA+SNA&A"HZ@K$(;Q7CR .R,/BC724- +FD07D%>%A!UEW",R/(6P" M'GD8,8UD6S\P-)HR1C"..8'79%5*2 8'LV5P.X3\|_<:0]GW BG@:*+YA@D M;K](R-8)R7+1]'44/@RH46 ,P%@L[(.,G,9:;/ X0S1!0V!"ZBQ#)=+(QC1E M)#:.!2N+)2T!]^5%'C:R"=5WBFJ2K!@M$11/%'N)0$U!I XP>G=$F*9:

*C_)250E MO+3"2D&JU^Z%%?DPZC5AI56I-Q=3KJ3!*HEDE1T96O8JJ]REW;9*9I'"PBV7_MI+E5"G&E1:KF,8852\RC5]C1K=7E12B*) MH0S6C;M,6-=QBPQ+NU E)(-+K5V?*
6M9K^Q= 1%-M^2ED {2J;K>[-QJ9Y\$N-MFRQ29ERM[U^R.1Q&0X6=Z/;434'^ M_L"!{$'X#VE:(Z:HR1^ACWUDY[+U 5I&KALX6*SJ>6+_ 8NMX08;O3@?4F>C!>L1@$H\%GJOS
*M0ARI3&>M7@?$K#;,U)K1\Z-<8G]J6Z*R V9$3J*7\/6O^BS,.CTAX(Z6NQ"6 MO>?NC*J85,:855L5LRIW,:ME69'DU:U@60->9 E(VXWG.O"KP2MHO%[HO5]K MMWJ]9J??WW%+*
\1;+5FWEEWXL11CN72+2B5Z_ 3TY 2FF1/@,;@?&Y=%$D* M/6V(13*83\T+L8KD7)&42JHH%=97H;Y8%5%'Z<)0A-A@AE KJC\VXN*/= ^%D-MHO/.8W<]-8(0)>Y"T(H
*JDW*DR0+K^-*T-I6ALX#A8!N&58_"A;.A,AVW*P M_B?6RN1EEGCQC:2HB 6/&KR/JHG1%](1A\(QO=F4G2I6]Y_L#KIN>4; MMHO5Q_R%_/OZ#KNG?+N^O]*:)]KEX.I6^_@R_<+
[>O%X.[[[<77BV_W=\= M8K+5)[B>(PH[Y3=K3C#$'52'1"I<4" M*^= TZB.3K->X?3@/=5^/S>7>^Q5=,&LU!@ C2]G6Z M%
[5&M=D9=]MVN!$M=\>#*]7W5KSXJ+1N6Q\;JB:%2K_?LMS?!K&TPOSC4W; NS~>8OJMNIV./_+;?'UFL]+7SAO'BFW1J1;$U2:LC06%\VGQY10PEGJ.I~MQ% :NK>O$2R*MX6'2?
*I%67=QFIU)2P8',47(X55+!/]6" M&RQP32T9E&2@s$%>"]=3%*GQ$!@E&>1(!@.*3%-2@4);":92%Z>D M@D. (06GQT-@E%20(Q5\I>;1_M&+!>KR-\9Q*=Z&R]"5T8 N,)L%B0D
*MZOY+>?_70QCTD?*N% "4$0""^.VX, DKD40![\!/2;Z*UI7QZ[\"-O'5W9?S M[!UI&*C++_/E*_%F*IO=0 'NX\;(TX\CX]A2)5CKB#G "#G_1?VR&RM_D&! MC@*=M4"GH4!'@"$
M*\"XL("*LYN,2C$?>1/,'-/N7U^8NR|)P|\^EF-.F\>UTGTKXR*XGV>I4HJ7-M'OLS9(XQHYYV\3/I8HMQD=R%5G??[\ZC4KO.=LC6?.EBL:"^'%?&OOUG,TSUC/".=.HL8W%"7]0Y
M/BC$4HUBV<\3;H=@1U$6<+$;NS'<1J'#1BC:QG9E;_QNB@PA4 -(&)C:HC;D 0-7:=*5QW\??#2[BKT MM0!X&-C +%!8*B;A&33Q=Q.HQB,'ELC" =.0H <^DG*3.3XB!LR(Z:(Z0NA0
M5)GTQPPV32"EPQ,>+'P*;R"\F6P8Q&.&K/J.*!IH@WH\OOH]XA4?G.G^$#N=1M%)\@1Z^H7TS[<;&%=#]-M ,X_,3QIGY[2#5HI;@>
*(/'WT)&Q!P"X<_]G[!V;$T>2]>&_SWP*A6=G3W<$ M,$C]$@3MX2T^K5.W?"\?EA@@N V+C M+3%)86);L[0A+7#R\7T';NE?WK\FW/B%I4!1JTC]!1O!?HR-A<8N/VCZ<\")
M+=;O6;/X2YV7XKW`\@[!T <9GY5IW3P^IY=.1&ZQ]=$]IV];+HMWC M7.[ICU__^+"]+GL#=D0ZN*R+G?K'WZ%6ZY'C/IXZ<.T#.#>$_>U]>;H>_ MUX=W3!0\
*(L5>7WQGU@'ATU'AF[JMX/IB@%2I!HTC;T+J/K%N.*X]P5;$;_&-PSH8TY?GV-*4+4UUH NNNN9TA*,:LJ3E>[G'<*IW_0*0F+(W5V#X,CG@7FV]@F]8G^C6[J3D#;X5(= M.?F%?
*@P11HX@S&P&3_{O)S5891[E %07HZF'RA9_G$Q@VN^>L"^^54LlO,/ MKX(K[W*=-\?P"M]K!6(V8C_^$V^ J\P\}?65V=F0B<@AHC3SXA,<_J+B:WKW M\N(5<"D'=-S;
*(3K+=@:2A5TMI"79+T@T$T,,F78D;<$O@+=WP;IZ+J.C Y#@ MH=VI@V.%"F_!C83*U>2><8&W^$92RDQ<5P 10!:X/iN5M:T'[^:Y:EL1:<+/@ M-H]EK@@8+@6[IS#/J-%"-
\0]+%BQH]6;TP^CR@WYY!5N3/Z7'\=0RX&H8% .T MX8NE82 !GW8("#OS;"OX1)=ACMT)/WLD;"0M7)"%_Z#S(:U.Q@RG@ L(7LI: M.%RAO< ,F@L0.G2#
*<3\'3OKW*0HAP#,&H,.6[?JI6\LPK!>NMZC5#B 8XA7<.MT#,WRID-]J+YMPQOI<,XQ]PB>19D*,1S<% L+;@ATQH2(JIJ.8/JZT05F__M6H#W4K]2'>XRS.;@LO#K^Z#
*(KVDS@_LNJ_.0#B4ZVC,1_Q@K<2XR_DI?:'V[MMAXE?0DQI.51)Y>>]ZI9W3(&/\+-M$OY@ZGOKZQ%UT#-^@/VC$C]<:@UUW\(N> ^:^["HBW#P8&90J=@=2X= M?
QTDQO42+P#?@H&L@<3>)/:!'^TA&.#Z06V-#;AVW5$KBW5W! R[3,KXL9 M0.9XY4Q+PS.M=KTIPW_^K|UZJQD<(BV<^G=5G;:+(CXT\KK*AJ44PPS^.ITG9
MX<$4?."K989^WQ6Z?:%Y?6+C]:G_M6 .CTH\P5BN,)ARP<_=;KMRYZH[Z-;; MG>&@WFZV. 6KYLUMO7]U==N2[ZIN@?M"XDY8W6.X1Y[P2Y">=>&+A[WML-W'H
^W27Y\ZG\ND),#MD(^ M75[XMP/F)_P[Y$;F X^/!.:'UW8X]N+1$1VWUSR"^(-G$?*T2>],ZTS)FOW) M;#=_*23S5EH>4*:37;9IDUU*R]-SBKR7P:G&TK<@-\0 [DMEYMPFCD+ZA?0+
MZ2];^UH$'+\!F+7A*5?==03J&<4*5?*=>REF] >T,%4IU[&,E7'Y-IG1E6!AFZ9'WI%CY-84R%"5$2(K_^1\;9E+MUMD.-D63K;PBBH%(B (M MVVRT:!P+$/T1B1C>?+!+WI
MR*$,O:4A1(2<\5+"Y^6K5%D:W+HXUJW\-)[TO&\GUE'<+NUVRGD_WGG?KOS% M(^075#!(%^%P>T">RH;BAC'?<:$9VSYN+K1))!L,:FAH?LO-MX3JNRHG&UX<2 M-
*B9K9F[M]^GKW<5EN]/H-.DV)Q.J1D_5^K15+5(S&Y3,8G'30*B=4+ML3371 M*R2B:X-J?8F)*/"G<*>O]>0VT+=A+!M4,?V":C;26SXVXT!87TCM.&O\N'Z
M/RU#=7E3Q?,^6,^:.T .S> ^4X>95!%R*I!'MHVN4#(2MZ/CP>=+_SJ0[^+AI6R:]Y1P0:.EE P$K>C MHV#YBQVKY*4+!R]LD[^HFMQH"DAA':(5?Y2/Q!=_ZL3VS&)'M+2YA*P&#[J.(?
M ["}*)@O'6]//!QZEX0Z$X1/V5&2.^P RX5_C036_^U_237VVE)WDMKG5Z.YT M*%:@//B-+"\NZS3&DRZ?G7S):X7(I_KC-.6SC5'M)JFH=G4=XC85?[A32G;1
*MP2P!^3A/&ZW'0\%6X1\6H92TG8-9A5.0U7;C0W-#5SYD5S9DTBDUB2=%_4XS M,.DM0!]4.8'0,@):5FKNSLY.1CXZZ1DSF@=LA**35<[?N=&?=8V9FO2J,T.K M8'3R!%(-.J7D\-
S^F+.QR[1 0K;"(Y'3/54|Q2\GD"^$.9()'LVMY^VIE+.+7+$-D$NNZ7D M\;3+):G\G1WELB/*LFCSMY6X"1D MM$,KOD\-
*IRL/&.F6FK03HWN$@HXJ[QBI9!UR,E]9%2LU8R>SBIT$WPZQC4TL MW$_=U1&MF/L;'0V.4'37^6QBAKL'8?KWY?/VF6F\U?XIPW_Q6N._RE
M"WB:E6O=/3W$4J+ZKJ<4N<';=Z>3NFV];+XX9H0AW7_|-^L>7U O'ARB#A5Z; M272!Y1YXP7 K7(_HC¥\^3,-0\)?WPXVW]ZN%V^"M]>/=T^ !.4HT7]=5Y+XTL
M&S0#0#Y\6WFJ]!4>=2:CS'^\E_P \,I-_B\N-NR=_?'K^E3^=A,_E9R9-NI$ M/GV[_JR:?X87UG1G;]@P0IHZ":KCPQ0^U@FW^J-+51V7|&9%AM&O?B/S'L MX%P=_\'>8N
GUE\,8\:K+V=0R#C8?T*%DJR)=(V "F#SX5?U,G95O1!<\P(E M2%((:4/O,F)' HOPIAHB_.OF0HU8A;N^YO:X/V]=]^O;.^6J5>_U>LUZ>S KZIG_;.M:=\.>CV4 HXZOL!RA$5!F*L:
G'XMS-7Q^:?GLA,=)//;SPXI.O;#L#*ITLW M-69R2/G!#RWXB8V'FJX=&=!O3,5AAT,Z]EG.T4YIBN@MEYY>I&R'TR.9R4+/ MI.(>;]/IZQ?5'D^+ZO8]EEXL?E'E73W_5B,!O6GQ{1E1=H#
*95>0A-JDE@^#QC:A X0HM.:ND],M;>$+H M6Y!S7#;Z/EFN:DC_5(V% &%*FOBWA&RD?-7&'-+QD_Y[V:/U^#=¥]MYF&M$? MCS?K642?=76$I.9R=:,[8\-R>,Z1GS?
*4S5ZJV$%WB\VT(0E6QH!?MA'D22M'-5QZ\DU+LE%]75<4@9+XKLGGZJ.JF!.:SY6"=KC#?9)#]\Y&,)BZ MP\9U_4=]JFL:,]\8 T RQ19(>XAXG>]'"'%$1QV_IR.
*(O9'#U^Y!UY98G!PP6W&<56 M!XE;B44J\%:$L.WL8!)K-%Z9W/Y@IUATFS;&CXGD34<7M6/VV$A6RO:SD)+'A MMQU*8SWAX-TV#Q/0+JLNMMT8"'X'H6?:]"POP4I1>G82-
>BT=8V0LW'V&ZDU M9P/TY$_F"E>#- 3FX[O9%P(?IZI]#GY&J]$EU2I'^!DDE2P?XTU!2G8J3@:I M%KQDG8RJ133^:1FJBWD@K^?M8IP4Q5I_0"/8]U2((BY%CNT$VA=7/:[
M#=%!EL;MZ*A5WK93Q:D5^4X=-]%HMHJ%R(VH6]P"&(G6)S9CDKVE4%)@7K&8 M=]#_(+;9U/S)WA37X445:CP)PCHUD'3_$73;)+Z1_.
*]36Y2:4T&WYR$!4:^]9O7S=BXK6+/(NQ1TM8N00U&U*(7H(DH3],K* MU\S3+8AB&H5H%43]=G04JZP$S?/]$=2B]UP?4GL$1?N$%-4E:.=N(6O3QYN# M9.CID>
ZN=9\TY$)KMW/],#];4[+M@XOZPNY=0K?]%D<$G7A6@4/#(%E8EFN M.;E, ^C$SWADJKALSZPOG@L;I-V5VTJGK]75_FA2;W?&W;JJ-)MUQEJ*TFDV M1\UFY^)R]/U!X0 HH.Y)
[I)FFXL7/V926PR ;C +CSX,C8GD^YM_1D 0[HW MU#'7X(;TR)B$4H2RK\KP;6>\P_5W0+&E%_]17; KCJ3: M3++9&(%&DU3X&WMU<>],YG^4@DD)99'90TL;6>8AVFS#8H."Z
M3D-Z @'D7_,_"S>8V\SQ!H RR\8VF!6&[^NF_SM\'-^;]+HM/2.-3B##*HX> M!A=<7WJ9,A-O/8=']-K_SSWA?T&%AF-*2[Y8!>8\TAO.FTS @[SK]VE7X MUW FK85K\,^-F&&]-
H4HMC>5IGZ5*WWMFHIPRM%;M6'5S>M>OOJ#GYK[>_]-MW5;[3KEMM(O=H2)Z6QUD6W]L?N[C5P]+2]1&D73FR>B?[^ M'PO -S#P,-JO8+/1P<<_Y=K25I$;\R.;N^%
(%>GOZFS^?F7'N"!!_NC4AL. MI@7H5BHZ#U08%^*K(#+H>;*QC?H%08C67I@IT1[+LI5=B(<&$?%"1C^]
MEJ%DX2"$[P6==5'"]R(;&0B5S:^RL&\W)*7'6>Y;%]9+R(:0#=IH7D%OO83& M"$)Q>4(>6"!$R$15T^)V7]@& M\HIM6JZDSN<&:,7(**2KI #]4Y&-+:#?XZ"O"-
"GM"\H7Z*TM_6Q;%NW;?Q MI.=]NTJL(R%TJJ!+6D9;@#*U+))D/N-SB\4]S\4EA*N5B@:+E@0I M%*8Q>KA4'R)%.?E80S!W#E/G@M0SS)L+<|,P#2WRAA+D?1V/6OW>9F&2 9E2
M'45I-G[DJGU):U:8);5S3QGO4%M2TT0>5(>.'86T-A)R8"]U,5I^E8=AI<U(^B ML+Q05H"# (?]P"$?XX@ AY,!!T+.796C4Y5N+W$"V]!|/H:80H!P%/|I\8M!P M1Y[\9D-01@O52U2!?
*WCZ*E>,,&G,]$]0GY)E8-.HE_%RNW:9$ Q7ZN_0D Q MA7?.036_^U_237VV2*>](^>LM+$39V>GIC[MHP)F'+O%Q66=QG@\Y4B4X'R] MVPA)L/KC)"6XW>B1(F]LDKM-
U9KD;.A&2[>S6!-R_KD^\?TCG5VY M[_Z1\U(H*R A+Z7*@6[1\HA@8$)N-@EG\:T;Z$8W]XQ-4G>[4:0!"0219=P M]ERZZ)O;,._<@8A4:V1]]%Y=(T(X>6M_(T*RI$E8D4-
9$<+93_M;$9*R2]J. M)#:H*]V1'=R6_1@;"XU=?M#TVZ#1SOW']]_CN_YLZH(_"E<%_A*V%]YUMW3 M0V1+F<@-UKX[G=1MZV7S16Q08)-U__/K'E^V\:C8V6EL%2K\TDHHKL)EMYJO?
2E'G3 MHV"K$'_'_G.3_XO;T?MO7?RZ/6 W<1/):]5R3N13]^N/^OFG^&%-=V9&RK, MD&YBBZSZR+#&?\;6QGO0I:F-ZOZS:XU724%>_"<&*^C]N'WW%@,_L?YBN--? M?3F#2L;Y-
KQE%78GNT;DY7UAU;O85?5^<-T+E"!)];,V'$Q"@X2ZHDPMP;*T MJUIM"3:4K[K]OMRI\YHW[7]]>755[[>O>O#GW>U Z5Y=]V\'HB/8OMYS1?CV M1$>PW:@N$QM4?5%?O8Z?
*HE.5.'07G:K.B'$)X6JE L*B9=5)-\F!35R^,NZG*?NB8KY^ MJ]B&5,%!E"+COJ'/T0'9&(LGS)^1K*[_^ 1^EW1! <>;N*@2)XO0[!ZR7G:[E2E+3N M2 %)4UK;C>Y.TBI(^M#
3AS03^1IS4#(3],65K)T@M.6K M.EW>_0G(@B(E)NE"%TCH6M>=EV^_0B$IJVJMY'E0/.HC,1 MR4'"4E96W4';#A'-_)$;.Z4AB.A!H26E89VT Y#1*6TO9N4BJ30HB&LC*>
M#MM,B*C6"=MP*-M05L;08?L&$153TL:9!>AC?8EF5J1K'8O&,\2VY>$K>>0#IEBI24'N:7_/D#V&WLC_KL[F[R71?D6<&(KV*V=)RRC:KPCY$.U7O)F,;+!R M-BK(CX7))+G-
>VNT*:R5$ TA&J2QO(*^NFB[!6EH M^/O0U(f0"B)_91:>5,EM?"8R*)PINO>+ \X=VQ8(N@\'84T52(MD%DY!9J#5K[BR8*U-+E$9DA8'6EK(R%/O%(1#M%IZ+0!,U_AZQ$!,T<+(II@
M*=,,9%2Z&)!#4Q7VTO 4VD][<05D5"?DN5(XBB)Q%S,S7^<"())BW65$1+E; M J4_\U08J0O=HZ%Z^S@=4=*K!H _^1,E(^09U+ER%]P-??XHCHN)1VAH1
M0TQ_J LU&16'&HFBG"^7A6EBS#!L\W=1+C3;/9)&OWR :ZZ]B1?.X32E3$C M2255%UP8E .:E#:Y%*^=#=D4B+,-D+0JA:625 IRB(]O)'K:!),.IVB51 PE
M*7=N$0I(0P$)Y@_FZ)!$U4^AK(&$_)0]A[LKWCN)%$C*C6.]W6B3R96IP/I3 M#4ZUR:5;"'1S"N6\-7DW0RF"4HFR2RY]X2#M5"C++K<:=)P\ZJU4=FYMLC9] MO)-
)A@8D"7ZM:\TWON5?#+ M$(R_71 M@ TFLMK4VFWMXG*H_7OA $Z@[DGNE$F;,BQ<_9E),#(!!)&L"7^9-[JXM_5G MP KIWE#'7(,TB-C$DH1RK)]P+>=|<\)Q$!K5$0!:@PM\,-
(-6I)$/2E&*6+O ML7:+G>_P802K1,/D^C ^%TNNYV<M[I.CK7$"@;FV9K#++>/W[$WU%[KEY&&]2KHY-A8:O*=* M#ZH[GC)7>IDRFXU>^767E'YH<8,YY=5@\,+"T*012J0OU6\MX
M[UQ/#,]-3#=5'"*VL/$3>(6_%]J-C07 ZL(;7U1[/)5:LL=+W9#^-66@59M/ M_:(ZRP>&C3[S%-D?:"TZ-LEF8S0!.+D: Q6&VP=1>[P*O*\M/,_&M7 EK!D\
M_+.J&_S9X35X968A==YR"AO2)QC7&"^LFC@>W9U*P\=KJ:\TO;NOWTHWDGG M!O#;>K #<&,S_/Z(N2\,'O6-_);.-5%U6WI&3N9@IM=G4Y_]V7683I"?>=="Z-M
S^X,5=JJ"72F|"'Y6.%=?(D"ZQRW8,_GF0&F!)DQU8:QOX1,@44J>4:F\-M8<3AA]20H.C0$'0F"=;* H.RI4J70%;_RD]CF&Y0+UGEL8,G'6XA\$_-V*& M]=(H$'SBVKIEZ|&VUM>M?
RM?#_K7WHX8KB@F)=6EW=*/9Q>8[CJ4MC%C\XA??:VA6XLH3 M0N:"SD;+1N,B^Y8)'<9EXZ_7:\R+W+P9 MO1503$@?M_0':6-_D$&C6T)7* '9IR$BG2:
(B"R3D!%"V%X5WWKUP$-@.R'% M+;XOF,!(DN_#;-EP>BET121MH8[7!*2B'N(>5$P0/@A1$6@5PE2E47:CZIJG<4C05G7JKEC)BD[(U:I:2*C2C8OH M;CS3*$<.U>7DO%R;'NF-
!NDFKI5B0X ;TKW,LX$YTCY*V4+=(C MNA.1!<.TWBZ'H,\7?@AO'3&@B8D$=*&ZJ!?6R>545(^R,T)9\0@Y(U6+A52^ MQP591.RF]04Z*!=~99T1RMSZ!'2ANJJ7UE/F5%2/LC-"6?
$(.2-5BXQXC2OT M4ZIL+PNZD'B@_-P-$O=N_J5TKZM*S>W^N>JUFT-!P(G;IR&3,Z!%@1108O0E1$>B BW4.?@(@0 M@O.J.-B"ZYBLW@JNX\HN_3.(@-
D=QJR@&S!=2SN(>Y!^AZ$$*(B3IW@.A:W M$HM4Q*T(8=O9QR(%U_$14JQV#U+K2H/K.#C^4&12F9W$>5:%*A)1Q=Z!BBS+ M9SLFJHC!1J]#5P!)^2IGOP_+R7#Q((2P!IF&RZ-
CLT45'H894U/ @ MQ9>ELP +)3QM%Z5JX13!$IP2#]2$4N%)[@H3-R-MK0W:+0H0:)@Q:&@> =I M.T*#*EBHW4YJ1\@)5]<1+ %D)7#@_1F(<463! 6VQ>7G4;;)BP24(?J:M)!
MVH40(@P6NG>]+DG5XB*",Y@L*!ZDFPLISF""L$B9O92 .E17^P[2/H00;,#0 MO5-U2:H6)?&8@P5M,#E(/%"]*P':8**GUTU:(6-RNE!9U>L?M'|(B#!O?]X]?
O%^E0UD91WDVQUE<477D*,X)5KW3T] MI#+!1FZP]MWII&Y,+YLO(L.P=/_QZQ]?ME/,:C@PP5*OS21,35T>U#_\"K?" M%8G^^.G#-'0>[X2:KRHKTY .XN.D
MJ"CS^\EWR7\N12K+V=0R3AKP#FF)6LB72/_MQ\^%6IC%U5]P?7O4 $Z@[DGNE$F;,BQ<_9E),#(!!)&L"7^9-[JXM_5G MP KIWE#'7(,TB-C$DH1RK)]P+>=|<\)Q$!K5$0!:@PM\,-
^[Z[M^K]D^*(7W
MBI"G[]L.R"H(N\OA-!&$W7D)NP51-ZU3F< 4]H"]%L0& FB;K'X@JB!ZL'I M]X*HFZ(.?E'M\512VIRGN2W@5ROJ-?'W!/.5W@N*;N+ZN(7,L]^ZN/Q:L]$A M0.8!1(2HB+2YB P(B
@A:*^*;RTHNLGJK:#HKNS2;X/L#H?LMH!L0=$M[B\N M0?H>A!"B(DZ=H.@6MQ*+5,2M"&';V<8(YF*+?.3A(1>PW']+H@O38*4B@ZC@-E=2+D.%0MXN"QY>JF)
*A5R0'=@1/+=F;M).4Q M[$S%26IO1$Z\]ZM-!^V'<21MHI5H1EJ7Z-'!LQON39]G,XR PME@H?D6O-- M?
R6X=C^COO:W^2;:*$G7%W+K%+Y1LS@=ZL*U"AX8XLC$LES3Y4R9INK%P]6.@\"FCJQGUN_"'XQTHU0J44^$P.84V-'\"FR_VVO*.KM7GPS8 MN-
Z6!U#]U!FUZIVF.FH.U(FB*2"PGTS.2^SXA#D@GKHY]NP)R\)S56UX#S9. MS#9>032D>\AN$8 >>X^U M6^Q\AP\C6*C+*WVRL,>]IX$WC"L]
(((#\W$%9CR>\%/^.4?/RW$6]PRB(_D MLVXUD7<++P>X/TV$@!2 @UY;)D0%GXBM(@V 0,IAWDA!+VL2#DUIOM]X"OZZ_)+!?RQZOVU(M=\N+OL X- ,>WXP_^,+!
<:K2%9B!/Z7'\=0R8&)FEL8,'+&U< W^N1$SK)=& M@=(21QJ>B0!\E3-\W+D9MI6;F^NZTAJTZ^U>>U#OWS5OZ[?#F]M.I]OL]>Z: M2]+PO$SA&VT"0H[>P7&YPU?]U] 8K-
I%02=^N'MLX5\1=.(I=.(A%B\M#[DQ M1O"5\"@]^[6T(;0(V84N"ET4NDA#%PF=>|7<'*'.%#ZD M/V+1MRIZ(T:58)<+>"T-YW/;@FUQQ=D SSX5X;WHC4!1%?U074?T1JC@TK]*
M2E[IT]A"!OGI;G'Y"%WCHFI0&+#I(T7H7IY'$$IQQ?U5>D+Q=NQN)6"!W+VNRO1 M1.$$\3"- Z@@:./.9?:R'N?- B$A3.!TUF2^.AH:5L)>)YM.EJ'2/!HVIQ#]$I MA"3ZI?
$&%81^VUHCE.9PI-,QH-\EOV& @,!75[_Z)Z9?I?@8.RI:BZBB$?(N MJA;7$*U%R*+@H'P$S-)'X12\C#;./:I#:7PDO@X".R6G]_JCJ&'5/HTTOF$'1 MTZA;'$/T(B&+@FF-&@L[1M[>>.$4/
W*_10("'UU=2RM42!5';/N:5!6-D*> M1M5B&E[S$M&YA!P&DD@/3>[4<"H)&@HMR",G\=55,!+YH!D5[!22,N1&GZZF M)=+@EI,J"C.^%?>%,-CC'\4?/%GPA>_(_G[#@U*MO#
>RHF(_5[,33P@O/] MF/<0/-.Q^Z5,[,B/@F7Z(*,DS3(M-%%HHM!$"II(*$@H^-X%WSLI8BS!]U[! M11=\[]4[O7DO^-XIJN)P;NN&I/0X[?=+H'"%EOX?"Y-)@_(6GA#ZGGV6WOMU
MOG>)=S(60$Q&&[0D2(BDB?C(@0@O.*.-<\UT .B%M%6SOE5WZ M;4]_*!N-T.R=P'4@NM=W$/<@^0]""%$15PYP?4N;B46]8A;$<*VLX]_"]HW
M4Z1_5/)3)T02AVI8R#T^PSL_RE)Z>)Q!I,*@W6ETI!6/4+.M:I;_-K\P-8NI MY,$3Q('0MUUK>2CX&V>_EQ+,]B<(@_G1$_,:$P1WYW FZ&DJGH9"'OC?]6Z%@ MU!0L?
VU^,0IV"DZ&TFKT26D:62>C:D$-0>).$O3R\R7L"7]YJ-N+\'UV9)1N M-DBUBA%49Q2T*G\7IB*UJA2'8C?UZE'MC$#(DZA:N$(0MI/%O?P-L?;$O=PT M[<0\"LX1=5B%8*(G2;RM4K,
MW=R1?IU@/D63,BDT 3FOKEJ5F*N9GW2=7!9%L]&C]U_T2=-W9L->F]YF\Y=,.M%-4)OI-KS3<]F>#;_8PZW-_FM6S,V=I*KB_DUBGD.6A,/1)UX5H\%#PRQ96)9
MKHG.\#IFQCM#Q75C9GWA7'"'DF8S&S4Z3-95Z<]0=U=OM3KNN^A.MKDZ:KD9Y.)H(5D3?C+J/K2/==F)MT;ZIAK M<$-Z9"R><5Y21!8S:W"!'#T:Z48]8["='8';*
[.AT\;8_&C3'HTFSWI=[K-X> MC<;UD:HJJ9,"FBUYU!MW6^TU@07;-KZ)H"@6N/QPK89.(3YY:Z@O@:LQ]A8 M:# R37\.>/WO/U!]'B_'FY35_BO$O8FD;ELO
MFR^BQDGW'[_\64I4?>&AC"0K+69A*FI*WZAU_A5[>=HS]^^C -]>-^^/&V M?O5P_.R]/KQ[HQT (39>U%V^/ M_;7W M.U2_]:F-KM?/X*==$.GAG.FZ[O<7 3ZR &.
!05U_.X_%>>"90;] MX#6ZMJ;K?/A5O8Q=5>|\U\|_"9+4;BL,):EFOI*LSU4A%E#'S(KXL97'&_ M0\'A!9_PY7#E,RO>N^9[[S+|%W'D X?8'+V^N[?97-4U]+Y-ASE#4_L&%M6^
MYE#E#AV'N?;J3;___^]NOC[.,T_'HC?7OZ[?9!NO{CX>'VZY,T?'R\)?7I<,KF?;L<@ M?UDDYJ^+D)[:9.'*2)X5<265KPVNMZ-SF^,[0Q/+,*P7,)KS1C=#&A[G[;MB
M>^/D$\E@CW;#)LSFK,PI?2XH-D@2]K/GMJU\Z)H$;N?;?5OV)@'TJ26 M7)H$1, ^\SA#N,K?UJ.I>G'#?(W1K2/7H$5)S&E+3(B4UA+(-"N[LU&N6W-DI
MV/[I)NQJMG40.OTSTIV+SA4R!Z;=E#R$R#GD'X\WZUMUVZ4HI(3MW]MEU$=NF+?RPXIR,8.6-;M]TAAS]O09;D=(=1(82R*1XW(B<+-@@U-[3&ZMGFPHPW802HIEYR\5%<\X_A^
M4HW:X<43"20Z=,63D&D[^W*TB&ESU1],6#)*4)"'DI/)_WW"%.U52BW>5/"G\$]N:\?I$BU??8C;_G-E]!8[$#I (61K:9!Y[BAU/W.C.W'}4XR/H MS_R3B95*NOG])B)
*WP+YB2V9/)DB1M#R8&9A=_*WR'&9;!5S0170G?>)"E/ M]IR6(RO/%C=;BET_("$1-"W!\/"*NQHGRO7-.1YUN<;,MF)&"S!#LQ98 MS:
<&&K3R\K*/.PGK=L[$63LK\NM[#XECH(9DC'^KBL9?]$>H'CMG A6A'N6E MO.93CW1>]%4:@N,7D9=RT\/R*P1'"%AYY!6[=]L%4RIT&M*GK_^_?KT[>%_ MI7/@3
BG^4PY$1[4Z8M#/9M$CZI#U&RYWY%>YE8=6_!(O,2_,\)<|IRM86B6!"-+>"-;ZLL&.) M,:V!$*X7(V04JY F=]>;NC-EFO3=LK0S-WXDDU02@:.?.W.K!(Y@<3_BVN.D
M1N@);@4*MR,DG[F3HPXGGW@(6FOWA#DCM,-$-Y7E@N7.A>7O69Y@651W"/T(*H'.[-'4H/-MP#Y#WNN4%E$05#ZDJGGL;=]ONZ[T!0QDB:VNU?"WV.?<;3[GKZ,>TGCUK5T\5&
MJ=_N;Q^>_.IGU[G;/A# M=^K>PL.;G\-E#S_VA3MEV\A[$N[QT:.K#NL4,J M^Y6.,#G5A35Q7U2;"5M+"(12V"TR M@5"PUN%[R!3@+W1I8-1N$>Y<+34#^JBON*.P8IRSNHO^2V-
YZM_[,5(=-+4.3 M]-G9;V\K41.2@&A*'EU')D0+!>931%Y*W$;4UT)&E%=57)52F6$$ M*A6@2H1+R8+0P52VHT-K=!7'C1^WD;NTKX[@G4 M"8J2FVMDN!26FXBLP.\&PU\
*IH8S"U3V/ZK75S4!PO*R)PW*Z[:V,XN"4)CS M49C<7"-F*TQ/T(Z(+6^>+;_@(*D,]X*BY.8@2<2K_%P.W3Z92)V@)*FV6N2F
M)#F'6O3I2DB1#R&9A=_*WR'&9;!5S0170G?>)"E/ M]IR6(RO/%C=;BET_("$1-"W!\/"*NQHGRO7-.1YUN<;,MF)&"S!#4Q98 MS:
<&&K3R\K*/.PGK=L[$63LK\NM[#XECH(9DC'^KBL9?]$>H'CMG A6A'N6E MO.93CW1>]%4:@N,7D9=RT\/R*P1'"%AYY!6[=]L%4RIT&M*GK_^_?KT[>%_ MI7/@3
BG^4PY$1[4Z8M#/9M$CZI#U&RYWY%>YE8=6_!(O,2_,\)<|IRM86B6!"-+>"-;ZLL&.) M,:V!$*X7(V04JY F=]>;NC-EFO3=LK0S-WXDDU02@:.?.W.K!(Y@<3_BVN.D
M1N@);@4*MR,DG[F3HPXGGW@(6FOWA#DCM,-$-Y7E@N7.A>7O69Y@651W"/T(*H'.[-'4H/-MP#Y#WNN4%E$05#ZDJGGL;=]ONZ[T!0QDB:VNU?"WV.?<;3[GKZ,>TGCUK5T\5&
MJ=_N;Q^>_.IGU[G;/A# M=^K>PL.;G\-E#S_VA3MEV\A[$N[QT:.K#NL4,J M^Y6.,#G5A35Q7U2;"5M+"(12V"TR M@5"PUN%[R!3@+W1I8-1N$>Y<+34#^JBON*.P8IRSNHO^2V-
YZM_[,5(=-+4.3 M]-G9;V\K41.2@&A*'EU')D0+!>931%Y*W$;4UT)&E%=57)52F6$$ M*A6@2H1+R8+0P52VHT-K=!7'C1^WD;NTKX[@G4 M"8J2FVMDN!26FXBLP.\&PU\
*IH8S"U3V/ZK75S4!PO*R)PW*Z[:V,XN"4)CS M49C<7"-F*TQ/T(Z(+6^>+;_@(*D,]X*BY.8@2<2K_%P.W3Z92)V@)*FV6N2F
M)#F'6O3I2DB1#R&9A=_*WR'&9;!5S0170G?>)"E/ M]IR6(RO/%C=;BET_("$1-"W!\/"*NQHGRO7-.1YUN<;,MF)&"S!#LQ98 MS:
<&&K3R\K*/.PGK=L[$63LK\NM[#XECH(9DC'^KBL9?]$>H'CMG A6A'N6E MO.93CW1>]%4:@N,7D9=RT\/R*P1'"%AYY!6[=]L%4RIT&M*GK_^_?KT[>%_ MI7/@3
BG^4PY$1[4Z8M#/9M$CZI#U&RYWY%>YE8=6_!(O,2_,\)<|IRM86B6!"-+>"-;ZLL&.) M,:V!$*X7(V04JY F=]>;NC-EFO3=LK0S-WXDDU02@:.?.W.K!(Y@<3_BVN.D
M1N@);@4*MR,DG[F3HPXGGW@(6FOWA#DCM,-$-Y7E@N7.A>7O69Y@651W"/T(*H'.[-'4H/-MP#Y#WNN4%E$05#ZDJGGL;=]ONZ[T!0QDB:VNU?"WV.?<;3[GKZ,>TGCUK5T\5&
MJ=_N;Q^>_.IGU[G;/A# M=^K>PL.;G\-E#S_VA3MEV\A[$N[QT:.K#NL4,J M^Y6.,#G5A35Q7U2;"5M+"(12V"TR M@5"PUN%[R!3@+W1I8-1N$>Y<+34#^JBON*.P8IRSNHO^2V-
YZM_[,5(=-+4.3 M]-G9;V\K41.2@&A*'EU')D0+!>931%Y*W$;4UT)&E%=57)52F6$$ M*A6@2H1+R8+0P52VHT-K=!7'C1^WD;NTKX[@G4 M"8J2FVMDN!26FXBLP.\&PU\
*IH8S"U3V/ZK75S4!PO*R)PW*Z[:V,XN"4)CS M49C<7"-F*TQ/T(Z(+6^>+;_@(*D,]X*BY.8@2<2K_%P.W3Z92)V@)*FV6N2F
M)#F'6O3I2DB1#R&9A=_*WR'&9;!5S0170G?>)"E/ M]IR6(RO/%C=;BET_("$1-"W!\/"*NQHGRO7-.1YUN<;,MF)&"S!#LQ98 MS:
<&&K3R\K*/.PGK=L[$63LK\NM[#XECH(9DC'^KBL9?]$>H'CMG A6A'N6E MO.93CW1>]%4:@N,7D9=RT\/R*P1'"%AYY!6[=]L%4RIT&M*GK_^_?KT[>%_ MI7/@3
BG^4PY$1[4Z8M#/9M$CZI#U&RYWY%>YE8=6_!(O,2_,\)<|IRM86B6!"-+>"-;ZLL&.) M,:V!$*X7(V04JY F=]>;NC-EFO3=LK0S-WXDDU02@:.?.W.K!(Y@<3_BVN.D
M1N@);@4*MR,DG[F3HPXGGW@(6FOWA#DCM,-$-Y7E@N7.A>7O69Y@651W"/T(*H'.[-'4H/-MP#Y#WNN4%E$05#ZDJGGL;=]ONZ[T!0QDB:VNU?"WV.?<;3[GKZ,>TGCUK5T\5&
MJ=_N;Q^>_.IGU[G;/A# M=^K>PL.;G\-E#S_VA3MEV\A[$N[QT:.K#NL4,J M^Y6.,#G5A35Q7U2;"5M+"(12V"TR M@5"PUN%[R!3@+W1I8-1N$>Y<+34#^JBON*.P8IRSNHO^2V-
YZM_[,5(=-+4.3 M]-G9;V\K41.2@&A*'EU')D0+!>931%Y*W$;4UT)&E%=57)52F6$$ M*A6@2H1+R8+0P52VHT-K=!7'C1^WD

H^G>MDTGOXKW$KSEY!G9N5;=TV/I171D1NL?77-M[;76B;PTZY!^<5E7Y+1/$+7ZXZ}_\>%N_>K@=_EX?WCW=/KR35.-% M?74"-P)W429;>:KWTI1YTZ.@1?

3WCS\W^;^XK:7_UL6OZU/YVTW\5.)ZY)I(MIV_7GW7SS_#"()=S0X49TDU#-UE!A+1"JSX9OQ]HD"J!=@(R_^Q:XXL5>7WQ

*MGU@'\-9O3^DM!GYB_<5P^!GZ<@:/),X)YCQ%{W7:%MX&I=Z&;NJW@:,_H$2_M)*F=M*%W&=U,7TG6YRY0PW1JM&/0E@W'8Y TU[E77W&B,*PT'MN-0)!U=:,0; ML*

*#.26$4V2B&^S)!^R5C, YER MESV.ITQ;&.S;9%{DN-9.2N!ZL+ZJ!H[L*Q3!5)'5%"857'U!869H# K*

*M73%.FXQ*4)@)J1$49J=V2DZ&P@Q##QA+7MG4O7$8D[Y.+I/D]MNJ'9E3._-+*

*M/;MKYVIL&2SXOW1W>KUP0*F8O;G)W:\W4{)2BD[5SK9/1WYS=;1@8:5]9+>6CO6&Z+NF!"MR,DI[F3BX\BIXHRH"NGA&Q:%79Q<:DK$]N:)64VGK?Y*

*M.W#A8^F'+#'XEPQ2*8R8!^NQOC.43?0?3*Q.A]G&&HD)#CP4_(9KT5=DY3V9 MD@E!G[6WXIQ6O7 [A5RS/.W9NK$EQ%LMJH5);m;'ZZ1JWBSZ%*N*32Y&.4!%U:LYGN M@-_?WWZ M#/7C[==KOR+HU&N!X%D_Z)>?3(W-3'T"'JK'KZ9?XL-)WKO#[S8+ ^,F]-T[] MJ8>.!!L5$$(L> *7F=G2#3-4[X@P0?>&Z";Z%(" JOFF$DONCN5=-Y11J_P M_< ;-U($K0?*

*3!X/"SUB\MY[M\.MHNLW&K@5_8=DUO.R]<&GVC/,IP2O6>,RA M=0Q??IG]!N.7]B^\'P@N(.G\\UBA#T#WC*59]AL=!X\L]-X[DLW^6C#'Q4=P*

M%N.I!#JCCG77+]UVX%Q5G1+PSL%-)+^0,)K1P84OF;H$^;"DGC7 MGZD_]-EB)]DS+/O#.\TM+(O4P4F?+'A+M_7;POT6IJ'#@C#MO32U7F!Z[-4Y MGL)C]\NYP)D-YD@W

*3#X*LUA'SQ^A>^IF @YP[7_[$?+.5<*>W,'"'R!7 MLJ$M>],6#Q&A@?<]+&M[Z-HI[B>33[C(WK%AB?A>WP.1\M'-UEL/8EA0!X#V&Y?*E&[6!'D?4KF;@L3D M<.,3O!9H=T0'=#83!\.GG,,B@3.JH.P\(\%*

MJ'/6SW!+58>MY@BN,4$MUB!W&+'!#8.T[!A7J7(W(&HT?.>5+P"LELY!QM-MQ2?D&N8CCLCJK]!T.\WF7;W3Z[7J;;E]4Q_T;X=U>7#=N^W)\AUHU=HBA0F-M\0S=_[D8-*

_OMOGS7Z=1OAW^GWAY>R_5!JWM5OI[H:7EVWA^UKN7N])YW/FH]L11[8N'9K<;E1V%TW\192^1LAL:GE_!-OM2;LW MP4+D)XC\F;.?*

*E;_A@J!*T)HJ:DBK9F0FM.0&H$\0T-'6NJ5$HQ'D[2LD4 MBM_"G.0Q6S MG!EEF8.O',AI;$F.)LO,2(3{D]V6+US5Q65ECV!*P&6*PE5=7&[ML8DI"Y>[*

MA'&9T%:G"MQL28',>H_3E'TE=2!:_=&Y'2%)33BJWN,095[) M[?2I2BJAW84X2$DX2!%;CY,)Y"4D'1S_@&4;1HE@WFG).Q%CFI"1PJ

OD;N5TX&N[E"BJ].HQF\Z1/MATE^2FG+AT,?._$1+/%(AGD=WY1 MV,78G*!.-;#^RK9>. ,AYX9\]FAB)?B "M>!USE%%]+F.!4IBE<'Y'%Z>11'-MR"$'7U>_1[\=H?GR:>0V/\UW74BG:

*<$CVMW\1OU^9K J267>S.DP!NQ^#U&3&1N!V8E>0Q(EO4)!A.?4=M+Hl:W MURRYMO=?OKM23W5ND WPE:FV\(.R0> 2VY'<2*N-O1+.UT*5GKH+?1*L.[\ MS2=89?*

*DBW.ZU5S99=8>-WVD+&R7@XK+5D-M\S>QQMRUE7 M.@<.E8O+#J6PX2^$A*BZ,MN+;1DK9';+S*9!N:-AQ9..<]!Y#4'6HJ*\,1DL M27V,/#4\,'@KQH@[YQG;+.BH7=<1A;%?*

*V@;_+K%^SG C_C&-I1U_];#6U%&/GD M@QW!3LG!#B]N6D#0:PFR141*0Z*4T0&4,.%_*V2VDQ_WGU(M/%R,Y-?&!(/MFXIVP1FVM\D% /HVN=/1Q/AO;F'S'6PKK6QIZ06(=/6VN90*

*K2.VMG0V";)\ M5 "Y6;'O<.FG%V8\,$Z\S0$[X:+<&E'8+9 &E@4Y25P *(4'1C@THZ(,\05AY M<-1-/A&. HY4T#'IG3>.9$X5(0*WF<>>A$[M0E)<WW9:4VR-^@%+)+N(R7*

*MDP*K]CD]3Q;F"OLMG>/SB\\;RTB"5#+ZM(^-/GD+L&OM9E>X0\(=VD 8%+QW MTJ?9?.'U$'>9S1SW0$&E$@[2FR2,ZAP%H_XP@YP6IMW^&,-'AS/*R=@@#0A5*

*MKR8D"K\EB%Z5)(,.'*RV0D +(@"S%G@(O88!:,3_Y4-7\]KB3H"M;@E';/Q+L2TK>]I<[7R=(":&H+7]OF\U"S99!\U M+AE!'Q_U>F';+/<^NM4GM)$6AIP^L-2]G'\/Z,X<9;H0!DR"]?*

*Z!8>]K98[W M0]I:B81U)W\N6C6_2,3]*A7W&XBXWYYQ/S)4;G!3]H.3.5]^T/3GH/3H_N/5 M[_%U4)OBY+_"Y9;_A$58*]>Z>WI()>&)W&#MN]-)W;9>-E_$$B[_N/7/[YL M9_=)+-*

*I;FTF8FKK2JG_X%6Z%Q7\]=.':&4[H2 M:KRHKTZ@6 82<#%>U;/1#"%S;X.SHB%7S6BIPYJO*2E'G3HZ"4^*;BYR;_%V=%_+@F]X^PYFX5I?C]'"%4:6]CLQ_L6N.+%?E[M\9]8!SS0T61XBX&?6'\QM"ZK+V?*

*0TCBSP(OXL&+R&C&*I^2HE[&KZOW@FAX"-8PH8PP"X/"""3_ARN'>YY3=WRNS/2_Y$+"LV+*1: MW"RO5)];Y95"8K],+K\^NW15AHTI+M/7X=?KS]]_2@-KY\^_?/3TZ?;OS"P M>*

<)UOQ_TRT?&I^6"Y=1:A(L-V?25>"V\!9G;GQ%L7T$(=$GX+::KC0<\S-|-MW!C>PW9B#.L5?D_&[[V76NN7NE-U6_HG9\'\XG%H^HEI]]^3F^M?!'WA#C.] M#Q_FQE?DS:_,9N*

*8/(+V_RG]2L5M=>.G.]2WQO@_,K4,@ PPR_(/?Z%-S<. M'EIWWTJW?RUX<&WE>DB.,89QIKH)#1$$ $KCW%,.-&^&]<+OA[89O0'5X-P> M"\=!_pEF%SZNFECY*Z&\.PSB,*

(W;&:H/(R^G/&Y/^A_0GJLOA9^,KU">GS>&DH3/[@:_MH9IEGH.7>F5)]O3B3XGM3XF[G!+I#7XOD.B=9M&7YK=@L-UI,SLA^YPP?/5 M-N756MG2&_UM.*

*Y'TAUGX37>>&1SE\U&S,:'4208[GQACZ<8/AI[:NF@CM7@ M^W"!1[7,'/#NAQWK;_6<]9++.]U!=?ZU^:UOJBOG#@PY3*H4&_TY\B5E%Q7 MDMZ OV0PU&1FO/*)4,#7_I:PO5)2*

*M*GG^[QH]MV3_Q[?I =TLH9PZSH,&S_GO^,+7S"H8$Q>^"]O;M+NF?TX53?) M2&)O=>L QCU>/7S3]=[UY' KU\R\E?OT]>]B4FET-O/P^5K8S">[,&$A8"6^*

MW'=7OGLK7A%!Y_(E2E$(O/4Z=-N%C9<#:9>M[2\BQHBON% 223V4@BUH-Q--9&%QL0=]@#^(X(#6&.2=7T"=PU_N+4#*

M_4J4V(3^EL>>]Y@(P[T_^#O;FOG?"'^9\60';S1YFZ%Q<-AN;D5)C)$!OS1. MW1Y&6=?AB;T ?1%QHQC(Z64\LYEFX #:)1,&$]K8\,-1"(?/++BU 0E+$%;Y MUP)\-

*_@2IF5]D$W\,"#.'G9OW#O@1A]Y+OP% ^TL094>'Z5-MO -+>0.\:W#5 M,1A83VO<^,N^@!!PHS-BP=85+NT/O]N%>M/FZ#_J.%ZPI:H<@W*T2QS]'0Q'2BIQBNIA@T64C[*)V&Q:^[*

*]W)98SY0'0M-[*_%5\WGW MHXN%O^.VF9/P3S+IQEEAA>X=+R%08$E4(+L@?X[KI IRH'_]VPD?O)=%O[M@5O69,L0F=4L1@'VDPP'>\]!B>O^M1GR.K6G[<91;"2*F$<2YTPE[TUW\+,(N/;,)#!AL^#B)>1/[" M:PXX?V.,6'.I]7=)/#H(-F?.3(?5P):[_L:(AUWP3BX6VX88Z>,C,_$R*Q1U M)P]WD2W](_@.NJ:CT?ZX4'$N80]0>Q@*

V9RB(!PSPU.FJ2TO46L^8!FL@B>_M@<8>#;>U;/1#"%S;X.SHB%7S6BIPYQ3#AA6=I;.FYN'IX.-6OL0A3=@&&$;PN+ M.+T=C+NB

^IUQ(O$/_/.1C7DCH(WXY'JPYDZW'5<:@NW0T[$!&C6/K$1C_'= M07] ?DS2\4:@NZ_2$$,!^,T:IP0T:0@ 8DA*S^N5$'/'S:.^NW[2&=[79S'KV MILJ#(&>JSZ4_3.O3Q ..,#V.PSSC&IU-

*T&,,@L!H;*Q-]K5T_0FLD:%_5[V% M-3\))/@-?G'9KPKP?F M)3K%3%B*Z MQ#<,_I+P/1AS_&5$[>(SR#,4A0GS+LX_M$A4+CX)TNT!P@3/A\?S64Z',K0U:>,L>*

*OP@SE\T^.9,\>/IHT7KF=+_M-&;H0<^M=34.8"%-,E:!9&Y;SSI:)-ZK*SJN5^^QY_YFU5UYWGO\0*@RS&#^_MGI;KYYCA?L(R88>WF/M6=VT'D !R$M.Y554#<(UN%-*

XX_]$0/UWQ)2GV6"64 M0%1Z$[#]25BFZ#6;RTNNK64H>B=HM""$G?]>P"Q/7E-V*CR@49-& #=:N"&/ MUZ]@R9T.WJ;'+ABW-.L8!8*D.RL[_XFW2EE"EJT$,LE676FGN+)\;&D;]^Q;

MJ]\\/-MXF.WS,BU"B"G7;VN[IYS.)[[M4XO)HZ6$-+Q-_5O4Z2<0\@$ST7(PB?+!< P-_$G3IF M>]5J=Y1-?N_E[@'$DH>M1F@?EC/J>5 9Y56)WX7QR3G4/,71HZ[>,'H)7WZ]

M\^+E1W+J]SLU>1VS$8_7EX;VU&.*)(>/L#32J!\.1+J'"RRTX95;VV>064+ M[6QU^%8#.P"NUIB[I(FSF'"DO.DS4,LRCN55W[9%ZK2+!9_XO&F$"?WLL@Q1XOA MNN#$+J787P*

MDE/W$;_XN6R9#25O(WI*3>ED=LO\)Q)&9!H>?B=$]K@3,YCVYVXG!VT!8D3$E?EMGU"O#,;UDYG-B1FJ_H;6[% MUCW!+#D7]I<CCA&@YWZ(@KZ3G"RIPNEIR\[7_**

($HK,>6\V6#M9HS3RV7) M.Z0]CL(7D@@6(RU!(EC"_@Y5"UAP$D""O G8&F, M\U"+Y;GLZ'Q'DM;](>$ZS1BX\9IE6-]?=]V6MN5]US:#=2LYIR|&]OW]S<9]

M)4Y37(1L5Q4(1('$=&W668;3Y4],JN1Z]M4;B/2DPGCA'J_6O8=VK.AZ#$=>]^_-/GO)-N&YB,16U3_D- MQL13/<)LKR 1+70B>):R;J16S;3CH^;-#IKJF(.Y;P#+X((:W">K(_,E.W ML,>-*

$SOX/GP/7CQ,(LANIKO5Y.S\&IKN]+R8[5F /%-UZTG%8HY>0=+,A(\" MO9G?ZAGYPA7*%NE8HSNU)H5"S8&.NJG3FHQ <5$G8RK;@DD(_+K,NOB$58% M%A

*G;R":N$]9R1>&1B$'+"LW\S[)KC:H&.+2-Q M.;9 *&+*@7;#:SDEOAQLKC8A-RT.V8D/Q:_.4;N .;H))2EBWP{JEF'(O'*_M8$ZFW)0PQ!.*:N*4QD? BQ>*

[52\CKX\@ITW=QM8^4>4|%=XRQ[#5QR)L]M<" M'M=X30BT>MGU<2'BN4>I.7#/%8^V3 MCB7(T5'^ 6\BB<[_F!8,+_>"I&RT4@/;R3X4B?S53GP8NQAC=YCH=8JJG$\.

*MJXAOEO??[HCXMHAOGS5C+)K--);83K=@EEBYV9"NOWWIY^W+TZ>KS[<2OG@>.M'+$\=IYWJ*8.?XI;HD20TRCC]PLR4@/PB%(AHR:,)_<3-HY>4 MJJB-)\Y<#U+1E^BCWM?*

*QZ?VV5]30SV0=\EEO+3,0B7@U\/ TPYSN%>1Z$]?9A M*$I:QJ("7PW7QJNE[X>?C]Z(9VVB4XZDP2BZWT*W;)53-*U:#0GJ-"1L]K2B MPW/4NOS:(Z,:L-:>*

*[[=L"7X6P9"I*9FIKY$B9<8KE^&32"GBG?2[_GM\3;TD MK) U,!$^<$EI7' 0^DFH.$LN6K\/Q\[#_)48C4',H0*(H7>|Q(EH\; 4\QQ] MRHN*

*Z2!0.$ 7W*1>=4PP5F@M7"1,)%'62+0Y%V'7Y.)2%<62+0Y%V'7Y.)2%<82+0Y%V'7Y.)2%<B2+0Y%V'7Y.)2%<F2+0Y%V'7Y.)2%<J2+0Y%V'7Y.)2%<N2+0Y%V'7Y.)2%<R2+0Y%V'7Y.)2%<V2+0Y%V'7Y.)2%<Z2+0Y%V'7Y.)2%<^2+0Y%V'7Y.)2%<b2+0Y%V'7Y.)2%<f2+0Y%V'7Y.)2%<j2+0Y%V'7Y.)2%<n2+0Y%V'7Y.)2%<r2+0Y%V'7Y.)2%<v2+0Y%V'7Y.)2%<z2+0Y%V'7Y.)2%<~2+0Y%V'7Y.)2%=2+0Y%V'7Y.)2%=62+0Y%V'7Y.)2%=B2+0Y%V'7Y.)2%=F2+0Y%V'7Y.)2%=J2+0Y%V'7Y.)2%=N2+0Y%V'7Y.)2%=R2+0Y%V'7Y.)2%=V2+0Y%V'7Y.)2%=Z2+0Y%V'7Y.)2%=^2+0Y%V'7Y.)2%=b2+0Y%V'7Y.)2%=f2+0Y%V'7Y.)2%=j2+0Y%V'7Y.)2%=n2+0Y%V'7Y.)2%=r2+0Y%V'7Y.)2%=v2+0Y%V'7Y.)2%=z2+0Y%V'7Y.)2%=~2+0Y%V'7Y.)2%>=2+0Y%V'7Y.)2%>=62+0Y%V'7Y.)2%>=B2+0Y%V'7Y.)2%>=F2+0Y%V'7Y.)2%>=J2+0Y%V'7Y.)2%>=N2+0Y%V'7Y.)2%>=R2+0Y%V'7Y.)2%>=V2+0Y%V'7Y.)2%>=Z2+0Y%V'7Y.)2%>=^2+0Y%V'7Y.)2%>=b2+0Y%V'7Y.)2%>=f2+0Y%V'7Y.)2%>=j2+0Y%V'7Y.)2%>=n2+0Y%V'7Y.)2%>=r2+0Y%V'7Y.)2%>=v2+0Y%V'7Y.)2%>=z2+0Y%V'7Y.)2%>=~2+0Y%V'7Y.)2%?=2+0Y%V'7Y.)2%?=62+0Y%V'7Y.)2%?=B2+0Y%V'7Y.)2%?=F2+0Y%V'7Y.)2%?=J2+0Y%V'7Y.)2%?=N2+0Y%V'7Y.)2%?=R2+0Y%V'7Y.)2%?=V2+0Y%V'7Y.)2%?=Z2+0Y%V'7Y.)2%?=^2+0Y%V'7Y.)2%?=b2+0Y%V'7Y.)2%?=f2+0Y%V'7Y.)2%?=j2+0Y%V'7Y.)2%?=n2+0Y%V'7Y.)2%?=r2+0Y%V'7Y.)2%?=v2+0Y%V'7Y.)2%?=z2+0Y%V'7Y.)2%?=~2+0Y%V'7Y.)2%@=2+0Y%V'7Y.)2%@=62+0Y%V'7Y.)2%@=B2+0Y%V'7Y.)2%@=F2+0Y%V'7Y.)2%@=J2+0Y%V'7Y.)2%@=N2+0Y%V'7Y.)2%@=R2+0Y%V'7Y.)2%@=V2+0Y%V'7Y.)2%@=Z2+0Y%V'7Y.)2%@=^2+0Y%V'7Y.)2%@=b2+0Y%V'7Y.)2%@=f2+0Y%V'7Y.)2%@=j2+0Y%V'7Y.)2%@=n2+0Y%V'7Y.)2%@=r2+0Y%V'7Y.)2%@=v2+0Y%V'7Y.)2%@=z2+0Y%V'7Y.)2%@=~2+0Y%V'7Y.)2%A=2+0Y%V'7Y.)2%A=62+0Y%V'7Y.)2%A=B2+0Y%V'7Y.)2%A=F2+0Y%V'7Y.)2%A=J2+0Y%V'7Y.)2%A=N2+0Y%V'7Y.)2%A=R2+0Y%V'7Y.)2%A=V2+0Y%V'7Y.)2%A=Z2+0Y%V'7Y.)2%A=^2+0Y%V'7Y.)2%A=b2+0Y%V'7Y.)2%A=f2+0Y%V'7Y.)2%A=j2+0Y%V'7Y.)2%A=n2+0Y%V'7Y.)2%A=r2+0Y%V'7Y.)2%A=v2+0Y%V'7Y.)2%A=z2+0Y%V'7Y.)2%A=~2+0Y%V'7Y.)2%B=2+0Y%V'7Y.)2%B=62+0Y%V'7Y.)2%B=B2+0Y%V'7Y.)2%B=F2+0Y%V'7Y.)2%B=J2+0Y%V'7Y.)2%B=N2+0Y%V'7Y.)2%B=R2+0Y%V'7Y.)2%B=V2+0Y%V'7Y.)2%B=Z2+0Y%V'7Y.)2%B=^2+0Y%V'7Y.)2%B=b2+0Y%V'7Y.)2%B=f2+0Y%V'7Y.)2%B=j2+0Y%V'7Y.)2%B=n2+0Y%V'7Y.)2%B=r2+0Y%V'7Y.)2%B=v2+0Y%V'7Y.)2%B=z2+0Y%V'7Y.)2%B=~2+0Y%V'7Y.)2%C=2+0Y%V'7Y.)2%C=62+0Y%V'7Y.)2%C=B2+0Y%V'7Y.)2%C=F2+0Y%V'7Y.)2%C=J2+0Y%V'7Y.)2%C=N2+0Y%V'7Y.)2%C=R2+0Y%V'7Y.)2%C=V2+0Y%V'7Y.)2%C=Z2+0Y%V'7Y.)2%C=^2+0Y%V'7Y.)2%C=b2+0Y%V'7Y.)2%C=f2+0Y%V'7Y.)2%C=j2+0Y%V'7Y.)2%C=n2+0Y%V'7Y.)2%C=r2+0Y%V'7Y.)2%C=v2+0Y%V'7Y.)2%C=z2+0Y%V'7Y.)2%C=~2+0Y%V'7Y.)2%D=2+0Y%V'7Y.)2%D=62+0Y%V'7Y.)2%D=B2+0Y%V'7Y.)2%D=F2+0Y%V'7Y.)2%D=J2+0Y%V'7Y.)2%D=N2+0Y%V'7Y.)2%D=R2+0Y%V'7Y.)2%D=V2+0Y%V'7Y.)2%D=Z2+0Y%V'7Y.)2%D=^2+0Y%V'7Y.)2%D=b2+0Y%V'7Y.)2%D=f2+0Y%V'7Y.)2%D=j2+0Y%V'7Y.)2%D=n2+0Y%V'7Y.)2%D=r2+0Y%V'7Y.)2%D=v2+0Y%V'7Y.)2%D=z2+0Y%V'7Y.)2%D=~2+0Y%V'7Y.)2%E=2+0Y%V'7Y.)2%E=62+0Y%V'7Y.)2%E=B2+0Y%V'7Y.)2%E=F2+0Y%V'7Y.)2%E=J2+0Y%V'7Y.)2%E=N2+0Y%V'7Y.)2%E=R2+0Y%V'7Y.)2%E=V2+0Y%V'7Y.)2%E=Z2+0Y%V'7Y.)2%E=^2+0Y%V'7Y.)2%E=b2+0Y%V'7Y.)2%E=f2+0Y%V'7Y.)2%E=j2+0Y%V'7Y.)2%E=n2+0Y%V'7Y.)2%E=r2+0Y%V'7Y.)2%E=v2+0Y%V'7Y.)2%E=z2+0Y%V'7Y.)2%E=~2+0Y%V'7Y.)2%F=2+0Y%V'7Y.)2%F=62+0Y%V'7Y.)2%F=B2+0Y%V'7Y.)2%F=F2+0Y%V'7Y.)2%F=J2+0Y%V'7Y.)2%F=N2+0Y%V'7Y.)2%F=R2+0Y%V'7Y.)2%F=V2+0Y%V'7Y.)2%F=Z2+0Y%V'7Y.)2%F=^2+0Y%V'7Y.)2%F=b2+0Y%V'7Y.)2%F=f2+0Y%V'7Y.)2%F=j2+0Y%V'7Y.)2%F=n2+0Y%V'7Y.)2%F=r2+0Y%V'7Y.)2%F=v2+0Y%V'7Y.)2%F=z2+0Y%V'7Y.)2%F=~2+0Y%V'7Y.)2%G=2+0Y%V'7Y.)2%G=62+0Y%V'7Y.)2%G=B2+0Y%V'7Y.)2%G=F2+0Y%V'7Y.)2%G=J2+0Y%V'7Y.)2%G=N2+0Y%V'7Y.)2%G=R2+0Y%V'7Y.)2%G=V2+0Y%V'7Y.)2%G=Z2+0Y%V'7Y.)2%G=^2+0Y%V'7Y.)2%G=b2+0Y%V'7Y.)2%G=f2+0Y%V'7Y.)2%G=j2+0Y%V'7Y.)2%G=n2+0Y%V'7Y.)2%G=r2+0Y%V'7Y.)2%G=v2+0Y%V'7Y.)2%G=z2+0Y%V'7Y.)2%G=~2+0Y%V'7Y.)2%H=2+0Y%V'7Y.)2%H=62+0Y%V'7Y.)2%H=B2+0Y%V'7Y.)2%H=F2+0Y%V'7Y.)2%H=J2+0Y%V'7Y.)2%H=N2+0Y%V'7Y.)2%H=R2+0Y%V'7Y.)2%H=V2+0Y%V'7Y.)2%H=Z2+0Y%V'7Y.)2%H=^2+0Y%V'7Y.)2%H=b2+0Y%V'7Y.)2%H=f2+0Y%V'7Y.)2%H=j2+0Y%V'7Y.)2%H=n2+0Y%V'7Y.)2%H=r2+0Y%V'7Y.)2%H=v2+0Y%V'7Y.)2%H=z2+0Y%V'7Y.)2%H=~2+0Y%V'7Y.)2%I=2+0Y%V'7Y.)2%I=62+0Y%V'7Y.)2%I=B2+0Y%V'7Y.)2%I=F2+0Y%V'7Y.)2%I=J2+0Y%V'7Y.)2%I=N2+0Y%V'7Y.)2%I=R2+0Y%V'7Y.)2%I=V2+0Y%V'7Y.)2%I=Z2+0Y%V'7Y.)2%I=^2+0Y%V'7Y.)2%I=b2+0Y%V'7Y.)2%I=f2+0Y%V'7Y.)2%I=j2+0Y%V'7Y.)2%I=n2+0Y%V'7Y.)2%I=r2+0Y%V'7Y.)2%I=v2+0Y%V'7Y.)2%I=z2+0Y%V'7Y.)2%I=~2+0Y%V'7Y.)2%J=2+0Y%V'7Y.)2%J=62+0Y%V'7Y.)2%J=B2+0Y%V'7Y.)2%J=F2+0Y%V'7Y.)2%J=J2+0Y%V'7Y.)2%J=N2+0Y%V'7Y.)2%J=R2+0Y%V'7Y.)2%J=V2+0Y%V'7Y.)2%J=Z2+0Y%V'7Y.)2%J=^2+0Y%V'7Y.)2%J=b2+0Y%V'7Y.)2%J=f2+0Y%V'7Y.)2%J=j2+0Y%V'7Y.)2%J=n2+0Y%V'7Y.)2%J=r2+0Y%V'7Y.)2%J=v2+0Y%V'7Y.)2%J=z2+0Y%V'7Y.)2%J=~2+0Y%V'7Y.)2%K=2+0Y%V'7Y.)2%K=62+0Y%V'7Y.)2%K=B2+0Y%V'7Y.)2%K=F2+0Y%V'7Y.)2%K=J2+0Y%V'7Y.)2%K=N2+0Y%V'7Y.)2%K=R2+0Y%V'7Y.)2%K=V2+0Y%V'7Y.)2%K=Z2+0Y%V'7Y.)2%K=^2+0Y%V'7Y.)2%K=b2+0Y%V'7Y.)2%K=f2+0Y%V'7Y.)2%K=j2+0Y%V'7Y.)2%K=n2+0Y%V'7Y.)2%K=r2+0Y%V'7Y.)2%K=v2+0Y%V'7Y.)2%K=z2+0Y%V'7Y.)2%K=~2+0Y%V'7Y.)2%L=2+0Y%V'7Y.)2%L=62+0Y%V'7Y.)2%L=B2+0Y%V'7Y.)2%L=F2+0Y%V'7Y.)2%L=J2+0Y%V'7Y.)2%L=N2+0Y%V'7Y.)2%L=R2+0Y%V'7Y.)2%L=V2+0Y%V'7Y.)2%L=Z2+0Y%V'7Y.)2%L=^2+0Y%V'7Y.)2%L=b2+0Y%V'7Y.)2%L=f2+0Y%V'7Y.)2%L=j2+0Y%V'7Y.)2%L=n2+0Y%V'7Y.)2%L=r2+0Y%V'7Y.)2%L=v2+0Y%V'7Y.)2%L=z2+0Y%V'7Y.)2%L=~2+0Y%V'7Y.)2%M=2+0Y%V'7Y.)2%M=62+0Y%V'7Y.)2%M=B2+0Y%V'7Y.)2%M=F2+0Y%V'7Y.)2%M=J2+0Y%V'7Y.)2%M=N2+0Y%V'7Y.)2%M=R2+0Y%V'7Y.)2%M=V2+0Y%V'7Y.)2%M=Z2+0Y%V'7Y.)2%M=^2+0Y%V'7Y.)2%M=b2+0Y%V'7Y.)2%M=f2+0Y%V'7Y.)2%M=j2+0Y%V'7Y.)2%M=n2+0Y%V'7Y.)2%M=r2+0Y%V'7Y.)2%M=v2+0Y%V'7Y.)2%M=z2+0Y%V'7Y.)2%M=~2+0Y%V'7Y.)2%N=2+0Y%V'7Y.)2%N=62+0Y%V'7Y.)2%N=B2+0Y%V'7Y.)2%N=F2+0Y%V'7Y.)2%N=J2+0Y%V'7Y.)2%N=N2+0Y%V'7Y.)2%N=R2+0Y%V'7Y.)2%N=V2+0Y%V'7Y.)2%N=Z2+0Y%V'7Y.)2%N=^2+0Y%V'7Y.)2%N=b2+0Y%V'7Y.)2%N=f2+0Y%V'7Y.)2%N=j2+0Y%V'7Y.)2%N=n2+0Y%V'7Y.)2%N=r2+0Y%V'7Y.)2%N=v2+0Y%V'7Y.)2%N=z2+0Y%V'7Y.)2%N=~2+0Y%V'7Y.)2%O=2+0Y%V'7Y.)2%O=62+0Y%V'7Y.)2%O=B2+0Y%V'7Y.)2%O=F2+0Y%V'7Y.)2%O=J2+0Y%V'7Y.)2%O=N2+0Y%V'7Y.)2%O=R2+0Y%V'7Y.)2%O=V2+0Y%V'7Y.)2%O=Z2+0Y%V'7Y.)2%O=^2+0Y%V'7Y.)2%O=b2+0Y%V'7Y.)2%O=f2+0Y%V'7Y.)2%O=j2+0Y%V'7Y.)2%O=n2+0Y%V'7Y.)2%O=r2+0Y%V'7Y.)2%O=v2+0Y%V'7Y.)2%O=z2+0Y%V'7Y.)2%O=~2+0Y%V'7Y.)2%P=2+0Y%V'7Y.)2%P=62+0Y%V'7Y.)2%P=B2+0Y%V'7Y.)2%P=F2+0Y%V'7Y.)2%P=J2+0Y%V'7Y.)2%P=N2+0Y%V'7Y.)2%P=R2+0Y%V'7Y.)2%P=V2+0Y%V'7Y.)2%P=Z2+0Y%V'7Y.)2%P=^2+0Y%V'7Y.)2%P=b2+0Y%V'7Y.)2%P=f2+0Y%V'7Y.)2%P=j2+0Y%V'7Y.)2%P=n2+0Y%V'7Y.)2%P=r2+0Y%V'7Y.)2%P=v2+0Y%V'7Y.)2%P=z2+0Y%V'7Y.)2%P=~2+0Y%V'7Y.)2%Q=2+0Y%V'7Y.)2%Q=62+0Y%V'7Y.)2%Q=B2+0Y%V'7Y.)2%Q=F2+0Y%V'7Y.)2%Q=J2+0Y%V'7Y.)2%Q=N2+0Y%V'7Y.)2%Q=R2+0Y%V'7Y.)2%Q=V2+0Y%V'7Y.)2%Q=Z2+0Y%V'7Y.)2%Q=^2+0Y%V'7Y.)2%Q=b2+0Y%V'7Y.)2%Q=f2+0Y%V'7Y.)2%Q=j2+0Y%V'7Y.)2%Q=n2+0Y%V'7Y.)2%Q=r2+0Y%V'7Y.)2%Q=v2+0Y%V'7Y.)2%Q=z2+0Y%V'7Y.)2%Q=~2+0Y%V'7Y.)2%R=2+0Y%V'7Y.)2%R=62+0Y%V'7Y.)2%R=B2+0Y%V'7Y.)2%R=F2+0Y%V'7Y.)2%R=J2+0Y%V'7Y.)2%R=N2+0Y%V'7Y.)2%R=R2+0Y%V'7Y.)2%R=V2+0Y%V'7Y.)2%R=Z2+0Y%V'7Y.)2%R=^2+0Y%V'7Y.)2%R=b2+0Y%V'7Y.)2%R=f2+0Y%V'7Y.)2%R=j2+0Y%V'7Y.)2%R=n2+0Y%V'7Y.)2%R=r2+0Y%V'7Y.)2%R=v2+0Y%V'7Y.)2%R=z2+0Y%V'7Y.)2%R=~2+0Y%V'7Y.)2%S=2+0Y%V'7Y.)2%S=62+0Y%V'7Y.)2%S=B2+0Y%V'7Y.)2%S=F2+0Y%V'7Y.)2%S=J2+0Y%V'7Y.)2%S=N2+0Y%V'7Y.)2%S=R2+0Y%V'7Y.)2%S=V2+0Y%V'7Y.)2%S=Z2+0Y%V'7Y.)2%S=^2+0Y%V'7Y.)2%S=b2+0Y%V'7Y.)2%S=f2+0Y%V'7Y.)2%S=j2+0Y%V'7Y.)2%S=n2+0Y%V'7Y.)2%S=r2+0Y%V'7Y.)2%S=v2+0Y%V'7Y.)2%S=z2+0Y%V'7Y.)2%S=~2+0Y%V'7Y.)2%T=2+0Y%V'7Y.)2%T=62+0Y%V'7Y.)2%T=B2+0Y%V'7Y.)2%T=F2+0Y%V'7Y.)2%T=J2+0Y%V'7Y.)2%T=N2+0Y%V'7Y.)2%T=R2+0Y%V'7Y.)2%T=V2+0Y%V'7Y.)2%T=Z2+0Y%V'7Y.)2%T=^2+0Y%V'7Y.)2%T=b2+0Y%V'7Y.)2%T=f2+0Y%V'7Y.)2%T=j2+0Y%V'7Y.)2%T=n2+0Y%V'7Y.)2%T=r2+0Y%V'7Y.)2%T=v2+0Y%V'7Y.)2%T=z2+0Y%V'7Y.)2%T=~2+0Y%V'7Y.)2%U=2+0Y%V'7Y.)2%U=62+0Y%V'7Y.)2%U=B2+0Y%V'7Y.)2%U=F2+0Y%V'7Y.)2%U=J2+0Y%V'7Y.)2%U=N2+0Y%V'7Y.)2%U=R2+0Y%V'7Y.)2%U=V2+0Y%V'7Y.)2%U=Z2+0Y%V'7Y.)2%U=^2+0Y%V'7Y.)2%U=b2+0Y%V'7Y.)2%U=f2+0Y%V'7Y.)2%U=j2+0Y%V'7Y.)2%U=n2+0Y%V'7Y.)2%U=r2+0Y%V'7Y.)2%U=v2+0Y%V'7Y.)2%U=z2+0Y%V'7Y.)2%U=~2+0Y%V'7Y.)2%V=2+0Y%V'7Y.)2%V=62+0Y%V'7Y.)2%V=B2+0Y%V'7Y.)2%V=F2+0Y%V'7Y.)2%V=J2+0Y%V'7Y.)2%V=N2+0Y%V'7Y.)2%V=R2+0Y%V'7Y.)2%V=V2+0Y%V'7Y.)2%V=Z2+0Y%V'7Y.)2%V=^2+0Y%V'7Y.)2%V=b2+0Y%V'7Y.)2%V=f2+0Y%V'7Y.)2%V=j2+0Y%V'7Y.)2%V=n2+0Y%V'7Y.)2%V=r2+0Y%V'7Y.)2%V=v2+0Y%V'7Y.)2%V=z2+0Y%V'7Y.)2%V=~2+0Y%V'7Y.)2%W=2+0Y%V'7Y.)2%W=62+0Y%V'7Y.)2%W=B2+0Y%V'7Y.)2%W=F2+0Y%V'7Y.)2%W=J2+0Y%V'7Y.)2%W=N2+0Y%V'7Y.)2%W=R2+0Y%V'7Y.)2%W=V2+0Y%V'7Y.)2%W=Z2+0Y%V'7Y.)2%W=^2+0Y%V'7Y.)2%W=b2+0Y%V'7Y.)2%W=f2+0Y%V'7Y.)2%W=j2+0Y%V'7Y.)2%W=n2+0Y%V'7Y.)2%W=r2+0Y%V'7Y.)2%W=v2+0Y%V'7Y.)2%W=z2+0Y%V'7Y.)2%W=~2+0Y%V'7Y.)2%X=2+0Y%V'7Y.)2%X=62+0Y%V'7Y.)2%X=B2+0Y%V'7Y.)2%X=F2+0Y%V'7Y.)2%X=J2+0Y%V'7Y.)2%X=N2+0Y%V'7Y.)2%X=R2+0Y%V'7Y.)2%X=V2+0Y%V'7Y.)2%X=Z2+0Y%V'7Y.)2%X=^2+0Y%V'7Y.)2%X=b2+0Y%V'7Y.)2%X=f2+0Y%V'7Y.)2%X=j2+0Y%V'7Y.)2%X=n2+0Y%V'7Y.)2%X=r2+0Y%V'7Y.)2%X=v2+0Y%V'7Y.)2%X=z2+0Y%V'7Y.)2%X=~2+0Y%V'7Y.)2%Y=2+0Y%V'7Y.)2%Y=62+0Y%V'7Y.)2%Y=B2+0Y%V'7Y.)2%Y

*[,9DHA;$^G:FL&^0'IT MK?&?01A&^]RK(]W079TV\/ P$Z/+M$&=PH,_31D(BF%8+VCY=4=2)9N!WHSA M.3G+-DZ&"Q\,,?B2R=T#4Y.8YRF.5$,UQS T +IQ9\E8SE+THRISL)F&OH4 M$U6W!6?56#)+LOOL![M[S(.W/F-,L*=K(4#-W#>-J1'QB246!R%:DBZZ:D:.MCFD.V[*OE@LN2DWZ^\]H16F^O\.K_Y-? _8MWTQF#K2%_5P;=$3TE$*BL$3W/K*.&58 M[J7[%Q(#')RCGV0O&+BO'S@R^-#-@TUC9A@^{(1_,W-U'/Z-2 N3)\M/^-6+ M=?AK-G)+9,,7O^>*<[L9" MQ$D2#94^-(M(@%TX_39U{'$K0)5;|FDTA)QQP+F^-FPW2}s%RHA-9W+IVKPP?%?]@.8|) M-CA2^.W@O-XH5;[#NO)RS37!?QOEFI\RG'(RIY5%0P1<.1+W0MM3,L41[7^.U MO#$_!:O\3/$:L)$OR0#/STK%]K3&N$'>!T*U0&/,X8-:72P_1VSN*T=M8(HE@:,0TRW>P!@%8*895"'N/_C32O+ .O++#2M6WMN6C_P,'1$7_IU-MMG2C7BJELHRV]#[HDWFLU M$E6[YF;7EI,'[X.Z6AS#GCN+=@=8[*LR^*%)6>C5*LIKE4 M<+QG_^!6]6_N>^/F.Z9'U1OO=7+C:U.^^_]R])Q_L.QGE1}U]_GC'_FY49,8 M+3\A)*6/,#$K\ZQ/C_? OP!)X;0+F<#!DR(@%QN!M(JZ]^S+Y(:9UL;O/-]^^.M3GWPI$2N\53&@_-JLU[!"LLA>>1_O'3AWXLVNXZGZ^]'^^O.GI4.Y\>K^Y_ M8X;S8HP"1=O(MEV>:OWK,%>:[)O5)@_;-: &_\N39?*K@U_'0?GI93XH\3R6 M!N3C[<47V_T>/]BR@Z%C (1LU[%=7NUB'EZ6)=%ZP)$,UO>13_PC],R###+Z^_MR#>V@978*,3$8> 5XQ_&\B]f\1Q4FB>&*+%/I-0"%E OLW&>>ZKB!U&>(H(B MLF,3=#5P[F4R\?*NDZ)O;ORN0P4?L 9#RC]HOOUQ>W3]@WC.Q^Y/W< D[MO+SZ=UQ_?B.7?W/M^O'_^Q"6K3(!^]%8=_SX2Z+49T NS"&=F@XNY+_/_1\TB8JJ/(: MXJY*^I&44Y[,?0HLL]9-,3?BU2H*;,69Q9O4.8^D15]'R2GN&P9?+U=JP#[MQW\3^@T+:!$$B"EJ!@*J&4#(37W"^I26=;/>\0Z8//=],JWT-=OSO.10+2W? M\P543;$1BY1Y\3YGJ@!.B8$0B+M:$)YW!N,L&F"]@^_G_JF&!QCS@AMS+;MO?18$7?G9?L/P=A4Y,_LH2=0|;_M^$!|O@VG0UG$TS-3FC6=F;)89DHA#F.Z'.57RW"YJBB8K*M8(!0"S$0&_3&T M6<1PFWF>.(7SNR:[6$19CD8,&91'4TXE&#N5K8^VS9>?O.UO.7]V77-%[M"+ MI7A88Z9MNP'FU:PT\E3EB82? R:3QL:RZ1EY67>S.GO!'B" MC58Z2*K((E< M#%BR#@:*6\WR7Z?D8$7_(H[*H&W"S:/Z!VP*5ZC<\^N;!.783^^? K7C')Y4*=F\!60ZJ6?IM)^% MLG6F.I7G)067VH5;WB!? LR#K=ZZ03"Z++0>K7"+(U\S+Q)5!OKG\KLVSU03Y MEA(:)0_R'8,&?):C)JF1L:N*\FD^NG(^NDBTK%4X6O(MHF4EYKV+1\M:>5[$ MMXB6E1AJ&XB6M?++<5TM$R^: ZD:C9;7%HF6: ^9:#^2;C &9QWKQ,M5:UUL2A MOOO$>?.C%M,8;T$|<2[D=13QMH[.YE>26^R3[0>A:#-)?N>XYTNL1++/D4$| M)3',X -2T-&M@e1$'S:05*QW-]G/D"U%O8Z\:WD.DMV=5,YBF/2"K3"+H550 M2MU&^VW9+(99^+BU60RMDR*'%8:O^O6U "I/)^0!^?*0EBC9U-W1,]V1&_H MCO2Z(_T:.|*_?2**:)B]6\DG#PME,9#V29?7Z_'U:; H/T%\0X^ZZ8FN;$,U-M>&VB_W>V>:UX1-7G#G533[4Q"E[5HO&H:%S!QDYOQ6N\Q=B%9,#";0^SE#B<-MA1@E1J=SX05A0!K 1R/@UTQHM#@$"&UNFZAS$TC^2"K'SL/5);NX_7IW-M=?/0>;R<3M'=>,A6\5M+!U0T_XQFLG8\W3+6](-MG(*,YMH)NQVX=C<*L'6Z,+Z. (,EIY4A7XW<3S1Q!D\3>WV 2$@_#.ZES(W(?-M8&&RN[,!S,JBWHQ@2QE!MET!?1H[#P-E!?&;,CC/],KR)O1/TI],2F**WR M#.HTV/VB.6E%\#O!. (=#'U1H<>2R=REVAQ\,'6_$.3U'S@B(VT7CZP 30.< M <[V\D#=E[O% M[IFX^^!(RA_5QUMUV4Q0.;8^_"=]M3LH\G9Y_UZX=G(,*I-+O1MP],9]R"W9 MJH]6G=%6/'=+E!#6B] ?.,4N5L,QHL#T:;/Z+F3?*$=K?2H9UQWY\.+-7+GW2(D*R3^0*R(??)(,>T)Y$S5YG"2L,:1'?N<[:X2- B6 MG@E E #ZU141%0M%O D"I2[5N(6$]4EL<1-G TY"$,L-8P] [-.H7W(KPC7B56'F MV0:F.\E^_/*Y<+O3Y].T"/;.N M:*<@*8!8$.E]#B^@^BDG,PODXU-3DM+')*[ND;_<,BA;CF/K[8+=]&Q\=_[<& 6\#,N$/MW4U.%Z?.&WML'HP,L2G'1X$L.3,E."6V7FQ+1 M4K^6C!MU+,L6,U[6QI<.E4,]K(@QR>1]H2%D? 05\5D8#Y&06D0!N*>U12X9 MC"5D%>)]\OS/*!R7[X1<.6Y.NND%N!,;!N M3)STP)RD(H'4OPI+14V,N@!MBR;"2=,)6=34*%#H)Y K) TY=$Y4.D7QMUG# MOQ -NK-QMCN.I, PLP\%4O7W$U*T$A1M(R\]>4/18\E3@^3X^%4O ,0/5,. MO/PB*W;<24- /3$>>R>_+BRNX/\VAF'I\Q_,='T$!'LT6GQB! MZ%;8!K 7>7B;5S!FGB>I%F+W "M+/D<881+CECGR.AYY\8GG3G&KB!D62'"S MJ2TG"OOJX[K 6@!N#PT_,7'EH+';>\KH- $C;*M>D^!;Z]!W@]CQA*<=\?)$ M+8Q-9-\T}4U(++.I.5[S8@Q>>TVETFN,T\OR*LFQ,M'(\P3\]Y(;X-EG!^<[M.-CLP\6045&OB%PH]F>DF5"]-IT4BGQI.5N>/?%@;H9R6#'TR&=Y? CN5C15+^U78:2[1U2_TECU@@G MO+U-X28S1'AV-']1X3HK<EX_V-WLD29"1-!QA-LB3_>M9%RXXE"F=/1LU%6*^L/_> MJAZL\O:C5!4LDI5;!XMS\,5ZQ!_Q#&M- $WXPA! MI2 P&O__;GH^^&NVDDVR3DA MKGA(0EN44-$L4AIJ2C*,6%[7_U7LI'N>G4L*ZH7Q+N:*!9GQJSNQG-1_TT,$ M=]'W-C/':Q40G8X*S$6[Q2OK(2[Y$L6\TA-(? 860Y1XAW>QYWQ2KQ)S)|&'Q6& MC$N\S2]VC[-#4FG?,PG_:]7=OYZ+8J+_A=H9C<(XB^OHOJSN*>1H* MK'>YLU^RI$1)BV_)EX$N1O*VBF.9FKM28DR#N"LF'A6[_OS|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|(M$+-SI@!">FE&CD$NAD!,S;5[/>YSU^2LR\,?SMV"X>;X*BZGF MZZHQJ[.C!7B-G-R;>=3X>,W.)%_8$QXR[$[.]+WYS\,5ZQ!_Q#&M- $WXPA! MI2 >SAGVC9#UC6>.8[O'WH"^_P@XWHL:S8L+I++=(PV1]SE[P/S.&X)[6@11F M7-*8?4ES]B6M@W/7D[-VRL];30$RN5T2M/GCM(EV/9UZ\?@=B8Q MIL)"+S03&)S@M_!'"SN2"3T(,KGX57;HY1L**9Z M@J€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~:!5V5H+MO?F)TMJ9$!(Z/3NNE MS:\]$3/:\VWJW@Z^5WL81K91\<9V-#X(.9/1-!993]7XB2VFWF=RBQ0AEXGAY8PA7S/'> M<$I;-OX^5LM#7UX"]XNYY-+-R8Z/Z]5R@96]LN,M<^:;#4YXJ%-F_4TYTD20G MJVXHS1,S/=F &P&(W#B=2*1^=D?LI6^,_50JF'+8WI7SXFP\(M29/SQ+'\ M2V%DA7FA41@G6<57)NY\I2L(564@RVPSV!H2"LBI|&?+1R&?>B\SQV/JLCK$3 M0T=/P2DE@H*."=85F;#)$8U+&,Q.2Y^^R)<% ,;|I<3QQ-(B3Q'.E#&1/0]XJCG9' !S;=O\1MMT87+-II*X7 G.W,+-N MQ"QUYU"(.?S:9Y8G\U*3^YZ!5AQ#)LT:R8V!2D>'\^$!YY2JTXLH27/;@9N: MQBI(/T[E8F@@F>IIY%11$6%%_/VP[/#8\%@$YQ+%PZR7VKJH<;]@:5!EG8,JKGN\-!#_T-/M1[X%V>]JYC9\Y^T83C[]1K9\FCWW;.I%+>1%WBPOGTJ;JQF25C -FB$KRS/.\C ML*_6FCE93HU?QW$i$^5M/E)?B9=;E@NU)_$PI(/H0VCCOT*.%3@O6F.L8=< M=CPYJ3(&6+8RH)(J2U852=-8N'"$I<4@&Q#HZS[5>]VQ+!VBI*E-0? 9+SW)7:TLO%FPMDF9=E6S,*VDYJ MM5E-$DYJ,!LQG-0:V$H'8U05(;&.C91P52%$Q:SW;@^2-Z M6ZPPCQPR8P-1QIW5R>>$RT+:^4FM(%]V7 2_4CO?HC]^(D#EF:FK-V.V"%#U M2]TY^?$F&7H1-9"-^#9TC_3<+$$350+$EHC]6\|/WH]T?)FN!SO'FKU"\9YWIV63==H'F>5*OK4Y77QWG6(]> M.J\:BJ7)MNKID\?Z?MA_4<1>C1EV4]_G^&UC.>-Z>X^V"#B-U5EDQM=.@!*8[_9A10+V6NMZS"]K'?5BH M6E")@N#=:V5NR%++<7F6N+GE2XL)OMfWQ/GC8(2_(Z;1RJCNM:$6GE8W-5HK[MF1SK?B:+-N!X)"LJTRY$64^E:L>AD6D+D F;XI0? E=+5,3O(AN?>T3F.X^_MM3"!B;%R):(EC37;@37EZJVEL68fL$;S&HTUV\YK[]\66OE\VXT-=SR]YP$W M?"SVP/0Q_LP=;XA1&EWOG%Z/!,ZCPOBU>,IUM>NZ0TH)$=:MR_2HZ>B>'3F MF J9G+CT)F\\)C>92UV:,F5-!"4A@KS(?DI.GB8"302[2P1Y&1PYF4O;2P0E M,EBAB: D1#!GM^/M)8+ZY"RXTE!!B>RV?6B[!V XLLY'C ,#LWJWS;123X>?M8$4%9?R+6&8/W"'@5{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}K>R]-PNM)$#[MY%\;3_8^P0U)^\$6]^!=A*B&/G^YO2AP8OHB5!_ZMFO:0T"'T4Q:,Q^_MI#4V268@X@[K!PIHC?X\:+QC#]!A1?A@@2:HU&H>\+O+A1Y"LTOPMM1++&:X+ M:YD<)36^W1-(A*!O|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}K>R]-PNM)$#[MY%\;3_8^P0U)^\$6]^!=A*B&/G^YO2AP8OHB5![ZMFO:0T"'T4Q:,Q^_MI#4V268@X@[K!PIHC?X\:+QC#]!A1?A@@2:HU&H>\+O+A1Y"LTOPMM1++&:X+ M:YD<)36^W1-(A*!O|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}K>R]-PNM)$#[MY%\;3_8^P0U)^\$6]^!=A*B&/G^YO2AP8OHB5![ZMFO:0T"'T4Q:,Q^_MI#4V268@X@[K!PIHC?X\:+QC#]!A1?A@@2:HU&H>\+O+A1Y"LTOPMM1++&:X+ M:YD<)36^W1-(A*!O|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

RT/S[+F+231KE(@T=EZ@%)5Q.9I>MF:-$M'+SHN2PD*$H3'"G,A\|:4S0M3 M[#%UI:>_@CGK=P*E7YEBUVCI8*/6-'(YIX^>|12FL=0,LY21Q6)^J4M>%^"7 MB,DI$_-U++/9.M$L4RN;DRSS-I(S)/I'[PWKW.O<#5V9/%?>Aj*-+T@:*^/% M]<;F>+'.X=@V:!W-0DZQYWW-[MAGOKWG1?(I%KRN[&;@U\=GIYI?:X5Z5LZ=M9LTZ\2[AU'Q;F^"UG'H'6/1",7<_P4\Q"^%7FN60.\E3S_)=_RS?$SW+5_R-MS5,FWFB6;ZFG);D>SB?R0@^IA=/S4]*QG9F"P:C[.S?[`|!*J_SP=?\5N9PU:V(0M('5LH*&3RTU[60J=2CRD3;@-_F|/?I"-'A2VS"'%5F[6/(J&/=-E!->4>B[4=(3QG%)[4-#P5'YYW.@-=K MZ/#666:-$#&OG8UKC%3QWOF=%)O9I?N9@L5,;Z'T/914J'^6.9"V:\F\3=RB+^9$'!3$__*B;]>.3VN;QGY MET@WV_G\T#C?*$ S<@]4L5)F[T&G]-TJU1(@ZQ\|,,1*LH3Z2W/7F>%:"KPMIMVV:?B]F.V]I26F(6.E!(M<-O[C 3R /2QI);6.MO:QY\HI6OQ7DPT<8=D<87^&T+VQ=[W6O/Z?Y4ZUZ;HONSVK;9 M7"52O7;>%9;IQ;<-W^Q3];K%G[GC#5'<-M[[8164HML5C].]M]LV_:'] *]V&GEPE.7PGYO*P!6-[TB]\0R1X2\YTEM[VVS M,A"G3El2]EB>D-5NZ3;P$7?.9I6K,I$?/4=6H+,L\'[CFOE9ST[T+HS]B/$M&F+B/*&VV#L|/CFOETWC(-'M4"*E;2\4:(!@+-=0NH#FU5O-JW6QS!*\.DZH>1US;K8VY\C22MP>$[XNEMD< MX=;S!5@#3]+-$BLS:'$R[F96OU!K MZ&}/|3=UPC[WE:|Y#QK/[H7;J5]TY4BRZAG2"*OC 261QDK&"2UH_;37!//MJ:X|V0RYGVT/N9=(W=(&F5Y#KU&Z-4K$(?;'(+OA(46=6,_W!D6CYW?<1INI M"C5!%;*\"*?&;)6LIN)|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{3 MC1U2$6X?-;1++GY>NPIV[V/>/M')2G@#.F9XE7.P7%<;=_/4S5$Y+-.6A=!2Q^P18 M])GH,;YO2(`G]0T.?]P2363O'"9W/A\:MA7/W27OKT?C$7>:,VE1'J+SN6?'3;_$_B, M>Q/8_"5!YF6G2.IH48F6*PL]-FHU72*P$7IL')?*"ZH=+F51;I*FF XBX?[H M.7L\:A?8L,[HG6)$9FJW%.]l=4^J9KT\"%A/UMX?4M>)PVLG!7:)G$=ZJG9YME"_1)O6F0H9SE>+VO=,,FF_NRXE'U'8'4&LF*P%X#5=SBKT,+6Q!$WV':*.MQ79BW%*.YE6IF2C5AZNNI,ZU+81ITY.WAAQ9C2BXO9)/~74?M:F>MK- GZ| MAEY#-X,8:?L(:V8'/:=)+Z4/2<|IVDDFAZHX"WW###2,/8XAP'4Z3YP)[D+W?;U[+=K7A>$18W32QLQGULT.P9'=1 PZ9G+5GZ5J-6P#KF[@JXW M3L3SMT$%LM;59:\DZ\)VP8E#:=-=_?.H>:LRG?;$F)P(MMDYUN4>!]OV6P'3 M56W3H@.Q(^:MHP-;3|L1\M\XK2^DI^E*NC>E_O*.9-IZY4W"'O4:>HW2K5$B M#K%'YITETWG1NB-3#^MRZ1?^W\A^!M%$OO3}-?%F*E--4*8L+*:XG&UKU@# MV.??=Z'%[^N!EHE=G$;-ZTB:?)/R;_NBX_W@CYERK]0T"&XG/_T4[[f]\\-^QK?[S?;(MVE5&OY:C51N MLBQBB&O LOP'8@__V#9S\Q$C/Q_!W>?/_YQ,ZZ6NV7O'>6GQ"-TD>@N66? M]>GQ/GY8FJQ-P%GNOV>I!<;Nf?>JOO"+I'S]lZ,=Z]UGW\U7UX_U5YX]fV)/CU?UOS'!>C%&@CF CJ_ME"I/O-5[UN<"/WT!TAM^A\U^E^>HBV_.OAU')2_7^:,#$L]C:4 ^WEY\L=WO M\8-!GQTZ!D#(=AW;Y=6NXYG?LQR9U@,]V6!]'IG /T+//,C@ZXM\8QLXA8T:MMC@,O&+\PU@9SWX\XGFBS+8,C5[BO0!7'D'L Y=7>6G> MDPLO2P-7"!R# =<,N =!8V;]7?9,@=_NC9+F@=0 +2 3<,N =!8V;]7?9,@=_NC9+F@=0 +2 3<,N =!8V;]7?9,@=_NC9+F@=0 +2 3

*<>6PC>*RUO[S]LC+L_M1T^FEO M-RO[!R5*XV]L[W6_%5.2%JJ1*^?X+^= MH#OZ"\5P*\??_IL,F3[Q}@4_O$^&XY&*\ RC$="3_P.:>,8KG_%'XBPI%E_X'363%?? 0[OKP7VDY)DI M^.Q'?SY%OL"WOHC0Z8,#H5_B^O0#XB!+=()[J0I4(V#-&/@RC/OJ&3>":0[A M;ZLOX*&.E+XE[NY"">2=BV37O<<20 LR6|&%(#[[JVGKM?9W,%6:0>1^MP;P7!_G@,W _IGXTFK4]'JW(RFMBR"6E@U^E!XH3R(< M_S@_U.6CH?1\;2V1%0?TQU=?)%T7*7$4P+|^I/Y%X0TBT&FZVS=:,Z5N15!) CZ0A0 M'D-%>S#LKN|X"> (UZQ">"^2%=3,,Q8B^R#:BF5(-Z=_,-F9&^C=S;Y$2 L8 M58Z5U!Q#^+]P&IB%\"ZQ *#PO^QKTE%E&)Q3T-K-4C."FN|@BUC@NC8(=&?WK1 M>NTR4O4IH (SBD[6R]|]'U@,&Z:S"YN=ES=Y1%+:XME-_Y1;,.ZU7;,&93+K% MP]'"%);K*.L!F)WX2);#;(\N#E8-51G_((D+F<1A<-7'%YB=?[QD8Q&?GX_U MX *8\ .P0D##D!'"&FR:GS??DI< 10"D$E'TVI;5Y7] ,(U# 5KMETDNFOZ$ M/!'Z:.OCV+M.;Z_3E^6=%T=B>Y#W5!FZ L=_V>]4P>'C\H2-!4*\^7WS|\NR+ M)\=BC:LR+B9;'ZO-5O7#+@P% Q;^\],'2AH'OSK\? %+I=\UR^$?U\/3VY/I7 M2W@/8A09KQICO+XLK,]!U>$/'6)4U=M5P6Y*RI&MIE*RFA?.)VN#'#18!.=U|<.41X M3C0Z[*+95R<>&N2\2 (M^0I%*4U7D%C;QH.O((F0EZ<467STY[]}-^,/-82< M-#GS^V/IX*4SH8IO_;F>C/3IC#1:"_>@OP-%|'((-A###F|/5791_I6@^]C: ME%5HA =07*B)/#'"%,(40WQ(62"MRA%>.'?W&U<>L29@_>N M9T"_F*'=[%0[*04#6"9HCL#YEM*/==% <=-'$6Y,F7%CYPK5)Y5!%/XPF7M)! MSU)A3!NE^,%NOTH9I=]L69M=)TT-'IY?$0[I C&>D=-&*]:G2*I_$ZF^P#. M9B8Z6E"7+C_S0=;S:}>|)B(S)WJ0[PA0>W]6]$UNS9]6'75";_8<5(CW?B%&DZ9<<=33ID]1GAB(BX.EZE012'($4GT\V+E/26^>49G;V&<\)ZL M"H Z//0[!.E!8H:8E0.:%|"5&W3?]$2<3S&KS3T^Q>13S-4]Q013D/DTZ/2X M"]J=N^#L=0V..O)#.KVXEA$X=0Y"D+)$R^<50B"\/>8$HP-+GHZ@$U'X![K M &B5PXL:O9CLEC]J^;F>B_T)E7MKO/F&;>S#Y;-#B,>STN%K&15S?>_QM&_# M,'"D[$99/E$A,' MP?(XTK]%OR*ALSE|2B.R7W[5$^'0Z1;Q:.V%A>Q-M9#& MRPNIYU+AK7="> (^3K2[:VH]3R/*?>U-^N8L4$D.W3O*.3C';M=I7EH^%+1 M8:0..)H45'#>SS@&?Z+G! N""5)*Q4$C\W*'F%*.ZP EO)DA%'L>.'C*0'1 M+ G*EE:1S$!\&-?UHUB*+LP54]DI%SV?,8_; XQ AH44B8I$11B)VK'^E"K- M?2A<'Q7_/NI4&(:=2!-+]-M^+0CEZAHV/ K2,(SQ.HA";,;[]*!41PPH!?WA<[X%[E_XGS_KD%,P'0@Z>4 M%&<$RN>=07 A@^);X$=V;;]B-_>LJ }B0+0K;L3M,_S^W)JZ ?P_<#\M 5YL M(HO^*[#64(P(5FBU,;[L9 A3& C0GVAC73\+Y>ZEC"M%Z+DR-&LD6:>D@OS\ MIX[6/*4@GN=S$VE^AA25+*!SD,9S4N?E4)U=N? B<"U[6LMCL^)OR-1K]X;IY MF"'*X_< #.8UTS$I]\CA%Q>Z>?4(I MOVR620O%%L8ZU5N 7*N!>8*9)@2GRE;@#2/H2#FPT4);&VW.#,,:>.@P;B MOP$I# R8O9@!%P(7HD #2P(L4V@=EX.I=K0;^!AAP'211#PLR9'=[%M=S %T M$E%A;\U9KC9YB/I0*M3H@X$,461.J$[VL* KVK$.4XWDC8]\DDXNRX[2}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{^#3X]GK5'.GZ:F2:4!W _K=WIQO'BO-)KSE"#?,U4B"]G%G415E-&O=H22] $^-O:3G)2@+@I&4F4!=<$^TS$KO<(2@ NZ M.B'4;N5&\$T]fA- U',4RY/1!/3X1&,FFM9]:.5+D78?;]5N;$]YBQAP$*$U2T M1+EL>,7;O8-)\WTQ9WA2{O=X>OZ$\N;PN!WD\U3;W8H*QU.!?Q6C2>%KBS_9> M_D=B^GQ&Q'Y/)35&.JM143[/DU0BBNR<%L6I9[)J.Z0[.%OX3$[\.E,V1LZ)-MPK#I,XV2*:19.P_-32$U\]DEKU5(>S,I)&++]QD21G4[RXU?GIY+_QH(? +>FB3O:5FX>F9OO>1]CGCK*@SNW:Z2DFT-OMY99W1L M54[T];.+3[7<,+=T-UWP#)K.?D7S!*7IM'??;9H-DW#(D'*C459.TGH]#6# MPX,P,^V:8*QB2&X7%<;X ? A^.9[&CO?GD>N5l-%*.H2F0ZK(0E 7S64FVV M^.R%SU6]ZPE9[$R*Y6W79/RU8LI8%SL "E[D(16<+'* G! +NR?T=0/ QROG\NFJ1*0^5]?/@OJSCT1NJ- [8BMJ*/J^2(MGEM+>L9[;=>%% 6T];IZC6+_X|K% 0H$%)FV\+FXM M&E*UCOQS.I99CPZCDMCU@(.[ZF34O#F;3F%UM#1UZ YK:!2HE/^)*0'(-D>M MB@I%5.K=RNNR(YW)DI?'(X">0&_?%40.3SQ$Z6F?/I&4DC-<*O"0Z.O^#?FG6@RR64]$XKE8H\-B(Q-SP[LKS MDK[0Q"2BEL7>S:MTGS+&L_?F&[N>9AR9'*@AEA- XR2>"#$%31W]YT+"NI9- MI4.'0N5Z#,&+1R8=",P& FV:@C5'=_3U1"<(*PII8^%X@F?/6)S2?ET92>07 M9#(E',;8/^U\)68E45-@G"Z%4K.HN69)FDY>0**B3NI4[?:TWA'Z[*H&*B M:COJ81F!Z\>Z6(PRDP>$O(DHJAEO MEB2F"]=VK%/A>I0-\MPDE712Cl,(C>M+C: PRR!+ZE\3F;SL!;J?A$B51[1RD5LY9FZ-NNF^L>:,\.V-%!$F7ZU14RQL>J2O M]?BD+W? 0M\=H.5CMY1WI$UZ3$(EZ;B@Q;T(.GZ^H1T]*(RL(6C2@7!D0G?[M(M)--.:*$\TVX(EBM78$;54.BP M6/%HB(.AHR.SH\/>%"IBZ?,[]"2N:CY?:RK'O9A B"VJDI:F%,L1#W]?6$ M8IZ6EN:/$:\D=67PJ,!O4P>:\!?3D_5))Z6<.0--+OR*$74(H!ECWFWV.YH_.M.1&(!"EW&996\(ROBGA^FZ=B>D%,!?RE`I>L&E]!,FG+INIY&FMJL?'"=Z5.MP']8F4E_]5*DC]4CG7AYBRUDM574AB%R2YKP9VD?UV"1C?"_2?=\7"$F&V=.MY!S1Z)-K?W1?$2'6_)U%#_T F$)X=,|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lN^H"451A)@WD<2?R"8DA @#'+SEV&UNW:IM L\'4 M$63^@3D U57"])JD@+.%YFCIX]/JDE%L9=2FRQHV3N MMY00%PI5]6X245;=EO1(L=-1]@!Z0=T,<10 +KZ\[- CA;T2LI,ZL!- M$2K;P1R P4 ?0'@-']!&DG;+'=.^)?TVWHV9YF[*S+.I K8%"0=!4/!N\A_MIG#PYL$2.3A3K(CHN+V^O+\AOR=[^O+HY-C='$VQ;$!"IRDU^)0H\;X=6# M*,$46@YT5LH5YB=WX>-H':+*AVE?96SB9WI-JQZ'U)C"-(]*PYND[C"A"^\Q MP],T,%PR=Z%0UK8Y2N!%]Y3FHN\NT^=]RKW"WH*:U@%YDYC!HOK?9L@&OSGJ MN{}GG:B>- *!N+!&3)+6J[EIGU#]HH)_)XK7ZF4JZ.K*G\&L_^]FVVQD]_B M8;K%&AC?EO\1X]-Z/,KCNDN"\T\A| WM=G7^('(0@5V0.\712GM\MO)A.*]B M:],F"8,G@ $#[UYWW)'? $?.KDZ7_)MT[@H:=44XZ=ZQ/62-/V0;VI0Z*F)10 MPI="]__):!?1QLN"FDUGF-]GLZ7C.YI_I>KKJ;MXFE:B\,)>*)(NN9T QRJY M=D78#@]C/RLO3]H_-'4K)ZKD"#H>B:]\/$#Q^Q>4* (FF*=(1\,2]DX)@J=ZE ME'K.(T$YC4UW)RW(N7VF/F(5W0"V<.Z879:0D69\99V2],12F2@=ZWB@7FK4 M5*Q('D_*1.$]DWW#I&((1CI,,$M7UQIP5HV.O M IW6)!1<9^;YIJX$6ZX! 5:- "D@>_D"FNXA.;$D;K4^E)%M((#27R22TF M2&^2]U3(%#N0&N<\Uf?6V=F.=7G[^\FU=79Q>GG]Y?#VI/+BC=4_ MQPUGBAO;'D 6;SQLF/OT<=30+EE>Q!0+/C_Y?'BNXH4GQV<7GSIFJSS9>NSVGRI!!OQ7UF/YH@A(+)D6&U\8YFE9IX=' MMY?7FZ.M@M":? |=AB\#4V6@BT6U+.=*9Y\0UTI.LAUS4VVQ:.JZBBXVB0%F M.'3>DX@"6129**94'V9]8;0G2'6(AZH02OF_^F[N[,?/_/I?RA6D[BWZXBG5 M3]^N5?^5=G@Q#J,*TJO;__1Q?MJB" ,F&%KI%OKMX_NPK\Q!15\D!]>* PLK M@JWP, ,E]51U!_9\465GI\7ZIUJ?OJ.3XY/3PZ_GMC?7UZO("1.]B M!/(2)WDL92QE;RUE3;P=E5]!#Z9E- !8;NGZWV/KY&ONO^+3G*U9L/_ZG_N51L@ M>KX8P#2ET_WU2QQZMS(<1)>]VI!]&(;W\.-/Z_]L$?I(-F_H@(Y *(]_TBK]OC MlLN/U+<^8FSFPRX^]W'B?|*<9'7- &)VWC]*&C9>]C'#5.F(DMT@R'EK;A+ M?S),]341;\]@\LD%N>9P93KY%IPF.88\&O] VS8],*/LM8;NCT499E2(9;[MN$=,;F"TV#L>|/C,S[U@0!D/1H.]9*,F66FS)2W>D4D[\B0Z MT]M#.W***]B93I:6;W^__'FC^GL$"?UM3+?<2ERD[4&X>G$HKG"C$[LOPNG&K& MX+!T9#BKCAKCD;U%Z^G54T7Y+;>.LI;@/TC=S27N5!R,B8X_RK],X6*908FG]VI_A77IC+]T4- E>N@D>B[AT M+NNK]|\8%UFF5Y4G$;M4K^7/^H[-;LH/X^&ON[L/#P\[D71VH+[MW9!W:[5Z_O!![OR^__6 MVWOM@X.=?CQ((XV4) " [B3=T_*K#_N_'$@EHM[O8F(9B9K^J2AT\LWQO;7W\ M0NU&Z6Y.O-+*NDI@7GCWQN%=*-55V*KJYT8.8]6;M+ZO;L6M8/@-JZ?$(-"L M%+I@LV(=GUQ_;>P&F(*@"EI/ OHVNY+QIF)!4V1MYPJ8J/[4]=^E.0UB/=1C MR:2;\!LC^'F3%82VVMC;;S-MEVZ0F*S3D25@M[!>15V^%FJ64>BZH=_ZH!]2 M+NM*%K&:_BV%HB"MUK'- BU|INCT{J&H:JN%.QL<_2P'[K3;M5K+WM]'W&G7 M]MOMUIQQYZ&^20$1X37@0(*81]E=5E@A4?G()&S6 M&%(RI%P]LC*D9$BY:F1MZ;S*VEKH6<;4ZX8I9\J[8$RYP.H>NV'OT? EVO55O M-?=6!U,V51$08TK&E*M'5L.4C"E7C;R *9ML&*_<85I8$5M;W]U6HLMEL-UJU1<\+N4#*B^!>-2RRFXPI&5.N M*ED94S*F7#6RVO:NW694R:BRG.S9V-EG5%D*5- FLV>V#1HT:"[7M@_9"@Y5S M._PV=X,RH&1 N7ID94#)@'+5R-K:;=C<,&C^>)(OH9];W,^D3AE2+K)C>G,__M1N7>#?QXWH*,!\XWQ(N/% MU2,KXT7&BZM&5@Q ;]:IX*;5 M:- AV8\X \M/($P1]_BR;3K!#SWIQ#!1U3_2;M#A=(//!#\G (!=N&#F6 M@;X_>+T%4_9)RNH!:VU^I&5?J11N>8 C)Sl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|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|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|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eb;>'K?HHT7B0-)Y-K M<>,JT8&P8GV6O@R%\X C\2/I4? BH:RG5&LH**\'8>LAK46>6VK>2 R_'CS5/G'9TRM"-MPEXZO1)#P@7$P@C)31?L/C^\N:UF4=V)X>LEAZ5;D\/2)H)_]#;UH\'WL?_ M#U!+ 0(4 Q0 (%V!#5DO^2]Y%@<< &T> -" 0 M !E>%\W,#DR,C4N:'1M4$L! A0#% @ 78$-634RU@T4!P TA\ T M (!00< &5X7S%\W,#DR,C@N:'1M4$L! A0#% @ 78$-68:B2EFO(I*D! ! M (!TQ8 &YB>2TR,#(T,#8S,"YX XML 98 nby20240630_10q_htm.xml IDEA: XBRL DOCUMENT 0001389545 2024-01-01 2024-06-30 0001389545 nby:PrefundedWarrants2024PublicOfferingMember us-gaap:SubsequentEventMember 2024-07-26 2024-08-09 0001389545 us-gaap:SubsequentEventMember nby:The2024PublicOfferingMember 2024-07-26 2024-07-29 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:SeriesF3WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:SeriesF3WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:SeriesF2WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:SeriesF2WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:SeriesF2WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:SeriesF2WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:SeriesF3WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:SeriesF3WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:UnderwritingAgreementMember nby:MaximumAmountPurchasableByUnderwriterMember nby:SeriesF3WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:MaximumAmountPurchasableByUnderwriterMember nby:SeriesF3WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:MaximumAmountPurchasableByUnderwriterMember nby:SeriesF2WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:MaximumAmountPurchasableByUnderwriterMember nby:SeriesF2WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:MaximumAmountPurchasableByUnderwriterMember nby:SeriesF1WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:UnderwriterFrom2024PublicOfferingMember nby:MaximumAmountPurchasableByUnderwriterMember nby:SeriesF1WarrantsMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-07-26 2024-07-26 0001389545 nby:ElectionOfTheHolderPriorToTheDateOfIssuanceMember us-gaap:SubsequentEventMember nby:The2024PublicOfferingMember 2024-07-26 2024-07-26 0001389545 us-gaap:SubsequentEventMember nby:The2024PublicOfferingMember 2024-07-26 2024-07-26 0001389545 nby:PrefundedWarrants2024PublicOfferingMember us-gaap:SubsequentEventMember 2024-07-26 2024-07-26 0001389545 nby:SeriesF3WarrantsMember us-gaap:SubsequentEventMember nby:SeriesF3WarrantsMember us-gaap:SubsequentEventMember 2024-07-26 2024-07-26 0001389545 nby:SeriesF2WarrantsMember us-gaap:SubsequentEventMember 2024-07-26 2024-07-26 0001389545 nby:SeriesF3WarrantsMember us-gaap:SubsequentEventMember nby:SeriesF3WarrantsMember us-gaap:SubsequentEventMember 2024-07-26 2024-07-26 0001389545 nby:SeriesF2WarrantsMember us-gaap:SubsequentEventMember nby:The2024PublicOfferingMember 2024-07-26 2024-07-26 0001389545 nby:SeriesF3WarrantsMember us-gaap:SubsequentEventMember nby:The2024PublicOfferingMember 2024-07-26 2024-07-26 0001389545 nby:SeriesF2WarrantsMember us-gaap:SubsequentEventMember nby:The2024PublicOfferingMember 2024-07-26 2024-07-26 0001389545 nby:SeriesF1WarrantsMember us-*

gaap:SubsequentEventMember nby:The2024PublicOfferingMember 2024-07-26 0001389545 nby:SeriesF1WarrantsMember us-gaap:SubsequentEventMember nby:The2024PublicOfferingMember 2024-07-26 2024-07-26 0001389545 nby:PrefundedWarrants2024PublicOfferingMember us-gaap:SubsequentEventMember nby:The2024PublicOfferingMember 2024-07-26 2024-07-26 0001389545 us-gaap:SubsequentEventMember nby:The2024PublicOfferingMember 2024-07-26 2024-07-26 0001389545 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nby:DermadoctorMember 2023-01-01 2023-06-30 0001389545 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nby:DermadoctorMember 2024-01-01 2024-06-30 0001389545 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nby:DermadoctorMember 2023-12-31 0001389545 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nby:DermadoctorMember 2024-03-25 2024-03-25 0001389545 2023-01-01 2023-12-31 0001389545 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001389545 us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001389545 us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001389545 us-gaap:RelatedPartyMember 2024-04-01 2024-06-30 0001389545 nby:The401kPlanContributionLevelTwoMember 2023-01-01 2023-06-30 0001389545 nby:The401kPlanContributionLevelTwoMember 2023-04-01 2023-06-30 0001389545 nby:The401kPlanContributionLevelTwoMember 2024-01-01 2024-06-30 0001389545 nby:The401kPlanContributionLevelTwoMember 2024-04-01 2024-06-30 0001389545 nby:The401kPlanContributionLevelOneMember 2024-01-01 2024-06-30 0001389545 nby:AvenovaDirectMember 2023-01-01 2023-06-30 0001389545 nby:AvenovaDirectMember 2024-01-01 2024-06-30 0001389545 nby:AvenovaDirectMember 2023-01-01 2023-03-31 0001389545 nby:AvenovaDirectMember 2024-01-01 2024-03-31 0001389545 nby:CostcoAndOthersMember nby:DermadoctorMember 2023-12-31 0001389545 nby:CostcoAndOthersMember nby:DermadoctorMember 2024-06-30 0001389545 nby:CostcoAndOthersMember nby:DermadoctorMember 2023-01-01 2023-06-30 0001389545 nby:CostcoAndOthersMember nby:DermadoctorMember 2024-01-01 2024-06-30 0001389545 nby:CostcoAndOthersMember nby:DermadoctorMember 2023-04-01 2023-06-30 0001389545 nby:CostcoAndOthersMember nby:DermadoctorMember 2024-04-01 2024-06-30 0001389545 2024-06-30 0001389545 nby:RebatesMember 2024-06-30 0001389545 nby:OtherCustomerFeesMember 2024-06-30 0001389545 nby:ChargebacksDiscountsForPromptPaymentAndOtherMember 2024-06-30 0001389545 nby:RebatesMember 2024-01-01 2024-06-30 0001389545 nby:OtherCustomerFeesMember 2024-01-01 2024-06-30 0001389545 nby:ChargebacksDiscountsForPromptPaymentAndOtherMember 2024-01-01 2024-06-30 0001389545 2023-12-31 0001389545 nby:RebatesMember 2023-12-31 0001389545 nby:OtherCustomerFeesMember 2023-12-31 0001389545 nby:ChargebacksDiscountsForPromptPaymentAndOtherMember 2023-12-31 0001389545 2023-01-01 2023-06-30 0001389545 2023-04-01 2023-06-30 0001389545 2024-04-01 2024-06-30 0001389545 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001389545 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001389545 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001389545 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001389545 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001389545 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-06-30 0001389545 us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001389545 us-gaap:SellingAndMarketingExpenseMember 2024-04-01 2024-06-30 0001389545 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001389545 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001389545 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001389545 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001389545 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-06-30 0001389545 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-04-01 2023-06-30 0001389545 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-01-01 2024-06-30 0001389545 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-04-01 2023-06-30 0001389545 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-04-01 2024-06-30 0001389545 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-06-30 0001389545 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-04-01 2023-06-30 0001389545 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-01-01 2024-06-30 0001389545 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-04-01 2024-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2023-04-01 2023-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2024-04-01 2024-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-06-30 0001389545 nby:EmployeesAndDirectorsMember 2023-01-01 2023-06-30 0001389545 nby:EmployeesAndDirectorsMember 2024-01-01 2024-06-30 0001389545 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 2024-06-30 0001389545 us-gaap:EmployeeStockOptionMember nby:The2017OmnibusIncentivePlanMember 2017-03-01 2017-03-31 0001389545 nby:ShareholderOfMoreThan10PercentMember srt:MaximumMember nby:IncentiveStockOptionsISOMember nby:The2017OmnibusIncentivePlanMember 2017-03-01 2017-03-31 0001389545 srt:MaximumMember nby:The2017OmnibusIncentivePlanMember 2017-03-01 2017-03-31 0001389545 nby:ShareholderOfMoreThan10PercentMember srt:MinimumMember nby:IncentiveStockOptionsISOMember nby:The2017OmnibusIncentivePlanMember 2017-03-01 2017-03-31 0001389545 nby:IncentiveStockOptionsISOMember nby:The2017OmnibusIncentivePlanMember 2017-03-01 2017-03-31 0001389545 srt:MinimumMember nby:The2017OmnibusIncentivePlanMember 2017-03-01 2017-03-31 0001389545 nby:The2017OmnibusIncentivePlanMember 2024-06-30 0001389545 nby:The2017OmnibusIncentivePlanMember 2023-03-31 2023-03-31 0001389545 nby:The2017OmnibusIncentivePlanMember 2017-03-31 0001389545 srt:MaximumMember nby:IncentiveStockOptionsISOMember nby:The2007OmnibusIncentivePlanMember 2007-10-01 2007-10-31 0001389545 us-gaap:SeriesCPreferredStockMember 2024-03-27 2024-03-27 0001389545 srt:MinimumMember us-gaap:SeriesCPreferredStockMember 2024-05-27 0001389545 us-gaap:SeriesCPreferredStockMember 2024-03-01 2024-03-31 0001389545 srt:RestatementAdjustmentMember us-gaap:SeriesCPreferredStockMember 2024-03-31 0001389545 srt:ScenarioPreviouslyReportedMember us-gaap:SeriesCPreferredStockMember 2024-03-31 0001389545 us-gaap:SeriesCPreferredStockMember 2023-12-21 2023-12-21 0001389545 srt:RestatementAdjustmentMember us-gaap:SeriesCPreferredStockMember 2023-12-21 0001389545 srt:ScenarioPreviouslyReportedMember us-gaap:SeriesCPreferredStockMember 2023-12-21 0001389545 us-gaap:SeriesCPreferredStockMember nby:The2023PrivatePlacementMember 2023-04-27 2023-04-27 0001389545 nby:May2023WarrantsMember 2023-04-27 0001389545 us-gaap:SeriesCPreferredStockMember 2023-04-27 0001389545 us-gaap:SeriesCPreferredStockMember nby:The2022PrivatePlacementMember 2023-06-30 0001389545 us-gaap:SeriesCPreferredStockMember nby:The2022PrivatePlacementMember 2024-06-30 0001389545 us-gaap:SeriesCPreferredStockMember nby:The2022PrivatePlacementMember 2022-09-09 2022-09-09 0001389545 us-gaap:SeriesBPreferredStockMember 2024-01-29 0001389545 us-gaap:SeriesBPreferredStockMember nby:The2021PrivatePlacementProgramMember 2021-10-29 2021-10-29 0001389545 srt:MinimumMember us-gaap:SeriesBPreferredStockMember 2024-01-29 0001389545 us-gaap:SeriesBPreferredStockMember 2023-12-21 2023-12-21 0001389545 srt:RestatementAdjustmentMember us-gaap:SeriesBPreferredStockMember 2023-12-21 0001389545 srt:ScenarioPreviouslyReportedMember us-gaap:SeriesBPreferredStockMember 2023-12-21 0001389545 us-gaap:SeriesBPreferredStockMember nby:The2023PrivatePlacementMember 2023-04-27 2023-04-27 0001389545 us-gaap:SeriesBPreferredStockMember 2023-04-27 0001389545 us-gaap:SeriesBPreferredStockMember 2022-09-09 2022-09-09 0001389545 srt:RestatementAdjustmentMember us-gaap:SeriesBPreferredStockMember 2022-09-09 0001389545 srt:ScenarioPreviouslyReportedMember us-gaap:SeriesBPreferredStockMember 2022-09-09 0001389545 us-gaap:SeriesBPreferredStockMember nby:The2021PrivatePlacementProgramMember 2023-06-30 0001389545 us-gaap:SeriesBPreferredStockMember nby:The2021PrivatePlacementProgramMember 2024-06-30 0001389545 nby:ReverseStockSplitMember 2024-05-30 2024-05-30 0001389545 nby:WarrantLiabilityMember 2024-06-30 0001389545 nby:March2024WarrantMember nby:WarrantLiabilityMember 2024-01-01 2024-06-30 0001389545 nby:TheDecember2023WarrantsMember nby:WarrantLiabilityMember 2024-01-01 2024-06-30 0001389545 nby:WarrantLiabilityMember 2023-12-31 0001389545 nby:June2024WarrantMember 2024-06-30 0001389545 nby:March2024WarrantMember 2024-06-30 0001389545 nby:TheDecember2023WarrantsMember 2024-06-30 0001389545 nby:TheNovember2022A1WarrantsMember 2024-06-30 0001389545 nby:TheAmendedSeptember2022WarrantsMember 2024-06-30 0001389545 nby:TheSeptember2022WarrantsMember 2024-06-30 0001389545 nby:TheAmendedNovember2021WarrantsMember 2024-06-30 0001389545 nby:TheNovember2021WarrantsMember 2024-06-30 0001389545 nby:TLFBioInnovation2021WarrantsMember 2024-06-30 0001389545 nby:TheAmendedJuly2020WarrantsMember 2024-06-30 0001389545 nby:TheJuly2020WarrantsMember 2024-06-30 0001389545 nby:The2019LadenburgWarrantsMember 2024-06-30 0001389545 2023-06-30 0001389545 2022-12-31 0001389545 nby:AmendedJuly2020WarrantsMember 2023-05-01 2023-05-01 0001389545 nby:AmendedJuly2020WarrantsMember 2022-09-09 2022-09-09 0001389545 nby:The2023PrivatePlacementMember 2023-05-01 0001389545 nby:AmendedJuly2020WarrantsMember 2023-05-01 0001389545 nby:AmendedJuly2020WarrantsMember 2022-09-09 0001389545 nby:TheJuly2020WarrantsMember 2020-07-31 0001389545 nby:TheJuly2020WarrantsMember 2020-09-09 0001389545 nby:AmendedNovember2021WarrantsExercisableFor150Member 2023-05-01 2023-05-01 0001389545 nby:AmendedNovember2021WarrantsExercisableFor650Member 2022-09-09 2022-09-09 0001389545 nby:AmendedNovember2021WarrantsExercisableFor150Member 2023-05-01 0001389545 nby:AmendedNovember2021WarrantsExercisableFor650Member 2023-05-01 0001389545 nby:TheNovember2021WarrantsMember 2023-05-01 0001389545 nby:AmendedNovember2021WarrantsExercisableFor650Member 2022-09-09 0001389545 nby:TheNovember2021WarrantsMember 2021-11-30 0001389545 nby:September2022WarrantsAmendedMember 2024-06-01 2024-06-30 0001389545 nby:September2022WarrantsAmendedMember 2023-05-01 2023-05-31 0001389545 nby:September2022WarrantsAmendedIn2024WarrantRepriseTransactionMember 2024-06-30 0001389545 nby:September2022WarrantsAmendedIn2023PrivatePlacementMember 2022-09-09 0001389545 nby:September2022WarrantsAmendedIn2023PrivatePlacementMember 2023-05-31 0001389545 nby:The2022WarrantRepriceTransactionMember 2022-09-09 0001389545 nby:TheAmendedNovember2022A1AndA2WarrantsMember 2024-06-01 2024-06-30 0001389545 nby:TheAmendedNovember2022A1AndA2WarrantsMember 2023-05-01 2023-05-31 0001389545 nby:November2022WarrantsAmendedBy2024WarrantRepriceTransactionMember 2024-06-30 0001389545 nby:TheNovember2022A1WarrantsMember 2023-05-31 0001389545 nby:TheNovember2022A2WarrantsMember 2024-05-01 2024-05-31 0001389545 nby:TheNovember2022A2WarrantsMember 2023-05-31 0001389545 nby:TheAmendedNovember2022A1AndA2WarrantsMember 2023-05-31 0001389545 nby:TheNovember2022A1AndA2WarrantsMember 2023-05-31 0001389545 nby:TheNovember2022A2WarrantsMember 2022-11-10 0001389545 nby:TheNovember2022A1WarrantsMember 2022-11-10 0001389545 nby:May2023WarrantsMember 2024-06-01 2024-06-30 0001389545 nby:May2023WarrantsMember 2023-12-01 2023-12-31 0001389545 nby:TheMay2023B2WarrantsMember 2024-06-01 2024-06-30 0001389545 nby:TheMay2023B1WarrantsMember 2024-06-01 2024-06-30 0001389545 nby:May2023WarrantsMember 2024-06-30 0001389545 nby:May2023WarrantsAmendedBy2024WarrantRepriceTransactionMember 2024-06-30 0001389545 nby:TheMay2023B2WarrantsMember 2023-12-01 2023-12-31 0001389545 nby:TheMay2023B1WarrantsMember 2023-12-01 2023-12-31 0001389545 nby:TheMay2023B1WarrantsMember 2023-12-31 0001389545 nby:May2023WarrantsAmendedBy2023WarrantRepriceTransactionMember 2023-12-31 0001389545 nby:TheMay2023B2WarrantsMember 2023-05-31 0001389545 nby:TheMay2023B1WarrantsMember 2023-05-31 0001389545 nby:TheDecember2023WarrantsMember 2023-12-31 0001389545 nby:March2024WarrantMember 2024-03-31 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2024-06-30 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2024-01-01 2024-06-30 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2024-04-01 2024-06-30 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2024-03-31 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2023-06-30 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2023-05-01 0001389545 nby:The2023PrivatePlacementMember 2023-05-01 2023-05-01 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2023-05-01 2023-05-01 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2023-06-09 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2023-04-27 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2024-03-01 2024-03-01 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2023-12-01 2023-12-31 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2023-04-27 2023-04-27 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember nby:MeasurementInputRedemptionInStockMember 2023-04-27 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember 2024-01-01 2024-03-31 0001389545 nby:UnsecuredConvertibleNotesMember 2024-06-30 2024-06-30 0001389545 nby:UnsecuredConvertibleNotesMember 2024-04-01 2024-06-30 0001389545 nby:UnsecuredConvertibleNotesMember 2024-06-30 0001389545 nby:UnsecuredConvertibleNotesMember 2024-03-24 0001389545 nby:UnsecuredConvertibleNotesMember 2024-04-01 2024-05-28 0001389545 nby:UnsecuredConvertibleNotesMember 2024-05-28 0001389545 nby:UnsecuredConvertibleNotesMember 2024-03-31 0001389545 nby:UnsecuredConvertibleNotesMember 2024-03-24 2024-03-24 0001389545 nby:OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember nby:The2023PrivatePlacementMember 2023-05-01 0001389545 nby:The2023PrivatePlacementMember 2023-05-01 2023-05-01 0001389545 nby:The2023PrivatePlacementMember 2023-05-01 0001389545 nby:The2023PrivatePlacementMember 2023-05-01 2023-05-31 0001389545 nby:The2023WarrantRepriceTransactionMember 2023-12-01 2023-12-31 0001389545 nby:The2023WarrantRepriceTransactionMember 2023-12-31 0001389545 nby:TheDecember2023WarrantsMember 2023-12-01 2023-12-31 0001389545 nby:May2023WarrantsMember 2023-12-31 0001389545 nby:March2024WarrantMember 2024-03-24 0001389545 nby:The2024WarrantRepriceTransactionMember 2024-01-01 2024-06-30 0001389545 nby:The2024WarrantRepriceTransactionMember 2024-04-01 2024-06-30 0001389545 nby:The2024WarrantRepriceTransactionMember 2024-06-30 0001389545 nby:The2024WarrantRepriceExistingWarrantsMember 2024-06-01 2024-06-30 0001389545 nby:The2024WarrantRepriceExistingWarrantsMember 2024-06-30 0001389545 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001389545 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001389545 nby:ComputerEquipmentAndSoftwareMember 2023-12-31 0001389545 nby:ComputerEquipmentAndSoftwareMember 2024-06-30 0001389545 us-

gaap:FurnitureAndFixturesMember 2023-12-31 0001389545 us-gaap:FurnitureAndFixturesMember 2024-06-30 0001389545 nby:OfficeAndLaboratoryEquipmentMember 2023-12-31 0001389545 nby:OfficeAndLaboratoryEquipmentMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 nby:IssuanceApril272023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:IssuanceApril272023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 nby:IssuanceApril272023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputOptionVolatilityMember 2024-06-30 0001389545 nby:IssuanceApril272023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputOptionVolatilityMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:IssuanceApril272023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:IssuanceApril272023Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member us-gaap:ConvertibleDebtMember 2024-01-01 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member us-gaap:ConvertibleDebtMember 2024-06-30 0001389545 nby:IssuanceApril272023Member us-gaap:ConvertibleDebtMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 nby:IssuanceMarch252024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:IssuanceMarch252024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 nby:IssuanceMarch252024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputOptionVolatilityMember 2024-06-30 0001389545 nby:IssuanceMarch252024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputOptionVolatilityMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:IssuanceMarch252024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:IssuanceMarch252024Member nby:UnsecuredConvertibleNotesMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:UnsecuredConvertibleNotesMember 2024-01-01 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:UnsecuredConvertibleNotesMember 2024-06-30 0001389545 nby:IssuanceMarch252024Member nby:UnsecuredConvertibleNotesMember 2024-06-30 0001389545 nby:AfterRatchetMarch242024Member us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetMarch242024Member us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetMarch242024Member us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetMarch242024Member us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetMarch242024Member us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetMarch242024Member us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetMarch242024Member us-gaap:MeasurementInputOptionVolatilityMember us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetMarch242024Member us-gaap:MeasurementInputOptionVolatilityMember us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetMarch242024Member us-gaap:MeasurementInputExercisePriceMember us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetMarch242024Member us-gaap:MeasurementInputExercisePriceMember us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetMarch242024Member us-gaap:SeriesCPreferredStockMember 2024-01-01 2024-06-30 0001389545 nby:AfterRatchetMarch242024Member us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetMarch242024Member us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetDecember212023Member us-gaap:MeasurementInputExpectedTermMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetDecember212023Member us-gaap:MeasurementInputExpectedTermMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetDecember212023Member us-gaap:MeasurementInputExpectedDividendRateMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetDecember212023Member us-gaap:MeasurementInputExpectedDividendRateMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetDecember212023Member us-gaap:MeasurementInputRiskFreeInterestRateMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetDecember212023Member us-gaap:MeasurementInputRiskFreeInterestRateMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetDecember212023Member us-gaap:MeasurementInputPriceVolatilityMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetDecember212023Member us-gaap:MeasurementInputPriceVolatilityMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetDecember212023Member us-gaap:MeasurementInputSharePriceMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetDecember212023Member us-gaap:MeasurementInputSharePriceMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetDecember212023Member us-gaap:MeasurementInputExercisePriceMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetDecember212023Member us-gaap:MeasurementInputExercisePriceMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetDecember212023Member nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-01-01 2024-06-30 0001389545 nby:AfterRatchetDecember212023Member nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetDecember212023Member nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetApril272023Member us-gaap:MeasurementInputExpectedTermMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetApril272023Member us-gaap:MeasurementInputExpectedTermMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetApril272023Member us-gaap:MeasurementInputExpectedDividendRateMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetApril272023Member us-gaap:MeasurementInputExpectedDividendRateMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetApril272023Member us-gaap:MeasurementInputRiskFreeInterestRateMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetApril272023Member us-gaap:MeasurementInputRiskFreeInterestRateMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetApril272023Member us-gaap:MeasurementInputPriceVolatilityMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetApril272023Member us-gaap:MeasurementInputPriceVolatilityMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetApril272023Member us-gaap:MeasurementInputSharePriceMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetApril272023Member us-gaap:MeasurementInputSharePriceMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetApril272023Member us-gaap:MeasurementInputExercisePriceMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetApril272023Member us-gaap:MeasurementInputExercisePriceMember nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:AfterRatchetApril272023Member nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-01-01 2024-06-30 0001389545 nby:AfterRatchetApril272023Member nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 nby:PriorToRatchetApril272023Member nby:SeriesBPreferredStockAndSeriesCPreferredStockMember 2024-06-30 0001389545 srt:MaximumMember nby:PostAmendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 srt:MinimumMember nby:PostAmendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 nby:PostAmendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:PreamendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 srt:MaximumMember nby:PreamendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MinimumMember nby:PostAmendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MaximumMember nby:PreamendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MinimumMember nby:PreamendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:PreamendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:PostAmendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:PreamendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:PostAmendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 srt:MaximumMember nby:PreamendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 srt:MinimumMember nby:PreamendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:PostAmendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember 2024-01-01 2024-06-30 0001389545 nby:PostAmendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember 2024-06-30 0001389545 nby:PreamendmentJune142024Member nby:September2022November2022AndMay2023WarrantsMember 2024-06-30 0001389545 srt:MaximumMember nby:PostamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 srt:MinimumMember nby:PostamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 srt:MaximumMember nby:PreamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 srt:MinimumMember nby:PreamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 nby:PostamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:PreamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 srt:MaximumMember nby:PostamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MinimumMember nby:PostamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MaximumMember nby:PreamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MinimumMember nby:PreamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 nby:PostamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:PreamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:PostamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:PreamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545

nby:PostamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:PreamendmentDecember212023Member nby:TheMay2023WarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:PostamendmentDecember212023Member nby:TheMay2023WarrantsMember 2024-01-01 2024-06-30 0001389545 nby:PostamendmentDecember212023Member nby:TheMay2023WarrantsMember 2024-06-30 0001389545 nby:PreamendmentDecember212023Member nby:TheMay2023WarrantsMember 2024-06-30 0001389545 srt:MaximumMember nby:PostamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 srt:MinimumMember nby:PostamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 srt:MaximumMember nby:PreamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 srt:MinimumMember nby:PreamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 nby:PostamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:PreamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 srt:MaximumMember nby:PostamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MinimumMember nby:PostamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MaximumMember nby:PreamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MinimumMember nby:PreamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 nby:PostamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:PreamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:PreamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:PostamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:PreamendmentMember nby:July2020November2021September2022November2022WarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:PostamendmentMember nby:July2020November2021September2022November2022WarrantsMember 2024-01-01 2024-06-30 0001389545 nby:PostamendmentMember nby:July2020November2021September2022November2022WarrantsMember 2024-06-30 0001389545 nby:PreamendmentMember nby:July2020November2021September2022November2022WarrantsMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:March2024WarrantMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 nby:ReportingDateMarch312024Member nby:March2024WarrantMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:March2024WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:ReportingDateMarch312024Member nby:March2024WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:March2024WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 nby:ReportingDateMarch312024Member nby:March2024WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:March2024WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:ReportingDateMarch312024Member nby:March2024WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:March2024WarrantMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:ReportingDateMarch312024Member nby:March2024WarrantMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:March2024WarrantMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:ReportingDateMarch312024Member nby:March2024WarrantMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:March2024WarrantMember 2024-01-01 2024-06-30 0001389545 nby:ReportingDateMarch312024Member nby:March2024WarrantMember 2024-01-01 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:March2024WarrantMember 2024-06-30 0001389545 nby:ReportingDateMarch312024Member nby:March2024WarrantMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 nby:ReportingDateDecember312023Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 srt:MaximumMember nby:StockholderApprovalJune92023Member nby:May2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 srt:MinimumMember nby:StockholderApprovalJune92023Member nby:May2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 srt:MaximumMember nby:IssuanceMay12023Member nby:May2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 srt:MinimumMember nby:IssuanceMay12023Member nby:May2023WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:ReportingDateDecember312023Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member nby:May2023WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:IssuanceMay12023Member nby:May2023WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 nby:ReportingDateDecember312023Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MaximumMember nby:StockholderApprovalJune92023Member nby:May2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MinimumMember nby:StockholderApprovalJune92023Member nby:May2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MaximumMember nby:IssuanceMay12023Member nby:May2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 srt:MinimumMember nby:IssuanceMay12023Member nby:May2023WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:ReportingDateDecember312023Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member nby:May2023WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:IssuanceMay12023Member nby:May2023WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:ReportingDateDecember312023Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member nby:May2023WarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:IssuanceMay12023Member nby:May2023WarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:ReportingDateDecember312023Member nby:TheDecember2023WarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member nby:May2023WarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:IssuanceMay12023Member nby:May2023WarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:May2023WarrantsMember 2024-01-01 2024-06-30 0001389545 nby:ReportingDateDecember312023Member nby:TheDecember2023WarrantsMember 2024-01-01 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member nby:May2023WarrantsMember 2024-01-01 2024-06-30 0001389545 nby:StockholderApprovalMay282024Member nby:TheDecember2023WarrantsMember 2024-06-30 0001389545 nby:ReportingDateDecember312021Member nby:TheDecember2023WarrantsMember 2024-06-30 0001389545 nby:StockholderApprovalJune92023Member nby:May2023WarrantsMember 2024-06-30 0001389545 nby:IssuanceMay12023Member nby:May2023WarrantsMember 2024-06-30 0001389545 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001389545 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001389545 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001389545 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001389545 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001389545 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001389545 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001389545 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001389545 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001389545 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001389545 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001389545 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001389545 us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-06-30 0001389545 us-gaap:SeriesCPreferredStockMember 2024-01-01 2024-06-30 0001389545 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-06-30 0001389545 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-06-30 0001389545 2024-01-01 2024-03-31 0001389545 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2024-06-30 0001389545 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2024-06-30 0001389545 srt:MaximumMember nby:ComputerEquipmentAndSoftwareMember 2024-06-30 0001389545 srt:MinimumMember nby:ComputerEquipmentAndSoftwareMember 2024-06-30 0001389545 srt:MaximumMember us-gaap:EquipmentMember 2024-06-30 0001389545 srt:MinimumMember us-gaap:EquipmentMember 2024-06-30 0001389545 nby:ChongqingPioneerPharmaHoldingsLimitedMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001389545 nby:DistributorBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001389545 nby:DistributorAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001389545 nby:DistributorAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001389545 nby:MajorUSRetailerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001389545 nby:MajorUSRetailerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001389545 nby:AvenovaSprayMember us-gaap:RevenueFromContractWithCustomerMember nby:DistributorConcentrationRiskMember 2023-01-01 2023-06-30 0001389545 nby:AvenovaSprayMember us-gaap:RevenueFromContractWithCustomerMember nby:DistributorConcentrationRiskMember 2024-01-01 2024-06-30 0001389545 nby:AvenovaSprayMember us-gaap:RevenueFromContractWithCustomerMember nby:DistributorConcentrationRiskMember 2023-04-01 2023-06-30 0001389545 nby:AvenovaSprayMember us-gaap:RevenueFromContractWithCustomerMember nby:DistributorConcentrationRiskMember 2024-04-01 2024-06-30 0001389545 2023-01-01 2024-06-30 0001389545 us-gaap:ProductAndServiceOtherMember 2023-01-01 2024-06-30 0001389545 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-06-30 0001389545 us-gaap:ProductAndServiceOtherMember 2023-04-01 2023-06-30 0001389545 us-gaap:ProductAndServiceOtherMember 2024-04-01 2024-06-30 0001389545 nby:TotalProductRevenueMember 2023-01-01 2024-06-30 0001389545 nby:TotalProductRevenueMember 2024-01-01 2024-06-30 0001389545 nby:TotalProductRevenueMember 2023-04-01 2023-06-30 0001389545 nby:TotalProductRevenueMember 2024-04-01 2024-06-30 0001389545 nby:OtherProductsMember 2023-01-01 2024-06-30 0001389545 nby:OtherProductsMember 2024-01-01 2024-06-30 0001389545 nby:OtherProductsMember 2023-04-01 2023-06-30 0001389545 nby:OtherProductsMember 2024-04-01 2024-06-30 0001389545 nby:NeutrophaseMember 2023-01-01 2024-06-30 0001389545 nby:NeutrophaseMember 2024-01-01 2024-06-30 0001389545 nby:NeutrophaseMember 2023-04-01 2023-06-30 0001389545 nby:NeutrophaseMember 2024-04-01 2024-06-30 0001389545 nby:AvenovaSprayMember 2023-01-01 2024-06-30 0001389545 nby:AvenovaSprayMember 2024-01-01 2024-06-30 0001389545 nby:AvenovaSprayMember 2023-04-01 2023-06-30 0001389545 nby:AvenovaSprayMember 2024-04-01 2024-06-30 0001389545 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nby:DermadoctorMember 2024-01-01 2024-03-31 0001389545 nby:WarrantLiabilityMember 2023-01-01 2023-06-30 0001389545 nby:WarrantLiabilityMember 2024-01-01 2024-06-30 0001389545 nby:ConvertibleNotesAndMay2023WarrantsMember 2023-01-01 2023-06-30 0001389545 nby:ConvertibleNotesAndMay2023WarrantsMember 2024-01-01 2024-06-30 0001389545 us-gaap:RetainedEarningsMember 2023-06-30 0001389545 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001389545 us-gaap:CommonStockMember 2023-06-30 0001389545 us-gaap:PreferredStockMember 2023-06-30 0001389545 srt:DirectorMember 2023-04-01 2023-06-30 0001389545 srt:DirectorMember us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001389545 srt:DirectorMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001389545 srt:DirectorMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001389545 srt:DirectorMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001389545 nby:EmployeesAndDirectorsMember 2023-04-01 2023-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001389545

nby:EmployeesAndDirectorsMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001389545 nby:May2023WarrantsMember 2023-04-01 2023-06-30 0001389545 nby:May2023WarrantsMember us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001389545 nby:May2023WarrantsMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001389545 nby:May2023WarrantsMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001389545 nby:May2023WarrantsMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001389545 us-gaap:SeriesCPreferredStockMember 2023-04-01 2023-06-30 0001389545 us-gaap:SeriesCPreferredStockMember us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001389545 us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001389545 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001389545 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001389545 us-gaap:SeriesBPreferredStockMember 2023-04-01 2023-06-30 0001389545 us-gaap:SeriesBPreferredStockMember us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001389545 us-gaap:SeriesBPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001389545 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001389545 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001389545 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001389545 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001389545 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001389545 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember 2023-04-01 2023-06-30 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember 2023-04-01 2023-06-30 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001389545 2023-03-31 0001389545 us-gaap:RetainedEarningsMember 2023-03-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001389545 us-gaap:CommonStockMember 2023-03-31 0001389545 us-gaap:PreferredStockMember 2023-03-31 0001389545 nby:EmployeesAndDirectorsMember 2023-01-01 2023-03-31 0001389545 nby:EmployeesAndDirectorsMember us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001389545 nby:EmployeesAndDirectorsMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001389545 nby:EmployeesAndDirectorsMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001389545 nby:EmployeesAndDirectorsMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001389545 2023-01-01 2023-03-31 0001389545 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001389545 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001389545 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001389545 us-gaap:RetainedEarningsMember 2022-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001389545 us-gaap:CommonStockMember 2022-12-31 0001389545 us-gaap:PreferredStockMember 2022-12-31 0001389545 us-gaap:RetainedEarningsMember 2024-06-30 0001389545 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001389545 us-gaap:CommonStockMember 2024-06-30 0001389545 us-gaap:PreferredStockMember 2024-06-30 0001389545 srt:DirectorMember 2024-04-01 2024-06-30 0001389545 srt:DirectorMember us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001389545 srt:DirectorMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001389545 srt:DirectorMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001389545 srt:DirectorMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001389545 nby:EmployeesAndDirectorsMember 2024-04-01 2024-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001389545 nby:EmployeesAndDirectorsMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001389545 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001389545 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001389545 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001389545 us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001389545 nby:ReverseStockSplitMember 2024-04-01 2024-06-30 0001389545 nby:March2024WarrantMember 2024-04-01 2024-06-30 0001389545 nby:March2024WarrantMember us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001389545 nby:March2024WarrantMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001389545 nby:March2024WarrantMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001389545 nby:March2024WarrantMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001389545 nby:TheDecember2023WarrantsMember 2024-04-01 2024-06-30 0001389545 nby:TheDecember2023WarrantsMember us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001389545 nby:TheDecember2023WarrantsMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001389545 nby:TheDecember2023WarrantsMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001389545 nby:TheDecember2023WarrantsMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001389545 nby:The2022WarrantRepriceTransactionMember 2024-04-01 2024-06-30 0001389545 nby:The2022WarrantRepriceTransactionMember us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001389545 nby:The2022WarrantRepriceTransactionMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001389545 nby:The2022WarrantRepriceTransactionMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001389545 nby:The2022WarrantRepriceTransactionMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember 2024-04-01 2024-06-30 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember 2024-04-01 2024-06-30 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001389545 2024-03-31 0001389545 us-gaap:RetainedEarningsMember 2024-03-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001389545 us-gaap:CommonStockMember 2024-03-31 0001389545 us-gaap:PreferredStockMember 2024-03-31 0001389545 nby:EmployeesAndDirectorsMember 2024-01-01 2024-03-31 0001389545 nby:EmployeesAndDirectorsMember us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001389545 nby:EmployeesAndDirectorsMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001389545 nby:EmployeesAndDirectorsMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001389545 nby:EmployeesAndDirectorsMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001389545 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001389545 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001389545 us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember 2024-01-01 2024-03-31 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001389545 nby:ConversionOfSeriesCPreferredStockToCommonStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember 2024-01-01 2024-03-31 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001389545 us-gaap:RetainedEarningsMember 2023-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001389545 us-gaap:CommonStockMember 2023-12-31 0001389545 us-gaap:PreferredStockMember 2023-12-31 0001389545 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-06-30 0001389545 us-gaap:ProductMember 2023-01-01 2023-06-30 0001389545 us-gaap:ProductMember 2024-01-01 2024-06-30 0001389545 us-gaap:ProductMember 2023-04-01 2023-06-30 0001389545 us-gaap:ProductMember 2024-04-01 2024-06-30 0001389545 us-gaap:SeriesCPreferredStockMember 2023-12-31 0001389545 us-gaap:SeriesCPreferredStockMember 2024-06-30 0001389545 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001389545 us-gaap:SeriesBPreferredStockMember 2024-06-30 0001389545 2024-08-09 thunderdome:item iso4217:USD shares pure iso4217:USD shares utr:Y utr:M utr:D Q2 2024 --12-31 false 0001389545 false false false false P1Y P6M P5Y 1 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 P4Y P5Y P10Y P10Y 0 P5Y6M 0 0 0 0 0 0 0 40000 200000 200000 -82000 200000 200000 400000 900000 500000 5100000 6800000 1700000 2000000 11600000 9600000 70000 100000 66000 100000 200000 56000 200000 500000 300000 -28000 21000 -51000 56000 200000 200000 300000 1400000 1600000 0 0 0 0 0 0 0 0 0 0 0 P7Y P5Y P5Y P3Y P7Y P5Y 1 2 10-Q true 2024-06-30 false 001-33678 NOVABAY PHARMACEUTICALS, INC. DE 68-0454536 2000 Powell Street, Suite 1150 Emeryville CA 94608 510 899-8800 Common Stock, par value $0.01 per share NBY NYSEAMER Yes Yes false Non-accelerated Filer true false 4885693 751000 2924000 3000 3000 547000 680000 204000 264000 700000 564000 255000 256000 0 2730000 2253000 7154000 1128000 1296000 68000 87000 476000 478000 0 19000 3925000 9034000 1235000 906000 1297000 1169000 655000 1137000 41000 0 382000 368000 0 698000 3610000 4278000 0 334000 932000 1108000 4542000 5720000 0.01 0.01 5000000 5000000 1000 1000 6000 6000 6000 275000 0 0 1 1 0 1675000 0.01 0.01 150000000 150000000 1348000 1348000 321000 321000 13000 3000 179392000 176210000 -180028000 -174849000 -617000 3314000 3925000 9034000 2387000 3523000 5011000 5855000 13000 11000 20000 18000 2400000 3534000 5031000 5873000 808000 1795000 1645000 2534000 1592000 1739000 3386000 3339000 9000 22000 28000 32000 1019000 1175000 2074000 2411000 1617000 1593000 3908000 3292000 -0 -0 -865000 -0 2645000 2790000 6875000 5735000 -1053000 -1051000 -3489000 -2396000 80000 -216000 -114000 -216000 83000 -40000 18000 -40000 300000 501000 733000 501000 -69000 -432000 -549000 -432000 -1585000 -1728000 -4675000 -3073000 0 -308000 -124000 -702000 -1585000 -2036000 -4799000 -3775000 -0 1996000 380000 1996000 -1585000 -4032000 -5179000 -5771000 -1.37 -41.04 -5.44 -68 0 -3.39 -0.13 -9.42 -1.37 -44.43 -5.57 -77.42 1155000 91000 930000 75000 7000 1950000 321000 3000 176210000 -174849000 3314000 0 0 0 -3214000 -3214000 5000 -231000 -537000 5000 226000 0 0 0 -234000 -57000 1000 233000 0 0 0 0 380000 -380000 0 0 0 60000 0 60000 2000 1485000 915000 9000 177109000 -178443000 160000 0 0 0 -1585000 -1585000 0 -37000 -88000 1000 36000 0 0 1000 -1442000 -148000 1000 1441000 0 0 0 0 69000 0 69000 0 0 90000 1000 129000 0 130000 0 0 212000 0 212000 0 0 100000 0 100000 0 0 242000 0 242000 35 0 0 107000 1000 -1000 0 0 0 0 55000 0 55000 0 0 0 0 0 0 0 1000 6000 1348000 13000 179392000 -180028000 -617000 14000 2973000 58000 165732000 -158152000 10554000 0 0 0 -1739000 -1739000 0 0 75000 0 75000 14000 2973000 58000 1000 165807000 -159891000 8890000 0 0 0 -2036000 -2036000 -3000 -121000 54000 1000 121000 0 0 -1000 -728000 8000 0 728000 0 0 0 0 285000 0 285000 0 0 1802000 -1802000 0 0 0 0 0 194000 -194000 0 0 0 1360000 0 1360000 0 0 64000 0 64000 0 0 0 0 0 0 0 10000 2124000 120000 1000 170361000 -163923000 8563000 -4799000 -3775000 -124000 -702000 23000 26000 115000 139000 -865000 -0 368000 0 69000 285000 -114000 -216000 18000 -40000 168000 140000 726000 457000 -133000 481000 144000 81000 -1000 83000 -2000 5000 457000 166000 -162000 -127000 -2150000 -2893000 1070000 0 4000 15000 1066000 -15000 226000 0 0 3000000 1200000 193000 115000 294000 -1089000 2513000 -2173000 -395000 -206000 -561000 -2379000 -956000 3606000 5846000 -0 16000 1227000 4874000 130000 47000 0 9000 1944000 849000 380000 1996000 224000 0 312000 1360000 242000 0 NOTE 1. ORGANIZATION   NovaBay Pharmaceuticals, Inc. (“our,” “we,” “us” or the “Company”) develops and sells scientifically-created and clinically-proven eyecare, and wound care products. Our leading product, Avenova® Antimicrobial Lid and Lash Solution, or Avenova Spray, is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with our proprietary, stable and pure form of hypochlorous acid and is cleared by the Food and Drug Administration (the “FDA”) for sale in the United States. Avenova Spray is available direct to consumers primarily through online distribution channels and is also available by prescription and dispensed by eyecare professionals for blepharitis and dry eye disease. Because dry eye is a complex condition, we offer a complementary portfolio of scientifically-developed products for each step of the standard at-home treatment regimen, including the Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health.   We also manufacture and sell our proprietary form of hypochlorous acid for the wound care market through our NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries. The Company currently sells these products through distributors.   Through our former subsidiary DERMAdoctor,

LLC (“DERMAdoctor”), the Company offered over 30 dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration and keratosis pilaris. On March 25, 2024, we announced that we had sold DERMAdoctor (the “DERMAdoctor Divestiture”).   The Company operated in principally two reportable segments: (1) Eyecare and Wound Care and (2) Skincare. As noted above, on March 25, 2024, we closed the DERMAdoctor Divestiture resulting in the sale of our skincare segment.   The Company was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc. It had no operations until July 1, 2002, on which date it acquired all of the operating assets of NovaCal Pharmaceuticals, LLC, a California limited liability company. In February 2007, the Company changed its name from NovaCal Pharmaceuticals, Inc. to NovaBay Pharmaceuticals, Inc. In June 2010, the Company changed the state in which it was incorporated (the “Reincorporation”) and is now incorporated under the laws of the State of Delaware. All references to “the Company” herein refer to the California corporation prior to the date of the Reincorporation and to the Delaware corporation on and after the date of the Reincorporation.   Effective May 30, 2024, the Company effected a 1-for-35 reverse split of our outstanding common stock (“Reverse Stock Split”) (See Note 12, “Stockholders’ (Deficit) Equity” for further details). Except as otherwise specifically noted, all share numbers, share prices, exercise/conversion prices and per share amounts have been adjusted, on a retroactive basis, to reflect this 1-for-35 reverse stock split.   Discontinued Operations   On March 25, 2024, the Company completed the DERMAdoctor Divestiture for an aggregate sale price of $1.1 million. The Company recognized a loss on the DERMAdoctor Divestiture amounting to $0.9 million in the period ended March 31, 2024, which is recorded in loss on divestiture of subsidiary in the unaudited condensed consolidated statements of operations.   In connection with the DERMAdoctor Divestiture, the Company has entered into Transition Services Agreement with New Age Investments, LLC to provide for a customary and orderly transition of the business, including warehousing services provided by New Age Investments, LLC and fulfillment services provided by the Company, which shall be included in continuing operations in subsequent periods.   Going Concern   The Company has sustained operating losses for the majority of its corporate history and expects that its 2024 expenses will exceed its 2024 revenues, as the Company continues to invest in its commercialization efforts. Additionally, the Company expects to continue incurring operating losses and negative cash flows until revenues reach a level sufficient to support ongoing growth and operations. Accordingly, the Company has determined that its planned operations raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. Additionally, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control that impact the broader economy such as periods of inflation, supply chain issues, global pandemics and international conflicts (e.g., the conflicts between Israel and Hamas, Russia and Ukraine, and China and Taiwan).   The Company’s long-term liquidity needs will be largely determined by the success of our commercialization efforts. To address the Company’s current liquidity and capital needs, the Company has and continues to evaluate different plans and strategic transactions to fund operations, including: (1) raising additional capital through debt and equity financings or from other sources; (2) reducing spending on operations, including reducing spending on one or more of its sales and marketing programs or restructuring operations to change its overhead structure; (3) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones or an upfront fee; (4) entering into license agreements to sell new products; and/or (5) the divestiture of certain business or product lines and related assets. The Company may issue securities, including common stock, preferred stock, convertible debt securities and warrants through additional private placement transactions or registered public offerings, which may require the filing of a Form S-1 or Form S-3 registration statement with the Securities and Exchange Commission (“SEC”). While the Company believes that the proceeds from the 2024 Public Offering (as defined in Note 19, “Subsequent Events”), 2024 Warrant Reprice Transaction (as defined in Note 9, “Financing Activities”), and the DERMAdoctor Divestiture improved the Company’s liquidity in the near term, there is no assurance that the Company will be successful in executing additional capital raising strategies at levels necessary to address the Company’s ongoing and future cash flow and liquidity needs. Accordingly, the Company continues to evaluate different plans and strategies to address the Company’s capital and liquidity needs, as well as evaluating potential other strategic alternatives and transactions. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.   35 35 1100000 -900000 NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of Presentation   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position and operating results.   Principles of Consolidation   The accompanying condensed consolidated financial statements include the accounts of NovaBay Pharmaceuticals, Inc. and its former wholly-owned subsidiary, DERMAdoctor, LLC, as of and for the six months ended June 30, 2024. All significant intercompany balances and transactions have been eliminated in consolidation. As of March 25, 2024, the Company divested its wholly-owned subsidiary pursuant to the DERMAdoctor Divestiture. The financial results for DERMAdoctor have been presented as discontinued operations in the accompanying condensed consolidated financial statements. For the six months ended June 30, 2024, all gains and losses on disposition, along with the sales, costs and expenses attributable to discontinued operations, have been aggregated in the captions entitled “Loss on divestiture of subsidiary” and “Net loss from discontinued operations” in our unaudited condensed consolidated statements of operations.   Financial Statement Reclassification   Certain account balances from prior periods have been reclassified in these unaudited condensed consolidated financial statements to conform to current period classifications. The prior year amounts have been modified in these unaudited condensed consolidated financial statements to properly report amounts under current operations and discontinued operations (see Note 18, “Divestiture and Discontinued Operations”).   Further, certain prior period operating lease balances on the Condensed Consolidated Statements of Cash Flows originally reported within changes in “Operating lease right-of-use assets” are now within “Non-cash right-of-use amortization” to conform to the current year presentation.   Use of Estimates   The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, contract liabilities related to product sales such as product returns, assumptions for valuing warrants, assumptions for valuing derivative liabilities, the fair value of contingent consideration, intangible assets, goodwill, stock-based compensation, income taxes and other contingencies.   These estimates are based on management’s best estimates and judgment. Actual results may differ from these estimates. Estimates, judgments, and assumptions are continuously evaluated and are based on management’s experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these assumptions, judgments and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.   Unaudited Condensed Consolidated Interim Financial Information   The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation.   The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The unaudited condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.   The condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 26, 2024 and amended on March 29, 2024 (collectively, the “2023 Annual Report”).   Cash, Cash Equivalents, and Restricted Cash   The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of June 30, 2024 and December 31, 2023, the Company’s cash and cash equivalents were held in a major financial institution in the United States.   The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Cash and cash equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">751</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,130</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash and cash equivalents, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">206</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted cash included in other assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">476</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">476</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,227</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,400</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.   Concentrations of Credit Risk and Major Partners   Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States.   The Company has a significant amount of its cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the three and six months ended June 30, 2024 and 2023, revenues from significant product categories were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three Months Ended June 30,</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Six Months Ended June 30,</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Avenova Spray</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,125</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,758</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,221</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,695</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> NeutroPhase </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,043</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,043</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other products </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">262</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">722</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif;

font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">790</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,117</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total product revenue, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,387</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,523</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,011</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,855</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other revenue, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total sales, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,400</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,534</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,031</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,873</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   During the three and six months ended June 30, 2024 and 2023, revenues were derived primarily from sales of Avenova branded products, directly to consumers through Amazon.com and Avenova.com. Sales of Avenova Spray via Amazon comprised 74% and 61% of total Avenova Spray net revenue during the three months ended June 30, 2024 and 2023, respectively. Sales of Avenova Spray via Amazon comprised 74% and 68% of total Avenova Spray net revenue during the six months ended June 30, 2024 and 2023, respectively.   As of June 30, 2024 and December 31, 2023, accounts receivable from continuing operations from our major distribution partners and major retailers greater than 10% were as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%; border-bottom: 1px solid rgb(0, 0, 0);"> Major distribution partner </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Major U.S. Retailer A </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Avenova Spray Pharmacy Distributor A </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Avenova Spray Pharmacy Distributor B </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">*</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Chongqing Pioneer Pharma Holdings Limited </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">*</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">36</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody></table>   * Less than 10%   The Company relies on one contract manufacturer to produce its products. The Company does not have any manufacturing facilities and intends to continue to rely on third parties for the supply of finished goods. Our contract manufacturer may or may not be able to meet the Company's needs with respect to timing, quantity or quality. In particular, it is possible that the Company may suffer from unexpected delays in light of the global supply chain issues.   <i>Fair Value of Financial

Assets and Liabilities   The Company's financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities, warrant liabilities, and contingent consideration. The Company's cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.   The Company follows Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Under this standard, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The standard also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. There are three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities; Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 – inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).   Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.   See additional information in Note 3, "Fair Value Measurements".   Allowance for Credit Losses   The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Company's future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. The allowance is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. Management recorded a reserve for allowance for credit losses of $3 thousand as of June 30, 2024 and December 31, 2023.   Inventory   Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes and pumps; (2) goods in progress, which are normally filled but unlabeled bottles; and (3) finished goods. The Company utilizes a contract manufacturer to produce our products and the price paid to these manufacturers is included in inventory. Inventory is stated at the lower of cost or estimated net realizable value determined by the first-in, first-out method. At June 30, 2024 and December 31, 2023, management had recorded an allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $204 thousand and $264 thousand, respectively.   Property and Equipment, net   Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five to seven years for office and laboratory equipment, three to five years for computer equipment and software, and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term.   The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.   Business Combinations, Goodwill and Indefinite-Lived Intangible Assets   We account for business combinations using the acquisition method of accounting, in accordance with ASC 805, Business Combinations. The acquisition method requires that identifiable assets acquired and liabilities assumed are recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. Intangible assets are measured at their respective fair values as of the acquisition date. Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination.   Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired.   Goodwill is evaluated for impairment by first performing a qualitative assessment to determine whether a quantitative goodwill test is necessary. If it is determined, based on qualitative factors, that the fair value of the reporting unit may more likely than not be less than carrying amount, or if significant adverse changes in the Company's future financial performance occur that could materially impact fair value, a quantitative goodwill impairment test would be required. Additionally, management can elect to forgo the qualitative assessment and perform the quantitative test. If the qualitative assessment indicates that the quantitative analysis should be performed, or if management elects to bypass a qualitative assessment, the Company then evaluates goodwill for impairment by comparing the fair value of the reporting unit to its carrying amount, including goodwill. The quantitative assessment for goodwill requires management to estimate the fair value of the Company's reporting units using either an income or market approach or a combination thereof.   Management makes critical assumptions and estimates in completing impairment assessments of goodwill and indefinite-lived intangible assets. The Company's cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates.   The Company did not record any goodwill or indefinite-lived asset impairment charges during the three or six months ended June 30, 2024 or June 30, 2023.   Valuation of Contingent Consideration Resulting from a Business Combination   In connection with the DERMAdoctor acquisition, the Company was subject to paying consideration that was contingent upon the achievement of specified milestone events. The Company recorded this contingent consideration at its fair value on the acquisition date. Each quarter thereafter, the Company revalued the contingent consideration and recorded changes in fair value within the condensed consolidated statements of operations. The DERMAdoctor acquisition milestone events consisted of financial targets for calendar years 2022 and 2023 which were not met. As a result, the liability recorded for potential earn out payments in the Company's condensed consolidated balance sheets was zero as of June 30, 2024 and December 31, 2023.   Long-Lived Assets   The Company's intangible assets that do not have indefinite lives, primarily trade secrets and product formulations, are amortized over their estimated useful lives. All of the Company's intangible assets subject to amortization and other long-lived assets, are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use are present. The Company reviews long-lived assets for impairment at least annually or whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the condensed consolidated statements of operations.   The Company did not record any long-lived asset impairments during the three or six months ended June 30, 2024 or June 30, 2023.   Leases   At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received.   The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not applied. Leases include variable components (e.g., common area maintenance) that are paid separately from the monthly base payment based on actual costs incurred and therefore were not included in the right-of-use assets and lease liability but are reflected as an expense in the period incurred.   The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the condensed consolidated balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.   Common Stock Warrants   The Company accounts for the issuance of common stock purchase warrants issued in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity and ASC 815, Derivatives and Hedging.   The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, the Company also classifies as liabilities any warrants during the period which the shares underlying the contract are subject to stockholder approval before the warrant can be exercised.   For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black Scholes option pricing model. These values are subject to a significant degree of management's judgment. See Note 3, "Fair Value Measurements", subheading "Black Scholes Valuation Models and Assumptions" and Note 11,

“Common Stock Warrants”, subheading “Summary of Common Stock Warrant Liabilities”.   Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black Scholes option pricing model. See Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions”.   Preferred Stock   Terms of the Company’s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (as defined and described in Note 12, “Stockholders’ (Deficit) Equity”). The applicable Ratchet provisions of the Company’s outstanding Preferred Stock terminated during the quarter ended March 31, 2024. When a conversion price was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend was measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the anti-dilution protection feature). These fair values were determined using the Black Scholes option pricing model. These values are subject to a significant degree of management’s judgment. See also Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions”.   Revenue Recognition   The Company’s product revenue recognition policies are established in accordance with ASC 606, Revenue from Contracts with Customers, in accordance with the following five steps: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> i. </td> <td style="width: auto;"> identify the contract(s) with a customer; </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ii. </td> <td style="width: auto;"> identify the performance obligations in the contract; </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> iii. </td> <td style="width: auto;"> determine the transaction price; </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> iv. </td> <td style="width: auto;"> allocate the transaction price to the performance obligations in the contract; and </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> v. </td> <td style="width: auto;"> recognize revenue when (or as) the entity satisfies performance obligations. </td> </tr> </tbody></table>   Revenue is recognized in accordance with the amount of consideration which the Company expects to receive.   Revenue generated from end consumers through third-party online retailers, such as Amazon, as well as the Company’s web store (Avenova.com) is recognized on a “sell-through” basis when control of the goods is transferred to the consumer, which generally occurs upon delivery of the products to the party fulfilling the consumer’s order. Revenue is recorded net of any discounts and estimates for refunds and product returns. Fees paid to third-party online retailers and fulfillment parties are recorded as incurred in the Company’s condensed consolidated statements of operations. Fulfillment and shipping and handling fees are recorded as product cost of goods sold. Selling commissions and advertising and promotion fees are recorded as sales and marketing expenses.   Revenue generated through major pharmacy distributors is recognized on a “sell-in” basis when control of the goods is transferred to the distributor, which generally occurs upon delivery of the products to the distributor. Revenue is recorded net of consideration for contract liabilities for distributor services, discounts, rebates, and product returns. The Company estimates returns and other contract liabilities based on historical data which is updated quarterly. Payment for products sold is typically due 60 days after delivery to the distributor.   Revenue generated from end consumers through the Company’s partner pharmacies is recognized on a “sell-through” basis when control of the goods is transferred to the consumer.   Revenue generated from other retailers is recognized on a “sell-through” basis, net of estimated future product returns, when control of the goods is transferred to the retailer, which generally occurs upon delivery of the products to a third-party carrier who is delivering the products to the retailer.   The Company defers recognition for pre-payments until the Company’s performance obligations are satisfied.   Cost of Goods Sold   Cost of goods sold includes third-party manufacturing costs, shipping and handling costs, third-party fulfillment fees, and other costs associated with products sold. Cost of goods sold also includes any necessary allowances for excess and obsolete inventory as well as lower of cost and estimated net realizable value.   Research and Development Costs   The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities.   Patent Costs   Patent costs are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations.   Advertising Costs   Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising expenses were $0.2 million for both of the three months ended June 30, 2024 and 2023. Advertising expenses were $0.4 million and $0.5 million for the six months ended June 30, 2024 and 2023, respectively.   Stock-Based Compensation   The Company’s stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company’s condensed consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black Scholes option pricing model. The Company accounts for RSUs issued to employees and non-employees (directors, consultants and advisory board members) based on the fair market value of the Company’s common stock on the date of issuance. See Note 13, “Equity-Based Compensation” for further information regarding stock-based compensation expense and the assumptions used in estimating the expense.   Income Taxes   The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.   Net Loss per Share   The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”) as shown in the Company’s condensed consolidated statements of operations.   Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive.   For the three and six months ended June 30, 2024 and 2023, the Series B Preferred Stock and Series C Preferred Stock were excluded from the computation of diluted net loss per share as their inclusion on an “if converted” basis would have been anti-dilutive. The Series B Preferred Stock and Series C Preferred Stock were considered anti-dilutive because such securities did not have a contractual obligation to participate in losses of the Company.   The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Balance at June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023* </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family:*

"Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the "Series B Preferred Stock") </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,065</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">201,432</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the "Series C Preferred Stock") </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,134</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,904</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,301</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">224,777</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">210,929</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">246,746</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">440,796</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">* </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. </td> </tr> </tbody></table>   Recent Accounting Pronouncements   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, "Summary of Significant Accounting Policies" included in our 2023 Annual Report. The Company continues to evaluate the potential impact of adopting the new accounting guidance on its consolidated financial position, results of operations and cash flows. Basis of Presentation   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and are expressed in U.S. dollars. In management's opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company's financial position and operating results.   Principles of Consolidation   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying condensed consolidated financial statements include the accounts of NovaBay Pharmaceuticals, Inc. and its former wholly-owned subsidiary, DERMAdoctor, LLC, as of and for the six months ended June 30, 2024. All significant intercompany balances and transactions have been eliminated in consolidation. As of March 25, 2024, the Company divested its wholly-owned subsidiary pursuant to the DERMAdoctor Divestiture. The financial results for DERMAdoctor have been presented as discontinued operations in the accompanying condensed consolidated financial statements. For the six months ended June 30, 2024, all gains and losses on disposition, along with the sales, costs and expenses attributable to discontinued operations, have been aggregated in the captions entitled "Loss on divestiture of subsidiary" and "Net loss from discontinued operations" in our unaudited condensed consolidated statements of operations.   Financial Statement Reclassification   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain account balances from prior periods have been reclassified in these unaudited condensed consolidated financial statements to conform to current period classifications. The prior year amounts have been modified in these unaudited condensed consolidated financial statements to properly report amounts under current operations and discontinued operations (see Note 18, "Divestiture and Discontinued Operations").   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Further, certain prior period operating lease balances on the Condensed Consolidated Statements of Cash Flows originally reported within changes in "Operating lease right-of-use assets" are now within "Non-cash right-of-use amortization" to conform to the current year presentation.   Use of Estimates   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, contract liabilities related to product sales such as product returns, assumptions for valuing warrants, assumptions for valuing derivative liabilities, the fair value of contingent consideration, intangible assets, goodwill, stock-based compensation, income taxes and other contingencies.   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt,">These estimates are based on management's best estimates and judgment. Actual results may differ from these estimates. Estimates, judgments, and assumptions are continuously evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these assumptions, judgments and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.   Unaudited Condensed Consolidated Interim Financial Information   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation.   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The unaudited condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2023, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 26, 2024 and amended on March 29, 2024 (collectively, the "2023 Annual Report"). Cash, Cash Equivalents, and Restricted Cash   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of June 30, 2024 and December 31, 2023, the Company's cash and cash equivalents were held in a major financial institution in the United States.   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <b>2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size:

10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Cash and cash equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">751</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,130</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash and cash equivalents, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(206</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted cash included in other assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">476</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">476</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,227</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,400</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Cash and cash equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">751</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,130</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash and cash equivalents, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(206</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted cash included in other assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">476</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">476</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,227</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,400</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 751000 3130000 -0 206000 476000 476000 1227000 3400000 Concentrations of Credit Risk and Major Partners   Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States.   The Company has a significant amount of its cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.   During the three and six months ended June 30, 2024 and 2023, revenues from significant product categories were as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six Months Ended June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times

New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Avenova Spray </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,125</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,758</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,221</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,695</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> NeutroPhase </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,043</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,043</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other products </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">262</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">722</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">790</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,117</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total product revenue, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,387</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,523</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,011</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,855</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other revenue, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total sales, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,400</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,534</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,031</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,873</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   During the three and six months ended June 30, 2024 and 2023, revenues were derived primarily from sales of Avenova branded products, directly to consumers through Amazon.com and Avenova.com. Sales of Avenova Spray via Amazon comprised 74% and 61% of total Avenova Spray net revenue during the three months ended June 30, 2024 and 2023, respectively. Sales of Avenova Spray via Amazon comprised 74% and 68% of total Avenova Spray net revenue during the six months ended June 30, 2024 and 2023, respectively.   As of June 30, 2024 and December 31, 2023, accounts receivable from continuing operations from our major distribution partners and major retailers greater than 10% were as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td> <td style="font-family: "Times New Roman", Times, serif;

font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%; border-bottom: 1px solid rgb(0, 0, 0);"> Major distribution partner </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Major U.S. Retailer A </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Avenova Spray Pharmacy Distributor A </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Avenova Spray Pharmacy Distributor B </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">*</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Chongqing Pioneer Pharma Holdings Limited </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">*</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">36</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody></table>   * Less than 10%   The Company relies on one contract manufacturer to produce its products. The Company does not have any manufacturing facilities and intends to continue to rely on third parties for the supply of finished goods. Our contract manufacturer may or may not be able to meet the Company's needs with respect to timing, quantity or quality. In particular, it is possible that the Company may suffer from unexpected delays in light of the global supply chain issues.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six Months Ended June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Avenova Spray </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,125</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,758</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,221</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,695</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> NeutroPhase </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,043</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,043</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other products </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">262</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">722</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">790</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td>

<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,117</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total product revenue, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,387</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,523</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,011</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,855</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other revenue, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total sales, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,400</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,534</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,031</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,873</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 2125000 1758000 4221000 3695000 0 1043000 0 1043000 262000 722000 790000 1117000 2387000 3523000 5011000 5855000 13000 11000 20000 18000 2400000 3534000 5031000 5873000 0.74 0.61 0.74 0.68 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%; border-bottom: 1px solid rgb(0, 0, 0);"> Major distribution partner </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Major U.S. Retailer A </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Avenova Spray Pharmacy Distributor A </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Avenova Spray Pharmacy Distributor B </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">*</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Chongqing Pioneer Pharma Holdings Limited </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">*</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">36</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody></table> 0.35 0.22 0.33 0.14 0.12 0.36 Fair Value of Financial Assets and Liabilities   The Company's financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Company's cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.   The Company follows Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Under this standard, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The standard also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. There are three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities; <p style="font-family:Times New

Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 – inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).   Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.   See additional information in Note 3, "Fair Value Measurements".   Allowance for Credit Losses   The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Company's future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. The allowance is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. Management recorded a reserve for allowance for credit losses of $3 thousand as of June 30, 2024 and December 31, 2023.   3000 3000 Inventory   Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes and pumps; (2) goods in progress, which are normally filled but unlabeled bottles; and (3) finished goods. The Company utilizes a contract manufacturer to produce our products and the price paid to these manufacturers is included in inventory. Inventory is stated at the lower of cost or estimated net realizable value determined by the first-in, first-out method. At June 30, 2024 and December 31, 2023, management had recorded an allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $204 thousand and $264 thousand, respectively.   204000 264000 Property and Equipment, net   Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five to seven years for office and laboratory equipment, three to five years for computer equipment and software, and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term.   The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.   Business Combinations, Goodwill and Indefinite-Lived Intangible Assets   We account for business combinations using the acquisition method of accounting, in accordance with ASC 805, Business Combinations. The acquisition method requires that identifiable assets acquired and liabilities assumed are recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. Intangible assets are measured at their respective fair values as of the acquisition date. Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination.   Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired.   Goodwill is evaluated for impairment by first performing a qualitative assessment to determine whether a quantitative goodwill test is necessary. If it is determined, based on qualitative factors, that the fair value of the reporting unit may more likely than not be less than carrying amount, or if significant adverse changes in the Company's future financial performance occur that could materially impact fair value, a quantitative goodwill impairment test would be required. Additionally, management can elect to forgo the qualitative assessment and perform the quantitative test. If the qualitative assessment indicates that the quantitative analysis should be performed, or if management elects to bypass a qualitative assessment, the Company then evaluates goodwill for impairment by comparing the fair value of the reporting unit to its carrying amount, including goodwill. The quantitative assessment for goodwill requires management to estimate the fair value of the Company's reporting units using either an income or market approach or a combination thereof.   Management makes critical assumptions and estimates in completing impairment assessments of goodwill and indefinite-lived intangible assets. The Company's cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates.   The Company did not record any goodwill or indefinite-lived asset impairment charges during the three or six months ended June 30, 2024 or June 30, 2023.   Valuation of Contingent Consideration Resulting from a Business Combination   In connection with the DERMAdoctor acquisition, the Company was subject to paying consideration that was contingent upon the achievement of specified milestone events. The Company recorded this contingent consideration at its fair value on the acquisition date. Each quarter thereafter, the Company revalued the contingent consideration and recorded changes in fair value within the condensed consolidated statements of operations. The DERMAdoctor acquisition milestone events consisted of financial targets for calendar years 2022 and 2023 which were not met. As a result, the liability recorded for potential earn out payments in the Company's condensed consolidated balance sheets was zero as of June 30, 2024 and December 31, 2023.   Long-Lived Assets   The Company's intangible assets that do not have indefinite lives, primarily trade secrets and product formulations, are amortized over their estimated useful lives. All of the Company's intangible assets subject to amortization and other long-lived assets, are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use are present. The Company reviews long-lived assets for impairment at least annually or whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the condensed consolidated statements of operations.   The Company did not record any long-lived asset impairments during the three or six months ended June 30, 2024 or June 30, 2023.   Leases   At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received.   The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not applied. Leases include variable components (e.g., common area maintenance) that are paid separately from the monthly base payment based on actual costs incurred and therefore were not included in the right-of-use assets and lease liability but are reflected as an expense in the period incurred.   The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the condensed consolidated balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.   Common Stock Warrants   The Company accounts for the issuance of common stock purchase warrants issued in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity and ASC 815, Derivatives and Hedging.   The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, the Company also classifies as liabilities any warrants during the period which the shares underlying the contract are subject to stockholder approval before the warrant can be exercised.   For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black Scholes option pricing model. These values are subject to a significant degree of management's judgment. See Note 3, "Fair Value Measurements", subheading "Black Scholes Valuation Models and Assumptions" and Note 11, "Common Stock Warrants", subheading "Summary of Common Stock Warrant Liabilities".   Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black Scholes option pricing model. See Note 3, "Fair Value Measurements", subheading "Black Scholes Valuation Models and Assumptions",   Preferred Stock   Terms of the Company's outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (as defined and described in Note 12, "Stockholders' (Deficit) Equity"). The applicable Ratchet provisions of the Company's outstanding Preferred Stock terminated during the quarter ended March 31, 2024. When a conversion price was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend was measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the anti-dilution protection feature). These fair values were determined using the Black Scholes option pricing model. These values are subject to a significant degree of management's judgment. See also Note 3, "Fair Value Measurements", subheading "Black Scholes Valuation Models and Assumptions". <p style="font-family:'Times New Roman';font-size:10pt;font-

variant:normal;margin:0pt;"> Revenue Recognition   The Company's product revenue recognition policies are established in accordance with ASC 606, Revenue from Contracts with Customers, in accordance with the following five steps: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> i. </td> <td style="width: auto;"> identify the contract(s) with a customer; </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ii. </td> <td style="width: auto;"> identify the performance obligations in the contract; </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> iii. </td> <td style="width: auto;"> determine the transaction price; </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> iv. </td> <td style="width: auto;"> allocate the transaction price to the performance obligations in the contract; and </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> v. </td> <td style="width: auto;"> recognize revenue when (or as) the entity satisfies performance obligations. </td> </tr> </tbody></table>   Revenue is recognized in accordance with the amount of consideration which the Company expects to receive.   Revenue generated from end consumers through third-party online retailers, such as Amazon, as well as the Company's web store (Avenova.com) is recognized on a "sell-through" basis when control of the goods is transferred to the consumer, which generally occurs upon delivery of the products to the party fulfilling the consumer's order. Revenue is recorded net of any discounts and estimates for refunds and product returns. Fees paid to third-party online retailers and fulfillment parties are recorded as incurred in the Company's condensed consolidated statements of operations. Fulfillment and shipping and handling fees are recorded as product cost of goods sold. Selling commissions and advertising and promotion fees are recorded as sales and marketing expenses.   Revenue generated through major pharmacy distributors is recognized on a "sell-in" basis when control of the goods is transferred to the distributor, which generally occurs upon delivery of the products to the distributor. Revenue is recorded net of consideration for contract liabilities for distributor services, discounts, rebates, and product returns. The Company estimates returns and other contract liabilities based on historical data which is updated quarterly. Payment for products sold is typically due 60 days after delivery to the distributor.   Revenue generated from end consumers through the Company's partner pharmacies is recognized on a "sell-through" basis when control of the goods is transferred to the consumer.   Revenue generated from other retailers is recognized on a "sell-through" basis, net of estimated future product returns, when control of the goods is transferred to the retailer, which generally occurs upon delivery of the products to a third-party carrier who is delivering the products to the retailer.   The Company defers recognition for pre-payments until the Company's performance obligations are satisfied. P60D Cost of Goods Sold   Cost of goods sold includes third-party manufacturing costs, shipping and handling costs, third-party fulfillment fees, and other costs associated with products sold. Cost of goods sold also includes any necessary allowances for excess and obsolete inventory as well as lower of cost and estimated net realizable value.   Research and Development Costs   The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities.   Patent Costs   Patent costs are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations.   Advertising Costs   Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising expenses were $0.2 million for both of the three months ended June 30, 2024 and 2023. Advertising expenses were $0.4 million and $0.5 million for the six months ended June 30, 2024 and 2023, respectively.   200000 200000 400000 500000 Stock-Based Compensation   The Company's stock-based compensation includes grants of stock options and restricted stock units ("RSUs") to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company's condensed consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black Scholes option pricing model. The Company accounts for RSUs issued to employees and non-employees (directors, consultants and advisory board members) based on the fair market value of the Company's common stock on the date of issuance. See Note 13, "Equity-Based Compensation" for further information regarding stock-based compensation expense and the assumptions used in estimating the expense.   Income Taxes   The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.   Net Loss per Share   The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share ("EPS") as shown in the Company's condensed consolidated statements of operations.   Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive.   For the three and six months ended June 30, 2024 and 2023, the Series B Preferred Stock and Series C Preferred Stock were excluded from the computation of diluted net loss per share as their inclusion on an "if converted" basis would have been anti-dilutive. The Series B Preferred Stock and Series C Preferred Stock were considered anti-dilutive because such securities did not have a contractual obligation to participate in losses of the Company.   The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Balance at June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024* </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023* </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the "Series B Preferred Stock") </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,065</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">201,432</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the "Series C Preferred Stock") </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,134</td> <td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,904</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,301</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Stock warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">224,777</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">210,929</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">246,746</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">440,796</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> * </td> <td style="width: auto;"> After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Balance at June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024* </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023* </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the “Series B Preferred Stock”) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,065</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">201,432</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the “Series C Preferred Stock”) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,134</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,904</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,301</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Stock warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">224,777</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">210,929</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">246,746</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">440,796</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 15065000 201432000 0 24134000 6904000 4301000 224777000 210929000 246746000 440796000 Recent Accounting Pronouncements   For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, “Summary of Significant Accounting Policies” included in our 2023 Annual Report. The Company continues to evaluate the potential impact of adopting the new accounting guidance on its consolidated financial position, results of operations and cash flows. NOTE 3. FAIR VALUE MEASUREMENTS   The following table presents the Company’s financial instruments measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value Measurements Using </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Quoted </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>

<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Prices in </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Active </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Markets </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> for </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Other </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Balance at </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Identical </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Observable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Unobservable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Items </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Inputs </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Inputs </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 1) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 2) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 3) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Assets </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted cash held as a certificate of deposit </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">476</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">476</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value Measurements Using </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Quoted </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Prices in </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Markets </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> for </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Other </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Balance at </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Identical </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Observable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Unobservable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Items </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Inputs </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Inputs </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 1) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 2) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 3) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Assets </td> <td style="font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> Issuance </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;">   Stockholder Approval   </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Reporting Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Stockholder Approval </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> May 1, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;">   June 9, 2023   </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> May 28, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Total Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $1.6 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $1.4 million   </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> $0.3 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> $0.2 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Gain (Loss) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.2 million   </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> $56 thousand</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c936">$(51 thousand) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Assumptions: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Exercise price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Market price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> $</p> </td> <td colspan="3" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">25.20</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;">(a) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",

Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.14</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.94</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">77.6</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">83.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.60</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.04</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.92</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.59</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.56</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">% </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.1</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.0</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Warrant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Warrant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Reporting Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Stockholder Approval </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March 31, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> May 28, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.1 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.1

million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Gain (Loss) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $21 thousand</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c970">$(28 thousand) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Assumptions: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercise price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.90</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.90</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Market price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.94</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">86.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">83.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.21</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.56</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> (a) </td> <td style="width: auto;"> Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. </td> </tr> </tbody></table>   Warrant Modifications   Amendments to warrant terms are recorded as a non-cash gain (or loss) on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black Scholes option pricing model. Fair value was determined using a Black Scholes model as outlined below.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 24%;"> July 2020, November 2021, September 2022 & November 2022 Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> Prior to amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> After amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> April 27, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> April 27, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Total Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.3 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.5 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times,

serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Loss </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.2 million</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assumptions:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercise price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Market price</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">$ </td> <td colspan="3" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">25.20</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;">(a) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> $ </td> <td colspan="3" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">25.20</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;">(a)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.59</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.73</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.59</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.73</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.1</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.6</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.1</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.6</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 24%;"> May 2023 Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> Prior to amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> After amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> December 21, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> December 21, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Total Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $56 thousand </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.2 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Loss </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.1 million</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assumptions:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercise price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Market price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.92</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.62</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.92</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.62</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.5</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.5</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 24%;"> September 2022, November 2022, & May 2023 Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> Prior to amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> After amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> June 14, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> June 14, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Total Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $66 thousand </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.1 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Loss </td> <td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $70 thousand</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Assumptions:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercise price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">52.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Market price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.51</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.51</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">89.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">89.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.27</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.08</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.27</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.08</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.0-4.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.0</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> (a) </td> <td style="width: auto;"> Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. </td> </tr> </tbody></table>   Preferred Stock Conversion Price Adjustments   Terms of the Company's outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (see Note 12, "Stockholders' (Deficit) Equity"). The applicable Ratchet provisions of the Company's outstanding Preferred Stock terminated during the quarter ended March 31, 2024. When a conversion price was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend is measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the anti-dilution protection feature). Fair value was determined using a Black Scholes model as outlined below.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Series B & C Preferred Stock </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Prior to Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> After Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> April 27, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> April 27, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total value (b) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right;

font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $9.6 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $11.6 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Deemed dividend </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $2.0 million</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assumptions:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercise price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Market price</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">$ </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25.20</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">(a)</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $ </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25.20</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">(a)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.91</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.91</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Term (in years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Series B & C Preferred Stock </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Prior to Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> After Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 21, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 21, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total value (b) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $1.7 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $6.8 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Deemed dividend </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:

"Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$5.1 million </p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assumptions:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercise price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Market price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.43</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.43</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Series C Preferred Stock </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Prior to Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> After Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March 24, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March 24, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total value (b) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.5 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.9 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Deemed dividend </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.4 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Assumptions: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-

family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercise price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.90</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Market price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.77</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.77</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.51</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.51</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Term (in years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> (a) </td> <td style="width: auto;"> Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> (b) </td> <td style="width: auto;"> Includes value of incremental shares underlying preferred stock and adjusted for probability of occurrence. </td> </tr> </tbody></table>   Bifurcatable Derivatives   Upon issuance in March 2024, the Unsecured Convertible Notes contained a lender's conversion option which represented an embedded call option requiring bifurcation as an embedded derivative liability at fair value (see Note 10, "Convertible Notes" for additional discussion). Fair value was determined using a Black Scholes model as outlined below.   <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 0pt; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: auto;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Unsecured Convertible Notes derivative </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Unsecured Convertible Notes derivative </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Issuance </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Shareholder Approval </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March 25, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> May 28, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.2 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.2 million</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gain (Loss)</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">not applicable</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c1102">$(82 thousand) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Assumptions: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercise price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.90</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.90</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Market price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.51</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.94</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">86.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">83.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.54</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.94</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   Upon issuance in May 2023, the Secured Convertible Notes contained a lender's conversion option which represented an embedded call option requiring bifurcation as an embedded derivative liability at fair value (see Note 10, "Convertible Notes" for additional discussion). Fair value was determined using a Black Scholes model as outlined below.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-left: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Secured Convertible Notes derivative </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Secured Convertible Notes derivative </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Issuance </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Shareholder Approval </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> April 27, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 9, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total value (b) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.2 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.2 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Gain </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $40 thousand </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Assumptions:

</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercise price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Market price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25.20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(a)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">76.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.88</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.41</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> (a) </td> <td style="width: auto;"> Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> (b) </td> <td style="width: auto;"> Adjusted for probability of occurrence. </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value Measurements Using </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Quoted </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Prices in </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Active </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Markets </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: "Times New Roman", Times, serif; font-size:

10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> for </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Other </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Balance at </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Identical </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Observable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Unobservable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Items </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Inputs </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Inputs </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 1) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 2) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 3) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Assets </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Active </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Markets </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> for </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Other </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Balance at </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Identical </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Observable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Unobservable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Items </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Inputs </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Inputs </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 1) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 2) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 3) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Assets </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrant liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">334</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">334</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 476000 476000 0 0 476000 476000 0 0 334000 0 334000 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> May 2023 Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> May 2023 Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> December 2023 Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> December 2023 Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> Issuance </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;">   Stockholder Approval   </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Reporting Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Stockholder Approval </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> May 1, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;">   June 9, 2023   </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> May 28, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Total Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $1.6 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $1.4 million   </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> $0.3 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> $0.2 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Gain (Loss) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.2 million   </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> $56 thousand</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c936">$(51 thousand) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-

family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Assumptions: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Exercise price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Market price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> $</p> </td> <td colspan="3" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">25.20</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;">(a) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.14</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.94</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">77.6</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">83.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.60</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.04</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.92</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.59</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.56</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">% </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.1</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.0</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Warrant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Warrant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Reporting Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Stockholder Approval </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March 31, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> May 28, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.1 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.1 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Gain (Loss) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $21 thousand</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c970">$(28 thousand) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Assumptions: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercise price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.90</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.90</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Market price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.94</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">86.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">83.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.21</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.56</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:

0pt;">5.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 24%;"> July 2020, November 2021, September 2022 & November 2022 Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> Prior to amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> After amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> April 27, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> April 27, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Total Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.3 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.5 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Loss </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.2 million </p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assumptions:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercise price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Market price</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">$ </td> <td colspan="3" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">25.20</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;">(a)</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> $ </td> <td colspan="3" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">25.20</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;">(a)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.59</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.73</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.59</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.73</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.1</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.6</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.1</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td

style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.6</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 24%;"> May 2023 Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> Prior to amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> After amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> December 21, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> December 21, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Total Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $56 thousand </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.2 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Loss </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.1 million </p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assumptions:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercise price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Market price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.92</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.62</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.92</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.62</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.5</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.5</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody>

<tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 24%;"> September 2022, November 2022, & May 2023 Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> Prior to amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> After amendment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> June 14, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> June 14, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Total Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $66 thousand </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $0.1 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Loss </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> $70 thousand </p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assumptions:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercise price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">52.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Market price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.51</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.51</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">89.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">89.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.27</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.08</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.27</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.08</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.0-4.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.0</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td

colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Series B & C Preferred Stock </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Prior to Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> After Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> April 27, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> April 27, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total value (b) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $9.6 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $11.6 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Deemed dividend </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $2.0 million</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assumptions:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercise price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Market price</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">$ </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25.20</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">(a)</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $ </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25.20</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">(a)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.91</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.91</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Term (in years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Series B & C Preferred Stock </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Prior to Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> After Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal;

margin: 0pt;">Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 21, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 21, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total value (b) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $1.7 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $6.8 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Deemed dividend </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $5.1 million</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Assumptions:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercise price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Market price</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.43</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.43</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Series C Preferred Stock </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Measurement event </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Prior to Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> After Ratchet </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March 24, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March 24, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total value (b) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.5 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.9 million </td> <td style="font-family: "Times

*New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Deemed dividend </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> not applicable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $0.4 million </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$(82 thousand)</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Assumptions: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercise price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Market price </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25.20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(a)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">80.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">76.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.88</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.41</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Term (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 45.5 45.5 8.75 8.75 25.2 23.8 7.14 4.94 0.801 0.776 0.793 0.839 0.036 0.0404 0.0392 0.0459 0.0385 0.0456 0 0 0 0 2.1 5.1 2 5 5.5 5.1 100000 100000 4.9 4.9 3.66 4.94 0.869 0.839 0.0421 0.0456 0 0 5.5 5.3 220.5 52.5 25.2 25.2 0.801 0.801 0.0359 0.0473 0.0359 0.0473 0 0 1.1 5.6 1.1 5.6 45.5 8.75 8.07 8.07 0.793 0.793 0.0392 0.0462 0.0392 0.0462 0 0 1.5 4.5 1.5 4.5 8.75 52.5 2.5 2.51 2.51 0.893 0.893 0.0427 0.0508 0.0427 0.0508 0 0 1 4.4 220.5 45.5 25.2 25.2 0.801 0.801 0.0491 0.0491 0 0 0.8 0.8 45.5 8.75 8.07 8.07 0.793 0.793 0.0543 0.0543 0 0 0.3 0.3 8.75 4.9 0.799 0.799 0.0551 0.0551 0 0 0.1 0.1 4.9 4.9 4.51 4.94 0.869 0.839 0.0454 0.0494 0 0 2 1.8 45.5 45.5 25.2 23.8 0.801 0.769 0.0488 0.0541 0 0 0.8 0.7 NOTE 4. PREPAID EXPENSES AND OTHER CURRENT ASSETS   Prepaid expenses and other current assets consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Prepaid insurance </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">94</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid dues and subscriptions </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid taxes </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">83</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid inventory </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">73</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td> <td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">94</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">81</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid expenses from discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(132</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total prepaid expenses and other current assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">255</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">256</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">94</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid dues and subscriptions </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid taxes </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">83</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid inventory </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">73</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">94</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">81</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid expenses from discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(132</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total prepaid expenses and other current assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">255</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">256</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 94000 66000 60000 85000 7000 83000 0 73000 94000 81000 -0 132000 255000 256000 NOTE 5. INVENTORY   Inventory consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif;

font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Raw materials and supplies </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">144</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,027</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Finished goods </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">760</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,477</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: Reserve for excess and obsolete inventory </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(204</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(627</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Inventory, net of reserves, from discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,313</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total inventory, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">700</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">564</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Raw materials and supplies </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">144</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,027</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Finished goods </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">760</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,477</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: Reserve for excess and obsolete inventory </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(204</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(627</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Inventory, net of reserves, from discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,313</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total inventory, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">700</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">564</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 144000 1027000 760000 2477000 204000 627000 -0 2313000 700000 564000 NOTE 6. PROPERTY AND EQUIPMENT   Property and equipment consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p

style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Office and laboratory equipment </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Furniture and fixtures </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">157</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">157</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Computer equipment and software </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">435</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">431</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Leasehold improvements </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">152</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">152</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total property and equipment, at cost </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">764</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">760</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: accumulated depreciation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(696</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(673</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total property and equipment, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">87</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   Depreciation expense related to continuing operations was $11 thousand and $13 thousand for the three months ended June 30, 2024 and 2023, respectively, and $23 thousand and $26 thousand for the six months ended June 30, 2024 and 2023, respectively. The Company recorded no depreciation expense during the three and six months ended June 30, 2024 and 2023, and no property and equipment as of June 30, 2024 and December 31, 2023 related to discontinued operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">June 30, </p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, </p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Office and laboratory equipment</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Furniture and fixtures </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">157</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">157</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin:

0pt;">Computer equipment and software </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">435</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">431</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Leasehold improvements </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">152</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">152</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total property and equipment, at cost </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">764</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">760</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: accumulated depreciation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(696</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(673</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total property and equipment, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">87</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 20000 20000 157000 157000 435000 431000 152000 152000 764000 760000 696000 673000 68000 87000 11000 13000 NOTE 7. ACCRUED LIABILITIES   Accrued liabilities consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Contract liabilities (see Note 14) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">773</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">946</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Employee payroll and benefits </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">380</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">341</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">144</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">229</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accrued liabilities from discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(347</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total accrued liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,297</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,169</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Contract liabilities (see Note 14) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">773</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">946</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Employee payroll and benefits </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">380</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">341</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">144</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">229</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accrued liabilities from discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(347</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total accrued liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,297</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,169</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 773000 946000 380000 341000 144000 229000 -0 347000 1297000 1169000 NOTE 8. COMMITMENTS AND CONTINGENCIES Indemnification Agreements   As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company's request in such capacity. The term of the indemnification period is for the officer's or director's lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may enable it to recover a portion of any future payments. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, it has not recorded any liabilities for these agreements as of June 30, 2024 or December 31, 2023.   In the normal course of business, the Company provides indemnification of varying scope under its agreements with other entities, typically its clinical research organizations, investigators, clinical sites, suppliers, and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third party with respect to its products. The term of these indemnification agreements is generally perpetual. The potential future payments the Company could be required to make under these indemnification agreements is unlimited. Historically, costs related to these indemnification provisions have been immaterial. The Company also maintains various liability insurance policies that limit its exposure. As a result, it believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of June 30, 2024 or December 31, 2023.   Legal Matters   From time to time, the Company is subject to various legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business. The ultimate outcome of any litigation or other legal dispute is uncertain. When a loss related to a legal proceeding or claim is probable and reasonably estimable, the Company accrues its best estimate for the ultimate resolution of the matter. If one or more legal matters are resolved against the Company in a reporting period for an amount above expectations, the Company's financial condition and operating results for that period may be adversely affected. As of June 30, 2024 and December 31, 2023, there were no legal matters that, in the opinion of management, would ultimately result in liability that would have a material adverse effect on the Company's financial position, results of operations or cash flows. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company due to legal costs and expenses, diversion of management attention and other factors. The Company cannot provide assurance that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against it in the future, and these matters could relate to prior, current, or future transactions or events.   Leases   The Company leases office space for its corporate headquarters located in Emeryville, California. The current lease term expires on July 31, 2027.   Lease costs for the three and six months ended June 30, 2024 and 2023 were as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the Three Months Ended June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the Six Months Ended June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Operating lease – expense </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times,

serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">200</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">200</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease from discontinued operations - expense</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease – included in operating cash flow</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">117</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">114</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">193</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">188</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease from discontinued operations - included in operating cash flow</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">32</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">64</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has measured its operating lease liabilities as the present value of minimum lease payments using its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate for operating leases from continuing operations are summarized as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">June 30, 2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">June 30, 2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term (in years)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Future lease payments under non-cancelable leases as of June 30, 2024 were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$ </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%; text-align: right;">233</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> 2025 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">439</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">444</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> 2027 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">290</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Total future minimum lease payments </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,406</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Less: Imputed interest </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px

solid rgb(0, 0, 0);">(92</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Total </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,314</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Reported as: </p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liability</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">382</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Operating lease liability- non-current </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">932</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Total </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,314</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">For the Three Months Ended </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">June 30,</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">For the Six Months Ended </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">June 30,</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease - expense</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">200</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">200</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating lease from discontinued operations - expense </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating lease – included in operating cash flow </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">117</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">114</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">193</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">188</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating lease from discontinued operations - included in operating cash flow </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">32</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">64</td> <td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Weighted-average remaining lease term (in years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted-average discount rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody></table> 100000 100000 200000 200000 0 31000 0 61000 117000 114000 193000 188000 0 32000 0 64000 P3Y1M6D P3Y9M18D 0.05 0.05 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> $</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%; text-align: right;">233</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">439</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">444</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">290</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total future minimum lease payments</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,406</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Imputed interest</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(92</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,314</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Reported as: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Operating lease liability </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">382</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liability- non-current</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">932</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,314</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 233000 439000 444000 290000 1406000 92000 1314000 382000 932000 1314000 NOTE 9. FINANCING ACTIVITIES   See Notes 2, “Summary of Significant Accounting Policies”; 3, “Fair Value Measurements”; 10, “Convertible Notes”; 11, “Common Stock Warrants” and 12, “Stockholders’ (Deficit) Equity” for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates.   2024 Warrant Reprice Transaction   In June 2024, the Company entered into a warrant reprice transaction (the “2024 Warrant Reprice Transaction”) with certain existing holders of our (i) warrants issued in September 2022 to purchase common stock, (ii) Series A-1 warrants issued in November 2022 to purchase common stock, (iii) Series B-1 Warrants issued in May 2023 to purchase common stock, and (iv) Series B-2 Warrants issued in May 2023 to purchase common stock (collectively (i) through (iv), the “Existing Warrants”). The participants agreed to exercise a portion of their Existing Warrants at a reduced exercise price of $2.50. There were an aggregate of 90,381 shares of common stock that were exercised, resulting in gross proceeds of approximately $0.2 million.   The Company also issued to participants in the 2024 Warrant Reprice Transaction, a new June 2024 Warrant to purchase a number of shares of common stock equal to 100% of the shares of common stock exercised. The June 2024 Warrants are substantially similar to the Existing Warrants, except that the June 2024 Warrants will (i) be initially exercisable on the six-month anniversary of the date of issuance; (ii) have an exercise price of $2.57; and (iii) have a term of five (5) years and six (6) months from the date of the closing of the 2024 Warrant Reprice Transaction.   The Company incurred total issuance costs of $96 thousand in conjunction with the 2024 Warrant Reprice Transaction. The Company incurred a $69 thousand non-cash loss on the modification of common stock warrants which was recorded in “Other expense, net” for the three and six months ended June 30, 2024.   2024

Subsidiary Guarantee Termination   On March 24, 2024, in connection with completing certain required conditions to close the DERMAdoctor Divestiture, the Company and the holders of the Secured Convertible Notes entered into a First Amendment (the "First Amendment") to the Company's Security Agreement, dated April 27, 2023 (the "Security Agreement"), to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company's obligations pursuant to the Secured Convertible Notes and for DERMAdoctor to be removed as a party to the Security Agreement, and a Consent and Release (the "Subsidiary Guarantee Consent"), to terminate the Subsidiary Guarantee, dated April 7, 2023 (the "Subsidiary Guarantee") (collectively, the "2024 Subsidiary Guarantee Termination"). To obtain the secured parties' consent that resulted in the reduction of the collateral available to secure the obligations under the Secured Convertible Notes and as consideration for the secured parties taking the necessary actions to execute and deliver the First Amendment and the Subsidiary Guarantee Consent, the Company provided each secured party the option, at the Secured Party's election, to receive only upon the closing of the DERMAdoctor Divestiture either a March 2024 Warrant (see Note 11, "Common Stock Warrants") or an Unsecured Convertible Note (see Note 10 "Convertible Notes").   The Company issued, based on the secured parties' elections, (i) a March 2024 Warrant to a secured party that is exercisable for an aggregate of 28,572 shares of common stock and (ii) Unsecured Convertible Notes to four secured parties that have an aggregate principal amount of $525 thousand or will be convertible into an aggregate of 107,146 shares of common stock.   The Company incurred total issuance costs of $130 thousand in conjunction with the 2024 Subsidiary Guarantee Termination. The Company allocated $19 thousand of the issuance costs to the Unsecured Convertible Notes which was recorded as a discount in the Company's condensed consolidated balance sheets. The remaining $111 thousand was allocated to the embedded derivative liability and warrant liability and expensed as "Other expense, net" in the Company's unaudited condensed consolidated statements of operations, during the six months ended June 30, 2024.   2023 Warrant Reprice Transaction   In December 2023, the Company entered into a warrant reprice transaction (the "2023 Warrant Reprice Transaction") whereby the price terms of certain May 2023 Warrants exercisable for 72,256 shares of common stock were amended and exercised. The price of the amended and exercised May 2023 Warrants was reduced from $45.50 to $8.75. The Company also issued to participants in the 2023 Warrant Reprice Transaction, the December 2023 Warrants exercisable for 72,256 shares of common stock.   The 2023 Warrant Reprice Transaction resulted in gross proceeds of approximately $0.6 million. The Company allocated the gross proceeds between the common stock and December 2023 Warrants issued to participants by applying the relative fair value allocation methodology. The Company allocated $0.2 million in gross proceeds to the common stock and $0.4 million to the December 2023 Warrants. The December 2023 Warrants were initially classified as liabilities from the date of issuance until Company stockholder approval on May 28, 2024, at which time they were reclassified to equity.   The Company incurred total issuance costs of $0.2 million in conjunction with the 2023 Warrant Reprice Transaction. The Company allocated $0.1 million of the issuance costs to the common stock which was recorded as a reduction of additional paid-in capital in the Company's condensed consolidated balance sheets. The remaining $0.1 million was allocated to the warrant liability and expensed as "Other expense, net" in the Company's unaudited condensed consolidated statements of operations.   2023 Private Placement   In May 2023, the Company closed a private placement (the "2023 Private Placement") with existing accredited institutional investors of the Company that provided for the issuance and sale of $3.3 million aggregate principal amount of the Secured Convertible Notes and the May 2023 Warrants exercisable for up to 145,056 shares of common stock.   The Company received gross proceeds of $3.0 million from the 2023 Private Placement. The Company allocated the proceeds from the 2023 Private Placement between the May 2023 Warrants, an embedded derivative liability, and the Secured Convertible Notes by applying the residual fair value methodology. The Company first allocated $1.6 million to the May 2023 Warrants and $0.2 million to the embedded derivative liability with the residual $1.2 million allocated to the Secured Convertible Notes. The embedded derivative liability was subsequently reclassified to equity upon stockholder approval.   The Company incurred total issuance costs of $0.7 million in conjunction with the 2023 Private Placement, including a $0.4 million non-cash loss on the warrant modification. The Company allocated $0.3 million of the issuance costs to the Secured Convertible Notes which was recorded as a discount in the Company's condensed consolidated balance sheets. The remaining $0.4 million was allocated to the embedded derivative liability and warrant liability and expensed as "Other expense, net" in the Company's unaudited condensed consolidated statements of operations.   2.5 90381 200000 2.57 96000 -69 -69 28572 525000 107146 130000 19000 111000 72256 45.5 8.75 72256 600000 200000 400000 200000 100000 100000 3300000 145056 3000000 1600000 200000 1200000 700000 400000 300000 400000 NOTE 10. CONVERTIBLE NOTES   Unsecured Convertible Note   In March 2024, the Company issued $525 thousand aggregate principal amount unsecured convertible notes (the "Unsecured Convertible Notes") in conjunction with the 2024 Subsidiary Guarantee Termination. The 2024 Subsidiary Guarantee Termination was executed with certain holders of the Secured Convertible Notes in order to close the DERMAdoctor Divestiture (see additional discussion in Note 9, "Financing Activities" and Note 18, "Divestiture and Discontinued Operations"). The Unsecured Convertible Notes are due March 25, 2026 and bear no stated interest.   The Unsecured Convertible Notes may be converted or redeemed for a conversion price equal to $4.90 per share at any time at the election of the holder up to the amount of outstanding principal at the time of conversion subject to certain limitations such as beneficial ownership limitations. Upon issuance and as of June 30, 2024, the Unsecured Convertible Notes were convertible for up to 107,146 shares of common stock.   Upon issuance in March 2024, the lender's conversion option under the Unsecured Convertible Notes represented an embedded call option requiring bifurcation as an embedded derivative liability because the common stock underlying the option required stockholder approval before the option could be exercised. The fair value of the embedded derivative was determined to be $159 thousand as of March 31, 2024 in accordance with a Black Scholes valuation model. See also Note 3, "Fair Value Measurements", subheading "Black Scholes Valuation Models and Assumptions". Upon stockholder approval on May 28, 2024, the embedded call option no longer required liability treatment and was reclassified to equity. The fair value of the embedded derivative liability was determined to be $242 thousand as of May 28, 2024. The change of $83 thousand in fair value between March 31, 2024 and May 28, 2024 was recorded as a non-cash loss on change in fair value of embedded derivative liability in the unaudited condensed consolidated statements of operations. See also Note 3, "Fair Value Measurements", subheading "Black Scholes Valuation Models and Assumptions".   The discount to the note recorded for the embedded derivative liability upon issuance and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Unsecured Convertible Notes, assuming that the Unsecured Convertible Notes will be redeemed for cash of $525 thousand at time of maturity as of March 25, 2026. During both the three and six months ended June 30, 2024, the effective interest rate on the Unsecured Convertible Notes was 144%. During the three and six months ended June 30, 2024, interest expense recognized, including amortization of the issuance costs and debt discount, was $14 thousand and $15 thousand, respectively, which was included in other expense, net in the unaudited condensed consolidated statements of operations.   Secured Convertible Note   In May 2023, the Company issued $3.3 million aggregate principal amount Original Issue Discount Senior Secured Convertible Debentures (the "Secured Convertible Notes") in conjunction with the 2023 Private Placement (see Note 9, "Financing Activities"). The Secured Convertible Notes were issued with a $300 thousand original issue discount. The Secured Convertible Notes are due November 1, 2024.   The Secured Convertible Notes may be converted or redeemed for a conversion price equal to $45.50 per share at any time at the election of the holder up to the amount of outstanding principal at the time of conversion subject to certain limitations such as beneficial ownership limitations. Upon issuance, the Secured Convertible Notes were convertible for up to 72,528 shares of common stock. As of June 30, 2024, the Secured Convertible Notes were convertible for up to 16,376 shares of common stock.   Beginning June 1, 2023, the Company was required to start making a monthly redemption of 1/18th of the original principal amount of the Secured Convertible Notes. Each monthly redemption reduces the outstanding principle of the Secured Convertible Note by $183 thousand and may be made in cash or, under limiting conditions, in stock at the election of the Company. Monthly redemption in cash requires a total payment of $193 thousand. Monthly redemption in stock requires the issuance of shares equal to $193 thousand divided by the lower of (i) $45.50 or (ii) 90% of the Company's common stock's average volume-weighted average price over 10 trading days prior to the redemption. The conditions allowing for redemption in stock have not been met through June 30, 2024 and the Company has made all monthly redemption payments in cash.   The Secured Convertible Notes also provide for a redemption equal to up to 20% of the gross proceeds received by the Company from any financing completed while the Secured Convertible Notes are outstanding. In connection with the 2023 Warrant Reprice Transaction (see Note 12, "Stockholders' (Deficit) Equity"), the Company made such a payment totaling $126 thousand in cash against the Secured Convertible Notes. In connection with the 2024 Warrant Reprice Transaction (see Note 12, "Stockholders' (Deficit) Equity"), the Company made such a payment totaling $45 thousand in cash against the Secured Convertible Notes.   If any event of default occurs, the outstanding principal amount of the Secured Convertible Notes, plus accrued but unpaid interest, liquidated damages and other amounts owing thereof become immediately due and payable in cash at the holder's election. After any event of default, the Secured Convertible Notes will also accrue interest at a rate up to 18% per year. The Secured Convertible Notes are secured obligations of the Company including a security interest, a lien upon and a right of set-off against all of the Company's assets as collateral security. DERMAdoctor was released of such obligations in connection with the DERMAdoctor Divestiture.   Upon issuance in May 2023, the lender's conversion option under the Secured Convertible Notes represented an embedded call option requiring bifurcation as an embedded derivative liability because the common stock underlying the option required stockholder approval before the option could be exercised. The fair value of the embedded derivative was determined to be $209 thousand as of the date of issuance. After stockholder approval of the underlying common stock, the embedded call option no longer required liability treatment and was reclassified to equity. The fair value of the embedded derivative liability was determined to be $169 thousand upon stockholder approval. The change of $40 thousand in fair value between the date of issuance and stockholder approval was recorded as a non-cash gain on change in fair value of embedded derivative liability in the consolidated statements of operations. See also Note 3, "Fair Value Measurements", subheading "Black Scholes Valuation Models and Assumptions".   The lender's subsequent financing redemption option and certain events of default also represent embedded call options and the Company's monthly share redemption option represents an embedded put option. The fair value of these options was determined to be immaterial upon issuance and at each subsequent reporting date.   The Company allocated $1.2 million of gross proceeds from the 2023 Private Placement to the Secured Convertible Notes.   The difference between the $1.2 million allocated to the Secured Convertible Notes and the $3.3 million aggregate principal amount represent

discounts for the portion of proceeds allocated to the embedded derivative liability and the May 2023 Warrants (See Note 11, “Common Stock Warrants”) as well as the $0.3 million original issue discount. The Company also allocated $0.3 million of debt issuance costs to the Secured Convertible Notes.   The discounts and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Secured Convertible Notes, assuming that the Secured Convertible Notes will be redeemed for cash of $193 thousand per month beginning in June 2023. The effective interest rate on the Secured Convertible Notes was 173%. During the three and six months ended June 30, 2024, interest expense recognized, including amortization of the issuance costs and debt discount, was $0.3 million and $0.7 million, respectively, which was included in other expense, net in the unaudited condensed consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Secured Convertible Notes are presented as follows as of June 30, 2024 (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Principal amount</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">762</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(92</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Unamortized debt issuance costs </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total Secured Convertible Notes, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">655</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   The Secured Convertible Notes, net, are classified as short term in the Company’s condensed consolidated balance sheets.   As of June 30, 2024, the Company’s contractual maturity of the principal balance of the Secured Convertible Notes was $762 thousand.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> 525000 4.9 107146 159000 242000 83000 525000 1.44 14000 15000 3300000 300000 45.5 72528 16376 -183000 193000 193000 45.5 0.90 10 0.20 126000 45000 0.18 209000 169000 40000 1200000 1200000 3300000 300000 300000 193000 1.73 300000 700000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Principal amount</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">762</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(92</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unamortized debt issuance costs </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total Secured Convertible Notes, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">655</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 762000 92000 15000 655000 762000 NOTE 11. COMMON STOCK WARRANTS   See Notes 2, “Summary of Significant Accounting Policies”, 3, “Fair Value Measurements”, 9, “Financing Activities”, and 12, “Stockholders’ (Deficit) Equity” for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates.   June 2024 Warrants   In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company issued new common stock purchase warrants (the “June 2024 Warrants”) exercisable for 90,381 shares of common stock for $2.57 per share through December 17, 2029.   March 2024 Warrant   In March 2024, the Company executed the First Amendment and Subsidiary Guarantee Consent as part of the 2024 Subsidiary Guarantee Termination with holders of the Secured Convertible Notes (see Note 10, “Convertible Notes”) in order to close the DERMAdoctor Divestiture (see additional discussion in Note 9, “Financing Activities” and Note 18, “Divestiture and Discontinued Operations”). In exchange for the consent of each holder, the option, at the holder’s election, to receive upon the closing of the DERMAdoctor sale either, a new common stock warrant (the “March 2024 Warrant”), or a new unsecured convertible note (see additional discussion in Note 18, “Divestiture and Discontinued Operations”). One holder elected the option to receive a March 2024 Warrant exercisable for 28,572 shares of common stock for $4.90 per share.   The March 2024 Warrant was initially classified as a liability from the date of issuance until Company stockholder approval on May 28, 2024, at which time it was reclassified to equity.   December 2023 Warrants   In December 2023, in conjunction with the 2023 Warrant Reprice Transaction, the Company issued new common stock purchase warrants (the “December 2023 Warrants”) exercisable for 72,256 shares of common stock for $8.75 per share through June 21, 2029.   The December 2023 Warrants were initially classified as liabilities from the date of issuance until Company stockholder approval on May 28, 2024, at which time it was reclassified to equity.   May 2023 Warrants   In May 2023, in conjunction with the 2023 Private Placement, the Company issued the following new common stock purchase warrants (collectively, the “May 2023 Warrants”):   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> May 2023 Series B-1 Warrants exercisable for 72,528 shares of common stock for $45.50 per share through June 9, 2028 (“May 2023 B-1 Warrants”); and </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> May 2023 Series B-2 Warrants exercisable for 72,528 shares of common stock for $45.50 per share through June 9, 2025 (“May 2023 B-2 Warrants”). </td> </tr> </tbody></table>   In December 2023, in conjunction with the 2023 Warrant Reprice Transaction, the Company amended certain May 2023 Warrants to reduce their exercise prices to $8.75. Immediately after amendment, the following May 2023 Warrants were exercised (while any unexercised May 2023 Warrants maintained an exercise price of $45.50):   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> May 2023 B-1 Warrants exercisable for 18,132 shares of common stock; and </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> May 2023 B-2 Warrants exercisable for 54,120 shares of common stock. </td> </tr> </tbody></table>   In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain May 2023 Warrants to reduce their exercise prices to $2.50. Immediately after amendment, the following May 2023 Warrants were exercised (while any unexercised May 2023 Warrants maintained an exercise price of $8.75):   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td

style="width: 18pt;"> ● </td> <td style="width: auto;"> May 2023 B-1 Warrants exercisable for 54,396 shares of common stock; and </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> May 2023 B-2 Warrants exercisable for 18,408 shares of common stock. </td> </tr> </tbody></table>   For the amendments in December 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the May 2023 Warrants of $170 thousand and $47 thousand, respectively.   November 2022 Warrants   In November 2022, in conjunction with the 2022 Private Placement, the Company issued the following common stock purchase warrants (collectively, the "November 2022 Warrants");   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> November 2022 Series A-1 Warrants exercisable for 14,741 shares of common stock for $220.50 per share through November 20, 2028 ("November 2022 A-1 Warrants"); and </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> November 2022 Series A-2 Warrants exercisable for 14,741 shares of common stock for $220.50 per share through May 20, 2024 ("November 2022 A-2 Warrants"). </td> </tr> </tbody> </table>   In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain November 2022 Warrants to reduce their exercise prices from $220.50 to $52.50 as follows: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> November 2022 A-1 Warrants exercisable for 12,473 shares of common stock; and </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> November 2022 A-2 Warrants exercisable for 12,473 shares of common stock. </td> </tr> </tbody></table>   In May 2024, all November 2022 Series A-2 Warrants for 14,741 shares of common stock remained unexercised and expired.   In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain November 2022 Warrants to reduce their exercise prices from $52.50 to $2.50 as follows: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> November 2022 A-1 Warrants exercisable for 12,473 shares of common stock. </td> </tr> </tbody></table>   For the amendments in May 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the November 2022 Warrants of $74 thousand and $16 thousand, respectively.   September 2022 Warrants   In September 2022, in conjunction with the warrant reprice transaction (the "2022 Warrant Reprice Transaction"), the Company issued new common stock purchase warrants (the "September 2022 Warrants") exercisable for 9,371 shares of common stock for $220.50 per share through September 11, 2028.   In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain September 2022 Warrants exercisable for 6,819 shares of common stock to reduce their exercise prices from $220.50 to $52.50.   In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain September 2022 Warrants exercisable for 5,104 shares of common stock to reduce their exercise prices from $52.50 to $2.50.   For the amendments in May 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the September 2022 Warrants of $28 thousand and $6 thousand, respectively.   November 2021 Warrants   In November 2021, in conjunction with a private placement transaction, the Company issued the new common stock purchase warrants (the "November 2021 Warrants") exercisable for 30,616 shares of common stock for $649.25 per share through March 9, 2023.   In September 2022, in conjunction with the 2022 Warrant Reprice Transaction, the Company amended all November 2021 Warrants to reduce their exercise prices from $649.25 to $220.50 and extend their termination date to September 11, 2028. Immediately after amendment, November 2021 Warrants were exercised for 7,654 shares of common stock.   In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain November 2021 Warrants exercisable for 15,308 shares of common stock to reduce their exercise prices from $220.50 to $52.50.   For the amendments in September 2022 and May 2023, the Company recognized a loss on modification of common stock warrants related to the November 2021 Warrants of $1.5 million and $0.1 million, respectively.   July 2020 Warrants   In July 2020, in conjunction with a private placement transaction, the Company issued the new common stock purchase warrants (the "July 2020 Warrants") exercisable for 5,635 shares of common stock for $2,021.25 per share through January 22, 2026.   In September 2022, in conjunction with the 2022 Warrant Reprice Transaction, the Company amended certain July 2020 Warrants exercisable for 3,921 shares of common stock to reduce their exercise prices from $2,021.25 to $220.50. Immediately after amendment, July 2020 Warrants were exercised for 1,715 shares of common stock.   In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain July 2020 Warrants exercisable for 2,206 shares of common stock to reduce their exercise prices from $220.50 to $52.50.   For the amendments in September 2022 and May 2023, the Company recognized a loss on modification of common stock warrants related to the July 2020 Warrants of $0.4 million and $9 thousand, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Summary of Common Stock Warrant Activity and Outstanding</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Activity related to common stock warrants outstanding at June 30, 2024 and 2023 were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Warrants</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Weighted-</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Average</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercise</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Price</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2022</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">65,886</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">269.54</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants granted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">145,056</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants exercised </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size:

10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants expired </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding at June 30, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">210,942</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">76.23</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">210,946</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">50.96</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants granted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">118,953</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.13</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants exercised </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(90,381</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants expired </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,741</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">78.35</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding at June 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">224,777</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">37.40</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr>
</tbody></table>   Common stock warrants outstanding as of June 30, 2024 were as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> Series </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%; border-bottom: 1px solid rgb(0, 0, 0);"> Expiration Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> 2019 Ladenburg Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,212.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">August 8, 2024</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">138</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">July 2020 Warrants</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,021.25</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> January 22, 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,714</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> July 2020 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> January 22, 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,206</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr

style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> TLF Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">822.96</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">January 15, 2026</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">November 2021 Warrants</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> September 11, 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,654</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> November 2021 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 11, 2028</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,308</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 2022 Warrants</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> September 11, 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,552</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> September 2022 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 11, 2028</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,715</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">November 2022 A-1 Warrants</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> November 20, 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,268</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> December 2023 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">June 21, 2029</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">72,256</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">March 2024 Warrant</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.90</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> March 24, 2029 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">28,572</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> June 2024 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.57</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> December 17, 2029 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">90,301</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Outstanding at June 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 25%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">224,777</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   Summary of Common Stock Warrant Liabilities   The following is a reconciliation of the beginning and ending balances for warrant liabilities measured at fair value on a recurring basis (in thousands). See additional information per Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions.”   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Warrant liabilities as of December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-

size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">334</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Decrease in fair value of December 2023 Warrant liability during period </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(122</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Fair value of March 2024 Warrant upon issuance </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">92</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Increase in fair value of March 2024 Warrant liability during period </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Reclassification of December 2023 Warrant liability to equity during period </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">212</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"></td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Reclassification of March 2024 Warrant liability to equity during period </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrant liabilities as of June 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">— </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> 90381 2.57 28572 4.9 72256 8.75 72528 45.5 72528 45.5 8.75 45.5 18132 54120 2.5 8.75 54396 18408 -170000 -47000 14741 220.5 14741 220.5 220.5 52.5 12473 12473 14741 52.5 2.5 12473 74000 16000 9371 220.5 6819 220.5 52.5 5104 52.5 2.5 28000 6000 30616 649.25 649.25 220.5 7654 15308 220.5 52.5 1500000 100000 5635 2021.25 3921 2021.25 220.5 1715 2206 220.5 52.5 400000 9000000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Warrants</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Weighted-</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Average</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercise</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Price</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2022</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">65,886</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">269.54</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants granted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">145,056</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants exercised </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">— </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">— </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants expired </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">— </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">— </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding at June 30, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">210,942</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">76.23</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants exercised </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(90,381</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants expired </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,741</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">78.35</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding at June 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">224,777</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">37.40</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 65886000 269.54 145056000 45.5 -0 0 0 0 210942000 76.23 210946000 50.96 118953000 3.13 90381000 2.5 -14741000 78.35 224777000 37.4 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> Series </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%; border-bottom: 1px solid rgb(0, 0, 0);"> Expiration Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Warrants </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> 2019 Ladenburg Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,212.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">August 8, 2024</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">138</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">July 2020 Warrants</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,021.25</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> January 22, 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,714</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> July 2020 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">January 22, 2026</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,206</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">TLF Warrants</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">822.96</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> January 15, 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> November 2021 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 11, 2028</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,654</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">November 2021 Warrants</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> September 11, 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,308</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> September 2022 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> September 11, 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,552</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New

Roman", Times, serif; font-size: 10pt; width: 40%;"> September 2022 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 11, 2028</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,715</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">November 2022 A-1 Warrants</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220.50</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> November 20, 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,268</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> December 2023 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">June 21, 2029</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">72,256</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">March 2024 Warrant</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.90</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> March 24, 2029 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">28,572</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> June 2024 Warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.57</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">December 17, 2029</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">90,381</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at June 30, 2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 25%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">224,777</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 1212.75 2024-08-08 138000 2021.25 2026-01-22 1714000 52.5 2026-01-22 2206000 822.96 2026-01-15 13000 220.5 2028-09-11 7654000 52.5 2028-09-11 15308000 220.5 2028-09-11 2552000 52.5 2028-09-11 1715000 220.5 2028-11-20 2268000 8.75 2029-06-21 72256000 4.9 2029-03-24 28572000 2.57 2029-12-17 90381000 224777000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrant liabilities as of December 31, 2023</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">334</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Decrease in fair value of December 2023 Warrant liability during period</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(122</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of March 2024 Warrant upon issuance</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">92</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Increase in fair value of March 2024 Warrant liability during period</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Reclassification of December 2023 Warrant liability to equity during period</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(212</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Reclassification of March 2024 Warrant liability to equity during period</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrant liabilities as of June 30, 2024</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 334000 -122000 92000 8000 -212000 -100000 0 NOTE 12. STOCKHOLDERS’ (DEFICIT) EQUITY   Authorized Share Capital   Under the Company’s Amended and Restated Certificate of Incorporation, as amended, the Company is authorized to issue up to 150,000,000 shares of common stock and up to 5,000,000 shares of preferred stock with rights and preferences as may be approved by the Company’s Board of Directors.   Reverse Stock Split   Effective May 30, 2024, the Company amended its Certificate of Incorporation to effect a 1-for-35 reverse split of its outstanding common stock. The Reverse Stock Split was approved by the Company’s stockholders on May 28, 2024. As a result of the Reverse Stock Split, every 35 shares of the Company’s pre-reverse split outstanding common stock were combined and reclassified into 1 share of

common stock. Proportionate voting rights and other rights of common stockholders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole share. All stock options outstanding, common stock reserved for issuance under the Company's equity incentive plans, common stock reserved for issuance under the Series B Preferred Stock and outstanding warrants were adjusted by dividing the number of affected shares of common stock by 35 and, as applicable, multiplying the exercise/conversion price by 35. Except as otherwise specifically noted, all share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis, to reflect this 1-for-35 reverse stock split.   Preferred Stock   There were two series of preferred stock of the Company outstanding during the three and six months ended June 30, 2024 and 2023 – the Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") and the Series C Non-Voting Convertible Preferred Stock ("Series C Preferred Stock") (and combined, the "Preferred Stock"). The rights and preferences of the Series B Preferred Stock and Series C Preferred Stock are nearly identical. The Preferred Stock does not have any preemptive rights or a preference upon any liquidation, dissolution or winding-up of the Company. Each share of Preferred Stock is convertible into $1,000 of common stock at the conversion price per share applicable at the time of conversion. Until its expiration (as described in more detail below), the Preferred Stock had anti-dilution protection (the "Ratchet") in the event that the Company sold or granted any of its common stock or any other securities, subject to certain limited exceptions, that would entitle the holder thereof to acquire common stock at an effective price per share that is lower than the then applicable conversion price of the Preferred Stock.   Series B Preferred Stock   The Company issued 15,000 shares of Series B Preferred Stock in November 2021 in connection with a private placement transaction. As of June 30, 2024 and 2023, 131 and 9,156 shares of Series B Preferred Stock remained outstanding, respectively. As of June 30, 2024 and 2023, outstanding shares of Series B Preferred Stock were convertible into 15,065 and 201,432 shares of common stock at a conversion price of $8.75 and $45.50, respectively.   In accordance with the Ratchet, the Series B Preferred Stock conversion price was reduced as follows (see also Notes 2, "Summary of Significant Accounting Policies" and 3, "Fair Value Measurements"):   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <tbody><tr style="vertical-align: top; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> ● </td> <td style="width: auto; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> In September 2022, from $490.00 to $220.50, as a result of the 2022 Warrant Reprice Transaction, resulting in a $5.7 million deemed dividend. </td> </tr> <tr style="vertical-align: top; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> ● </td> <td style="width: auto; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> In April 2023, from $220.50 to $45.50, as a result of the 2023 Private Placement, resulting in a $1.8 million deemed dividend. </td> </tr> <tr style="vertical-align: top; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> ● </td> <td style="width: auto; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> In December 2023, from $45.50 to $8.75, as a result of the 2023 Warrant Reprice Transaction, resulting in a $4.5 million deemed dividend.</td> </tr> </tbody></table>   On January 29, 2024, the Ratchet of the Series B Preferred Stock expired with no further impact because greater than 75% of the originally issued 15,000 Series B Preferred Stock had been converted into common stock. The Series B Preferred Stock conversion price will remain at $8.75 until all remaining Series B Preferred Stock has been converted.   Series C Preferred Stock   The Company issued 3,250 shares of Series C Preferred Stock in November 2022 in connection with the 2022 Private Placement (see Note 9, "Financing Activities"). As of June 30, 2024 and 2023, zero and 1,097 shares of Series C Preferred Stock remained outstanding, respectively. As of June 30, 2023, outstanding shares of Series C Preferred Stock were convertible into 24,134 shares of common stock at a conversion price of $45.50.   In accordance with the Ratchet, the Series C Preferred Stock conversion price was reduced as follows during the six months ended June 30, 2024 and 2023 (see also Notes 2, "Summary of Significant Accounting Policies" and 3, "Fair Value Measurements"):   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> In April 2023, from $220.50 to $45.50, as a result of the 2023 Private Placement, resulting in a $194 thousand deemed dividend. </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> In December 2023, from $45.50 to $8.75, as a result of the 2023 Warrant Reprice Transaction, resulting in a $0.5 million deemed dividend. </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> ● </td> <td style="width: auto;"> In March 2024, from $8.75 to $4.90, as a result of the 2024 First Amendment and the Subsidiary Guarantee Consent, resulting in a $0.4 million deemed dividend. </td> </tr> </tbody></table>   On March 27, 2024, the Ratchet of the Series C Preferred Stock expired with no further impact because greater than 75% of the originally issued 3,250 Series C Preferred Stock had been converted into common stock.   Common Stock   See Note 9, "Financing Activities" and Note 11, "Common Stock Warrants" for a description of common stock and common stock warrant-related transactions during the three and six months ended June 30, 2024 and 2023. 150000000 5000000 35 1000 15000 131 9156 15065 201432 8.75 45.5 490 220.5 5700000 220.5 45.5 1800000 45.5 8.75 4500000 75 15000 8.75 3250 1097 24134 45.5 220.5 45.5 194000000 45.5 8.75 500000 8.75 4.9 400000 75 3250 NOTE 13. EQUITY-BASED COMPENSATION   Equity Compensation Plans   In October 2007, the Company adopted the 2007 Omnibus Incentive Plan (the "2007 Plan") to provide for the granting of equity awards, such as stock options, unrestricted and restricted common stock, stock units, dividend equivalent rights, and stock appreciation rights to employees, directors and outside consultants, as determined by the Board. The 2007 Plan expired on March 15, 2017. Upon expiration, new awards cannot be issued pursuant to the 2007 Plan, but outstanding awards continue to be governed by its terms. Stock options granted under the 2007 Plan expire no later than ten years from the date of grant. All stock options outstanding under the 2007 Plan were fully vested as of December 31, 2021.   In March 2017, the Company adopted the 2017 Omnibus Incentive Plan (the "2017 Plan"), which was approved by stockholders on June 2, 2017, to provide for the granting of equity awards, such as nonqualified stock options ("NQSOs"), incentive stock options ("ISOs"), restricted stock, performance shares, stock appreciation rights ("SARs"), RSUs and other share-based awards to employees, directors, and consultants, as determined by the Board. The 2017 Plan does not affect awards previously granted under the 2007 Plan. Upon adoption, the 2017 Plan allowed for awards of up to 1,892 shares of the Company's common stock, plus an automatic annual increase in the number of shares authorized for awards on the first day of each of the Company's fiscal years beginning January 1, 2018 through January 1, 2027 equal to (i) 4% of the number of shares of common stock outstanding on the last day of the immediately preceding fiscal year or (ii) such lesser number of shares of common stock as determined by the Board. On June 21, 2024, the number of shares available for future awards under the 2017 Plan was increased by 12,219 shares. As of June 30, 2024, there were 13,630 shares available for future awards under the 2017 Plan.   Under the terms of the 2017 Plan, the exercise price of NQSOs, ISOs and SARs may not be less than 100% of the fair market value of the common stock on the date of grant and, if ISOs are granted to an owner of more than 10% of the Company's stock, then not less than 110% of the fair market value of the common stock on the date of grant. The term of awards will not be longer than ten years or, in the case of ISOs, no longer than five years with respect to holders of more than 10% of the Company's stock. Stock options granted to employees generally vest over four years, while options granted to directors and consultants typically vest over a shorter period, subject to continued service. The Company issues new shares to satisfy options under the 2007 Plan and the 2017 Plan.   Summary of Outstanding Equity Awards   The following table summarizes information about the Company's stock options and restricted stock outstanding at December 31, 2023, and activity during the six months ended June 30, 2024:   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%; border-bottom: 1px solid rgb(0, 0, 0);"> (in thousands, except years
 and per share data) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Awards </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted- Average Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted- Average Remaining Contractual Life (years) </td> <td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,145.87</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted stock units granted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10

hidden:c1684">no stock option awards exercised during the three and six months ended June 30, 2024 and 2023.   As of June 30, 2024, total unrecognized compensation cost related to unvested stock options and restricted stock units was approximately $0.1 million. This amount is expected to be recognized as stock-based compensation expense in the Company's unaudited condensed consolidated statements of operations over the remaining weighted average vesting period of 1.34 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Equity Awards to Employees and Directors</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, "Summary of Significant Accounting Policies," for a description of the accounting policies that the Company applied to value its stock-based awards. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the six months ended June 30, 2024 and 2023, the Company granted options to employees and directors to purchase an aggregate of zero and 1,209 shares of common stock, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted-average assumptions used in determining the value of options were as follows: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assumption</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">For the Six </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Months Ended </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">June 30, 2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected price volatility</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">152.99</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.81</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.47</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average fair value of options granted during the period</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">56.19</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   Expected Price Volatility—This is a measure of the amount by which the stock price has fluctuated or is expected to fluctuate. The computation of expected volatility was based on the historical volatility of our own stock.   Expected Term—This is the period of time over which the options granted are expected to remain outstanding. The expected life assumption is based on the Company's historical data.   Risk-Free Interest Rate—This is the U.S. Treasury rate for the week of the grant having a term approximating the expected life of the option.   Dividend Yield—The Company has not made any dividend payments nor does the Company have plans to pay dividends in the foreseeable future.   Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate.   During the six months ended June 30, 2024, the Company granted 5,148 shares of restricted stock to employees and directors. During the six months ended June 30, 2023, the Company granted 150 shares of restricted stock to employees and directors.   For the three months ended June 30, 2024 and 2023, the Company recognized stock-based compensation expense of $55 thousand and $64 thousand, respectively, for option awards to employees and directors. For the six months ended June 30, 2024 and 2023, the Company recognized stock-based compensation expense of $102 thousand and $139 thousand, respectively, for option awards to employees and directors.   Stock-Based Awards to Non-Employees   During the three and six months ended June 30, 2024, the Company did not grant options to non-employees in exchange for advisory and consulting services. During the three and six months ended June 30, 2023, the Company granted 1,032 options to non-employees. These options were cancelled in June 2024.   The Company did not grant restricted stock to non-employees during the three and six months ended June 30, 2024 and 2023.   For the three and six months ended June 30, 2024 the Company recognized stock-based compensation expense of zero and $13 thousand, respectively as it relates to non-employees. For both the three and six months ended June 30, 2023, the Company recognized stock-based compensation expense of $3 thousand, as it relates to non-employees.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Summary of Stock-Based Compensation Expense</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A summary of the stock-based compensation expense included in results of operations for the options and restricted stock awards discussed above is as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three Months Ended June 30,</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Six Months Ended June 30, </p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sales and marketing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">40</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">32</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">96</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">115</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">139</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1892 0.04 12219 13630 1 0.10 1.10 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(in thousands, except years
 and per share data)</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Awards</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Weighted-</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Average </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercise </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Price</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Weighted-</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Average</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Remaining </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Contractual </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Life (years) </p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Aggregate </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Intrinsic </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Value</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2023</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,145.87</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Restricted stock units granted</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options forfeited/cancelled </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">392.58</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding at June 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">505.54</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Six Months Ended June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Research and development </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Sales and marketing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">40</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">32</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> General and administrative </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">96</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total stock-based compensation expense </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">115</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">139</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 5000 5000 9000 11000 14000 17000 40000 32000 36000 42000 66000 96000 55000 64000 115000 139000 NOTE 14. DISTRIBUTION AGREEMENTS   Transactions under the Company's major distribution agreements are recognized upon transfer of control of products sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns.   Product Sales Discounts and Allowances   The following table presents activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration, for the six months ended June 30, 2024 (in thousands).   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Chargebacks, Discounts for Prompt Payment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Other Customer Fees </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Rebates </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Balance at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">913</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%;

font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">946</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(218</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(218</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Continuing operations balance at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">695</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">728</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Provision related to sales made in: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

 Discounts for Prompt Payment </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Other Customer Fees </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Rebates </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">913</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">946</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(218</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(218</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Continuing operations balance at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">695</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">728</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Provision related to sales made in: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

border-bottom: 3px double rgb(0, 0, 0);">773</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 913000 12000 21000 946000 218000 -0 -0 218000 695000 12000 21000 728000 57000 23000 52000 132000 11000 22000 54000 87000 741000 13000 19000 773000 108000 195000 232000 287 800000 700000 1800000 1300000 3500000 2900000 NOTE 15. EMPLOYEE BENEFIT PLAN   The Company has a 401(k) plan covering all eligible employees. The Company provides matching contributions equal to 100% of the first 3% of compensation deferred, plus 50% of the next 2% of compensation deferred. The Company contributed $25 thousand and $23 thousand to the 401(k) plan from continuing operations in the three months ended June 30, 2024 and 2023, respectively. The Company contributed $49 thousand and $46 thousand to the 401(k) plan from continuing operations in the six months ended June 30, 2024 and 2023, respectively. The Company contributed $9 thousand and $17 thousand to the 401(k) plan from discontinued operations in the three and six months ended June 30, 2023. 1 0.03 0.50 0.02 25000 23000 49000 46000 9000 17000 NOTE 16. RELATED PARTY TRANSACTIONS   The following table summarizes information about the Company's related party revenue and cost of goods sold (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six Months Ended June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Chongqing Pioneer Pharma Holdings Limited: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,043</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,043</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of goods sold</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">895</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">895</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 0 1043000 0 1043000 0 895000 0 895000 NOTE 17. SEGMENT REPORTING   The Company operates as one reportable segment, Eyecare and Wound Care, which is described in further detail below. This is based on the objectives of the business and how our chief operating decision maker ("CODM"), the President and Chief Executive Officer, monitors operating performance and allocates resources.   Change in Reportable Segments   The Company previously operated in principally two reportable segments, (1) Eyecare and Wound Care and (2) Skincare. During the six months ended June 30, 2024, in connection with the previously announced strategic shift and upon the DERMAdoctor Divestiture, the Company has ceased to operate the Skincare segment. As a result, the Company changed the level of detail at which our CODM regularly reviews and manages the businesses, resulting in a change to our reportable segments.   We now manage and report our operating results through one reportable segment: Eyecare and Wound Care. This change allows us to better align our business models, resources, and cost structure to the specific current and future growth of our business, while maintaining the necessary information and transparency to our stockholders. Our historical segment information has been recast to conform to the current segment structure.   NOTE 18. DIVESTITURE AND DISCONTINUED OPERATIONS   On March 12, 2024, the Company entered into an agreement to sell 100% of the membership units of DERMAdoctor for a closing purchase price of $1.1 million. The sale of the membership units closed, and the DERMAdoctor Divestiture occurred, on March 25, 2024. In order to close the sale, the Company was required to obtain the consent of the holders of the Secured Convertibles Notes (see Note 10, "Convertible Notes") issued in May 2023 to (i) amend the Security Agreement to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company's obligations pursuant to the Secured Convertible Notes and for DERMAdoctor to be removed as a party to the Security Agreement and (ii) terminate the Subsidiary Guarantee, which DERMAdoctor entered into in connection with the issuance of the Secured Convertible Notes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On March 24, 2024, the Company and the secured parties entered into a First Amendment to the Security Agreement, to effect an amendment to the Security Agreement and a Consent and Release to terminate the Subsidiary Guarantee. To obtain the secured parties' consent and as consideration for the secured parties taking the necessary actions to execute and deliver the First Amendment and the Subsidiary Guarantee Consent, the Company provided each secured party the option, at the secured party's election, to receive only upon the closing of the DERMAdoctor Sale Transaction either: a March 2024 Warrant or the Unsecured Convertible Notes (see Note 10 "Convertible Notes").</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accounting requirements for reporting the DERMAdoctor business as discontinued operations were met during the first quarter of 2024. Accordingly, the condensed consolidated financial statements and notes to the condensed consolidated financial statements reflect the results of the DERMAdoctor business as a discontinued operation for the periods presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the condensed consolidated balance sheets. The assets and liabilities have been reflected as discontinued operations in the condensed consolidated balance sheets as of December 31, 2023, and consist of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Balance at</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31,</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ASSETS</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Current assets:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Cash and cash equivalents</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">206</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,313</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Prepaid expenses and other current assets</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">132</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total current assets, discontinued operations</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,730</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal;

margin: 0pt;">Other assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total assets, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,749</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">LIABILITIES</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Current liabilities:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Accounts payable</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">224</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accrued liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">347</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating lease liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">127</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total current liabilities, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">698</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total liabilities, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">698</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the unaudited condensed consolidated statements of operations. The results of DERMAdoctor's operations for the six months ended June 30, 2024 and 2023 have been reflected as discontinued operations in the unaudited condensed consolidated statements of operations and consist of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Six Months Ended </p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sales:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Product revenue, net</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">717</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,861</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total sales, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">717</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,861</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cost of goods sold </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">493</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">958</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;

background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Gross profit </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">224</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">903</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating expenses </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Research and development </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Sales and marketing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">292</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">960</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> General and administrative </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">48</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">615</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total operating expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">342</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,596</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating loss </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(118</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(693</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other expense, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net loss from discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(124</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(702</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </tbody></table>   In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the unaudited condensed consolidated statements of cash flows. The results of DERMAdoctor for the six months ended June 30, 2024 and 2023 have been reflected as discontinued operations in the unaudited condensed consolidated statements of cash flows and consist of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six Months Ended June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Operating activities: </td> <td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net loss from discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(124</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(702</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Adjustments to reconcile net loss to net cash used in operating activities: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Amortization of intangible assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">76</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Non-cash right-of-use amortization</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">—</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">55</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Changes in operating assets and liabilities: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accounts receivable </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(262</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(169</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Inventory </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">183</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(142</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid expenses and other current assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">125</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accounts payable and accrued liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">63</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">264</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating lease liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(59</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net cash used in operating activities, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(160</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(561</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Investing activities: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash transferred to New Age Investments, LLC </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif;

font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(46</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net cash used in investing activities, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(46</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net decrease in cash and cash equivalents, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(206</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(561</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </tbody></table>   1 1100000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Balance at December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> ASSETS </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Current assets: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash and cash equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">206</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,313</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Prepaid expenses and other current assets</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">132</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total current assets, discontinued operations</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,730</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other assets</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets, discontinued operations</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,749</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> LIABILITIES </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Liabilities: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Current liabilities: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;

background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accounts payable </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">224</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Accrued liabilities</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">347</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Operating lease liabilities</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">127</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total current liabilities, discontinued operations</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">698</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities, discontinued operations</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">698</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six Months Ended </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Sales: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Product revenue, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">717</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,861</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total sales, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">717</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,861</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cost of goods sold </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">493</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">958</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Gross profit </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">224</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">903</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating expenses </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Research and development </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Sales and marketing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">292</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">960</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal;

margin: 0pt 0pt 0pt 18pt;">General and administrative </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">48</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">615</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total operating expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">342</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,596</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating loss </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(118</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(693</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accounts receivable </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(262</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(169</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Inventory </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">183</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(142</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid expenses and other current assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">125</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accounts payable and accrued liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">63</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">264</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating lease liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(59</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net cash used in operating activities, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(160</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(561</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Investing activities: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash transferred to New Age Investments, LLC </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(46</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net cash used in investing activities, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(46</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net decrease in cash and cash equivalents, discontinued operations </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(206</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(561</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </tbody></table> 206000 0 79000 363000 2313000 132000 2730000 19000 2749000 224000 347000 127000 698000 698000 717000 1861000 717000 1861000 493000 958000 224000 903000 2000 21000 292000 960000 48000 615000 342000 1596000 -118000 -693000 6000 9000 -124000 -702000 -124000 -702000 0 76000 0 55000 -262000 -169000 -183000 142000 4000 -125000 -15000 9000 63000 264000 -31000 -59000 -160000 -561000 46000 -0 -46000 0 -206000 -561000 NOTE 19. SUBSEQUENT EVENTS   The Company has evaluated all subsequent events through the filing date of this Form 10-Q with the SEC, to ensure that this filing includes appropriate disclosure of events both recognized in the unaudited condensed consolidated financial statements as of June 30, 2024, and events which occurred subsequently but were not recognized in the unaudited condensed

consolidated financial statements. Except as described below, there were no subsequent events which required recognition, adjustment to or disclosure in the unaudited condensed consolidated financial statements.   On July 26, 2024, NovaBay Pharmaceuticals, Inc. entered into an underwriting agreement (the "Underwriting Agreement") with Ladenburg Thalmann & Co., Inc., as the sole underwriter (the "Underwriter"), relating to the issuance and sale in a public offering (the "2024 Public Offering") of: (i) 1,158,566 shares of common stock, par value $0.01 per share, of the Company common stock and 2,041,814 pre-funded warrants, in lieu of shares of common stock (the "Pre-Funded Warrants"), (ii) 3,200,380 Series F-1 warrants to purchase up to 3,200,380 shares of common stock (the "Series F-1 Warrants"), (iii) 3,200,380 Series F-2 warrants to purchase up to 3,200,380 shares of common stock (the "Series F-2 Warrants") and (iv) 3,200,380 Series F-3 warrants to purchase up to 3,200,380 shares of common stock (the "Series F-3 Warrants", and together with the Pre-Funded Warrants, Series F-1 Warrants and Series F-2 Warrants, the "July 2024 Warrants").   The Series F-1 Warrants have an exercise price of $1.10 per share, are exercisable immediately upon issuance, and will expire on the five-year anniversary of the date of issuance. The Series F-2 Warrants have an exercise price of $1.10 per share, are exercisable immediately upon issuance, and will expire on the six-month anniversary of the date of issuance. The Series F-3 Warrants have an exercise price of $1.10 per share, are exercisable immediately upon issuance, and will expire on the one-year anniversary of the date of issuance. The Pre-Funded Warrants are immediately exercisable at a nominal exercise price of $0.01 per share and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The Series F-1 Warrants, the Series F-2 Warrants and the Series F-3 Warrants each include a one-time reset of the exercise price to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the volume weighted average prices for the five (5) trading days immediately preceding the date that is sixty calendar days after issuance of the Series F-1 Warrants, the Series F-2 Warrants and the Series F-3 Warrants, as applicable. The exercise price and number of shares of common stock issuable upon exercise of the July 2024 Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price. Subject to limited exceptions, a holder may not exercise any portion of its July 2024 Warrants to the extent that the holder would beneficially own more than 4.99% (or, at the election of the holder prior to the date of issuance, 9.99%) of the Company's outstanding common stock after exercise.   In addition, the Company has granted the Underwriter a 45-day option to purchase up to 477,272 additional shares of common stock and/or 477,272 Series F-1 Warrants to purchase up to 477,272 shares of common stock, 477,272 Series F-2 Warrants to purchase up to 477,272 shares of common stock and 477,272 Series F-3 Warrants to purchase up to 477,272 shares of common stock, or any combination thereof, as determined by the Underwriter, at the public offering price, less underwriting discounts and commissions, in each case solely to cover over-allotments, if any.   The Underwriter partially exercised this option on July 26, 2024, for (i) 336,832 shares of common stock, (ii) 336,832 Series F-1 Warrants to purchase up to 336,832 shares of common stock, (iii) 336,832 Series F-2 Warrants to purchase up to 336,832 shares of common stock and (iv) 336,832 Series F-3 Warrants to purchase up to 336,832 shares of common stock.   The 2024 Public Offering closed on July 29, 2024, and the Company received gross proceeds of $3.9 million, without taking into account any underwriting discounts and commissions. A portion of the proceeds were used towards the Secured Convertible Notes, which were repaid in full during the third quarter of 2024.   As of August 9, 2024, all of the Pre-Funded Warrants were exercised resulting in net proceeds of $20 thousand.   1158566 0.01 2041814 3200380 3200380 3200380 3200380 3200380 3200380 1.1 1.1 1.1 0.01 0.0499 0.0999 477272 477272 477272 477272 477272 477272 477272 477272 336832 336832 336832 336832 336832 336832 336832 3900000 20 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 54pt;"> ITEM 5. </td> <td style="width: auto;"> OTHER INFORMATION </td> </tr> </tbody></table>   Rule 10b5-1 Trading Arrangements   During the six months ended June 30, 2024, none of our directors or Section 16 officers adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each such term is defined in Item 408 of Regulation S-K.   After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. Includes value of incremental shares underlying preferred stock and adjusted for probability of occurrence. Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. Adjusted for probability of occurrence. After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. After giving retroactive effect to a 1-for-35 reverse stock split that became effective May 30, 2024. '"